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Preface to ”Cancer Nanomedicine”
Welcome to the special issue on Cancer Nanomedicine within Cancers. It has been a real delight
to edit this special edition bringing together cutting edge research within the field with insightful
reviews and opinions reflecting our community.
Cancer nanomedicine is a large umbrella under which researchers spanning the physical,
chemical and biological sciences. I think this is well reflected in this edition.
Cancer treatments are often hindered by the lack of drug specificity, poor physicochemical
properties of active pharmaceutical ingredients, poor penetration ability and drug resistance.
With the discovery and characterization of an increasing number of cancer types with little
improvement of the ability to diagnose, treatment options or patient prognosis, more advanced
technologies are urgently required. Nanotechnology defines particulates within the 1×10−9 m range.
Particulates within the nano-sized domain often exhibit unique properties compared to their larger
size scale. These can be exploited in biomedicine for applications such as imaging, cell sorting, drug
delivery and targeting. Cancer nanomedicine is rapidly becoming one of the leading areas of promise
for cancer therapy, with first-generation treatments already available to patients.
The exciting advances within this field have lead to cancer nanomedicines already been used
clinically today. Sceptics would argue that the translation of nanotechnologies into the clinic have
not matched the initial hype, however, I believe moving forward more and more commercial success
will be achieved. It is estimated that the global nanomedicine market will be worth US$334 billion
by 2025, with cancer nanomedicine dominating in this field. As the science develops and leads us
down new avenues, the findings and their meaning are closely scrutinised and debated within the
community. This all leads to a thriving and exciting field in which to work.
I hope you enjoy reading the manuscripts within this special edition, since it has been such a
great success with 46 papers being accepted for publication. In order to continue to showcase work in
our strong field, a Topical Collection has been permanently opened within Cancers, and I invite you
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Abstract: Nanoparticle-based drug delivery systems are among the most popular research topics
in recent years. Compared with traditional drug carriers, mesoporous silica nanoparticles (MSN)
offer modifiable surfaces, adjustable pore sizes and good biocompatibility. Nanoparticle-based
drug delivery systems have become a research direction for many scientists. With the active target
factionalized, scientists could deliver drug carriers into cancer cells successfully. However, drugs in
cancer cells could elicit drug resistance and induce cell exocytosis. Thus, the drug cannot be delivered
to its pharmacological location, such as the nucleus. Therefore, binding the cell membrane and the
nuclear target on the nanomaterial so that the anticancer drug can be delivered to its pharmacological
action site is our goal. In this study, MSN-EuGd was synthesized by doping Eu3+ and Gd3+ during the
synthesis of MSN. The surface of the material was then connected to the TAT peptide as the nucleus
target for targeting the cancer nucleus and then loaded with the anticancer drug camptothecin (CPT).
Then, the surface of MSN-EuGd was bonded to the hyaluronic acid as an active target and gatekeeper.
With this system, it is possible and desirable to achieve dual imaging and dual targeting, as well
as to deliver drugs to the cell nucleus under a hyaluronidase-controlled release. The experimental
approach is divided into three parts. First, we conferred the material with fluorescent and magnetic
dual-imaging property by doping Eu3+ and Gd3+ into the MSN. Second, modification of the cell
membrane target molecule and the nucleus target molecule occurred on the surface of the nanoparticle,
making the nanoparticle a target drug carrier. Third, the loading of drug molecules into the carrier
gave the entire carrier a specific target profile and enabled the ability to treat cancer. In this study,
we investigated the basic properties of the drug carrier, including physical properties, chemical
properties, and in vitro tests. The result showed that we have successfully designed a drug delivery
system that recognizes normal cells and cancer cells and has good anticancer effects.
Keywords: Mesoporous silica nanoparticle; drug delivery system; target treatment; lanthanide metal;
TAT peptide; hyaluronic acid; hyaluronidase
1. Introduction
Drug release systems based on nanoparticles have been widely used for cancer treatment.
An effective drug release system needs to have sufficient drug loading capability and the ability
to target to bring nanoparticles into the cancer cells preferentially [1]. However, drugs in cancer
cells could elicit drug resistance and induce cell exocytosis. Thus, the drug cannot be delivered to
its pharmacological location [2], such as the nucleus. Therefore, we will bind the cell membrane
Cancers 2019, 11, 697; doi:10.3390/cancers11050697 www.mdpi.com/journal/cancers1
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target and the nuclear target on the nanomaterial so that the anticancer drug can be delivered to its
pharmacological action site and increase therapeutic efficiency.
A good drug carrier for a drug release system must have large drug loading efficiency, good
biocompatibility, uniform size, and high stability. In recent years, many drug carriers have been
developed [3]. Examples include liposomes [4], polymers [5], micelle [6], magnetic nanoparticles [7]
and quantum dots [8]. Almost all nanoparticles are limited by instability and insufficient drug loading
or toxicity and cannot be widely used. Mesoporous silica nanoparticles (MSN) as the carrier of the
drug delivery system could overcome the previous disadvantage because: their high specific surface
area allows MSN to modify more molecules on the surface [9]. Large and tunable pore volume can
load more drug molecules [10], it has good biocompatibility, can be biodegraded and does not easily
accumulate in the body [11]. The overall structure is composed of silica and Si-OH groups, which can
provide a good environment to load and protect drugs and create many chemical surface modifications.
Most of the nanoparticle-based drug delivery systems enter the tumor tissue via the enhanced
permeability and retention effect (EPR effect) [12], a postulate that nanoparticles, as well as molecules
of certain size, are prone to accumulate in tumor tissue more than in normal tissue. To further enable
nanoparticles to be effectively endocytosed by tumor cells, scientists will modify the active target on
the surface of the nanoparticle [13,14]. Active targets are usually molecules that bind to receptors that
are overexpressed on the surface of tumor cells compared to normal cells so that the nanoparticles can
recognize the difference between normal cells and tumor cells.
However, successful entry of the nanoparticles through the cell membrane does not guarantee
that the drug can be smoothly delivered to the desired pharmacological site. The drug carriers may be
re-extracted out of a cancer cell via exocytosis, resulting in the insufficient concentration of the drug
in the cell and reducing the cytotoxic effect. To solve this problem, scientists have simultaneously
modified the cell membrane target and its drug-acting organelle target on the surface of the drug
carrier. After the drug carrier enters the cell by endocytosis, the organelle target can lead the drug
carrier to its targeting organelle [15].
Hyaluronic acid (HA) is the target selected for this experiment, and it is one of the main components
of the extracellular matrix, which plays an important role in cell proliferation and migration [16].
Because cancer need to perform a large amount of proliferation and migration, hyaluronic acid receptors
(CD44 receptor) are expressed to an excessive degree on the cancer cell surface [17], and the drug
carrier can enter the cell by endocytosis through the binding of HA and CD44 receptor.
The nucleus is an important storage space for genetic material and plays an important role in the
processes of cell metabolism, growth, and differentiation. Some anticancer drugs such as doxorubicin
(DOX) or camptothecin (CPT) [18] induce cell apoptosis through drug entry into the nucleus, so it is
very important to ensure that the drugs can enter the nucleus. For the drug carrier to pass through the
nuclear membrane, it is necessary to interact with the nuclear pore complexes (NPC) on the nuclear
membrane through a protein target which contains a nuclear localization signal (NLS) to allow the
carrier to enter the nucleus [19]. TAT peptides [20], like other nuclear targets, such as dexamethasone
(DEX) [21], are common nuclear targets. In this study, besides modifying HA, we will further modify
the NLS contained TAT peptide, which can transport the drug carrier to the nucleus for drug release.
In addition to carrying the drug to the pharmacological site through the target on the surface
of the drug carrier, we must have a gatekeeper to keep the drug in the drug carrier pore so that
the drug does not release prematurely. Controlled release systems are mainly divided into external
stimuli response and intrinsic stimuli response. External stimuli response is to make the gatekeeper
decompose or structurally change by light or magnetic stimulation and then release the drug [22].
The intrinsic response is to use the difference between the internal and external environment of the
cell, such as the change in pH or the difference in enzyme concentration, the gatekeeper can break
down and release the drug after entering the cell due to environmental changes [23–25]. In this study,
HA is not only used as an active target but also as a gatekeeper because of its polymer properties.
Hyaluronidase (HAase) is an enzyme that catalyzes the hydrolysis of HA. There are six types of HAase
2
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in the human body [26], of which type I and type II are the primary enzymes that hydrolyze HA in
the majority of tissues. Type II is mainly linked to the CD44 receptor and is responsible for cleaving
the HA of the polymer, then further hydrolyzing the HA into the cell via endocytosis by type II [27].
Studies have shown that cancer cells use hyaluronidase to hydrolysis hyaluronic acid into smaller
molecular fragments and elicit significant angiogenic effect [28]. When the drug carrier enters the
cancer tissue and penetrates into the cell through endocytosis, the gatekeeper collapses due to the
action of HAase, thereby achieving the purpose of releasing the drug into the cell [18].
According to previous laboratory research [29], two kinds of lanthanide metals with fluorescence [30]
and magnetic imaging [31] functions, Eu3+ and Gd3+, are added to the synthetic process of MSN.
The nuclear penetrating peptide (TAT peptide (sequence: YGRKKRRQRRR)) as a nuclear target was
attached to the surface of MSN, then the anti-cancer drug (CPT) was loaded into the pore. Finally,
the hyaluronic acid (HA) is used to attach to the surface of MSN as cell membrane target and gatekeeper.
When the nanoparticles enter the cancer cells, the HA is decomposed by the HAase in the lysosome,
and the nuclear target TAT is exposed, introduced nanoparticle into the nucleus for drug release. The study
combines three functions of dual imaging with a controlled release switch and dual targeted treatment so
that the material can simultaneously manifest the controlled release effect and increase the accumulation
of drugs within cancer tissues. Finally, the imaging function is used to track the lesion location in clinical
application (Scheme 1).
 
Scheme 1. MSN-EuGd@CPT-TAT-HA enters the cell membrane by binding to CD44 receptor on tumor
cells. Then, after the HA (Hyaluronic acid) is hydrolyzed by the HAase (Hyaluronidase) between
the cell membrane and the endosome and caused the proton sponge effect [32] to escape endosome,
the exposed TAT peptide on MSN (mesoporous silica nanoparticles) is used to deliver the MSN to the
nucleus for drug release.
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2. Materials and Methods
2.1. Materials
Tetraethyl orthosilicate (TEOS), hexadecyltrimethylammonium bromide (CTAB), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC), N-hydroxysuccinimide (NHS), hyaluronic acid sodium
salt from Streptococcus equi (HA, mol wt: ~1.5–1.8 × 106 Da), (3-aminopropyl) triethoxysilane (APTES),
hyaluronidase from bovine test: Type I-S (HAase), camptothecin (CPT), and thiazolyl blue tetrazolium
bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MI, USA). Sodium hydroxide (NaOH),
toluene, and dimethyl sulfoxide (DMSO) were purchased from J.T.Baker and the N-acetyl TAT peptide
(YGRKKRRQRRR) was synthesized by @GenMark company (Carlsbad, CA, USA). Minimum essential
media (MEM), F-12K (Kaighn’s) medium, fetal bovine serum (FBS), and antibiotic-antimycotic (AA)
were purchased from Gibco (Waltham, MA, USA).
2.2. Synthesis of Eu(NO3)3 and Gd(NO3)3
Here, 4.40 g and 4.53 g of Eu2O3 and Gd2O3 were mixed with 4.89 mL and 5.03 mL of 16 M HNO3,
respectively, and then hydrothermally heated at 180 ◦C for 24 h, after which the mixed mixture was
added to the D.I. water to obtain 50 mL of 0.5 M Eu(NO3)3 and Gd(NO3)3.
2.3. Synthesis of MSN-EuGd-NH2
Ninety-seven milliliters of deionized water was added into 1.4 mL of 1 M NaOH and 0.2 g of
surfactant CTAB. After stirring at 80 ◦C for one hour, 1 mL of TEOS and 3 mL of 0.5 M Eu(NO3)3,
Gd(NO3)3 were added dropwise and stirred for two hours. The substances were washed with water,
ethanol, and methanol and then calcinated at 650 ◦C for six hours to generate MSN-EuGd. Next, 0.1 g
of MSN-EuGd was added to 15 mL of toluene and 0.2 mL of APTES, and it was stirred at 120 ◦C for
four hours, centrifuged, and washed twice with alcohol to obtain MSN-EuGd-NH2.
2.4. MSN-EuGd-NH2 loaded into CPT (MSN-EGd-NH2@CPT)
10 mg of CPT was dissolved in 5 mL of dimethyl sulfoxide (DMSO), and 50 mg of MSN-EuGd-NH2
was added and mixed with ultrasonic waves for one hour. It was then stirred for 24 h, centrifuged
three times and wash with deionized water to remove the most of solvent, then dried under vacuum
for 48 h.
2.5. Synthesis of MSN-EuGd-TAT (or MSN-EuGd@CPT-TAT)
10 mg of N-acetylated TAT peptide was dissolved in 10 mL phosphate-buffered saline (PBS) (0.2 M,
pH 7.4), and then, 9.6 mg EDC and 5.8 mg NHS were added at room temperature for half an hour. Next,
40 mL PBS (0.2 M, 80 mg of MSN-EuGd-NH2 (or MSN-EuGd-NH2@CPT) at pH 7.4) was dissolved,
stirred for 12 h, centrifuged to remove the supernatant and lyophilized.
2.6. Synthesis of MSN-EuGd-TAT-HA (or MSN-EuGd@CPT-TAT-HA)
10 mg of MSN-EuGd-TAT (or MSN-EuGd@CPT-TAT) were dissolved in 4 mL MES solution
(0.01 M, pH 5.5), 10 mg HA, 10 mg EDC and 10 mg NHS were added. After stirring at room temperature
for 12 h, the supernatant liquid was removed by centrifugation and lyophilized.
2.7. Characterization
X-ray powder diffraction (XRD) was performed using a Bruker D2 Phase instrument. Particle
size and zeta potential analyses were performed using dynamic light scattering (Malvern Zetasizer
Nano ZS system, Malvern, Worcestershire, UK). Transmission electron microscopy images and energy
dispersive X-ray (EDX) spectra were taken using a Tecnai F30 instrument. The analysis of nitrogen
adsorption isotherms was performed using a Barrett–Joyner–Halenda (BJH) analysis (ASAP 2020,
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Micromeritics, Norcross, GA, USA). The surface area and pore size distribution curves of the undoped
or various-doped mesoporous silica nanoparticles were determined by the Brunauer–Emmett–Teller
(BET) method. The Fourier transform infrared (FTIR) spectra of the functionalized MSNs were recorded
by using a BRUKER TENSOR Series II Spectrometer (Billerica, MA, USA). The luminescence excitation
spectra were recorded using a Jasco FP-6300 photoluminescence spectrophotometer (Easton, MD, USA)
with an excitation wavelength of 394 nm. The thermal gravimetric analysis (TGA) curves were
obtained using a Netzsch TG 209 F3 apparatus to determine the conjugation efficiency of the TAT
and HA when the temperature was increased to 800 ◦C. The drug release curve of the camptothecin
was analyzed using an Enzyme-Linked Immunosorbent Assay (ELISA) reader (BioTek Synergy Mx,
Winooski, VT, USA) at 430 nm. The T1-weighted magnetic resonance (MR) imaging was performed
using conventional spin-echo acquisition (TR/TE = 300 ms/10.6 ms, slice thickness = 2.00 mm) using
a 7 T scanner (BRUKER S300 BIOSPEC/MEDSPEC MRI, Karlsruhe, Germany). The concentrations of
Eu3+ and Gd3+ ions that were doped into the MSNs were measured by inductively coupled plasma
AES spectrometry (ICP-MS, Santa Clara, CA, USA) and reported as mass percentages.
2.8. Drug Release
10 mg of MSN-EuGd@CPT-HA was first stirred with 150 U/mL of 3 mL of HAase/PBS aqueous
solution for 12 h, then the supernatant was removed by centrifugation and dried under vacuum.
Next, the HAase-treated MSN-EuGd@CPT-HA and the HAase-untreated MSN@CPT-HA were
compressed into bracts, placed in 3 mL of DMSO and shaken evenly, and 100 μL of the supernatant
was aspirated into the 96-well disk at 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, 180, 210, 240, 270, 300, 360,
420, and 480 min. The ELISA reader then measured the optical density (OD) value at 430 nm, and the
total drug release amount was calculated according to the concentration calibration curve of the OD
value of 430 nm previously read by ELISA.
2.9. In Vitro Experiments
2.9.1. Cell Culture
L929 (Mus musculus fibroblast cell line) was cultured in minimum essential medium (MEM)
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics (AA) at 37 ◦C in an environment
containing 5% CO2, A549 (adenocarcinomic human alveolar basal epithelial cells) was cultured in F-12K
supplemented with 10% FBS and 1% antibiotics (AA) at 37 ◦C in an environment containing 5% CO2.
2.9.2. Cell Viability Assay
Normal cell model L929 and cancer cell model A549 were selected as test cells in this experiment.
The procedures were as follows:
First, we seed 10,000 cells/well of cells in a 96-well culture dish and incubate the cell for 24 h
in a 37 ◦C cell culture incubator. Then we add 25/50/100/200 μg/mL of drug carrier/culture solution
in each well respectively. Next, after co-culture with the drug carrier for 24 h, 20 μL of MTT was
added into the wells for four hours’ reaction. Finally, after the reaction, we add 100 μL of DMSO into
each well and shake the dish for 15 min to induce its color. By reading the OD value at 540 nm with
an enzyme immunoassay analyzer (ELISA reader, Winooski, VT, USA), the ability of cells reducing
MTT can be known and can be used as an indicator of cell viability. The cell viability is calculated by
the following formula:
Cell viability = OD540 (test group)/OD540 (control group) × 100%
2.9.3. Confocal Image Analysis
The sterilized 13 mm glass coverslip was placed in a 24-well plate. Then, 2 × 104 cells were seeded
in each well, cultured for 24 h (5% CO2, 37 ◦C), and then cultured with a 500 μL (100 μg/mL) mixture of
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the drug carrier and the culture solution for six hours. After the completion of the culture, the culture
medium was washed with PBS, and then 300 μL of a 3.7% formaldehyde/PBS solution was added for
10 min to fix the current state of the cells. After the end of the reaction time, the cells were washed with
PBS, and then 4′,6-diamidino-2-phenylindole (DAPI) was used to stain the nuclei for five minutes.
After washing with PBS, the coverslips were mounted onto a glass slide, and the cells were visualized
and observed under a confocal laser-scanning microscope (CLSM, SP5, Leica, Wetzlar, Germany).
3. Results and Discussion
3.1. Structure, Formation, Morphology, and Properties of MSNs and EuGd-MSNs
Figure 1a shows the results of the low-angle XRD pattern. Both MSN and MSN-EuGd have
characteristic peaks at (100) (110) (200), indicating that they are in the form of MCM-41 with regular
hexagonal pore structure [33]. It can be seen that the structure of MSN-EuGd is similar to that of
MSN, and MSN-EuGd does not cause a large change in structure due to the doping of Eu and Gd,
its structural arrangement is similar to MSN. The MSN d-spacing was calculated by XRD pattern to be
3.68 nm, and the MSN-EuGd d100-spacing was 3.99 nm (Table 1). These results indicate that the MSN
pore structure will change through the doping of metal ions, but this does not affect the main structure
of MSN. The experiment uses BET analysis of MSN and MSN-EuGd. From Figure 1b nitrogen constant
temperature adsorption and the pore size distribution pattern, it can be seen that the curve is of type IV
and that all structures have a mesoporous structure as determined by hysteresis loop. MSN properties
can be known by BET model calculation. The pore diameter of MSN-EuGd is 2.75 nm (Figure S1).
After analysis, the specific surface area of MSN-EuGd is 608.19 m2/g, it is much larger than non-porous
silica nanoparticle compared with the previous research [34], and the pore volume is 0.93 cm3/g
(Table 1). The structure and size can be observed by TEM analysis. MSN has a regular hexagonal
hole structure, and each particle has a uniform size. From Figure 1c–d, the hole size is approximately
2~3 nm as determined by XRD and BET. The measured data is consistent, and the particle size is
approximately 120 nm. All of these geometric parameters are summarized in Table S1. The DLS can
transmit the laser light through the solution containing the nanoparticles, and the receiver receives the
light and is affected by the particles to generate a scattering signal to calculate the hydration radius
of the particles. It can be seen from Table 1 that the size of MSN-EuGd is 271 nm, and the size of
the organic molecule can be changed as it is grafted onto the material. The surface charge of the
nanoparticles is also measured. Confirming that each molecule connected to MSN-EuGd: The surface
charge of MSN-EuGd is −14.5 mV, and the potential rises to −10 mV due to its positive charge when
connected to -NH2 [35]. After the TAT peptide was attached, the potential was raised to 4.08 because
the TAT peptide itself was positively charged [36]. Regarding HA attachment, the potential reached
−17.3 because the HA itself was rich in negatively charged -COOH [37].
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Figure 1. (a) Small-angle X-ray powder diffraction (XRD) analysis of mesoporous silica nanoparticles
(MSN) and MSN-EuGd, (b) isothermal nitrogen adsorption of MSN and MSN-EuGd, (c,d) analysis of
MSN structure and size using transmission electron microscopy (TEM). Scale bar: (c) 20 nm, (d) 0.5 μm.
Table 1. Properties analysis of mesoporous silica nanoparticles (MSNs) and MSN-EuGd.
Physical Data MSN MSN-EuGd
Brunauer–Emmett–Teller (BET) Surface Area (m2/g) 947.57 608.19
Pore Volume (cm3/g) 0.77 0.93
Barrett–Joyner–Halenda (BJH) Desorption Diameter (nm) 2.29 2.75
X-ray diffraction (XRD) 2θ (◦) 2.40 2.21
d100-spacing (nm) 3.68 3.99
Wall thickness (nm) 1.95 1.86
Mean particle diameters (nm) 197 271
The EDX can be used to determine the elements contained in the material. From Figure S2, it can
be found that elements such as silicon, oxygen, europium, and gadolinium are detected in MSN-EuGd,
while MSN is only silicon (Si), oxygen (O), and then further quantified by inductively coupled plasma
mass spectrometry (ICP-MS) to obtain Eu and Gd contents of 4.91% and 4.82%, respectively, as shown
in Table S2.
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The MSN-EuGd measurement by PL found that: if 394 nm is used as the excitation wavelength,
it will produce radiation absorption peaks at 590 nm and 615 nm, primarily from the red light emission
peak of Eu3+ from 5D0→7F1 (590 nm) and 5D0→7F2 (614 nm) after receiving excitation light [38].
If a radiation wavelength of 615 nm is used, an absorption peak is observed at 394 nm as shown in
Figure 2a, and Eu3+ is indeed dopeddop into MSN. In addition, if the material is irradiated with 254 nm
UV light, MSN-EuGd will emit red excitation light, as shown in Figure S3. We used IVIS to illuminate
MSN-EuGd at 430 nm excitation wavelength. From Figure 2b, MSN and blank were observed to
have no obvious fluorescence characteristics, while MSN-EuGd showed very obvious fluorescence
excitation, confirming that IVIS can effectively detect materials. The nature of the fluorescent light also
confirms that the MSN-EuGd can use the IVIS system as an imaging tracking function.
For the magnetic properties of the material, we synthesized MSN-EuGd with different ratios of
lanthanides and measured the results with a superconducting quantum interference device. It was
found that the undoped Gd3+ material showed no magnetic properties, but MSN-EuGd doped with
Gd3+ exhibits a paramagnetic phenomenon. As the concentration of Gd3+ escalates, the paramagnetic
property is more pronounced, confirming that the material is paramagnetic (Figure 2c) [39]. MSN-EuGd
can also be applied to MR imaging to perform in vitro MRI testing. The parameters are set in a magnetic
field of 7 T, setting the parameter value TR/TE = 300 ms, FOV = 7 cm, NEX = 1, slice thickness = 2.00,
matrix = 256 × 256, and material concentration from 4 to 0.25 mg/mL3. From Figure 2d, it can be
seen that the T1-weighted image appears increasingly bright as the material concentration increases,
confirming that MSN-EuGd can be used as the T1 positive development image [40].
 
Figure 2. (a) PLE and PL results showing emission spectra of the MSN-EuGd. (b) IVIS optical imaging
of Blank, MSN, and MSN-EuGd. (c) The magnetization curves of MSN-EuGd. (d) T1-weighted MRI
of MSN-EuGd.
To confirm whether the organic molecule was successfully attached to MSN-EuGd, we can use
the FTIR to analyze the functional groups on the material (Figure S4). The -OH group was observed
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at 3400 cm−1 and 2931 cm−1, and the Si-O-Si signal [41] at 1068 cm−1 and 953 cm−1. When the -NH2
was modified, it was found that an additional N-H bond peak [42] on the amine group at 1552 cm−1
confirmed that the amino group was successfully attached to MSN-EuGd. Then, when TAT was
modified, it was observed that 1415 cm−1 and 1715 cm−1, respectively, represent the C-O-H stretching
vibration of the amide bond and the stretching vibration of C = O, which proved that TAT was
successfully connected to MSN-EuGd. MSN-EuGd-TAT-HA showed an additional peak at 1409 cm−1,
representing the asymmetric stretching vibration of the -COOH group of HA [43]. The amount of
MSN-EuGd modified by organic molecules and its drug loading were determined by TGA analysis.
In this experiment, the temperature of each material is increased to 800 degrees from 40 degrees Celsius
in the environment of pure oxygen, and the mass loss percentage of each material is observed. Finally,
the amount of each molecule connected to MSN-EuGd is converted into Table S3. The modification
amount of -NH2, -TAT and HA is approximately 129.17 mg/g, 26.27 mg/g, and 65.53 mg/g, respectively.
The loading amount of CPT is 15.22 mg/g.
To confirm that MSN-EuGd@CPT-TAT-HA can be utilized for drug release, we first reacted
MSN-EuGd@CPT-HA with 150 U/mL HAase for 12 h, then centrifuged to remove the supernatant
liquid and added the residual material into DMSO for drug release test. As a result, it was found that
the amount of MSN@CPT-HA that was not treated with HAase was approximately 44.86%, and the
material treated with HAase was approximately 83.57% at eight hours. It can be seen that the design of
this experiment can achieve the purpose of drug-controlled release, as shown in Figure 3.
Figure 3. Drug release of MSN-EuGd@CPT-HA and HAase-treated MSN-EuGd@CPT-HA in Dimethyl
sulfoxide (DMSO).
3.2. In Vitro Cytotoxicity and Cellular Uptake of Functionalized MSN-EuGd
To confirm the phagocytosis between cells for each material, mouse fibroblasts (L929) were
compared with human lung adenocarcinoma cells (A549) as a CD44 receptor control group, and CLSM
images were taken after six hours of coculture with each material. As shown in Figure 4, the bare
MSN-EuGd is barely phagocytized by L929 cells and A549 cells, while the MSN-EuGd-TAT
demonstrates a slight overlap of the material signal (red) and the nuclear signal (blue). It is
speculated that MSN-EuGd-TAT can successfully enter the nucleus by TAT after being phagocytized.
The MSN-EuGd-HA also exhibited that A549 cells contained more phagocytic material than did L929
9
Cancers 2019, 11, 697
cells. It is speculated that the overexpressed CD44 receptor on A549 cells enables MSN-EuGd-HA to be
introduced into the cells by receptor-mediated endocytosis of A549 cells. The MSN-EuGd-TAT-HA can
be found to be similar to MSN-EuGd-HA, but it can be observed that the signal of MSN-EuGd-TAT-HA
overlaps with the nuclear signal of A549 cells. The material is successfully predicted by cell membrane
target (HA), and nuclear target (TAT) enter the nucleus of cancer cells.
 
Figure 4. Confocal Laser Scanning Microscope (CLSM) image of MSN-EuGd, MSN-EuGd-TAT,
MSN-EuGd-HA, and MSN-EuGd-TAT-HA incubated with L929 cell line and A549 cell line for six hours.
Blue: 4′,6-diamidino-2-phenylindole (DAPI), red: MSN-EuGd, scale bar: 20 μm.
Cell viability tests confirm that the material is cytotoxic to cancer cells and less harmful to normal
cells. As shown in Figures 5 and 6. In order to avoid possible cytotoxic interference caused by excessive
uptake of MSNs by the cells, therefore, referred to the results of Chou et al. in 2017 and we choose
the concentration of 200 μg/mL as the highest dose [44]. The results obtained were that L929 and
A549 cells had a cell viability of more than 80% when using a drug carrier without a loading drug,
indicating that the material itself is not cytotoxic to the cells. However, it was observed in the A549
group that MSN-EuGd@CPT-TAT was slightly more toxic to cells than MSN-EuGd, and the reason
was that MSN-EuGd@CPT-TAT was introduced into the nucleus after entering the cells. Different
concentrations of MSN-EuGd@CPT-HA showed that MSN-EuGd@CPT-HA had a better cytotoxic effect
on A549 compared with A549 and L929. It is speculated that the binding of the CD44 receptor on the
HA and A549 cells causes the cells to increase drug phagocytosis. Finally, MSN-EuGd@CPT-TAT-HA
exhibits better cytotoxic effects against A549 than does MSN-EuGd@CPT-HA. This is primarily because
MSN-EuGd@CPT-TAT-HA enters the cancer tissue and then carries the drug into the cell and onward
to the nucleus via cell membrane and nucleus targeting, thus furthering cytotoxicity.
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Figure 5. MTT assays for MSN-EuGd, MSN-EuGd@CPT, MSN-EuGd@CPT-TAT, MSN-EuGd@CPT-HA,
and MSN-EuGd-TAT-HA using L929 and A549 cells.
 
Figure 6. Comparison of cell viability between L929 cells and A549 cells at various concentrations of
MSN-EuGd@CPT-TAT-HA, ** p < 0.01.
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4. Conclusions
This study demonstrates the successful synthesis of a novel drug delivery system (MSN-
EuGd@CPT-TAT-HA) that possesses dual development and dual targets and controls the release of
drugs into the nucleus. The system is used to overcome the side effects of chemotherapy and multiple
drug resistance problems.
The experiment used MSN with Eu and Gd as the carrier and loaded the anticancer drug CPT.
After attaching the nuclear target TAT, it was connected with the HA which functions as both cell
membrane target and gatekeeper. A nanoparticle, MSN-EuGd@CPT-TAT-HA, with dual target and
dual development and HAase as a release switch was synthesized as a drug delivery system. After the
material enters the tumor via the cell membrane target HA, HA is decomposed by HAase in the cytosol
to expose the nuclear target TAT on the surface of MSN-EuGd, and the remaining particle enters the
nucleus by TAT to release the drug.
The material confirms that doped lanthanides Eu and Gd through the PL and SQUID provided
the material with a fluorescent imaging and magnetic imaging function. It is also confirmed from the
IVIS and MRI images that the cancer tissue distribution can be tracked in vitro. The drug release test
also confirmed the sealing ability of HA and the release of the drug by HAase decomposition of HA.
It was confirmed from the CLSM image that the MSN-EuGd was attached to the cell membrane
target HA and the nuclear target TAT. The material can be introduced into the cell by endocytosis
via the expression receptor and then onward into the nucleus. The cell viability test showed that
MSN-EuGd alone demonstrated excellent cytocompatibility. When the material is loaded with the
drug, it can also obtain better cancer cell cytotoxic effects with the cell membrane target HA and the
nuclear target TAT attached to MSN-EuGd. Hopefully, this intelligent drug carrier can successfully
become a potential therapeutic material for cancer.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/5/697/s1,
Table S1: Hydrodynamic size and zeta potential for MSN-EuGd and functionalized MSN-EuGd, Table S2:
ICP-MS analyze of MSN and MSN-EuGd, Table S3: TGA for the MSN-EuGd@CPT-TAT-PEG-FA, Figure S1:
BJH pore size distribution of MSN and MSN-EuGd, Figure S2: EDX spectral analyses of the (a) MSN and (b)
MSN-EuGd, Figure S3: MSN and MSN-EuGd powder taken under illumination by a 254 nm UV lamp, Figure S4:
FTIR spectrum of MSN-EuGd and functionized MSN-EuGd, Figure S5: TGA patterns for the MSN-EuGd and
functionized MSN-EuGd.
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Abstract: Image-guided intra-arterial therapies play a key role in the management of hepatic
malignancies. However, limited clinical outcomes suggest the need for new multifunctional drug
delivery systems to enhance local drug concentration while reducing systemic adverse reactions.
Therefore, we developed the albumin-doxorubicin nanoparticle conjugated microbubble (ADMB) to
enhance therapeutic efficiency by sonoporation under exposure to ultrasound. ADMB demonstrated
a size distribution of 2.33 ± 1.34 μm and a doxorubicin loading efficiency of 82.7%. The echogenicity
of ADMBs was sufficiently generated in the 2–9 MHz frequency range and cavitation depended on
the strength of the irradiating ultrasound. In the VX2 rabbit tumor model, ADMB enhanced the
therapeutic efficiency under ultrasound exposure, compared to free doxorubicin. The intra-arterial
administration of ADMBs sufficiently reduced tumor growth by five times, compared to the control
group. Changes in the ADC values and viable tumor fraction supported the fact that the antitumor
effect of ADMBs were enhanced by evidence of necrosis ratio (over 70%) and survival tumor cell
fraction (20%). Liver toxicity was comparable to that of conventional therapies. In conclusion,
this study shows that tumor suppression can be sufficiently maximized by combining ultrasound
exposure with intra-arterial ADMB administration.
Keywords: albumin nanoparticles; microbubble; ultrasound; theranostics; hepatocellular carcinoma;
VX2 tumor; intra-arterial chemotherapy
1. Introduction
Image-guided intra-arterial (IA) therapies, such as hepatic arterial infusion chemotherapy (HAIC)
or trans-arterial chemoembolization (TACE) are frequently used for the treatment of primary or
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secondary liver cancers [1–6]. HAIC involves the local and targeted delivery of high concentrations of
chemotherapeutic drugs directly to the tumor, whereas TACE, with or without drug-eluting beads,
combines local and targeted drug delivery with concurrent tumor-feeding artery embolization. The
theory behind this treatment recommends delivering the maximal dose of the chemotherapeutic
agent to the target tissue while minimizing systemic toxicity. However, clinical response is still
unsatisfactory, as local tumor control rates achieved following TACE is only 15–60%, and increases
median survival without treatment from 16 months to 20 months [7,8]. One possible reason for these
poor results is perhaps the limited delivery of the drug to the target tumor [9–11]. Changes in tumor
microenvironment including decreased pH, hypoxia, and abnormal vascularity impede drug delivery
to the target. Moreover, local tumor recurrences at the periphery of the treated area are common
and are often a cause for treatment failures [12]. Another limitation in clinical field is side effects.
Concentrations of drugs in the bloodstream are increased even though drugs are administered via
IA injection. Therefore, a decrease of the drug concentration in the bloodstream is also necessary
to reduce the side effects caused by target delivery of drugs. The simultaneous monitoring of drug
delivery is an unmet clinical need for enhancing tumor control. Thus, novel drug delivery carriers for
IA chemotherapy are mandatory for better drug delivery and to allow multimodal imaging which
enables the carriers to be simultaneously visualized with various imaging modalities.
In the last decade, studies have used ultrasound as an external trigger for enhancing local drug
penetration through artificial pore formation in the cell membrane. This phenomenon is known
as the sonoporation effect [13,14]. Theoretically, sonoporation is based on the cavitation between
ultrasound and microbubbles. Microbubbles are made to repetitively expand and shrink under
ultrasound irradiation. This behavior of microbubbles induces a microstream in the blood vessel
and continually puts the cellular membrane under stress (stable cavitation). The microbubbles
upon extreme oscillations finally explode at the critical elastic point under the strong ultrasound
intensity. At the moment of microbubble explosion, microjets and shock waves are generated and
temporally drill the cell membrane near the microbubble with pores of 100–300 nm in size (inertial
cavitation) [15]. This cavitation approach is utilized for enhancing local drug delivery to the target
site and for improving the intracellular uptake of large molecules and non-permeable drugs. Several
groups have shown that sonoporation can enhance the therapeutic efficiency of chemotherapy and
gene therapy [16,17]. These researches successfully demonstrated that microbubble-encapsulated
drugs induce the well-penetration to target site and functionalization for therapeutic effect. However,
the use of microbubbles as drug carriers has been limited since a small portion of drug encapsulation
is possible structurally, and the undesirable release of drugs by degradation in the blood stream. To
overcome these limitations, nanoparticles are studied for increasing drug loading and protection. In
our previous study, human serum albumin nanoparticles (HSA-NPs) were effectively delivered to
the tumor site by sonoporation [18,19]. Microbubble-conjugated anticancer drug-loaded HSA-NPs
enhanced the selective delivery of drugs to the tumor and led to the improvement of therapeutic
efficiency, compared to the administration of pure drugs and administration without ultrasound
irradiation. Nanoparticle-based drug delivery has been advantageous for improving drug loading
efficiency, protection of drugs from degradation, and intracellular penetration via characteristics of the
nanoparticles which allow a sustained drug release. These advantages have progressed tumor-selective
delivery and functional release of the drug to the target site. However, the systemic circulation of all
agents including nanoparticles is biologically limited for clearance by accumulation in the liver or
kidney rather than in the tumor region [20]. Therefore, the therapeutic efficiency is not maximized
for tumor treatment owing to drug cleavage. Thus, some of microbubble during the circulation
are ruptured by diffusion of gas in the core part. Sequentially, the sonoporation effect should be
decreased at the tumor site, compared to direct administration such as IA injection. Therefore, a more
effective administration route for maximizing therapeutic efficiency would be tumor vessels rather
than the systemic circulation. Unfortunately, there are few or no studies that compare the therapeutic
efficiency of systemic administration to that of specific administration routes, which is a surgical
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procedure performed at present on humans in the clinic. In the case of hepatocellular carcinoma,
the IA administration of drugs using microcatheters has been intensively applied in clinical practice,
for the local administration of anticancer drugs and chemotherapeutic embolic agents [1,3,4]. The
purpose of our study was to explore the antitumor effect of ADMBs combined with ultrasound-targeted
microbubble activation (ADMB/US) in rabbit VX2 liver tumor model. (Figure 1A) and to compare
antitumor effect via IA administration to IV administration. (Figure 1B).
Figure 1. Schematic illustrations of (A) the ADMB complex and (B) treatment procedure for the
intra-arterial administration of the ADMB complex using microcatheters under ultrasound exposure.
2. Results
2.1. Preparation of the ADMB Complex
For the enhancement of therapeutic effect by sonoporation phenomenon, ADMB
complex was developed by self-assembled microbubble and albumin-doxorubicin nanoparticles.
Albumin-doxorubicin nanoparticles were fabricated by the dropwise addition of ethanol to albumin.
A size distribution of albumin-doxorubicin nanoparticles of 205.5 ± 45.3 nm. (PDI; 0.172) was
demonstrated. Transmission electron microscope images of the albumin-doxorubicin nanoparticles
demonstrated a uniform and spherical morphology (Figure 2A). The loading efficiency of doxorubicin
into the albumin-doxorubicin nanoparticles was 82.7%. The doxorubicin was released in a sustained
manner from the albumin-doxorubicin nanoparticles at an in vitro release rate of 24.2% for 50 h with
the initial burst. Thus, albumin-doxorubicin nanoparticles demonstrated a similar release profile as
doxorubicin in cell culture medium containing 10% fetal bovine serum and 1% antibiotics (25.2%). The
size distribution of albumin-doxorubicin nanoparticles in cell culture medium (158.23 ± 42.9 nm; PDI:
0.155) demonstrated a similar size distribution to albumin-doxorubicin nanoparticles in PBS (Figure S2).
According to these results, albumin-doxorubicin nanoparticles are sufficiently stable against serum
proteins. However, compared to the in vitro release profile of doxorubicin in PBS and cell culture
medium, doxorubicin was more rapidly released from the albumin-doxorubicin nanoparticles at pH 4.7.
41.5 % of doxorubicin was released at pH 4.7 for 50 h. Regarding to this result, doxorubicin was
electrostatically bound to albumin and was pH-dependently released (Figure 2B).
The phospholipid-based microbubbles were filled with a SF6 gas core and had size distributions of
1.73 ± 0.34 μm (PDI: 0.297). The albumin-doxorubicin nanoparticles were conjugated onto the surface
of the microbubbles and the subsequent size distribution was 2.33 ± 1.34 μm (PDI: 0.395). Following
albumin-doxorubicin nanoparticle conjugation, the size distribution of the ADMB complex was slightly
larger in comparison to that of the free microbubbles. To increase doxorubicin loading efficiency by
raising conjugation ratio of albumin-doxorubicin nanoparticles to microbubbles, albumin-doxorubicin
nanoparticles (2 mg of doxorubicin loaded nanoparticle) were conjugated to microbubbles so that
the number of microbubbles was 1 × 109. However, the ADMBs were aggregated heterogeneously
(Figure S3) Aggressive aggregates of ADMBs were observed by optical microscopy images and the size
distribution was incorrectly defined by DLS. This aggregation was induced by numerous reactions
between both amine groups on the albumin-doxorubicin nanoparticles and N-hydroxysuccinimide
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on the microbubble surface. Hence, ADMBs were optimized with a ratio of 1 mg of doxorubicin in
albumin-doxorubicin nanoparticles to 1 × 109 microbubbles. In optimized ADMBs, the conjugation of
the albumin-doxorubicin nanoparticles to the microbubbles was confirmed by fluorescence emission
from the doxorubicin conjugated onto the surface of microbubble without ADMB aggregates (Figure 2C).
Figure 2. Characteristics of the albumin-doxorubicin nanoparticle and the ADMB complex (A) size
distribution and TEM image (inset image, scale bar:100 nm) of the albumin-doxorubicin nanoparticle.
(B) In vitro release of doxorubicin from albumin-doxorubicin nanoparticles at pH 7.4, pH 4.7 and
DMEM containing 10% of fetal bovine serum and 1% of antibiotics. (C) size distribution of free MB
(gray) and ADMB (red). Merged fluorescence and optical images (inset image, scale bar: 20 μm).
2.2. Phantom Study for Echogenicity of ADMB Complex
To investigate if the ADMB complex was capable of resonance to ultrasound irradiation for the
cavitation effect, the echogenicity was evaluated by visualization with a clinical ultrasound scanner.
For the ultrasound imaging, 2% of home-made agarose phantom containing 2-holes was used. A
contrast-enhanced ultrasound imaging mode demonstrated echogenicity only from the microbubbles.
At a low MI of 0.06, the ADMB complexes were stably visualized by microbubble oscillations. However,
the echogenicity decreased upon microbubble destruction, depending on the number of manual flashes
(mechanical index: 0.68). Manual flashes strengthen the intensity of ultrasound exposure and lead to
the destruction of the microbubbles. About 100 times of manual flashing decreased the echogenicity of
the microbubbles by about half (55.45%). The echogenicity consistently decreased upon increasing the
number of manual flashes (Figure 3A,B). The differences of echogenicity between the free microbubbles
and the ADMB complexes were also investigated from the ultrasound images in the same frame,
to analyze whether the cavitation effect was altered by conjugation with the doxorubicin-albumin
nanoparticles. The echogenicity of the ADMB complexes did not differ from the free microbubbles.
The percentages of echogenic area of the ADMB complexes and the free microbubbles were 79.6% and
76.5% respectively, in a relatively equal area (Figure 3C, Table S1).
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Figure 3. Contrast-enhanced ultrasound images and relative quantification of ultrasound images.
(A) contrast-enhanced ultrasound images captured at varying numbers of manual flashes. (B) Relative
quantification of ultrasound image. (C) Ultrasound image of the ADMB complex and the
free microbubble.
2.3. Enhancement of Cell Uptake and Cell Viability of ADMBs by Sonoporation Effect
Intracellular uptake and cell viability of ADMB with or without ultrasound exposure were
evaluated to investigate the enhancement of the anticancer effect by the sonoporation phenomenon. For
tracking nanoparticle uptake into the cell, Alexa555 dye was conjugated to the nanoparticles and the
nucleus was stained by DAPI. As shown in Figure 4, albumin nanoparticles were rarely permeable into
the cytoplasm within 3 h without ultrasound exposure. A slight fluorescence intensity was detected
from nanoparticles at 6 and 24 h post-incubation in the group without ultrasound exposure, because
the large size of MBs disturbed the cellular uptake of nanoparticlesr. On the other hands, albumin
nanoparticles rapidly penetrated into the cytoplasm within 3 h with the ultrasound exposure. Thus,
cellular uptake of albumin nanoparticles was continuously increased time-dependently. At 6 and
24 h post-incubation, albumin nanoparticles were effectively located in the cytoplasm. Regarding
these results, the cell viability of ADMBs was evaluated with or without ultrasound exposure. In vitro
cell viability was confirmed using a hepatocellular carcinoma cell line (HepG2). To accurately verify
that the sonoporation effect between microbubbles and ultrasound is non-toxic, we evaluated the cell
viability under various ultrasound exposure conditions with or without microbubbles (Figure S4).
Hence, we analyzed cell viability with 1 W/cm2 of ultrasound strength and 5% duty cycle (Figure 5). At
24 h post-incubation, the cell viability in all groups was demonstrably similar. However, cell viability
was decreased time-dependently after 48 h of incubation. Specifically, ADMBs only demonstrated
enhancement of cell viability under the ultrasound exposure after 72 h (p < 0.05). As microbubbles
resonate with the ultrasound and generated cavitation, albumin-doxorubicin nanoparticles were capable
of penetration through the cell membrane more easily than other treatment groups. The treatment
groups without microbubbles showed similar levels of cytotoxicity regardless of the ultrasound
exposure. In conclusion, cellular uptake and cell viability results demonstrated that ADMBs were
capable of not only generating sonoporation effects by cavitation with ultrasound, but also enhancing
nanoparticle penetration through the pores in cellular membranes, hence the anticancer effect was
enhanced by ADMBs under ultrasound exposure.
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Figure 4. Cellular uptake of albumin nanoparticles after exposure of HepG2 cells to ADMBs. fluorescent
image of albumin nanoparticles (A) under the ultrasound exposure and (B) without ultrasound exposure
at 3, 6 and 24 h, respectively (blue; nucleus, green; albumin nanoparticle). Scale bar: 20 μm.
Figure 5. Cytotoxicity of doxorubicin (free-DOX) albumin-doxorubicin nanoparticle (alb-DOX-NPs)
and ADMBs at (a) 24 h, (b) 48 h and (c) 72 h with (light gray) or without (dark gray) ultrasound
exposure (* p < 0.05).
2.4. Animal Models and Ultrasound Imaging during Treatment Procedure
A total of 25 VX2 liver tumor rabbit models were created. All rabbits having tumors survived
through the tenure of the experiment. The tumors were visualized using ultrasound during the
experiments. A strong enhancement of intra-tumoral vessels was clearly demonstrated from the
beginning of the injection in the IA-ADMBs and IA-free MB groups (Figure 6B,D). Individuals receiving
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IV microbubbles (Figure 6C) showed a moderate tumor parenchymal enhancement accompanied by
enhanced liver parenchyma and liver vessels. Ultrasound images without microbubbles demonstrated
non-enhanced echogenicity (Figure 6A,E) The enhancement of ultrasound echogenicity demonstrated
that the delivery efficiency of ADMB in the groups receiving IA microbubbles was higher than that of
the groups receiving IV microbubbles. Interestingly, echogenicity of the both IA-ADMBs and IA-free
MB demonstrated a similar degree of enhancement. However, the echogenicity enhancement patterns
were slightly different. In the US image of ADMBs, increased echogenicity was noted separately at the
tumor vessels and tumor parenchyma, whereas the echogenicity of the tumor and adjacent liver tissue
in the US image of IA-free MB was enhanced simultaneously. This discrepancy was probably due to
the fact that albumin was capable of binding glycoprotein 60 receptor around liver tumor epithelium
and of enhancing the anti-cancer effect by targeted delivery [21].
Figure 6. Representative ultrasound images of (A) control, (B) intraarterial injection of ADMB
(IAMB/US), (C) intravenous injection of ADMB (IVMB/US), (D) intraarterial injection of microbubble
(IA Free MB/US) and (E) intraarterial doxorubicin (IA Dox/US). Note that strong rim-like enhancement
of intratumoral vessels (arrow) with posterior shadow (arrowhead) in IAMB/US group.
2.5. Antitumor Efficacy of Albumin-Doxorubicin Nanoparticle-MB Complex by Quantitative MR Imaging
and Pathology
The anticancer efficacy of ADMB was evaluated using quantitative MR imaging (Figure 8A).
The measured mean tumor volume at baseline and at 7 days after drug administration, volume
inhibition rate (VIR), and change in ADC values are summarized in Figure 7. There was no
significant difference in tumor size among groups at baseline (p = 0.614). The mean tumor volume
of IA-ADMB.US (2156.57 ± 849.86 mm3) was significantly small compared to that of IV-ADMB/US
(3777.47± 1950.72 mm3). The mean tumor volume of IV-ADMB/US was larger than that of IA-ADMB/US.
And the tumor volume of IA-Dox/US, IA-free MB/US and control were 4811.02 ± 2132.69 mm3,
5770.06 ± 1382.78 mm3, and 6063.97 ± 3432.51 mm3, respectively. Comparison of tumor volume
IA-Dox/US, IA-free MB/US and control was not statistically significant. Among the five groups,
IA-ADMB/US achieved a maximal reduction in tumor volume of 64.44 ± 15.35% on day 7 as indicated
by the MRI (Table 1). Both the IA-ADMB/US and IV-ADMB/US showed an increase in the ADC values
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after treatment by more than 50%, compared to pre-treatment values, which suggested the loss of
diffusion-restrictive lesions such as tumor parenchyma. For group of IA-ADMB/US, the VIR and percent
change in ADC value were significantly higher than others (Figure 7). In addition, the VIR and percent
change in ADC value in IV-ADMB/US tended to be lower than the corresponding values of group
IA-ADMB/US and higher than the corresponding values of IA-Dox/US, IA-free MB/US and control.
However, the results were not statistically significant. The histologically viable tumor percentage was
quantified using a slide-by-slide segmentation of the H&E staining images and TUNEL-stained images
that were generated to investigate the entire section of the whole tumors. The pathological analysis
performed on day 7 showed low viable tumors in IA-ADMB/US (19.60 ± 12.1%, 25.29 ± 14.00% and
33.65 ± 4.09%, 42.48 ± 8.85%, 37.42 ± 5.80% for IA-ADMB/US, IV-ADMB/US, IA- Dox/US, IA-free
MB/US and control, respectively; Figure 8A,B, Figure S5 and Table 2). IA-ADMB/US demonstrated
a significantly higher necrotic fraction and a lower estimated viable tumor volume, compared to
IA- Dox/US, IA-free MB/US and control (Figure 8B,C). Similar to the MR-based analysis, the viable
tumor percentage and the estimated viable tumor volume of IV-ADMB/US tended to be higher than
the corresponding values of IA-ADMB/US and lower than the corresponding values of others; the
difference, however, was not statistically significant.
Figure 7. Quantitative volumetric image analysis at baseline and on day 7 after treatment, in IA
ADMB/US, IV ADMB/US, IA Doxorubicin/US, IA free MB/US, and the untreated control groups.
(A) Change in tumor volumes. (B) The Volume Inhibition Rate (VIR) of each group. (C) Percent
change in ADC values across the experimental period among the groups. Each bar represents mean SD,
* p < 0.05 versus IA Doxorubicin/US, IA free MB/US, and untreated control group.
Table 1. The tumor volume and volume inhibition rate (VIR) of each group.
Group
Tumor Volume (mm3) at
Baseline
Tumor Volume (mm3) at
7 Days after Delivery
VIR (%)
Control 1331.21 ± 481.67 6063.97 ± 3432.51 -
IA-free MB/US 1266.54 ± 527.06 5770.06 ± 1382.78 4.85 ± 22.80
IA-Dox/US 1712.71 ± 431.79 4811.02 ± 2132.69 20.66 ± 35.16
IV-ADMB/US 1245.30 ± 811.94 3777.47 ± 1950.72 34.10 ± 30.09 *
IA-ADMB/US 1313.08 ± 740.77 2156.57 ± 849.86 64.44 ± 15.35 *,**
* p < 0.05 compared with the control group; ** p < 0.05 compared with IA-Dox/US and IA-free MB/US groups.
Table 2. The viable tumor percentage and estimated viable tumor volume of each group.
Group Viable Tumor (%) Estimated Viable Tumor Volume (mm3)
Control 37.42 ± 5.80 2339.55 ± 1433.18
IA-free MB/US 42.48 ± 8.85 2503.82 ± 975.32
IA-Dox/US 33.65 ± 4.09 1526.89 ± 731.75
IV-ADMB/US 25.29 ± 14.00 1130.98 ± 1003.78
IA-ADMB/US 19.60 ± 10.55 *,** 429.0 ± 291.09 *,**
* p < 0.05 compared with the control group. ** p < 0.05 compared with IA Dox/US and IA free MB/US groups.
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Figure 8. Representative MRI and histo-segmentation images of each group, Scale bar: 10 mm (A).
Quantitative analysis of viable tumor fraction (B). Estimated viable tumor volume (C) at day 7 after
treatment. Red area represents the viable portion of tumor; each bar represents mean SEM., * p < 0.05
versus IA doxorubicin/US, IA free MB/US, and untreated control group.
2.6. Biochemical Liver Toxicity Evaluation
All the animals showed a tendency to reach the highest values of AST and ALT enzymes at 24 h
after treatment, which gradually decreased and returned to baseline values at 7 days after treatment.
The AST and ALT values, noted at specific intervals of time starting from baseline to the end of the
observation period, did not differ significantly among the five groups (Figure 9).
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Figure 9. Graphs depicting liver enzyme values (AST and ALT) changes over the observation period for
each treatment group. (A) Graph depicting the plasma concentration changes in aspartate transaminase
(AST) over the 7-day observation period (expressed in mg/dl). (B) Graph depicting the plasma
concentration changes in alanine transaminase (ALT) over the 7-day observation period. No significant
changes in AST and ALT levels at each time interval throughout the observation period among the
five groups.
3. Discussion
In this study, we prepared a novel drug delivery system with a dual function, acting as a drug
carrier and an ultrasound contrast, by combining the advantages of microbubbles and bio-compatible
nanoparticles. Albumin-doxorubicin nanoparticles were synthesized by a desolvation technique. The
doxorubicin was strongly bound to the albumin and the correlation coefficient between doxorubicin and
albumin was 0.98 [22]. The albumin-doxorubicin complexes were conjugated to the nanoparticles by
cross-links between the amine group of albumins and aldehyde groups [23]. Being covalent in nature,
these bonds were extremely strong. The doxorubicin molecules were stably loaded by both surface
absorption and incorporation into the nanoparticles [22,24]. This structure is advantageous since the
nanoparticles are not easily degraded and the doxorubicin incorporated within the nanoparticle is
safely protected from different enzymes in the blood vessels. In addition, as shown in Figure 2B and
Figure S2, doxorubicin was released in a sustained manner for a long period of time owing to the
solid structure [25]. The conjugation of albumin-doxorubicin nanoparticles onto the surface of the
microbubbles was also based on the amide bonding previously described. This amide bond forms
between the numerous primary amines of albumin and N-hydroxysuccinimide of the microbubbles [18].
This rapid and strong bond is also easily induced within 1 h. The albumin-doxorubicin nanoparticles
do not easily extravasate owing to the large size of the microbubbles, and are capable of safely
delivering doxorubicin to the target site without mid-way losses, until the target site is exposed to
ultrasound irradiation.
To confirm that the ADMBs resonate to ultrasound, we investigated the echogenicity of ADMBs
using a commercial ultrasound scanner, which is equipped with a transducer having a frequency
range of 2–9 MHz. In an in vitro phantom experiment, microbubbles were continuously visualized
during ultrasound irradiation at a low MI of 0.06. The results showed that the microbubbles oscillated
and generated acoustic wave pressure necessary for a stable cavitation. However, at a MI of 0.06,
this behavior is not enough to generate sonoporation, because a MI of 0.06 is sufficiently low and
this MI value is only for adaptation to diagnosis by ultrasound. However, collapse of microbubbles
was demonstrated under the ultrasound radiation with MI 0.68 by manual flash. The destruction of
microbubbles by the application of strong, intense ultrasound irradiation leads to an asymmetric gas
infusion with high pressure from the core, which induces a temporary stress on the cellular membrane.
This phenomenon is known as inertial cavitation and our ADMB complex was proven to induce
inertial cavitation, as depicted in Figure 3. In addition, the driving frequency for inertial cavitation
was 2–9 MHz, and this is the frequency which is generally applied to abdominal organs in the clinical
field. Theoretically, the penetration depth and frequency of ultrasound are critically related. A lower
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frequency permeates more to deeper regions, whereas the resolution of ultrasound imaging is clear in
the diagnostic field. However, in clinical research, studies generally use low frequency ultrasounds for a
deeper penetration and high intensity ultrasounds for an enhanced ultrasound trigger. In our previous
study, we measured that the optimal resonance frequency of the albumin nanoparticle-conjugated
microbubble is 3 MHz [18]. Therefore, a resonance frequency of 2–9 MHz was optimum for both our
ADMBs and the hepatocellular carcinoma. We also analyzed the influence of albumin-doxorubicin
nanoparticle conjugation on the echogenicity. As conjugation induces changes in the microbubble
surface, corresponding changes in shell elasticity and stiffness are possible [26,27]. It is perhaps this
change which is able to reduce the echogenicity. However, as shown in Figure 3C, the echogenicity
was rarely influenced.
Regarding these characteristics of ADMBs, intracellular uptake and anticancer effect was evaluated,
in order to study the generation of sonoporation effects by ADMBS and to enhance the anticancer effect.
Cytotoxicity of ADMBs was enhanced under ultrasound, whereas the cytotoxicity of doxorubicin
or albumin-doxorubicin was not related to ultrasound exposure. Theoretically, a high intensity of
ultrasound such as HIFU can generate sonoporation and enhance intracellular delivery. However, high
intensity of ultrasound to open cellular membranes usually stresses the surroundings and occasionally
induces cytotoxicity to the normal cells or organs. Therefore, microbubbles were sufficiently beneficial
for the generation of sonoporation effects with lower ultrasound pressure and enhancement of drug
delivery into the cytoplasm. In our study we proved, as shown in Figures 4 and 5, that intracellular
delivery and anticancer effects in the presence of microbubbles under ultrasound were enhanced within
3 h, whereas ADMBs without ultrasound exposure did not penetrate in 6 h, because sonoporation was
not induced and large size of microbubbles interfered with penetration through the cell membrane.
Therefore, the cytotoxicity of ADMBs under the ultrasound exposure was strongest, compared to
doxorubicin and albumin-doxorubicin nanoparticles.
The second section of our study comprehensively evaluated the in vivo antitumor effect of
ADMB following ultrasound activation. As we had expected, the combined therapy of IA ADMB/US
administration led to the highest reduction in tumor volume. This was also supported by the fact
that IA-ADMB/US group showed the maximal increase in ADC values post-treatment in MR, the
highest necrotic fraction and the lowest viable tumor volume revealed by histosegmentation analyses.
Moreover, pathological analysis revealed intense and homogeneous necrosis throughout the whole
tumor section in the IA-ADMB/US group and viable tumors were nearly absent on the tumor periphery.
In contrast, tumor necrosis in the untreated control group was focal and heterogeneous, and there
were abundant finger-like viable tumor portions in the periphery. It is presumed that the IA route
delivered a high concentration of ADMB which resulted in maximal cavitation and sonoporation
in the target tumor site, causing enhanced drug penetration and cytotoxicity to tumor tissues. To
our knowledge, this study a first of its kind to investigate and report the promise of IA delivery of
ADMB following ultrasound activation in an orthotropic liver tumor animal model larger than rodents.
Interestingly, tumor suppression in the IV ADMB/US group was modest but not statistically significant
to other groups. Unlike previous studies which primarily used small animals [28–30], our study
used rabbits, which are relatively large animals with more blood volumes, and have longer distances
between tumors and ultrasound probes. It is perhaps these differences which resulted in the diverse
treatment outcomes in the IV ADMB/US group. Previous studies [18,19,28,31–33] used high-intensity,
low-intensity focused ultrasound or self-made ultrasound transducers to elucidate the feasibility of
sonochemotherapy. However, these probes are not generally used in diagnostic imaging, and therefore
cannot be applied for the same. In our study, we used an ultrasound scanner used for clinical purposes
to simultaneously visualize the tissues of the target tumor and to deliver ultrasound irradiation for
activating microbubble-assisted drug delivery. This allows the advantage of directly monitoring drug
delivery while treating the target tumor, which means that it can be easily applied to clinical studies in
the future. It is important to evaluate the safety profile while investigating new drug delivery systems.
In our study, there were no significant differences in the liver enzyme levels analyzed at specific time
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intervals, between the IA ADMB/US group and other groups. In addition, no animal deaths occurred
due to complications arising from microbubble injection. This indicates that the IA ADMB/US therapy
could be effective and safe for the treatment of liver cancers.
We acknowledge several limitations of our study. First, we did not study the treatment outcomes
when only ADMB was administered without ultrasound irradiation. However, the efficacy of
drug-loaded microbubbles in combination with microbubble destruction is a well-known drug delivery
system, as many previous reports suggest [18,28,31–36]. Second, the concentration of doxorubicin
in tumors was not directly measured. However, the IA ADMB/US group showed excellent tumor
suppression as observed by both volumetric and quantitative analyses, indicated by changes in the
ADC values, MR and necrotic fraction, and viable tumor volume. Moreover, the free MB/US group
did not show significant tumor inhibition compared to the control group. These findings indirectly
support that the enhanced anticancer effect in the IA ADMB/US group was caused by the application
of an improved drug delivery system.
4. Materials and Methods
4.1. Materials
1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) was purchased from NOF Corporation (Tokyo,
Japan). 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[succinyl(polyethylene glycol)-2000]
(DSPE-PEG2k-NHS) was purchased from Nanocs Incorporated (Boston, MA, USA). Human serum
albumin, 8%-glutaraldehyde, and 99%-ethanol were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Doxorubicin was purchased from the Il-Dong Pharmaceutical Company (Seoul, Korea).
Microcatheters (Progreat 2.0F, Terumo, Japan) were obtained from the Terumo Korea Corporation
(Seoul, Korea). The animals were purchased from Orient Bio Co. (Seongnam, Korea). All the other
chemicals and solvents were of analytical grade.
4.2. Preparation of ADMB Complex
The ADMB complex consisted of two main parts: the albumin nanoparticle loaded with
doxorubicin and the phospholipid-based microbubble; the complex was fabricated as per the sequence
of procedures mentioned hereafter. First, the albumin nanoparticle was fabricated by a desolvation
method; 150 mg of human serum albumin and 5 mg of doxorubicin were dissolved in water
and the pH was adjusted to 8.5 by using 1 M NaOH. After stirring (at 600 rpm) for 2 h, 8 mL
of ethanol (99.9%) was continuously added in a dropwise manner for transforming the mixture
into doxorubicin-albumin nanoparticles, indicated by the development of turbidity in the mixture;
100 μL of 8%-glutaraldehyde was added cross-linking the nanoparticles. After stirring overnight, the
albumin-doxorubicin nanoparticles were purified by centrifugation for 10 min at 4 ◦C at 15,000 rpm,
and were resuspended in equal volume of 0.01 M phosphate buffer saline (pH 7.4). The loading
efficiency of doxorubicin was calculated by analyzing the quantity of unloaded doxorubicin in the
supernatant after centrifugation. The amount of doxorubicin in the supernatant was measured by a
UV-Vis spectrometer.
DSPC and DSPE-PEG2k-NHS dissolved in chloroform in a 9:1 molar ratio. The chloroform was
fully evaporated for fabrication of a thin phospholipid film. This thin phospholipid film was hydrated
by 0.01 M PBS at a temperature above the phase transition temperature of DSPC (55 ◦C). A 2 mL vial
was filled with the volume of phospholipid solution (at a concentration of 0.5 mg/mL) and sulfur
hexafluoride gas (SF6) at the headspace. Sequentially, the microbubbles were formulated by activation
with VialmixTM for 45 s.
The albumin-doxorubicin nanoparticles were conjugated with the microbubbles by adding
the albumin-doxorubicin nanoparticles to the microbubbles at a concentration of 1 mg/mL. The
albumin-doxorubicin nanoparticles were conjugated to the microbubbles via amide bonds between the
primary amine of the nanoparticles and the NHS from the microbubble surface. After 1 h for conjugation
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of albumin-doxorubicin to surface of NHS functionalize microbubble, centrifugation at 3000 rpm for
5 min was performed at three times for purification of ADMBs. Unbound albumin-doxorubicin was
removed and ADMBs were re-suspended by 0.01 M PBS.
4.3. In Vitro Release Test for the ADMB Complex
In order to investigate doxorubicin release from the ADMB complex, the complex was sealed with
a 3000 Da (MW) cut-off dialysis membrane. The ADMBs loading 1 mg of doxorubicin in the dialysis
membrane was placed into the tube filled with 10 mL of phosphate buffer saline, saline with adjustment
to pH 4.7 or cell culture medium containing 10% of fetal bovine serum and 1% of antibiotics. This
ADMBS was stored at 37 ◦C and 500 rpm of shakes (n = 3). The released doxorubicin was measured by
a UV-Vis spectrometer.
4.4. Phantom Study for Echogenicity of the ADMB Complex
The echogenicity of the ADMB complex was evaluated using a commercial ultrasound scanner
equipped with a transducer having a frequency range of 2–9 MHz. For the ultrasound imaging,
home-made agarose phantoms containing two holes of 2 cm depth was used. The holes in the
agarose phantoms were filled with the ADMB complex at the concentration of 5 μg/mL and degassed
water, respectively. For studying microbubble stability, ultrasound imaging was performed at a
Mechanical Index (MI) of 0.06 and manual flash mode (MI:0.68) was performed with 3 s time interval
for microbubble destruction (iu-22 Philips Medical System, Philips, Bothell, WA, USA). The stability of
the ADMB complex was analyzed by decreasing the ratio of echogenic area (pixel) with the ImageJ
software (version 1.45 s; National Institutes of Health, Bethesda, MD, USA).
4.5. Cellular Uptake and Cell Viability of ADMB under the Ultrasound Exposure
To determine that ADMB enhances cell permeability under the ultrasound exposure, hepatic
cellular carcinoma cell line, HepG2, was applied. HepG2 cells (5 × 104) were seed to the 8 well
cell culture chamber and incubated for overnight. To fluorescently visualize, fluorescence dye,
NHS-alexa488, was labeled to human serum albumin nanoparticle without doxorubicin loadings.
Florescence dye was conjugated by amide bond between albumin nanoparticle and NHS. Fluorescently
labeled ADMBs were treated and were exposed to the ultrasound wave (Sonidel SP100 sonoporator,
Sonidel Ltd., Dublin, Ireland). Ultrasound was irradiated to each well with the 1 W/cm2 of strength
and 5% of duty cycle for the 1 min. At the post-incubation of 3, 6 and 24, HepG2 cells were washed
three times and fixed by 4%-paraformaldehyde. And nucleus was stained by DAPI. Cellular uptake of
ADMBs were observed by confocal laser microscopy.
Cell viability of ADMBs under the ultrasound exposure was measured by MTT assay. HepG2
cells (1 × 104) were seeded in each well of 96 well plate. After overnight for incubation, doxorubicin,
free-microbubble, doxorubicin loaded albumin nanoparticles or ADMBs were treated to each well. The
mass of doxorubicin in each well was equalized to 5 μg. Ultrasound was irradiated with the 1 W/cm2
of strength and 5% of duty cycle for 30 s. And each well was washed 3 times at the post incubation of
3 h. And cell viability after 24, 48, 72 h was measured at the wavelength of 540 nm by ELIZA reader.
4.6. Animal Model Preparation
The animal research protocols followed in this study were approved by Seoul National University
of medicine institutional Animal Care and Use Committee. Twenty-five male New Zealand white
rabbits weighing between 3000 and 3500× g were used for our study. The animals were housed in cages
with a 12-hour light/dark cycle and ad libitum access to standard rabbit chow diet and water. During
all procedures, the animals were anesthetized with intramuscular injections of 5 mg/kg body weight of
tiletamine-zolazepam (Zoletil 50; Virbac, Carros, France) and a 2 mg/kg body weight of 2% xylazine
hydrochloride (Rompun; Bayer, Seoul, Korea). The VX2 carcinoma strain was maintained in the right
hind limb of a carrier rabbit through deep intramuscular injection throughout the study. Briefly, the
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left lobe of the animal’s liver was exposed surgically and a small piece of tumor tissue (1 mm3) freshly
harvested from the maintained tumor was directly implanted at the subcapsular area of the liver for
each rabbit, as described in previous studies [10,37,38]. The tumor was incubated for 17–18 days.
4.7. MR Imaging
All animals underwent MR imaging at day 0 (baseline before treatment) and at day 7 following
IA or IV infusion in the groups A to D which received treatment, and the untreated group E. A 3.0-T
clinical MR scanner (TimTrio; Siemens Healthcare, Erlangen, Germany) with a knee coil was used to
improve SNR and spatial resolution. The animals were fixed on a board in a supine position, and an
abdominal bandage was tightly applied to reduce any movement artifact. Axial T2-weighted turbo
spin-echo (repetition time/echo time: 4100 milliseconds/150 milliseconds; echo train length: 14; section
thickness: 3 mm; field of view: 130 × 130 mm, matrix: 512 × 358; number of excitations: 2.0) and
IVIM Diffusion-weighted image (free breathing single-shot echo-planar imaging pulse sequence with
diffusion gradients applied in three orthogonal directions: 2700/63; section thickness: 3 mm; number
of sections: 20; number of signals acquired: 8; field of view: 14 × 14 cm2; matrix: 128 × 128; and four b
values (0, 15, 200, and 800 s/mm2)) were acquired [39]. The images were evaluated using a dedicated
workstation for picture archiving and communication system (m-view; Marotech, Seoul, Korea).
4.8. Grouping and Drug Delivery
The study design is summarized in Figure S1. On the basis of the treatment procedure, the animals
were divided into five groups having similar tumor volumes: animals receiving an intra-arterial (IA)
infusion of ADMB/US (group IA-ADMB/US, n = 6), animals receiving an intravenous (IV) infusion of
ADMB/US (group IV-ADMB/US, n = 6), animals receiving an IA infusion of free MB/US (group IA-free
MB/US, n = 5), animals receiving an IA infusion of doxorubicin/US (group IA- Dox/US, n = 3), and the
untreated control (n = 5). The dose of doxorubicin delivered was 1 mg for all groups except for groups
of IA-free MB/US and control. In each group except the control, an infusion pump (Genie plus, Kent
Scientific Corporation, Torrington, CT, USA) was used. IA-ADMB/US underwent an IA delivery of
ADMB in 3 mL of Iopamidol (Pamiray®, Seoul, Korea) contrast media via the proper hepatic artery.
ADMB was administered in group of IV-ADMB/US via the left marginal ear vein. In IA-free MB/US,
the microbubble-contrast solution without doxorubicin was administered via the proper hepatic artery
under the same conditions as group of IA-ADMB/US. The number of microbubbles in group IA-and
IV-ADMB/US and IA-free MB/US were 9 × 108 in 3 mL of Iopamidol, respectively. Group of IA- Dox/US
received a mixture of 1 mg of doxorubicin in 3 mL of contrast media via the proper hepatic artery. All
the injections for groups were administered at a rate of 1 mL/min for 3 min, using the infusion pump
for an accurate and homogenous infusion.
For the IA delivery, an 18-gauge catheter (BD Angiocath Plus with intravenous catheter,
Becton-Dickinson, Korea) was inserted into the right central auricular artery for arterial access.
To reach the proper hepatic artery, a 2.0-Fr microcatheter (Progreat; Terumo, Tokyo, Japan) was
advanced via the catheter into the descending aorta [37,40]. After performing hepatic arteriography
to confirm tumor staining and following visualization of the proper hepatic artery, the microcatheter
was advanced selectively until the catheter tip was gently positioned at the proximal portion of the
proper hepatic artery. The solution prepared for each group was then administered using an infusion
pump (Genie plus, Kent Scientific Corporation) through the microcatheter at a rate of 1 mL/min for
3 min, to avoid reflux of the injected complex from the proper hepatic artery [31,37]. To access the
systemic venous system, an 18-gauge catheter was inserted into the left marginal ear vein. The pressure
line was then connected to catheter, and the solution was infused similarly. When the solution was
completely injected, the microcatheter was removed, and the puncture site was compressed carefully
to achieve hemostasis.
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4.9. Ultrasound and Microbubble Activation
The abdominal hairs of the rabbits were carefully removed just prior to ultrasonography. The
ultrasonography was performed by a radiologist both before and during drug administration in groups
IA-ADMB/US, IV-ADMB/US, IA- Dox/US and IA-free MB/US using the Aplio 500 ultrasonographic
system (Toshiba Medical Systems, Otawara, Japan), with 674 BT with an 8 MHz center frequency
convex transducer. A fundamental B-mode ultrasound (a dynamic range of 65; a mechanical index of
1.5; a gain of 90; and a depth of 4 cm) was used to detect the VX2 tumors. After localization and a
morphological examination of the tumor, the optimal plane was determined and the skin was marked.
The vascular recognition imaging mode with a low MI of 0.06 was used to detect signals generated by
the microbubbles. As soon as an IA or IV delivery of the mixture through the infusion pump began, the
vascular recognition mode was used to confirm the presence of tumor enhancement. Simultaneously,
using a continuous up-and-down sweeping of the probe at the skin marking site, the B-mode was used
to irradiate ultrasound energy to the tumor for 3 min (J.H.L). After cessation of infusion, additional
ultrasound irradiation was applied for 5 min for activating the microbubbles, resulting in a total of
8 min of bubble activation for each rabbit using the B-mode ultrasound.
4.10. Imaging Analysis
A radiologist who was blind to the information regarding the experimental group evaluated the
MR images on a picture archiving and communications system workstation. The T2-weighted images
were used to confirm tumor formation and to measure the maximal longitudinal diameter (length)
and maximal transverse diameter (width) of the tumors. Tumor volume was calculated from the
measurements determined by MR imaging, using the modified ellipsoidal formula, tumor volume =
1/2(length ×width2) [34,38]. The volume inhibition rate (VIR) of tumor growth was calculated using
the formula IR = (Tc − Tt)/Tc × 100%, where Tc represented the tumor volume of group E (control
group) and Tt represents the tumor volume of each treatment group. The value of the Apparent
Diffusion Coefficient (ADC) was measured quantitatively using the largest cross-section of the tumor
visualized on the ADC map. The changes in the ADC values before and after TACE were evaluated.
4.11. Pathological Analysis
On day 7, all animals were pre-anesthetized and sacrificed with an intravenous injection of xylazine
hydrochloride, and the whole tumor was harvested after follow-up imaging. Each tumor was fixed in
10% buffered formalin. The specimen was then embedded in paraffin, cut into 4 μm sections, and the
largest cross-section of the tumor was stained with hematoxylin and eosin for basic histopathological
examinations. The section was consecutively treated with terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) staining (ApopTag® Peroxidase in situ Apoptosis Detection Kit, Merck
KGaA, Darmstadt, Germany) for evaluating tumor viability. After digital images of the histology slides
were obtained (Leica Microsystems, Mannheim, Germany), the viable tumor percentage per tumor
was calculated using image analysis software (ImageJ, version 1.45 s; National Institutes of Health,
Bethesda, MD, USA). In brief, the viable portion of each TUNEL stained image of the whole tumor
was measured by threshold intensity. Then, percentage of viable tumor region was calculated by ratio
between whole tumor area and viable tumor region. This analysis was performed by an experienced
radiologist who was blind to all experimental data, in order to ensure concordance. The estimated
viable tumor volume after treatment was calculated as follows: Calculated tumor volume on day
7× viable percentage of the tumor.
4.12. Biochemical Liver Toxicity Assessment
Blood samples for assessing liver toxicity were gathered at baseline and at 1-, 3-, and 7-day
intervals after treatment. Liver function tests included the assessment of liver enzymes (aspartate
transaminase (AST) and alanine transaminase (ALT)).
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4.13. Statistical Analysis
All the data in the study are reported as the mean± SD. The nonparametric analysis was conducted
using the Kruskal-Wallis test to compare the tumor volume, volume inhibition rate, changes in ADC
value, tumor viability, and estimated viable tumor volume in the 5 experimental groups. When positive
results were encountered, the Mann-Whitney post-hoc test was used for one-to-one group comparisons.
Data processing and analysis were performed using the Statistical Package for the Social Sciences
version 18.0 (SPSS Inc, IBM, Chicago, IL, USA). A two-sided p-value of less than 0.05 indicated that the
groups differed significantly in terms of statistical results.
5. Conclusions
In the present study, the ADMB complex was developed for enhancing the therapeutic efficiency
of drugs used in hepatocellular carcinoma. This complex can resonate to ultrasound irradiation
and induce sonoporation. Using orthotopic experiments, we proved the anticancer effect of this
treatment strategy using the VX2 rabbit tumor model. Our strategy is more effective than existing
systems because it: (1) has an enhanced loading efficiency; (2) is optimized to resonate at ultrasound
frequencies of 2–9 MHz, making it ideal for the treatment of hepatocellular carcinomas, and (3) induces
a more effective anticancer effect when combined with an intra-arterial administration route in rabbits.
In conclusion, the IA administration of ADMB followed by microbubble activation using a clinical
ultrasound probe can take advantage of simultaneously monitoring drug delivery while treating the
target, to achieve a better antitumor effect. This novel drug delivery system may help to effectively
deliver chemotherapeutics to liver tumors and warrants further investigation for the treatment of
advanced liver cancers.
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and microbubble, Figure S5:TUNEL assay images of tumor region in (A) IA-ADMBs, (B)IV-ADMBs (C) blend
microbubble, Table S1: Percentage of echogenic area depending on the number of manual flashes.
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Abstract: Despite aggressive multi-modality treatment with surgery, radiation and chemotherapies,
malignant glioma inevitably recurs and has dismal survival rates. Recent progress in immunotherapy
has led to a resurgence of interest, and immunotherapies are being investigated for treatment of glioma.
However, the unique brain anatomy and a highly immunosuppressive glioma microenvironment
pose significant challenges to achieving efficacy. Thus, there is a critical need for assessment of
next-generation immunotherapies for glioma. In this study, we have investigated the efficacy of
the nanoparticle platform technology based on plant-derived Cowpea mosaic virus like particles
(empty CPMV or eCPMV) to instigate a potent immune response against intracranial glioma.
CPMV immunotherapy has been shown to efficiently reverse the immunosuppressive tumor
microenvironments in pre-clinical murine models of dermal melanoma and metastatic melanoma,
metastatic breast cancer, intraperitoneal ovarian cancer and in canine patients with oral melanoma.
In the present study, we demonstrate that in situ administration of CPMV immunotherapy in the
setting of glioma can effectively recruit unique subset of effector innate and adaptive immune cells to
the brain parenchyma while reducing immune suppressive cellular population, leading to regression
of intracranial glioma. The in situ CPMV nanoparticle vaccine offers a potent yet safe and localized
immunotherapy for intracranial glioma.
Keywords: intracranial glioma; immunotherapy; CPMV; viral nanoparticles; in situ vaccine
1. Introduction
Malignant glioma represents one of the most aggressive forms of cancer, with poor survival rates
that have not changed in the past three decades despite advancements in detection and treatment
modalities. Even with aggressive treatments including debulking, chemotherapy and radiation the
median survival rates for malignant glioma is 12 months, with a five-year relative survival of about
5% [1,2]. Glioma is also associated with high rates of morbidity due to damage to functional regions of
the brain. Surgery, radiation and chemotherapy are the mainstay of treatment regimens [3]. Malignant
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glioma is incurable surgically due to the infiltrative nature of these tumors and the surgeon’s inability
to safely resect a “margin” as is typical in most other solid cancers. The blood brain barrier (BBB) also
limits the penetration and clinical efficacy of most systemic chemotherapies [4]. Moreover, residual
tumor subpopulations resistant to radio- and chemotherapy eventually lead to recurrence and treatment
failure [5,6].
Success of immunotherapies for other solid tumors has led to renewed interest in immunotherapy for
gliomas [7,8]. However, the unique anatomical and physiological features of the brain are critical barriers
for such interventions [9]. The BBB, blood-cerebrospinal fluid (CSF) and blood-meningeal barriers
limit the entry of most small molecules as well as immune cells into the brain [10]. Recent advances
in the understanding of the central nervous system (CNS) have however, reversed the longstanding
theory that the brain is “immunologically privileged” and demonstrated that the BBB in patients with
malignant glioma is typically disrupted [11]. It has recently been noted that activated T cells can cross the
blood-brain-barrier, however, many of the inflammatory cells recruited to malignant gliomas contribute
to the highly immunosuppressive tumor microenvironment (TME). The glioma TME is characterized by
the prevalence of M2 polarized resident macrophages and microglial cells, myeloid-derived suppressor
cells (MDSCs), and a significantly smaller population of antigen presenting cells (APCs) including
exhausted dendritic cells (DCs) and T cells. The expression of vascular endothelial growth factor
(VEGF), tumor growth factor-β (TGF-β), prostaglandin E2 (PGE2) and interleukin-10 (IL-10) further
impair T cell proliferation and activation in response to pro-inflammatory signals, and downregulate
expression of major histocompatibility complexes (MHCs) and DC maturation [12]. Malignant
glioma also has a considerable infiltration of regulatory T cells (Tregs), which can further suppress
proliferation and activation of tumor infiltrating T lymphocytes [13]. Additionally, glioma stem cells
(GSCs) and glioma initiating cells (GIC), which drive glioma growth and invasion, contribute to
the immunosuppressive tumor microenvironment by recruiting tumor-supportive macrophages and
microglia, expressing immunosuppressive cytokines, and down regulating Toll-like receptors (TLRs)
thereby avoiding immune-mediated rejection [14].
Several immunotherapeutic approaches targeting gliomas are currently under pre-clinical
development and clinical evaluation. These include vaccines, adoptive T cell therapies, monoclonal
antibodies, checkpoint inhibitors and oncolytic virotherapies [8]. Immune escape with loss of targeted
antigens and glioma heterogeneity pose significant challenges for vaccines based on single or multiple
antigens, respectively [15]. Additionally, lack of a robust population of resident APCs in the brain
contributes to the reduced efficacy of glioma vaccines [12]. DC vaccines can overcome this hurdle by
reintroducing the patient’s own antigen pulsed DCs, however besides the technological challenges, this
approach suffers from low efficacy attributed to poor migration of DCs to secondary lymphoid tissues
for T cell activation [16]. Adoptive cell therapies (ACT) [17] that can circumvent DC dependence
have proven to be challenging in malignant gliomas due to their low densities within tumors, tumor
mediated exhaustion, and inefficient delivery through intravenous administrations [8,9]. Similarly,
restrictive delivery through the BBB and lack of effector cells or cytotoxic T cells (CTLs) renders
antibody drug conjugates and checkpoint inhibitors less effective as brain tumor treatments [18,19].
Oncolytic virotherapy utilizing genetically engineered mammalian viruses to selectively invade
glioma cells and express cytotoxic proteins has emerged as a potent therapeutic strategy for glioma.
Several oncolytic viruses have been studied including adenoviral vector Ad-RTS-hIL-12 that expresses
IL12 in the presence of an orally administered ligand, which can efficiently cross the BBB to reach the
tumor bed [20]. Similarly, engineered poliovirus PVSRIPO [21], oncolytic herpes simplex virus type-1
(oHSV-1) [22], measles virus [23] and Zika virus [24] have been shown to selectively replicate in and
lyse CNS tumor cells or tumor stem cells. While highly effective, applicability of virotherapy to the
brain remains under investigation, as uncontrolled inflammatory responses posing a threat to healthy
brain cells and delivery to the brain remain major hurdles [9].
Here, we present data from an in situ vaccine immunotherapy against malignant glioma utilizing
the plant virus like particles (VLPs) derived from Cowpea mosaic virus (CPMV). The CPMV VLPs
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lacks their nucleic acids and are referred to as empty CPMV (eCPMV). Recently, we have shown that
eCPMV (as well as CPMV) can induce anti-tumor responses in several murine models of cancers when
introduced into the tumor microenvironment (TME) as an in situ vaccine [25]. Results from canine
trials have also demonstrated efficacy in large animals with spontaneous melanoma [26]. Mechanistic
insights have indicated that CPMV stimulates an anti-tumor response through recruitment of innate
cells including monocytes, tumor infiltrating neutrophils (TINs) and natural killer (NK) cells, which
exert cancer cell toxicity resulting in the release of tumor antigens. Furthermore, through elevated
influx of APCs into the treated tumors, the CPMV in situ vaccine also facilitates priming of an adaptive
anti-tumor response with CD4+/CD8+ cells, therefore leading to systemic efficacy and immunological
memory [25]. Thus, CPMV activates the innate immune response, recalibrating the cancer–immunity
cycle to eliminate cancer cells via the adaptive immune system. Unlike the oncolytic viruses, plant
viruses are non-infectious and non-replicative in mammalian cells and the immune modulation is
driven by the unique proteinaceous architecture of the viral capsid. While previously validated in
various mouse model of dermal and metastatic melanoma, lung metastasis from breast cancer, and
intraperitoneal ovarian cancer, in the present study we set out to assess the efficacy of eCPMV in situ
vaccine against intracranial glioma using the syngeneic GL261 glioma mouse model.
2. Results
CPMV VLPs were produced by co-expression of the precursor to the L and S coat proteins
(VP60) and the viral proteinase (24K) using N. benthamiana plants and agroinfiltration as previously
described (Figure 1A) [27]. Typical purification yields are around 0.5 mg of VLP from each gram of
leaf tissue. The eCPMV VLP is a 30 nm-sized icosahedral particle devoid of nucleic acid and consists
of 60 copies each of a small (S) and large (L) coat protein subunits (Figure 1B) [28]. Post-purification
quality assurance of the self-assembled VLP was performed using TEM imaging and size exclusion
chromatography (SEC) confirming the presence of intact 30 nm particles with the typical elution
profiles from the Superose column; the absorbance ratio of A260:280 of 0.67 indicates that particles
devoid of RNA were produced (in contrast RNA-containing wild-type CPMV has a A260:280 of
1.8 [29] (Figure 1C,D). For imaging and tracking studies, N-hydroxysuccinimide chemistry was used
to conjugate the NHS esters of sulfo-Cy5 fluorophores to eCPMV capsid via the exposed lysine
residues [30] (Figure 1E). SDS-gel electrophoresis was used to confirm fluorescent tagging of the viral
coat proteins (Figure 1F). Unmodified eCPMV is represented by two distinct bands corresponding
to the ~24 kDa small coat protein (S-CP) subunit and the ~42 kDa large coat protein subunit (L-CP).
In eCPMV-Cy5 particles both these protein bands appear fluorescent when excited at 632 nm, indicating
successful dye conjugation. The ratio of Cy5 dyes per eCPMV particle were quantified by UV/Vis
spectroscopy and using the particles’ specific extinction coefficient εeCPMV of 1.28 mL mg−1 cm−1 at
280 nm and the molar extinction coefficient εCy5 of 271,000 at 660 nm. The reaction yielded ~50 dyes
per eCPMV.
To assess the potential for development of CPMV immunotherapy for treatment of glioma, we first
determined the feasibility of delivering VLP immunotherapy through intracranial injections into the
brain using fluorescently labeled eCPMV-Cy5 VLPs. All mouse studies were performed in compliance
with the Institutional Animal Care and Use Committee of Case Western Reserve University.
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Figure 1. eCPMV propagation, purification and characterization. (A) eCPMV VLPs were propagated
using N. benthamiana plants; leaves were infiltrated when plants were 45 days old. (B) Structure
of eCPMV, chimera image created using PDB file 1NY7 (CPMV) (C,D) Purified eCPMV particles
were characterized for structural integrity using TEM and size exclusion chromatography (FPLC).
(E) One-step-NHS chemistry was used to bioconjugate Cy5 dyes to the lysine residues on eCPMV
CPs. (F) SDS-gel electrophoresis was used to confirm conjugation of Cy5 dyes to eCPMV coat proteins:
the fluorescence derived from conjugated Cy5 is detected by exposing the gel to 632 nm excitation;
the small (S) and large (L) protein are detected after protein staining (GelCode™ Blue Safe protein stain)
and visualization under white light.
Following the intracranial injection, presence and retention of VLPs in brain was detected using
ex vivo Maestro fluorescence imaging (Figure 2A). At 24 h post injection eCPMV can be readily detected
at and around the injection site as evident by a strong fluorescent signal, whereas at day 7 the weak signal
intensity suggested degradation and loss of proteinaceous VLPs from the brain microenvironment
(Figure 2A). This observation is consistent with clearance of viral nanoparticles from other tissues [31].
During this period, mice were monitored for any signs of stress and discomfort resulting from particle
administration and no apparent adverse effects were observed. We also evaluated intravenous route
for eCPMV VLP administration as a mean of delivery immunotherapy to the brain. However, the
VLPs were sequestered in the liver and spleen by the mononuclear phagocyte system (MPS) system
with minimal doses reaching other tissues, including the brain. Therefore, we selected the intracranial
injection as the mode of delivery for our studies. Based on the weeklong retention of eCPMV in brain,
we set weekly intratumoral administration schedules for glioma immunotherapy.
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Figure 2. Intracranial eCPMV injection and immunotherapy. (A) eCPMV retention in brain following
intracranial administration was determined using eCPMV-Cy5 and Maestro fluorescence imaging
system. (B) For in situ immunotherapy, C57BL6 mice (n = 4) were inoculated with 3 × 103 GL261 cells
intracranially and administered PBS or eCPMV via intracranial injections on days 8, 16 and 24. (C) On
day 30, MRI imaging (7 Tesla) was used to visualize glioma post-treatment. Yellow circles highlight
solid tumors in PBS administered mice, whereas blue circle highlights the residual tumor and/or edema
in one of the mice in the eCPMV treatment group.
Next, we assessed the immunotherapeutic potential of the eCPMV in situ vaccine in a mouse
model of GL261 glioma. This syngeneic model based on immunocompetent mice is one of the most
widely used animal models for gliomas [32]. C57BL6 mice were challenged with syngeneic GL261
tumors via intracranial injections of 3 × 103 cells in 3 μL of PBS. Pre-treatment MRI was performed on
day 6 post-tumor inoculations to establish onset of tumor growth; then mice were randomly assigned to
treatment groups (Figure 2B). eCPMV immunotherapy at a dose of 50 μg VLP in 3 μL sterilized PBS was
administered via weekly intracranial injections starting on day 8 post tumor inoculation. The control
group received sterile PBS. Mice were observed for signs associated with glioma progression including
weight loss, irregular breathing, hunched back and decreased activity; upon appearance of these signs,
mice were euthanized. Following three intracranial injections, a second MRI was performed on day 30
post-tumor inoculations to assess treatment efficacy (Figure 2B).
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Representative brain MRI images from PBS or eCPMV treated mice highlighted the therapeutic
effects of the eCPMV in situ vaccination. Untreated mice developed large intracranial tumors by
day thirty following the tumor inoculation (Figure 2C, upper panel; area marked with orange circle).
In some mice, peritumoral edema was also observed as bright spots at the tumor edges. These mice
also displayed the characteristic neurological and physiological symptoms associated with glioma
including hunched posture, lack of activity and labored breathing. In stark contrast, eCPMV-treated
mice showed absence of tumors or appeared to have regressed intracranial tumors (Figure 2C, lower
panel) suggesting a therapeutic effect of the intratumoral eCPMV administrations. Presence of cerebral
edema (blue circle) indicates stimulation of an inflammatory response to the in situ eCPMV.
To validate the underlying immunology of the eCPMV in situ vaccine, we used flow cytometry
and IHC analysis. For flow cytometry, brains were harvested from immunized mice 24 hours post
single or three weekly eCPMV administrations (Figure 3A). The single cell suspension from brains that
received a single dose of CPMV VLPs were used for characterization of the innate immune response
(Figure 3A) whereas tissues and cells derived from animals that received multiple eCPMV doses were
used to characterize the adaptive immune response (Figure 3B). Flow cytometry analysis after a single
intracranial injection indicates enhanced immune cells infiltration into the brain of mice receiving
eCPMV in situ vaccine (black bars) over tumor bearing mice receiving PBS (white bars). Specifically,
eCPMV treated mice showed significantly elevated levels of leukocytes (CD45+ cells), CD11b+CD11c+
DCs, CD11bint-lowNK1.1+ NK cells, CD11b+Ly6G−monocytes, and CD11b+Ly6G+MHCII+CD86+ TINs
compared with PBS-treated tumor bearing mice. Several other immune cells including macrophages,
granulocytes, activated neutrophils and G-MDSCs showed an increasing trend, but were not statistically
significantly different from PBS treated mice.
 
Figure 3. Flow cytometry analysis to characterize immune infiltration in the brain parenchyma.
(A) GL261 glioma bearing C57BL6 mice (n = 3) were treated 1× or 3×with eCPMV immunotherapy and
the brain tissues were harvested 24 h following the last treatments to determine innate (B) and adaptive
(C) immune cell infiltrates in eCPMV treated (black bars) or untreated (white bars) GL261 bearing
brain tissues. Error bars represent SEM. Statistical comparisons were performed using unpaired t-test
(**** p < 0.0001, *** p < 0.001, ** p < 0.01 and * p < 0.05).
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The innate response to the in situ vaccine is consistent with our earlier studies using mouse
models of melanoma [33]. Here, we observed monocytes being recruited; in particular elevated levels
of CD11b+Ly6G− monocytes in eCPMV-treated brain could suggest local inflammation in response to
the intracranial injection of the VLPs. Further, both monocytic CD11b+CD11c+ DCs and CD11b+F4/80+
macrophages were elevated in response to eCPMV immunotherapy. Additionally, eCPMV treatment
also resulted in significant influx of the CD11b+Ly6G+MHCII+CD86+ tumor infiltrating neutrophils
(TINs) that also displayed high expression levels of CD86 and MHCII molecules (Figure 3B).
Next, brain tissues harvested from mice following three treatments of eCPMV or PBS were
analyzed by flow cytometry to evaluate the role of adaptive immunity (Figure 3C). Unlike the innate
response, tumor-specific CD8+ and CD4+ T cells proliferate in an antigen-specific manner following
stimulation by APCs. The potent innate response generated by the eCPMV in situ vaccine indeed led
to significant recruitment of CD3+ T cells. Specifically, CD8+ T cell levels were significantly higher in
eCPMV-treated mice over PBS-treated tumor-bearing mice. The increase in the CD4+ T cell population
was not significantly different comparing eCPMV-vs PBS-treated tumor-bearing mice. A similar
trend was observed for the effector memory T cells (EMTs), where a significant increase in the levels
of CD8+ CD44+ CD62L− EMTs and a non-significant increase in the levels of CD4+CD44+CD62L−
EMTs was noted comparing eCPMV- vs. PBS-treated animals. Interestingly, eCPMV treated mice
also demonstrated significantly enhanced levels of CD3+NK1.1+ NKT cells. Overall, these results
demonstrate efficient recruitment of both innate and adaptive immune cells to the brain tissue as a result
of the eCPMV in situ vaccination, indicating that the anti-tumor response is indeed immune-mediated.
Finally, we used immunohistochemistry (IHC) to characterize the changing cellular landscape of
the innate immune system within the glioma itself. To gauge the effects of single or multiple doses of
eCPMV, brains from tumor-bearing mice were harvested 24 h after either a single dose or three doses
(Figure 4A). Fixed tissue sections were then stained for immune cell markers IBA-1, CD68, CD45 and
FoxP3 and cellular densities were quantified using Zeiss image analysis program (Axiovision Rel 4.5,
Zeiss, Thornwood, NY, USA) (Figure 4B). IHC staining revealed significantly elevated levels of CD45+
leucocytes in the tumor tissue following the eCPMV treatment, which mirrors the flow cytometry data
indicating an overall increase in the CD45+ cells in the brain parenchyma. When compared to a single
administration, the overall CD45+ optical density doubled following three doses of eCPMV in situ
vaccine; this may indicate engagement of adaptive cell response that results in an influx of effector
cells including T lymphocytes and NKT cells. Further, we quantified the changes in IBA-1 and CD68
expression to evaluate microglia/macrophage (IBA-1/CD68) invasion into the tumors. As observed in
IHC panel (Figure 4B), eCPMV administration resulted in increased intratumoral expression levels
of both IBA-1 and CD68. We also compared the population of Tregs in glioma bearing mice with
and without CPMV immunotherapy by staining for FoxP3 expression, which is a regulatory T cells
specific transcription factor [34]. Our results indicate abundance of FoxP3+ Tregs in non-treated glioma,
whereas a significant reduction in intratumoral FoxP3+ Tregs is observed with CPMV immunotherapy
(Figure 4B).
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Figure 4. Immunohistochemical analysis. (A) Brain tissues from GL261 glioma bearing mice (n = 3)
were harvested on day 25 from tumor inoculation after 24 h of receiving 1× eCPMV treatment or the
last dose of 3× eCPMV treatment. (B) Tumor sections (6 μm thick) were stained with α-CD45 antibody,
α-IBA-1 antibody, α-CD68 antibody and α-FoxP3 antibody. The scale bar is 50 μm in all images.
Quantitative analysis was performed using Zeiss software to determine relative optical densities of the
stained sections. Error bars represent SEM. Statistical analysis was performed using ordinary one-way
ANOVA (Tukey’s multiple comparison test (**** p < 0.0001, *** p < 0.001, ** p < 0.01).
3. Discussion
We and others have demonstrated that intratumorally administered VLPs can modulate the local
tumor microenvironment via recruitment and activation of immune cells [25,35]. The immunomodulatory
properties of VLPs arise from the repetitive architectures of the coat proteins that present potent
pathogen-associated molecular patterns (PAMPs) [36]. VLPs are recognized by TLRs [37] and TLR
signaling can stimulate innate as well as adaptive immune responses. Previously, GL261 cells have
also been shown to express TLR2, TLR3 and TLR4, and TLR ligands have been used as treatments
against established glioma [38,39]. Here we show that intratumoral administration of the eCPMV VLP
generates an antitumor immune response leading to immunological regression of glioma. In some
cases, inflammatory responses were also noted. The formation of such cerebral edema induced
by inflammatory response has been previously observed following glioma radiotherapy [40] and
oncolytic viral therapies [41]. The risk management of the immune responses in the brain as part of the
immunotherapy will require future detailed investigation.
Profiling of the innate and adaptive immune cells following the in situ vaccination provides insight
into the mechanism. Consistent with our previous studies in other tumor models, the innate immune cell
cohort consists of monocytic DCs and macrophages and TINs. TINs have been identified as the primary
modulators of the anti-tumor innate responses. Direct physical contact between neutrophils and cancer
cells has been shown as a pre-requisite for cancer cell cytotoxicity. The cytotoxicity is attributed to
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neutrophil-secreted H2O2 that induces influx of Ca2+ in cancer cells leading to apoptosis [42] or to
neutrophil Fas ligand-cancer cell Fas receptor interactions, which stalls tumor cell cycle progression
from G1 to S phase [43]. In addition to direct cytotoxicity, neutrophils also mediate anti-tumor immune
response through recruitment of effector immune cells. Pro-inflammatory N1 neutrophils promote
CD8+ T recruitment and activation by secreting chemokines (e.g., CCL3, CXCL9, and CXCL10) and
cytokines (e.g., IL-12, TNF-α, GM-CSF) that attract T cells [44]. Moreover, neutrophils can also
coordinate adaptive immune responses through interactions with dendritic cells [44].
Another significant population of infiltrating innate immune cells was identified as NK cells.
NK cells are among the most potent cytotoxic cells against tumor cells and high levels of tumor
infiltrating NK cells are associated with a favorable tumor outcome in patients [45]. Transformed
cells with reduced or absent MHC-I expression are therefore NK cells targets. Additionally, cellular
stress and DNA damage results in upregulation of NK cell activation ligands on tumors. NK cells
can kill tumor cells by releasing cytolytic granules containing perforin and granzymes, which leads to
cancer cell apoptosis; NK cells also induce death receptor-mediated apoptosis [45,46]. Furthermore,
activated NK cells secrete IFN-γ that can induce CD8+ T cells to CTL transformation and promote
CD4+ T cells towards Th1 response, which promotes CTL differentiation. NK cells also promote
recruitment of conventional DC-type 1 (cDCs) in the tumor microenvironment via secreted CCL5 and
XCL1 cytokines [47]. cDCs are particularly efficient in carrying tumor antigens and cross presenting
them to CD8 T cells to stimulate an adaptive immune response [48]. Therefore, tumor antigens released
from cells lysed by activated NK cells can be taken up by APCs including the DCs and TINs described
above, which subsequently can contribute towards development of an adaptive immune response
mediated by tumor-specific CTLs [45].
Recent advances in the understanding of the structural and functional aspects of CNS lymphatic
vessels have revealed the mechanism of CNS immune surveillance, including the entrance and exit
of immune cells [11]. Functional studies of such meningeal lymphatic vessels have revealed their
role in transporting CD11c+ cells, B220+ cells and T cells. Additionally, these meningeal lymphatic
vessels have been shown connected to deep cervical lymph nodes, which are known to elicit immune
responses to antigens from cerebrospinal fluids [49,50]. Thus, APCs carrying tumor antigens from
lysed cells following eCPMV treatment are likely transported to the draining deep cervical lymph
nodes and present the tumor antigens to naïve T cells resulting in expansion of tumor antigen specific
adaptive immune response.
Indeed, our data indicate engagement of cells of the adaptive immune system. We note a significant
increase in CD8+ T cells levels, effector memory CD8 T cells and NKT cells. NKTs are a unique lineage
of innate T cells that express markers for T lymphocytes as well as NK cells. These cells can kill tumor
cells by direct cytolysis using perforin and granzyme B, but also by modulating the recruitment of other
effector immune including T cells, B cells, NK cells and DCs [51]. Thus, NKT cells may also play a key
role in linking the innate and adaptive immune response against tumors. NKT cells can also reverse
the immunosuppression mediated by MDSCs and tumor associated macrophages [52]. In the case of
glioma that display highly immunosuppressive tumor microenvironment, the role of NKT as boosters
of adaptive immune response and suppressor of immune regulation is therefore considered critical.
Furthermore, IHC highlighted the changing immunological landscape following in situ vaccination
with eCPMV. Our data indicate significantly elevated levels of CD45+ cells in the brain paranchyma
following CPMV administration, which corroborates earlier studies in melanoma models where
intratumoral administrations of CPMV lead to massive influx of effector immune cells [33]. In particular,
we observed enhanced influx of IBA-1/CD68+ microglia/macrophage cells. Microglia are the resident
innate immune cells of CNS that participate in immune surveillance and host defense against infectious
agents. Together with infiltrating bone marrow-derived macrophages, microglia functions to restore
homeostasis in brain parenchyma to counter inflammatory responses including malignancies. The dual
role of microglia/macrophages in gliomas has been extensively studied. Under immunosuppressive
TME, microglia/macrophages appear to promote glioma proliferation and invasiveness [53,54].
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However, microglia-secreted factors and TLR agonists have been shown to simulate apoptosis
in glioma cells [55,56]. Also, while genetic ablation of monocytoid cells has been shown to promote
glioma, drug mediated activation of monocytoid cells in brain results in microglia-mediated reduction
of brain tumor initiating cells [57]. This functional duality has been attributed to the polarization of
microglia to tumor suppressive M1 and tumor supportive M2 cells [58,59]. M1 cells are activated
by type I cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) and other
immunostimulants such as lipopolysaccharide (LPS), and lipoproteins. The activated M1 polarized
microglia have been shown to possess antigen-presenting capabilities to Th1 cells leading to anti-tumor
CTL activity [58]. CPMV has been shown to stimulate IFN-γ and TNF-α in the TME in our previous
studies, and therefore is likely to influence the glioma TME similarly. These results are consistent with
elevated staining observed in glioma treated with LPS or myeloid cell activation agents that also lead
to increased iNOS expression (M1 phenotype) and a significant reduction in tumor volumes [57].
Tumor-mediated immune suppression is a critical barrier to glioma immunotherapies. In addition
to M2 polarized microglia/macrophages described above, regulatory T cells (Tregs) accumulated
in the TME contribute to glioblastoma-mediated immune suppression [60]. In high grade brain
tumors, Tregs suppress activation, proliferation and cytokine production of CD4+/CD8+ T cells via
secreted cytokines such as TGF-B and IL-10 or via cell-to cell contact mediated by the constitutively
expressed CTLA-4 and PD-L1 checkpoints [61]. Thus, expansion of Tregs is associated with decreased
efficacy of immunotherapies and therapeutic targeting of Tregs has been used to improve survival
in glioma studies [62,63]. The significant reduction in intratumoral FoxP3+ Tregs following CPMV
immunotherapy mirrors the effects of intratumoral IL-12+CTLA-4 combination therapy which enhanced
infiltration of CD4/CD8 cells while significantly reducing the FoxP3+ Tregs [64]. Pro-inflammatory
cytokines including IL-12 are key component of eCPMV-mediated immune response and likely
contribute to reduced Tregs population in the glioma TME [25,33]. Overall, eCPMV immunotherapy
leads to an effective reversal of the immunosuppressive tumor microenvironment. In conjugation
with the elevated CD8+ T cells and NKT cells infiltration and enhanced activation of resident
microglia, this immunomodulation renders the glioma TME conducive for progression of an anti-tumor
immune response.
4. Materials and Methods
4.1. Production of eCPMV VLPs
eCPMV VLP was produced as described elsewhere [25,27]. Briefly, Agrobacterium LBA4404
cultures harboring the binary plasmid pEAQexpress-VP60-24K that encodes the coat protein precursor
VP60 and viral proteinase 24K, were introduced into N. benthamiana leaves using syringe-infiltration.
Infiltrated tissue was harvested 6 days post-infiltration, homogenized in 0.1 M sodium phosphate buffer
(pH 7.0) and purified using established protocols [27]. VLP concentration was determined by UV/vis
spectroscopy (ε280 nm = 1.28 mg−1 mL cm−1). Particle integrity was examined using transmission
electron microscopy (TEM) on a FEI Technai20 and by size exclusion chromatography using a Superose
6 column on the AKTA Explorer chromatography system (GE Healthcare, Chicago, IL, USA).
4.2. Synthesis and Characterization of eCPMV-Cy5 Particles
eCPMV VLPs were covalently modified with Cy5 using N-hydroxysuccinimide-activated ester
targeting surface exposed lysine residues on the capsid. Briefly, 3000 molar excess of Sulfo-Cyanine5
NHS ester (NHS-Sulfo Cy5) were reacted with eCPMV in 0.1M KP buffer at final protein concentration
of 2 mg/mL in presence of 10% (v/v) DMSO. Following overnight reactions, eCPMV-Cy5 was purified
from unconjugated reactants over a 40% (w/v) sucrose cushion at 160,000× g for 3 h and resuspended
in sterile KP buffer. UV spectroscopy was used to determine the eCPMV-Cy5 concentrations and to
determine Cy5/VLPs ratios using molar extinction coefficient εeCPMV of 1.28 mL mg−1 cm−1 at 280 nm
and sulfo-Cy5-specific molar extinction coefficient εCy5 of 271,000 at 660 nm.
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The conjugation of fluorophore on eCPMV was determined using SDS-gel electrophoresis. Briefly,
10 μg of unmodified eCPMV and eCPMV-Cy5 mixed with SDS running buffer and heated at 100 ◦C
for 5 min were loaded on pre-cast NuPAGE™ 4–12% Bis-Tris proteins gels (ThermoFisher Scientific,
Hampton, NH, USA) and electrophoresis was performed for 40 min at 200 V. Fluorescent bands
representing Cy5 modified eCPMV coat proteins were visualized on an AlphaImage gel documentation
system (Protein simple) using a 632 nm excitation. The gels were then stained using GelCode™ Blue
Safe protein stain (ThermoFisher Scientific).
4.3. Cell Line
GL261 cell line was obtained from the Tumor Repository at National Cancer Institute (NCI) and
maintained in suspension culture prior to engraftment intracranially. Briefly, cells were grown in
a suspension flask (CytoOne, CC-672-4175, USA Scientific, Oscala, FL, USA) and kept in a 5% CO2
37 ◦C humidified incubator in serum-free neuro medium (MACs neuro medium with Neurobrew-21
(130-093-570 and 130-097-263 respectively, Miltenyi Biotec Inc., Auburn, CA, USA), 20 ng/mL EGF
(AF-100-15, Peprotech, Rocky Hill, NJ, USA) and 20 ng/mL FGF (100-18B, Peprotech) with 1% (w/v)
pencillin-streptomycin (15140122, Gibco Invitrogen, Waltham, MA, USA) and 1% (w/v) L-glutamine
(25030081, Gibco Invitrogen). Cultured cells were pelleted and re-suspended in media to 3 × 103 cells
per 3 μL in growth medium and placed on ice prior to implantation.
4.4. Tumor Inoculation
All mouse studies were performed in compliance with the Institutional Animal Care and Use
Committee of Case Western Reserve University (Assurance number is A-3145-01, valid until 20 April 2019).
Immunocompetent animals (C57BL6, Jackson Labs, Bar Harbor, MA, USA), 4–6 weeks of age, males
and females, were utilized for intracranial implantation of GL261 cells (n = 4). Briefly, animals were
placed under anesthesia (inhaled isoflurane). Once fully anesthetized, lidocaine was applied and a
small incision was made through the scalp and the bregma was identified. A small 25-gauge burr
hole was made 2 mm caudal and 3 mm to the right of bregma. A 22-gauge Hamilton syringe (88011,
ThermoFisher Scientific) was inserted and placed 3 mm below the skull and then retracted 0.5 mm to
establish a pocket for implantation of cells. Cells, 3 × 103 cells per 3 μL PBS, were slowly injected into
the right frontal lobe and the Hamilton syringe was held in place for 3 min post injection to prevent
reflux. The burr hole was sealed with bone wax and the incision was closed with surgical glue and
non-dissolvable sutures. Animals were given analgesia and maintained on a heating pad until recovery.
Control and CPMV treated animals were placed under anesthesia weekly and given intratumoral
injections of either vehicle or CPMV (50 μg) in 3 μL dosages. Injections were made within the same
burr hole as done with inoculation of tumor. This was performed weekly for a total of 3 weeks.
Care and housing of the animals was provided by the University Animal Resource Center following
IACUC oversight. The facility follows recommendations from the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. Mice were maintained in microisolator cages and exposed to
12 h light/12 h darkness cycles with standard food and water ad libitum. Mice were weighed weekly and
checked daily for tumor growth symptoms according to the IACUC tumor burden policy.
4.5. Small Animal MRI
MRI imaging was performed prior to start of immunotherapy at day 6 from tumor inoculation
and post-treatment on day 30. The in vivo MRI studies were performed on the same Biospec 7 T
scanner equipped with a 3 cm birdcage 1H coil (Bruker, Erlangen, Germany). During MR imaging, mice
were anesthetized by isoflurane, respiration rate was maintained at 70–80/min. After reaching surgical
plane of anesthesia, the mouse was placed on an animal holder with its nose inserted into a nose cone.
A head restrainer was utilized to prevent potential motion. An animal monitoring system was in place
to monitor body temperature and respiration/cardiac cycle. After securing the animal and monitoring
the components, the animal was positioned at the center of the RF coil. The RF coil was placed into the
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magnet. We conducted shimming process using a single pulse sequence and the RF pulse was maximized
to keep the pulse length constant and a long enough recycle delay to conduct an image. A fast image
acquisition was used to acquire sample images to determine animal placement and imaging setup.
4.6. Flow Cytometry
The following antibodies and reagents were used for flow cytometry, all obtained from BioLegend
(San Diego, CA, USA): Pacific Blue anti-mouse CD45 (clone 30-F11), FITC anti-mouse CD11b (clone
M1/70), APC anti-mouse CD11c (clone N418), PE anti-mouse F4/80 (clone BM8), Brilliant Violet 605
anti-mouse CD86 (clone GL-1), Alexa Fluro 700 anti-mouse I-A/I-E (clone M5/114.15.2), APC/Cy7
anti-mouse CD3 (clone 145-2C11), FITC anti-mouse CD4 (clone Gk1.5), APC anti-mouse CD8 (clone
53-6.7), Alexa Fluor 700 anti-mouse CD25 (clone PC61), PE anti-mouse FOXP3 (clone MF-14), Zombie
yellow fixable viability kit, and anti-mouse CD16/32 (clone 93). GL261 Glioma bearing mice (n = 3)
were treated once or thrice with CPMV immunotherapy or PBS and brain tissues were harvested 24 h
following the intratumoral therapy. Single-cell suspensions were prepared as previously described [25]
and incubated for 15 min at 4 ◦C with a CD16/CD32 antibody (diluted in PBS) to block Fc receptors
before washing with PBS. Tumor cells harvested on following single CPMV dose were tested using
the innate panel and were incubated at 4 ◦C in triplicate with the cocktail of zombie yellow viability,
CD45, CD11b, CD11c, F4/80, CD86 and I-A/I-E antibodies diluted in PBS. Tumor cells harvested
at 24 h following three doses of CPMV immunotherapy were tested using the adaptive panel and
were incubated at 4 ◦C in triplicate with the cocktail of zombie yellow viability, CD45, CD3, CD25,
CD4, CD8 and FOXP3 antibodies. Cells were washed twice with PBS and then fixed with 3% (v/v)
paraformaldehyde for flow cytometry using an LSR II (BD Biosciences, San Jose, CA, USA). The data
were analyzed using the FlowJo v8.6.3 software (Flow Jo, Ashland, OR, USA).
4.7. Immunohistochemistry and H&E-Staining
Brain tissues harvested from treated and untreated mice (n = 3) were fixed in 10% (v/v)
buffered formalin, embedded in paraffin, sectioned at 6 μm, and mounted on Superfrost® Plus
slides (12-550-15, ThermoFisher Scientific). Sections were then hydrated through descending ethanol
to water. Endogenous peroxidase activity was eliminated by incubation in 3% (v/v) H2O2 for 30 min
prior to heat induced epitope retrieval (HIER). HIER was performed using a citrate based retrieval
buffer, pH 6.1 (S1699, Dako, Santa Clara, CA, USA) for 10 min in a 96 ◦C water bath. The mouse antigen
blocking kit (PK-2200, Vector laboratories, Burlingame, CA, USA) was utilized to reduce background
staining according to manufacturer protocols for mouse derived antibodies. To reduce non-specific
binding sections were incubated in 10% (v/v) normal goat serum (PCN5000, ThermoFisher Scientific) in
Tris-buffered saline, (TBS; 50 mM Tris-HCl 150 mM NaCl, pH 7.6, Bio-Rad, 170-6435, Hercules, CA,
USA) for 30 min prior to application of the primary antibody. Antibodies used in this study were
mouse monoclonal antibody specific CD68 (ab201340, Abcam, Cambridge, UK) and rabbit monoclonal
antibodies to IBA1 (ab178846, Abcam); CD45 (ab10558, Abcam) and Foxp3 (700914, Invitrogen, Camarillo,
CA, USA). Immunohistochemistry was visualized via the peroxidase-anti-peroxidase method using
3,3′-diaminobenzidine (DAB) as a chromogen (TA-125-QHDX, ThermoFisher Scientific, Waltham, MA,
USA). Serial sections were stained with hematoxylin and eosin to note the areas of tumor cell growth.
Images were acquired with an Azio Scope A.1 (Zeiss, Thronwood, NY, USA) from three adjacent fields
containing tumor. The immunoreactive intensity of positive cells were measured utilizing the Zeiss
image analysis program (Axiovision Red 4.5, Zeiss) with background levels substracted from the stroma
of the tumor. Statistical analysis was completed by ordinary one-way ANOVA using the Tukey’s
multiple comparisons test on the GraphPad Prism software (GraphPad Software, San Diego, CA, USA).
5. Conclusions
In conclusion, our results illustrate that eCPMV-mediated modulation of the immunological
landscape in the brain TME supports anti-tumor response in our murine model. With its non-pathogenic
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and non-replicating nature, ability to reverse the tumor immunosuppression and recruit immune
effector cells, eCPMV nanoparticles offer a promising immunotherapy for glioma. In this study,
we performed multiple intracranial treatments; in the future one may consider the development of
slow-release formulations, or continuous low flow infusion to better control the immune response and
alleviate the edema and complications associated with immunotherapy. Delivery of therapeutics to the
brain is an active area of research that has evolved from biodegradable polymer implants [65,66] to
more recent miniaturized implantable system MiNDS [67]. We have already developed and tested
slow-release formulations for VLP vaccines [68], including in situ vaccines [69]. By formulating
slow-release devices or implants incorporating VLPs, it will likely be possible to circumvent the need
for repeated invasive administrations; thereby improving the translational potential of plant virus
based immunotherapy for glioma.
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Abstract: Mesenchymal stem cells (MSCs) accumulate specifically in both primary tumors and
metastases following systemic administration. However, the poor payload capacity of MSCs limits
their use in small molecule drug delivery. To improve drug payload in MSCs, we explored polymeric
nanoparticles that were functionalized with transactivator of transcription (TAT) peptide. Paclitaxel
loaded poly(DL-lactide-co-glycolide) (PLGA) nanoparticles (15–16% w/w paclitaxel; diameter of
225 ± 7 nm; and zeta potential of −15 ± 4 mV) were fabricated by emulsion-solvent evaporation
method, followed by TAT-conjugation to the surface of nanoparticles via maleimide-thiol chemistry.
Our studies demonstrated that TAT functionalization improved the intracellular accumulation and
retention of nanoparticles in MSCs. Further, nano-engineering of MSCs did not alter the migration
and differentiation potential of MSCs. Treatment with nano-engineered MSCs resulted in significant
(p < 0.05) inhibition of tumor growth and improved survival (p < 0.0001) in a mouse orthotopic
model of lung cancer compared to that with free or nanoparticle encapsulated drug. In summary,
our results demonstrated that MSCs engineered using TAT functionalized nanoparticles serve as
an efficient carrier for tumor specific delivery of anticancer drugs, resulting in greatly improved
therapeutic efficacy.
Keywords: mesenchymal stem cells (MSCs); TAT peptide; PLGA; paclitaxel; nano-engineered MSCs;
orthotopic lung tumor model
1. Introduction
Tumors are characterized by uneven vascular perfusion. The outer-most regions often have near
normal blood flow while the inner regions can be avascular [1–3]. In addition, elevated interstitial
fluid pressure and rigid extracellular matrix compromise intra-tumoral solute transport [4]. This leads
to poor drug delivery to the under-perfused regions within the tumor and the eventual development
of drug resistance [5–7]. Cell-based drug delivery can overcome these critical tissue barriers faced
by synthetic nano drug delivery systems [8–10]. Because of their ability to respond to cytokine and
chemokine gradients, various cell types including T cells [11], macrophages [12] and non-hematopoietic
mesenchymal stem cells (MSCs) have been investigated for drug delivery [13]. Initial studies with
these cell-based systems typically involved genetic modification of the cells to express anti-tumor
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peptides and proteins [14]. More recently, techniques that allow the functionalization of cells with
nano drug delivery systems without affecting their viability or migratory phenotype have enabled the
utilization of MSCs for small molecule drug delivery [15–17].
A critical parameter that influences the effectiveness of cell-based drug delivery is payload
capacity. Previous studies have loaded nanoparticle-encapsulated drugs into cells through either
simple endocytosis mediated uptake of nanoparticles or by covalent conjugation of nanoparticles to
cell surface [15,16,18]. Rapid recycling and exocytosis of internalized nanoparticles [19] results in low
loading capacities when relying on non-specific endocytosis of drug-loaded nanoparticles. Similarly,
cells continuously internalize and recycle their outer membranes, which can result in lysosomal
degradation of membrane-conjugated nanoparticles.
In the current study, we evaluated nanoparticles functionalized with cell penetrating peptide
(CPP) to enhance drug payload capacity of MSCs. CPPs are typically 5–30 amino acids long,
and are characterized by their intrinsic ability to bypass lysosomes and enter cytoplasm through
macropinocytosis [20]. Among the various CPPs identified so far, transactivator of transcription (TAT)
peptide has been widely investigated to improve the intracellular delivery of various cargoes [21].
TAT peptide fragments are derived from the human immunodeficiency virus 1 protein containing
86–102 amino acid residues. The arginine-rich basic domain 48–60 (GRKKRRQRRRPPQ) is responsible
for the transactivation [22]. TAT peptide (47 to 57 YGRKKRRQRRR, Figure 1A) has been successfully
used to deliver biologically active antibodies [23], proteins [24], nucleic acids [25], small molecules [26],
and nanocarriers [27,28] both in vitro and in vivo. TAT peptide and TAT conjugated systems are
known to be internalized primarily through endocytic pathways [27,29,30]. Cellular internalization
of TAT peptide is temperature-dependent, dynamin-1-independent, and is inhibited by drugs that
block macropinocytosis [31]. However, some studies suggest that clathrin and caveolae-mediated
endocytosis are likely also involved [32–34].
We hypothesized that surface functionalization of polymeric nanoparticles with TAT peptide
will enable their improved internalization into and retention by MSCs, resulting in enhanced payload
carrying capacity. We covalently conjugated TAT peptide to the surface of nanoparticles encapsulating
paclitaxel (PTX) and used these nanoparticles to incorporate PTX in MSCs. Our studies show that
these nano-engineered MSCs are effective in inhibiting tumor growth in a mouse orthotopic model of
lung cancer.
2. Results
2.1. Synthesis of Thiolated TAT Peptide
To conjugate TAT peptide to nanoparticles having surface maleimide groups, the primary
amine groups in the TAT peptide was converted into free thiol (-SH) using N-Succinimidyl
3-(2-pyridyldithio)propionate (SPDP) reagent and reducing agent tris(2-carboxyethyl)phosphine
hydrochloride (TCEP). The detailed mechanism for the conversion is provided in the supporting
information (Supplementary Figure S1). This reaction resulted in the conversion of one amine group
(1.02 ± 0.12) per TAT peptide molecule into a free thiol as determined by thiol quantitation method.
2.2. Physicochemical Characterization of Nanoparticles
The hydrodynamic diameter (particle size) and zeta potential (surface charge) of nanoparticles were
measured by dynamic light scattering (DLS) technique. Particle size of PTX loaded poly(DL-lactide-
co-glycolide) (PLGA) nanoparticles (PTX NP), TAT functionalized PLGA nanoparticles (TAT NP),
and PTX loaded TAT functionalized PLGA nanoparticles (TAT PTX NP) was 213 ± 6, 227± 18,
and 225 ± 7 nm, respectively (Figure 1D). The surface charge of PTX NP, TAT NP, and TAT PTX NP was
found to be −21 ± 1, −8.7 ± 2.5, and −15 ± 4 mV, respectively. PTX loading was in the range of 15–16%
w/w. The efficiency of TAT peptide conjugation to NPs was 57 ± 4% (2.42 ± 0.14 μg/mg of NP).
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The goal of the in vitro drug release study was to confirm that the incorporation of TAT peptide
did not influence the drug release characteristics of nanoparticles. In order to maintain sink condition,
PTX release study was conducted in cell culture medium supplemented with 10% (w/v) Captisol®.
In vitro release of PTX from nanoparticles is shown in Figure 1E. An initial burst release of about
20% of the encapsulated PTX was observed in the first 1 h, followed by a steady release over the
study period. The total PTX released over 8 days was ~76%. This was similar to that observed with
non-functionalized PLGA nanoparticles in our previous studies [35], suggesting that TAT peptide
functionalization did not affect the release profile of PTX from the nanoparticles. The initial burst
release of PTX is primarily ascribed to the drug molecules present on or near the nanoparticle surface.
However, it is noteworthy that the burst release took place within first 4 h, which is equivalent to
optimal time for nano-engineering of MSCs. Thus, loosely bound PTX molecules are released during
the nano-engineering process and nanoparticles loaded in the MSCs are in the sustained release phase.
 
Figure 1. Preparation and characterization of PTX loaded TAT functionalized PLGA nanoparticles (TAT
PTX NP). (A) Chemical structure of HIV-1 TAT peptide (47–57, YGRKKRRQRRR). (B) Synthetic scheme
for the preparation of sulfhydryl activated TAT peptide using SPDP and TCEP. (C) Diagrammatic
representation for the preparation of TAT PTX NP. (D) Particle size distribution of TAT PTX NP.
(E) In vitro release profile of PTX from TAT PTX NP in cell culture medium supplemented with 10%
(w/v) Captisol® at 37 ◦C. Data shown is mean ± SD (n = 4).
2.3. Nanoparticles Uptake and Retention in MSCs
In order to determine the optimal incubation time to achieve the maximum nanoparticle loading
in MSCs, we performed quantitative uptake studies. The uptake of TAT NP was 3-fold higher when
compared to that of non-TAT NP (Figure 2A). These findings demonstrated the effectiveness of TAT
peptide-functionalized nanoparticles in increasing the drug payload in MSCs. However, there was
no significant difference in amount of TAT NP taken up at 4 or 6 h and hence 4 h was used as the
optimal incubation time for subsequent nano-engineering processes. The amount of PTX loading
in nano-engineered MSCs was quantified using HPLC. The average PTX content was found to be
16.1 ± 0.9 pg/cell in MSCs incubated with TAT PTX NP. As shown in Figure 2B, TAT-NP demonstrated
a 5-fold increase in the % retained in the cells when compared to non-TAT-NP, suggesting that the
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TAT-functionalized nanoparticles not only enhanced payload capacity, but also improved the cellular
retention of nanoparticles.
 
Figure 2. In vitro endocytosis (A) and exocytosis (B) of TAT-modified or non-TAT nanoparticles in
MSCs. Cells were incubated with 100 μg/mL rhodamine-labeled PLGA nanoparticles. Data shown is
mean ± SD, n = 4. (C,D) Cytotoxicity profiles of PTX solution, TAT PTX NP, and nano-engineered MSCs
in A549 cells. Cells were treated with PTX solution or TAT PTX NP (C) or nano-engineered MSCs (D).
MTS assay was performed after 72 h of treatment. Data shown is mean ± SD, n = 6. (E) Differentiation
(adipogenic and osteogenic) potential of nano-engineered MSCs (MSCs engineered with TAT NP;
TAT NP). Untreated MSCs and nano-engineered MSCs were grown in adipogenic and osteogenic
differentiation media for 3 weeks. The cells were fixed and stained with oil red O or alizarin red to
detect lipid vacuoles or calcium deposits, respectively. MSCs cultured in regular growth media were
used as negative control. Scale bar: 200 μm. (F) The migratory potential of MSCs from a serum free
media towards serum free, tumor reconditioned or 5% (v/v) serum containing media in a Transwell®
plate. Data shown is mean ± SD, n = 6. (G) Cell viability of nano-engineered MSCs. Data shown is
mean ± SD, n = 5.
2.4. In Vitro Cytotoxicity Studies
The in vitro cytotoxicity potential of nano-engineered MSCs was determined in A549 cells using
a standard MTS assay. PTX solution and TAT PTX NP were used as controls. IC50 values for
nano-engineered MSCs, PTX solution, and TAT PTX NP were 1171 MSCs (Figure 2D) (equivalent to
22 nM PTX), 1.96 nM, and 2.10 nM (Figure 2C), respectively.
2.5. Characterization of Nano-Engineered MSCs
Nano-engineered MSCs were characterized for adipogenic and osteogenic differentiation potential.
There were no apparent differences in the formation of neutral lipid vacuoles and calcium deposits,
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confirming that nano-engineered MSCs retain adipogenic and osteogenic differentiation potential,
respectively (Figure 2E).
Next, we also confirmed the functional ability of the nano-engineered MSCs using an in vitro
migration assay. As shown in Figure 2F, there was no significant change in the migration properties
of nano-engineered MSCs when compared to untreated MSCs. In response to cytokines present in
5% serum media, 21% of untreated MSCs, 20% MSCs treated with TAT NP, and 19% MSCs treated
with TAT PTX NP migrated to the lower chamber of the Transwell® plate (Figure 2F). Similarly, 23% of
untreated MSCs, 23% of MSCs treated with TAT NP, and 20% MSCs treated with TAT PTX NP migrated
towards tumor reconditioned media (Figure 2F). These findings clearly demonstrated that loading
MSCs with TAT PTX NP did not significantly affect the migratory ability of the MSCs.
2.6. Cell Viability of Nano-Engineered MSCs
The effect of TAT PTX NP on MSCs survival was evaluated by incubating MSCs with 100 μg/mL
nanoparticles. There was no significant effect of TAT PTX NP on viability of MSCs (Figure 2G). Further,
there was no difference in cell viability of TAT PTX NP and PTX NP treated MSCs, suggesting TAT
conjugation did not alter the cytotoxic potential of nanoparticles.
2.7. Therapeutic Efficacy of Nano-Engineered MSCs in Orthotopic Lung Tumor Model
The anticancer efficacy of nano-engineered MSCs was evaluated in an orthotopic lung tumor
model. Mice treated with MSCs + TAT PTX NP showed significant inhibition of tumor progression
(p < 0.05) compared to other treatment groups (Figure 3A). Furthermore, MSCs + TAT PTX NP treated
mice had significantly longer survival than those in control groups (log-rank test, p < 0.0001) (Figure 3B).
Notably, the median survival of MSCs + TAT PTX NP treated mice was 109 days after treatment
initiation, while the median survival of mice in control groups was in the range of 76–86 days.
 
Figure 3. Nano-engineered MSCs were more effective in inhibiting orthotopic tumor growth and
increased the overall survival of tumor bearing mice. (A) SCID beige mice bearing orthotopic A549
lung tumors were intravenously injected with Dulbecco’s phosphate buffered saline (Saline); 4 Million
MSCs engineered with TAT NP (MSCs + TAT NP); PTX solution; TAT PTX NP; 4 Million MSCs
engineered with TAT PTX NP (MSCs + TAT PTX NP). Plot of normalized bioluminescence readings
(n = 10 for MSCs + TAT PTX NP and n = 8 for all other groups). Arrowheads indicate injection days.
(*) Indicates significantly different (p < 0.05) from PTX solution; # indicates significantly different
(p < 0.05) from TAT PTX NP. (B) Kaplan–Meier survival curves for the different treatment groups.
Log rank test of MSCs + TAT PTX NP and control groups yields p < 0.0001 (*).
2.8. Immunohistological Staining of Lung Tumors
In order to study the mechanism of improved anticancer efficacy with nano-engineered MSCs,
lung tumor sections were stained for CD31, Ki-67, and cleaved caspase 3 (Figure 4A). Lung tumors
from the mice treated with nano-engineered MSCs showed significantly fewer angiogenic blood vessels
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compared to saline or MSCs + TAT NP treatment groups (p < 0.05). In addition, lung tumors from
the mice treated with nano-engineered MSCs showed significantly fewer proliferating cells (Ki-67
positive cells) compared to other treatment groups (p < 0.05). Densities of the cleaved caspase 3 positive
apoptotic cells in tumors from nano-engineered MSC treatment group was significantly higher (panel 3
of Figure 4A) than those in other groups (p < 0.05).
Figure 4. Immunohistological analysis of lung tumors collected from therapeutic efficacy study.
(A) Lung tumors were stained for CD31 (angiogenesis marker), Ki-67 (proliferation marker),
and caspase-3 (apoptosis marker). Images were taken at 20× magnification. Quantification of (B) CD31,
(C) Ki67, and (D) cleaved caspase-3 staining. Data represented as mean ± SD, n = 9 images; * p < 0.05
compared with other treatment groups and # p < 0.05 compared with saline and MSCs + TAT NP.
2.9. Toxicology Assessment of Nano-Engineered MSCs
To examine the possible side effects of nano-engineered MSCs, we evaluated various biochemical
and hematological parameters in healthy mice. We did not observe any signs of distress or significant
differences in the body weights of the mice in different groups. Levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase
(ALP), total protein (TP), albumin (ALB), globulin (GLOB), albumin/globulin (A/G) ratio, and total
bilirubin (TBIL) in serum collected from treated mice were not different than those in the saline group
(Table 1). Treatments with MSCs + TAT NP and MSCs + TAT PTX NP resulted in about 30% to 60%
increase in platelet count (Table 2). Previous studies have shown that MSCs can increase platelet
count through induction of interlukein-10 (IL-10) and TGF-β [36]. None of the other hematological
parameters were affected by the treatments (Table 2, Table S1).
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3. Discussion
Current approaches to tumor targeted drug delivery rely on passive accumulation of the drug
carrier in the tumor through the ‘enhanced permeation and retention’ (EPR) effect, followed by
internalization into tumor cells through either non-specific endocytosis or specific receptor-mediated
endocytosis. However, the leaky tumor vasculature and dysfunctional lymphatics that allow for
enhanced permeation of nano delivery systems also result in elevated interstitial fluid pressure that
inhibits convective transport within the tumor microenvironment. In addition, tumors have a dense
extracellular matrix that hinders diffusion. These physiologic and anatomic barriers constrain the
extent of drug distribution within the tumor and limit the overall therapeutic effectiveness of synthetic
delivery systems.
Recent studies have shown that cell-based drug carriers such as MSCs can infiltrate tumor
tissue more uniformly, and thus improve the intra-tumoral distribution of the therapeutic payload.
MSCs have been shown to actively traffic to both primary tumors and metastases, in response
to inflammatory signals secreted by neutrophils and macrophages infiltrating the tumor, which
enables the possibility of true active targeting of anticancer agents to the tumor tissue [13]. However,
it is difficult to load small molecules in cells because of their diffusional clearance out of the cells.
In addition, overexpression of drug efflux transporters such as P-glycoprotein in MSCs limits the
loading of anticancer drugs, many of which are substrates for efflux transporters [37]. Several attempts
have been made to load MSCs with anticancer therapeutics using polymeric nanoparticles [17,35,38],
micelles [39], liposomes [40], carbon nanotubes [15], and dendrimers [41]. A key limitation with
these methods is the limited drug loading efficiency [35,37]. For example, Zhang et al. investigated
MSCs to deliver doxorubicin-polymer conjugates for glioma therapy [41]. However, the doxorubicin
content in MSCs (5.81 ± 0.27 pg/cell) was found to be inadequate to meet the effective dose needed
for systemic administration based on the maximum number of cells that could be injected. In our
previous study, PTX loaded PLGA nanoparticles were used to load MSCs, but exocytosis of PLGA
nanoparticles from MSCs reduced the amount of nanoparticle- and PTX payload that can could
be loaded in MSCs (4.7 pg/cell) [35]. We hypothesized that this limitation can be overcome by
increasing the cellular uptake and retention of nanoparticles. It has been previously shown that TAT
peptide can be used to enhance the intracellular delivery of diverse bioactive molecules [23–28].
Attachment of TAT peptide to the surface of a drug carrier was shown to enhance the cellular
uptake of the carrier [42]. Feiner-Gracia et al. also demonstrated that TAT functionalized PLGA
nanoparticles were efficient in crossing plasma membrane and releasing their cargo inside the cells [43].
The increased uptake of TAT functionalized nanoparticles was attributed to the cationic nature of
peptide, which was responsible for strong electrostatic interactions with anionic cell membrane,
resulting in permeabilization and hence enhanced penetration inside the cells. Based on these findings,
PLGA nanoparticles surface functionalized with TAT peptide were used to increase the drug loading
capacity of MSCs. Our results further demonstrated that TAT functionalization improved drug loading
in MSCs by ~3.4-fold compared to that with non-functionalized nanoparticles by increasing the uptake
as well as retention of nanoparticles inside MSCs.
Although our aim was to generate nano-engineered MSCs with high drug loading, it was also
critical to ensure that nano-engineering process did not alter MSCs phenotype or their viability.
Our studies demonstrate that MSCs engineered with TAT NP retained their capacity to undergo
osteogenic and adipogenic differentiation. Similarly, loading MSCs with TAT PTX NP did not affect
their migration and tumor tropism, a property critical for their use in tumor-targeted drug delivery.
Additionally, the viability of nano-engineered MSCs is essential for their tumor homing and sustained
release of drugs at the tumor site. TAT conjugated nanoparticles did not result in toxicity when
incubated with MSCs at the concentrations required for nano-engineering process. These results
confirmed that TAT PTX NP loading had no negative impact on the phenotype or viability of MSCs.
Systemic injection of high number of MSCs can cause micro embolism, which could further
lead to vascular obstruction, stroke and/or death. To evaluate the maximum number of MSCs that
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can be administered intravenously without causing adverse effects, we dosed 2, 4, and 6 million
MSCs/mouse. This preliminary study showed that a bolus dose of 2 or 4 million MSCs did not cause
any gross toxicity or adverse effects over a one-week observation period. Based on the results of this
study, we selected a dose of 4 million nano-engineered MSCs/mouse (equivalent to 3.2 mg per kg BW
PTX). Despite significantly lower total dose of PTX (25.6 mg/kg total dose for MSCs + TAT PTX NP Vs
120 mg/kg total dose for free drug), nano-engineered MSCs resulted in significantly greater tumor
inhibition compared to free drug. Importantly, the mean survival of mice treated with nano-engineered
MSCs (109 days for MSCs + TAT PTX NP) was higher than that for the mice treated with PTX
solution (86 days). Further, PTX has been shown to cause several dose-dependent toxicities such as
leukopenia, neutropenia, and abnormalities in liver enzymes, including ALP, ALT and bilirubin [44,45].
Our previous studies also demonstrated that treatment with PTX solution (administered at 40 mg/kg
on day 0, 4, and 8) led to decrease in both WBC and RBC count as well as abnormalities in liver enzyme
induction [16]. However, in our current studies we did not observe any of these toxicities.
Finally, immunohistochemical studies confirmed that PTX delivered using nano-engineered
MSCs resulted in greater inhibition of angiogenesis, decreased tumor cell proliferation and increased
apoptosis, all of which point to improved tumor delivery of the drug with MSCs nano-engineered
using TAT PTX NP.
4. Materials and Methods
4.1. Materials
TAT peptide, TCEP, polyvinyl alcohol (PVA), alizarin red and oil red O were obtained from
Sigma (St. Louis, MO, USA). SPDP was purchased from Biovision (Milpitas, CA, USA). Amplite™
fluorimetric total thiol quantitation assay kit was purchased from AAT Bioquest, Inc. (Sunnyvale,
CA, USA). PTX was purchased from TCI America, Portland, OR, USA. FITC labeled TAT peptide
(FITC-LC-YGRKKRRQRRR-NH2) was purchased from AnaSpec (Fremont, CA, USA). Ester-terminated
50:50 poly (DL-lactide-co-glycolide) (inherent viscosity: 0.55–0.75 dL/g) was purchased from Lactel
Absorbable Polymers (Birmingham, AL, USA). Poly (L-lactide)-b-polyethylene glycol-maleimide and
poly (lactide-co-glycolide)-rhodamine B (lactide to glycolide ratio of 50:50, rhodamine B endcap,
Mn 10,000–30,000 Da) were purchased from PolySciTech (West Lafayette, IN, USA). Fetal bovine
serum (FBS) and penicillin/streptomycin were procured from Bioexpress (Kaysville, UT, USA). RPMI
1640, Dulbecco’s phosphate buffered saline (DPBS), and trypsin-EDTA solutions were purchased from
Invitrogen Corporation (Carlsbad, CA, USA). Mesenchymal stem cell media (MSCM) and human
MSCs were obtained from ScienCell Research Laboratories (Carlsbad, CA, USA). A549-luc cell line
was purchased from Caliper Life sciences (Waltham, MA, USA). D-Luciferin potassium salt was
purchased from Gold Biotechnology (Saint Louis, MO, USA). Female Fox Chase SCID Beige mice
(CB17.Cg-PrkdcscidLystbg-J/Crl) were purchased from Charles River Laboratories.
4.2. Synthesis of Sulfhydryl Activated TAT Peptide
Amine groups in the TAT peptide were converted into free thiols using the heterobifunctional
cross-linker SPDP followed by treatment with TCEP (Figure 1B). TAT peptide (1 mg) was dissolved
in PBS buffer. A 2-fold molar excess of SPDP was added to TAT peptide solution and incubated
on a rotating platform for 2 h, followed by reduction with a 20-fold molar excess of TCEP for 2 h.
The thiolated TAT peptide was purified using a polyacrylamide desalting column. The presence of
thiol in TAT peptide was quantified using amplite™ fluorimetric total thiol quantitation assay kit
(AAT Bioquest, Inc., Sunnyvale, CA, USA). The thiolated TAT peptide was subsequently used to
functionalize nanoparticles containing surface maleimide groups.
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4.3. Preparation of TAT-functionalized PLGA Nanoparticles
PTX loaded PLGA nanoparticles were prepared according to a previously described single
emulsion-solvent evaporation technique (Figure 1C) [38]. In brief, PTX (7 mg) and PLGA (32 mg)
were dissolved in 1 mL of chloroform and added to 8 mL of 2.5% w/v PVA solution. The mixture was
sonicated using a probe sonicator set at an output of 18–21 W for 5 min (Sonicator XL, Misonix, NY,
USA). The block co-polymer poly(L-lactide)-b-polyethylene glycol-maleimide (PLA-PEG-Mal; 8 mg)
was dissolved in 0.2 mL chloroform and added to the emulsion with continuous stirring. The emulsion
was further stirred overnight under ambient conditions, followed by 1 h stirring under vacuum to
completely remove chloroform. The resulting nanoparticles were washed by ultracentrifugation at
35,000 rpm for 35 min at 4 ◦C (Optima XPN-80 Ultracentrifuge, Rotor type: 50.2 Ti, Beckman Coulter)
followed by resuspension in deionized water three times. After the final wash, the nanoparticle pellet
was dispersed in deionized water and centrifuged at 1000 rpm for 10 min. The supernatant was then
reacted with thiolated TAT peptide. The resulting dispersion was stirred overnight at 4 ◦C. TAT peptide
functionalized nanoparticles (TAT PTX NP) were then centrifuged to remove unreacted TAT peptide,
and lyophilized (Labconco, FreeZone4.5). Blank nanoparticle formulation without the drug (TAT NP)
was synthesized similarly. Drug-free, rhodamine-labeled nanoparticles were formulated by adding
5 mg PLGA-rhodamine B to 27 mg PLGA (total 32 mg polymer).
4.4. Characterization of Nanoparticles
Delsa Nano C particle analyzer (Beckman Coulter, California, USA) was used to determine
the hydrodynamic diameter and zeta potential (surface charge). Nanoparticles were dispersed in
deionized water (0.1 mg/mL) using probe sonication (18–21 W for one min). Analysis was performed
at 25 ◦C and a scattering angle of 165◦.
To determine PTX loading, nanoparticles were dispersed in methanol (1 mg/mL) and the drug
was extracted overnight using a rotary extractor at room temperature. Nanoparticles were separated
from free PTX by centrifugation at 13,000 rpm for 30 min, and PTX concentration of the methanolic
extract was analyzed using HPLC [46].
To determine the extent of TAT peptide conjugation, nanoparticles were prepared with
FITC-labeled TAT peptide and fluorescence spectroscopy was used to measure TAT associated
fluorescence. Briefly, 1 mg of FITC-TAT nanoparticles was dispersed in deionized water and
fluorescence intensity (λex: 493 and λem: 522 nm) was recorded using a SpectraMax i3x multi-mode
microplate reader (Molecular Devices, LLC, CA, USA). Nanoparticles formulated without FITC-TAT
were used as blank control. The amount of TAT peptide conjugated to nanoparticles was quantified
using the standard curve of FITC-TAT solutions in deionized water (0.25–32 μg/mL).
The release of PTX from TAT PTX NPs was determined in MSC culture medium supplemented
with 10% w/v Captisol® (Cydex Pharmaceuticals, Lawrence, KS). Aliquots of nanoparticle dispersion
(0.5 mL, 0.1 mg/mL) were kept in an incubator shaker (37 ◦C; 100 rpm). At each time point (1 h, 2 h,
4 h, 1 day, 2 days, 3 days, 5 days, and 8 days), samples (n = 4) were centrifuged at 13,000 rpm for
15 min. The supernatant (0.45 mL) was collected and analyzed directly for PTX content by HPLC as
described above.
4.5. Cell Culture
Human MSCs were cultured in human MSC complete medium (ScienCell Research Laboratories,
Carlsbad, CA, USA). A549-luc cells were cultured in RPMI 1640 medium containing 10% FBS,
penicillin (100 IU/mL) and streptomycin (100μg/mL). All the cells were cultured at 37 ◦C in a
humidified incubator containing 5% CO2 and 95% air and monitored regularly for morphology and
growth characteristics.
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4.6. Nanoparticle Uptake and Retention in MSCs
For uptake studies, nanoparticles were fabricated using PLGA polymer that was covalently
labeled with rhodamine. MSCs were plated onto a 24-well plate at a density of 1 × 104 cells/well in
0.5 mL of MSC growth medium. Next day, the growth medium was removed, and cells were incubated
with nanoparticle dispersion in culture medium (100 μg/mL) for 0.5 h, 1 h, 2 h, 4 h, and 6 h at 37 ◦C.
At each time point, a group of wells were washed 3 times with DPBS and the cells in those wells were
lysed in 300 μL of DPBS by subjecting them to 3 freeze thaw cycles. The amount of nanoparticles
in the cell lysates was determined by monitoring rhodamine fluorescence using an IVIS spectrum
imaging system (Caliper Life Sciences, λex: 535 nm and λem: 580 nm). For the retention study, cells
were incubated with nanoparticles for 4 h followed by two washes with DPBS (this was designated
as the 0 h time point). Cells were further incubated with fresh culture medium at 37 ◦C. At various
time points over 4 h, cells were washed with DPBS, lysed and the amount of nanoparticles in the cell
lysate was determined. Data was represents % of nanoparticles retained insides cells relative to the 0 h
time point.
4.7. Preparation of Nano-Engineered MSCs
MSCs in suspension (2 × 105 cells/mL) were incubated with nanoparticle dispersion in cell
culture medium (100 μg/mL) in a rotating shaker at 37 ◦C. After 4 h of incubation, the cell suspension
was washed thrice by centrifugation at 1000 rpm for 5 min (Allegra X-30R Centrifuge, Rotor type:
SX4400, Beckman Coulter) followed by resuspension in DPBS to remove uninternalized nanoparticles.
The final cell pellet was resuspended in DPBS for further studies.
4.8. In Vitro Migration Potential of Nano-Engineered MSCs
In vitro migration potential of nano-engineered MSCs was evaluated using a 96-Transwell®
plate. MSCs were serum starved for 24 h prior to the migration study. To initiate the study, 5 ×103
untreated or nano-engineered MSCs in 50 μL serum-free medium were added to the top well of a
96-well Transwell® plate separated by an 8.0 μm pore size PET membrane (Corning Life Sciences,
Lowell, MA, USA). Bottom wells were filled with 200 μL of 5% (v/v) serum containing, serum-free,
or tumor-reconditioned media. Tumor reconditioned media was generated by incubating A549 cells
with 5% (v/v) serum containing media for 24 h. After incubating at 37 ◦C for 24 h, both top and bottom
wells were washed with DPBS and 150 μL of calcein AM solution (1.2 μg/mL) in cell dissociation media
was added to the bottom well followed by 1 h incubation in the dark at 37 ◦C. The cell suspension was
transferred to a black-walled 96-well plate and the fluorescence intensities were recorded at excitation
and emission wavelengths of 485 nm and 520 nm, respectively. The number of migrated cells was
quantified using standard curves constructed using untreated and nano-engineered MSCs stained
with calcein AM.
4.9. Effect of Nano-Engineering on MSC Viability
MSCs were seeded in a 24 well plate at a density of 1 × 104 cells/well. Next day, cells were
treated with 100 μg/mL nanoparticles at 37 ◦C. After 4 h incubation, nanoparticle dispersion was
removed, cells were washed three times with DPBS, and the cell viability was determined by MTS assay.
MSCs grown in cell culture medium was used as a control and percent cell survival was calculated
using the following equation:
Cell survival (%) =
(Absorbance o f treated cells − background)
(Absorbance o f untreated cells − background) × 100 (1)
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4.10. Differentiation Potential of Nano-Engineered MSCs
Nano-engineered MSCs were seeded at a density of ~4 × 104 cells/well in a 24-well plate, and then
incubated with adipogenic or osteogenic differentiation media (StemPro Osteogenesis or Adipogenesis
Differentiation Kits, Life Technologies, Carlsbad, CA, USA) for 3 weeks. The medium was replaced
every 3–4 days. The untreated MSCs incubated with differentiation media and those incubated with
regular culture media were used as positive and negative controls, respectively. After a 3-week
incubation period, cells were fixed with 4% formalin and stained with alizarin red or oil red O to
visualize osteogenic and adipogenic differentiation, respectively. Images were captured using a light
microscope at 20× magnification.
4.11. In Vitro Cell Growth Inhibition Studies
The cytotoxicity of nano-engineered MSCs against A549 (human lung adenocarcinoma) cells
was evaluated using MTS assay. A549 cells were seeded at a density of ~2 × 104 cells per well in
600 μL of RPMI 1640 medium in the bottom chamber of a 24 well Transwell® plate. Nano-engineered
MSCs at different cell densities (in 100 μL medium) were added to the top well of the Transwell® plate
separated by a 0.2 μm pore size PET membrane. PTX solution and TAT PTX NP were used as positive
controls. After 3 days of incubation, A549 cell viability was determined by MTS assay. A549 cells
grown in RPMI 1640 medium was used as a control, and the percentage of cell survival was calculated
using Equation 1.
4.12. Therapeutic Efficacy of Nano-Engineered MSCs in Orthotopic Lung Tumor Model
All experiments involving animals were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Minnesota (Animal protocol No.: 1605-33821A, approval
date: 25 July 2016). Female Fox Chase SCID Beige mice (CB17.Cg-PrkdcscidLystbg-J/Crl), 6–8 weeks
old (each weighing 18–21 g), were injected intravenously with 1 × 106 A549-luc cells dispersed in
200 μL DPBS. Tumor growth in the lungs was monitored by bioluminescence imaging. Mice were
injected intraperitoneally with 150 mg/kg of D-luciferin potassium salt solution prior to imaging
on an IVIS spectrum in vivo imaging system (Caliper Life Sciences). When tumor bioluminescence
reached ~5 × 105 photons/sec, mice were randomly assigned to five groups and were treated with
intravenous injection of DPBS (200 μL at every 14 days, ‘Saline’; n = 8), PTX solution (administered at
40 mg/kg on day 0, 4, and 8; ‘PTX solution’; n = 8), TAT PTX NP (equivalent to 3.2 mg/kg PTX every
2 weeks; ‘TAT PTX NP’; n = 8), MSCs loaded with TAT NP (4 × 106 every 2 weeks, ‘MSCs + TAT NP’,
n = 8), or MSCs loaded with TAT PTX NP (4 × 106 MSCs equivalent to 3.2 mg/kg PTX every 2 weeks,
‘MSCs + TAT PTX NP’, n = 10). Dosing regimen for PTX solution was selected based on our previously
published results [16]. Tumor growth was monitored by imaging tumor bioluminescence twice weekly
initially and then once a week. Animals were euthanized using CO2 when they showed signs of stress
such as loss of appetite, weight loss, and/or ruffled hair. Tumor-bearing lungs were collected at the
end of the study and processed for immunohistochemistry.
4.13. Toxicology Assessment of Intravenously Administered Nano-Engineered MSCs
Healthy SCID beige mice were administered with DPBS (control, n = 8), TAT PTX NP
(administered at 3.2 mg per kg BW PTX on day 0 and 14, n = 8); MSCs + TAT NP (4 × 106 cells
on day 0 and 14, n = 8); MSCs + TAT PTX NP (4 × 106 cells, equivalent to 3.2 mg per kg BW PTX on
day 0 and 14, n = 8). For complete blood count (CBC), ~250 μL blood per mouse was collected from
four mice in each group into EDTA tubes and gently mixed to prevent clotting. For liver function test,
~300 μL blood was collected from remaining four mice in each group into heparin-coated tubes. All the
samples were analyzed by Charles River Clinical Pathology Services (Shrewsbury, MA, USA).
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4.14. Immunohistological Staining of Lung Tumors
Lung tumors from the therapeutic study were fixed in 4% w/v formaldehyde solution for 24 h
and subsequently transferred to 70% (v/v) ethanol. Tissue samples were embedded in paraffin and
sectioned into 4 μm-thick slices. The sections were deparaffinized and stained for cleaved caspase-3,
Ki67, and CD31. Both cleaved-caspase 3 (Cell Signaling Technology, Danvers, MA, USA) and Ki-67
clone SP-6 (Biocare Medical, Concord, CA, USA) staining used a 1:100 antibody concentration followed
by Envision Rabbit Horseradish Peroxidase (HRP) detection system (Dako, Carpinteria, CA, USA).
CD31 assay used a 1:1200 antibody concentration (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
followed by Goat-on-Rodent HRP polymer system (Biocare Medical). All the sections were developed
using DAB chromogen (Dako) and counterstained with Mayer’s Hematoxylin (Dako). The relative
staining for each target was analyzed by Image J software (https://imagej.nih.gov/ij/download.html)
to determine the fraction of positive stain per unit tissue area.
4.15. Statistical Analysis
The statistical significance of observed differences between groups was determined by one-way
ANOVA, followed by Bonferroni-Holm post-hoc analysis for comparison between individual groups.
Log-rank test was conducted to compare the survival distribution of different treatment groups.
A probability level of p < 0.05 was considered significant.
5. Conclusions
In summary, we demonstrated significantly improved drug loading in MSCs by using TAT
functionalized nanoparticles. These nano-engineered MSCs retained their osteogenic and adipogenic
differentiation properties and tumor-tropism. Moreover, nano-engineered MSCs were effective in
inhibiting tumor growth and increasing the overall survival in a mouse orthotopic lung tumor model.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/4/491/s1,
Figure S1: Preparation of TAT functionalized PLGA nanoparticles, Table S1: Effects of different treatments on
complete blood count.
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Abstract: Non-viral, polymeric-based, siRNA nanoparticles (NPs) have been proposed as promising
gene delivery systems. Encapsulating siRNA in targeted NPs could confer improved biological
stability, extended half-life, enhanced permeability, effective tumor accumulation, and therapy.
In this work, a peptide derived from apolipoprotein B100 (ApoB-P), the protein moiety of
low-density lipoprotein, was used to target siRNA-loaded PEGylated NPs to the extracellular
matrix/proteoglycans (ECM/PGs) of a mammary carcinoma tumor. siRNA against osteopontin
(siOPN), a protein involved in breast cancer development and progression, was encapsulated into
PEGylated poly(D,L-lactic-co-glycolic acid) (PLGA) NPs using the double emulsion solvent diffusion
technique. The NPs obtained possessed desired physicochemical properties including ~200 nm size,
a neutral surface charge, and high siOPN loading of ~5 μg/mg. ApoB-P-targeted NPs exhibited both
enhanced binding to isolated ECM and internalization by MDA-MB-231 human mammary carcinoma
cells, in comparison to non-targeted NPs. Increased accumulation of the targeted NPs was achieved
in the primary mammary tumor of mice xenografted with MDA-MB-231 mammary carcinoma cells
as well as in the lungs, one of the main sites affected by metastases. siOPN NPs treatment resulted in
significant inhibition of tumor growth (similar bioactivity of both formulations), accompanied with
significant reduction of OPN mRNA levels (~40% knockdown of mRNA levels). We demonstrated
that targeted NPs possessed enhanced tumor accumulation with increased therapeutic potential in
mice models of mammary carcinoma.
Keywords: nanoparticles; targeted delivery system; siRNA; osteopontin; mammary carcinoma
1. Introduction
Polymeric nanoparticles (NPs), formulated with poly(D,L-lactic-co-glycolic acid) (PLGA)
copolymer, have emerged as promising carriers for cancer therapy by delivering a wide variety
of drugs, including small interfering RNAs (siRNAs) [1–5]. The unique characteristics that make
PLGA-based NPs promising candidates for siRNA delivery include their ability to protect the siRNA
molecules from degradation, overcoming the cell membrane absorption barrier thereby enabling
siRNA internalization into the target cells, tunable sustained release properties, facile possibilities
for surface functionalization, and their biocompatibility and biodegradability properties [6–9]. NPs
accumulation in solid tumors is mediated mainly by a passive process (i.e., the enhanced permeability
and retention effect (EPR)), based on the leaky vasculature and poor lymphatic drainage present in
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the tumor [10–13]. Nanosized particles with neutral surface charges and/or a hydrophilic surfaces
(PEGylation) have the propensity for increased circulation time because of decreased phagocytosis
by the mononuclear phagocytic system (MPS), which consequently increases their EPR-based tumor
accumulation [14]. Their ultimate fate is similar, however, to that of conventional NPs, and the
liver/spleen will eventually take up the majority of circulating NPs [15,16]. Hence, for efficient NPs
accumulation at the tumor site, a long circulation time and efficient particle targeting are critical.
Incorporation of a targeting ligand in NPs’ surfaces enables binding of the carrier with specific
targets in the tumor tissue, which most often can be overexpressed, resulting in enhanced tumor
accumulation and/or retention [17–19]. A broad range of ligands have been used for formulating
targeted nanocarriers for enhanced tumor accumulation, including small molecules, carbohydrates,
aptamers, peptides, proteins, or antibodies [20].
In our previous studies, PLGA-based NPs, containing antisense [7,21] and siRNAs [22,23] that
were neither PEGylated nor targeted, have been examined in mammary carcinoma animal models.
In the present study we sought to examine the feasibility of targeting siRNA-containing NPs to
the cancer tissue by linking a specific navigator peptide to the NPs surface. In cancer, the tumor
vasculature is highly permeable, and the sub-endothelial retention in the extracellular matrix (ECM) of
low-density lipoproteins (LDLs) through their interaction with proteoglycans (PGs) is enhanced [24–26].
In vitro studies have identified sequences derived from the protein moiety of LDL, apolipoprotein
B100 (apoB100), which binds the negatively charged PGs and LDL receptor (LDLr) with a high
affinity [27–29]. We hypothesized that by linking an apoB100-derived peptide (25 AA; ApoB-P) to the
NPs surface [30], the decorated NPs will be targeted to the tumor’s ECM through their interaction
with PGs in the tumor’s microenvironment. As a model drug, we used an siRNA sequence specifically
designed to knockdown the human osteopontin protein (OPN) [22,23]. OPN, a member of the
small integrin-binding ligand N-linked glycoproteins (SIBLINGs) family [31], is considered as a
multifunctional protein that plays a central role in malignancy [32–34]. Knockdown of OPN expression
was shown by us and others to have antimetastatic and antitumorigenic effects [23,35–37]. We have
shown that siRNA against OPN (siOPN) delivered by NPs inhibits tumor growth in an ectopic model
of mammary carcinoma [22]. In this work, we examine whether the use of targeted NPs leads to both
enhanced tumor accumulation and superior therapeutic efficacy. We evaluated the targeting efficiency
of the ApoB-P NPs in vitro by examining their binding to both isolated basement membrane (BM) and
ECM, and their uptake into breast cancer cells. In vivo, we further assessed their biodistribution and
bioactivity in mammary carcinoma mice models.
2. Results
2.1. Poly(D,L-Lactic-Co-Glycolic Acid) Apolipoprotein B100 Peptide (PLGA-ApoB-P) Synthesis
The targeting peptide, ApoB-P, was linked to PLGA with a polyethylene glycol (PEG) spacer.
PLGA-PEG-maleimide (PLGA-PEG-MAL) was synthesized by linking a heterobifunctional PEG
containing a maleimide (MAL) group at one terminus to PLGA (Figure 1a). The successful linking
between the PEG linker and PLGA was verified by 1H NMR spectroscopy (Figure S1). ApoB-P linking
in the final step of the synthesis (thiol-maleimide click reaction) was confirmed by amino acid analysis
and by elemental analysis. The linking efficiency was >70%.
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Figure 1. Schematic representation of PolyD,L-lactic-co-glycolic acid) apolipoprotein B100 peptide
(PLGA-ApoB-P) synthesis (a), and targeted nanoparticle (NP) preparation (b), by two methods (I and II).
2.2. Nanoparticles (NPs) Physicochemical Properties
Targeted NPs (prepared by either method I or II, Figure 1b) and non-targeted NPs were
successfully prepared using the double emulsion solvent diffusion (DESD) method. The NPs had a
mean diameter of ~200 nm (empty and siOPN-loaded) with a narrow size distribution and a neutral
surface charge (Table 1). siOPN was encapsulated in both targeted and non-targeted NPs, using
polyethyleneimine (PEI) of 800 Da as the counter-ion for siOPN complexation, resulting in a relatively
high siOPN loading of 4.9 and 5.1 μg/mg, and an encapsulation yield of 29.6% and 31.0%, respectively
(Table 1).
Table 1. Physicochemical properties of targeted and non-targeted NPs (mean ± SD).









Targeted empty 212.4 ± 3.6 0.21 ± 0.02 −0.9 ± 0.2 - -
Non-targeted empty 207.3 ± 4.3 0.17 ± 0.02 −1.1 ± 0.1 - -
Targeted siOPN 233.9 ± 3.7 0.29 ± 0.01 −0.6 ± 0.2 4.9 ± 0.2 29.6 ± 0.9
Non-targeted siOPN 228.5 ± 23.0 0.31 ± 0.04 −0.5 ± 0.1 5.1 ± 0.2 31.0 ± 1.4
2.3. In Vitro Binding and Uptake
2.3.1. Binding to Isolated Extracellular Matrix (ECM)
The binding affinity of targeted NPs to the ECM was evaluated by incubating the NPs with
isolated ECM derived from porcine aortic endothelial cells. We validated the presence of ECM in
the wells by fluorescent labeling for heparan sulfate proteoglycan (HSPG). No differences between
targeted and non-targeted NPs were observed below NPs concentration of 5 mg/mL (Figure 2a).
However, at a concentration of 10 mg/mL the targeted NPs showed enhanced binding to the ECM,
compared to non-targeted NPs that remained almost undetected (Figure 2a).
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Figure 2. NPs binding to extracellular matrix (ECM) isolated from endothelial cells (a), and to basement
membrane (b). Data is presented as mean ± SD, * p < 0.05. Validation of ECM matrix presence in the
coated well is shown in the inset (a) conducted by fluorescent labeling for heparan sulfate proteoglycan
(HSPG) (perlecan protein; basement membrane-specific heparan sulfate proteoglycan core protein).
2.3.2. Binding to the Basement Membrane (BM) Matrix
The binding affinity of targeted NPs to the BM was evaluated by incubating the NPs in wells
pre-coated with Matrigel matrix, using 10 mg/mL of NPs. As in the isolated ECM model, targeted
NPs exhibited higher binding affinities in comparison to non-targeted NPs (Figure 2b). Moreover,
pre-incubation of the coated wells with free ApoB-P abolished the increased binding of the targeted
NPs (Figure 2b). This further supported our hypothesis that the attachment of the NPs was to a specific
target in the ECM, which was apparently saturated by the presence of the free ligand.
2.3.3. Uptake into the MDA-MB-231 Cell Line
To evaluate the enhanced uptake of the targeted NPs into MDA-MB-231 breast cancer cells,
targeted and non-targeted fluorescent NPs were incubated with the cells for different durations, and
internalized NPs were analyzed by flow cytometry (FACS). The number of cells with internalized
targeted NPs was significantly higher at all time points (Figure 3(ai)), in comparison to cells with
non-targeted NPs, by a factor of 4.4, 2.3, and 1.3 after 0.5, 1, and 2 h of incubation, respectively. At
longer incubation time periods, the difference between the uptakes of targeted and non-targeted
NPs declined.
In addition to the higher number of cells internalizing the targeted NPs, each cell engulfed a
higher amount of the targeted formulation, demonstrated by the higher fluorescent intensity measured
within the cells (Figure 3(aii)). The enhanced uptake of targeted NPs was further observed qualitatively
by confocal laser scanning microscopy (Figure 3b), shown by the higher green staining of cells treated
with the targeted formulation after 0.5 and 6 h (Figure 3b).
To further examine the mechanism of NPs internalization, targeted and non-targeted NPs were
incubated with MDA-MB-231 cells at 4 ◦C and at 37 ◦C (Figure S2). Higher uptake of targeted compared
to non-targeted NPs was observed at 37 ◦C (Figure S2). Lowering the temperature significantly reduced
both targeted and non-targeted NPs uptakes, suggesting an active and energy-dependent endocytosis
(Figure S2). Nevertheless, targeted NPs maintained their higher affinity and uptake at all time points
examined, even at reduced temperatures (Figure S2). Of note, after 60 min of incubation, targeted NPs
incubated at 4 ◦C demonstrated higher affinity compared with non-targeted NPs at 37 ◦C (Figure S2).
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Figure 3. Cellular uptake of NPs by the MDA-MB-231 cell line. Cells internalizing NPs were analyzed
quantitatively by means of flow cytometry (FACS) (a), and qualitatively by means of confocal laser
scanning microscopy (b). A total of 10,000 cells were counted in each measurement (n = 2). Data is
presented as the mean ± SD, * p < 0.05 for targeted (Tar) versus non-targeted (Non-tar) at 0.5 h. ** p < 0.01
at 1, 2, 4, and 6 h for targeted versus non-targeted comparisons. NPs are shown in green (PLGA-BODIPY);
magnification 60×; size bar, 30 μm. The fluorescent intensity was normalized to untreated cells.
2.4. In Vivo Biodistribution—4T1 Intravenous (IV) Model
To evaluate the ability of NPs to accumulate at metastatic sites, the 4T1 IV model, a commonly
employed model to study breast cancer lung metastasis, was used [38]. Metastatic lesions in the lungs
were confirmed using bioluminescence (Figure S3), and the biodistribution of the NPs was studied as
reported earlier [22]. Higher accumulation of the targeted NPs in the liver and spleen was noted after
8 h, but was similar after 24 h (Figure 4). There was no difference in the biodistribution of NPs in the
kidneys. Significantly higher accumulation of the targeted NPs was observed in the metastatic lungs
(1.8 times higher compared to non-targeted NPs) at 8 h after NPs injection (Figure 4). The same trend
was observed after 24 h (borderline significance, p = 0.07).
Figure 4. Biodistribution of NPs in the 4T1 intravenous (IV) model. Typhoon images (a) followed
by ImageJ analysis (b) demonstrating targeted (n = 3) and non-targeted (n = 3) NPs accumulation in
different organs. (Non-targeted NPs are described in [22].) The mean fluorescent intensity in each
organ was normalized to untreated control. Data is presented as mean ± SD, * p < 0.05, and ** p < 0.001.
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2.5. In Vivo Biodistribution—Orthotopic Xenograft Model
To evaluate the capability of the targeted formulation to accumulate in a primary tumor site,
biodistribution was studied in the xenograft model of MDA-MB-231 human mammary carcinoma.
Targeted NPs accumulated to a greater extent in the primary tumor site, at ~1.4 times higher than
the non-targeted NPs (Figure 5c,d). A similar accumulation of targeted and non-targeted NPs was
observed in the liver, spleen, and kidneys (Figure 5a,b). Of note, significantly increased uptake of the
targeted NPs was observed in the lungs (Figure 5a,b).
Figure 5. Biodistribution of NPs in the orthotopic xenografted mice model of MDA-MB-231 human
mammary carcinoma cells. NPs biodistributions in selected organs (a,b) and in the primary tumor
site (c,d) following treatment with targeted (n = 2) and non-targeted (n = 3) NPs was determined by
Typhoon images followed by ImageJ analyses, 24 h after IV treatment. The mean fluorescent intensity in
each organ was normalized to untreated control (mean ± SD, ** p < 0.01, and * p < 0.05). Representative
confocal microscopy images for qualitative assessment of NPs accumulation in tumor cryosections is
shown in (e); magnification 60×; size bar, 20 μm. NPs are shown in red (PLGA-Cy5). The fluorescent
intensity was normalized to tumor cryosections of untreated control.
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2.6. In Vivo Bioactivity—Orthotopic Xenograft Model
The bioactivity of the NPs was evaluated in the orthotopic MDA-MB-231 model, but not in the
4T1 model, because the siOPN sequence used was designed to knockdown human OPN, which is not
expressed in the 4T1 cell line (mice origin). Treatment of mice xenografted with MDA-MB-231 human
mammary carcinoma cells with targeted and non-targeted siOPN NPs resulted in a similar, significant
suppression of tumor growth (Figure 6a). Congruent with significant tumor growth inhibition, a ~40%
knockdown of OPN mRNA levels was also observed (Figure 6b).
 
Figure 6. Tumor growth inhibition by siOPN NPs in the orthotopic xenograft MDA-MB-231 mammary
carcinoma mice model. Targeted vs. non-targeted siOPN NPs were injected at a dose of 1 mg/kg
by body weight of siOPN (arrows, (a)). Tumor size is presented as the tumor volume ratio, V/V0. V
and V0, tumor volume measured at each time point and initial tumor volume (day 1), respectively,
(mean ± SEM; n= 5–7 in each group, * p < 0.05, treatment vs. control). Knockdown of OPN mRNA
levels evaluated by RT-PCR is shown in (b). OPN mRNA levels were normalized to GAPDH and to
untreated control animals (mean ± SEM; n = 5–7 in each group, * p < 0.05, ** p < 0.01, treatment vs.
control).
3. Discussion
Polymeric NPs based on the biocompatible and biodegradable PLGA have been explored for the
delivery of siRNA [5,22,23,39]. PEGylated NPs, termed “stealth NPs”, are characterized by increased
residence times in the circulation and provide increased tumor accumulation via the EPR effect [1,40,41].
Nevertheless, a targeted delivery system (i.e., NPs decorated with a specific tissue/cell ligand) could
further increase retention time at the diseased tissue [20,42,43]. In the present study, PLGA-PEG NPs
containing siOPN were decorated with a navigator peptide (ApoB-P), which has affinity to PGs in the
ECM of the tumor and to LDLr. We demonstrated that targeted NPs possessed significantly enhanced
tumor accumulations and increased therapeutic potentials in mice models of mammary carcinoma.
The ligand, ApoB-P, is composed of two consecutive peptide dimers, derived from aa 3145
through 3157 and 3359 through 3367 (of apoB100), linked with a glycine–cysteine–glycine bridge (GCG;
3145–3157-GCG-3359–3367) [30]. The role of the individual dimers in the binding of LDL-apoB100 to
PGs and to LDLr has been well established [44–47]. Olsson et al. [45] have shown that a heterodimer,
linked by a glycine tripeptide (3145–3157-GGG-3359–3367), has higher affinity to PGs and LDLr
than the two separated segments. We hypothesized that linking the two peptide dimers with the
tripeptide, glycine–cysteine–glycine (GCG rather than GGG), could enable facile linking to PLGA-PEG,
bestowing a U-shape orientation of the ligand—a conformation resembling that of the native apoB100
protein [27,44,48].
Targeted and non-targeted NPs containing siOPN, prepared by the DESD method, yielded NPs
with a size of ~200 nm, a narrow size distribution (low PDI), and a neutral surface charge. The
positively charged PEI of 800 Da, which was shown to be less toxic than the routinely used PEI of
25 kDa [22,49], was used as a counter-ion to the negatively charged siRNA in order to achieve efficient
encapsulation. Depending on the N:P ratio (cation to anion molar ratio, e.g., the PEI nitrogen to siRNA
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phosphate ratio), relatively high loading of siOPN was achieved (~5 μg of siOPN/mg of NPs). No
difference in the loading of siOPN was found between targeted and non-targeted NPs, suggesting
that the presence of PEG-linked ApoB-P to the surface of the NPs did not hamper the encapsulation
of siOPN.
The competitive affinity studies, in the two models of BM and isolated ECM (Figure 2), validated
the preferred binding of targeted NPs to BM/ECM, indicating their potential to bind and be retained in
the tumor’s extracellular space. In addition to the enhanced binding to BM/ECM, the targeted ApoB-P
NPs demonstrated an increased uptake into MDA-MB-231 breast cancer cells up to 6 h of incubation
(Figure 3). As expected, at longer incubation periods (4 and 6 h), differences between targeted and
non-targeted NPs diminished since all the cells eventually engulfed the NPs. The increased uptake
of targeted NPs by MDA-MB-231 cells, even at 4 ◦C (Figure S2), further supports the affinity of the
targeted NPs to specific substrate(s) in the cells’ membrane. Cell surface PGs [45] and LDLr, which
are upregulated in tumor cells [50–52], are the most probable binding sites for the ApoB-P-decorated
NPs. Taken together, we postulate that enhanced accumulation of the targeted NPs in the primary
tumor could arise from their increased binding/retention at the tumor’s ECM as well as their enhanced
uptake into the tumor cells by receptor-mediated endocytosis.
Since Paget’s “seed and soil” hypothesis [53], it is now well established that the lungs are among
the primary organs affected in metastatic breast cancer [54,55]. We demonstrate preferred accumulation
of the targeted NPs in the metastatic lungs of the 4T1-transplanted mice. A higher accumulation of
the targeted NPs in the lungs was also observed in the orthotopic model of MDA-MB-231. Although
lung macro-metastases were not observed at the time of sacrifice, micro-metastases are expected
to form [56]. Another explanation for the higher accumulation in the lungs of the targeted NPs in
the orthotopic model could be due to changes occurring in the pre-metastatic lungs. Evidence has
emerged that early influx of neutrophils and other factors (including OPN) secreted by the primary
tumor are key mechanisms in establishing the pre-metastatic niche for subsequent engraftment of
tumor cells [57], and this leads to increased endothelial permeability and vascular leakiness [58,59].
In addition, PGs, being a major component of the ECM in the alveolar wall [60], are prevalent on the
surface of lung capillary endothelium [61]. Nevertheless, the enhanced uptake in the lungs could be,
at least in part, due to the abundant interstitial monocytes in this organ [62–64]. This is corroborated
by the finding (Figure S4) that targeted NPs are engulfed to a higher extent than non-targeted NPs
by white blood cells (WBCs), specifically by monocytes. This in turn is most likely because of the
different PEGylation type of the NPs. PEG in non-targeted NPs (PLGA-PEG) is expected to be entirely
functional in structure in comparison to that in targeted NPs since the PEG moiety is blocked at the
end by the peptide (PLGA-PEG-ApoB-P). Taken together, the enhanced accumulation in the lungs of
targeted NPs represents a significant potential for lung metastases therapy.
The major MPS organs responsible for particulate system sequestration and disposal are the
liver and the spleen [21,65,66]. Indeed, in both mammary carcinoma models, substantial amounts
of both targeted and non-targeted NPs were observed in these clearing organs, and similar levels
were observed after 24 h (Figures 4 and 5a,b). Similarly, no difference in the disposition of targeted
and non-targeted NPs was observed in kidneys, which exhibited the lowest level of biodistribution,
probably because the size of the NPs was too large for renal filtration [65].
Finally, a significantly higher amount of the targeted vs. non-targeted NPs (1.4 times) was detected
in the primary tumor site (Figure 5c,d). Of note, both targeted and non-targeted NPs were distributed
throughout the tumor tissue, located in between the tumor cells (ECM) and inside the cells (Figure 5e).
We anticipate that after reducing the uptake of targeted NPs by WBCs, higher levels in the tumor
would be obtained. This can be achieved, for example, by adding PEG-PLGA chains in between the
ApoB peptide-PEG-PLGA. Nonetheless, their accumulation in the tumor was significantly higher in
comparison to non-targeted NPs, indicating their high affinity to the tumor tissue.
There are two possible explanations to the observation that both treatments of targeted and
non-targeted siOPN NPs exhibited similar inhibition of tumor growth (Figure 6a). Perhaps the
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higher levels of targeted NPs detected in the tumor were insufficient to exert a superior therapeutic
effect. In addition, retention of the targeted NPs in the ECM of the tumor could have also limited
their internalization into the cancer cells, resulting in similar bioactivity as the non-targeted NPs.
Nevertheless, it is plausible to assume that the higher levels of targeted NPs found in the tumor could
translate to superior efficacy at a later time period (tumor size was measured for a period of nine days
since the first NPs injection). The therapeutic effect was in accord with that obtained in an ectopic
xenograft model (MDA-MB-231 cells injected SC) treated with non-targeted siOPN NPs [22]. Although
siOPN levels in the suppressed tumor were not determined, the therapeutic effect obtained by siOPN
NPs was mediated by OPN mRNA knockdown (~40%; Figure 6b), validating our hypothesis. Overall,
we developed a new platform for targeted siRNA delivery. This protean platform can be specifically
tailored to deliver any siRNA of choice or, for that matter, any other drug intended to inhibit tumor
growth. It should be noted that numerous reports describe tumor uptake of drugs following systemic
administration by various types of NPs, mainly by the EPR principle [1,10,12,15,16,67–70]. The fate
of nanomedicine has been criticized for lack of effective tumor accumulation [10,62,71–75]. In a
recent review summarizing hundreds of studies performed in the field of tumor delivery systems [76],
accumulation in the tumor tissue is on average 0.9% and 0.6% of the injected dose (ID), targeted and
non-targeted NPs, respectively, and only 0.0014% ID of targeted NPs are detected in the tumor cells [77].
Our study provides a foundation for rationally developing new delivery strategies for cancer therapy.
4. Materials and Methods
4.1. Materials
PLGA (50:50, ester terminated, MW of 30–60 kDa), tris-EDTA buffer (TE buffer, RNase-free,
10 mM Tris-HCl, 1 mM EDTA), PEI (branched, 800 Da), poly(vinyl alcohol) (PVA, 30–70 kDa),
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), 1-Hydroxybenzotriazole
(HOBt), and Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) were purchased from Sigma-Aldrich
(Rehovot, Israel). PLGA 50:50, acid terminated, MW of 50–60 kDa was purchased from
Lakeshore Biomaterials (Birmingham, AL, USA). PLGA-PEG copolymer (RGP d 50105, PLGA,
45 kDa, and PEG, 5 kDa) was purchased from Boehringer Ingelheim (Ingelheim, Germany). The
heterobifunctional PEG, amine-PEG-maleimide (NH2-PEG-MAL; PEG, 2 kDa) was purchased from
Creative PEGWorks (Chapel Hill, NC, USA). siOPN (described in [22,23]) was custom synthesized by
Thermo Fisher Scientific (Waltham, MA, USA). The navigator peptide, ApoB-P (a 25 AA sequence:
SVKAQWKKNKHRHGCGRLTRKRGLK [30]; MW of ~3 kDa) was purchased from CASLO ApS
(Lyngby, Denmark). Mannitol and organic solvents were obtained from J.T. Baker Chemicals (Radnor,
PA, USA). Tissue culture reagents and phosphate buffered saline (PBS) were purchased from Biological
Industries (Beit-Haemek, Israel).
4.2. PLGA-ApoB-P Synthesis
ApoB-P was linked to PLGA through a PEG spacer, as shown in Figure 1a. In the first step of
the synthesis, a maleimide-functionalized di-block copolymer, PLGA-PEG-MAL, was synthesized
by the conjugation of PLGA-COOH to the bi-functional NH2-PEG-MAL. PLGA-COOH (0.017 mmol)
dissolved in acetonitrile (ACN) was converted to an active ester using an excess of HOBt (0.7 mmol) and
EDC (1 mmol), followed by a reaction with NH2-PEG-MAL (0.034 mmol, NH2-PEG-MAL/PLGA molar
ratio of 2/1). The reaction mixture was left overnight, under constant stirring, at room temperature
(RT; 23 ◦C). PLGA-PEG-MAL was precipitated by the addition of water, followed by centrifugation
(4000 rpm, 10 min). PLGA-PEG-MAL was re-dissolved in ACN and precipitated again by the addition
of water in order to eliminate residual HOBt, EDC, and unreacted PEG. These washing steps were
repeated 3–4 times. After the final washing, the polymer was lyophilized and kept at −20 ◦C under
nitrogen until further use. In order to confirm the linking of PEG-MAL to PLGA, a sample of the
resultant polymer was dissolved in deuterated chloroform, and was analyzed by 1H NMR (Bruker
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Avance III 500 MHz NMR). The 1H NMR analysis revealed four characteristic peaks, three of them
originated from the PLGA at 1.6, 4.8, and 5.2 ppm, corresponding to CH3, CH2, and CH protons,
respectively (Figure S1a,c), and the fourth originated from the PEG protons (CH2–CH2 protons) at
3.6 ppm (Figure S1a,b). A small peak was observed at 6.7 ppm corresponding to the MAL group
protons (Figure S1a,b). These results confirmed the successful linking of the PEG linker as well as the
presence of the MAL group, which was essential for further peptide-linking, utilizing a thiol-maleimide
click-reaction [78]. In the final step of the synthesis, ApoB-P was reacted with the reducing agent
TCEP (10× molar excess of TCEP) in order to break disulfide bonds in the peptide, forming free thiol
groups for reacting with the MAL end group. Following 1 h of incubation, the reduced peptide was
added (2× molar excess of peptide) to a solution of PLGA-PEG-MAL in ACN/dimethylformamide
(DMF) under constant stirring. The reaction was left overnight at RT followed by three washing steps
as described above. The final PLGA-ApoB-P was lyophilized and kept at −20 ◦C until further use.
ApoB-P-linking in the final step of the synthesis was confirmed by amino acid analysis (Aminolab Ltd.,
Nes Ziona, Israel) and by elemental analysis, and the content of nitrogen was derived primarily from
the peptide (Analytical Chemistry Lab, The Hebrew University of Jerusalem, Jerusalem, Israel).
4.3. Nanoparticles Preparation
The DESD method, previously described by us [22], was employed for preparing siOPN-loaded
NPs. A solution of siOPN (1500 μg/mL) in RNase-free TE buffer was emulsified in 3 mL of ethyl
acetate (EtAc), containing 90 mg of PLGA and PLGA-PEG-ApoB-P (8:1 weight ratio), and 325 μg
PEI, by means of a microtip probe sonicator (Vibra-Cell tip sonicator, Sonic & Materials, Inc., CT,
USA), at 20 W output for 90 s. The resulting primary emulsion was further emulsified into a 2%
PVA solution (in 10 mL TE buffer), and was sonicated for 90 s at 50% amplitude to form a double
emulsion (W/O/W). EtAc was evaporated under reduced pressure using a rotary evaporator (Buchi,
Switzerland) resulting in the formation of NPs. NPs were washed twice (TE buffer and double-distilled
water) using ultracentrifugation (25,000 rpm, 30 min, 4 ◦C), re-suspended in a sterile 2% mannitol
solution, and lyophilized. Dry lyophilized NPs were stored at −20 ◦C until use. Fluorescent NPs
were prepared by replacing 10% of the PLGA content in the NPs with PLGA-BODIPY (505/515) or
PLGA-Cy5, both synthesized in our lab. For comparisons, non-targeted NPs were prepared containing
PLGA and PLGA-PEG (8:1 weight ratio as above), and non-pegylated NPs as previously reported [22].
Additional method for preparing ApoB-P targeted NPs was examined by linking the navigator
peptide, ApoB-P to pre-formed NPs of PLGA and PLGA-PEG-MAL (Figure 1b, II). The intermediate
compound, PLGA-PEG-MAL, and PLGA were dissolved in EtAc, and the NPs were prepared as
described above. NPs were washed once (ultracentrifuge) and were then incubated with the free
ApoB-P (pre-incubated with TCEP) at a ×2 molar excess. The reaction was kept overnight at 4 ◦C, NPs
were washed (ultracentrifuge) and lyophilized in 2% mannitol.
4.4. Determination of NP Size, Polydispersity, and Surface Charge
NPs size, size distribution, and surface charge (ζ potential) were determined by dynamic light
scattering at 25 ◦C (Zetasizer Nano-ZSP, Malvern Instruments, UK) of 1 mg/mL NPs in TE buffer. The
size distribution and mean diameter were analyzed by intensity. For each formulation, the mean value
was recorded as the average of three measurements.
4.5. Determination of siOPN Content
For each batch, accurately weighted ~5 mg of NPs was dissolved in 1.5 mL of 0.5 N NaOH under
constant stirring (100 rpm), at 37 ◦C, until a limpid solution was achieved. Following centrifugation
(3000 rpm, 15 min), the supernatant was analyzed by UV spectrophotometry at 260 nm. siOPN
concentration was calculated against a suitable calibration curve (degraded siRNA, dissolved in
0.5 N NaOH). Each batch was weighed and assayed in duplicates, and siOPN concentration and
encapsulation yield (%) were calculated as previously described [22].
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4.6. In Vitro Binding Studies
4.6.1. NPs Binding to the Isolated ECM
Porcine aortic endothelial cells were isolated from porcine aortae by the collagenase dispersion
method [79], and passages four to nine were used. Cells were maintained in a low glucose Dulbecco’s
Modified Eagle’s Medium (DMEM), supplemented with 5% fetal bovine serum (FBS), 1% L-glutamine
and 1% penicillin–streptomycin. For ECM isolation, cells were seeded in 96-well plates and cultured
for four days. ECM was isolated by 20 mM NH4OH containing 0.5% Triton X-100. Solutions of
fluorescently-labeled NPs (PLGA-BODIPY; 200 μL, 2.5, 5, and 10 mg/mL; targeted NPs prepared
by method I, Figure 1b, I) were added to wells coated with ECM on a rocker, for 2 h at RT. The
NPs suspension was aspirated, and the wells were washed three times with PBS. PBS (200 μL) was
added to each well, and the fluorescence intensity was measured by means of a microplate reader
(ex/em 484/515 nm). The number of NPs that remained bound to the ECM was extracted from a
calibration curve.
4.6.2. NPs Binding to the BM Matrix
Plates (96 wells) were coated with a non-gelled protein layer of a Matrigel® matrix (from mouse
sarcoma; Corning, Tewksbury, MA, USA), which contained heparan sulfate proteoglycans as a third
major component after laminin and collagen IV. Coated wells (thin coating method according to the
manufacturer’s protocol) were incubated with either free ApoB-P (1 mM in PBS) or PBS only, for 1 h
at 37 ◦C. The solution of unbound peptide was aspirated, and fluorescently labeled NPs (PLGA-Cy5;
targeted NPs prepared by method II, Figure 1b, II) were then added at a concentration of 10 mg/mL
and incubated at 37 ◦C for 4 h. The wells were washed three times with PBS, and 200 μL of PBS
were added to each well. Fluorescent intensity was measured using the Typhoon scanner (FLA 9500
biomolecular imager, GE Healthcare, Hatfield, UK) followed by image analysis (ImageJ software,
https://imagej.nih.gov).
4.7. Cellular Uptake Studies
The human breast adenocarcinoma cell line, MDA-MB-231, was obtained from ATCC (Manassas,
VA, USA). Cells were routinely cultivated in RPMI 1640 medium supplemented with 10% FBS, 2 mM
L-glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin at 37 ◦C and humidified 5%
CO2 atmosphere.
4.7.1. Quantification of NPs Cellular Uptake
MDA-MB-231 cells were seeded in 12-well plates (0.2 × 106 cells/well) and were left to attach
overnight. The following day, the cells were treated with fluorescently labeled NPs (PLGA-BODIPY;
targeted NPs prepared by method I, Figure 1b, I) at a concentration of 100 μg/mL and were incubated
for 0.5, 1, 2, 4, and 6 h. The cells were washed with PBS three times, harvested, and analyzed for
cell-associated NPs by FACS (BDTM LSR II, BD Biosciences, Franklin Lakes, NJ, USA). Non-treated
cells were used as controls and were set as a background. The number of stained cells (expressed
as the % of total cells) and the fluorescent intensities were calculated based on the obtained FACS
histograms (Figure S5), using FCS Express 4 software (De Novo software, Glendale, CA, USA). The
energy-dependent uptake was examined by incubating the cells at 37 ◦C and 4 ◦C.
4.7.2. Visualization of NPs Cellular Uptake
MDA-MB-231 cells were seeded on coverslips in 12-well plates (0.2 × 106 cells/well) and were
left to attach overnight. Cells were incubated for 0.5 and 6 h with 100 μg/mL of fluorescently labeled
NPs (PLGA-BODIPY; targeted NPs prepared by method I, Figure 1b, I). The cells were thereafter
washed with PBS (×3), fixed using 4% formaldehyde solution for 10 min, washed again with PBS (×3),
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and mounted onto a microscope slide. Slides were analyzed using an Olympus FV 10i confocal laser
scanning microscope (magnification of 60×). Non-treated cells were used as controls and were set as
a background.
4.8. In Vivo Mice Models
In all in vivo animal experiments, animals were used and treated according to the guidelines of the
animal care and use committee of the Hebrew University of Jerusalem (MD-13-13685-5; 1 August 2013
and MD-17-15238-5; 20 October 2017), Israel, and the NIH. The biodistribution of the NPs was evaluated
in the 4T1 model of tumor-bearing mice [22] and in the xenograft (human-derived, MDA-MB-231 cells)
mammary carcinoma orthotopic mice model. The advantage of the 4T1 model is the formation of lung
metastases (Figure S3) as in humans [54]. The bioactivity of siOPN was evaluated in the xenografted
MDA-MB-231 mice model since the siOPN sequence, which was designed to human OPN, is inactive
in the 4T1 model.
4.8.1. Mammary Carcinoma 4T1 IV Model
4T1 mouse breast cancer cells (ATCC) were cultured in DMEM containing 10% FBS. 4T1 cells,
stably expressing firefly luciferase (4T1-Luc) suspended in PBS (1 × 105), were injected intravenously
via the tail vein of 6–7 weeks old female BALB/c mice (Envigo Laboratories, Rehovot, Israel). Two
weeks after tumor cell injection, metastatic lesions were observed only in the lungs (confirmed by
bioluminescence [22], Figure S3). At this time, fluorescently labeled empty NPs (PLGA-BODIPY;
targeted NPs prepared by method I, Figure 1b, I) were injected intravenously into the tail vein
(10 mg/mice). The mice were sacrificed 8 and 24 h (n = 3 in each group) post-injection, perfused with
PBS, and the lungs, liver, kidney, and spleen were harvested. Accumulation of the fluorescent NPs
in the organs was evaluated by fluorescent imaging (Typhoon FLA 9500 biomolecular imager, GE
Healthcare) followed by image analysis (ImageJ software). The mean fluorescent intensity in each
organ was normalized to an untreated control (organ autofluorescence). To evaluate the fate of NPs
in the circulation, 8 h after NPs injection, heparinized blood was drawn by cardiac puncture under
anesthesia. The red blood cells were lysed (Erythrolyse, AbD, Serotec, Oxford, UK), and the pellet was
washed twice with FACS buffer (1% BSA in PBS). Samples were analyzed for cell-associated NPs by
FACS (BDTM LSR II), and FCS Express 4 software was used for quantitative analysis. The different
populations of WBCs were gated according to their typical forward (size) and side (granularity)
scattering, and the fluorescence of the gated cells was measured. The percentage of positive fluorescent
WBCs and monocytes was extracted. Data were presented as mean ± SD.
4.8.2. Mammary Carcinoma Orthotopic Mice Model
The biodistribution and bioactivity of targeted and non-targeted NPs were evaluated in the
orthotopic model of mice xenografted with MDA-MB-231 mammary carcinoma cells [80]. Mammary
carcinoma cells (1 × 106 in 50 μL PBS) were injected into the inguinal mammary fat pad of 6–7 weeks
old female athymic nude mice (Envigo). The tumor was visible 2–3 weeks after transplantation,
measured externally by a caliper. Mice with similar tumor sizes were randomly assigned to treatments
of targeted NPs vs. non-targeted NPs.
Empty NPs, fluorescently labeled with Cy5, were used for evaluating the accumulation of NPs in
the tumor and selected organs (lungs, liver, kidneys, and spleen) and their uptake by WBC. Targeted
(n = 2; NPs prepared by method II, Figure 1b, II) and non-targeted (n = 3) NPs (10 mg/mice) were
intravenously injected via the tail vein. The mice were sacrificed 24 h post-injection, and the NPs
fluorescent signal in the harvested organs was determined by means of fluorescent imaging (Typhoon
FLA 9500 biomolecular imager) followed by image analysis (ImageJ software). The mean fluorescent
intensity in each organ was normalized to an untreated control (organ autofluorescence). In addition,
tumor cryo-sections were visualized by confocal laser scanning microscopy. Immediately after Typhoon
scanning, the tumors were embedded in OCT (Bar-Naor, Ramat Gan, Israel) followed by snap-freezing
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in liquid nitrogen, and stored at −80 ◦C for further cryo-sectioning (CM1950 cryostat, Leica Biosystems,
Wetzlar, Germany). Tumor cryo-sections were performed at a 10 μm width, washed with PBS, fixed (4%
formaldehyde), mounted, and visualized using an Olympus FV10I confocal laser scanning microscope.
The fluorescent intensity was normalized to cryo-sections of untreated mice. For evaluating the NPs
uptake by WBC, blood was collected (24 h post-injection) and analyzed for cell-associated NPs by
FACS, as described above.
The bioactivity of siOPN NPs was evaluated in the mice orthotopic xenograft model since the
siOPN sequence was designed for human OPN (expressed in the human-originated MDA-MB-231
cells, but not in the 4T1 cells, which are of mice origin). MDA-MB-231 cells were transplanted and
examined as mentioned above. Mice having similar tumor sizes were randomly assigned to the
different treatment groups and treated with either targeted siOPN NPs (n = 7; NPs prepared by method
II, Figure 1b, II), non-targeted siOPN NPs (n = 5), or left untreated (n = 5). The NPs were intravenously
injected (tail vein) at a siOPN dose of 1 mg/kg of body weight, every other day for a total of three
injections. The tumor size was measured, blinded to the operator, externally by a caliper for a period
of nine days after the first injection. Tumor volume was calculated by the formula 12 × L × W2, where
L is the length (in cm) and W is the width (cm).
For determining the mechanism of siOPN treatment, OPN mRNA levels in the excised tumors
were analyzed using real-time PCR (RT-PCR). Tumor samples were embedded in 1 mL TRI reagent
(Sigma-Aldrich), homogenized, and the total RNA was isolated according to the manufacturer’s
protocol. For each sample, RNA concentration was determined by means of a NanoDrop 1000
spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized from 1 μg of extracted RNA
using the Moloney murine leukemia virus reverse transcriptase (M-MLV RT, Promega, Madison, WI,
USA), and oligo dT primer (Promega). mRNA levels of OPN and GAPDH (housekeeping gene) were
quantified by SYBR green-based quantitative RT-PCR (qRT-PCR), performed using the CFX Connect™
Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). The following primers were used:
human OPN, forward: 5′-CGC AGA CCT GAC ATC CAG T-3′, reverse: 5′-GGC TGT CCC AAT CAG
AAG G-3′; human GAPDH, forward: 5′-TCA AGC TCA TTT CCT GGT ATG-3′, reverse: 5′-GTG GTC
CAG GGG TCT TAC TC-3′. Thermal cycling parameters for amplification were: 95 ◦C for 10 min,
followed by 40 cycles of 95 ◦C for 5 s, and 60 ◦C for 15 s. OPN mRNA levels were normalized to
GAPDH and to untreated control mice. Each cDNA sample was measured in triplicate, and mean
cycle threshold (Ct) values were reported. ΔCt of each sample was calculated as follows: Ct of the
target gene (OPN) minus Ct of the reference gene (GAPDH, housekeeping gene). Then, the mean ΔCt
of the untreated control mice was chosen as the reference for the relative quantification calculation
(2−ΔΔCt). Data were expressed as OPN/GAPDH (mean ± SEM).
4.9. Statistical Analysis
Data was expressed as the mean ± standard deviation/error. For statistical analysis, the Student’s
t-test for independent means was used. Differences were termed significant at p < 0.05.
5. Conclusions
PLGA-PEG NPs containing siOPN, decorated with ApoB-P as a targeting ligand to the tumor,
were successfully formulated. Because of the high affinity to ApoB substrates, both increased ECM
binding and cellular uptake were obtained. Biodistribution studies revealed enhanced accumulation
in the metastatic lungs of mice mammary carcinoma models (4T1 transplantable breast tumor, and
orthotopic MDA-MB-231 mammary carcinoma). Despite the significantly higher retention of siOPN
NPs in the tumor following intravenous treatment with targeted NPs, a similar therapeutic effect
resulted following treatment with non-targeted siOPN NPs. It is suggested that further improvement
of the targeting could be of value, and/or that a longer observation time is required. The obtained
significant tumor growth suppression was accompanied by a significant reduction of OPN mRNA
77
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levels. This validates our hypothesis that systemically administered ApoB-P-targeted siOPN NPs
could inhibit tumor progression by inhibiting OPN.
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and monocytes, examined in the 4T1 IV model and in the orthotopic xenograft model, Figure S5: Cellular uptake
of NPs by MDA-MB-231 cell line.
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Abstract: Overexpression and secretion of the enzymes cathepsin D (CathD) and cathepsin L (CathL)
is associated with metastasis in several human cancers. As a superfamily, extracellularly, these
proteins may act within the tumor microenvironment to drive cancer progression, proliferation,
invasion and metastasis. Therefore, it is important to discover novel therapeutic treatment strategies
to target CathD and CathL and potentially impede metastasis. Graphene oxide (GO) could form
the basis of such a strategy by acting as an adsorbent for pro-metastatic enzymes. Here, we have
conducted research into the potential of targeted anti-metastatic therapy using GO to adsorb these
pro-tumorigenic enzymes. Binding of CathD/L to GO revealed that CathD/L were adsorbed onto
the surface of GO through its cationic and hydrophilic residues. This work could provide a roadmap
for the rational integration of CathD/L-targeting agents into clinical settings.
Keywords: graphene oxide; adsorption; cathepsin D; cathepsin L; anti-metastatic enzyme cancer
therapy
1. Introduction
Every year more than 2.28 million new cases of breast and ovarian cancers are diagnosed
worldwide, principally in developed countries and 807,440 women die of them [1–3], with these
cancers representing the first and fifth most common cause of female malignancies, respectively [4,5].
Although these diseases have different pathologies they share a common set of molecular mechanisms
such as the misfolding/aggregation, overexpression and hypersecretion of specific proteins typically
involved in degrading cross-linked, abnormal, short-lived self- and foreign- proteins in lysosomes and
phagocytosis. The intracellular and extracellular responses of the tumor microenvironment tend to
be more prominent in response to conditions such as acidic pH [6], the enhanced permeability and
retention effect [7], the enzyme abundance in the tumor extracellular matrix, [8] and overexpression of
particular cell membrane receptors [9]. Typically, this emanates from the misfolding of proteins which
potentially tend to form pathogenic aggregates, including harmful oligomeric and/or cytotoxic factors
involved in the molecular etiology of these diseases and other pathologies (which are linked with
the ability of the proteins to fully execute their physiological functions provided by certain regions
of their protein sequence) [10]. When the intracellular protein degradation within the cells’ acidic
Cancers 2019, 11, 319; doi:10.3390/cancers11030319 www.mdpi.com/journal/cancers83
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endosomal/lysosome compartments increases, the proteolytic activity becomes particularly high in
lysosomal proteases such as cathepsin D (CathD) and cathepsin L (CathL). However, in tumor invasion
and development, these enzymes play a significant role by extracellularly influencing cell proliferation,
differentiation, cell migration, programmed cell death, angiogenesis, immune defence, inflammation
and extracellular tissue remodelling [11,12].
Higher CathL and CathD concentrations are closely related to an increased risk of metastasis [13].
For example, CathL is considered to be associated with tumor invasion and metastasis, by degrading
subunits of extracellular matrix including proteoglycans, elastin, entactin (nidogen), laminin,
fibronectin, perlecan and interstitial and basement-membrane collagens. Recently, we showed a
significantly higher expression of CathL in the omentum hosting metastatic ovarian serous carcinoma
compared with omentum from normal and benign controls with ovarian cystadenoma. We found that
exogenous CathL induced pro-angiogenic effects on omental microvascular endothelial cells which
may aid metastasis [14]. Recent studies have investigated the enhanced immunohistochemical CathD
expression as an indicator of potential malignancy in serous ovarian cancer [13]. For example Losch et
al. [15] demonstrated that CathD was detected in more than 70% of invasive ovarian cancers. Secreted
CathD from breast cancer cells and its proteolytic role in degrading ECM proteins and subsequently
releasing growth factors such as bFGF, have also been reported, which provide an ability for cancer
cells to invade nearby tissue [16,17]. Misfolding, overexpression and hypersecretion of CathD and
CathL have now been demonstrated in numerous cancer types such as ovarian, breast, lung and
prostate, endometrial, as well as malignant glioma and melanoma and are recognized as critical
players in cancer biology by regulating diverse proteolytic functions in triggering the breakdown of
the tumor basement membrane and fueling tumor invasion [18–21]. Adsorption of these enzymes to
two-dimensional materials opens a window of opportunity to develop a wide range of new approaches
in the prevention of cancer.
Nanotechnology and its underpinning sciences have significantly contributed to the improvement
of nanodrug bioavailability and therapeutic index in cancer therapy [22]. Recently, graphene oxide
(GO) formulations have been developed into adaptable nanoscale platforms for medical interventions
as one of the most sophisticated and minimally toxic tools [23] that permit direct contact with,
and manipulation of, the intracellular environment. Graphene is a two-dimensional sheet composed
of a single layer of sp2-hybridized carbon atoms arranged in a honeycomb lattice [24]. Graphene and
its analogues have attracted tremendous interest over the last decade for use in biomedicine owing to
their unique physicochemical and mechanical properties, interesting optical and electronic properties,
large surface area and good biofunctionality [25]. GO has many advantages over conventional
nanosheets and other derivatives of graphene, such as a small size, chemical inertness, high specific
surface area, photo-stability, good water solubility, high drug loading capacity, high purity, good
fluorescence capability and biocompatibility. These properties make GO a promising candidate in
novel delivery systems for target-specific therapeutic drugs and for the diagnosis of different medical
conditions as well as for wound healing [26,27]. Furthermore, GO could offer a potential therapeutic
tool by adsorbing the pro-metastatic enzymes, which are cancer-associated factors. GO has a large
interfacial area and spatial constraints for biological interaction, ideally suited to constructing a
robust and cost-effective extracellular tumor-specific enzyme binding method [28]. This capability
of GO to bind and track an active enzyme could open the door to new clinical algorithms based on
‘enzyme-targeted therapy’. GO nanoformulations which take up these enzymes could be key enablers
of novel anti-metastatic enzyme therapy by breaking down the functional and structural integrity of
extracellular enzymes. These GO nanoplatfoms offer a simple, safe and robust strategy in boosting the
concept of ‘anti-metastatic enzyme-targeted therapy’, a neologism coined to indicate an innovative
and revolutionary approach useful to adsorb and treat ‘pro-tumorigenic’ enzymes with a number of
outcomes: notably the clearance of these enzymes, their structural breakdown, their digestion to active
site-directed specific adsorbents and the deregulation of pro-tumorigenic enzymes. It is generally
understood that the biocompatibility of graphene-based materials is limited by their sharp edges
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and two-dimensional monolayered structures, which is evident from concentration-dependent toxic
effects in numerous cell lines. Targeting and therapeutic adsorption of CathD and CathL in cancer
treatment are currently unknown and undefined. The process of enzyme adsorption, and its therapeutic
efficacy are affected by several factors such as: the properties of proteins and their concentrations
in solution; pH and ionic strength; the temperature of the medium; pH-dependent adsorption
performance; the structural stability of proteins; the selection and nature of adsorbent, porous
sites/vacancies in adsorbents to take up the proteins; and strength/stability of adsorbate-adsorbent
interface. The mechanistic aspects of protein adsorption and/or protein corona formation as a result of
the interaction of proteins with graphene may involve electrostatic and hydrophobic interactions [29].
The intrinsic stability of the adsorbent matrix structure, which can be revealed by undergoing structural
rearrangements, and conformational alterations, resulting in protein denaturation and/or loss of
functional activities and a change in surface energy, allows a wide range of chemical changes in
functional groups and wettabilities. The established method of fluorescence quenching and absorbance,
together with vibrational spectrometry, wetting transparency, adsorption kinetics, and regression
analysis can be used to reveal the fundamental aspects of the enzyme-graphene interaction and to
address a variety of pre-clinical unknowns in the same theranostic session.
 
Figure 1. Proposed mechanism of cathepsin function in cancer metastasis and use of graphene oxide
(GO) as an adsorbent to remove cathepsin from a living system. There are three panels in this diagram:
(1) role of cathepsins in cancer progression: (2) structure of GO and its parameters relevant to the
adsorption of cathepsins: and (3) the mechanism of adsorption. The left panel (1) illustrates possible
tumorigenic and proangiogenic roles of cathepsin D (CathD) and cathepsin L (CathL) within the
cancerous stroma or extracellular matrix (ECM) on endothelial cells (EC) acting via an unknown
receptor(s) (RCP). The bottom panel (2) shows the structure of GO. This is prepared from graphite
using the modified Hummer’s method [26–28]. GO has suitable properties for the efficient adsorption
of these enzymes such as surface charge, surface area, functional groups, electronic and chemical
properties. The right panel (3) shows the potential mechanism involved in enzyme internalization,
the interaction of GO with CathD/CathL and the further breakdown of cathepsins which may lead to
cathepsin removal. Electrostatic and van der Waals forces, osmotic depletion and solvophobicity play a
pivotal role in adsorption of such enzymes.
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Secretion of CathD and CathL poses a unique therapeutic challenge in breast and ovarian cancers.
Therefore, a fuller clearance of these proteins before their involvement in secondary tumour progression
may help advancement of treatment modalities. We have previously reported on the expression and
secretion of CathL and CathD in the omentum and ascites of ovarian malignant patients, as well as in
the tumor-based conditioned media ovarian cancer cell lines [14]. In the present paper, we report the
use of GO to investigate whether CathD and CathL might be cleared out through an adsorption process.
To help visualize the role that GO plays, we used a cost-effective and scalable batch adsorption approach,
where complementary information is channeled via multimodal kinetic and regression models as an
analogy of a multiplexed toxicity-dependent clearance of pro-metastasis enzymes. Our study reveals
that inhibition of CathD and CathL could indeed help overcome the therapeutic challenges faced in
breast and ovarian cancers. The idea of enzyme-targeting therapy is explained in Figure 1.
2. Results
2.1. Synthesis and In Vitro Toxic Effects of GO on Lung Cancer Cells
Similar to our previously reported work, exfoliated GO was synthesized following the modified
Hummer’s method [30–32]. The basic characterization is given in Supplementary Note 1 and Figures
S1–S9. TEM imaging showed the flake-like shapes of GO (Figure S1). We first characterized GO,
referred to as GO sheets, indicating atomic compositions of C (1s) and O(1s) as 91%, and 9%
(Figure S2A), respectively. The binding energy of 285.0 eV was related to the C−C, C=C, and C−H
bonds (Figure S2B). The other C1s peaks of GO contained three main components belonging to
C−O (hydroxyl and epoxy, 286.7 eV), C=C/C−C (284.7 eV) and O=C−O (carboxyl, 288.8 eV) and a
minor component of the C=O (carbonyl, 287.4 eV) and O=C−OH (289.1 eV) functional groups [33].
The Raman spectrum of GO (Figure S3) exhibited a D band at 1358 cm−1 (the presence of defects) and
a G band at 1595 cm−1 (the in-plane stretching motion of pairs of sp2 atoms) [34]. The surface area of
the GO was measured by the N2 absorption Brunauer−Emmett−Teller (BET) method and found to
be 25 m2/g with a pore volume of 0.07 cm3/g (Figure S4). The surface charge of the GO sheets was
determined by the zeta potential measurements (Figure S5). The GO sheets were highly negatively
charged (−63.54 mV) due to the presence in their molecular structure of the carboxyl group in the
free state. Furthermore, the FTIR spectrum of GO (Figure S6) showed the specific functional groups
of C−O−C (~1000 cm−1), C−O (1230 cm−1), C=C (~1620 cm−1) and C=O (1740–1720 cm−1) bonds.
The band in the region of 3600–3300 cm−1 corresponds to O−H stretching vibrations of hydroxyl and
carboxyl groups of GO [35]. The Lambert–Beer law, which describes the linear relationship between
the absorbance and the concentration of the compound in a given solution was used to examine the
dispersibility of GO. A calibration curve was constructed by measuring the absorbance at 232 nm of
nine different concentrations (0.039–10 mg/mL) of the GO solution, in which there was good water
dispersibility of GO (Figure S7) [36]. The XRD pattern of GO, as prepared in the present study, gave a
(001) reflection peak at 2θ = 13.7◦ (Figure S8), which corresponds to a d-spacing of 0.75 nm, and exhibits
an increased interlayer distance compared to that (3.34 Å) (2 theta 1/4 26.7◦) in the typical graphite
oxide structure (sp2 hybridization) [37]. This suggested the complete disintegration of the graphite
structure to form GO under ultra-sonic vibration. Initially, GO exhibited weight loss of 8.7 wt% at
temperature below 150 ◦C as a result of the loss of absorbed water, while in second stage GO lost
more weight (23.6 wt%) in the temperature range of 180–250 ◦C due to thermal decomposition of
oxygen-containing functional groups including hydroxyl and epoxy (Figure S9).
The in vitro toxic effects of GO were determined by measuring cell viability, early and late
apoptosis, and necrosis in two well-characterized lung cancer cell lines at different concentrations of
GO (5–500 μg/mL). We measured both early and late apoptosis, where the latter can be distinguished
from the former by the presence of a disintegrated cell membrane (detected by PI internalization).
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Figure 2A demonstrates a slight but significant (p < 0.05) reduction in cell viability of both A549
and SKMES-1 cells after 24 h GO exposure statistically at concentrations of 250 and 500 μg/mL,
compared to the control group (0 μg/mL). Significant early apoptosis was also detected (Figure 2B),
in A549 cells at 500 μg/mL of GO (p < 0.05) compared to controls (0 μg/mL), and in SKMES-1
cells at 50 and 250 μg/mL of GO (p < 0.05) compared to controls. Late apoptosis (Figure 2C) and
necrosis (Figure 2D) measurements were also carried out for A549 cells. Interestingly, in SKMES-1 cells,
250 and 500 μg/mL of GO significantly induced late apoptosis while necrotic cells were detected at GO
concentrations of 50–500 μg/mL. Figure 2E illustrates the representative analysis of one flow cytometry
experiment in SKMES-1 and A549. GO induced apoptosis and necrosis at concentrations higher than
50 μg/mL in both cell lines. However, the percentage count of apoptotic cells remained higher
compared to necrosis, suggesting that GO may not cause significant damage to the cell membrane,
allowing only the binding of annexin V to PS on the cell surface membrane. This indicates that the cell
death observed at higher concentrations of GO is probably due to apoptosis rather than necrosis.
For the toxicity exposures undertaken, GO has been shown to be less toxic than other forms of
graphene such as reduced GO, which we recently reported for similar cell lines [38]. However, GO
has proven to be more toxic than graphene quantum dots as reported by Zhu et al. [39] where it was
demonstrated that quantum dots have little toxicity to MG63 (80–90% of cell viability at low dose).
This may be because dots are smaller than GO, and hence cause less damage to the cell membrane. GO
has been proven to be less cytotoxic, with a reduced free radical production, and cell death compared
to reduced GO because of the two-dimensional nature of thin sheets, functional groups and surface
charges of GO that allows its efficient cellular uptake [40]. Oxidative stress is thought to be a key factor
resulting in graphene toxicity, reducing the number of viable cells and hindering uptake of essential
proteins and nutrients [41]. Furthermore, GO may induce various levels of toxicity in in vitro and
in vivo models as a result of concentration and dosage patterns, administration routes, entry paths
and accumulation of GO via barriers, distribution among different organs, cellular uptake, localisation
and clearance [42]. These biological mechanisms depend on physio-chemical properties, sheet size,
shape, lateral dimension, functional groups, surface charge and hydrodynamic diameter of the GO. It is
evident that a sheet size of GO below 40 nm does not cause off-target toxicity [43–45]. We have explored
the in vitro toxicity of GO in cancer cells at various concentrations, giving insights into the safe and
biocompatible doses of GO to be used for the adsorption and clearance of enzymes. Our results
demonstrate that GO at low concentrations did not exhibit obvious toxicity and did not interrupt the
course of cell metabolism, gene transcription or cell death. Owing to the flake-like shape of the GO
sheet, a readily available surface area is provided to adsorb enzymes while remaining non-toxic to
healthy surrounding tissues. However, the neurotoxicity and neuroprotection of GO towards brain
cells remain largely unknown and still need further research to explore the possible mechanism of
interaction between GO and brain cells, and the capacity of GO not to cross the blood-brain barrier,
in improving therapeutic responses to GO.
2.2. Basic Characterization of Enzymes
The proteolytic activity of CathD was investigated using a specific fluorogenic substrate at the
two pHs, 3.6 and 7, while the proteolytic activity of CathL was investigated using the CathL-specific
fluorogenic substrate ZVA (5 nM) at the two pHs 5 and 7. CathD was more active at pH (3.6). When the
pH was increased to 7, the fluorescence signals were observed to be reduced (Figure 3A). The result
suggests that CathD is not proteolytically active at neutral pHs. On the other hand, CathL was more
active at pH 5.5 (Figure 3B). Fluorescence signals remained almost two times higher than the control at
pH 7 (pH of the cell culture medium). The data suggested that CathL is proteolytically active at pH 7.
The representative FTIR spectra of CathD and CathL are given in Figure 3C for the spectral
range (3200–500 cm−1). In the case of CathD, most of the observed bands appearing at 1100, 1243,
1280, 1413, 1713, and 2050–2150 cm−1 are C−O stretch, CH wagging, C−O stretch, carboxylate ion
(COO−) symmetry, C=O stretch carboxylic acid and C−H alkyl stretch respectively [46,47]. The most
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prominent band assignments of CathL at 1100, 1243, 1280, 1413, 1713, and 2050–2150 cm−1 are C−O
stretch, CH wagging, C−O stretch, carboxylate ion (COO−) symmetry, C=O stretch carboxylic acid
and C−H alkyl stretch respectively [46–48]. These bands were not observed in control experiments
without CathD/CathL and substrate agents (data not shown). The regions with the widest ranges
and their corresponding spectral signatures have been given in Table S1. The representative Raman
spectra of CathD and CathL are given in Figure 3D for the spectral range (500–2500 cm−1). The most
prominent band set of the CathD are 2243, 2024 and 1603 cm−1 while assignments of CathL are 2024
and 1603 cm−1. The prominent peak at 1608 cm−1 relates to the known bands for the Fmoc group as
reported earlier [49]. The Raman bands at 2024 and 2243 cm−1 could be assigned to the C≡C stretching
vibration, which was present in the propargyl group [49]. The surface free energy and its polar and
dispersive parts were calculated to investigate the binding capacity and weight of electrostatic and/or
van der Waals interactions between GO and the enzymes. The binding capacity of GO, CathD and
CathL were calculated using the contact angle method and their respective contact angles have been
shown in Figure 3E. The surface free energies, polar and dispersive parts of GO, CathD and CathL are
shown in Figure 3F. CathD has the highest total surface energy of 77.4 mN/m, although GO, CathD
and CathL have similar trends of surface energies of total and their respective parts because of the
similar amount and weight of functional groups. As a result, the use of GO as an adsorbent could allow
enzymes to be adsorbed and substituted to improve the binding of CathD/CathL with GO. Therefore,
it appeared that amino-acid replacement at the basal planes of GO can lead to protein-ligand binding.
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Figure 3. Characterization of cathepsin D (CathD) and cathepsin L (CathL). (A) CathD is highly active
at pH 3.5–4 (optimum) and inactive at pH 7 and above. The CathD-specific fluorogenic substrate
(10 μM) was incubated ± CathD (50 ng/mL) at the pH’s 3.6 and 7, and fluorescence intensity was
measured at Ex/Em: 320/393 nm. Each data point represents n = 4 experiments. The horizontal
bars represent SDs. (B) CathL is highly active in ionic buffer. A specific fluorogenic substrate ZVA
(5 nM) was incubated ± CathL (50 ng/mL) at pH’s 5 and 7, and its fluorescence signals were measured
at Ex/Em: 365/440 nm. Control wells contained substrate alone. The data are presented here as
percentage of control (the relevant 100%). Each data point represents n = 4 experiments. The horizontal
bars represent SDs. (C) FTIR spectra of CathD and CathL. (D) Raman spectra of CathD and CathL show
bands at 1602 and 2024 cm−1. (E) Water contact angle profile of GO, CathD and CathL gives the values
of 20◦, 9◦ and 11.5◦. (F) Surface energy profile of GO, CathD and CathL. (G) Representative image of
wettability quantification as measured by water and diiodomethane contact angles of GO, CathD and
CathL. The images were taken using a digital camera and analysed for contact angle measurements
using the ImageJ processing program.
2.3. Enzyme Interaction with GO
Batch adsorption studies were performed to measure the effect of pH on the adsorption process
of CathD and CathL using GO as an adsorbent. Figure 4 shows absorbance variations at different
concentrations of GO (0, 50, 500 and 1000 μg/mL) mixed with CathD and CathL at different time
points (0–20 min). The decrease in absorbance signals of CathD and CathL at pH’s of 3.6 and
5, respectively revealed the amount of CathD and CathL adsorbed to GO. At optimal incubation
times and concentrations of GO, CathD and CathL were almost fully adsorbed onto the GO surface.
The CathD and CathL adsorption process was found to be pH-dependent and concentration-dependent,
demonstrating that the highest adsorbed amounts were at more acidic pHs (3.6 and 5). For pH 3.6,
the amount of CathD adsorbed increased from 50 to 1000 μg/mL over a time scale of 0 to 20 min.
The adsorption capacity of GO (1000 μg/mL) was above 90% after 20 min. CathL adsorption onto the
GO surface followed a similar pattern at pH 5 and at 1000 μg/mL GO the highest value of efficiency
was attained after 20 min. Figure 5 shows that an increase in adsorption capacity occurred for both
enzymes over a 20 min time period, reaching a maximum capacity of above 90%. The capacity was
found to be slightly greater for higher concentrations of GO. The results are in good agreement with
experimental data (Figure 6A,B).
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Figure 4. Effect of various concentrations of GO on CathD and CathL activities. Absorption of CathD
(A–D) and CathL (E–H) by GO at different concentrations (50, 500, and 1000 μg/mL) incubated for
2, 5, 10, 15, and 20 min. Absorbance signals were measured using a PHERAstar BMG plate reader at
λ = 280 nm. Each data point represents n = 4 experiments. The horizontal bars represent SDs. For some
data points, the error bar is smaller than the diameter of the data point.
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Figure 5. (A,B) Kinetic models fitting to the data for CathD and CathL using piecewise linear regression
analysis of experiments in which (A) CathD and (B) CathL were adsorbed onto GO. (C–F) Gaussian
process regression models to find the prediction and uncertainty in adsorption of CathD (C,D)
and CathL (E,F) relating independent variables (time and concentration) to the dependent variable
(absorption). In (C) and (E), the mean predictions are depicted, and the uncertainty in predictions is
shown in (D) and (F).
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Figure 6. (A,B) FTIR spectra of CathD/CathL-linked graphene oxide (GO) at 50, 500 and 1000 μg/mL
concentrations of GO. (C,D) Raman spectra of CathD/CathL-linked GO at 50, 500 and 1000 μg/mL
GO concentrations. (E,F) Contact angle profiles of CathD/CathL-linked GO interfaces at 50, 500 and
1000 μg/mL concentrations of GO. The diiodomethane contact angle was determined to calculate
the surface energy of the enzymes, GO and the interfaces of GO with enzymes. (G,H) The surface
energy profile of GO-CathD/CathL interfaces which have three segments of total surface energy,
dispersive surface energy and polar surface energy—the profiles correspond to 50, 500 and 1000 μg/mL
concentrations of GO which had been treated with CathD and CathL.
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Adsorption kinetics are useful to evaluate the adsorption process and adsorption rate. In this
study, we have used an intraparticle diffusion model. This multi-linearity graph plot of intraparticle
diffusion shows three segments: the first portion is the instantaneous adsorption segment which shows
the adsorption of external surface of GO; the second step is the gradual adsorption stage assigned to
intraparticle diffusion; and the third straight portion depicts the final equilibrium stage due to the
low adsorbate concentration left in the solution. Figure 6A,B show that the intraparticle diffusion
plot at each concentration did not pass through the origin, indicating that the intraparticle diffusion
was not the only rate-controlling process. This is indicative of an additional role of boundary layer
diffusion control. The intraparticle diffusion constant values are shown in Table S2. Gaussian process
regression models for CathD and CathL relating independent variables (time and concentrations) to
the dependent variable of adsorption are shown in Figure 5C–F. In Figure 5C,E, the mean predictions
for CathD and CathL are depicted respectively, and the uncertainty in these predictions has been
shown in Figure 5D,F. The mean predictions for CathD indicate that promising (lower) absorption
can be achieved with a concentration of around 100 μg/mL when CathD is incubated with GO for
15 to 20 min. The models also revealed that concentrations of CathD greater than 900 μg/mL which
are incubated for about 18 min could also be promising. Figure 5E,F show similar trends for CathL.
The fluorescence of GO only has been shown in Figure S10. Figure S11 illustrates the measurement
of normalised fluorescence intensities of various concentrations of GO (0, 50, 500 and 1000 μg/mL)
exposed to CathD and CathL at different time points (0–20 min). CathD and CathL were enzymatically
cleaving a GO substrate which gave rise to a fluorescent product, at increasing concentrations of
GO (0, 50, 500 and 1000 μg/mL). GO was able to concentration-dependently increase the catalytic
activity of CathD and CathL at all pHs tested. A slight difference in emission spectra also occurs,
suggesting that lower pH values represent an improved exposure of non-polar sites of adsorbate in
the enzymes. Fluorescence loss was observed in the case of CathL at pH 7, due to the reversible nature
of CathL inhibition. The lack of any significant difference in fluorescence signals might be because
of the adsorption of enzymes induced by GO. This uptake allows localization of internalized GO
under different pH conditions [50,51]. This uptake could be attributable to the large size of GO which
blocks fluorescence signals. The binding of CathD and CathL to GO shows that both the enzymes
and GO sheets form a new tertiary structure. These tertiary structures may contribute significantly
to the self-fluorescence characteristics of GO. Understanding the pre-clinical and clinical effects of
such factors to allow the development and adsorption of pro-tumorigenic and pro-metastatic enzymes,
released into the extracellular matrix from malignant tumors, will be the focus of further studies.
FTIR and Raman spectroscopic findings can be used to monitor the macromolecular movements
and vibrational/rotational states of specific chemical groupings which bind target biomolecules with
high specificity during the formation of the nano-bio-interface of CathD- and CathL-GO. Figure 6A,B
illustrates FTIR spectra of GO-CathD/CathL at the concentrations of 50, 500 and 1000 μg/mL of GO
after 20 min. The FTIR spectrum of CathD-linked GO revealed a range of CathD and CathL absorption
bands including C=O (υC=O at 1714 cm−1), and the peak of the C−N stretch mode (υC=O at 1100 cm−1)
at all the concentrations represents the CH stretching and NH bending. The specific band of GO-CathD
(at two concentrations of 500 and 1000 μg/mL GO) (Figure 6A) showed the characteristic peak of
an alkoxy group at 980 cm−1 which is associated with the C=O functional groups of GO and CathD.
The peaks at 1413 cm−1, ascribed to NH bending and CN stretching, also confirmed the presence of
CathD and CathL. Figure 6C,D show Raman spectra of GO-CathD/CathL. The amide-1 vibration at
1590 cm−1 arose from the typical υC=O stretching vibration. The band in the range of 2020–2250 cm−1
was assigned to the specific C−H3 and C−H2 deformation vibrations which mainly arose from the
side chains of different amino acids. The band in the range of 1200–1340 cm−1 was assigned to
the amide-III vibration which typically arose from the combination of the N-H bending and C−C
stretching vibration [52,53]. In the Raman spectra of GO and GO-CathD/CathL, the slight shifting
of peaks towards lower wavenumber can be observed. GO has two typical peaks at ca. 1355 cm−1
and 1580 cm−1. The spectra at 1600–1620 cm−1 can be assigned to the C=O stretching of carboxylate
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and C−H2 deformation vibrations. Based on these bands, it is concluded that the CathD and CathL
interacted with GO through its amide groups. Both cathepsins have a deep bonding pocket with the
binding groups identified by FTIR, which are held together with GO by electrostatic attractions.
The functional groups present at the outermost surface of GO readily facilitate its coverage
with inert molecules, which increases surface hydrophilicity and subsequently enhances the bonding
strength of these nanostructures [54]. Several site-specific variants of GO have been employed in
attempts to alter the surface-inactivation of ‘wild-type’ enzymes. The extent of enzyme absorption
(and the mechanistic insight this provides in relation to the proteins’ interactions with surfaces)
have been probed by water contact angle (WCA) measurements and surface energy determinations
(Figure 6E,F). The CathD and CathL displayed higher binding activity towards GO, as demonstrated
by the WCA values. Upon CathD and CathL interactions, the WCA profiles of GO shifted to higher
values, suggesting that a good level of surface hydrophilicity was achieved (Figure 6F). The effect
was more pronounced for the higher concentrations, whose average WCA value increased by 8.5
and 15.0 degrees for CathD and CathL, respectively. The changes in diiodomethane contact angle
(Figure 6F) showed the surface energy profile (Figure 6G,H). The binding free energies of GO to
CathD and CathL are shown in Figure 6G,H. The intermolecular vdW and electrostatic interactions
are believed to improve the desolvation process because of the substitution of one oxygen-containing
functional group with an amino group, which in turn increases the total free energy of the compound.
However, the polar penalties upon binding of these two proteins to GO were decreased.
These findings have provided significant information about the surface interactions of GO sheets
with CathD and CathL: (i) the number and amount of the functional groups and their reactivity;
(ii) the critical role of surface hydrophobicity in the adsorption process. The WCA of CathD and CathL
is shown in Figure 3. Moreover, the key differences in the amount and number of functional groups
and bonding affinities are responsible for the rise in total and dispersive surface energy. The low
polar and high dispersion parts (Figure 6G,H) of the surface energy profiles revealed that the polar
and nonpolar side-chains of CathD/CathL facilitate conformational alterations in the CathD/CathL
structure, which in turn lead to a high adsorption capacity of GO for CathD/CathL.
3. Discussion
Potential cancer therapies include the development of innovative treatment modalities that
are capable of clearing the pro-tumorigenic enzyme by developing a novel platform based on
biocompatible adsorbents. The currently available mainstream treatment options have resulted in
improved survival and quality of life, although ovarian and breast cancers remain progressive diseases.
Thus, there is an ever-growing need for the development of alternative approaches. Conventional
biological drug therapies have limitations due to unwanted side effects on normal tissues/cells that
adversely affect the efficacy and safety of the treatment. The emerging paradigm of personalised
and precision medicine provokes the concept that adsorption of these enzymes in the local tumor
environment could be achieved by using porous adsorbents. Enzyme-targeted therapy provides a
great opportunity for this by addressing the mechanisms of pro-tumorigenic enzyme clearance and
therapeutic action. In this study, we developed a GO that breaks down and takes up enzymes which
promote increased invasiveness and metastasis. The surface charge, surface area, chemical reactivity
and electronic characteristics of GO were used to target these enzymes with sustained release of
functional groups, free radical and porous sites for entrapment of CathD and CathL. The inhibition
of CathD and CathL was observed at specific pH values which support metastasis. Inhibition of
CathD and CathL was verified by enzyme activity using specific substrates. The analysis of the
released CathD and CathL libraries was carried out using a wide variety of analytical tools such as
FTIR, Raman, WCA and surface energy profiles (see Figure 2; Figure 6), thus posing a significantly
fast-tracked identification procedure and considerable output compared with conventional tools to
analyse nanoparticle interactions with proteins. In this manner, the characterization of the studied
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enzymes for their binding and bioactivity is carried out to better understand their structural and
functional behaviours.
The current approach of enzyme targeting offers a number of important advantages over
conventional approaches. First, it permits the simplistic tagging of cathepsins with very high
transformation/removal efficiencies using GO, which considerably increases the likelihood of
recognising biomolecular fractions. Secondly, the clinical relevance and biosafety of this modality
would further benefit from utilising a GO system that is already used in clinical trials to introduce
drug/gene carrier vehicles. Finally, the approach presented here is greatly adaptable and can be used
largely for the innovation of theranostic saviours of disease-associated enzymes. The present work was
mainly applied to targeting two ovarian and breast cancer-associated enzymes. The two-dimensional
and adsorbing nature of GO could reduce the likelihood of abundance of these enzymes to induce
tumor cell invasion and metastasis, and thereby maximize the broad applicability of GO. Furthermore,
the GO not only allows for robust interactions with enzymes but also enables the compact packaging of
the GO within dissolvable capsules, facilitating non-invasive oral administration to track these proteins,
which could be used as a diagnostic tool. Given the clear benefits achievable by using enzyme-targeted
therapy (compared with the currently available modalities such as chemotherapy, radiation therapy
etc.), the cost-effectiveness involved in producing GO is another advantage for implementing this
material as a standard-of-care in the treatment of cancer. Currently, clinical-scale manufacturing of GO
entails a range of protocols to fabricate, modify, functionalise, deliver and selectively accumulate and
administrate into the living systems. Future work will address cell-based and pre-clinical metastatic
disease models and will possibly include further developments to integrate targeted and safe delivery
of GO to the tumor sites with sufficient selectivity to facilitate the removal of disseminated enzymes.
4. Experimental Section
4.1. Synthesis and Characterization
Exfoliated graphene oxide (GO) flakes were synthesized from exfoliated graphite using the
modified Hummer’s method as previously reported by us [27,28,38]. NaNO3 (1.5 g) and H2SO4
(150 mL, 98%) were added to a 800 mL round-bottom flask with graphite flakes (2 g). The reaction
mixture was mixed under magnetic stirring following by the immersion of the flask in an oil bath.
The mixture was then heated at the temperature of 35 ◦C, before adding KMnO4 (9 g) into the flask.
The mixture was subjected to constant continuous stirring for 24 h, followed by addition of more
H2SO4 (280 mL, 5%) and the temperature was increased to 85–95 ◦C. The mixture was stirred for
another 2 h before removing the bath. The flask was allowed to cool down to 60 ◦C. Finally, H2O2
(15 mL, 30 wt%) was added and the mixture was stirred for another 2 h. The resultant product was
washed 7–8 times with HCl (3 wt%) and then washed 4–5 times with distilled water to eliminate any
contaminants. As obtained GO was dispersed in water under stirring. As prepared GO was then used
for further characterization. Transmission electron microscopy (TEM) (JEOL-2100 TEM, JEOL, Madrid,
Spain), at an accelerating voltage of 200 kV) was used to obtain high resolution microstructural images.
A drop of the as prepared GO was deposited on a holey carbon Cu grid to prepare the TEM samples.
X-ray diffraction (XRD) analysis was conducted using Cu Kα radiation. X-ray measurements were
performed at a voltage of 40 kV and a current of 40 mA and spectrum was collected a step size of 0.02◦
(2θ) and a step time of 1 s. Fourier-transform infrared (FTIR) spectroscopy was conducted by means of
a Tensor-27 FTIR spectrometer (Bruker Optics, Champs-sur-Marne, France) in the wavenumber range
of 4000–500 cm−1. FTIR samples were prepared by mixing the sample with KBr. Raman spectroscopy
was carried out with laser excitation at 532 nm (Renishaw, Stroud, UK). To calculate the surface charge
of GO, zeta potential measurements were performed using a colloidal dynamics zeta probe. UV/Vis
spectrophotometry was performed using a 6715 UV–Vis instrument (Jenway, Staffordshire, UK).
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4.2. Cell Viability
Cell viability experiments using flow cytometry has been described elsewhere [34]. Briefly,
cells were treated with or without 5, 50, 250, 500 and 1000 μg/mL of GO for 24 h. After trypsinisation,
cells were stained with annexin V (BioLegend, London, UK) and propidium iodide (PI, Sigma-Aldrich,
Gillingham, Dorset, UK)) and subjected to flow analysis using a Guava flow cytometer (Millipore UK
Limited, Hertfordshire, UK). The data were analysed using the Guava 3.1.1 software. The experiment
was carried out at least three times and the data obtained were analysed using GraphPad Prism 5.04
(GraphPad Software, San Diego, CA, USA), and expressed as % cell count ± SD, Mann Whitney.
4.3. Regression Model
We were particularly interested in determining a good estimate of the most effective level of
concentration of CathD and CathL and the experiment time required for biological applications.
As such we built a model that may indicate which pair of concentrations and times are promising
and subsequently help in our decision making. However, we had limited data (due to the expense of
conducting many experiments) and repeated measurements are always noisy (in that we obtained a
slightly different measurement for the same concentration and time). Therefore, it is of paramount
importance to consider these uncertainties in modelling the performance of these enzymes. Standard
non-linear regression models usually predict the general trend without capturing such uncertainties.
As an alternative, we used Gaussian processes (GPs) to model absorption (dependent variable) with
respect to time and concentration (independent variables) for both CathD and CathL. A GP model
allowed us to inspect the expected performance and the predictive uncertainty for the enzymes.
Thus we were able to strike a balance between predicted performance and uncertainty to make an
informed decision.
Formally, a GP may be considered as a collection of random variables, which is jointly Guassian
distributed [38,52]. This essentially allows us to encapsulate the intuition that for a small change in
concentration and time there should be a small change in performance. Let D = {xi, yi} be a data set
consisting of n data points, where the i-th vector xi consists of a time and a concentration (independent
variables), and yi is the associated absorption (dependent variable). A trained GP model then produces
the following posterior predictive Gaussian distribution: P(yn+1|xn+1, D, θ) ~ N(μ(xn+1), σ(xn+1)),
where θ is a set of hyperparameters that are optimised using collected data D, μ(xn+1) is the expected
performance for xn+1, and σ(xn+1) is the predictive uncertainty. The details of training a GP model can
be found in [52].
4.4. Water Contact Angle Measurements and Surface Energy Calculations
A contact angle goniometer was used to calculate the wettability of GO, CathD and CathL.
A digital camera was used to capture the images and the contact angle was measured using the ImageJ
processing program. The contact angle surfaces were developed by dropping a 10 μL drop onto a glass
slide. The surface free energies were estimated by quantifying the contact angle of diiodomethane
(DIIO) on the surface of the sample. 10 μl drop of DIIO was used in each measurement. The surface
free energy of a solid sample is expressed by Young’s equation, where S is solid and L is liquid:
σS = σSL + σL × cosθ (1)
where σL, and σSL represent the surface tension of the liquid and the interfacial tension between the
liquid and the solid, respectively and θ is the contact angle shaped by the liquid on the surface of the
sample respectively. Here, we are measuring σS with the help of known value of σL and unknown
value of σSL. According to the Fowkes method [53], the surface tension is given by:
σSL = σL + σS - 2((σLD × σSD)1/2 + (σLP × σSP)1/2) (2)
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where the surface free energies are mixture of dispersive (D) and polar (P) parts together. This would
be used to exclude the unknown value in Equation (1).
The polar part of liquid is zero for DIIO, so:
σS
D = σL × (cosθ + 1)2/4 (3)
where σL = σLD = 50.8 mN/m. The dispersive part of the surface free energy of the sample can directly
be found from the contact angle.
The polar and dispersive parts of water are: σLD = 26.4 mN/m and σLP = 46.4 mN/m. Equations
(1) and (2) can be reorganised to calculate the polar part of the surface energy of the sample:
σS
P = (σL × (cosθ + 1)/2 - (σLD × σSD)1/2)2/σLP (4)
If the values of the dispersive and polar parts are known, the total surface energy of the sample
will be:
σS = σSD + σSP (5)
Contact angles of water and DIIO on surface of GO are 33.4◦ and 20◦ respectively. The dispersive
component, polar component and total surface energies of GO are 42.8, 29.6 and 72.4 mN/m
respectively [53]. The other surface energies were calculated in the same manner.
4.5. Proteolytic Activities
Citrate and phosphate buffer solutions were prepared at pHs 3.6, 5.0 and 7.0. Their composition
is given in Supplementary notes 2 and 3. The measurement of proteolytic activities has been described
elsewhere [18,20]. A brief description of each enzyme activity is presented below:
4.6. CathD Experiment
The buffers required to test CathD-proteolytic activities contained 0.005% of Tween20
(Sigma-Aldrich) and the pHs were adjusted to 3.6 and 7. CathD-fluorogenic substrate (100 nM;
Enzo Life Sciences, Exeter, UK) was incubated ± CathD (50 ng/mL; recombinant from human liver,
Sigma-Aldrich) and plates were read after 60 s of shaking at Ex/Em: 320/393 nm.
4.7. CathL Experiment
The buffers contained 1 mM DTT to disrupt the disulfide bonds, resulting in an active enzyme.
CathL fluorogenic substrate Z-Val-Val-Arg-AMC (ZVA; 5 nM) was incubated ± CathL (50 ng/mL;
recombinant from human liver, Sigma-Aldrich) at pHs 5 and 7. The plate was shaken for 60 s in a
plate-reader prior to fluorescence reading at Ex/Em: 365/440 nm.
Both enzyme activities were measured using a SpectraMax plate reader (Molecular Devices UK
Limited, Berkshire, UK). The data was normalised to control and represented as a percentage of
the control.
4.8. Enzyme Interaction with GO
An interaction between CathD or CathL (50 ng/mL) and GO (50, 500 and 1000 μg/mL) was
tested in pH buffers (pHs 3.6 and 7 for CathD, and pHs 5.5 and 7 for CathL). pH values of 3.6 and
5.5 are optimum for CathD and CathL activity, respectively. CathD and/or CathL was incubated
with GO at different concentrations for 2, 5, 10, 15 and 20 min. The experiment was performed in
×4 96 well black opaque plates (Greiner Bio-One Ltd., Gloucestershire, UK). Plates were read at the
same time scale as previously mentioned, of incubation at room temperature to measure absorbance at
280 nm for CathD and CathL using a SpectraMAX plate reader. The data normalised to the control
and represented as a percentage of this control. The fluorescence intensity of the GO hydrolysis was
identified kinetically using a SpectraMax plate reader. This was repeated (n = 4) with CathL at different
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concentrations of GO (50, 500 and 1000 μg/mL). The control wells contained GO only. FTIR, Raman
spectroscopy, wettabilities and surface energies were carried out in the same manner as explained in
the previous section.
To verify the adsorption of CathD and CathL, an intra-particle diffusion model was used. Fick’s
second law was used to find out the intraparticle diffusion model as a rate-determining step during the




t + I (6)
where I represents the boundary layer effect (a large value corresponds to a larger boundary layer
thickness and kid is the intraparticle rate constant and kint (g/mg min1/2) and C represent the adsorption
constant and the intercept, respectively [56,57]. The intercept is measured from the plot of qt versus t1/2.
4.9. Statistical Analysis
Statistical analysis was carried out between two groups by the Mann-Whitney test, and between
multiple groups were compared by one-way analysis of variance (ANOVA) with Tukey post-hoc testing
or two-way ANOVA with a Bonferroni post-hoc test, using GraphPad Prism 5 software. The results
are shown as mean ± s.d, (standard deviation) unless otherwise indicated. The value of p < 0.05 was
considered statistically significant.
5. Conclusions
In summary, our findings represent a straightforward and highly reliable approach for the rapid
and facile removal of pro-metastasis enzymes. GO with its variable zeta potential, variety of functional
groups and very large (and in principle fully accessible) surface area, is an extremely promising
candidate for the adsorption of such enzymes. Our results show that this material is compatible
with cells. In addition, the adsorbent preparation is based on abundantly available and cost-effective
graphite as the main precursor. Graphene oxide nanostructures are straightforward to prepare and are
highly stable, which streamlines long-term storage at room temperature and correspondingly eases the
manufacturing cost. Therefore, if employed in clinical settings as an innovative platform, this highly
adaptable strategy could provide a real-world, cost-effective and broadly relevant procedure to treat
chronic and complex diseases.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/3/319/s1,
Figure S1: Transmission electron microscopy image of graphene oxide, Figure S2: Basic characterization of
exfoliated graphene oxide (GO). (A) XPS survey. (B) The C1s spectrum of the GO shows three main components
arising from C−O (hydroxyl and epoxy, 286.7 eV), C=C/C−C (284.7 eV) and O=C−O (carboxyl, 288.8 eV) and a
minor component of the C=O (carbonyl, 287.4 eV) and O=C−OH (289.1 eV) species, Figure S3: Raman spectrum
of the graphene oxide sample shows intense D (1358 cm−1) and G peaks (1595 cm−1) of defects and the in-plane
stretching motion of pairs of sp2 atoms, respectively, Figure S4: BET surface area of graphene oxide measured by
nitrogen sorption isotherms measured at –196 ◦C. The BET surface area value obtained for this sample using the
BET method was 25 m2/g, Figure S5: Representative zeta potential of graphene oxide over a range of different
pH values, Figure S6: The Fourier transformed infrared (FTIR) spectrum of graphene oxide shows vibrations of
functional groups of C−O−C (~1000 cm−1), C−O (1230 cm−1), C=C (~1620 cm−1), C=O (1740–1720 cm−1) bonds
and O−H (3600–3300 cm−1), Figure S7: (A) UV/Vis absorption spectra of graphene oxide solutions with different
concentrations (from 0.039–10 mg/mL) show the main peak around 232 nm. (B) The plot of the absorbance
(λ = 232 nm) divided by the cell length, versus the concentration. The Lambert–Beer law (A = α × C × l), allowed
the determination of the absorption coefficient (α). This linear relationship fits well with the Lambert-Beer Law,
indicating the good water solubility of the GO product, Figure S8: The XRD pattern recorded from graphene
oxide shows a (001) peak at 2θ of 13.7◦, Figure S9: TGA of exfoliated graphene oxide. TGA was performed in the
nitrogen atmosphere, Figure S10: Photoluminescence emission spectrum of graphene oxide, Figure S11: Effect of
different concentrations of GO on CathD and CathL fluorescence activities. GO at different concentrations (50, 500,
and 1000 μg/mL) were incubated with CathD (A, B) and CathL (C, D) in 96 well plates at different time-points
(2, 5, 10, 15, and 20 min) as shown where RFU is relative fluorescence units. Fluorescence signals were determined
using a plate reader at Ex/Em: 355/450 nm. Each data point represents the mean of n = 4 experiments. Bars show
SDs, Table S1: Characteristic IR bands of the protein linkages, Table S2: Kinetic parameters obtained for CathD
and CathL for GO using an intraparticle diffusion model.
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Abstract: Targeting immune checkpoint molecules such as programmed death ligand-1 (PDL1) is an
emerging strategy for anti-cancer therapy. However, transient expression of PDL1 and difficulty in
tumor stroma penetration has limited the utility of anti-PDL1 therapy. To overcome these limitations,
we report a new conjugate between the clinically approved PDL1 antibody (PDL1 AB) and drug
Doxorubicin (Dox), named PDL1-Dox. We conjugated PDL1-Dox through a hydrazone linker
containing a polyethylene glycol (PEG) spacer, which allows it to dissociate in a tumor environment
and improves solubility. The purpose of using Dox is to disrupt the tumor extracellular environment
so that PDL-1 antibody can penetrate the tumor core. PDL1-Dox demonstrates significant cell killing,
disruption of tumor spheroid and induction of apoptosis in a breast cancer cell line. Significant release
of IFN-γ suggests PDL1-Dox can upmodulate T cell activation. Optical imaging of dye conjugate
supports the selective tumor targeting ability and core penetration of the construct.
Keywords: antibody drug conjugate (ADC); PD-L1; tumor spheroid disruption; immune
modulation; doxorubicin
1. Introduction
Antibody-drug conjugates (ADCs) are a clinically effective treatment for targeted therapy of
cancer. They typically consist of a monoclonal antibody, a cytotoxic drug, and a conditionally stable
linker to conjugate the two. In cancer treatment, such combinations are especially useful because the
antibody (Ab) serves as a specific targeting ligand to an overexpressed tumor cell surface protein in
order to effectively deliver the cytotoxic drug [1]. So far, three ADCs (Adcetris, Kadcyla and Mylotarg)
have been approved by the US FDA and more than 30 ADCs are currently being investigated in
clinical trials for both solid tumors and hematological cancers [2]. Recently, groundbreaking results of
immunotherapy have opened a new paradigm for several cancer treatments [3]. A promising target in
anticancer therapy is immune checkpoint inhibition which resurrects the function of exhausted T-cells
to kill tumor cells. Tumor cells evade immune surveillance by upmodulating immunosuppressive
immune checkpoint molecules, resulting in downplay of antitumor immunity [3,4]. This involves the
interaction between the surface receptor programmed death-1 (PD1) and its corresponding ligand
(PDL1), which are expressed on the surface of immune cells (monocytes, T cells, B cells) and tumor
cells, respectively [3]. The interaction between PD1 of T-cells with PDL1 of cancer cells inhibits
T-cell mediated cancer cell killing. To alleviate the function of T-cells against cancer cells several
Cancers 2019, 11, 232; doi:10.3390/cancers11020232 www.mdpi.com/journal/cancers103
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immune checkpoint antibody inhibitors have been developed that target either PD1 or PDL1 and stop
this interaction.
Tecentriq®(Atezolizumab), an FDA approved antibody, has already been used for metastatic
urothelial carcinoma, non-small cell lung cancer, and triple negative breast cancer (TNBC) [5].
Hypothetically, this antibody can be used against other types of tumors that have overexpression of
PDL1. Several studies have shown that TNBC cells, including MDA-MB-231, have high expression of
PDL1 [6], which suggests that an anti-PDL1 antibody is a promising platform for TNBC therapy [4].
Since TNBC cells lack receptors for estrogen, progesterone, and HER-2 [7], using the PDL1 biomarker
is a rational option for its treatment. Alongside its clinical success, the treatment of anti-PDL1 antibody
showed a patient specific response. However, its use is limited to the few types of tumors that are
linked with several factors, such as the transient and heterogeneous expression of PDL1 in tumor
microenvironment and poor penetration of the larger molecular weight PDL1 antibody (144.61 Kda)
through dense tumor stroma [8,9]. Thus, an attempt to conjugate a cytotoxic drug with anti-PDL1
antibody would be a significant direction especially for solid tumors consisting of dense tumor
stroma. In this regard, PDL1 antibody drug conjugate (ADC) can serve the purpose of chemo-guided
immune therapy.
Chemotherapeutics such as Doxorubicin (Dox) have been utilized as potent anticancer agents
for a long time. They work by slowing the growth of cancer cells through induction of apoptosis
and arresting cell cycle that leads to cell death [10,11]. The poor selectivity and acute cardiotoxicity
of Dox has limited its use in clinic, requiring a selective delivery system. Clinical use of Doxil is
widespread and the predicted market size is expected to be $1.39 billion by 2024 [12]. Alongside this, a
few antibody-Dox conjugates, including BR96-Dox (NCT00031187) and PL1-Dox (NCT01101594), have
been studied in clinical trials for cancer [13]. These data support the idea that there is a significant scope
in repurposing Dox for efficient therapy in cancer. Toward this end, we report for the first time a Dox
conjugated PDL1 antibody (PDL1-Dox) for the broader application of chemo-guided immunotherapy.
As the tumor extracellular environment is acidic in nature, acidic pH responsive linkers have been
utilized to conjugate ADCs so that they can selectively release drugs (Dox in this case) in the tumor
environment [14]. Likewise, we have introduced a hydrazone linker to the PDL1-Dox ADC that will be
selectively cleaved in the tumor cell environment. Additionally, we used a PEG-spacer for improving
the aqueous solubility of the antibody and sustain the plasma circulation of PDL1-Dox. The hydrazone
linker is extensively used for clinically approved ADCs such as Mylotarg. The monoclonal IgG1
antibody, PDL1 AB, has a high affinity for human PDL1 receptor with a dissociation constant (Kd) of
0.43 nM [15]. PDL1 AB binds to the PDL1 on the surface of the cancer cell and it does not internalize via
endocytosis, resulting in inhibition of PDL1 with PD1 of T cells. Alongside the superior clinical outcome
of PDL1 AB, several studies have revealed that its effect is limited to the small percent of patient
population [16]. This is attributed to poor T cell infiltration through dense tumor stroma [17] and
inadequate tumor core penetration of PDL1 AB, as depicted in Figure 1. To overcome these challenges,
several combination therapies have emerged, including combination of PDL1 AB with chemotherapy
and immunotherapies, namely anti-PD1 or CTLA-4 therapy [3–5]. Combination treatment, however,
produced nonspecific toxicity and immune related adverse events (irAEs) [18,19]. To improve the
selectivity and efficacy of PDL1 AB, we have developed the ADC, PDL1-Dox and evaluated its
anticancer effect and mechanism of action in MDA-MB-231 cells. The chemical formation of PDL1-Dox
was confirmed by MALDI-MS spectroscopy and UV-Vis spectrophotometry. We performed a tumor
3D- culture study to demonstrate the tumor spheroid disruption ability of PDL1-Dox and measured
IFN-γ production in PDL1-Dox treated cell suspension, obtained from a co-culture of MDA-MB-231
and activated RAW 264.7 cells. We developed near-infrared (NIR) dye-conjugated PDL1-S0456 and
tested its specificity as well as tumor retention ability in patient derived TNBC (BR1126) and NSCLC
(LG703) model. The tumor specificity of PDL1-S0456 was confirmed by ex-vivo biodistribution on
treated PDx mice. This proof-of-concept study demonstrates that PDL1-Dox can improve the current
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therapeutic outcome beyond PDL1 AB and that PDL1 antibody can further be developed for tumor
diagnosis and image-guided surgery [20].
Figure 1. The interaction of the cancer cell with the T-cell through the binding of the major
histocompatibility complex (MHC) and the T-cell receptor (TCR) leads to activation of the T-cell
and releasing cancer cell death signal. The ligation of PD1 with PDL1 downmodulates the tumor cell
killing function of T-cell. It is hypothesized that Dox of PDL1-Dox could disrupt the tumor stromal
components and improve antitumor response of PDL1 antibody.
2. Materials and Methods
2.1. Materials
Atezolizumab (Tecentriq®, Genentech, South San Francisco, CA, USA) was obtained from
Karmanos Cancer Institute pharmacy. SH-PEG-COOH was obtained from Biochempeg Scientific
Inc., (Watertown, MA, USA). Other reagents and solvents were obtained from fisher scientific and
Sigma Aldrich and used directly without further purification. RAW 264.7 cells were obtained as a kind
gift of Shunbin Xu, Wayne State University School of Medicine (Detroit, MI, USA).
2.2. Synthesis of PDL1-Dox
The synthesis of the ADC began with the coupling of the monoclonal IgG antibody Atezolizumab
(Tecentriq®, Genentech) to SH-PEG-COOH by EDC/sulfo-NHS, according to previously published
method [21]. Clinically used PDL1 AB was dialyzed to separate the excipient and PDL1 AB
was lyophilized to obtain the powered. For coupling between SH-PEG-COOH and PDL1 AB,
SH-PEG-COOH (15 mg) was taken in a in mixture of water with catalytic amount DMSO in presence
of EDC/sulfo-NHS and stirred for 1 h, followed by PDL1 AB powder (18 mg) was added to the
mixture and stirred for 6 h. The resulting solution was transferred to a 12 Kd dialysis bag and dialyzed
overnight at 4 ◦C to obtain PDL1-PEG-SH. Next PDL1-PEG-SH was then reacted with maleimide group
of Aldoxorubicin in pH 7.4 using reagent free thiol-maleimide chemistry for 4 h. Followed by dialysis
and lyophilization was performed with 12 Kd dialysis bag to obtain PDL1-Dox. The concentration of
Dox was determined by the UV-Vis spectroscopy method.
2.3. Characterization of PDL1-Dox
PDL1-Dox was analyzed in UV/Vis spectroscopy (Agilent Technologies, Santa Clara, CA, USA)
to evaluate the presence of Dox in the PDL1-Dox construct and compared with PDL1 AB.
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2.4. Cell Culture
TNBC cell line (MDA-MB-231) was obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA) and grown in with Dulbecco’s modified eagle medium, containing 1% antibiotic
(penicillin and streptomycin) and 10% fetal bovine serum at 37 ◦C in a 5% CO2 environment.
MTT based cell viability assay was performed as per previously performed procedures [5,22,23].
Briefly, the cells were seeded in a 96 well plate at a density of 5000 cells per well and incubated
overnight. Afterwards, the cells were treated with various concentrations of PDL1-DOX in a range
of 2.5 μM to 0.156 μM with respect to Dox concentration and cells were incubated for 48 h or 72 h.
The same amount of commercial Dox was used as a positive control. At the end of incubation,
3-(3,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) was added and cell viability
was determined. Standard manufacturer procedure was followed for 3D-spheroid culture method.
Briefly, 5000 MDA-MB-231 cells were slowly added to U-shaped well of 96-well plate and incubated
for overnight. This was followed by PDL1-Dox, with Dox being treated for 48 h or kept untreated.
2.5. Apoptosis Assay
In preparation for the apoptosis assay, cells were seeded in 6-well plates for 24 hours. The cells
were then treated with PDL1-DOX or kept untreated (UT) at concentrations of 2.5 μM and then
incubated for 24 h, until a microscopically visible morphology change was occurred. The cells were
then collected, centrifuged, counted, resuspended, and analyzed with a guava Guava®easyCyte™
flow cytometer (Austin, TX, USA).
2.6. Cellular Imaging with Confocal Microscopy
Confocal imaging was performed based on previously published literature [22]. Briefly,
MDA-MB-231 cells were plated with a density of 200,000 cells per 60 mm petri dish and waited
48 h until confluency reached up to 70%, then cells were treated with 1 μM concentration of PDL1-Dox
or Dox with respect to Dox concertation for 1 h in 10% FBS containing DMEM. The cells that followed
were washed 3 times with PBS and fixed with 2% formalin in PBS for 15 min. 15 min prior to confocal
imaging, cells were stained with Hoechst 33342. Dox was visualized in red channel (Ex. 488 nm and
Em. 560 nm) and Hoechst was visualized in blue channel (Ex. 350 nm, Em. 461 nm) and images were
merged to demonstrate the localization of PDL1-Dox and Dox in cells [11].
2.7. 3D-spheroid Culture Study
5,000 MDA-MB231 cells/well were plated in 3D-matrix containing 96-well plate and waited for
18 h to form 3D-spehroid. Following this, spheroids were treated with 5 μM and 2.5 μM of Dox and
PDL1-Dox with respect to Dox concentration for 20 h and bight field images were taken in a phase
contrast microscope under 4× objective.
2.8. IFN-γ ELISA
The enzyme linked immunosorbent assay (ELISA) of the IFN-γ cytokine was performed with
bioligand ELISA kit as per manufacturer protocol. Briefly, 5000 RAW 264.7 cells/well were seeded to
96-well plate for 18 h. In day 2, media was changed with 1 μg/mL LPS containing DMEM for 24 h.
On Day 3, 4000 MDA-MB-231 cells/well were co-cultured with RAW 264.7 cells containing wells in
presence of 1 μg/mL LPS. Day 4, cells were treated with Dox (2.5 μM), PDL1-Dox (2.5 μM) or left UT
for 24 h. Day 5, media was collected and run for Elisa assay. The quantity of IFN-γ was quantified
with the IFN-γ standard.
2.9. Animal Studies
All animal procedures and imaging experiments was done according to protocols approved by
the Institutional Laboratory Animal Care & Use Committee (IACUC) at the Wayne State University.
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Near-infrared (NIR) dye, S0456 was conjugated with PDL1-PEG-SH to obtain PDL1-S0456 and free
S0456 was separated by dialysis [7]. The 8-weeks old tumor bearing TNBC and NSCLC patient derived
tumor xenograft (PDx) mice were intravenously injected with 10 nmole of PDL1-S0456 TNBC and
the bio-distribution of NIR dye was monitored after 24 h of the single dose of 10 nmole NIR dye
per mouse. Non-specific BSA-S0456 was used as a control. Fluorescence images were collected in
Bruker Carestream Xtreme in vivo imaging system at excitation (750 nm) and emission (830 nm)
wavelength as per previously published method [7]. The instrument has dual fluorescence and X-ray
imaging modalities with light source and fluorescence and X-ray images of the mouse were merged to
demonstrate the localization of NIR dye. PDx tumor mice were obtained from Jackson laboratory, and
tumor fragments were passaged to Nod-Scid mice.
2.10. Statistical Analysis
The statistical analysis was done using GraphPad Prism 7 software (GraphPad Software Inc.,
La Jolla, CA, USA). The data were expressed as mean ± SD and analyzed using a two-tailed
Student t-test, or one-way ANOVA followed by a post hoc test. A p-value of <0.05 was considered
statistically significant.
3. Results
3.1. Synthesis and Characterization
The synthesis of the ADC was performed similar to previously published literature using the
clinically used PDL1 antibody, COOH-PEG-SH and Aldoxorubicin [24]. The PDL1 AB itself does not
have any significant absorbance at the same wavelength of max absorbance of Doxorubicin (481 nm) as
can be found in Figure 2A. Therefore, the intensity of the absorbance at 481 nm was used to determine
the concentration of Dox present in the PDL1-Dox formulation. This concentration of Dox in PDL1-Dox
was considered as the basis for performing biological studies of PDL1-Dox, as it could be compared
to free Dox. This is justified because the difference between in vitro activity of PDL1-Dox compared
to free Dox could be attributed to the presence of PDL1 AB. The data from Figure 2A demonstrate
the successful conjugation of Dox with PDL1 AB through PEG linker to produce PDL1-Dox ADC.
As mentioned, the use of hydrazone linker in PDL1-Dox is needed to selectively deliver Dox to the
extracellular acidic milieu of the tumor so that it can disrupt the tumor environment and enhance the
penetration of PDL1-antibody into the core of the tumor [1]. To demonstrate the acidic pH responsive
release of Dox from PDL1-Dox, we studied the release kinetics of PDL1-Dox in PBS of pH 5.5 and
pH 7.4. Figure 2B indicates that 90% of Dox was released in pH 5.5 at 50 h, whereas the released
amount of Dox was less than 30% in pH 7.5 at 50 h. The sustained and acidic pH stimuli-responsive
release of Dox from PDL1-Dox supports the hypothesis of using PDL1-Dox ADC for chemo-guided
immunotherapy in preclinical model.
Figure 2. (A) The presence of the Dox absorbance peak in PDL1-Dox indicates successful conjugation
of Dox. (B) The Dox is more completely released from the conjugate in more acidic conditions due to
hydrazone linker degradation.
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3.2. Cell Killing
Figure 3A shows the MTT-based cytotoxicity assay in MDA-MB-231 cells that displayed a dose
dependent cell killing of PDL1-Dox treatment. The difference of cell killing of PDL1-Dox and Dox is
more prominent at 72 h as compared to 48 h, indicating time dependent cell killing effect of PDL1-Dox
in PDL1 overexpressing MDA-MB-231 cells [6]. The cell killing effect of PDL1-Dox is significantly
higher in the range of 0.625 μM to 2.5 μM as compared to Dox treated cells for 72 h treatment. The
reason for the superior cell killing effect of PDL1-Dox in the lower concentrations can be attributed
to PDL-1 receptor mediated and acidic pH triggered Dox release. The IC50 of Dox and PDL1-Dox is
4 μM and 1.25 μM respectively. Thus, the cell viability data indicate conjugation of Dox with PDL-1
antibody significantly improved the cell killing effect of Dox at 72 h that corroborated with sustain
drug release kinetics data obtained in acidic pH, as shown in Figure 2B. This observation supports the
notion that PDL1-Dox will function as a potent tumor environment specific Dox delivery agent. To
demonstrate the cell killing mechanism of PDL1-Dox, we performed Annexin-V/PE based apoptosis
assay and the data is shown in Figure 3B. The results indicate a significant increase in early phase
apoptosis in PDL1-Dox in comparison to untreated control (UT). The percent of early stage apoptosis
in PDL1-Dox treated MDA-MB-231 is 2-fold higher compared to UT cells, suggesting that PDL1-Dox
is highly efficient in inducing apoptosis-mediated cell death. With this efficient anticancer effect of
PDL1-Dox, we sought to explore the cross-talk mechanism of PDL1-Dox with the MDA-MB-231 cells.
The PDL1 AB binds with extracellularly overexpressed PDL1 receptor of cancer cells, resulting in the
inhibition of interaction between PDL1 with PD-1 of T cell and the induction of T cell mediated tumor
cell killing.
Figure 3. (A) The MTT based cell viability assay in MDA-MB-231 indicates the PDL1-Dox is more
effective in killing PDL-1 overexpressing MDA-MB-231 cells as compared to Dox (n = 6). (B) The cell
killing of PDL1-Dox is mediated by early apoptosis pathway. ** p < 0.01.
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3.3. Cell Uptake
The data in Figure 4A,B clearly indicate that PDL1-Dox is unable to reach the nucleus of the
MDA-MB-231 cells and thus localizes predominantly on the cell surface. This is in contrast to
Dox treated cells in Figure 4C,D showing its non-specific accumulation in the nucleus. PDL1-Dox
specifically binds to PDL1 receptor and the complex remains mainly on the surface of the cells 24. The
presence of tumor stroma is a major barrier for any anti-tumor therapeutic as well as for PDL1 AB.
In order to determine the efficacy of the tumor environment disruption of PDL1-Dox, we treated the
MDA-MB-231 3D-spheroid culture with 2.5 μM PDL1-Dox, Dox or left it untreated (UT). The data from
Figure 4E shows that PDL1-Dox is more effective in disrupting the tumor spheroid compared to Dox.
This data resembles the observation in Figure 3A and indicates that the development of PDL1-Dox is a
worthwhile approach for the disruption of tumor environment. Furthermore, to evaluate the activation
of T-cells in PDL1-Dox treatment, we measured the production of IFN-γ, CD8+ T cell activation
cytokine that is released during innate and adaptive immune responses, and its inhibition of the
PD-1 stimulatory mechanism. From Figure 4F, it can be seen that the IFN-γ production in PDL1-Dox
treatment is significantly higher compared to Dox in a co-cultured condition of MDA-MB-231 and
activated RAW 264.7 cells. Literature reports indicate that activation of RAW 264.7 (macrophage) cells
with lipopolysaccharide (LPS) can significantly upregulate the PD-1 expression [25,26]. Towards this
end, we have utilized the LPS activated RAW 265.7 cells co-cultured with MDA-MB-231 and found the
up-modulation of IFN-γ, suggesting the PDL1-Dox mediated inhibition of PD1 and PDL1 interaction.
Thus, PDL1-Dox is compatible with the mechanism of ligand association, like the PDL1 AB antibody,
and is effective in inducing the synergistic effect of destabilizing tumor spheroid formation and
up-modulation of immune cell activation. The rationale of co-culturing the PD1 triggered macrophages
with PDL-1 overexpressing MDA-MB-231 [6] would mimic the PD-1 and PDL-1 interaction model in
cell culture condition. In this Raw-264.7 and MDA-MB231 co-cultured flask, treatment of PDL1-Dox
can inhibit the PD-1 and PDL-1 interaction, resulting activation of macrophages and thus significant
upregulation of tumor suppressing pro-inflammatory cytokine, such as IFN-γ.
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Figure 4. (A) Cell uptake study in MDA-MB-231 cells treated with PDL1-Dox indicates that PDL-Dox
is predominately accumulated in cell surface and unable to reach the nucleus (40× magnified). (B) The
magnified view of individual cells suggests presence of PDL1-Dox in cell surface (40× magnified).
(C) Dox is non-specifically accumulated in the nucleus (40× magnified). (D) Magnified view suggests
the colocalization of Dox with Hoechst dye (as indicated by arrow) (40× magnified). (E) The disruption
of MDA-MB-231 tumor spheroid in PDL-1-Dox treatment supports the notion that PDL1-Dox can be a
potential therapeutic for tumor environment disruption in preclinical tumor model. Arrows indicate
the disruption of spheroid in PDL1-Dox treatment (n = 3). (F) Significant increase in IFN-γ production
(pg/mL) in culture media treated with PDL1-Dox using coculture of MDA-MB-231 and activated RAW
264.5 cells as compared to Dox treatment is seen. * p < 0.05 (n = 4 independent experiment) and results
are presented as STDEV in excel.
3.4. Imaging
With the selective anticancer effect and significant immune activation of PDL1-Dox at the cellular
level, we performed near infrared (NIR) optical imaging in TNBC and NSCLC patient derived
tumor xenograft (PDx) model with ATZ-conjugated NIR dye, PDL1-S0456. In this regard, we chose
PDx models because it generates tumors with features that very closely mimic a human tumor
microenvironment that is most ideal for future clinical translation. The rationale of performing
NIR-imaging with PDL1-S0456 is due to its significant advantage as a (i) tumor image guided surgery
tool in the clinic, and to (ii) understanding tumor selective delivery, tumor retention, and safety to
predict therapeutic outcome in different tumor models. The results from Figure 5A,B clearly indicate
the selective accumulation and tumor core penetration of PDL1-S0456. The sustained NIR intensity at
4 h and 24 h in NSCLC tumor as shown in Figure 5A indicates the retention of PDL1-S0456, suggesting
tumor specificity. The biodistribution in Figure 5B confirms the tumor selectivity of PDL1-S0456 with
low non-specific accumulation in liver and spleen. Similarly, PDL1-S0456 is selectively delivered to
the TNBC PDx tumor and shows tumor specific delivery and favorable biodistribution as shown in
Figure 5C,D. The bovine serum albumin (BSA) conjugated S0456, BSA-S0456 control showed poor
specificity to tumor and majority of the dye is accumulated in the liver as compared to the tumor. This
data indicates the longer retention and selectivity of PDL1-S0456 in tumors needed for achieving a
tumor diagnosis.
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Figure 5. (A) NIR imaging of PDL1-S0456 in NSCLC PDx model indicates selective accumulation
and retention of dye in tumor mass. (B) Higher accumulation of dye in tumor core as compared to
other organs support tumor selectivity of the PDL1-S0456 formulation. (C,D) Higher tumor uptake
compared to liver and spleen in TNBC PDX supports PDL1-S0456 as a smart diagnostic tracer for
multiple tumor imaging and targeted therapy. (E,F) indicates high non-specific liver accumulation of
non-targeted serum albumin-dye conjugate as compared to tumor (n = 2 independent experiment).
4. Discussion
Extensive research is ongoing to improve therapeutic outcome ADCs that can enhance their
targetability and therapeutic efficacy against tumors. The majority of ADC are used to target
the extracellular receptor of cancer cells, followed by receptor mediated-internalization of ADC
in cytosol and delivery of payload in endosome [1,27]. Utilizing this mechanism, one can only
achieve chemotherapeutic benefits against cancer. In contrast, our approach was to use PDL-1
antibody inhibitor in PDL1-Dox formulation that will bind to the surface of cancer cell and selectively
delivery both PDL-1 inhibitor and Dox, resulting a synergistic outcome of chemotherapeutic and
immunostimulatory effects. The extensive research majority (two out of three) of clinically approved
ADCs are used blood cancer with limited benefits in solid tumor [28]. The phase I/II clinical study of
anti-CD74 antibody-doxorubicin conjugate, (IMMU-110) was developed for multiple myeloma [29].
These limitations and challenges of current ADCs technology warranted us to develop PDL1-Dox
conjugate for achieving the dual chemo and immunotherapeutic benefits against the solid tumor. In
the clinical setting, several antibody-NIR imaging agents have shown an excellent ability to distinguish
the tumor lesion from healthy tissue during image-guided surgery as noted in NCT01987375 and
NCT01508572 [30] for targeting extracellularly overexpressed VEGF and EGFR receptor. With this
note, PDL-1 is an excellent target for developing antibody-NIR or a radio imaging agent that can be
utilized for multiple cancer diagnosis and for understanding the cross-talk between cancer cell and
T-cell in immune evasion. The up modulation of tumor suppressing pro-inflammatory cytokines, such
as IFN-γ in PDL1-Dox treatment supports PDL1-Dox mediated anti-tumor immune cell activation [31].
Furthermore, PDL1-S0456 can be engineered with potent drugs to obtain antibody-dye-drug conjugate
for the multimodal image guided therapy and immune modulation. Towards this end, our first
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approach in developing immune checkpoint antibody inhibitor-drug conjugate and imaging agent
demonstrates a rational platform for chemo-guided immunotherapy that can be further developed for
other types of cancer.
5. Conclusions
In this study we have demonstrated the development of PDL1 antibody drug conjugate to improve
the antitumor efficacy of current treatment. The PDL1-Dox treatment has multimodal anticancer effects
including tumor acidic pH responsive drug release, apoptosis mediated cancer cell death, targetability
of PDL1 receptor and tumor 3D-spheroid disruption, and upmodulating of tumor suppressing IFN-γ
mediated immune cell activation. The PDL1-S0456 tool has demonstrated the selective tumor targeting
ability in a patient derived tumor model, which is a positive step towards further developing tumor
NIR imaging tool for imaging guided surgery of PDL-1 positive tumor in a clinical set up.
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Abstract: For localized tumors, gold nanorod (AuNR)-assisted plasmonic photothermal therapy
(PPTT) is a potentially effective alternative to traditional surgery, in which AuNRs absorb near-infrared
light and convert it to heat in order to kill cancer cells. However, for large tumors (volume ≥ 20 cm3),
an uneven distribution of AuNRs might cause inhomogeneity of the heat distribution inside the
tumor. Surgery is frequently recommended for removing large tumors, but it is associated with
a high risk of cancer recurrence and metastasis. Here, we applied PPTT before surgery, which
showed improved treatment for large tumors. We divided the animals (eight cats/dogs) into two
groups: Group I (control), where three cases were solely treated with surgery, laser, or AuNRs
alone, resulting in recurrence and metastasis; and Group II, where animals were treated with PPTT
before surgery. In Group II, four out of the five cases had tumor regression without any recurrence
or metastasis. Interestingly, we observed that applying PPTT before surgery displayed reduced
bleeding during tumor removal, supported by histopathology that showed altered blood vessels.
In conclusion, our study showed that applying AuNR-assisted PPTT (AuNRs-PPTT) before surgery
could significantly affect blood vessels inside the tumor, leading to a decreased amount of bleeding
during surgery, which can potentially decrease the risk of metastasis and blood loss during surgery.
Keywords: plasmonic photothermal therapy; gold nanorods; surgery; bleeding; dogs; cats; breast cancer
1. Introduction
Gold nanorods (AuNRs)-based plasmonic photothermal therapy (PPTT) is a cancer therapy in
which AuNRs are injected into the tumor before exposure to near-infrared (NIR) light [1,2]. The NIR
light capable of deeply penetrating the tissue is transiently applied to the tumor, producing localized
heat that could lead to tumor necrosis and apoptosis [3]. PPTT modulation to induce cell apoptosis
might be a more favorable option than triggering necrosis, as during necrosis, the broken plasma
membrane leads to the leaking of cytoplasmic components and inflammation, which could further
induce cancer growth and metastasis [4–7]. The high efficiency of PPTT in getting rid of cancer cells
by inducing apoptosis has been demonstrated both in vitro and in vivo [3,8]. The reason for using
canines and felines is because of their molecular and biological similarity to human mammary tumors,
which makes these animals a model system [9,10]. The surgery is usually the first line of treatment in
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the animals. In many animal cases, the tumors often metastasize. We have shown the efficacy of this
treatment in tumor-bearing mice [8,11] and have recently demonstrated the treatment of mammary
carcinoma in dogs and cats, where the malignant mammary tumors of ≤20 cm3 in volume could be
treated by intratumoral inoculation of AuNRs, followed by PPTT [5]. During these studies, we observed
that animals with induced or spontaneous tumors have noteworthy regression without any recurrence
nor metastasis. Our recent studies have also shown the ability of gold nanorod-assisted plasmonic
photothermal therapy (AuNRs-PPTT) in vitro to inhibit cancer cell migration [12,13]. In addition,
the toxicity of this treatment has been examined in mice, dogs, and cats, which indicates that there
are no toxic effects on the animals for long periods of time [5,8]. Therefore, PPTT is believed to be a
favorable alternative for treating solid tumors with relatively small sizes and preventing metastasis [14].
For large tumors (volume ≥ 20 cm3), PPTT could be hard to achieve because of an uneven
distribution of injected AuNRs that causes an inhomogeneity of the heat in the tumor. In these
cases, surgery is usually recommended to remove primary solid tumors. However, the surgical
resection of primary breast cancer tumors commonly has a risk for metastatic recurrence [15]. It has
been recognized that the tumors contain large amounts of blood vessels that provide nutrients that
support tumor growth [16]. Blood vessels are also critical for metastasis, as extensive and highly
permeable blood vessels provide ways for cancer cells to exit primary tumor sites and enter into the
bloodstream. Surgery usually disrupts the blood and lymphatic vessels, thus releasing cancer cells into
the vasculature and promoting metastasis [17]. Therefore, the development of novel therapies that aid
in the surgical process to prevent blood loss, tumor recurrences, and metastasis are of great importance.
In this study, we are focusing on introducing a new treatment regimen featuring the combination
of PPTT and surgery in dogs and cats with large tumors, as well as examining the efficacy of this new
regimen. Interestingly, we observed that applying AuNRs-PPTT before surgery could significantly
decrease bleeding, which could potentially avoid the risk of metastasis caused by surgery.
2. Results
2.1. Preparation and Characterization of the AuNRs
AuNRs with an average size of 27 (±5) × 6 (±1) nm (length × width) were used in this study,
as they showed enhanced efficacy of PPTT [18]. AuNRs were synthesized according to our reported
method [19], and these AuNRs are shown in the transmission electron microscope (TEM) image
(Figure 1A). AuNRs have a surface plasmon resonance wavelength of around 800 nm (Figure 1B).
After synthesis, AuNRs were successfully coated with Methoxy polyethylene glycol thiol (mPEG-SH)
and Arg−Gly−Asp (RGD) peptides, as demonstrated by the red-shift of the surface plasmon peak
(Figure 1B). The average number of ligands on each particle is quantified to be 1000 mPEG-SH and
10,000 RGD. RGD is known to bind to integrin, which is over-expressed on the surface of breast cancer
cells and associated with breast cancer progression and metastasis [20]. RGD binding could enhance
the receptor-mediated endocytosis of the nanoparticles [21].
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Figure 1. Characterization of gold nanorods (length 27 ± 5 nm, width 6 ± 1 nm). (A) Transmission electron
microscope (TEM) image with 100 nm scale bar. (B) UV–VIS absorbance spectra showing the surface plasmon
resonance peaks of gold nanorods (AuNRs) after synthesis (AuNRs@CTAB (cetyltrimethylammonium
bromide)), then after conjugation with polyethylene glycol (PEG) (AuNRs@PEG), then after conjugation
with (Arg−Gly−Asp) RGD (AuNRs@PEG@RGD).
2.2. PPTT Decreases Bleeding during Surgery
In our earlier studies, we optimized the PPTT conditions for treating dogs and cats, including
the AuNR dosage and laser conditions (7.5 nM of AuNRs irradiated by NIR laser with 0.5 W/cm2
intensity for 2 min). The optimized conditions were conducted multiple times (2 weeks apart) until
complete regression via apoptosis was shown, and this apoptosis proved to be better than necrosis [5].
Herein, we devised a new treatment regimen for treating animals with tumor volumes ≥20 cm3 by
combining surgery with PPTT.
Before treatment, all animal tumors showed varied growth, as shown in Tables 1 and 2. In the
control group (I), three cases with 10 tumors were solely treated by a mastectomy, laser, or AuNR
treatment alone. As shown in Figure 2A,B, photographic images of case 1 (GI-1) revealed three large
tumors located at the cranioabdominal and inguinal lymph nodes. All three tumors connected to
form one chain. Figure 2C is a picture of a tumor during surgery with obvious bleeding (over 100 g).
Figure 2D is a histopathology of the tumor tissue showing ductal carcinoma in situ, grade II.
In Group II, five cases with eleven tumors were treated with three sessions of PPTT (in 2 week
intervals) and were followed by surgery after the last PPTT session. Figure 3A,B shows case 1 (GI-1),
where the animal was treated with surgery only, and Figure 3C,D shows one case with surgery after
PPTT. Interestingly, we observed that when applying PPTT before surgery, reduced bleeding during the
surgery was observed for all of the treated tumors in Group II when compared to Group I (Figure 3A,C
and Videos S1 [surgery only] and S2 [surgery after PPTT]).
The decrease of bleeding might be explained by the histopathology of the tumor bed vasculature
(Figure 3B,D). With surgery only, the blood vessels were normal and intact (Figure 3B) while after PPTT,
the tumor bed vasculature showed swelling and sloughing of the endothelial lining and destruction of
the blood vessel walls Hematoxylin& Eosin (H&E ×400) (Figure 3D).
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Table 1. Animal groups, tumor clinical features, and therapeutic approaches.




1-R caudoabdominal ulcerated (8 × 5)
II Only mastectomy
2-R cranioabdominal (18 × 4)
3-R inguinal Lymph node All the
three connected to form one chain
GI-2 Dog—Griffon,7 years 1-R Cranioinquinal (4.1 × 2.9) II Laser only, followed by mastectomy
GI-3 Cat—15 years
1-R caudo
abdominal (4 × 4.5).
II
1 + 2 + 3 tumors form chain; Laser only,
followed by mastectomy2-R inguinal LN (3 × 2.1).
3-L cranioabdominal (5 × 2)
4-R inguinal (1 × 2)
I
4 + 5 + 6 tumors treated by AuNRs only,
followed by mastectomy
5-L inguinal (1 × 1)
6-L caudothoracic (1 × 1)
GII-1 Cat—9 years
L caudothoracic (4.5 × 4)
III
Three sessions of plasmonic photothermal
therapy (PPTT), followed by surgeryR caudothoracic (4 × 4)




1-L inguinal (5 × 5)
II
Three session of PPTT, followed by surgery
2-L inguinal (2 × 1.5) PPTT only
















Three session of PPTT, followed by surgery
2-small caudal abdomenial 2 and 3 treated by PPTT only
3-two attached small tumors
The control group, GI, included three cases (two dogs and one cat with 10 tumors) treated with either surgery only,
laser only, or AuNRs only. All cases developed metastasis and died after treatment. Group II (GII) included five
cases (four dogs and one cat with 11 tumors) treated with PPTT (AuNRs and laser together) for three sessions,
followed by surgery. At the time of death, there was no presence of disease; however, one case succumbed to
metastatic disease.
Table 2. Survival, bleeding loss, and metastasis for both GI and GII.
No. # EBL (g) LR DM (Time Mo) OSS (mo) Status
GI-1 >100 +1 month +(CS, LN) 3 DOD
GI-2 66.5 - +(CS, LN) 1 DOC
GI-3 47.5 - +(LN) 1 DOC
GII-1 <1 - - 24 ADF
GII-2 <1 - - 48 ADF
GII-3 <1 - - 3 DOC (pneumonia)
GII-4 <1 - +(LN, CS) 1 DOD
GII-5 <1 - - 6 DOC (pneumonia)
Group I (GI) were solely treated with surgery, laser, or AuNrs alone. Group II (GII) were treated with PPTT (AuNrs
and laser together) before surgery. Estimate blood loss significant test p-value and statistical significance: the
two-tailed p-value = 0.0010—by conventional criteria, this difference is considered to be statistically significant.
ADF, alive disease free; DM, distant metastases; CS, clinical stage; DOC, dead other cause; DOD, dead of disease;
EBL, estimated blood loss; LN, lymph node; LR, local recurrence.
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Figure 2. (A) Photographic image of control case 1 (Group 1, case 1) treated with surgery. (B) A
magnified figure of (A) for the tumor area. (C) Photo of case during surgery with high amount of
bleeding. (D) Photomicrograph of tumor tissue, showing ductal carcinoma in situ grade II (H&E ×100).
Three images for each tumor were evaluated.
Figure 3. Left side (A,B) shows case 1 in Group I (surgery only). Right side (C,D) shows one
case in Group II (treated with PPTT for three sessions (2 week intervals) before the surgery).
(A,C) Photographic images indicating the decrease of bleeding after PPTT (C), compared with the
control (A). (B,D) Photomicrograph of tumor bed vasculature showing (B) normal intact blood vessels
with surgery only, and (D) swelling and sloughing of the endothelial lining and the destruction of the
blood vessel wall (arrow) after PPTT (H&E ×400). Three images for each tumor were evaluated.
In addition, the regimen of PPTT before surgery has shown to be effective for achieving complete
tumor regression, as shown in Table 2. For example, in one case from Group II, a nine-year-old mixed
breed cat suffered from mammary neoplasms as shown in Figure 4A. The site of two tumors located
at her left axillary lymph node (black arrow) and left cranial thoracic (blue arrow) is demonstrated
in Figure 4B. After PPTT, followed by surgical excision of the tumors (Figure 4C), tumor regression
was achieved. The histopathology showed that after PPTT, well-developed granulation tissues were
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observed, indicating tumor recovery (Figure 4D). After 12 months, this case showed complete recovery
from the surgery (Figure 4E) without evidence of recurrence or chest metastasis (Figure 4F).
Figure 4. (A) A nine-year-old mixed breed cat suffered from mammary neoplasm (Group 2, case 1).
(B) The sites of tumors at the left axillary lymph node (black arrow) and left cranial thoracic (blue arrow)
(C) after surgical excision and (D) the subcutaneous layer showing well-developed granulation tissue at
the site of suture (arrow) (H&E ×100). (E) The case after 12 months showed complete recovery from the
surgery without any evidence of recurrence. (F) X-ray shows no metastasis in the chest. Three images
for each tumor were evaluated.
3. Discussion
Three cases among the five in Group II died a few months after PPTT and surgery treatment
because of viral pneumonia, but evidence of tumor recurrence or metastasis was not observed.
Earlier, we have shown in our study on mice that there was no toxicity after 15 months of AuNRs
injection, whose bio-distribution mainly locates at the liver and spleen [8]. However, we do find that
other types of nanoparticles, such as TiO2, iron, Cr3+-doped zinc gallate, and silver, could accumulate
in the lung, and might cause toxicity [22–25], while AuNPs have better biocompatibility than these
nanoparticles. To the best of our knowledge, there are not many systematic studies discussing the
blood circulating (not airborne) AuNRs and their relation with pneumonia thus far. This can be a
separate study in future.
In this report, we observed that PPTT affected the tumor blood vessels that, in turn, decreased the
blood flow inside the tumor. The reason is still not fully understood. Previous reports have shown that
AuNPs could affect blood vessels and tumor angiogenesis [26–28]. In addition, the temperature increase
would cause the destruction of blood vessels. For instance, it has been reported that photothermal
ablation of breast cancer in mice models using doxorubicin-loaded DNA-wrapped AuNRs could
disturb the blood vessels [29]. Furthermore, it is reported that AuNPs with sizes around 30 nm could
induce tumor endothelial leakiness [30]. In addition, the abnormal vascular nature of the tumor tissues
allows them to uptake more AuNRs [31], which might explain why the AuNRs-PPTT is more effective
on the tumor blood vessels. The importance of applying AuNRs-PPTT before surgery could also be
very important in decreasing blood loss, especially for the patients who have injury-healing problems,
including chronic diseases such as diabetes, and need tumor surgery.
4. Materials and Methods
4.1. Synthesis and Surface Modification of AuNRs
AuNRs were prepared according to the seedless method [19]. Briefly, 5 mL of 1 mM HAuCl4
(Sigma-Aldrich Co., St Louis, MO, USA) was mixed with 5 mL of 0.20 M cetyltrimethylammonium
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bromide (CTAB; Sigma-Aldrich Co.), followed by adding 250 μL of 4 mM AgNO3 (Sigma-Aldrich Co.)
and adjusting the pH of the solution to be 1–1.15 by 37% HCl. Then, 70 μL of 78.8 mM ascorbic acid
(Sigma-Aldrich Co.) was added to the solution until the solution became clear. A total of 15 μL of
0.01 M ice-cold NaBH4 (Sigma-Aldrich Co.) was injected into the growth solution immediately, and the
solution was left unstirred for 6 hours. To remove the extra CTAB and prepare for surface modification,
the AuNRs were centrifuged at 19,000 rcf for 1 hour, and the pellet was redispersed in deionized
water and centrifuged at 14,000 rcf for 15 min. The AuNRs were rinsed with water, then conjugated
with different surface ligands (polyethylene glycol (PEG) thiol and Arg−Gly−Asp (RGD) peptides).
For surface modification, methoxy PEG thiol (m-PEG-Th, PEG; Laysan Bio, Arab, AL, USA) was added
to AuNRs and stirred overnight to achieve a concentration of around 1000 PEG molecules per AuNR.
For preparation of the AuNRs@RGD, the PEGylated nanoparticles (1 nM) were treated with RGD
(1 mM) to achieve 10,000 ligands on each AuNR. Afterward, the solution was kept overnight to be
shaken at normal temperature, and the extra ligands were removed by centrifugation. A UV–VIS
spectrometer was used to confirm the conjugation.
4.2. Characterization of AuNRs
A JEOL 100 CX transmission electron microscope (TEM) (JEOL Ltd., Tokyo, Japan) was used to
measure the size and homogeneity of the samples. A Cary 500 UV–VIS spectrometer (Agilent
Technologies, Santa Clara, CA, USA) was used for measuring the absorbance of the AuNRs.
To characterize the surface conjugation with PEG, a ZetaSizer 3000 HAS (Malvern Instruments,
Worcestershire, UK) was used for measuring the surface Zeta potentials. In addition, Ellman’s reagents
(Sigma-Aldrich Co.), which react with free-Thiol groups (calorimetrically measured at 412 nm), were
used to quantify the number of PEG molecules boun to the surface of the AuNRs.
4.3. Animal Diagnosis and X-ray Examination
All animals were handled in accordance with Association for Assessment and Accreditation of
Laboratory Animal Care and Office of Laboratory Animal Welfare guidelines under the direction of the
Institutional Animal Care and Use Committee at Cairo University. The pet animals were admitted to the
Department of Surgery Clinic of the Faculty of Veterinary Medicine at Cairo University. This research
was approved by the Institutional Animal Care and Use Committee (CU-IACUC) Cairo University
(code: CU II F 9 16).
All pets’ owners claimed that their animals did not receive any treatment before their arrival at
the university. Written informed consent was provided by the owners of the pets for the treatments.
Eight female animals were treated in this study, including two canines and six felines, with a total
of 21 tumors with varied grades (I to III). The tumor dimensions were measured using calipers.
Histopathology tests were used to diagnose the tumor types/grades. At the tumor site, the animal’s hair
was shaved, and subsequently, radiographic recordings were taken with an X-ray machine (Fischer,
Berlin, Germany). The radiographic setting factors were 58–70 kVp, 10 mAs, and a 90 cm focal
spot film distance. The radiographic exposures were conducted dorsoventrally and right laterally.
Blood loss was quantified by measuring the blood volume and weighing surgical sponges used for
blood collection before and after the surgery.
General anesthesia was applied for animals during the surgical mastectomy and postsurgical
application of PPTT. Under general injectable anesthesia, each animal was pre-medicated with atropine
sulphate (1%, 0.05–0.1 mg/kg b. wt.; Adwia Co. S.A.E., Cairo, Egypt) and xylazine (Xyla-Ject 2%,
1 mg/kg b. wt.; Adwia Co. S.A.E.), and then anesthesia was induced using ketamine HCl (Ketalar,
10–15 mg/kg b. wt.; Sigma-Aldrich Co.) and maintained by ketamine HCl [32,33].
4.4. Performing PPTT in Animals
Each animal was subjected to three sessions of PPTT treatment in 2 week intervals using an
808 nm diode laser with a power of 0.5 W/cm2 and a spot size of around 5.6 mm2. An effective dose
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of AuNR solution (7.5 nM AuNRs) for each 100 cm3 was used for 2 min, and the amount used was
scaled up based on the volume of the tumor, and then injected directly into the tumor. Five minutes
after injection, the entirety of the tumor was irradiated with the laser. The AuNR concentration was
decreased by 50% for each subsequent treatment. The temperature increase of a tumor during the laser
irradiation was measured by placing a 33-gauge hypodermic thermocouple (OMEGA Engineering,
Inc., Stamford, CT, USA) needle directly inside the tumor (42–44 ◦C).
4.5. Histopathology Evaluation of the Animal Tumors
The detailed pathologic evaluation of tumors was conducted by members of the pathology
department of the Faculty of Veterinary Medicine at Cairo University. Histopathological analysis was
performed on 5 μm sections from tumor tissue that were fixed in 10% buffered formalin. The samples
were stained with H&E to assess pathology.
5. Conclusions
Surgery is often used for tumor removal; however, it might trigger metastasis [34]. PPTT could be a
better alternative to replace traditional chemotherapy and radiotherapy for localized tumors, especially
for tumors with a volume ≤20 cm3 [5]. Therefore, for effective treatment of large tumors (volume ≥
20 cm3), we applied PPTT before surgical resection to naturally occurring tumors in the mammary
glands of dogs and cats. Five cases were treated with this regimen and showed complete remission
without any recurrence after therapy. Three cases died in the few months following treatment, but in
two cases from three, there was no evidence of any tumors upon examination (the animals died because
of other reasons, such as pneumonia). Histopathology results showed a decrease in cancer grades
compared to before (variant grades from 1 to 4) and after 2 weeks of treatment via PPTT and surgery
(grade 0). X-ray diffraction revealed an absence of metastasis 1–2 years after treatment. In conclusion,
our study demonstrates the feasibility of applying PPTT before surgery to large tumors in dogs and
cats. Applying AuNRs-PPTT before surgery in treating large tumors could significantly affect blood
vessels inside the tumor and potentially avoid the risk of bleeding during surgery. PPTT could be
incorporated before the surgery to decrease the bleeding and potentially avoid the risk of bleeding
during surgery that could lead to excessive blood loss and metastasis.
6. Patents
This work has been filed in the US-Patent Publication of US20190008964A1.
Supplementary Materials: The following are available online at https://zenodo.org/record/3251162#.XR3I5_YRU2x,
Video S1 [surgery only] and Video S2 [surgery after PPTT]).
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Abstract: Recently, nanomedicines have gained a great deal of attention in diverse biomedical
applications, including anti-cancer therapy. Being different from normal tissue, the biophysical
microenvironment of tumor cells and cancer cell mechanics should be considered for the development
of nanostructures as anti-cancer agents. Throughout the last decades, many efforts devoted to
investigating the distinct cancer environment and understanding the interactions between tumor cells
and have been applied bio-nanomaterials. This review highlights the microenvironment of cancer cells
and how it is different from that of healthy tissue. We gave special emphasis to the physiological shear
stresses existing in the cancerous surroundings, since these stresses have a profound effect on cancer
cell/nanoparticle interaction. Finally, this study reviews relevant examples of investigations aimed at
clarifying the cellular nanoparticle uptake behavior under both static and dynamic conditions.
Keywords: nanomedicine; nanoparticle; targeted therapy; anti-cancer; shear stress; flow; in vitro
1. Introduction
In 1959, Richard Feynman delivered his pioneering lecture about nanotechnology in which
he gave a foundation about materials miniaturization [1]. Since then, nano-scaled materials have
been investigated and studied extensively for use in various fields, including the medical field [2].
When the power of nanotechnology is harnessed for biomedical applications, it is designated as
nano-biotechnology or bio-nanotechnology to indicate the combination of nanotechnology with the
biological system [3]. Nanomaterials are considered promising and favorable materials due to their
unique properties as well as their extremely small size and high surface area to volume ratio, which
means better surface interaction and effective cellular uptake. Nanobiotechnology has been applied in
diverse medical applications, such as drug delivery platforms, contrast agents for magnetic resonance
imaging, tissue engineering, and anti-cancer therapy.
Today, cancer is rated as the second leading cause of mortality worldwide [4]. In cancer cases,
the signals that control normal cell division and normal cell death are disregarded due to genetic or
environmental conditions. Consequently, uncontrolled cell division gives rise to rapid cell growth and
the formation lumps, which is known as localized tumors. These tumor cells are characterized by fast
proliferation, metastasis, and the ability to induce the formation of new blood vessels, which is also
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known as “angiogenesis” [5]. Current cancer therapies are known for their lack of selectivity for tumor
cells, as well as severe side effects such as damage to healthy organs, hair loss, and uncontrolled gastric
problems. The integration of nano-scaled structures for anti-cancer therapy can be in the form of carriers
for chemotherapeutic agents, cancer diagnostic agents, or targeting moieties. Nanomedicine holds the
potential to minimize the undesired and severe adverse side effects of anti-cancer therapy, as well as to
increase the efficacy and selectivity against tumor cells. In that regard, significant efforts have been
devoted to developing nanoplatforms for specific cancer therapy or nanomedicine [6–9]. To design
an effective nanomedicine, specific characteristics of cancer cells such as cancer cell mechanics or
microenvironment of the tumor, which will influence the binding or internalization of the nanoparticles
to cancer cells, should be taken into consideration.
Cancer cells are exposed to different forces and mechanical stresses than normal cells in the body,
such as compressive forces due to tumor growth plus the interstitial pressure and shear stresses due to
blood and interstitial fluid flow [10]. The biophysical microenvironment of tumor cells is different
from normal cells. To illustrate this, blood flow in cancer microenvironment is irregular compared to
normal circulation and subsequently, causes the tumor to be less oxygenated as the tumor grows [11].
Furthermore, the tumor site (extracellular fluid) is more acidic than normal tissues [12]. All these
differences have substantial influences on the interactions of tumor cell with applied nanostructures.
For example, shear forces in the extracellular environment can activate some cellular processes and affect
the cellular uptake mechanism, which is important for targeted cancer therapy via nanoparticles [13].
Generally, fluid shear stress (FSS) in the biological systems can be categorized as resulting from
blood flow, interstitial fluid flow or lymphatic fluid flow. Cancer cells mainly encounter interstitial
fluid flow in localized tumor and also blood flow in case of metastasis [14]. Tumor cells can be exposed
to additional fluid flows in the body, such as fluid flow in peritoneal cavity during ovarian cancer,
which increases FSS [15]. Consequently, FSS is accepted as an important factor regulating the behavior
of cancer cells and, more particularly, FSS acting on tumor cells will be discussed later in this article.
The major objectives of this review are to: (a) demonstrate the main types of physiological shear
stresses that are affecting the tumor cells; (b) shed light on the interactions between cancer cells and
applied nanomaterials in both static and dynamic conditions; (c) summarize findings on the influence
of uptake of nanomaterials by cancer cells.
2. Physiological Shear Stresses Affecting the Tumor Cells
2.1. Shear Stress Due to Blood Flow
Circulating tumor cells (CTC) or metastatic cells are cancer cells that shed from the localized
primary tumor and migrate to other body sites through the blood stream [16]. These cells experience
shear stress due to blood flow [17,18]. Studies showed that, CTC can be influenced by FSS in two ways:
either the cell cycle will be arrested due to mechanical force [19] or certain cellular process will be
activated resulting in migration of CTC and invasion of other organs [20]. It has been reported that
high levels of FSS (~60 dyn/cm2) can induce apoptosis and eliminate 90% of cancer cells from the blood
stream [21]. This elimination and cell death have been related to destruction of the cell’s cytoskeleton
due to high shear, thus preventing cell adhesion. Furthermore, at high shear rate, cells produce more
reactive oxygen species, resulting in cell death due to oxidative stress [22]. On the other hand, low FSS
(2 dyn/cm2) can activate certain mechanosensitive cytokines such as IGF-2, VEGF, ROCK, and Cav-1.
This activation prompts their downstream molecular pathways which induce metastasis [23].
2.2. Shear Stress Due to Interstitial Fluid Flow
Molecular diffusion and convection are the basic mechanism of biological mass transport.
In molecular diffusion, random molecular movements lead to net transport of solutes or particles
down the gradient in concentration. During convection, a solute or particle is carried by moving fluid.
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In a region where a fluid (for example, blood or interstitial fluid) is flowing, diffusive and convective
transport can occur simultaneously [24].
In normal tissue, the way that cells get their nutrition is by diffusion of the blood plasma to
the stromal space between the cells, which is also known as the interstitial space. The cells excrete
their wastes by diffusion of waste products to the nearby lymphatics that drain them to the venous
blood stream [25] (Figure 1). In normal situations, the flow of interstitial fluid is only maintained
by the diffusion of nutrients from the blood stream to the interstitial space, and waste products
from the cells to the interstitial space, and then to the lymphatic vessels. This mechanism prevents
excessive fluid accumulation in interstitial site. However, the situation is different in the cancer
microenvironment. As cancer cells keep growing, it becomes difficult for them to support a good waste
drainage. Furthermore, tumor endothelial cells proliferate fast due to production of vascular endothelial
growth factor (VEGF) by tumor cells. However, they form less tight junctions than endothelial cells in
normal tissue, causing leaky endothelial cell junctions and hyperpermeability [26]. Therefore, although
the fluid will be absorbed from the blood vessels, it will not be drained back to the venous system.
This fluid accumulation will cause pressure difference between cancer microenvironment and healthy
tissue, resulting in fluid flow from tumor to its surroundings [25]. The flow of interstitial fluid was
shown to induce shear stresses on the cancer cells within the localized tumor [27] with a shear stress
level of 0.1 dyn/cm2 [13]. Interstitial flow has much slower velocity than blood flow. The interstitial
flow velocity ranges from 0.1–4 um/s compared to blood flow at 0.6–0.9 m/s in pulmonary artery [28].
Table 1 represents levels of FSS in the body and Figure 2 shows different types of FSS that cancer cells
are exposed to.
 
Figure 1. Mechanism in which normal cells get their nutrients and excrete their wastes.
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Table 1. Different shear rate values in physiological and pathological conditions.
Fluid Flow Shear Stress (Dyn/cm2) Reference
Interstitial flow 0.1 [13]
Normal vein 1–6 [29]
Normal artery 10–70 [29]
Lymphatic fluid flow 0.64 [14]
Liver 0.1–0.5 [30]
Peritoneal fluid flow <5 [15]
Figure 2. Shear stresses experienced by cells in solid tumor and circulating tumor cells.
2.3. Important Aspects for the Development of Nanomedicine for Targeted Cancer Therapy
One important aspect to consider is the mode of transport of drugs to cancer tumor, which is
combination of convection and diffusion. Once infused, anti-cancer agent is transported in the systemic
circulation via convection. Upon reaching to microcirculation, exchange occurs between blood and
tissue. Here, drug passes through vessel walls toward cancer cells by combination of convection and
diffusion in interstitial fluid. For low molecular mass drugs and small nanoparticles, diffusion is the
dominant transport mechanism [31].
For efficient targeted anti-cancer therapy using nanoparticles, the tumor microenvironment should
be considered during the design process. Ideally, nanomaterials, i.e., nanoparticles, or photothermal
nano-agents should be tested on pre-clinical animal models of cancer therapy. However, using
animal models is limited by ethical guidelines, also it is time and labor intensive [32]. To avoid the
uncritical testing on animals, in-vitro and in-silico testing are used as preliminary evaluation due
to their low cost, simplicity and better control on experimental conditions. In silico simulations are
developed to analyze nanoparticle/cancer cell interactions by solving governing physical equations.
These computational models provide quantitative analyses to describe biological mechanisms under
certain conditions. However, in most situations, in-vitro experiments should be designed to verify
in-silico test results [33]. For example, using a combination of in-vitro flow chamber set up and in-silico
simulations, Boso et al. showed that artificial neural networks can determine the optimal nanoparticle
size for maximal adherence to a targeted tissue. This optimal size depends on the wall shear rate in the
target location [34]. The results suggested that the number of in-vitro experiments can be successfully
reduced by using artificial neural networks, without compromising the accuracy of the study.
One of the major limitations for the in vitro approach is the discrepancies compared to in-vivo
systems. The reason for these discrepancies is related to the fact that cells in the body are influenced
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by many factors in their native environment. For example, FSS is one important factor affecting
cell behavior. Therefore, static cell cultures are limited to mimicking the native cancer environment.
To resemble the real conditions in organized system, FSS can be induced to static cell culture by
using microfluidic devices [35]. FSS is the force experienced by cells as a result of flow of viscous
fluids [17]. FSS can be applied on cells using parallel plate flow chambers (PPFCs), cone plate chambers
or microfluidic chambers. Different chambers are used based on the site where FSS is intended to be
mimicked. For example, cone-plate chambers are used to mimic FSS in abdominal aorta and brachial
artery due to resemblance of their geometry [36], whereas parallel plate or microfluidic chambers are
used to mimick FSS in smaller vessels.
PPFC were commonly used to mimick FSS in cancer microenvironment since cancer cells in the
body are constantly exposed to FSS by interstitial flow or blood flow. It was previously suggested that
FSS is an important factor for nanoparticle internalization by cancer cells. Therefore, association of
FSS and cellular uptake of some nanomaterials has been studied [37,38]. We will explain this in detail
in the following section. One of the first PPFCs was developed in 1995 by Ruel et al. [39]. A typical
PPFC would have an inlet port and an outlet port for flow perfusion, silicon gaskets to form the flow
chamber, and a coverslip where cells are grown on (Figure 4).
These flow chambers are mostly connected to syringe or peristaltic pumps that can pump a certain
fluid (mostly cell media) at specific flow rates for extended flow perfusion. Shear stress can be calculated




where Q represents the fluid flow rate, τ is the shear stress acting on the cells, w and h are width and
height of the flow chamber, and μ is the viscosity of the fluid, which is the cell medium [40]. Figure 4
illustrates a typical chamber setup representing the flow of the fluid in a closed circuit.
PPFCs offer a model that is not as simple as static cell culture, but not as complex as animal
models; thus, cellular interactions and nanomaterials uptake can be studied in a practical and reliant
manner as represented in Figure 3 [41].
 
Figure 3. Microfluidic devices as models in which they provide conditions similar to in-vivo
animal models and in-vivo models still retaining the simplicity of in-vitro testing. Adapted from
Björnmalm et al. [41].
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Figure 4. A typical flow chamber setup. (A) depicts a closed-circuit chamber, in which the chamber is
connected to a peristaltic pump and a reservoir (cell media). (B) illustrates the flow chamber assembly
where coverslip containing the cells is allowed for fluid flow. Adapted from bioptechs [42].
3. Interactions between Nanoparticles and Cancer Cells
Nanomaterials interact with cells differently in static and dynamic cultures. These differences
include production of reactive oxygen species (ROS) [43] as well as the viability and uptake of the
nanomaterials by cells [44]. Dynamic culture is more relevant to physiological conditions present in
an animal or human body, as the biological systems are more complex and dynamic. Usually, it is
easier to study the influence of nanomaterials using static cultures, but the results from such studies
might be misleading and/or contradictory when compared to animal models or dynamic cultures.
For example, nanomaterials tend to sediment and settle down in static cultures, inducing stresses on
cells. Furthermore, nanomaterials form aggregates in static cultures, which might alter their uptake by
the cells, and therefore, altering the viability of the results explained in Figure 5 [43].
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Figure 5. Comparison between distributions of nanomaterials under static (A) and dynamic
(B) conditions. In static culture, nanoparticles tend to sediment and aggregate due to their high
surface energy. This condition create physiochemical stress on cells, which might alter cells viability
as well as particles uptake On the other hand, in dynamic culture, the particles will be uniformly
distributed allowing better cellular interaction, which can be charge-dependent as the direction of the
negatively-charged particles will be away from the cell surface, unlike positively-charged particles,
where the particle direction will be towards the cell surface. Adapted from Mahto et al. [43].
When nanomaterials form aggregates, the aggregate size should be much smaller than the cell
size for uptake. There are different mechanisms by which cells uptake nanomaterials. These include
diffusion or passive penetration through the plasma membrane, and endocytosis that involves
pinocytosis and phagocytosis. Pinocytosis involves the internalization of molecules or fluid by the
formation of small vesicles, whereas phagocytosis involves the engulfment of large materials by
the formation of intracellular phagosomes [45]. It was reported that the uptake of nanomaterials
is size-dependent, and in some cases, it is easier for the cells to uptake larger nanomaterials by
endocytosis, than smaller nanomaterials by diffusion [46]. Moreover, the formation of aggregates and
sedimentation of nanomaterials will alter the effective concentration of nanomaterials delivered to
the cells [47]. Therefore, nanoparticle aggregation should be prevented in most cases for nanoparticle
studies. To uniformly distribute the nanomaterials over cells in culture without aggregate formation or
sedimentation, it is suggested to use dynamic culture, and grow the cells under flow conditions using
flow chambers [35].
It was reported that the uptake of nanomaterials is different under flow conditions compared to
static cultures and that these changes are due to material’s surface charge, surface ligands, stiffness,
size and shape [48]. Cells can uptake nanomaterials in two steps: the first step is binding of the
nanomaterial to cell surface and the second step is internalization of the nanoparticles. In the first step,
electrostatic interactions, which are due to the physio-chemical properties of the nanomaterial, play an
important role. As the cell membrane is negatively charged, it is more favorable for positively charged
materials to interact with its surface than neutral or negatively charged particles. The second step
is the internalization of the nanoparticle from the cell membrane. After nanomaterials interact and
bind to the cell surface by electrostatic interactions, they can then be internalized by different uptake
mechanisms [49]. Although surface charge is considered as an important contributor to higher uptake,
other parameters influence the cellular uptake as well, such as elasticity [50] and the shape of the
material especially under flow conditions [51]. Under flow conditions, the alignment of non-spherical
nanomaterials can be different from that in static culture, thus altering the uptake. It has been reported
that fibrous or 2D materials have a flow-aligning effect, which impacts their cellular adhesion and
uptake [41], as demonstrated in Figure 6.
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Figure 6. Filamentations or 2D nanomaterials align differently when there is fluid flow in cancer
microenvironment. This flow-aligning effect can change the way that the cells interact with nanoparticles
thus their cellular uptake would be influenced. Adapted from Björnmalm et al. [41].
4. Shear Stresses and Cellular Uptake of Nanomaterials for Cancer and Normal Cells
Owing to the effect of the dynamic environment in different biological processes, tissue engineering,
and drug-delivery [52,53], many studies have investigated the role of FSS in the interactions between cells
and nanoparticles [54–56]. One of these significant interactions is the cellular uptake of nanoparticles.
To illustrate this, the uptake of the applied nanomaterials by cells is considered an important aspect,
especially in drug-delivery and other therapeutic purposes, which require sufficient uptake by the
targeted tissue. One important factor playing a role in cell-nanomaterial interaction under flow is
the surface e charge of the nanoparticles. For instance, the interaction of endothelial cells with two
negatively charged nanoparticles has been scrutinized by Samuel et al. by the application of varying
levels of FSS on cells [57]. The authors revealed that, the cellular uptake increased under low shear
stresses (0.05 Pa) compared to high shear stresses (0.5 Pa). In static conditions (0 Pa), cellular uptake
was lower compared to low shear stress (0.05). The higher uptake of these particles under stress was
mainly attributed to the formation of cytoskeletal stress fibers and membrane ruffles, which enhance
endocytosis. Such changes in the cytoskeleton were not observed in the non-shear exposed cells.
Additionally, Rigau and Städler correlated between the uptake of nano-sized drug delivery systems
and the subsequent therapeutic effect using skeletal mouse myoblast cell model (C2C12) in the absence
or presence of FSS [58]. They concluded that, the liposomes with positively charged lipids result in
higher cellular interaction in the presence of shear, in contrast to those contained negatively charged
lipids or zwitterionic ones. Furthermore, the authors investigated the therapeutic effect, in terms of
cell viability, after treatment with the positively charged liposomes carrying a small cytotoxic molecule
in static and dynamic conditions. Their findings stated that, there was a higher therapeutic response
(i.e., higher cell mortality) in the case of dynamic conditions, which demonstrates the relationship
between the higher cellular association of positive carriers and more effective therapy in the presence
of shear. In another relevant study by Rinkenauer et al., authors investigated the effect of FSS on the
uptake of co-polymers (negatively charged PMMA -co-PMAA with different ratios of MAA (3%, 5%,
8%, and 13%) and positively charged PMMA-co-PDMAEMA with 20% PDMAEMA) using different
cell lines (HUVEC, HEK293, L929, and primary muscle cells). They found that, increasing the negative
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charge (MMA) increases the uptake by different cells under static conditions. However, the uptake is
not as efficient as that resulting from the use of positive particles (20 % PDMAEMA). A similar trend
was observed in different cell lines, but not in co-culture which reduced the cellular uptake due to
cellular interactions. When the uptake was assessed under flow conditions (0.7, 3, 6, and 10 Dyn/cm2),
it was observed that, increasing shear stress is positively correlated with cellular uptake. Nevertheless,
compared to static culture, 13% PMMA showed more efficient uptake compared to positively charged
20% PDMAEMA. This is probably related to the differences in surface receptor patterns observed
under flow conditions, which can alter the cellular uptake [38]. In our group, we are developing
two-dimensional Mxene sheets as photothermal agents. Our initial findings show successful uptake
on MXene sheets by MDA 231 breast cancer cells. When we compared static and dynamic cultures, we
did not see any significant difference.
Another important aspect in cell-nanoparticle interaction is the surface modification.
Toe et al. studied the cell response to modified liposomes with and without FSS using two cell
lines. The former cell line was the immortalized skeletal mouse myoblast (C2C12), a tumor cell model,
which is important to estimate the activity of the applied liposomes as drug carriers in drug delivery
systems. The later cell model was hepatic cells (HepG2), which was chosen as a model for hepatic
clearance due to their importance in eliminating drug-loaded nanocarriers from the body. To illustrate,
the authors fabricated PEGylated poly (dopamine) coated liposomes and quantified their cellular
uptake by myoblasts and hepatocytes using flow cytometry in both static and dynamic conditions.
The results manifested that the hepatocytes response in the dynamic conditions was significantly
higher after only 30 minutes, while the myoblasts demonstrated a significant increase after a relatively
longer time (4 h). The authors explained these findings as the nature of the two cell lines were different.
The hepatic cells were concerned with clearance, so their responses were instantaneous in the presence
of physiological shear. On the other hand, the cancer cell model needed a longer time to show a
response in low shear stress (0.146 dyn/cm2) [59]. Additionally, the uptake of lipidic NPs by MCF-7
breast cancer cells and Hela human cervical cancer cells was reported by Palchetti et al., under flow
conditions. Authors produced two types of lipidic NPs, one with surface modification (PEGylated)
while the other without modification. They incubated the cells with particles at two different incubation
durations (5 and 90 minutes). MCF-7 cells showed a significantly lower uptake of unmodified NPs in
dynamic culture in comparison to static condition at both incubation durations, whereas Hela cells
showed a higher NPs cellular uptake after 90 minutes incubation in dynamic culture [53]. On the other
hand, an insignificant difference in uptake of modified NPs by MCF-7 was observed under flow and
static conditions. However, NPs uptake by Hela cells in dynamic conditions was still higher than static
culture. They clarified that shear stress can affect the protein corona (protein corona is formed when
NPs absorb biomolecules as they interact with cells and the biological system) by changing its surface
chemistry and properties, which in turn affect their uptake by cells [60].
Particle elasticity is suggested to affect cellular uptake [61,62]. In a very important investigation,
Guo et al. revealed experimental evidence that indicates how elasticity alters in-vitro cellular uptake
and in-vivo tumor uptake [50] They studied uptake of nanolipogels (NLGs) which consist of lipid
bilayer capsule and hydrogel core with tunable elasticity. The elasticity of NLGs could be modulated
independent from other physical properties such as size, shape and surface charge. Both normal
cells and cancer cells showed higher uptake of soft NLGs (NLP-45KPa) compared to rigid NLGs
(NLG-19MPa). Authors explained the higher uptake of soft particles by usage of different cell
internalization pathways. While NLP-45KPa entered the cells through fusion and endocytosis,
NLG-19MPa was internalized by only endocytosis (Figure 7). Fusion requires low energy compared to
endocytosis. Therefore, cells take more time and energy to uptake the same amount of NLG-19MPa
than NLP-45KPa. The in-vivo test results showed that particles with higher elasticity were more likely
to accumulate into tumors. This is strong evidence that particle stiffness controls the tumor uptake of
systematically applied nanoparticles.
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a NLP-45KPa b NLG-19MPa 
  
Figure 7. Cell internalization pathways of particles with different elasticity. Soft NLP-45KPa (a)
enters the cell via two pathways: fusion and endocytosis. Hard NLG-19MPa (b) enters cell via only
endocytosis. Adapted from Guo et al. [50].
Surface ligand is another aspect that affects cellular intake. Several studies were conducted
on selective tumor targeting in order to eradicate tumor cells without harming normal body cells.
The experiments were based on decorating nanoparticles with molecular recognition ligands that
bind to selective proteins expressed on the surface of cancer cells. Engelberg et al. studied the
internalization of quantum dots (QDs) decorated with S15-APT ligand into human non-small cell
lung cancer A549 cells [63,64]. S15-APTs is a selective targeting moiety for uptake by A549 cells.
These APT-decorated QDs bound themselves selectively to the target A549 cells and were internalized
by them. However, they were neither bound to, nor were internalized by normal human bronchial
epithelial BEAS2B, cervical carcinoma (HeLa), and colon adenocarcinoma CaCo-2 cells, thereby
demonstrating high specificity. The shape and size of the particle is known to affect the uptake as
well. Particle shape- and size-dependent uptake under physiological shear stress was reported by
Jurney et al. They produced negatively charged rod-shaped PEG NPs with different aspect ratios and
assessed their uptake by human umbilical vein endothelial cells (HUVEC) under flow conditions at
different incubation durations (1, 12, and 24 hours). In all cases, the uptake of larger particles was
found to be higher than smaller ones under flow in comparison to static culture. In contrast, smaller
particles are internalized more in static conditions than in flow conditions. The trend of larger NPs
being internalized more under flow conditions is contradictory with what was reported in literature
with similar-sized spherical NPs. This indicates that particles with higher aspect ratios interact more
with cells under flow conditions [65].
Moreover, Klingberg and Oddershede studied the effect of FSS on the uptake of spherical 80 nm
gold nanoparticles (Au NPs) by HUVEC [66]. They categorized the cells into two groups, one group
was cultured in static conditions for 24 hours (non-adapted group), while the other group was cultured
for 24 hours under 10 dyn/cm2 shear stress (shear adapted group). Then, each group was either kept in
static culture for three hours in the presence of 5 μg/mL Au NPs or kept in dynamic culture for three
hours in presence of 5 μg/mL Au NPs. The highest uptake was achieved by non-adapted group with
three hours additional static culture and lowest uptake was realized by the shear adapted group with
three hours additional dynamic culture. [66]. One more study was conducted by Fede et al. to reveal the
effect of FSS and size of spherical citrate stabilized gold nanoparticles on HUVEC [32]. They tested two
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batches of gold NPs (Batch 24 nm and Batch 13 nm). It was observed that, the viability is significantly
more when testing gold NPs under flow conditions in comparison to static culture, regardless of NPs
size or concentration. They measured the NPs concentration in two methods, one based on the surface
area per unit volume, while the other based on the number of NPs per unit volume. They found that
the cells were less viable when the surface area was increased per unit volume irrespective of the
NPs size [32]. Yazdimamaghani et al. studied the effect of silica NPs density and flow conditions on
cell cytotoxicity, uptake and sedimentation. They produced four types of silica NPs with different
densities and surface charges and tested the cytotoxicity and uptake on RAW 264.7 macrophage cells
after 24 hours of incubation with the cells, in static or under flow conditions. They found that the cell
viability is enhanced under flow conditions, compared to static culture. Moreover, none of the four
particles showed a toxic effect on macrophage cells up to 250 μg/mL in dynamic conditions. Also,
particle sedimentation was reduced in dynamic conditions, and the distribution of particles was more
homogeneous. Authors also found that, cellular uptake of silica NPs was more in static conditions
compared to dynamic conditions. Furthermore, low density particles, showed lower uptake under
flow conditions compared to high density particles [67].
Finally, application of different FSS levels is considered as an important parameter for detailed
investigation of the effect of dynamic conditions on cellular responses, where the cellular uptake could
be studied as a consequence of all applied FSS levels. Hence, more relevant correlation between the
cell response and FSS levels can be stated. For instance, Kona and co-workers developed a novel
drug delivery system that imitates the natural platelet adhesion to the injured vascular walls under
different shear flow rates [68]. Their results implied that when the shear stress level was increased to
20dyn/cm2, the cellular uptake fell dramatically by three folds when compared to the control static
group. The authors explained their findings through computational model revealing that the high
shear rates induce huge dislodging forces that are able to detach the adhered particles [69,70]. Table 2
summarizes important works on the effect of FSS nanoparticle internalization.
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5. Conclusions
Cancer is a wide spreading disease with no definitive treatment. Researchers have been working
on cancer therapy for decades with some improvements, yet many limitations remain. Lately,
nanomaterials are being used for various biomedical applications including the targeted anti-cancer
therapy due to their superior properties. Usually, when nanomaterials are tested for biomedical
applications, cell culture techniques are used for preliminary testing. Cell culture is the most convenient
method to test the toxicity and efficacy of nanomaterials, but it is limited due to particle aggregation,
sedimentation and it does not mimic the native conditions in animal model and human body. FSS is
one important parameter that affect nanomaterial-cell interaction, mainly cell viability and particle
uptake. FSS can be due to blood flow, with variable flow rates based on the diameter size of the
blood vessel where it affects endothelial cells lining the blood vessels or the circulating tumor cells.
FSS can be due to interstitial fluid flow as well with very low flow rate, which occurs mainly around
cancer cells in solid tumors. Here we summarized findings on the relation between shear stress and
nanomaterials uptake mainly for cancer as well as for normal cells using in-vitro systems. There are
variety of factors affecting nanomaterials uptake particularly under dynamic conditions. Some of these
factors are related to the nanomaterials, while other factors are cell related. Nanomaterial size, shape
surface charge, surface ligands, and particle elasticity are the main factors in cellular uptake under
fluid flow. However, these factors are affecting nanomaterial-cell interaction differently depending on
the cell type (i.e., origin of tissue and cancer vs healthy). There is no general rule on how nanomaterials
will interact with cells. However, in most of the cases, negatively charged particles show less uptake
by cells due to inefficient electrostatic interactions between nanomaterials and cells. Furthermore, soft
particles show more uptake than rigid particles which can be attributed to the ability of the cell to
uptake soft particles by different pathways compared to rigid particles. Additionally, the uptake of
2D materials will be different under flow conditions due to the effect of flow aligninment. Coating
the cell surface with ligands is an efficient way to guarantee the uptake of particles, at the same time
reducing the side effects by preventing internalization by non-cancerous cells. Other factors that might
affect cellular uptake, are cell related. For example, the cytoskeletal structure and the formation of
membrane ruffles after flow, as well as, cell rigidity under dynamic culture. However, these details
are not the main focus of this paper. Further investigations will shed light on optimal nanoparticle
parameters that can be used as smart nanoparticles for anti-cancer therapies.
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Abstract: Active targeting can improve the retention of drugs and drug delivery systems in tumors,
thereby enhancing their therapeutic efficacy. In this context, vitamin receptors that are overexpressed
in many cancers are promising targets. In the last decade, attention and research were mainly
centered on vitamin B9 (folate) targeting; however, the focus is slowly shifting towards vitamin B2
(riboflavin). Interestingly, while the riboflavin carrier protein was discovered in the 1960s, the three
riboflavin transporters (RFVT 1-3) were only identified recently. It has been shown that riboflavin
transporters and the riboflavin carrier protein are overexpressed in many tumor types, tumor stem
cells, and the tumor neovasculature. Furthermore, a clinical study has demonstrated that tumor
cells exhibit increased riboflavin metabolism as compared to normal cells. Moreover, riboflavin and
its derivatives have been conjugated to ultrasmall iron oxide nanoparticles, polyethylene glycol
polymers, dendrimers, and liposomes. These conjugates have shown a high affinity towards tumors
in preclinical studies. This review article summarizes knowledge on RFVT expression in healthy
and pathological tissues, discusses riboflavin internalization pathways, and provides an overview of
RF-targeted diagnostics and therapeutics.
Keywords: riboflavin; vitamin B2; targeted drug delivery; active targeting; theranostics; nanomedicines;
molecular imaging; nanoparticle
1. Introduction
Nanomedicines are nano-sized systems conjugated to anti-cancer drugs. Owing to their size, the
nanoparticles accumulate more at the tumor site based on the enhanced permeability and retention (EPR)
effect and are expected to show less side effects compared to conventional chemotherapeutics [1]. The
EPR effect occurs due to the leaky vasculature and the poor venous and lymphatic drainage of tumors.
Nanomedicines can be further functionalized to actively target tumors or their microenvironment.
Active targeting can increase the uptake and retention of nanomedicines and, thus, the therapeutic
efficacy [2]. The most common targeting moieties are antibodies as well as peptides, aptamers, and
small molecules. However, due to their considerably large size, antibodies can significantly alter drug
pharmacokinetics and are relatively expensive to produce [3]. Moreover, the coupling of antibodies
to drug delivery systems is difficult to control, and their receptor affinities tend to decrease upon
conjugation [4–6]. Thus, researchers are shifting their focus to small (targeting) molecules, such as
vitamins. Among the vitamins, folate-receptors were the most commonly selected cancer targets,
particularly for ovarian cancers [7–10]. However, in recent years, the vitamin B2 (riboflavin (RF))
internalization pathway has also been gaining attention since its carrier protein and three transporters
have been identified to be highly overexpressed in several cancers. Therefore, this review article will
summarize the current knowledge of the mechanisms of RF internalization and report on studies using
this pathway for targeted cancer diagnostics and nanomedicines.
Cancers 2020, 12, 295; doi:10.3390/cancers12020295 www.mdpi.com/journal/cancers141
Cancers 2020, 12, 295
2. Riboflavin and Its Transport
RF is a water-soluble molecule that is important for oxidation-reduction reactions [11], protein
folding [12], and normal immune function [13,14]. It also has antioxidant and anti-inflammatory
properties [15,16]. RF acts as a precursor for flavin mononucleotide (FMN) and flavin adenine
dinucleotide (FAD), which are involved in various redox reactions that regulate the metabolism of
carbohydrates, amino acids, and lipids (Figure 1) [17]. RF is considered to be relatively nontoxic as an
excess of it is excreted via kidneys. Humans do not synthesize RF; thus, they need to get it from their
diet. RF deficiency may result in oxidative damage, cell cycle arrest, and cell stress response. It also may
impair iron absorption, cause hearing loss and cranial nerve deficits [18,19]. Besides an unbalanced
diet, RF deficiency may also occur in inflammatory bowel diseases [20], chronic alcoholism [21], and
diabetes mellitus [22].
Figure 1. Chemical structures of riboflavin (RF) (with the numbering of isoalloxazine ring), Flavin
Mononucleotide, Flavin Adenine Dinucleotide, Lumiflavin, Lumichrome, Lumazine, and D-Ribose.
2.1. Riboflavin Carrier Protein
The riboflavin carrier protein (RCP) is not a membrane-spanning carrier but a soluble protein
that binds RF; however, the exact role in storing and transporting RF is still unknown. RCP was
first identified in oviparous species in the 1960s [23,24]. Chicken RCP (cRCP) has been extensively
investigated, as it is easy to isolate and purify in large quantities. cRCP has a high affinity to RF
and its co-enzyme forms [23,25,26]. Further investigations using model compounds have indicated
that the functionalization of either the isoalloxazine ring or the side-chain of RF results in decreased
binding to cRCP [27,28]. During binding, the RF ring is stacked between parallel planes of cRCP [29],
while the side chain is oriented inside the cRCP to form hydrogen bonds with it [27]. Furthermore,
it was seen that the binding is pH-dependent, confirming the hydrophobic nature of the binding site.
Based on these observations, only modification of the C-2 and N-3 positions of the isoalloxazine ring
(see Figure 1) should not influence the binding affinity of RF to cRCP [27].
Human RCP (hRCP) shows many similarities to cRCP: molecular size, isoelectric point (pI), and
preferential binding to RF over the flavin co-enzymes. hRCP is present during pregnancy and in
umbilical cord serum [25]. Suppressing RCP during pregnancy induces abortion in mice and rats,
while the well-being of the animals is not affected [30,31]. It is thus assumed that RCP is involved in
RF transport to the fetus.
Moreover, overexpression of RCP in patients with malignant disease has been identified. RCP
levels in serum were found to be higher in women with breast cancer (6.06 ng/mL) compared to
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healthy women (0.70 ng/mL) [32]. Another study elucidated that RCP levels correlate with the stage
of the disease. Women with early-stage breast cancer had 8.4 ng/mL RCP in serum, 3–4 folds higher
than healthy controls (2.8 ng/mL), and patients with advanced tumor stages had even higher levels
(20.4 ng/mL) [33]. Similar observations were made in hepatocellular carcinoma, where RCP serum
levels were significantly increased (21.75 ng/mL) compared to healthy patients (0.73 ng/mL) [34].
Moreover, RCP overexpression was seen in prostate cancer cells (LnCaP, PC3, and DU-145) in vitro and
in tumor tissues in vivo [35]. RCP overexpression in malignant cells makes it a potential biomarker for
tumor detection, therapy monitoring, and a promising tool for targeted drug delivery systems.
2.2. Riboflavin Transporters
Solute carriers (SLC) transport diverse substrates through membranes such as inorganic ions,
amino acids, lipids, and drugs [36,37]. Recently, the SLC52 transporter family has been identified,
consisting of riboflavin transporters: RFVT1/SLC52A1, RFVT2/SLC52A2, and RFVT3/SLC52A3 [38–43].
RFVT1 and RFVT2 show the most similarity to each other (86.7% amino acid identity), while RFVT3
shows only 42.9% identity with RFVT1 and 44.1% with RFVT2 [43]. RFVT1 is expressed in the placenta,
small intestine, plasma membrane, kidney, colon, lungs, uterus, and thymus [38,40]. RFVT2 can be
mainly found in the brain, small intestine, and salivary gland [40]. Whereas, RFVT3 is found in the testis,
small intestine, and prostate [39,44]. RFVT1, RFVT2, and RFVT3 have Michaelis-Menten constants
of 1.38, 0.33, and 0.98 μM, respectively [45]. All three transporters exhibit sodium-independent
and temperature-dependent behavior [40,46–49]; however, only RFVT3 has higher activity in acidic
environments; the other transporters do not show pH-dependent behavior [39].
Substances can enter a cell via pinocytosis (Figure 2a), a form of fluid endocytosis, where the cell
membrane forms a vesicle encapsulating the fluids and molecules. By this mechanism, small (RF) and
large (RF-conjugates) molecules can be transported across the membrane. In addition to pinocytosis,
RF is internalized with the help of RCP and RFVTs; however, the exact mechanism remains unclear.
It is assumed to be a combination of clathrin-mediated endocytosis (Figure 2b) and carrier-mediated
transport (Figure 2c). In the case of clathrin-mediated endocytosis, the substrate binds to receptors
(RFVTs) located on the cell surface; and with the help of clathrin, a vesicle containing absorbed substrate
is formed. In this way, small and large molecules can be internalized. Moreover, the uptake can be
inhibited by receptor saturation. In carrier-mediated transportation, membrane proteins have substrate
binding sites that allow specific molecules to pass through the membrane. The substrate size is very
important, as it has been shown that upon conjugation to larger molecules, the substrate can lose the
ability to pass through the membrane.
Figure 2. Internalization pathways: (a) pinocytosis; (b) clathrin-mediated endocytosis; (c) carrier-mediated
transport. Abbreviations are defined as follows: riboflavin (RF); riboflavin transporter (RFVT); riboflavin
carrier protein (RCP).
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In vitro, high RFVT expression was observed in human epidermoid carcinoma (A431), human
renal proximal tube epithelial cells (HK-2), and human umbilical vein endothelial cells (HUVEC) [50].
In vivo, low levels of all three RF transporters have been found in most healthy tissues, whilst tumors
seem to overexpress RFVTs: all three transporters were significantly overexpressed in squamous
cell carcinoma (SCC), melanoma, and luminal A breast cancer. RFVT3, in particular, was shown to
be 187-fold more expressed in SCC compared to healthy tissue [50]. High amounts of RFVT3 were
also found in esophageal squamous cell carcinoma, squamous cell carcinoma, and glioma [51–53].
Moreover, the SLC42A3 protein level was seen to increase with the stepwise development of esophageal
squamous cell carcinoma [54]. RFVTs are thus promising cancer biomarkers and may act as targets
for therapeutic drugs or diagnostics, due to their solute carrier function and high overexpression in
cancerous tissue.
2.3. Riboflavin Internalization
Riboflavin transport processes have been investigated in various cell lines. In all tested cell lines,
it was seen that RF uptake is a temperature-dependent and sodium-independent process. The rate
of transport decreases with temperature from 37 to 4 ◦C, whereas the presence or absence of sodium
ions in the incubation buffer does not change the uptake kinetics. Additionally, pH-dependent RF
internalization was observed in some cases. In human pancreatic cells, RF uptake was increased with
decreasing pH from 8 to 6. This cell line has a high expression of RFVT3, which shows better activity at
acidic pH [39,55]. Interestingly, in human liver and human retinal pigment epithelial cells, the opposite
trend was observed, most likely because these cells function better at a neutral rather than acidic pH.
Thus, since tumors are usually characterized by an acidic pH, RFVT3 may be particularly active in
tumors and, thus, the receptor to be preferentially targeted.
The kinetic parameters of RF transport vary depending on the cell line (Table 1). It is assumed
that this is due to differences in the dominant transport mechanisms, which have not been investigated
in detail yet. Among the tested cell lines, the Michaelis-Menten constants (Km) of rat brain capillary
endothelial cells were almost 50 times higher compared to other cell lines. This means that RF
internalization into rat brain capillary cells is an extremely slow process compared to other cell lines.
As for the transport rate (Vmax), human intestinal epithelial cells stand out with a relatively high Vmax
value. This is not surprising since humans receive RF mainly from their diet. Taken into account that
most other cell lines display Km values below 1 μM, and Vmax values in the order of fmol/min/mg
protein to pmol/min/mg protein, it is assumed that RF transportation is a fast process. This is highly
advantageous when using RF as a targeting moiety for diagnostic or therapeutic compounds.
Table 1. Summary of riboflavin uptake kinetics in different cell lines.
Cell Line Km in μM Vmax in pmol/min/mg Protein
Human intestinal epithelial cells (Caco-2) [46] 0.30 ± 0.03 69.97 ± 8.13
Xenopus laevis oocytes [56] 0.41 ± 0.02 0.00005 ± 0.0000007
Human liver cells (Hep G2) [57] 0.41 ± 0.08 1.19 ± 0.08
Human renal proximal tubule epithelial cells (HK-2) [47] 0.67 ± 0.21 3.35 ± 0.29
Human colonic epithelial cells (NCM460) [58] 0.14 ± 0.004 1.10 ± 0.19
Peripheral blood mononuclear cells (PBMC) [59] 0.955 ± 0.344 0.04 ± 0.02
Human trophoblast cells (BeWo) [48] 0.0013 ± 0.00068 0.01 ± 0.001
Human retinoblastoma cells (Y-79) [60] 0.019 ± 0.00037 6.98 ± 0.30
Human retinal pigment epithelial cells (ARPE-19) [61] 0.08 ± 0.014 0.45 ± 0.03
Rabbit corneal epithelial cells (rPCEC) [62] 2.05 3.99
Human embryonic kidney cells (HEK293) [38] 0.0350 ± 0.0041 0.17 ± 0.16
Human breast adenocarcinoma cells (MCF-7) [63] 0.106 ± 0.009 0.52
Human pancreatic cells (β-TC-6) [55] 0.17 ± 0.02 4.45 ± 0.16
Rat brain capillary endothelial cells (BRE4) [64] 19 ± 3 0.24 ± 0.01
Human colorectal carcinoma cells (T84) [65] 0.0532 ± 0.0216 0.36 ± 0.08
Abbreviations are defined as follows: Michaelis-Menten constant (Km); maximum uptake rate (Vmax).
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RF internalization can be blocked by competing compounds (Table 2). To test which part of the
molecular structure of RF is responsible for blocking uptake, cells were pre-treated with RF or with
structural analogs (see Figure 1 for chemical structures) before exposure to RF. In pre-treatment, at least
a 20-fold excess of the competing structure was used compared to RF. The pre-treatment with free
RF showed that RFVTs can be saturated, reducing RF uptake. The inhibitory effect was also seen
when cells were pre-treated with lumiflavin and lumichrome, both of which have an isoalloxazine ring
similar to RF. The specificity of the tricyclic isoalloxazine ring to RFVT was further confirmed since
bicyclic lumazine did not alter RF uptake. Moreover, pre-treatment with D-Ribose did not saturate
RFVTs, indicating that the ribityl side chain of RF is not necessary for internalization. Interestingly,
FMN and FAD (co-enzymes of RF) showed varying results depending on the cell line. Though in
PBMC cells FMN and FAD did not significantly inhibit RF uptake, a decrease in the uptake was seen.
It is likely that the amount of the competing structures was too low to significantly inhibit the uptake.
On the other hand, all cells listed in Table 2 have not been tested for their expression of different RFVTs.
It could be that different RFVTs have preferred affinity towards RF over FMN or FAD. Thus, blocking
with FMN or FAD in the cells expressing these receptors would not be efficient.
Table 2. Effects of pre-treatment with competing structures on riboflavin uptake.
Cell Line RF FMN FAD Lumiflavin Lumichrome Lumazine D-Ribose
Caco-2 [46] + nt nt + + - -
Oocytes [56] + nt - + + - -
Hep G2 [57] nt nt nt + + - nt
HK-2 [47] + nt nt + + - -
NCM460 [58] nt nt nt + + nt nt
PBMC [59] + - - nt + nt -
BeWo [48] + + + + + nt -
Y-79 [60] + nt nt + + nt nt
ARPE-19 [61] + nt nt + + - nt
rPCEC [62] + nt nt + + nt -
HEK293 [38] nt + + + nt nt nt
β-TC-6 [55] + nt nt + + nt nt
BRE4 [64] + + + + + nt -
Abbreviations and symbols are defined as follows: significant uptake inhibition (+); no uptake inhibition (-);
not tested (nt); riboflavin (RF); flavin mononucleotide (FMN); flavin adenine dinucleotide (FAD).
Furthermore, different inhibitory compounds have been tested to see if they affect RF internalization
(Table 3). Na-K-ATPase inhibitor ouabain showed no inhibitory effect on RF uptake, proving once more
that the RF internalization is not sodium-dependent. In contrast, sodium azide and 2,4 –dinitrophenol
(DNP) both significantly reduced RF uptake. Sodium azide inhibits oxidative phosphorylation,
whereas DNP reduces intracellular adenosine triphosphate (ATP) levels. Hence, internalization
is an energy-dependent process. Moreover, the sulfhydryl group modifying agents (p-CMPS and
iodoacetate) also inhibited RF internalization. This shows that sulfhydryl groups are important for
uptake. Additionally, concentration-dependent inhibition by calmidazolium has been observed,
indicating that RF uptake is a Ca2+/calmodulin mediated pathway. In general, RF internalization seems
to be sodium-independent but energy-dependent, mediated via the Ca2+/calmodulin pathway.
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Table 3. Effects of different inhibitory compounds on riboflavin uptake.
Cell Line Ouabain Sodium Azide DNP p-CMPS Iodoacetate Calmidazolium
Caco-2 [46] nt + + nt nt nt
Oocytes [56] - nt + + nt nt
Hep G2 [57] - + + + + +
HK-2 [47] nt + + + + +
NCM460 [58] - + + + nt +
PBMC [59] - nt + nt - nt
BeWo [48] nt + nt nt nt +
Y-79 [60] - + + nt nt +
ARPE-19 [61] nt nt + + + +
rPCEC [62] - + + nt nt nt
β-TC-6 [55] nt nt nt nt nt +
BRE4 [64] + + + nt nt +
Abbreviations and symbols are defined as follows: significant uptake inhibition (+); no uptake inhibition (-); not
tested (nt); 2,4 –dinitrophenol (DNP); p-chloromercuriphenyl sulfonate (p-CMPS).
3. Riboflavin Targeting
Though RF has started to gain interest as a ligand for active targeting, not much research has been
performed thus far. Only a few research groups have synthesized probes functionalized with RF, FAD,
or FMN and tested their performance in vitro and in vivo (see Figure 3 for structures).
Figure 3. Probes designed to actively target RFVTs: (a) Bovine serum albumin-RF conjugate;
(b) Ultrasmall superparamagnetic iron oxide nanoparticles coated with FMN/FAD; (c) Dendrimer-RF
conjugate; (d) Liposome-RF conjugate; (e) Poly(N-(2-Hydroxypropyl)methacrylamide-RF conjugate;
(f) 4-arm polyethylene glycol-RF conjugate.
3.1. Bioconjugates
The first RF conjugate was synthesized in the 1990s [66,67]. RF was covalently linked to bovine
serum albumin (BSA) via the ribityl side chain. According to spectrophotometry, five RF molecules
were attached per one BSA molecule. BSA-RF and BSA internalization were tested in vitro on
human nasopharyngeal carcinoma (KB), human lung adenocarcinoma (SK-LU-1), human ovary
adenocarcinoma (SK-OV), and human lung carcinoma (A549) cells [65]. Uptake of the RF conjugate
was significantly higher than non-functionalized BSA in all cell lines. Surprisingly, the internalization
of the conjugate was not inhibited when cells were pre-treated with an excess of RF or FMN. This is
in contrast with analogous studies using other vitamins. For example, in the case of BSA-folate and
BSA-biotin, strong inhibition was observed when cells were pre-treated with free vitamins [68,69].
Since other studies using RF targeted systems reported successful competitive binding experiments
(see following text), it is likely that either not enough RF was used to saturate the RFVTs or BSA-RF
was not taken up via an RF-mediated pathway. The latter could have been due to RF conjugation
using the ribityl side chain that has been shown to reduce the binding affinity to RCP [27]. It is likely
that BSA-RF could have had higher internalization than BSA due to an increase in hydrophobicity
and/or size. Beyond the in vitro study, BSA-RF transport across the distal pulmonary epithelium
was tested in vivo [64]. The measurements showed that a higher amount of the conjugate moved
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from the trachea to blood compared to free BSA. Hence, conjugation to RF seems to increase the
transcytosis of BSA through distal pulmonary epithelial cells. Nonetheless, it is unclear if this effect is
specifically associated with RF and targeting of its transporters. To address this interesting finding,
further experiments are required.
3.2. Ultrasmall Superparamagnetic Iron Oxide Nanoparticles
Ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) have been synthesized with
FAD or FMN coating for targeted diagnostic imaging [70–73]. In both cases, USPIO were synthesized
via a co-precipitation method and coated with FAD or FMN via phosphate group adsorption. The
co-enzymes cannot fully coat the iron particles; thus, guanosine monophosphate (GMP) was also used
as a spacer to achieve stable particles. All USPIO had cores of 5 nm according to transmission electron
microscopy (TEM) images (Figure 4) and hydrodynamic size of 97 nm for FMN coated [71] and 118 nm
for FAD [70]. FMN/FAD coated USPIO (FLUSPIO) had r2 relaxivities that were sufficiently high for
use as magnetic resonance (MR) contrast agents and close to that of clinically approved agents.
Figure 4. TEM images of different ultrasmall superparamagnetic iron oxide (USPIO) formulations:
(a) USPIO; (b) FMN USPIO; (c) FAD USPIO; (d) and (e) different absorptive coating FMN USPIO: (d)
GMP-FMN USPIO; (e) AMP-FMN USPIO, ADP-FMN USPIO, and ATP-FMN USPIO (left to right);
Adapted with permission from [70–72].
The particles were further tested in vitro on LnCaP, PC3, and HUVEC. FLUSPIO did not
induce toxic effects on cells in concentrations of up to 0.3 μmol Fe/mL according to Trypan blue
staining, TUNEL (transferase-mediated deoxyuridine triphosphate nick end tunneling), and MTT
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays. MRI experiments showed at
least two times higher relaxation rates in cells exposed to FMN USPIO compared to those exposed to
USPIO. The competitive binding experiments with FMN decreased the relaxation rates significantly,
suggesting an RF-mediated uptake of FMN USPIO. Similar results were observed for USPIO coated
with FAD.
In another study, instead of using GMP to produce stable FMN USPIO, ATP, adenosine diphosphate
(ADP), and adenosine monophosphate (AMP) were used [73]. The new coatings produced nanoparticle
clusters (Figure 4e), which had r2 relaxivities higher than that of GMP coated FLUSPIO (Table 4).
A cluster consists of a large number of small particles; thus, it is assumed that smaller particles produce
higher relaxation rates due to their higher surface area. According to fluorescence measurements,
AMP coated FLUSPIO had the highest amount of FMN molecules on its surface, which was likely
the reason for the high cellular internalization. Furthermore, ATP, ADP, and AMP did not decrease
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biocompatibility. In line with this, MR relaxometry using LNCaP, PC3, MCF-7, MLS (human ovarian
serous cystadenocarcinoma), A431, and HUVECs showed higher relaxation rate changes when
incubated with AMP coated FLUSPIO compared to other FLUSPIO. According to these findings,
AMP coating proved to be ideal with respect to good MRI visibility and RF targeting properties.
Thus, it is important to find a spacer that ensures stable particles and does not reduce the amount of
targeting ligands.
Table 4. Properties of different USPIO.
USPIO formulation Hydrodynamic Diameter MRI r2 Relaxivity at 3T
GMP-FMN USPIO [71] 97 nm 203 ± 1 s−1mM−1
AMP-FMN USPIO [73] 160 nm 228 ± 3 s−1mM−1
ADP-FMN USPIO [73] 168 nm 233 ± 9 s−1mM−1
ATP-FMN USPIO [73] 106 nm 259 ± 8 s−1mM−1
Resovist®[73] 72 nm 233 ± 1 s−1mM−1
Although FLUSPIO proved promising in vitro, there have been only two studies that investigated
their performance in vivo. In both studies, mice bearing LnCaP tumor xenografts were used. The first
study compared tumor uptake of FAD USPIO and Resovist® [70]. Instead of R2, R2* relaxation
rates were determined in the in vivo experiments due to the higher sensitivity of T2*-weighted MR
sequences for iron oxide nanoparticles. MRI scans showed a higher R2* relaxation rate at the tumor
site after 1 and 3 h in animals injected with FAD USPIO compared to Resovist®(Figure 5a). It is
important to note that FAD USPIO were only compared to Resovist®, which has a different core size
and different coating that does not exactly match non-targeted USPIO. Hence, the increase in R2* could
have multiple underlying causes besides the FAD coating. However, at this time, Resovist® was the
only clinically approved diagnostic iron oxide nanoparticle; hence, its use as a control was justified to
evaluate FAD USPIO performance against the clinical gold standard.
Figure 5. MRI T2 weighted images of subcutaneous right hind limb LnCaP tumors overlaid with
color-coded R2* maps: (a) FAD USPIO show higher relaxation rates than Resovist®; (b) the relaxation
rates of FMN competition are lower than FMN USPIO (FLUSPIO). Adapted with permission from [70,72].
Another study investigated the biodistribution and tumor uptake of FMN USPIO. Biodistribution
analysis assessed by iron colorimetry showed the highest accumulation at the tumor site followed by
the liver and spleen. Competitive binding of FMN USPIO after free FMN administration revealed
that 1 and 3 h after injection of FMN USPIO R2*, relaxation rates of tumors were lower when the
animals were pre-exposed to free FMN (Figure 5b) [72], suggesting RF-mediated FMN USPIO uptake.
This goes in line with in vitro results showing RF-specific uptake of FMN USPIO by PC3 cells and
HUVECs [71,72]. Further histological evaluation of the tumor tissue was performed to elucidate which
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cell types in the tumors predominantly internalize FMN USPIO. Interestingly, FMN USPIO were
internalized by tumor cells, endothelial cells, and macrophages. Although the uptake in macrophages
and endothelial cells—to a certain degree—can be attributed to unspecific phagocytosis, enhanced
uptake can also be the consequence of the upregulation of SLC52 transporters due to the enhanced
metabolic activity of these cells [14,50]. In summary, FMN USPIO showed tumor specific accumulation
in cancer cells and the tumor stroma, i.e., the tumor associated endothelial cells and macrophages.
These results suggest that FMN is a promising diagnostic tag for diagnostic probes to simultaneously
target different tumor compartments, including the cancer cells and its stroma.
3.3. Dendrimers
The first RFVT targeted drug delivery system was a fifth generation polyamidoamine (PAMAM)
dendrimer functionalized with RF [74,75]. The dendrimer (diameter 5.4 nm) was covalently linked
to RF via a ribityl side chain and a fluorescent dye or methotrexate (MTX). The fluorescent
dendrimer was used to study uptake in KB and HeLa (human cervix adenocarcinoma) cells. FACS
quantification showed a dose- and time-dependent uptake of the targeted dendrimers. The XTT assay
(2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) using KB cells confirmed
the time- and dose-dependent toxicity of PAMAM-RF-MTX. However, the conjugate had lower
therapeutic efficacy than the free chemotherapeutic drug (IC50 values after 4 h incubation: 72 nM for
the conjugate, 48 nM for MTX). The free RF and RF-PAMAM did not reduce cell viability, indicating that
only MTX induced the toxic effects. Moreover, the uptake and, thus, the efficacy of PAMAM-RF-MTX
was reduced using PAMAM-RF for competition. Surprisingly, competition with RF did not reduce the
therapeutic efficacy of PAMAM-RF-MTX. Similar to the BSA-RF conjugate [67], it could be the case
that not enough RF was used for competition. This may be particularly true when considering that, in
contrast to competitively blocking with PAMAM-RF, RF may enter the cells via the transporter pathway,
which is very fast and efficient so that the carrier-related transport was not significantly affected.
Furthermore, the RF-targeted dendrimer conjugate (N-10 position) was used to coat gold
nanoparticles (AuNP) [76]. The AuNP were prepared by the gold (III) reduction method and
had a hydrodynamic size of 30 nm according to dynamic light scattering (DLS), while atomic force
microscopy (AFM) showed a 13.5 nm core diameter. The dendrimer conjugates were attached to
the AuNP via gold-sulfur chemisorption and had a size of 20.5 nm measured by AFM. The uptake
of AuNP-PAMAM-RF was tested in KB cells [76]. According to surface plasmon resonance (SPR)
and luminescence of AuNP, the RF-targeted nanocomposite showed higher internalization into cells
than the control. Moreover, the interaction of the nanocomposite with RCP was tested using UV-vis
spectroscopy. The absorption peak of AuNP-PAMAM-RF decreased depending on the amount of RCP
in the solution and shifted by 6 nm to the right (659 nm). In contrast, for non-targeted particles, the
absorption peak shifted to the left (622 nm). The distinct different spectral trend suggested that the
targeted nanocomposite had specific interactions with RCP. This interaction was further confirmed by
AFM measurements of the particle size. The samples showed heterogeneity (two sizes), suggesting
that different amounts of dendrimer were absorbed onto the AuNP. Despite this, AFM showed that the
particles tended to increase in size when exposed to RCP, thus suggesting interactions between the gold
nanocomposites and the RCP. However, as a limitation, the authors reported that AuNP-PAMAM-RF
particles need further improvements to yield a homogeneous distribution of RF on the nanocomposites.
Nonetheless, this is the only RF-conjugate to date that can be detected using two methods: SPR and
luminescence. In conclusion, AuNP-PAMAM-RF is another promising conjugate that could be used
for RF-targeted in vitro diagnostics.
Additionally, the same research group also investigated the selectivity of RCP [77,78]. Firstly, it
was tested if coupling to different sites of RF changes the binding affinity towards RCP [77]. For this
purpose, the PAMAM dendrimer was conjugated to RF via the isoalloxazine ring (N-3 position) or
ribityl side chain (N-10 position) (see Figure 1 for isoalloxazine ring numbering). Isothermal titration
calorimetry (ITC) and differential scanning calorimetry (DSC) were used to assess the binding affinity
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of RCP to the dendrimers. The dissociation constant obtained from ITC measurements showed that
PAMAM-RF conjugates had a higher affinity to RCP when coupled at the N-3 position than at N-10.
Additionally, a higher denaturation temperature was observed for RCP when it was exposed to the
dendrimers, confirming increased structural stability. Dendrimer N-3 showed a higher denaturation
temperature than N-10, confirming ITC results that the N-3 dendrimer has a better affinity towards
RCP. These results support the previous study [27], further confirming that changes at the N-3 position
do not alter RF binding affinity to RCP.
Secondly, the dendrimers with zero, three, or five RF moieties coupled using the N-3 position were
used to test if the number of targeting ligands changes, the avidity of the conjugate-RCP complex [78].
The force needed to break the bond between an AFM tip coated with one of the conjugates and the
RCP-immobilized surface was measured. Non-targeted PAMAM had a weak attraction to the RCP
surface, while in the case of PAMAM-RF with increasing number of RF moieties, higher forces were
needed to break the bond. Thus, the study showed that increasing the amount of RF ligands on
the dendrimer increases the bond strength of the conjugate-RCP complex. It is possible that at a
certain number of targeting ligands the avidity starts to decrease due to steric hindrance. Thus, when
designing an RF-targeted system, the number of targeting moieties should be balanced.
3.4. Liposomes
The largest structures functionalized with RF so far were liposomes [79]. Here, the RF ribityl chain
was substituted by a glycerolipid moiety using a phosphate linker. The resulting RF-phospholipid was
then incorporated into liposomes that were prepared by the thin film hydration method. Control and
targeted liposomes had hydrodynamic diameters of 115 nm with PDI < 0.1 according to DLS. In vitro
experiments showed that A431 cells preferentially internalized targeted over non-targeted liposomes.
In detail, the uptake was up to 16 times higher with similar results being obtained for PC3 cells and
HUVECs. Furthermore, competitive binding experiments pointed to an RF-mediated uptake. The
liposomes did not reduce the viability of A431, PC3, or HUVECs after 72 h of incubation according
to MTT assay, proving their biocompatibility. To assess the in vivo performance of RF-targeted
liposomes, long circulating liposomes (LCL) were prepared by incorporating polyethylene glycol
(PEG) spacers. The hydrodynamic diameter of the control LCL was 137 and 141 nm for targeted ones.
A six times higher uptake of targeted LCL was found in PC3 cells compared to control liposomes.
In vivo experiments using PC3 tumor xenografted mice indicated that control and targeted LCL had a
similar biodistribution and blood half-life. However, histological analyses showed that targeted LCL
underwent higher tumor cell uptake than the control ones (Figure 6). This study further confirms that
RF-targeting does enhance tumor cell internalization. As liposomes have a high loading capacity and
can entrap hydrophobic drugs without altering their structure, RF-targeted liposomes could be an
ideal system for targeted drug delivery.
Figure 6. Fluorescence microscopy images of PC3 tumor cryosections (dissected from right hind limb)
after 48 h post injection showing higher targeted LCL internalization than control. Liposomes are
depicted in red, nuclei in blue, and endothelial cells in green. Adapted with permission from [79].
Copyright© 2020 American Chemical Society.
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3.5. Polymers
In addition to dendrimers, other polymers have been conjugated to RF. One example is
poly(N-(2-Hydroxypropyl) methacrylamide) (PHPMA), which was conjugated to folic acid (FA)
or RF (via ribityl side chain) and mitomycin C (MMC) to target breast cancer [80]. It was shown that
both conjugates (PHPMA-RF and PHPMA-FA) were similarly taken up by SKBR-3 cells, while MCF-7
cells predominantly internalized PHPMA-RF. The MMC-PHPMA-RF conjugate showed significantly
higher cellular accumulation than free MMC and MMC-PHPMA in MCF-7 cells. However, when cells
were exposed to the lysosomotropic agents monensin and primaquine, only free MMC was taken up.
This further proves that RF-conjugates are internalized via an endocytic process. Additionally, the
drug efficiency was tested using an MTT assay. The IC50 value of free MMC, MMC-PHPMA-RF, and
PHPMA-RF were 0.05 μg/mL, 0.10 μg/mL, and 0.61 μg/mL, respectively. Hence, cytotoxicity derives
mainly from the chemotherapeutic drug, and the conjugation to the polymer does not inhibit drug
efficacy. Thus, the PHPMA based RF-targeted drug delivery system showed RF specific tumor cell
internalization via endocytosis and therapeutic effects associated with MMC. This is the first study to
show that RF-targeted drug delivery improves the therapeutic efficacy of anti-cancer drugs in vitro.
These promising results encourage further research on RF-targeted drug delivery systems.
Another polymer functionalized with RF was 4-arm PEG (also known as PEGstar) [81]. One of the
four arms was labeled with Cy5.5 fluorescent dye, while the other three were conjugated to RF via the
N-3 position. In the study, two sizes of PEGstars were used: 10 kDa (7 nm) and 40 kDa (13 nm). The
uptake experiments using A431 and PC3 cells showed higher uptake of RF-targeted polymers compared
to controls, while competition experiments confirmed RF-meditated internalization. Furthermore,
in vivo experiments using mice bearing PC3 or A431 tumor xenografts were performed, showing a
longer blood half-life for the bigger particles (40 kDa) due to the lack of renal clearance. Computed
tomography/fluorescence molecular tomography (CT/FMT) measurements indicated that 10 kDa
RF-PEGstars were retained at the tumor site 3 h post injection, while control polymers dispersed.
In the case of 40 kDa PEGstars, both targeted and control polymers were retained in the tumor
(Figure 7a). Due to their size, small particles quickly penetrated the tissue but also rapidly redistributed
into circulation, leaving only RFVT-bound and internalized particles at the tumor site. In contrast,
larger particles passively accumulate at the tumor site and do not rapidly re-enter circulation. While
rapid clearance is certainly necessary for a diagnostic probe, intended to display RFVT expression,
maximization of overall tumor accumulation may be a necessity for most therapeutics independent
of the accumulation mechanism. However, high tumor accumulation does not always mean high
tumor cell uptake since the nanomedicines can be accumulated in the interstitial space. In this context,
the histological evaluation revealed that targeted PEGstars of both sizes had better internalization
compared to controls, clearly indicating the added value of RF-targeting (Figure 7b). Furthermore,
10 kDa RF-PEGstars were mainly internalized by tumor cells, followed by macrophages and endothelial
cells, while 40 kDa ones were taken up more by macrophages. It is postulated that the larger polymer
was deposited in the tumor stroma for a longer period of time, and thus internalized by macrophages to
a higher extent. Nonetheless, high macrophage internalization does not mean that the larger particles
would not be a promising drug delivery system; as these cells act as a reservoir of drugs, mediating their
slow release towards the cancer cells [82]. In summary, this study revealed a few important facts about
targeting with RF and active targeting in general. Firstly, the RF-targeting enhances internalization of
the particles into tumor cells but improves tumor retention only for the very small conjugates that
do not significantly benefit from EPR. Secondly, the ideal targeted system should be large enough
to benefit from EPR but small enough to transit to the tumor cells, which might ideally be given for
systems of antibody sizes.
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Figure 7. (a) Two-dimensional fluorescence reflectance images indicating PEGstar accumulation in mice
bearing A431 tumors; (b) fluorescence microscopy images of A431 tumors showing the internalization
of PEGstars. Polymers are depicted in magenta, macrophages in yellow, proliferating cells in green, and
cell nuclei in blue. Adapted with permission from [81]. Copyright© 2020 American Chemical Society.
4. Conclusions and Future Perspectives
RF seems to play an important role in cancer development and progression, as its carrier protein
and transporters are highly overexpressed in several cancer tissues. Thus, RFVTs and RCP have the
potential to be used as biomarkers for cancer detection. Furthermore, fast and efficient RF uptake also
renders it a promising targeting ligand for cancer diagnostics and therapeutics. In this context, it can
be advantageous that both tumor cells and cells of the tumor microenvironment (endothelial cells
and macrophages) show enhanced RF internalization. However, the exploration of this interesting
pathway is in its infancy, and it is unclear why different cells upregulate different RFVTs and how this
influences targeting efficacy. Additionally, the mechanism of RF internalization, depending on the
size and composition of the RF-targeted diagnostics and therapeutics, require extensive investigation.
Furthermore, the reviewed literature clearly indicates that diagnostic and therapeutic RF-targeted
probes require different design considerations. Diagnostic RF-targeted agents should be small molecules
with fast exchange kinetics between the tumor compartments and rapid elimination from the body to
display the RFVT status. RF-targeted therapeutics, on the other hand, should be larger molecules that
strongly accumulate via the EPR but still be small enough to penetrate the tumor tissue and benefit
from the enhanced RF-mediated internalization. Thus, if these aspects are taken into consideration,
RFVTs may become powerful targets for various theranostic and tumor targeted drug delivery systems.
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Abbreviations
A431 Human epidermoid carcinoma
A549 Human lung adenocarcinoma cells
ADP Adenosine diphosphate
AFM Atomic force microscope
AMP Adenosine monophosphate
ARPE-19 Human retinal pigment epithelial cells
ATP Adenosine triphosphate
AuNP Gold nanoparticles
BeWo Human trophoblast cells
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BRE4 Rat brain capillary endothelial cells
BSA Bovine serum albumin
Caco-2 Human intestinal epithelial cells
cRCP Chicken riboflavin carrier protein
CT/FMT Computed tomography/fluorescence molecular tomography
DNP 2,4-dinitrophenol
DSC Differential scanning calorimetry
DU-145 Human prostate adenocarcinoma cells
EPR Enhanced permeability and retention
FACS Fluorescence-activated cell sorting
FAD Flavin adenine dinucleotide
FLUSPIO FMN/FAD coated USPIO
FMN Flavin mononucleotide
GMP Guanosine monophosphate
HEL293 Human embryonic kidney cells
HeLa Human cervix adenocarcinoma cells
Hep G2 Human liver cells
HK-2 Human renal proximal tubule epithelial cells
hRCP Human riboflavin carrier protein
HUVEC Human umbilical vein epithelial cells
ITC Isothermal titration calorimetry
KB Human nasopharyngeal carcinoma cells
LCL Long circulating liposomes
LnCaP Human prostate adenocarcinoma cells
MCF-7 Human breast adenocarcinoma cells
MLS Human ovarian serous cystadenocarcinoma
MMC Mitomycin C
MR Magnetic resonance
MRI Magnetic resonance imaging
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MTX Methotrexate
NCM460 Human colonic epithelial cells
PAMAM Polyamidoamine
PBMC Human peripheral blood mononuclear cells






RCP Riboflavin carrier protein
RF Riboflavin
RFVT Riboflavin transporter
rPCEC Rabbit corneal epithelial cells
SCC Squamous cell carcinoma
SKBR-3 Human adenocarcinoma cells
SK-LU-1 Human lung adenocarcinoma cells
SK-OV Human ovary adenocarcinoma cells
SLC Solute carriers
SPR Surface plasmon resonance
T84 Human colorectal carcinoma cells
TUNEL Transferase-mediated deoxyuridine triphosphate nick end tunneling
USPIO Ultrasmall superparamagnetic iron oxide nanoparticles
XTT 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide
Y-79 Human retinoblastoma cells
β-TC-6 Human pancreatic cells
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Abstract: Despite advances achieved in medicine, chemotherapeutics still has detrimental side effects
with ovarian cancer (OC), accounting for numerous deaths among females. The provision of safe,
early detection and active treatment of OC remains a challenge, in spite of improvements in new
antineoplastic discovery. Nanosystems have shown remarkable progress with impact in diagnosis
and chemotherapy of various cancers, due to their ideal size; improved drug encapsulation within
its interior core; potential to minimize drug degradation; improve in vivo drug release kinetics; and
prolong blood circulation times. However, nanodrug delivery systems have few limitations regarding
its accuracy of tumour targeting and the ability to provide sustained drug release. Hence, a cogent
and strategic approach has focused on nanosystem functionalization with antibody-based ligands
to selectively enhance cellular uptake of antineoplastics. Antibody functionalized nanosystems
are (advanced) synthetic candidates, with a broad range of efficiency in specific tumour targeting,
whilst leaving normal cells unaffected. This article comprehensively reviews the present status of
nanosystems, with particular emphasis on nanomicelles for molecular diagnosis and treatment of OC.
In addition, biomarkers of nanosystems provide important prospects as chemotherapeutic strategies
to upsurge the survival rate of patients with OC.
Keywords: nanosystems; drug delivery; nanomicelles; ovarian cancer; tumour targeting; chemotherapeutics
1. Introduction
Globally, ovarian cancer (OC) is a lethal condition that accounts for millions of deaths annually
in females, making this condition a major health issue [1–6]. In the last five-year survey, statistics
reflected approximately 21.9 million new patients clinically diagnosed with OC on a yearly basis, with
14,270 deaths predicted in the United States every year [7]. According to the World Health Organization
(WHO), OC is one of the most lethal genital malignancies in females in developing countries, with
this asymptomatic disease exacerbated by lack of early diagnostic strategies and access to expensive
chemotherapeutic drugs [1]. In Africa (South Africa), the Cancer Council of Southern Africa (CANSA)
confirmed more than 500 cases of OC [8]. Globally, the five-year survival rate ranges from 15%–20% for
the population with advanced stage ovarian cancer, even though patients undergo operative surgery
and platinum chemotherapy [9].
The treatment of OC employs invasive surgery for the removal of infected ovaries, uterus, fallopian
tubes, cervix and lymph nodules in the abdomen. The surgical approach is followed by external
beam radiotherapy or systemic chemotherapy, depending on the stage at which the OC disease is
identified. Intravenous paclitaxel and alkylating cisplatin are conventional therapeutics employed
for treatment of OC with antimetabolite methotrexate also considered as a possibility. However,
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conventional treatment has its own share of drawbacks, including toxicities and subsequent disease
relapse, due to the development of multidrug resistance. In addition, the chemodrug is not specific for
OC destruction, hence exhibiting dose cytotoxicity [10–12]. Furthermore, the long-term prognosis is
usually adversative with expression and development of chemoresistant tumours. Patients undergo
diverse side effects including excessive nausea, hair loss and deterioration in plasma cell counts linked
with the administration of chemotherapy for OC treatment [13]. To circumvent treatment drawbacks of
conventional antineoplastics, several targeted drug delivery platforms have been developed to direct
antineoplastics to specific tumour sites [14].
New advances in polymeric nanotechnology—with particular emphasis on nanomicelles—provide
feasible alternatives for early detection and targeted treatment of metastatic OC, thereby minimizing
systemic toxicity associated with administration of chemotherapeutic drugs. The nanosystems
employed as theranostics include polymeric nanoparticles, nanomicelles, nanoconjugates, as well as
dendrimers [14–16].
In order to improve diagnosis and chemotherapeutic efficacy in ovarian cancer treatment,
this article presents a critique of, (a) formulation of nanoparticulate delivery systems (including
nanomicelles), and (b) nanoparticulate delivery systems functionalized with ligands such as antibodies
to expedite specific elimination of tumours, imaging analysis and aid in decreasing drug-related side
effects (Figure 1). Thus, the basics of design of these delivery systems are to improve blood circulation
in vivo, polymeric biodegradability, and theranostic compatibility with adequate retention time, for
nanocarrier-related therapeutics. Furthermore, the synthetic building blocks of the carrier systems
are nontoxic, noninteractive with inflammatory responses, and biocompatible. Other significant
properties of polymeric carrier systems are biodegradability and clearance by hepatic/ renal pathways
post-drug release, with the prospect to be further traced with additional benefits in molecular imaging
technologies [17].
This review thus aims to present advances in nanosytems-based molecular diagnosis and
treatment of OC. A particular focus is on nanomicelles as one of the most researched nanoarchetypes
for imaging/diagnosis and targeted OC treatment. The status of OC biomarkers is concise, with
the integration of studies conducted on mucins and possible application in early diagnostics and
management of OC. These approaches are defined to potentially identify the disease at an early stage,
halt disease progression and promote recovery.
2. Current Nano-Based Drug Delivery Approaches for Ovarian Cancer Theranostic
Numerous nanodrug delivery vehicles have been developed including nanoconjugates, branched
dendrimers, liposomes, nanostructured lipid formulations and polymer nanomicelles (Table 1) [18,19].
These drug delivery systems have many advantages including the promotion of therapeutic drug
delivery and fulfilling several (biopharmaceutical) parameters, such as a marked increase in therapeutic
impact compared to the free drug, good biodegradability and biocompatibility, nontoxic and
noninflammatory characteristics, as well as future prospects in scaling-up manufacturing [20].
In chemotherapeutic systems, a nanoformulation must possess high drug-loading capacity, the
ability to dissolve drugs within the inner core and selectively accumulate in tumour tissue through
permeability and retention influence (passive or active targeting). Targeted chemotherapy, such
as intraperitoneal implantable treatment, provides targeted therapy within the peritoneal cavity
(Figure 1) [21–25]. In addition, the preparation of nanoformulations functionalized with specific
ligands facilitates preferential targeting of OC tumours and ultimately increases the therapeutic effect
in comparison to nonfunctionalized nanosystems [25–30].
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Figure 1. Illustration of the expression of cancer-associated mucins, accompanying the development
of ovarian cancer and the intraperitoneal implant treatment, providing targeted therapy within the
peritoneal cavity (Adapted with permission from [21].
In this context, there is a significant need to develop stable molecular biomarkers for early
detection of OC [14]. Various prospective biomarkers of OC are reported. Epithelial ovarian tumours
display modified cell antigens including, Human Epididymis Protein 4 (HE4 gene), Cancer Antigen
72-4(CA 72-4), Renal Estimated Glomerular Filtration Rate (EGFR), Soluble Mesothelin-Related Peptides
(SMRP), Mesothelin, Osteopontin (OPN), Alpha-Fetoprotein (AFP), Cytotoxic T-Lymphocyte-associated
Protein 4 (CTLA4), Interferon-alpha (IFNα), Kallikrein-6 (KLK6), phospholipase A2 group 2A
(PLA2G2A), Erythroblastic Oncogene B2 (ErbB2), Interleukin-10 (IL-10) and Mucin-16 (MUC1–16),
that differentiate cancerous cells from healthy ovarian tissue and other ordinary cells covering the
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intraperitoneum [23–30]. Mucin proteins (specifically MUC16) show prospective as biomarkers and
antibody functionalized micelles to provide a broad range of prospects for OC therapy [32].
Nanomicelles are synthetic nanovehicles, with high potential loading capacity for chemotherapeutics
designed for site-specific ovarian tumour targeting [33–36]. A size range of a micelle between 10–100 nm
promotes significant permeability, endocytosis by OC cells and decreases nonselective targeting of
normal cells [37]. Nanomicelles can perforate and assemble in regions with permeated vasculatures,
including tumours and inflamed tissues [37–39]. In addition, improved biocompatibility, in vivo
stability, ability to incorporate a wide range of hydrophobic chemotherapeutics, as well as extended
plasma circulation periods, are achieved [40,41].
3. Critical Comparison of Nanosystems to Nanomicelles for OC Treatment
Polymer–drug conjugates or prodrugs are macromolecular dispersed systems that require covalent
binding of the active principle while nanoparticles on the contrary are physically attached to the active
principle. Polymer–drug conjugates have low molecular weight (specific to polymer incorporation),
which permits molecular targeting within the cancer cell [42,43]. Physicochemical properties of
polymer–drug conjugates (pH, enzymatic-alteration, acid (H+)-catalytic chemical reactions) are vital for
drug release at a tumour site. Polymer–drug conjugates are extensively evaluated for prolonged drug
release in cancer cells, tumour mass invasion, and enhancement of anti-tumour proliferation [44–46].
Therapeutics in ovarian cancer also utilize branched dendrimers formulated from several polymers
and genetic DNA, however acrylamide branched nanodendrimers are usually utilized [46]. Branched
dendrimers have characteristic design components including (i) peripheral surface with several
potential attachment sites, (ii) the central inner core where diverse dendrons demarcate the alienated
constituent stratums covering the inner core and (iii) the location for dendronic conjugation. The three
fragments of branched dendrimers are modified for several uses, including drug transport and DNA
delivery [47]. Polymer–drug conjugates and dendrimers have covalently bonded drug molecules to
the polymeric carriers. This consecutively necessitates the association of the complex with specific
biochemical processes, shielding the complex from in vivo catalytic enzymatic destruction and protonic
acid-hydrolytic reactions [48–50]. Furthermore, the minute-size of these carriers (normally 10 nm),
enables perforation through plasma membranes of the glomeruli [17]. Significant assemblies and
differentiating properties of these delivery systems are demonstrated in Table 1, as well as in Figure 2.
Figure 2. Schematic depicting examples of nanosized delivery systems; (a) liposomes, (b) nanomicelles,
(c,d) polymer–drug conjugates, and (e) dendrimers, which are currently explored in detail for transport
of chemotherapeutic agents (adapted with permission from (a) Trucillo et al. [31], (b) Brandta et al. [51],
(c,d) Tong et al. [52], (e) Huang &Wu [53].
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Liposomes are similar to nanomicelles due to microscopic spherical shape, consisting of a lipid
bilayer, encapsulating aqueous components for hydrophobic drug incorporation. Nonpolar lipophilic
drugs are incorporated within the lipid bicoating, while water-soluble drugs reside in the vesicle.
Entrapment of antineoplastic therapies in lipophilic liposomes result in pharmacokinetic modifications
and pharmacodynamics features, with a resultant decline in drug degradation and improved dose
cytotoxicity [31,51–53]. These lipophilic nanocarriers can be utilised for specific targeting and imaging
of tumour tissues; however, ligands applied to the phospholipid coating improve cellular uptake
thus enabling a pronounced therapeutic effect to the targeted specific-sites [31,51–54]. Solid lipid
nanoparticles (SLNs) also have similar properties to nanomicelles. On the contrary, the major challenges
with liposomes include instability and difficulty in large-scale synthesis.
Poorly water-soluble drugs are encapsulated in the hydrophobic interior of SLNs, but the
distribution ability is hindered by membrane destabilization. However, most liposomal and SLNs
are above 90 nm in size, due to intrinsic structural parameters which significantly restrict delivery
to ovarian tumour tissue. To surmount the setbacks associated with liposomes and SLNs, other
nanoplatforms, including nanoemulsions, polymeric nanoparticles and polymeric nanomicelles are
employed [19].
Nanoemulsions are used as templates for polymeric nanoparticle preparation. Therapeutic-loaded
nanoemulsions are formed by oil-in-water (o/w) solvent evaporation techniques, employing miscible
organic solvents (diethyl ether, chloroform, N, N-dimethylformamide (DMF), acetonitrile, THF).
Simple liquid emulsions are either oil-suspended in an aqueous state (o/w), or water-suspended in oil
(w/o). Nanoemulsions are aqueous emulsions with sizes normally between 20–200 nm. Nanoemulsions
are formulated employing low-energy emulsification procedures, in which the nanosize is adjusted
by the physicochemical parameters of the process [55], allowing the development of small-scale and
homogeneous droplets, employing a high-energy system, in which a nanosized droplet is adjusted by
the degree of the peripheral energy contribution. Among the low-energy emulsification approaches,
the Phase Inversion Composition (PIC) system is highly beneficial for structures with thermo-labile
composites, including therapeutics, as it can be accomplished at ambient temperature. In the PIC
system, the emulsification process is activated by the variations in the voluntary amphiphilic curvature
generated in emulsification, changing the constituent at stable temperatures [55].
Morphology, Composition and Mechanism of the Formation of Nanomicelles
Nanomicelles are spontaneously self-assembled or aggregated as versatile nanoparticles formed
in water at certain physicochemical parameters including concentration (above Critical Nanomicelle
Concentration-CNC), temperature and conductivity; employing surfactants (hydrophilic–hydrophobic
polymers), with opposite affinities towards a particular solution [55]. The assembly of amphiphilic
components generates the structure or shape of nanomicelles. The copolymer sequence controls
the configuration of the prepared nanomicelles. Thin rod designed nanomicelles are also generated
when the water-insoluble component is greater than the water-soluble component. Sphere-shaped
nanomicelles are usually indicative of a longer hydrophilic component with a minor hydrophobic
component, or possibly a result of equal degrees of the amphiphilic components [56]. Constituents of
the prepared supramolecular structure of polymeric micelles are usually di- or tri-segment/block, or a
stable copolymer (Figure 3). Poly (ethylene oxide) (PEO) forms a barrier to nanomicelles, collapsing
and displaying dissolution in an aqueous solvent [33,57]. The inner central component normally
possesses a biodegradable polymer such as PEO/β-amino polyesters that can be utilised as an inner core
to dissolve hydrophobic pharmaceutical drugs, thus shielding loaded constituents from the aqueous
environment; increasing the bioavailability and in vivo efficacy [58–60].
At low ratios in aqueous media, copolymers exist separately, however, once the molar concentration
is increased, aggregation occurs [61]. The aggregates known as nanomicelles, comprises of several
copolymers in a spherical arrangement [62,63]. When attachments to the polymer functional groups
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are anticipated, complexes including carboxylic (COO−) conjugate bases and amine (NH) bases are
joined as the sequence terminating clusters [33].
Figure 3. Schematic representation of the supramolecular structure of polymeric micelles (adapted
with permission from Lu and Park [47]).
4. Classification of Nanomicelles
Nanomicelles are classified into three key distinct nanosystems i.e., colloidal nanomicelles formulated
from an aggregation of polar and nonpolar molecules in an aqueous solution (amphiphilic aggregates),
polyionic nanomicelles formulated from oppositely charged polymers generating an agglomeration due
to electrostatic interaction, and nanomicelles originating from metal complexation [63–66].
4.1. Amphiphilic Nanomicelles
Amphiphilic colloidal nanomicelles are formed from hydrophobic interactions between the
inner core and the outer shell of the surfactant molecules in a solution [60]. An active surfactant
retains amphiphilic configurations, comprised of hydrophobic and hydrophilic functional groups [66].
The hydrophilic groups form the polar clusters constructed from several moieties including ionised
carboxyl, conjugated sulfonate, ammonium, active hydroxyl and amides. Hydrophobic clusters are
nonpolar ends, including molecular hydrocarbon chains with eight or additional carbon molecules,
and can be rectilinear or separated structures. Lipophilic and hydrophilic polymers self-assemble into
nanomicelles with adequate surfactant concentration. The resultant concentration of surfactant for the
formation of nanomicelles is known as critical micelle concentration (CMC). Figure 4 depicts the settings
of surfactant alignment on air/aqueous interface to form nanomicelles when subjected to a particular
solution with opposite charge affinities to hydrophobic and hydrophilic molecules. The polar ends
form the outer surface of nanomicelles with the nonpolar portions, establishes the inner central core.
The quantity of drug incorporated into copolymeric nanomicelles is influenced by physicochemical
parameters that result in hydrophobic interactions between the drug and the hydrophobic segment of
the polymers. Hence, a consideration of physicochemical trends is an invaluable tool in the synthesis
of drug loaded copolymeric nanomicelles. The amphiphilic block copolymer, Pluronic® poloxamer,
generates amphiphilic nanomicelles in response to electrostatic interactions [63,67].
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Figure 4. Schematic depiction of surfactant molecules aligning on water/air interface at pre-
and post-‘Critical Nanomicelle Concentration (CNC)’ threshold (adapted with permission from
Mukherjee et al. [68]).
4.2. Polycharged Composite Nanomicelles
Polycharged complex nanomicelles (PCCMs) are formulated by the self-assembly of oppositely
charged polymers that form aggregates when distributed in an aqueous solution by hydrophilic groups,
usually poly(ethylene glycol) (PEG), and are covalently attached to one of the two ionic polymers.
Electrostatic interactions are the intermolecular cohesive forces of the assembled composite; with
electrostatic and hydrophobic exchanges employed in formulated nanomicelle complexes. PCCMs are
prepared using various synthetic methods, including common synthetic procedures and spontaneous
self-assemblage or aggregation in solution. PCCMs are prepared from segment copolymers in an
aqueous solution, thus circumventing associated cytotoxicity of organic solvent. These nanomicelles
are stable with low CMC values—as low as 10−6 M. The central core of PCCMs encapsulates several
therapeutics, such as hydrophilic and hydrophobic drugs employing intermolecular cohesive forces
and hydrogen bond interactions. Therapeutics such as cisplatin and ionic large-scale drugs are released
from PCCMs, subsequent to induction from appropriate stimuli [68].
4.3. Noncovalent Connected Polymeric Nanomicelles
These nanomicelles are prepared to employ homopolymeric material or monomer units for
nanomicelle agglomeration. The inner and the outer surface are bonded at the polymer edges via
specific intermolecular interactions including hydrogen bonds or metal coordinate bonds; for this
reason, are known as noncovalently linked nanomicelles. Poly (4-vinylpyridine) functionalized with
carboxyl-terminated polybutadiene are the mainstay of intermolecular interaction due to the formation
of hydrogen linkages in a common organic solvent such as chloroform [63].
5. Surfactants Employed in Nanomicelle Targeted Platforms for Ovarian Cancer
Surfactant nanomicelles utilized for drug delivery have hydrophobic esters, including polypropylene
oxide (PPO), poly(L-lactide) (PLA), poly(D,L- lactide) (PDLLA), as well as amino functional groups such
as poly lactide-co-gycolide (PLGA), polycaprolactone (PCL), poly (β-amino ester), and polylactic acid
(PLA) in their inner core segment for dissolving hydrophobic chemotherapeutics, as illustrated in Table 2.
The hydrophobic core segment is compatible, nontoxic, biodegradable and permitted by the U.S. Food and
Drug Administration (FDA) for biopharmaceutical application. On the contrary, the soluble hydrophilic
corona surface of the nanomicelle used in therapeutic release is composed of poly(ethylene glycol) PEG,
poly(ethylene oxide) PEO, poly N-vinyl pyrrolidone (PVP), poly N-isopropyacrylamide (PNIPAM), poly
N-vinyl alcohol (PVA), and poly N-2-hydroxyproyl methacrylamide (PHPMAm), as displayed in the
first section of Table 2. In this context, the surfactants self-assemble to form micelles in an aqueous
solution with the central amino or ester section, which is structurally neutral/uncharged and connected
to the hydrophilic corona. Protein copolymers (including drug peptide copolymers) employed in
chemotherapeutic delivery enhance the accumulation at pathological sites and improve endocytotic
uptake into the tumour cells. Modification of a specific sequence of the amino acid alters enzymatic
functioning and the degree of immune system response [53].
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6. Preparation of Drug-Loaded Nanomicelles for Application in Ovarian Cancer
Preparation of therapeutic-loaded nanomicelles involves two major categories of therapeutic
loading, reliant on the physicochemical properties of a block copolymer (Figure 5) [69]. The first
category is the dissolution of co-polymer with a drug in a solution. This method is used in insoluble
polymers, including Pluronics poloxamers, and necessitate the warming of the solution for nanomicelle
aggregation, utilizing the dehydrated core profiling portion. This dissolution technique is also employed
in preparation of PCCMs, with therapeutic polymer dissolved separately, and nanomicelle aggregates
impelled by mixing of the two solutions to stabilize therapeutic–polymer ionic proportions [70,71].
The drawback of this technique is the low drug loading that occurs in nanomicelles [60,72].
Figure 5. Commonly employed methods of drug-loaded micelle preparation.
The second method of therapeutic loading involves the surfactant, which are partially water-soluble
and for which an organic solvent (such as, tert-butyl alcohol, ethyl acetic acid, methyl alcohol, toluene,
dichloromethane (DCM), aprotic diethyl ether and chloroform/trichloromethane) is required to dissolve
the polymer and therapeutic [73]. Nanomicelle aggregation is reliant on the liquid extraction technique.
For homogenous solutions, nanomicelle formulations are extracted via a dialysis exchange method,
with slow extraction of the organic solvent that activates nanomicelle aggregation. A drawback of the
dialysis technique is that the dissolving of a drug–polymer involves the use of chlorinated solvents,
which are toxic and thus necessitate extra time (<36 h) for the adequate encapsulation of therapeutics
into the nanomicelles. Alternatively, the solvent-evaporation technique is utilized for the removal
of organic solvents by air diffusion to form a polymeric film. The introduction of water to the film
with heating facilitates the aggregation of drug-loaded nanomicelles. Nanomicelles synthesized from
solvent-evaporation technique have increased potential of dissolving high quantities of partially
soluble drugs. These methods all require sterilization and freeze-drying stabilization processes for
preservation of the synthesized formulations. Figure 5 depicts the drug loading techniques for
nanomicelle formulation.
The limitations in preparations of therapeutic-loaded nanomicelles are surmounted by employing
improved approaches such as the tert-butanol (TBA) method, which incorporates the solution of
copolymer and therapeutic liquid/TBA medium followed by freeze-drying, to form a dry powdered
lyophilized cake. Stable nanomicelles spontaneously self-aggregate, upon resuspension of the
lyophilized powdered polymer–therapeutic cake in an aqueous solution [74,75].
167
Cancers 2020, 12, 213
7. Applications of Nanomicelles in Ovarian Cancer
Nanomicelles are considered as prospective carriers for imaging agents and therapeutics due
to their extended circulatory times, improved drug stability, specific targeting and proliferation into
tumour tissue. Nanomicelles are employed as multifunctional molecular probes for identification
(diagnosis), noninvasive screening and early treatment of ovarian cancer [72].
7.1. Diagnosis of Ovarian Cancer Employing Nanomicelles
Ovarian carcinoma is commonly identified in late stages due to comparative lack of early detection
and diagnostic techniques in early stages [44]. The delivery and controlled release of therapeutics
for site-specific targeted chemotherapy and imaging for early cancer identification are of great
pertinence [76,77]. Imaging involves visualization of OC disease development, treatment efficacy and
bio-distribution of therapeutics to the tumour, or investigation of molecular biomarkers [78]. Disease
inspection and monitoring of therapeutic efficiency can be achieved by employing current medical
visualizing modalities such as basic radiography, anatomical probes (CT scanning), ultrasound and
magnetic resonance imaging (MRI) [74].
These imaging techniques can be categorized according to the energy utilized to develop visual
images (heterogeneous X-ray beams, positron emissions, photon emissions), spatial specific resolution
accomplished (macroscopic-, meso-scale, microscopic), or the nature of the captured information
(anatomical, physiological or molecular/cellular imaging) [44,75]. However, these imaging techniques
rely on a diagnosis of cancer when tumours have developed to approximately 1 cm3, and at this stage,
the malignancy has around 1 billion metastatic tumour cells [79]. Furthermore, imaging probes have
low signal transmission, instability, imprecise interactions, and rapid degradation from the circulatory
system [80].
Nanotherapeutic applications incorporating noninvasive tumour molecular imaging have
prospects in early prognosis by increasing the precision, efficacy of chemotherapeutics, and facilitating
improved infection detection [44]. If image modalities are utilized to image tumours, improved tumour
intensity is assimilated with contrast nanocarrier systems. Nanoparticles have distinct techniques
for molecular-targeted delivery, drug encapsulation, or improvement of pathological areal imaging.
Polymeric nanoparticles, including PEG-b-poly(Lysine) copolymers have great potential in analytic
molecular imaging, monitoring of cancer development or regression [44]. Small particles within
nanometer range, such as gold-plated-based molecules and coated metallic quantum molecules, are
the most usually employed; however, other nanoparticles and biomarkers display possibilities as
potent tools for potential transmission development and therapeutic delivery in diagnosis of infected
sites [44]. Various one-off administered nanomicelle-based therapeutic delivery systems for tracking
and targeting of ovarian cancer are outlined in Table 3.
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Several nanomicellar technologies have been established and are presently undergoing extensive
preclinical and clinical trials for application in chemotherapeutics and diagnostic imaging of ovarian
cancer. Amphiphilic block-copolymers aggregate to form dual-layered nanomicelles and are future
carriers of hydrophobic treatments and diagnostic probes. Partially soluble drugs and imaging agents
are encapsulated into the inner core with hydrophilic surface of amphiphilic nanomicelles, forming a
stable outer shell in an aqueous solution [77].
Diagnostic modalities for three main imaging probes are radioactive metals, including indium-111
(111 In), and radioactive metal complexes such as ortechnetium-99 m (99 m Tc), used for scintigraphy;
clustered/chelated magnetic metals, including gold, for magnetic resonance imaging (MRI); and iodine
for conventional X-ray computed tomography (CT). The conventional contrast agents employed in
medical therapeutics are low-molecular-weight complexes composed of these chemical probes. Several
diagnostically significant amphiphilic composites have been effectively integrated into nanomicelles,
including diethylene-triamine penta-acetic acid (DTPA), which are chelating agents for diagnostic
imaging of various nanomicellar platforms utilized in MR diagnostic imaging. Polymeric nanomicelle
systems, including iodine-containing PLL-PEG nanomicelles, are employed for cancer diagnostic
imaging, utilizing conventional sectional tomography (CT) imaging and Single Photon Emission
Computed Tomography SPECT using gamma rays. Furthermore, to monitor nanomicelles formulations
and exchanges in cancer disease, nanomicelle co-encapsulated with imaging clustered/chelated metallic
groups have been employed, for example, in gold compounds, manganese oxide-loaded nanoparticles,
as well as being utilized with ultrasound (US) and magnetic resonance imaging (MRI) [76]. Currently,
gadolinium (Gd)-contrast medium, including Magnevist®, are medically employed where visual
contrast is increased by limiting the T1 reduction period (period of high longitudinal magnetization
with brighter image) of aqueous protons. Integration of Gd compound on the nanomicelles’ surface
upsurge the T1 reductivity and reactivity of diagnosis. The reactivity is improved by utilization of
various developed architectural iron oxide nanoparticles such as surface designed Super Paramagnetic
Iron Oxide Nanoparticles (SPIONS) that assemble in nanomicelle inner core and exhibit MRI reactivity
at a nanomolar rate. Nanomicellar loading with therapeutics and imaging tools such as fluorescence
Rhodamine and FITC probes are used for drug released imaging at specific tumour sites with distinctive
designed image. Hence, nanomicelles are favourable as carriers for combinational chemotherapeutics
and nanodiagnostic tools [98–100].
7.2. Treatment of Ovarian Cancer Using Nanomicelles
Nanomicelles are mainly administered intravenously (IV) and are usually exposed to several
challenges of the blood circulatory system with resultant cytotoxicity before reaching the peritoneal
cavity [101]. The intraperitoneal (IP) cavity is the principal site of OC disease [102]. Metastatic OC cells
accountable for high mortality rate disseminate and recur at the intraperitoneal site [103]. Hence, IP
nanomicellar chemotherapy is the favorable route of administration of OC treatment, with improved
patient compliance as compared to intravenous (IV) treatment [104–106].
7.3. Targeting Strategies of Nanomicelles
Targeted delivery of polymeric nanomicelles loaded with chemotherapeutic agents, present many
diverse advantages [107]. Targeting is usually achieved using two delivery mechanisms as depicted in
Figure 6; (i) passive targeting with improved vascular permeability and absorbency effect [39],
(ii) specific active receptor-mediated targeting, employing ligand functionalized-nanomicelles,
including the attachment of antibodies [63].
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Figure 6. Schematic representation of drug loaded micelles (spheres) with imaging agents, from the
administration site to the tumour tissue. After administration, micelles (10–200 nm) display specific
targeting of tumour growth via passive targeting with cellular endocytotic uptake from exterior fluid to
the cancer cells. Active targeting through receptor-mediated internalization is achieved by attachment
of antibody ligand molecules, to the surface of micelles (Adapted with permission from Chen et al. [81]).
7.3.1. Passive Targeting by Enhanced Permeability Effect of Tumour Tubular Blood Vessels
When nonfunctionalised nanomicelles have significant continual blood circulation period and
successfully accumulate in tumour tissue through the passive enhanced permeability effect (EPR),
this is indicative of passive targeting [76,108]. The therapeutic payloads are distributed to the tumour
extracellular matrix and dispensed into the tumour cells and tissues. EPR targeting is ascribed to
pathophysiological properties of tumours that are not identified in health tissue. These properties
include the architecture of leaky tumour blood vasculature, impaired lymphatic drainage scheme, and
increase in formation of permeability agents [109–112]. Several passive targeting nanocarrier systems
have a PEG coating for stealth and “concealment” properties, including Genexol-PM, SP1049C, NK911,
Opaxio™ (formerly Xyotax™), CRLX101, ProLindac™, SPI-77 and CPT-11 [76].
7.3.2. Specific Active Receptor-Mediated Targeting
The active targeting approach involves the attachment of functional ligands to the nanomicelle
surface. These ligands identify tumour-specific receptors that are overexpressed on the cancer cell
plasma membranes, resulting in increased uptake and increased internalization of nanomicelles into
tumour tissue via the receptor-mediated endocytosis process [113–115]. Commonly utilized affinity
ligands are classified into the following categories: small unrefined molecules, nucleotides (RGD
sequence), oligopeptides, sugar groups, folates, monoclonal antibodies (mAb), and nucleic DNA/RNA
aptamers [116].
There are several tools that are being utilized to target particles to tumour tissue. The use of
an activating ligand is a dynamic approach that is reliant on specific receptors at an attachment
site. These interactions include (glycoproteins/antibody), antigens and activating attachment groups
(Figure 7). The “magic bullet concept” Ehrlich hypothesized that antibody-bounded nanocarriers have
progressed into a model using three components: a therapeutic, a copolymer and active functionalizing
agents associated with one formulation. This targeting therapeutic strategy provides rewards,
including high target specificity for the pathological/infected area and minimal toxicity to the healthy
cells. Furthermore, this therapeutic strategy also improves tumour treatment, chemotherapeutics
of metastatic cancer of early stage carcinoma, when the primary papillary fallopian tubes are still
immature [113–115].
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Figure 7. Schematic depiction of (a) active targeting, (b–g) confocal images of A431 cellular uptake
incubated with cetuximab encapsulated micelles and lysotracker. The fluorescence intensity of A431 cells
(b–d) treated with targeting micelles was 1.45 times higher than in cells incubated with antibody-free
micelles (e–g) (Adapted with permission from Sudimack et al. [117]; Liao et al. [118].
8. Mucins as Targets for Antibodies in Chemotherapeutics
Most ovarian carcinomas are of epithelial origin and express mucins utilized as prospective
diagnostics and treatment targets. Mucin glycoproteins are extracellular, glycosylated protein molecules,
originating in the mucus coating and increased expression has been linked with various types of
malignant pathology including OC. Currently, there are 20 identified mucins with two classifications:
epithelial mucins (gelating, nongelating, film attached mucins) and lycoproteins (MUC9, MUC10,
MUC18 and MUC20) [116–118]. Various research studies on the expression of mucin antigen in ovarian
cancer have identified overexpression of film-attached mucins, especially MUC4, MUC5AC, and
MUC16, but their biological applications are not defined. Mucin 16 (CA125) is used as a clinical
biological marker in OC due to its elevated expression which results in CA125 release into the blood
serum [119,120]. CA125 is a very huge cell surface mucin, first established by Robert Knapp in 1981.
He identified this glycoprotein whilst exploiting identical monoclonal antibody-mAb [121]. Serum
levels of CA125 are clinically utilized to diagnose OC patients on basis of regression or progression
of the disease, subsequent to standard chemotherapy [122]. Moreover, abnormal mucin expression
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can trigger immunity and probably cause a strong antibody response. The antibody response is
symptomatic of disease expression [123]. Immunoglobulin Ig (antibodies) affiliated with mucins, can
have potential application in the progression towards the detection and therapy of ovarian cancer;
however, there are still few studies conducted to date [121–123].
9. Stimulus-Responsive Nanomicelles
Stimuli-responsive nanomicelles (SRM) are smart nanoparticles engineered to respond to internal/
external stimuli of physical, chemical or biochemical origin, to control and release drug payloads at
specific sites. SRM deliver drug payloads by structural alterations in response to the eliciting stimulus.
The response presents with the degradation/disruption, polymerization or assembly of nanomicelles.
The common internal stimuli in a cancer microenvironment are acidic pH, electrochemical redox
potentials of the cell, and the availability of certain over-produced matrix enzymes, while external
stimuli include temperature, attraction via magnetic field, light illumination (UV, visible, infrared) and
ultrasound waves [95]. In this context, the formulation of nanomicelle, sensitive to external or internal
stimuli is an alternative approach to targeted therapeutic release. In vitro models have provided
evidence of progress for a number of stimuli-responsive approaches, however only a small proportion
have been validated in animal preclinical prototypes, and also few (thermosensitive liposomes and iron
oxide nanoparticles) are clinically approved by the FDA in terms of treatments and diagnostics [81].
10. Nanomicelles in Clinical Evaluations
Several therapeutic-loaded nanomicelles for chemotherapy have been evaluated for determination
of toxicity and bioavailability [124]. While the impetus is on ovarian cancer, some examples of polymeric
nanomicelles cited are for other types of cancer and applied for OC treatment. Preclinical evaluations
and findings have revealed lots of positive data utilizing nanomicelles as therapeutic delivery systems
for loading hydrophobic chemotherapeutic drugs [125]. Several micellar nanoformulations that are
now under clinical evaluations are all stealth nanomicelle formulations, and specifically have a surface
coating for stabilization to guarantee a compact conformational covering and protection against
opsonisation by plasma proteins (Table 4) [69]. Genexol-PM micelle formulation is paclitaxel-loaded
PEG-PLA micelle preparation [126]. NK012 micellar nanoformulation is also composed of a
PEG coating with amino-acid repeat units, polyglutamate (PGlu) combined with antineoplastic
7-ethyl-10-hydroxy-camptothecin (SN-38) [69]. The hydrophobic PGlu component results in micelle
aggregation. In vivo trials with NK012 micelle formulations validated the potency of antineoplastic
action in a mice model. Recently, the accomplishments and applicability of NK012 were also screened
in phase II trials in prominent breast tumour patients [69]. New paclitaxel (PTX) experimental
formulations evaluated include NK105 that are composed of PEG coating and modified polyaspartate
hydrophobic ration [69]. PTX drug is incorporated in the central core by hydrophobic links with the
hydrophilic portion. Furthermore, a major decrease in cytotoxicity, from Cremophor EL and ethanol
subsequent to primary PTX administration, was practical with NK105. In phase I trials with NK105
formulation, minor allergic reactions were identified in patients with bile duct, pancreatic, gastric, and
colonic cancers compared to primary PTX treatment [69].
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A SP1049C phase II cancer trial in cases with advanced stomach cancer has been conducted.
SP1049C has been formulated as doxorubicin (DOX)-loaded Pluronic micelles [69]. In these phase II
cancer trials, SP1049C displayed to be more effective than clinical doxorubicin in therapy of various
types of carcinoma [69]. SP1049C displayed superior antineoplastic action, efficiency and increased in
cancer cells in several pre-clinical carcinoma models as well as doxorubicin-resistant malignancies as
compared to clinical doxorubicin [69]. SP1049C formulations have been screened in phase III trials in
patients with metastatic adenocarcinoma of the gastrointestinal route [69]. To minimise toxicity and
increase the efficacy of cisplatin, the micellar pharmaceutical preparation NC-6004 (Nanoplatin™)
was developed. The NC-6004 consists of PEG coating with poly (γ-benzyl L-glutamate)/CDDP
composite [69]. A small phase I pilot showed that NC-6004 was acknowledged by carcinoma patients
that were affected by colorectal carcinoma, upper oesophageal carcinoma, and lung carcinoma [69].
The Genexol-PM formulation was a micellar PTX nanoformulation formulated from PEG with polylactic
acid [68,134,135]. Preclinical in vivo trials with Genexol-PM formulation exhibited a threefold increase
in average dissolution time and a significantly improved antineoplastic efficacy as compared with
clinical paclitaxel [69].
11. Patents in Micellar Technologies for Targeted Chemotherapeutic Drug Delivery
In a patent by Kwon and associates (2015), solubilisation of cotton gossypol (a yellow, natural
phenolic aldehyde plant pigment for inhibition of various dehydrogenase enzymes) with nanomicelles
was conducted. Polymeric-nanomicelles integrated chemodrugs such as gossypol, and a combination of
chemodrugs were evaluated, including mixture of a platinum-derived (cisplatin-(CDDP) or carboplatin)
as well as a taxane (paclitaxel (PTX) or docetaxel-(DTX)), commonly used to cure nonsmall cell-lung
(NSCLC) and ovarian cancers. The nanomicelle carrier’s composition enabled efficacious incorporation
of the hydrophobic drugs [135–137]. Hence, this discovery provided stable and nontoxic biocompatible
therapeutic formulations that potentially increased drug bioavailability. In another patent, nanomicelles
encapsulating SN-38 formulation for chemotherapy of carcinoma were investigated. This development
provided a nanomicelle formulation, including extended multiblock co-polymer with a SN-38 resulting
from encapsulated camptothecin [61,138]. This SN-38 formulation is dominant over its camptothecin
derivative since it is not reliant on stimulation by the detoxifying liver in vivo (Table 5) [138].
Bodrati in 2018 demonstrated the application of block-co-polymer nanomicelle of
poly(oxyethylene)–block-poly(oxypropylene) copolymer in the administration of chemotherapeutic
agents, providing noncovalent dissolvation, which minimized solubility issues [61]. Several copolymers
are readily obtainable under the generic name of “poloxamers”/ “pluronics”. Innovation by Hao et al.
(2017) comprised of nanomicelle aggregates, composites with self-aggregated/assembled nanomicelles
and methods for formulating nanomicelle aggregates and composites. Nanoformulation also included a
plant prolamin proteins attached to polyethylene glycol (PEG)-coated nanomicelle [139]. This invention
further derived methods for integration of drugs utilizing the conjugates of the protein nanomicelle
formulation. In a patent by Rhymer (2008) micellar structures, techniques of micellar assemblies,
methods of nanoimaging, approaches of chemotherapeutic delivery and life biological composites were
investigated [140]. This patent presented a therapeutic technique utilizing hydrophilic, high molecular
mass block copolymer for facilitation of an intraperitoneally dosed antineoplastic agent for prolonged
release in the peritoneal region. The patent further described a therapeutic-loaded nanomicelle
formulation, consisting of a copolymer with an exterior water-soluble moiety, a polycarboxylic acid
functional group; and an anti-tumour agent attached to or incorporated in the nanomicelle. Patents in
micellar technologies for antineoplastic drugs delivery are presented in Table 5.
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12. Future Recommendations
Nanomicelles are employed as drug carrier nanosystems or imaging agents. Extensive
differentiation in physicochemical, pharmacological and immunological platforms is necessary
prior to approval for application in humans. Antineoplastic efficacy of most chemotherapeutic
nanoformulations has not advanced to an appropriate degree to evolve the formulated nanomedicines
into clinical application. Thus, great research studies are conducted on optimization of physicochemical
profiles of nanomicelles. Combinational chemotherapy against ovarian cancer is another approach used
to enhance antineoplastic efficacy. Future trends in nanomicelle development and delivery includes
circulatory computational evaluations, simulating ecosystems of the pathogens and patient-derived
cell lines, induced pluripotent stem cell (iPSC) technology, three-dimensional coculture, organotypic
systems, improvements in cell imaging, microfluidics, nanotechnologies and gene-editing technologies.
The main challenge is now linked with the interpretation of various productive and validated
experimental findings into clinical translation. The efficacy of the therapeutics is limited due to
degradation, interactions with cells, and poor tissue permeability. Furthermore, encapsulation of two
or more therapeutics in a single nanocarrier system can be challenging due to different solubilities of
the optimal drug combination. Nanotheranostics are therapeutics activated by a positive diagnosis of
an ovarian cancer disease and will be in use in the near future for chemotherapeutics.
13. Conclusions
Novel nanomicellar technologies developed to date are focused on improving pharmacodynamics
and pharmacokinetic profiles of the incorporated therapeutic agents, whilst increasing safety and
compliance, to upsurge the five-year survival rate of OC patients. Nanomicellar systems have advanced
as significant chemotherapeutic delivery platforms. These nanocarriers can be specifically loaded with
a wide range of active drug compounds, providing a strategy to improve the bioavailability of drugs,
including those abandoned due to insoluble characteristics and cytotoxicity challenges. Nanomicelles
have also shown to be applicable for theranostic applications. Multipurpose polymeric nanomicelles
have more attributes as therapeutic carriers, as shown by their considerable outcomes in the scope
of clinical diagnosis and chemotherapeutics. These include nanomicelles attached with ligands, the
enabling of specific active targeting of tumour metastasis, increased restorative effects, and reduced
side effects—thus promoting more effective therapy. Although no panacea may be eminent at this
time, it is anticipated that through tailored, safe, multifaceted, and rational design of nanomicelles,
advanced drug delivery systems will be developed for the future treatment and diagnosis of OC.
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Abstract: Malignant gliomas are one of the deadliest forms of brain cancer and despite advancements
in treatment, patient prognosis remains poor, with an average survival of 15 months. Treatment using
conventional chemotherapy does not deliver the required drug dose to the tumour site, owing to
insufficient blood brain barrier (BBB) penetration, especially by hydrophilic drugs. Additionally,
low molecular weight drugs cannot achieve specific accumulation in cancerous tissues and are
characterized by a short circulation half-life. Nanoparticles can be designed to cross the BBB and
deliver their drugs within the brain, thus improving their effectiveness for treatment when compared
to administration of the free drug. The efficacy of nanoparticles can be enhanced by surface PEGylation
to allow more specificity towards tumour receptors. This review will provide an overview of the
different therapeutic strategies for the treatment of malignant gliomas, risk factors entailing them as
well as the latest developments for brain drug delivery. It will also address the potential of polymeric
nanoparticles in the treatment of malignant gliomas, including the importance of their coating and
functionalization on their ability to cross the BBB and the chemistry underlying that.
Keywords: brain tumours; glioma; blood brain barrier; drug delivery; nanomedicine; polymeric
nanoparticles; PEGylation
1. Introduction
In the past decade, there has been a great development in medicine and cancer treatment. However,
cancer remains a challenging health issue owing to its complicated nature [1,2]. The number of cancer
cases is expected to rise to 27.5 million in 2040, as stated by the American Cancer Society [1]. Among
the most troublesome malignant cancers are the primary brain cancers that can rarely be cured, with a
5-year overall survival of only 35%. Gliomas count as the most common form of malignant primary
brain tumours in adults [3].
The speed and ability to infiltrate and metastasize to nearby brain tissues are the main factors
that determine if glioma cells are of low grade (WHO I and II) or high grade (WHO III and IV) [4].
Gliomas have the ability to infiltrate to surrounding tissue and their margins are difficult to determine.
This results in conventional treatment approaches being insufficient to produce a curative outcome.
Also, the difficulty in achieving successful therapeutic approaches is caused by the physical and
chemical barriers that exist, hampering drugs from reaching tumour sites [5–8]. The blood brain barrier
(BBB) and blood brain tumour barrier (BBTB) represent the main barriers that stop drugs from entering
the brain unless they possess certain characteristics. Also, the multipotent stem cells that give rise to
glioma cells, have the ability to self-renew and are responsible for glioma recurrence [9]. Efforts have
Cancers 2020, 12, 175; doi:10.3390/cancers11081175 www.mdpi.com/journal/cancers185
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been extended towards overcoming physical hurdles by developing techniques that deliver therapeutics
to the brain, however, most of these approaches are invasive and fraught with serious side effects,
so curative measures should not be only be based on extending survival, but also towards improving
the quality of life of patients by reducing side effects. Among the advanced therapeutic strategies is
using polymeric nanoparticles for drug delivery and targeting. As will be discussed later in this review,
in vitro and in vivo studies have reported promising results for drug loaded nanoparticles targeted to
gliomas. Therefore, more efforts should be made towards the betterment of these nanomedicines in
terms of improving their loading efficiencies, coating and ability to target gliomas.
2. High Grade Gliomas
Primary malignant brain tumours in adults are mostly gliomas, 75% of which are high grade
gliomas (HGG) diagnosed in the central nervous system (CNS). The rate of incidence is 3 to 5 per
100,000 every year, afflicting mostly men. HGG can occur at any age, however, they mainly occur in
the 5th and 6th decades of life [10].
Bailey and Cushing developed the seminal system for defining the morphology of glial tumours
in the 1920s which is based on the glia stage of growth [11]. This system was used by the WHO in
2000 to classify Gliomas based on their morphology [12]. Gliomas were further stratified based on
genetic and molecular factors that were recognized and reported by the WHO in 2016. These factors
include isocitrate dehydrogenase (IDH) mutation status, the co-deletion status of 1p/19q and the
mutation status of alpha thalassemia/mental retardation syndrome X-linked protein/gene (ATRX) [12].
According to the 2016 WHO classification, grade III tumours which include anaplastic astrocytoma,
anaplastic oligodendroglioma and mixed anaplastic oligoastrocytoma are among HGGs, in addition to
grade IV glioblastoma (GBM) [12]. GBM has the highest incident rate among HGGs with up to 60–70%
of cases being a GBM. This is followed by anaplastic astrocytoma which makes up 10–15% of cases.
Whereas, anaplastic oligodendrogliomas and anaplastic oligoastrocytomas have the least frequent
incidence rate of only 10% [13]. Some other types of malignant gliomas, such as the WHO grade
III gliomas, anaplastic ganglioglioma, anaplastic pilocytic astrocytoma and anaplastic pleomorphic
xanthoastrocytoma and the grade IV gliomas, giant cell and small cell GBM, epithelioid GBM, and
gliosarcoma are not very common. The main cause for HGGs is still enigmatic, with ionizing radiation
only identified as a possible risk factor [14].
3. Treatment
3.1. Surgical Resection
The site, grade and morphology of the tumour will determine if complete surgical resection of the
tumour can be achieved. Patients with high grade tumours require near complete resection in order to
reduce the burden of the tumour and pressure inside the skull, which in turn improves the survival
rate [15–18]. GBM cannot be fully cured with surgical resection as it is invasive in nature and 80% of
cases result in relapse within 2 to 3 cm of the original tumour margin [19].
3.2. Radiation Treatment
Radiation therapy (RT) can be administered internally or externally and is considered the standard
treatment protocol for HGGs [20]. The standard treatment using external RT involves 25 to 35 treatments
on a daily basis for (5–7) weeks. Several factors control the total radiation dose to be administered
which are: tumour site, grade, histology and the extent of resection [21]. A randomized trial conducted
in the 1970s reported that whole brain irradiation with 60 Gy after surgical resection enhanced survival
for patients suffering from HGG. This resulted in RT as being a standard therapy following tumour
eradication for HGG [22]. On the other hand, studies that investigated the difference between partial
and whole brain irradiation for HGG treatment proved that whole brain irradiation did not provide
extra benefit compared to partial irradiation of the brain [23]. However, there was an improvement
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in the delineation accuracy that was achieved employing tomography and magnetic resonance for
maintaining a partial irradiation of the brain for HGG cases [24]. The developments that have occurred
in imaging and RT have enabled irradiation of tumour regions with higher doses while reducing
the volume of normal brain tissue exposed to irradiation. Therefore, involved field RT was granted
acceptance as the standard of care for HGGs. However, the issue of RT delivery for smaller surface
areas remains debatable with efforts towards targeting infiltrating tumour cells [25]. Some techniques
that have been recognized for providing a more targeted irradiation towards tumour tissues include
fixed field intensity modulated RT (IMRT), dynamic arc IMRT, volumetric-modulated arc therapy
(VMAT) and stereotactic radiosurgery (SRS). These techniques were reported to provide a more focused
approach towards affected tissues while reducing toxicity to normal tissues [26]. SRS is used to treat
recurrent GBM and is used as a complementary treatment after external beam RT. However, the use
of SRS for the treatment of recently diagnosed malignant gliomas is still under review [21]. Another
approach for RT is interstitial RT or brachytherapy where radioactive material is implanted inside the
tumour with the use of surgery. Proton therapy could also aid in targeting affected areas and may be
used instead of photon irradiation [26]. RT is associated with some limitations including necrosis of
normal brain tissue, neuronal damage and radiation resistance of tumour cells [19].
3.3. Chemotherapy
The chemotherapeutic drug temozolomide (TMZ) is used in combination with RT in patients with
HGG in order to improve the survival rate of patients. This protocol, known as the Stupp protocol,
demonstrated a median survival rate of 14.6 month compared to 12.1 months (when RT alone was
administered) in a phase III clinical trial. TMZ is initially administered at a daily dose of 75 mg/m2 for
6 weeks, with a 1-month rest period upon the completion of RT treatment. TMZ treatment begins again
with a daily dose of 150 mg/m2 for 5 days in the first month. If this dose can be withstood by the patient,
a higher daily dose of 200 mg/m2 is administered for 5 consecutive days each month until the end of
the treatment period. The stupp protocol administers the TMZ therapy for 6 months following RT [27].
Synergistic effect of combined therapy using RT and adjuvant chemotherapy with TMZ continued over
a 5-year follow up treatment period. Also, the inclusion of TMZ was more beneficial for patients with
a methylated gene promoter that encodes O-6-methylguanine-DNA methyltransferase (MGMT). This
in turn had resulted in identifying MGMT as the first biomarker in brain tumours to help anticipate
the responsiveness to the TMZ treatment and selection of patients accordingly [28]. However, MGMT
is unreliable for patients who do not have a methylated promoter of MGMT except for elderly GBM
patients [29]. Some other chemotherapeutic drugs have shown efficacy against recurrent malignant
gliomas. These drugs are methylating agents such as irinotecan or those that target the vascular
endothelial growth factor such as bevacizumab. Other chemotherapy drugs such as gefitinib, erlotinib
and imatinib target the epidermal and platelet-derived growth factor receptors [30].
Among the latest therapeutic approaches is a device named Optune® that received approval by
the U.S. Food and Drug Administration (FDA) in October 2015. This device allows for the delivery of
electric fields that enable the treatment of tumours by interrupting the division of cells causing cell
death. It is used as an adjuvant therapy with TMZ following surgical resection and is the standard of
care for adults that have been recently diagnosed with supratentorial GBM. The Optune® treatment
regimen alongside TMZ increased survival from 4 to 7 months when compared to treatment with TMZ
alone [31]. Optune® was initially approved by the FDA in 2011 as a single treatment for recurrent
GBM. Optune® is alternatively used as a treatment for primary GBM after surgery and RT have been
shown to be ineffective. A randomized clinical trial exhibited similar rate of survival and less side
effects with a significant reduction in the infectious, gastrointestinal and hematologic complications for
the Optune® treatment group compared to the standard chemotherapy group [32]. The reduced side
effects and practicality of use encouraged the National Comprehensive Cancer Network (NCCN) to
include Optune® as a treatment for recurrent GBM [33].
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Other treatment approaches such as radioimmunotherapy, iodine-125 brachytherapy,
hyperfractionation and SRS have been investigated for their ability to localise treatment and protect
normal brain tissues. However, none have been shown to improve survival rates [34]. Therefore, it was
concluded that chemotherapy used concomitantly and adjuvantly with RT is the standard of care in
current application for GBM patients until more effective treatments become available [28].
4. Postoperative Treatment
Follow up is necessary to monitor the postoperative complications and control the
disease symptoms, which include seizures, cerebral edema, turbulences in the gastrointestinal
tract, osteoporosis, venous thromboembolism, dysfunction of the cognitive abilities and mood
deterioration [35]. Magnetic Resonance Imaging (MRI) scans are used to monitor the size of the tumour
and preformed 3 days following the surgical operation to determine how much of the tumour was
eradicated. Steroids are administered to patients suffering vasogenic edema. However, treatments
based on steroids are associated with adverse side effects such as myopathy [36] which affects 10%
of patients with HGGs with an increased incidence rate in elderly patients that are administered
corticosteroids for long time periods [37]. Also, patients become vulnerable to mental impairment,
hyperglycemic and gastrointestinal complications, in addition to opportunistic bacterial infections such
as Pneumocystis jiroveci. Dexamethasone is a more favourable corticosteroid as it is lower in activity and
upon its discontinuation, myopathy can be reversed [37,38]. Patients with GBM and CNS lymphoma
are more susceptible to venous thromboembolism, especially after craniotomy. Treatment using
warfarin or heparin of low molecular weight is more favourable than vena cava filters in controlling
the anticoagulation and reducing the complications. Levetiracetam is usually administered to patients
suffering seizures due to its low toxicity and the fact that it does not interact with the chemotherapy
drugs [38].
5. Prognosis
Patient prognosis remains depressing with a 15-month median survival, despite the advancements
in surgical resection of the tumours [39]. Anaplastic astrocytoma afflicted patients average between 2
to 3 years survival [40]. The best prognosis is shown in cases suffering anaplastic oligodendroglioma
leaving them with expected average survival of 12 to 15 years [41]. The prognostic factors involve:
the extent of tumour resected, age of the patient and the Karnofsky Performance Status. Younger age
and higher performance status could imply longer survival. Negative results have been linked to
tumours larger than 5 to 6 cm [42]. Surgically curable tumours such as those that arise in the cerebrum
or cerebellum have a better prognosis than those that arise in the brainstem or diencephalon [43].
6. Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is a malignant tumour that arises in the brain and is known
to be the most common form of brain tumours. It represents 16% of the tumours that originate in
the brain and CNS [39]. GBM has an incidence rate of 3.2 per 100,000 population [44,45]. GBMs are
mainly located in the brain but can also occur in the brain stem, cerebellum and spinal cord. Moreover,
the four lobes of the brain (frontal, temporal, parietal and occipital) represent the main sites for the
development of the primary gliomas, with an overall incidence rate of 61% and individual incidence
rate of 25%, 20%, 13% and 3%, respectively [46]. Initially, glial cells were thought to be the only source
of GBMs, however, it has been shown that several types of cells possessing the characteristics of neural
stem cells, could give rise to GBMs. These cells vary in their differentiation stage where they start out
as stem cells then give rise to neurons and glia. This is accompanied with changes in their phenotype,
mainly caused by the variation in their signaling pathways instead of the differences in the origin of
the cell type [47]. The average age in which GBMs develop is 64 [39]. Nevertheless, GBMs can develop
at any age including children. Men are more likely to develop a GBM than women with a rate of 1.6 for
every woman. Caucasians are also more likely to be stricken with the disease than other ethnicities [42].
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GBMs can vary in their classification, for example a GBM would be classed as primary or de novo
in origin if it has developed without a defined precursor. If a GBM develops from a transformed
low-grade tumour it will be termed secondary. Most GBMs are primary in nature and mainly afflict the
elderly, who have a poorer prognosis than their counterparts who develop secondary GBM [48]. GBMs
can be further classified into four subtypes which are, classical, pro-neural, neural, and mesenchymal.
Each subtype varies in its mode of development and survival [49,50]. GBMs are invasive in nature and
are difficult to completely remove by surgical resection. They often exist in sensitive areas of the brain
which mainly control speech, movement or the senses. The tumour cells also possess the ability to
infiltrate and remain in areas that surround the brain, which leads to further disease recurrence [48].
Current Management
The current treatment regimen for GBM is the Stupp protocol which was discussed earlier as the
standard of care for glioma management [28]. The main action of TMZ involves methylation of the DNA
at the N7 and O6 positions on guanine which halts the DNA mismatch repair mechanism resulting
in DNA nicks that halts the cell cycle at the G2-M level, causing apoptosis. However, the elevated
level of MGMT activity which functions by protecting tumour cells against chemotherapeutic
agents can negatively impact the TMZ response. Moreover, TMZ, is reported to be fraught with
deleterious complications such as hematological issues, fatigue and susceptibility to infections [51].
Another chemotherapeutic agent used to treat GBM is the Gliadel® Wafer, which is a disc shaped
200 mg wafer made of biodegradable copolymers that contain 3.85% w/w of the alkylating agent
bis-chloroethylnitrosourea (carmustine, also known as BCNU). Carmustine was initially approved by
the FDA as a potent antineoplastic agent for the treatment of GBM by intravenous administration [52].
Gliadel® is used for local administration of carmustine, with up to 8 discs placed into the resection
cavity during surgery. After treatment with Gliadel® Wafers, the median survival in a group of
patients with malignant glioma (95% of which was GBM) was 42 weeks, eight patients survived one
year, and four patients survived more than 18 months. Local treatment allows the chemotherapy to
be concentrated at the site of the tumour while avoiding systemic side effects. However, patients
suffered perioperative infections, seizures and required addition steroid treatment [53]. Moreover, the
drug penetration into tissues after diffusion from the implants does not exceed 1mm which limits its
efficacy [54].
In summary, the drawback of these treatments is that they are associated with serious unwanted
side effects in addition to the development of resistance, limiting their efficacy. Some patients do
not respond to the TMZ or BCNU, therefore, there has been a second line of drugs developed
which include carboplatin, oxaliplatin, etoposide and irinotecan. Additional chemotherapeutic
agents for GBM include anti-angiogenic agents like anti-VEGF monoclonal antibodies (bevacizumab),
anti-FGF antibodies, monoclonal antibodies targeting EGFR (erlotinib and gefitinib) and tyrosine
kinase inhibitors [19,55–57]. Despite developments in tumour diagnosis and treatment using RT and
concomitant chemotherapy with TMZ, nearly all GBM patients experience tumour recurrence.
7. The Blood Brain Barrier
One of the main limitations in the systemic treatment of malignant gliomas is the presence of the
BBB, which is a complex structure that comprises endothelial cells, pericytes, astroglia and perivascular
mast cells and acts as a barrier to most cells, pathogens and drugs circulating in the blood. The BBB is
compact in nature due to the presence of tight junctions between the endothelial cells of the vascular
layer that are closely stuck together. The BBB surrounds both the brain and spinal cord capillaries
and its compactness halts small molecules and ions from passing through the BBB and into the brain.
The tightness of the BBB stops integral membrane proteins from moving between the apical and
basolateral membranes of the cell, thus protecting the cell membrane from loss of function [58–60].
The tight junctions of the BBB have three fundamental proteins which are occludin, claudins,
and junctional adhesion molecules. Occludin and claudins form the pillar of junction strands. Whereas,
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when there is an immunologic response in the brain, the junctional adhesion molecules function
in the transport of lymphocytes, neutrophils, and dendritic cells from the vascular system. The
tight endothelial junctions and adherens junctions are made of cadherins and catenin proteins that
are responsible for the adherence of the BBB endothelial cells, forming a transelectrical resistance
>1500 Ω cm2. Although the BBB acts as a physical barrier, it still regulates the transport of metabolic
molecules to the brain for nutrition. Small molecules such as glucose or amino acids have specific
transporters that convey them to the brain. While, macromolecules such as cytokines and neurotrophils
enter the brain by receptor mediated endocytosis [61,62].
The BBB limits the passage of chemotherapeutic drugs with only low molecular weight, electrically
neutral, hydrophobic drugs able to cross the BBB with a preference towards molecular weight less
than 500 Da and lipophilicity expressed in log P as (2–3) [63]. Most chemotherapeutic drugs are
large, ionically charged, hydrophilic molecules and thus cannot easily cross the BBB at the levels
required for therapeutic effect, which means a large systemic dose is required. For example, irinotecan
hydrochloride, which is a potent anionic chemotherapy drug, possesses a molecular weight of 623.1 Da
and is hydrophilic in nature, therefore it will face difficulty crossing the BBB and accumulating in the
tumour in its initial administered dose. Even if the drug crosses the BBB, it can very quickly diffuse
back making it difficult to obtain constant drug levels in the brain after systemic administration.
8. Drug Delivery to the Brain
Two strategies, crossing the BBB and bypassing the BBB, are currently used for the delivery of
drugs to the brain. Crossing the BBB can take place via six main pathways: paracellular transport,
passive transcellular diffusion, carrier-mediated transport (CMT), receptor-mediated transcytosis
(RMT), adsorptive-mediated transcytosis (AMT), and cell- mediated transport. The normal physiology
of the BBB does not afford paracellular permeability [64]. However, it can take place when the BBB is
compromised in CNS disorders such as GBM, which could facilitate drug delivery to the brain [65].
Transmembrane diffusion allows for the intake of most of the compounds based on their molecular
weight and lipid solubility. Influx and efflux transporters facilitate mediated transport, which relies on
protein carriers that bind solutes and transport them from the luminal side of the BBB to the other side of
the membrane via passive or active transport mechanism [51]. Among the influx transporters are l-type
amino acid transporter (LAT1), glucose transporter (GLUT1), monocarboxylate lactate transporter
(MCT1), cationic amino acid transporter (CAT1), choline transporter (ChT), sodium-coupled glucose
transporters (SGLTs). Influx transporters facilitate particle uptake by the BBB. Efflux transporters, on the
other hand, mediate molecules exclusion form the BBB. These transporters are like p-glycoprotein (P-gp),
peptide transport system-6 (PTS-6), and breast cancer resistant protein (BCRP) [66–69]. RMT involves
the uptake of macromolecules by clathrin-mediated or caveolin-mediated endocytosis. This route
has been previously used to deliver both free drugs and nanoparticles into the brain [70]. RMT is
the route by which actively targeted drugs are internalized. Receptors expressed on the surface of
cells are recognized and bound by complementary ligands coating the drug loaded nanoparticles and
this complex structure enters the cell in vesicles coated with clathrin. This process is 1000 times more
efficient than pinocytosis [71]. The size of clathrin-coated vesicles is determined by the size of the drug
delivery vehicle which they carry [72]. Several receptors aid in transporting compounds across the BBB,
such as the insulin receptor, low-density lipoprotein (LDL) receptor, transferrin receptor, neonatal Fc
receptor and leptin receptor [73–77]. Whether internalization occurs by pinocytosis or RMT, the cargo
is delivered to the early endosome, which is of slightly acidic pH (6–6.8). The endosome has a sorting
function, where it either allows the recycling of molecules back to the plasma membrane or sends them
to late endosome and lysosome for degradation [78]. Whereas, caveolin-mediated endocytosis forms
caveolae which are invaginations in the plasma membrane that take the shape of small flasks that engulf
large molecules and transport them internally. AMT relies on the electrostatic interaction between
positively charged substances and the plasma membrane, leading to internalization of molecules
followed by their transport across the BBB. This pathway could be exploited by developing drugs
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or nanoparticles with positive charges or by conjugating the drug or nanoparticles with a positively
charged ligand [79,80]. CMT exploits the natural mechanism involved in inflammation with drugs and
nanoparticles engulfed by immune cells such as monocytes and macrophages [81,82]. In diseases such
as neuroinflammation, or GBM, immune cells such as leukocytes are transported towards the brain
parenchyma by chemotaxis and diapedesis processes. This process could be exploited in designing
drugs or nanoparticles that can be phagocytosed by leukocytes and thus transported into the brain.
The efficacy of free drugs and nanoparticles delivered by this natural mechanism, also known as the
Trojan Horse mechanism has been shown to increase. This mechanism allows for larger sized particles
to enter the brain, however, their larger size can result in increased toxicity [83–85]. There are a number
of options for bypassing the BBB. Intracerebroventricular (ICV) administration is performed through
an invasive procedure of skull penetration and drug injection directly into the brain. An implantable
reservoir or a pump is used to introduce the drug through an outlet catheter. The pump allows for
a constant drug supply at high concentrations. The ICV process is extremely invasive and can lead
to infections and increased intracranial pressure [86]. Intracerebral/intraparenchymal administration
involves the delivery of drugs directly into brain tissue either via stereotactic injection or by formulating
into an implant that can be implanted during resection surgery (i.e., Gliadel®) or via stereotactic
surgery. The issue with this type of delivery is that drug diffusion occurs slowly and allows drug to
travel only 2 mm from the injection/implantation site [86]. Convection Enhanced Delivery (CED) is a
slightly less invasive surgical procedure where catheters are placed inside the interstitial space of the
brain parenchyma. A drug solution is administered into the brain under a positive pressure gradient
using a pump, leading to a higher distribution volume compared to intracerebral/intraparenchymal
administration [86]. This procedure is still, however, invasive in nature and could subject patients to the
risk of infections, tissue injury and air bubbles. Furthermore, due to the high pressure used, the drug
solution could leak into sensitive areas of the brain, such as subarachnoid space [86]. Intrathecal
administration is considered one of the least invasive procedures, where drugs are injected into the
subarachnoid space of the spinal cord via a lumbar puncture where they reach the CNS parenchyma in
the cerebral spinal fluid [87]. However, possible side effects such as infections and adverse immune
response could occur due to this technique [87]. In addition, although the ICV and intrathecal techniques
can bypass the BBB and cerebrospinal fluid (CSF) hurdles, there remain the ependymal cell layer and
glial cells which come in the way between the CSF and the brain parenchyma limiting the efficacy of
drug diffusion to reach the brain parenchyma via these techniques [88]. Intratympanic administration
employs the route of the middle ear to administer drugs, which are transported via pinocytosis,
eventually reaching the brain where they bypass the labyrinthine barrier (BLB) which is similar to the
BBB. This route can be suitable for therapeutics up to 1 μm size [89]. Poly(d,l-lactide-co-glycolide)
(PLGA) nanoparticles were used to administer drugs via this route with promising efficacy [90].
Intranasal delivery is a non-invasive route of administration for bypassing of the BBB through spraying
drugs into the nasal cavity, where they diffuse extracellularly or via convection. Another route is
through olfactory sensory neuron termed intraneuronal transport or through trigeminal nerve, termed
intraneuronal transport [91]. The intranasal route is beneficial in terms of being convenient to patients,
allowing for rapid absorption and avoiding first pass metabolism [92]. Some other methods for crossing
the BBB have been investigated, most of which are invasive in nature, such as osmotic opening of the
BBB [93]. Other non-invasive methods have also been investigated, for example, the Trojan Horse
technology which relies on coupling drugs to genetically engineered proteins that can cross the BBB by
receptor mediated transport processes [94]. Such methods are also fraught with side effects and thus
alternative more effective and less toxic methods for delivery of drugs to the brain are needed in order
to improve the treatment of brain tumours [95].
9. Nanomedicine: A Non-Invasive Approach towards a Better Quality of Life
Nanotechnology has provided us with a promising tool that can be used to enhance the uptake
of drugs across the BBB [96,97]. This is because nanoparticles have the ability to be loaded with
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therapeutic agents and functionalized with multiple ligands that enable targeting and crossing of
the BBB. In this case, the ability to cross the BBB will not be dependent on the structure of the drug,
which cannot readily be altered, but on the physicochemical properties of the nanoparticles, which
can be altered. Nanoparticles are proposed to perform their action in delivering drugs across BBB by
concentrating the drug inside or at the surface of the BBB, which will result in a high concentration
gradient between blood and brain, encouraging passive diffusion of the drug into the brain [98].
Nanoparticles have the ability to diffuse into the leaky vasculature of tumour tissues by the
enhanced permeability and retention effect (EPR). This cancer-specific attribute is characterized by
poor lymphatic drainage allowing the accumulation of nanoparticles to reach concentrations much
higher than their concentrations in plasma [99]. The effective treatment of GBM can be accomplished
by achieving three main goals: (1) Improving the ability of chemotherapeutic agents to cross the BBB,
penetrate into brain tissue reaching the tumour tissue at therapeutic concentrations (2) Avoiding or
reducing side effects and (3) Sustaining therapeutic concentrations of the drugs at the site of the tumour,
increasing their half-life and avoiding rapid clearance [99].
10. Physicochemical Properties of Nanoparticles
The different physicochemical properties of nanoparticles such as the particle size, surface charge,
hydrophobicity and coating material have an impact on the targeting process. They also impact the
interaction of particles with the cell membrane and passage through biological body barriers [100]. Size
is an important factor that allows transport of nanoparticles in the blood stream and enables delivery of
nanoparticles to the site of the tumour. Small sized nanoparticles can easily reach the leaky blood vessels
of the tumour, however, they can extravasate into the normal tissues [101]. Therefore, optimization
of nanoparticles size can enhance their uptake into tumour tissues. The shape of nanoparticles is
also of importance as it influences the fluid dynamics and thus particle uptake. The current trend
is towards using spherical nanoparticles owing to the ease in their synthesis and application [102].
In addition, the stability of nanoparticles is affected by their surface charge which also impacts their
distribution in the bloodstream. Previous studies have shown that positively charged nanoparticles
could be more effective in targeting tumour vessels. However, this has been replaced by neutrally
charged nanoparticles which extravasate quicker into the tumour tissue [103].
11. Nanoparticles as a Treatment for Malignant Gliomas
A range of different nanoparticle formulations have been investigated to deliver chemotherapeutic
drugs to the brain. The majority of these formulations have utilized polymers that have met the strict
requirements needed to be accepted for biological applications [104]. During recent years, nanoparticles
for the treatment of CNS diseases such as GBM have received significant attention [105,106]. With
systemic administration of free drug, a small percentage of the drug crosses the BBB with non-specific
accumulation in off target tissues resulting in serious unwanted side effects. Therefore, the use
of nanoparticles for delivery to the brain has the potential to increase the percentage of drug that
crosses the BBB while reducing non-specific accumulation in other tissues [107,108]. For example,
gadolinium-loaded nanoparticles increased the level of gadolinium 100 fold when compared to
free gadolinium [109]. The manufacture of nanoparticles has improved in the last few years with
optimization of drug loading, encapsulation efficiency and release profile. Furthermore, improvements
in the stealth capabilities of nanoparticles have increased their protection from agglutination with
proteins in the blood, enabling them to avoid being cleared from the blood by the reticuloendothelial
system (RES). Nanoparticles whose surface has been modified with ligands have been used to facilitate
imaging of brain tumours nanoparticles [110,111]. PEGylation of nanoparticles has been widely
used in drug delivery in order to protect nanoparticles from blood protein interaction and from the
RES [112,113]. Dawson et al. demonstrated that the PEGylation of nanoparticles completely prevented
their interaction with proteins in the plasma. However, other studies have shown that PEGlylation
does not completely prevent the interaction between proteins and nanoparticles in the blood [114].
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Nanoparticles offer a non-invasive method for drug delivery to the brain. However, they need to be
optimized in relation to size, release kinetics, chemical properties, while modifying their surface could
improve their ability to cross the BBB as well as protecting the drug from the biological environment
and enhancing drug solubility [115]. Nanoparticles for drug delivery to the brain need to meet certain
essential requirements to be most effective, with reduced toxicity. The requirements include non-toxic,
biodegradable, prolonged circulation period, no aggregation in the blood, good encapsulation efficiency
and the ability to cross the BBB [116].
12. Routes of Administration of Nanoparticles in the Treatment of Malignant Gliomas
There are three main routes of administration for nanoparticles designed to treat brain tumours:
(1) direct delivery to the brain; (2) direct systemic delivery to the brain and (3) indirect systemic delivery
to the brain.
Direct delivery to the brain offers a way of bypassing the BBB by direct injection of the nanoparticles
into the brain. CED has been used to infuse a nanoparticle suspension directly into brain tissue. Lollo
et al. used CED to deliver 10 μL of paclitaxel-loaded lipid nanocapsules directly into the brain of
mice. The results showed that the overall survival of mice treated with the lipid nanocapsules was
significantly increased in comparison with mice treated with free paclitaxel [117,118]. Fourniols et al.
described the direct injection of a photopolymerizable hydrogel containing TMZ-loaded micelles to the
brain using a syringe to inject through an incision drilled in the skull. The TMZ-loaded micelles and
injection were well tolerated while the hydrogel improved the drug release profile [119]. The major
limitations of direct delivery to the brain is its invasive nature, the risk of infection and the need
to control critical parameters such as pH and osmolarity which if not optimized may lead to brain
damage [120]. Direct systemic delivery to the brain is where nanoparticles are directly administered
into blood stream through carotid artery and transported to the brain avoiding the rest of the systemic
circulation. This technique has shown improved survival compared to CED with reduced risk of
brain damage [121]. Huynh et al. administered ferrociphekunol-loaded nanoparticles to the brain of
GBM inflicted rats using both CED and direct systemic delivery. Direct systemic delivery provided
a survival of 28 days compared to 24 days for the CED group. The results indicated that direct
systemic delivery could provide a modest increase in survival when compared to direct delivery
to the brain [120,122]. Indirect systemic delivery involves the delivery of nanoparticles into the
systemic circulation via routes of administration that require absorption such as oral, topical, nasal,
and peritoneal administration. The major advantages of oral administration are the convenience,
non-invasiveness, and patient compliance. Kumar et al. administered two curcumin formulations
(nanoparticles and plain suspension) orally to a rat intestinal ex-vivo model. The results showed that
the bioavailability of nanoparticles formulation was 12 times greater than the plain suspension [123].
Intraperitoneal administration is widely used as an indirect systematic delivery method by injecting
the drug into peritoneal tissue. It is used when administering large doses or when it is difficult to
locate a vein for direct systemic delivery [124].
13. The Chemistry of Coating and Bioconjugation of Nanoparticles
Tumour tissues with their leaky vasculature allow the passive accumulation of particles from
10 to 200 nm in size by the EPR effect. However, chemotherapeutics penetration over time becomes
challenging due to the increased interstitial pressure and the dense structure of the tumour tissues
caused by hydrophobic regions in the brain extracellular space which block therapeutic particles,
by steric hindrance, from accessing the tumour. Instead, chemotherapeutics diffuse towards the tumour
edge and leak to blood vessels formed by angiogenesis. Additionally, nanoparticles are spotted by the
RES as foreign particles and cleared by phagocytosis [125,126].
Advanced nanomedicine research has focused on developing stealth nanoparticles, which are
designed with special coatings such as polyethylene glycol (PEG) that mask them from the RES
system allowing them to circulate for longer in the bloodstream increasing tumour penetration and
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physiological stability. Furthermore, the coating enables targeting of brain tumour tissues in a more
specific manner than uncoated particles [127,128]. Such coated nanoparticles are chemically and
physically developed using different techniques which involve grafting, coprecipitation and surface
adsorption [129]. Such bioconjugation involves using coatings that are either biological in nature or
synthetic but specifically designed for biological applications [130].
Nanoparticles could have their surface modified through covalent and non-covalent ligand binding
Covalent binding takes place via either disulphide bonds, primary amines cross linking, primary
amine-carboxylic acid reaction, maleimide-thiol reaction, aldehyde-hydrazide reaction and primary
amine-free aldehyde reaction [131]. Bioconjugates are also formed by using reactive crosslinking
agents or reactive groups that aid in the coupling reaction. Some secondary activating agents could
act as intermediates in the coupling process that facilitate binding specific functional groups. This
process is specific in nature and resembles the selection of building blocks in order to create the whole
structure. Affinity molecules act as an important part in the functionalized entity and they aim at
targeting biomolecules [130].
Non-covalent or physical interaction between targeting ligands and nanoparticles does not involve
chemical bonds, however, it may not create as strong a binding as is the case in covalent binding [132].
The process of PEGylation could take place by coupling with linear or branched PEG molecules
which provides a more stable structure with enhanced water solubility and half-life while reducing
cytotoxicity and adverse immune response [133,134].
Surfactants offer a major advantage for nanoparticles by helping them penetrate the BBB as well
as enhancing their uptake by tumour cells. These surfactants could be polysaccharides, poloxamers
or polysorbates. A study reported that Polysorbate 80 (p80) coated polymeric nanoparticles carrying
paclitaxel had enhanced uptake by GBM cells due to the coating masking them from the P-gps, which
are responsible for drug resistance, as well as by allowing their penetration of the BBB [135]. Previously
published studies have demonstrated the beneficial role of p80 and Poloxamer 107 as surface ligands
in facilitating transport across the BBB with proven efficacy in GBM rats [70,136–138]. However,
the main issue with these particles is that they could only travel through endothelial cells to neurons
in close proximity with the BBB, via cell to cell processes. As a result, the parenchyma barrier of the
brain tumour will remain unpenetrated. Therefore, the focus on developing nanoparticles that can
exceed this hurdle is necessary for a better treatment response. Another study used a similar approach
of coating their PLGA nanoparticles with two different surfactants (p80 or poloxamer 188) for the
intravenous delivery of two model drugs; loperamide and doxorubicin to the brain. Good efficacy
was observed in rats containing an intracranial GBM when treated with doxorubicin loaded particles,
while an analgesic effect was observed in mice when treated with the loperamide loaded particles,
which confirms successful transport across the BBB at therapeutic levels. On the other hand, uncoated
nanoparticles used in the same study had no effect for either drugs [127].
Other targeting moieties have been investigated for the treatment of malignant gliomas. Kuo and
Chen (2015) reported that using lactoferrin and folic acid as grafting ligands for PLGA nanoparticles
were effective in crossing the BBB and delivering etoposide in GBM U87MG cells [139]. Lactoferrin and
folic acid coated nanoparticles had aided in the permeability of etoposide by almost 2-fold as compared
to the uncoated nanoparticles. This resulted in a two-fold tumour suppression by the etoposide-loaded
nanoparticles when compared to the free etoposide over 48 h. Furthermore, these nanoparticles
were prepared with a cationic surfactant, didodecyl dimethyl ammonium bromide (DMAB) which
was previously reported to enhance the affinity of the nanoparticles to the walls of arteries allowing
for their uptake via AMT [140,141]. Other studies also highlighted the role of lactoferrin and other
blood proteins (transferrin, insulin and leptin) as surface ligands in traversing through the BBB by
RMT [77,139,142].
Another study demonstrated that a hydrogel made of polymeric micelles coated with polyethylene
glycol dimethacrylate could provide sustained release of TMZ over a 1-week period in GBM bearing
mice. This study indicated a dramatic decrease in the tumour volume following treatment with
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the TMZ photopolymerized hydrogel as well as increased apoptosis as compared with the other
groups [119].
Dual coating of polymeric nanoparticles is also an interesting therapeutic trend. A study
investigating polymeric nanoparticles with PEG and a covalently attached ligand called peptide-22
was shown to enhance BBB permeability, recognition by LDL receptor on the surface of glioma cells
and increased delivery of paclitaxel [143]. The benefit of dual coating was further investigated in a
study that coated PEGylated PCL nanoparticles with angiopep-2 which is a peptide that facilitates BBB
permeation and drug delivery in glioma cells. This study has also employed cell penetrating peptides
to allow deep permeation towards glioma cells and delivery of docetaxel which improved the rate of
survival in glioma afflicted mice [144].
Another targeting protein moiety named EGFP-EGF1 was bound to polymeric nanoparticles
carrying paclitaxel to form a dual coating alongside PEG aimed at targeting glioma in mice. This
targeting protein has specific affinity towards tissue factor over-expressed in glioma cells therefore
provided better penetration than non-fused nanoparticles. This study has reported enhanced apoptosis
and necrosis and extended time of survival for mice treated with PLA-PEG-EGFP-EGF1 compared to
the other groups [145].
An in vitro study using murine glioma cell lines C6 and F98 compared the cytotoxicity of etoposide
loaded and unloaded PLGA nanoparticles with and without surface coatings. Their results have
indicated enhanced cytotoxic effect on both glioma cell lines as compared to unloaded nanoparticles or
free drug [146]. Surface coating of PLGA nanoparticles with protamine, which is a cationic protein that
enhances drug transport across BBB, also significantly improved the delivery of cisplatin in bovine
endothelial cells and also were cytotoxic in U87 GBM cells [147].
14. Drug-Loading of Nanoparticles
Drugs employed in the treatment of cancer can be loaded either by entrapment within, adsorption
on or by covalently bonding to the nanoparticle [148]. The process of drug entrapment could take place
either during or after the process of nanoparticles manufacture. Several factors, such as the solubility
of the chemotherapy drug in the nanoparticles matrix, the molecular mass of the drug, the type of
interaction between the drug and the nanoparticles and the functional groups on the surface of the
nanoparticles influence their loading process [148].
The method of drug loading could result in drug within the core or on the surface of the
nanoparticles. Drugs loaded on the surface by covalent bonding or physical adsorption as for example
by electrostatic interactions between the nanoparticle and drug usually exhibit low stability and become
pH liable [149,150]. Drugs entrapped within the nanoparticles usually have greater stability and tend
be released over a sustained period of time.
15. Polymeric Nanoparticles for the Treatment of Malignant Gliomas
Polymeric nanoparticles are defined as submicron colloidal nanoparticles and are used as carriers
for different drugs such as chemotherapeutic drugs which are either adsorbed on the surface or
encapsulated within the nanoparticles [151]. There are many types of polymers which have been
used in the manufacture of nanoparticles, such as poly(lactic acid) (PLA), poly(ε-caprolactone) (PCL),
poly(butyl-cyanoacrylate) (PBCA), poly(glycolic acid) (PGA), PLGA and poly (amino acids). PLGA,
PGA, PLA are the most extensively utilized polymers in drug delivery to the brain, because of
their biocompatibility and low toxicity compared to other polymers [152]. They all degrade into
lactic acid and glycolic acid that enter into the Krebs cycle where their metabolites are eliminated
as carbon dioxide and water from the body [153]. Polymeric nanoparticles have advantages over
other types of nanoparticles such as improved release kinetics, better compatibility with some active
agents, no oxidation issues as with phospholipids and improved shelf-life [154–156]. The successful
development of polymeric nanoparticles for drug delivery to the brain will require an understanding of
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the molecular weight, crystallinity and stability of the polymers as well as physicochemical properties
of the drug [157].
The first polymeric nanoparticles developed to deliver drugs to the brain was performed by
Kreuter et al. The BBB penetration of dalargin was significantly increased by formulating it into
PBCA nanoparticles [158]. In 2001, Kreuter et al. used the same dalargin-loaded PBCA nanoparticles
coated with p80, to increase penetration into brain tissue. This nanoparticle formulation was utilized
for the delivery of other drugs, such as doxorubicin and loperamide into the brain [70]. Calvo et al.
prepared PEG-PHDCA (poly(hexadecyl cyanoacrylate)) nanoparticles which demonstrated a greater
accumulation in the brain when compared to the p80 formulation, which may be due to passive diffusion
or intake via macrophage [159]. The density of the PEG coating on the surface of the nanoparticles can
affect the level at which they cross the BBB. Vila et al. produced PEG-PLA nanoparicles with different
densities of PEG coating and demonstrated that the smaller nanoparticles with the highest density of
PEG had a greater accumulation in the brain [160].
16. Targeted Polymeric Nanoparticles for the Treatment of Malignant Gliomas
The active targeting of polymeric nanoparticles via surface modification with ligands that bind to
target molecules on the surface of cancer cells or other cells within the body is a significant development
in nanotechnology [161]. Table 1 shows examples of developed targeted polymer nanoparticles as
targeted drug delivery system for treatment of malignant gliomas. The affinity ligands bind directly
to antigens that are differentially overexpressed on the plasma membrane of cells or to extracellular
proteins on the target tissue [161]. Active targeting of nanoparticles can be used for either extracellular
or intracellular delivery of drugs. Nanoparticles are more effective if they are targeted to intracellular
sites [154,162]. For example, Alexis et al. demonstrated increased cytotoxicty of paclitaxel-loaded
nanoparticles using a ligand targeted to the extracellular domain of the trans-membrane human
epidermal growth factor receptor 2 (HER-2) when compred with non trageted nanoparicles. This
increase in cytotoxicty was due to an increased cellular uptake by the targeted nanoparticles [163].
Studies have confirmed that enhancing cellular uptake is the most important role of using targeted
nanoparticles [164,165]. Targeted nanoparticles can have either single or multi ligands attached to
their surfaces. To date, most researchers have prefered to use a single ligand as multi-ligands are
associated with some disadvantges, particulalry when used for penetration of the BBB and tumour
cells. For example, multi-ligands influence drug release as well as the mobility of the nanoparticles.
Furthermore, competitive binding and/or an interaction between ligands may reduce the targeting
effeciency of the nanoparticles [166].
Transferrin receptors and low density lipoprotein receptor related protein (LRP) are known to
be overexpressed on glioma cells [166]. These two receptors have been used to target polymeric
nanoparticles to glioma cells by attaching the anti-transferrin and angiopep ligands to their surface.
Anti-transferrin can cross the BBB through transferrin receptors while the angiopep ligand binds to
LRP on the surface of glioma cells [166,171]. The transferrin receptor is the most widely characterized
receptor-mediated transport system, which provides an efficient cellular uptake and is over expressed
in numerous tumour cells [167]. The targeting of BBB of an in vitro model has increased 20-fold
with transferrin-PLGA nanoparticles compared to non-coated PLGA nanoparticles. Chang et al.
demonstrated, using an in vitro model of the BBB, that transferrin-PLGA nanoparticles had a 20 fold
increase in uptake by the BBB when compared to un-coated PLGA nanoparticles. The uptake of the
transferrin-PLGA nanoparticles by the BBB was by endocytosis [167]. The major disadvantages of
using transferrin as a ligand for nanoparticles is the competition with endogenous transferrin for
receptor binding. This may result in reducing the cellular uptake and thus the effectiveness of the
nanoparticles [178]. An antibody directed against the transferrin has been used as an alternative ligand
to the endogenous transferrin as it binds to an epitope of the transferrin receptor which is located at a
different location from transferrin binding. Therefore, the nanoparticles have less binding competition
as they do not interfere with the transferrin intake mechanism. This will increase their cellular uptake
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and thus their effectivness [179]. Different antibodies such as OX26 (anti-rat TfR mAbs), R17-217 and
8D3 (both anti-mouse TfR mAbs) have been developed for enhancing brain uptake. OX26 mAbs has
been shown to have a high affinity for cells that overexpress transferrin, including GBM cells [180,181].
The level of brain uptake for each of the antibodies is different. For example, the brain uptake of 8D3
mAbs was relatively high compared to R17-217 mAbs. 8D3 and R17-217 mAbs were more selective for
brain than liver and kidney [182]. Rmalho et al. developed receptor mediated TMZ-loaded PLGA
nanoparticles for GBM treatment functionalized with an OX26 mAbs. The cellular internalization of
the OX26mAbs nanoparticles was signifcantly enhanced compared to the PLGA nanoparticles with no
mAbs [176].
Table 1. Examples of developed targeted polymer nanoparticles as targeted drug delivery system for






Targeting Strategy Targeted Site Ref.
PLGA Dil 90 Transferrin Transferrin receptors [167]
PMLA Antisense ON 25 mAbs antisense oligonucleotides(AONs)
(proteins)
laminin-411 [168]
PEG-PCL Paclitaxel <100 Angiopep LRP [169]
PEG-PLGA Coumarin 6 125 Peptide (12 amino-acid) Peptide [170]
PEG-PCL PaclitaxelRhodamine 90 Angiopep LRP [171]
PLGA Methotrexate 85 Transferrin Transferrin receptors [166]
PEG-PLGA Doxorubicin 100–300 Endogenous tripeptide thiol(glutathione)
Glutathione
transporters [172]
PLGA Loperamide 100 mAbs (8D3) Transferrin receptors [173]
PLGA Curcumin 100 Magnetic guidance Peptide (T7) Transferrin receptors [174]
PLGA Doxorubicin 120 Poloxamer 188 LRP [175]
PEG-PLGA TMZ 19 mAbs (OX26) Transferrin receptors [176]
PLGA Paclitaxel 230–255 Tripeptide(RGD) Superparamaciron oxide (SPIO) αvβ3 integrin [177]
Another approach to enhancing the uptake of nanoparticles by the BBB is to coat them with
a polymer that will facilitate cellular uptake. As discussed earlier about the role of surfactants in
coating, Kreuter demonstrated that intravenously injected doxorubicin-loaded p80-coated nanoparticles
had a 40% cure rate in rats with intracranially transplanted GBMs. Although not fully elucitated,
he hypothesised that the most likely mechanism for transport of the nanoparticles across the BBB was
endocytosis by the endothelial cells lining the brain blood capillaries. Coating the nanoparticles with
p80 lead to the adsorption of apolipoprotein E from blood plasma onto the nanoparticles’ surface.
The particles then mimiced LDL particles and could thus interact with the LDL receptor leading to
their enhanced uptake by the endothelial cells [70]. The first polymeric nanoparticles for penetration
of the BBB were investigated by Schröder et al. in 1995. PBCA nanoparticle coated with p80 enhanced
BBB penetration of hexapeptide dalargin-loaded nanoparticles [183]. Wohlfart et al. demonstrated,
using a rat glioma model, that poloxamer 188-coated PLGA nanoparticles enabled the delivery of
doxorubicin across the BBB in the therapeutically effective concentrations. The basis for their transport
across the BBB was hypothesised to be adsorption of blood apolipoproteins (ApoE or ApoA-I) onto the
nanoparticles surface due to the poloxamer 188 coating, followed by RMT of the nanoparticles [184].
Manlioovskaya et al. demonstrated that these same nanoparticles entered U87 human GBM cells
via clathrin-mediated endocytosis. They also demonstrated that the nanoparticles released their
doxorubicin via diffusion rather than by intracellular degradation [175]. These studies prove that PLGA
nanoparticles coated with poloxamer 188 could improve the delivery of doxorubicin and potentially
other chemotherapeutic drugs into brain tumours.
Another promising LPR ligand for delivering nanoparticles to the CNS and BBB penetration is
angiopep. It is from a peptide family that is derived from aprotinin and human proteins [185]. The
transcytosis capacity and parenchymal accumulation of angiopep-2 is much greater compared to
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transferrin [186]. The ability of angiopep to facilitate penetration of the BBB of polymeric nanoparticles
has been confirmed in a number of studies [169,187]. Xin et al. fabricated dual targeting nanoparticles
to improve the drug delivery of paclitaxel to glioma cells. Angiopep-PEG-PCL nanoparticles were
highly endocytosed by U87 GBM cells compared with non-targeted PEG-PCL nanoparticles. These
nanoparticles have also shown higher penetration, distribution, and accumulation in 3D glioma
spheroids as well as increased efficacy in U87 tumour bearing mice [169,171].
17. Challenges Associated with Nanomedicine as a Treatment for Malignant Gliomas
17.1. Reticuloendothelial System
The RES also termed the mononuclear phagocyte system (MPS), possesses cellular and noncellular
components. Phagocytes could cause the clearance of nanoparticles by binding to them and triggering
cytokine cascade, which causes inflammation [188]. Moreover, macromolecules such as proteins and
lipids and others could attach to the surface of the nanoparticles forming a biological corona that gets
recognized by the immune system and cleared from the blood stream [189]. This challenge could be
overcome by surface modification of the nanoparticles that could conceal them from being recognized
by the RES and allow their existence for longer periods in bloodstream. Surface modification is done
using zwitterionic ligands such as cysteine, glutathione or by PEGylation [188]. In a study performed by
Choi et al. using zwitterionic (cysteine) or neutral dihydrolipoic acid ((DHLA)-connected polyethylene
glycol; DHLA-PEG) coatings to coat quantum dots has prevented adsorption of serum proteins and
enhanced their renal clearance [190]. An in vivo study showed that using nanoparticles of PEGylated
human serum albumin loaded with paclitaxel accomplished long systemic circulation of more than 96
h and enhanced accumulation in the tumour providing high efficacy against cancer and extension in
the life span of animals [191]
17.2. Renal System
The main obstacle facing nanoparticles with the renal system is the process of blood filtration.
Nanoparticles will follow certain routes by passing through fenestrated endothelium that has 70–100 nm
pores, then they will go through the capillary endothelium and podocytes that are programmed to
clear particles sized between 2 and 8 nm, whereas nanoparticles >8 nm will face difficulty crossing
the glomerular filtration barrier. In addition, the fact that the glomerular basement membrane carries
a negative charge, cationic nanoparticles (2–6 nm) will exhibit more renal clearance than neutral
or anionic same sized nanoparticles [188]. The shape of a nanoparticle could also influence renal
clearance, with enhanced clearance of rod shaped nanoparticles of size 0.8–1.2 nm diameters as
reported by Ruggiero et al. [192]. Size exclusion is a major challenge that affects the overall benefit
of using the nanoparticles. The solution to this problem could lie through developing nanoparticles
of biodegradable materials that can break down into particles prone to renal clearance. However,
this could result in premature release of the therapeutic agents before reaching their target site [193].
Therefore, in designing nanomedicines for clinical applications, it is necessary to keep the balance
between formulating nanoparticles that have renal clearance to avoid long term toxicity as well as
maintaining the therapeutic levels of the drugs in the plasma [188].
17.3. Blood Brain Barrier
As mentioned previously, the BBB is a barrier consisting of tight junctions that limit the entry of
nanoparticles into the brain. However, nanoparticles with ligands attached have been used to pass
through the BBB by the receptor mediated endocytosis [188].
17.4. Pathophysiological Barriers in Cancer
The composition and structure of the tumour extracellular matrix and its vasculature vary
according to the nature of the cancer, it’s position and stage, alongside personal characteristics [188].
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Therefore, deep penetration of the nanoparticles could be difficult to achieve [194]. Three steps
are involved in the transport of pharmaceutical agents to tumour cells. These involve flow of the
nanoparticles through blood vessels, then passage through the walls of the blood vessels, eventually
crossing the interstitial space to reach the tumour site. The morphological discrepancy between
tumour and normal tissues affect the delivery of the therapeutic agents. The abnormal environment of
tumourous tissues results in leaky vessels, abnormal blood flow, dysfunctional lymphatic vessels and
vascular hyperpermeability that causes interstitial hypertension. The high pressure of the interstitial
fluid and dense extracellular matrix hinder the process of diffusion [195,196]. Several strategies
have been addressed to enhance drug delivery such as: (1) Normalization of tumour vasculature
by using antiangiogenic agents that repair the imbalance that took place between the overexpressed
proangiogenic and antiangiogenic factors in tumour tissues [196]. This approach has rapidly normalized
the tumour microenvironment and reduced vessel size and vascular permeability in GBM patients
after receiving cediranib as an antiangiogenic therapy [197]. In a preclinical study, surface modified
nanoparticles (20–40 nm) could successfully penetrate into breast cancer tissues following vascular
normalization therapy [198]. Nevertheless, normalized vasculature would not grant entry to extra large
nanoparticles due to the reduced pore vessel size. In addition, vessel normalization is impermanent
and requires drug administration within the normalization period [196]. (2) Normalization of tumour
matrix that is mainly composed of collagen and glycosaminoglycan. The normalization process is
based on degrading such components to improve nanoparticles penetration. Bacterial collagenase
treatment has been administered in high collagen containing tumours such as HSTS26T sarcoma and
Mu89 melanoma and has improved penetration of IgG antibodies (4.5 nm size) by two fold [199].
Also, interstitial distribution of herpes simplex virus (size 75 nm) was improved by three-fold [200].
Other strategies have been suggested to improve penetration of nanoparticles into cancerous tissues.
Inhibiting growth factor-β in pancreatic adenocarcinoma was reported to enhance the penetration of
polymeric nanoparticles 100 nm in size [201]. Alternatively, using multi-staged nanoparticles could
enhance drug delivery in cancer. This involves using large nanoparticles that have longer half-life in
the blood stream [202]. These large particles dissociate upon entry into the tumour microenvironment
and release smaller nanoparticles that diffuse on a deeper level into the tumour tissue. A multistage
nanoparticle system (100 nm) was engineered with a gelatin core to dissociate and release nanoparticles
(10 nm) when it comes in contact with matrix metalloproteinases, for a deeper tumour penetration [203].
Designing nanoparticles that can have deep penetration into tumour tissues are under development.
Additionally, smart nanoparticles are being developed that can respond to the surrounding conditions
and allow a better bioavailability for treatment [204].
17.5. Multidrug Resistance
Multidrug resistance (MDR), whether hereditary or gained by long term exposure to drugs,
involves discharge of drugs outside the cells leading to reduced drug concentration and efficacy inside
the cell lumen. Cancer cells can be resistant to chemotherapeutic drugs causing increased toxicity of
healthy cells which get exposed to drugs that get ejected by cancer cells. Some chemotherapy drugs that
cancer cells are resistant to include taxanes, anthracyclines and vinca alkaloids [205]. In cancer, MDR
usually comes from overexpressed P-gp which is an ATP-binding cassette (ABC) transporter that acts
as an efflux pump with the ability of binding many various hydrophobic drugs [206]. Such transporter
is present in several organs such as brain, liver and placenta, for example and it functions by protecting
organs from toxins [207]. Some other MDR associated proteins involve MDR-associated protein-1 and
the breast cancer resistance protein (BCRP) [208]. Efflux pump inhibitors such as verapamil (covera) and
cyclosporine have been investigated and are emerging as first-generation antagonists [209]. Addressing
MDR in cancer has involved the exploitation of nanoparticles drug delivery systems in encapsulating
chemotherapy drugs. Liposomes nanoparticles encapsulating doxorubicin and verapamil have been
formulated for the targeted inhibition of P-gp [210]. Furthermore, hybrid nanoparticles of lipids and
co-polymers were developed and loaded with doxorubicin and GG918 to target BCRP [211]. Both
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of the previously stated studies have accomplished higher cytotoxicity against leukemia and breast
cancer cell lines, respectively, compared to free drug administration. PCL polymer was also employed
alongside other co-polymers in the development of micelle nanoparticles of siRNA to target MDR-1
and perform silencing of the gene responsible for P-gp expression [212].
18. Clinical Transition of Polymeric Nanoparticles
Polymeric nanoparticle formulations utilizing different polymers, coatings and targeting ligands
have been introduced into the clinic. As can be seen from above a wide range of different nanoparticle
delivery systems have been investigated pre-clinically, which may lead to more nanoparticles reaching
the clinic. Furthermore the FDA has approved a range of different routes of administration for
nanoparticles, such as systemic, local, and oral administration [213]. The main route of administration
used in most preclinical and clinical studies is intravenous administration due to the nanoparticles
being able to reach all parts of the body giving them a high potential to influence clinical care by
targeting both the primary cancer and any associated metastasis [214,215]. All of the nanoparticle
formulations approved for cancer treatment are liposomal formulations. The first approved nanoparticle
formulation was PEG-functionalized liposomal doxorubicin (Doxil) in 1995, and the most recently
approved nanoparticle is irinotecan liposomal formulation (Onivyde) [216,217]. The majority of all
approved liposomal nanoparticle formulations are not PEGylated except for Doxil and Onivyde,
which have been shown to have advantages over non-PEGylated nanoparticle formulations even
with their low amount of PEG [213,218]. Preclinical research performed in the 1970s, 1980s, and
1990s, using polymers as controlled release systems for drug delivery has led to a number of clinically
approved products [161]. The clinical success of using polymers for controlled release, and the
ability to manufacture polymeric formulations on the nanoscale have driven the research of polymeric
depots away from the macro/micro scale to the nano scale [219]. A Number of PEGylated polymeric
nanoparticle formulations such as SP1049C, NK911, and Genexol-PM are in early phase clinical trials
for various types of cancers [220–224]. SP1049C is a pluronic polymeric micelle nanoparticle containg
entrapped doxorubicin, that is currently evaluated for patients with esophagus and esophageal
junction metastatic cancer in a phase II clinical trial [220]. The other two polymeric nanoparticles, K911
(doxorubicin-loaded PEG-poly(aspartic acid)) and Genexol-PM (paclitaxel-loaded PEG-PLA) are in
phase II clinical trials for various cancers [221,223]. These first generation, polymeric nanoparticles
have shown promising effect for various cancers with wider therapeutic windows and lower side effects.
However, these nanoparticles are associated with number of limitations related to targeting, therefore
targeted polymeric nanoparticles are now under preclinical and clinical investigation [161]. The first
targeted polymeric nanoparticles to reach the clinic is BIND-014, which is composed of a prostate
specific membrane antigen (PSMA) conjugated to a docetaxel-loaded PLGA nanoparticles [161,223].
There are only two other targeted polymeric nanoparticles currently in clinical trials, CALAA-01 (phase
I), and SEL-068 (phase I) [225–227]. The synthesis of targeted nanoparticles is complex and is difficult to
scale-up. The tuning of ligand density is very difficult because the target ligands attach to the surface of
the pre-prepared nanoparticles through post-coupling processes. In order to achieve a high efficiency
of the coupling of the ligands excessive amounts of reagents and purification techniques for removing
unbound ligands are needed. These issues have lead to batch-to-batch variability and difficulty in
reproducing the surface properties. Consequently, the clinical transition for targeted nanoparticles
will be difficult unless they are prepared using pre-functionalized polymeric materials and minimum
number of components [161,228]. However, this will require the development and registration of new
polymeric excipients.
19. Conclusions
Malignant gliomas remain to be among the most aggressive forms of tumours that may not
respond to most of the conventional treatments of chemotherapy and RT. This in fact is attributed
to the selective nature of the BBB that prevents most particles from entry inside the brain including
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therapeutics. Moreover, conventional management strategies for glioma only allow patients some extra
time to survive while struggling with deleterious side effects that develop mostly from the invasiveness
of the treatment approaches. Nanomedicine is a flexible and non-invasive therapeutic field that allows
the design of materials with nanometer size dimensions to act as drug carriers and delivery agents
crossing the BBB via targeting ligands and special coatings. Such designed nanoparticles will aim only
towards receptors of interest that are overexpressed on tumour tissues, for instance, while sparing
normal tissues. The promising pre-clinical data have paved the way for more nanoparticles to be
introduced in the clinic. The FDA has approved various routes of administration of nanoparticles with
a preference towards the intravenous route which offers advantages towards treatment of metastasized
tumours. Polymeric nanoparticles are gaining more attention for the treatment of malignant gliomas
owing to their biodegradable and biocompatible behaviour inside the human body and the unlimited
designs and characteristics they can be manipulated into. Polymeric nanoparticles can be extra
advantageous when PEGylated as discussed earlier in this review. However, further efforts are needed
to optimize their size, drug loading capacity and release of hydrophilic and hydrophobic drugs, taking
in consideration the different physicochemical properties of drugs and the physiological barriers that
may hamper their success.
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Abstract: Hypoxia is one of the most common phenotypes of malignant tumours. Hypoxia leads
to the increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of
genes controlling a raft of pro-tumour phenotypes. These include maintenance of the cancer stem
cell compartment, epithelial-mesenchymal transition (EMT), angiogenesis, immunosuppression,
and metabolic reprogramming. Hypoxia can also contribute to the tumour progression in a
HIF-independent manner via the activation of a complex signalling network pathway, including
JAK-STAT, RhoA/ROCK, NF-κB and PI3/AKT. Recent studies suggest that nanotherapeutics offer
a unique opportunity to target the hypoxic microenvironment, enhancing the therapeutic window
of conventional therapeutics. In this review, we summarise recent advances in understanding the
impact of hypoxia on tumour progression, while outlining possible nanotherapeutic approaches for
overcoming hypoxia-mediated resistance.
Keywords: angiogenesis; epithelial-to-mesenchymal transition; hypoxia; immunosuppression;
metabolism; nanoparticle; nanotherapeutics; tumour microenvironment
1. Introduction
The hostile microenvironment within a solid tumour is increasingly recognized as a major
impediment to effective cancer therapy [1]. Hypoxia, a hallmark of malignancy, is one of the most
typical and important features of the tumour microenvironment (TME), caused by the imbalance
between oxygen supply and consumption by cancer and stromal cells [2,3]. Failure of the local
environment to overcome this deficit due to the aberrant vascular architecture results in tumour
hypoxia. Hypoxia has been shown to contribute to malignant progression and treatment failure,
in particular, resistance to radiotherapy.
1.1. Defining Tumour Hypoxia
Since the development of the oxygen electrode, direct measurements of tissue oxygenation
has revealed considerable heterogeneity in oxygen concentration in normal and pathological tissue.
Physiological hypoxia is typically defined as ≤2% O2 (15 mmHg), while pathological hypoxia defined
as ≤1% O2 and radiobiological hypoxia as ≤0.4% [3]. Hypoxia is classified as perfusion-limited (acute)
hypoxia or diffusion-limited (chronic) hypoxia [4]. Perfusion-limited hypoxia is often caused by the
structural and functional abnormality of tumour microvasculature, characterized by an immature
endothelial cell lining and basement membrane, disorganized vascular network and wide intercellular
spaces. These structural abnormalities lead to the rapid oxygen fluctuations between hypoxia, anoxia
and reoxygenation [4]. The lifetime of perfusion related hypoxia ranges from less than a minute to
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several hours in experimental tumours [5]. In contrast, diffusion-limited hypoxia is mainly due to an
increase in diffusion distance, attributed to a rapidly expanding tumour. Tumour cells are often far from
nutritive blood vessels, where most of the accessible molecular oxygen is consumed by proliferating
cells before diffusion to deep tumour layers occurs. This results in the development of a hypoxic
tumour core [6].These two forms of tumour hypoxia often overlap spatio-temporally, influencing the
interaction between cancer, stromal and immune host cells. Additionally, tissue oxygenation may also
be perturbed by anaemia, which can often occur following chemotherapy, radiotherapy, blood loss and
low haemoglobin levels [7].
1.2. Implications of Tumour Hypoxia and Nanotherapeutic Opportunities
It has previously been suggested that up to 60% of solid tumours contain hypoxic or anoxic regions,
conferring major implications for chemo- and radiotherapy [8]. Biologically, hypoxia can trigger
proteomic alterations within neoplastic and stromal cells, further promoting malignant progression
and poor survival. Furthermore, hypoxia is the leading cause of treatment failure for radiotherapy
and photodynamic therapy since both approaches rely on the creation of reactive oxygen species.
For chemotherapy, solid tumour hypoxia is associated with elevated HIF gene expression, promoting
double-strand DNA repair and subsequently, chemo-resistance [9]. Hypoxia is also a potential
barrier to immunotherapy. Several studies suggest that the recruitment of immunosuppressive
cells within hypoxic regions promote immune suppression. Furthermore, hypoxia-driven adaptive
mechanisms diminish the immune cell response via expression of immune check-point molecules
such as PDL-1 (programmed death ligand-1) and HLA-G (human leukocyte antigen G), altering both
tumour metabolism and metabolite formation [10]. Nanotherapeutics offer a unique approach to
exploit the physiological and pathophysiological response to hypoxia within the TME. Interest in the
use of nanoparticles (NPs) for biological applications, including enhanced drug delivery, diagnostic
imaging and as radiosensitisers, has increased over the last 25 years [11,12].
1.3. Scope of the Review
In this review, we summarise recent advances relating to the biological consequence and therapeutic
efficacy of tumour hypoxia [13,14]. We outline the negative impact of tumour hypoxia on the
propagation of cancer stem cells, malignant progression, metastasis immunosuppression and metabolic
reprogramming. We also consider the use of nanoparticles to manipulate hypoxia-induced features of
the TME for therapeutic gain (Figure 1).
 
Figure 1. Nanotherapeutic approaches to exploit the hypoxic tumour microenvironment.
The response of the tumour microenvironment to reduced oxygenation, including cancer stem cell
enrichment, angiogenesis, invasion and metastasis, metabolic reprogramming and immunosuppression,
and the nanotherapeutic approaches to exploit or manipulate these features. Abbreviations:
AuNP, gold nanoparticle; CTL, cytotoxic T lymphocyte; EMT, epithelial to mesenchymal
transition; MDSCs, myeloid-derived suppressor cells; OXPHOS, oxidative phosphorylation;
TAM, tumour-associated macrophage.
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2. Biological Response and Therapeutic Opportunities of Tumour Hypoxia
The presence of hypoxia strongly correlates with an aggressive tumour phenotype, therapeutic
resistance and poor patient survival. Initially, we outline the mechanisms by which hypoxia promotes
an aggressive tumour phenotype, and discuss the treatment opportunities that may exist using
nanotherapeutic strategies (Table 1). The full biological response and therapeutic implications to
hypoxia are extensive and well beyond the limits of this review paper. As such, we will review
only recent discoveries related to the cellular response of hypoxia-driven malignant progression and
resistance, which have been summarised in Figure 2.
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Figure 2. Hypoxia regulates tumour progression via various mechanisms, including HIF independent
(blue arrow) and HIF-dependent manner (black arrow). Intratumoural hypoxia causes overexpression
of HIF-1α and HIF-2α, leading to transactivation of multiple target genes outlined above. These regulate
the cellular response to CSCs maintenance, EMT induction, angiogenesis, metabolic reprogramming,
and immunosuppression. Tumour progression is also influenced by numerous HIF-independent factors
including miRNA expression and cytokine release, activating various pro-tumour signalling pathways.
Abbreviations: IL-6, interleukin 6; SV, supervillain; PIP2, phosphatidylinositol (4,5) biphosphate; RORA,
RAR-related orphan receptor; MDSCs, myeloid-derived suppressor cells; TAMs, tumour-associated
macrophages; Treg, regulatory T cells; CTLs, cytotoxic T lymphocytes.
2.1. Enrichment and Propagation of Cancer Stem Cells
Cancer stem cells (CSCs) or tumour initiating cells are a small subpopulation of cells which
share progenitor-like characteristics including self-renewal, tumour initiation and multi-lineage
differentiation. Furthermore, tumour hypoxia has been directly correlated with metastatic potential
and treatment resistance. CSCs can induce cell cycle arrest, conferring resistance to both chemo- and
radiotherapy. Post-treatment, surviving CSCs are released from dormancy driving repopulation and
dissemination. Therefore, a deep understanding of the influence of hypoxia in CSCs biology is central
to the development of future therapeutic approaches.
The CSCs model is driven by many key regulatory factors including genetic diversity, epigenetics
and the TME. Recent evidence points to the influence of the microenvironment on cell plasticity and
differentiation. Tumour hypoxia is a key environmental stress associated with CSC self-renewal,
epithelial-to-mesenchymal transition (EMT) and treatment resistance. Hypoxia expands the CSCs
population through several molecular mechanisms. Hypoxia mediated epigenetics act as a possible
driving force for promoting cancer stemness. These epigenetic factors include DNA methylation,
histone modification, chromatin remodelling and microRNA expression. Kang et al. (2019) identified
hypoxia as a key driver of cancer stemness and EMT in multiple lung cancer models, driven by a
decrease in E-cadherin and a corresponding increase in the mesenchymal markers fibronectin, vimentin,
α-SMA, slug and ZEB1 [50]. Additionally, significant activation of the CSC marker CXCR4 was reported.
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The impact of CXCR4 was demonstrated following the induction of strong CXCR4 immunoreactivity
following the intratumoural injection of hypoxic cells. Furthermore, methylation-specific PCR and
sequencing data further confirmed a decrease in CXCR4 promoter methylation under hypoxia,
thus promoting CXCR4 expression and the acquisition of CSC-like properties. Prasad et al. (2017)
investigated the role of hypoxia in regulating stemness in an aggressive glioblastoma tumour model [51].
The authors reported hypoxia-mediated self-renewal of A172 cells through elevated neurosphere
formation. Furthermore, at the molecular level, OCT-4, NANOG, SOX-2 and Stat3 gene and protein
expression were highly upregulated following chronic hypoxia (Figure 2). Importantly, hypoxia was
shown to reduce 5-methyltosine (5-mC) expression by at least three-fold at all OCT-4 regulatory regions
(OA, OB, OC), and within the promoter region of NANOG. Furthermore, a concomitant enrichment
of 5-hydroxymethylcytosine (5-hmC) at OCT-4 regions (OA (2.5-fold), OB (4.6-fold)), together with
a significant reduction of H3K27me3 methylation confirmed hypoxia-meditated regulation of stem
associated genes. N6-methyladenosine (m6A) modification has recently been identified as an important
regulator of stem cell pluripotency. Zhang et al. (2016) showed that hypoxia induced HIF-1α and
HIF-2α dependent expression of AlkB homolog 5 (ALKBH5) [52], a m6A demethylase in breast cancer
models. This resulted in demethylation at m6A residues within the 3′-UTR of NANOG, upregulating
functional NANOG protein and contributing to breast CSC enrichment.
The influence of hypoxia on cell cycle progression in glioma CSCs has been demonstrated by
Li et al. (2013) [53]. Cells maintained in 1% O2 for 48 h significantly increased G0/G1 accumulation with
a corresponding reduction in G2/M cells, indicating elevated quiescence. This phenotype corresponded
with elevated OCT-4 and SOX-2 and reduced expression of GFAP, a marker of stem cell differentiation,
implying that hypoxia stemness is primarily attributed to dedifferentiation. Hypoxia has also been
shown to promote dedifferentiation of mature glioma cells into stem-like glioma stem cells (GSCs).
Hypoxia induced single differentiated CD133-/CD15-/NESTIN- glioma cells into viable neurospheres
through elevated expression of critical genes including SOX-2, OCT-4, KLF-4, NANOG, CD133, CD15,
NESTIN and ABCG2 [54]. Interestingly, hypoxia induced CSC enrichment also resulted in increased
tumourgenicity and mortality in vivo. At the molecular level, higher levels of HIF-1α were measured
in both neurosphere and tumour samples, with the importance of HIF-1α further illustrated through
interference experiments, potently suppressing neurosphere formation and stem cell marker expression
(CD133, CD15 and NESTIN).
Recent mechanistic evidence supported the CSC maintenance function of hypoxia stimulated
JAK-STAT signalling in breast cancer models [55]. Conditioned medium (CM) from hypoxic estrogen
receptor (ER-α) positive tumour cells enriched the fraction of CSCs compared to normal growth
conditions. Conversely, conditioned medium from ERα -negative tumour cells decreases the CSC
subpopulations. The authors reported that JAK-STAT signalling activity regulates the contrasting
secretome of ERα positive and ERα negative breast cancer cells, through differential cytokine (IL6,
IL12RB2) secretion dependent on estrogen receptor status, acting as a key regulator of JAK-STAT
phosphorylation (Figure 2).
Nanotherapeutic Approaches to Target Cancer Stem Cells
Targeting CSCs is of particular interest, given their purported therapeutic resistance and capacity
for tumour repopulation following treatment. ALDH, CD44, CD133 and other cell surface markers
outlined above have frequently been used as putative CSC markers. In addition, CSCs are dependent
on cell signalling pathways including Wnt and Notch, which may act as therapeutic drug targets for
intervention [56,57]. A number of therapeutic agents that have effects on eliminating or inhibiting
CSCs have been proposed and confirmed, including, doxorubicin, paclitaxel, salinomycin, curcumin
and all-trans retinoic acid. However, most of the agents have characteristics limiting their effective
application in vivo, including poor solubility, low specificity, poor stability, and short circulation
time. Nanotechnology drug delivery approaches hold significant potential for tackling these
limitations. A series of therapeutic agents have been loaded into CD133 or CD44 functionalized
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nanosystems, demonstrating an increased efficacy for eliminating CSC populations both in vitro
and in vivo. Doxorubicin, a widely used clinical agent, was loaded into chitosan decorated NPs,
with the nanoformulation exhibiting six-fold increased cytotoxicity over free doxorubicin. Importantly,
this approach was shown to eliminate CD44+ CSCs-like cells leading to a significant reduction in
tumour growth [20].
All-trans retinoic acid (ATRA), an active metabolite of vitamin A, has shown therapeutic efficacy
in modulating CSC subpopulations, evidenced by reductions in the CSC markers CD44 and ALDH in
gastric carcinoma models in vitro and in vivo and the attenuation of CSC-like properties in ALDH-high
expressing ovarian CSCs [58,59]. When ATRA was incorporated into lipid-polymer NPs conjugated with
CD133 aptamers, increased targeting and therapeutic efficacy against osteosarcoma CSCs was reported
over ATRA alone (tumour volume inhibitory rates of 81.1% and 44.3%, respectively) [18]. Salinomycin,
a polyether ionophore antibiotic, has also shown potential in killing CSCs. Poly (lactic-co-glycolic acid)
NPs conjugated with CD133 aptamers, specifically delivered salinomycin to CD133+ Saos-2 CSCs
significantly attenuating osteosarcoma tumour growth in comparison to salinomycin-only treatment
(7.1-fold increase in tumour growth over 60 days in comparison to 17.4-fold increase) as well as
reducing the frequency of CD133+ cells in vivo [15]. Similar observations have been shown in models
of ovarian cancer in vivo, and in models of osteosarcoma following dual targeting with CD133 and
EGFR aptamers [16,17]. Curcumin, a well-known dietary polyphenol derived from the rhizomes
of turmeric, has shown excellent therapeutic efficacy against CSCs through the suppression of both
CSC self-renewal pathways (Wnt/β-catenin, hedgehog (Hh), and Notch) and specific microRNA
involved in the acquisition of EMT [60]. Furthermore, curcumin loaded CD44+ targeting nanomicelles
resulted in the potent suppression of pro-tumour NF-κB signalling [19]. The inhibition of Notch
signalling using γ-secretase inhibitors has been shown to slow tumour growth using xenograft models
of medulloblastoma and by reducing CSC (CD133+) subpopulations [61]. However, inhibiting key CSC
signalling pathways may inadvertently affect normal stem cell function. Targeted inhibition of Notch
signalling in breast CSCs was achieved using a γ-secretase inhibitor loaded on a glucose-functionalised
mesoporous silica nanoparticle. These co-functionalised NPs successfully reduced the MDA-MB-231
CSC ALDH side-population in a chick embryo chorioallantoic membrane (CAM) model, reducing
tumour growth in vivo [26].
The combination of chemotherapy agents and salinomycin or ATRA has also received increased
attention due to an enhanced synergy achieved through eradicating both terminally differentiated
tumour cells and CSCs (Figure 1). For example, Gong et al. (2016) reported that a nanoliposome
delivery system co-delivering salinomycin and doxorubicin possessed the best tumour inhibitory
rate, significantly reducing the percentage of liver CSCs in vivo [21]. A similar study reported that
co-delivery of salinomycin and paclitaxel using hyaluronic acid decorated poly (lactic-co-glycolic acid)
NPs showed the highest cytotoxicity against CD44+ breast CSCs compared to salinomycin or paclitaxel
used as monotherapies [22]. Sun et al. (2015) also reported that co-delivery of ATRA and doxorubicin
in a nanoparticle formulation effectively delivered the agents to both non-CSCs and CSCs, forcing CSC
differentiation into a more treatment sensitive phenotype, with the effect of markedly suppressing
tumour growth [23].
Recently, ATP-binding cassette subfamily G member 2 (ABCG2), a member of the ABC transporter
family, has also been recognized as a promising target for CSCs. ABCG2 has been proposed as the main
driver contributing to a subpopulation of slow-cycling CSCs, endowed with enhanced tumourigenic
potential and multidrug resistance [62]. Targeting and suppressing ABCG2 function, therefore,
represents a sensible strategy to sensitise CSCs populations to chemotherapy. For example, Qi et al. (2015)
loaded NPs with siRNA targeting ABCG2 and a chemotherapeutic (cisplatin, 5-fluoroucail or paclitaxel)
for the treatment of CD133+ laryngeal carcinoma. The authors reported that the downregulation of
ABCG2 significantly enhanced chemotherapeutic drug-induced apoptosis, leading to superior control
of tumour growth [24]. Similarly, co-delivery of wedelolatone (Wdl) and paclitaxel incorporated within
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PLGA NPs downregulated the ABCG2 and SOX-2 expression, sensitising tumour cells to paclitaxel
treatment, and reducing the overall percentage of ALDH+ CSCs in vitro and in solid tumours [25].
2.2. Invasions and Metastasis
Malignant tumours frequently exhibit hypoxia and nutrient deprivation, closely correlated with
therapeutic treatment resistance and tumour relapse. Despite significant advances in the treatment
of metastatic disease, the underlying mechanisms of metastasis are less well developed. Growing
evidence indicates that the hypoxic microenvironment promotes tumour progression by triggering a
series of transcriptional responses that regulate migration, invasion, cell proliferation, angiogenesis
and cell metabolism, ultimately contributing to an aggressive tumour phenotype [63,64].
Metastasis is a complicated process comprised of a series of highly regulated steps where tumour
cells gain more invasive properties. It begins with a change in tumour plasticity, through a process called
epithelial-mesenchymal transition (EMT), where epithelial cells lose cell–cell adherence, endowing
tumour cells with an enhanced migratory and invasive potential [65]. A critical hallmark of EMT
is the repression of E-cadherin expression and the upregulation of associated mesenchymal genes.
This transformation results in the disruption of cell–cell adhesion and cell polarity. Hypoxia can induce
EMT and invasion via the regulation of EMT-associated transcriptional factors including TWIST, SNAIL,
ZEB1, ZEB2 (Figure 2) [66,67]. Pancreatic cancer cells display enhanced cell proliferation and EMT
under hypoxic conditions, mediated through an upregulation of HIF-1α and TWIST, corresponding
with a dramatic decrease in the expression of E-cadherin and p16Ink4A (p16). However, knockdown of
HIF-1α was shown to mask the effect of TWIST overexpression, hypoxia-induced EMT and proliferation
through HIF-1α /TWIST signalling, indicating the dominant nature of HIF-1α expression [68].
EMT induction is also controlled by other regulatory mechanisms, with recent studies reporting
the influence of specific miRNAs. MicroRNAs suppress protein expression through a combination of
mRNA destabilisation and translational repression. Recent reports have shown that hypoxia alters
miRNA expression including exosome derived miR-193a-3p, miR-210-3p and miR-5100 (released from
hypoxic bone marrow-derived mesenchymal stem cells), promoting epithelial cancer cell invasion
and lung metastasis through JAK-STAT overactivation (Figure 2) [69]. Similarly, hypoxia was shown
to upregulate miR-210-5P and miR-210-3p [70], upstream precursors N-cadherin, Twist, MMP-2 in
hepatoma cell models. Inhibition of miR-210-5P and miR-210-3p suppressed EMT induction and cell
progression, indicating that hypoxia-induced miR-210-5p and miR-210 3p are important regulators
of a hypoxia-induced metastatic phenotype. Hypoxia-regulated expression of miR-310a-3p has also
been shown to push macrophage differentiation towards an M2 phenotype in a HIF-1α or HIF-2α
dependent manner [71]. Importantly, invasion and migration potential appeared to be significantly
enhanced in macrophages exposed to miR-301a-3p loaded exosomes, providing a mechanism by which
hypoxia can stimulate immune cell-mediated tumour progression.
Exosome liberated miR-310a-30p is understood to polarize macrophages into an M2 phenotype
via the activation of PTEN/P13Kγ signalling, favouring the malignant properties of tumour cells,
due in part to the expression of the anti-inflammatory cytokine (IL-10) and arginase-1 (Arg1) [72].
Additionally, hypoxia can stimulate EMT through a number of other cell-signalling pathways which
include RhoA/ROCK-ERK/P38, PI3/Akt. Kaneka et al. (2016) showed that hypoxia treatment induced
cell invasion, migration and EMT using oral squamous cell carcinoma (OSCC) cell lines [73]. The authors
reported that overexpression of HIF-1α triggers PI3/Akt signalling and the subsequent phosphorylation
of GSK3-β (p-GSK3-β). Conversely, inhibition of PI3/Akt signalling led to reduced phosphorylation of
GSK3-β and Akt, suppressing EMT induction. These data suggest that hypoxia-induced pGSK3-β
is an important regulator in the invasion and metastasis of OSCC. Additionally, supervillin (SV),
a protein with two recognised isoforms (SV4 and SV5) was also shown to be upregulated in HCC
tumour models under hypoxic conditions, with elevated SV4 and SV5 levels associated with enhanced
cell migration and reorganization of the action cytoskeleton, thus promoting EMT [74]. RhoA/Rock
and MAPK/ERK/p38 signalling were identified as companion proteins involved in supervillin-driven
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HCC migration and invasion. Perhaps more importantly, ERK/p38 phosphorylation is downstream
of RhoA/ROCK activation. Therefore, it could be suggested that supervillain-induced EMT is
mainly mediated through the RhoA/ROCK and ERK/p38 pathways. Similar results were reported
by Huang et al. (2019) in hepatocellular carcinoma models, where the induction of EMT due to actin
cytoskeleton remodelling was controlled by the negative regulation of CAPZA1 (capping actin protein
of muscle Z-line alpha subunit 1; Figure 2) [75]. As such, the downregulation of CAPZA1 promoted
cell invasion, migration and the induction of EMT. CAPZA1 regulation in actin remodelling was
primarily mediated via the interaction between CAPZA1 and phosphatidylinositol (4,5) bisphosphate
(PIP2), in which the combination of PIP2 and CAPZA1 would lead to CAPZA1 depletion and a
subsequent increase in F-actin levels. The authors reported that levels of PIP2 under hypoxia could
be modulated by HIF-1α/RhoA/Rock1 signalling, in which hypoxia treatment led to the increased
expression of HIF-1α, RhoA and Rock1, hence resulting in elevated PIP2 levels and subsequent actin
cytoskeleton remodelling.
Targeting EMT and Metastatic Progression with Nanoparticle Formulations
As outlined above, the ability of cancer cells to invade local tissue and spread to distant sites
is a critical step in disease progression, often accompanied by a poorer clinical prognosis. EMT is
the proposed mechanism by which cells acquire the properties necessary for invasion and migration.
Intrinsic properties of NPs have the potential to inhibit cancer progression through the regulation
of EMT. For example, Arvizao et al. (2013) reported that gold NP (AuNP) treatment can delay
tumour metastases through the inhibition of MAPK signalling and EMT reversal. They found that
unmodified AuNPs not only downregulated the phosphorylation of MAPK but also reversed EMT by
downregulating Snail, N-Cadherin, Vimentin [27]. Polyethylenimine coated superparamagnetic iron
NPs (SPIONs) are proven to inhibit tumour cell migration and invasion through the inhibition of Src
kinase activity and downregulation of MT1-MMP and MMP2 matrix-metalloproteinases. In addition,
SPIONs treatment can downregulate miR-21, upregulating cell migration inhibitors PTEN, PDCD4
and sproutyl-1 [28].
Targeting metastatic signalling pathways involving EMT induction represents another approach
for inhibiting metastasis [76]. PEGylated AuNPs combined with cold plasma, were proven to
inhibit glioblastoma cell proliferation in vitro by blocking PI3K/Akt signalling (Figure 1). In addition,
co-treatment of glioma xenografts suppressed tumour growth and mesenchymal markers expression
including N-Cad, Zeb-1 and Slug, while increasing the epithelial cell marker E-cadherin; suggesting a
reversal of EMT [31]. The aberrant activation of JAK-STAT signalling confers malignant properties to
cancer cells, including EMT induction and malignant progression [77]. Inhibition of JAK-STAT signalling
has been shown to reduce cancer proliferation and metastasis. Guo et al. (2019) loaded miR-125-5p
into a folate acid coated Fa-polyethyleneglycol (PEG)–g-polyetherimide (PEI) superparamagnetic iron
oxide nanocarrier (SPIONs), evaluating its therapeutic effect against hepatocellular carcinoma (HCC).
The authors reported that the miR-125-5p loaded nanomedicine effectively inhibited the EMT potential
of HCC cells via the inhibition of STAT and the inactivation of Wnt/β-Catenin, inhibiting tumour
growth in HCC-bearing mice [29]. Similar work by Huang et al. (2019) demonstrated that silica-coated
zinc arsenite NPs (ZnAs@SiO2 NPs) significantly inhibited the proliferation, migration and invasion
of HCC cell lines, attenuating in vivo tumour growth by 2.2-fold in comparison to NP-only control,
mediated through the upregulation of SH2-containing protein tyrosine phosphatase 1 (SHP-1) and the
corresponding suppression of JAK2/STAT3 signalling [30].
Hypoxia exposure leads to an increase in TWIST expression. Hyaluronic-acid conjugated
mesoporous silica nanoparticles (MSN-HAs) loaded with TWIST siRNA successfully suppressed
TWIST expression in vitro, subsequently reducing the tumour burden in a model of epithelial ovarian
cancer in vivo [33]. Furthermore, amphiphilic polymer-based nanoparticles loaded with siRNAs
against SNAIL and TWIST, and used in combination with the chemotherapeutic paclitaxel, inhibited
tumour growth and metastasis of the 4T1 breast cancer model in vivo, while siRNA alone exhibited
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only modest benefits (Figure 1) [32]. Therefore, co-delivery of EMT targeted molecules loaded on
nanoparticles may provide enhanced metastatic inhibition.
2.3. Angiogenesis
Abnormal angiogenesis is a common feature of tumour malignant progression, where rapid
growing tumours outstrip oxygen supply, yielding a hypoxic tumour mass. Consequently, hypoxia
induces the formation of new blood vessels in an attempt to ameliorate oxygen depletion stress.
Hypoxia and HIF-1 expression trigger an imbalance between pro- and anti-angiogenic factors and
cytokines modulating gene expression involved in the angiogenetic response [78,79]. This typically
includes the activation of angiogenic genes and receptors such as VEGF (vascular endothelial growth
factor), PLGF (placental growth factor), PDGFB (platelet-derived factor) and integrins among others
(Figure 2) [80]. Integrins, particularly alpha v beta 3 (αvβ3), have been shown to be upregulated within
the TME, expressed on both tumour cells and the vasculature [81]. Hypoxia (1%O2) has been shown to
upregulate αv expression in human microvascular endothelial (HMEC-1) cells in vitro. Furthermore,
knockdown of HIF-1α was shown to inhibit hypoxia stimulated β3-integrin expression, suggesting
induction of β3-integrin is HIF-dependent [82]. The effect of HIF-1α on the angiogenic potential
of small cell lung cancer (SCLC) significantly upregulated the expression of pro-angiogenic genes
including VEGF-A, TNFA1P6, PDGFC, FN1, MMP 28 and MMP14 [83]. Myocyte enhancer factor 2D
(MEF2D) has also been proven to play a central role in tumour angiogenesis [84]. MEF2D expression
positively correlated with colorectal tumour angiogenesis, through the induction of pro-angiogenic
factors including PDGF-BB, PDGF-C, PLGF, milk fat globule factor (MFG)-E8, and tumour necrosis
factor superfamily member (TNFRSF). Furthermore, it was observed that MEF2D is a downstream
effector of HIF-1α transcriptional activity.
As with EMT, exosomal miRNA has also been proven to promote angiogenesis.
Matsuura et al. (2019) compared the angiogenic activity of HUVEC cells co-cultured with exosomes
derived from hepatocarcinoma cells cultured under variable oxygen tensions [85]. Harvested exosomes
collected under hypoxic stress displayed enhanced tubule formation in HUVECs cells, mediated through
miR-155 upregulation. Conversely, miR-155 knockdown attenuated tubule formation, implying that
exosomal miR-155 regulates angiogenic potential. Similarly, Hsu et al. (2017) demonstrated that
exosomal miR-23a derived from lung cancer was significantly upregulated by hypoxia [86]. Exosomal
miR-23a suppressed prolyl-hydroxylase 1 and 2 (PHD 1 and 2) and inhibited tight junction protein
ZO-1, with the effect of increased vascular permeability and tumour cell transendothelial migration,
effects reversed in knockout experiments.
Overcoming Hypoxia-Driven Angiogenesis Using Nanoparticles
Angiogenesis modulating strategies have largely focused on either inhibiting, disrupting or
normalising the aberrant tumour vasculature. In this context, nanoparticles are at an advantage as they
may exploit the leaky and aberrant vascular architecture of the TME, accumulating within tumour
tissue via the enhanced permeability and retention (EPR) effect [87]. Interestingly, gold NPs (AuNPs)
have been shown to have intrinsic anti-angiogenic effects in vivo, likely through inhibition of the
VEGF/VEGFR2 signalling pathway (Figure 1) [34,88,89]. Evidence from an in vivo melanoma model
has shown that AuNPs could normalise tumour vasculature, alleviate tumour hypoxia and reduce
metastatic spread to the lungs (20% of AuNP-treated tumour-bearing animals developed metastasis in
comparison to 66.7% of control-treated) [35]. However, the anti-angiogenic potential of AuNPs appears
to be transient: In a xenograft model of colorectal cancer (CRC), AuNPs treatment reduced vessel
density and increased pericyte coverage concomitant with vascular normalization and improvements in
tumour hypoxia until day 9 of treatment, after which these improvements were lost [36]. This suggests
that AuNPs may provide a therapeutic window of vascular normalisation, in which chemotherapy
and radiotherapy could be more effectively utilised.
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Of note, only 0.7% of systemically administered nanoparticles reach their intended site of the solid
tumour [90]. Furthermore, the “passive targeting” approaches afforded by the EPR effect does not
appear to be meaningfully replicated clinically, likely attributed to the considerable heterogeneity of
the TME and metabolic differences of pre-clinical tumour models [91]. Therefore, tumour-targeted
approaches are required to increase specificity. Integrins have become attractive anti-angiogenic
targets given their role in tumour vascularisation [92]. In models of normal angiogenesis, liposome
NPs functionalised with the αvβ3-integrin targeting peptide Arg-Gly-Asp (RGD) encapsulating
doxorubicin exhibited potent antiangiogenic properties in vivo, inhibiting angiogenesis by up to 70%
compared to controls [93]. In pre-clinical models, the co-functionalisation of AuNPs with RGD induced
specific vascular damage in pancreatic tumour xenografts when coupled with image-guided radiation
therapy [37]. Furthermore, RGD-functionalised AuNPs have also been shown to reduce MDA-MB-231
breast cancer cell invasiveness following radiotherapy in vitro [38]. Functionalisation of nanoparticles
with other integrin targeting peptides such as the αvβ1-targeted ATN-161, which has been shown
to reduce tumour microvessels by almost 50% in pre-clinical murine models of colon cancer when
combined with 5-fluoroucail infusion, may improve vascular targeting and TME anti-angiogenic
strategies [94].
2.4. Immunosuppression
A critical event in malignant tumour progression is the ability for tumour cells to acquire
immunosuppression. Tumour hypoxia has been reported to promote an immunosuppressive
microenvironment by recruiting regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs)
and tumour associated macrophages (TAMs) [95,96]. Tregs are an important stromal cell population that
support tumour progression by immune evasion. Tumour hypoxia has been implicated in promoting
the generation and the recruitment of Tregs via the production of TGF-β and chemokine ligand 28
(CCL28) (Figure 2). Treg recruitment and CCL28 expression were shown to be significantly upregulated
under hypoxic conditions. In a xenograft model of liver cancer, CCL28 upregulation promoted tumour
growth and Treg recruitment in vivo in a HIF-1α dependent manner. While knocking down of CCL28
could reverse hypoxia-induced recruitment, overexpression or knockdown of CCL28 did not pose any
effect on colony formation or cell proliferation, indicating that CCL-28 most likely exerts its oncogenic
role in a non-cell autonomous manner by recruiting Tregs [97].
Severe hypoxia has been observed in the colon of mice suffering from colitis-associated colon
cancer (CAC), accompanied by reduced T cell CD4+ effector cell differentiation and the enhanced
activity of suppressive Tregs. Furthermore, downregulation of pro-inflammatory cytokines (IL-2, IL-17,
IFN-γ, and IL-9) and upregulation of the anti-inflammatory cytokine IL-10 was detected in CD4+ T
cells stimulated under hypoxic conditions. Furthermore, the proportion of IFN-γ producing Th1 cells
were significantly decreased under hypoxia. It is interesting to note that there is only a slight expression
of PD-1 by CD4+Foxp-T cells in the colon of mice suffering from CAC compared to healthy control
mice after stimulation under hypoxia. In contrast, significant upregulation of PD-1 in CD4+Foxp+
Tregs occurred following CAC hypoxic exposure. This indicates that hypoxia enhanced Tregs mediate
immunosuppression rather than T-cell exhaustion dominating [98].
MDSCs represent another type of immune suppressor in the TME which has been proven to
confer a negative impact on T-cell and NK cells. Hypoxia-promoted secretion of glioma-derived
exosomes (GDEs) can be endocytosed by murine MDSCs. These hypoxia stimulated GDEs resulted in
an enhanced ability to induce MDSCs activation and expansion compared to normoxic stimulated cells.
This effect was mediated by targeting RAR-related orphan receptor alpha (RORA) and phosphatase
and tensin homolog (PTEN) via miR-10a and miR-21 in GDEs (Figure 2) [99]. In addition, hypoxia
has been reported to stimulate the migration of CD11b+Gr-1+ myeloid cells via the secretion of
macrophage migration inhibitory factor (MIF) and interleukin-6 (IL-6) by head and neck squamous
carcinoma (HNSCC). HIF-1α/2α dependent MIF and IL-6 regulate the chemotaxis, differentiation and
pro-angiogenic function of CD11b+Gr-1+ myeloid cells. This is mediated through the binding of
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CD74/CXCR4, CD74/CXCR2 and subsequent activation of MAPK and PI3K/AKT signalling pathways.
Knockdown of HIF-1α/2α fails to inhibit the migration of CD11b+Gr-1+ myeloid cells due to the
compensatory effect of NF-κB under hypoxic condition, whereas dual blockade of HIF-1α/2α and
NF-κB successfully inhibited this effect [100].
Hypoxia also serves as an important driver of MDSCs recruitment. In a model of hepatocellular
carcinoma (HCC), HIF-1α upregulated the expression of chemokine (C-C motif) ligand 26 (CCL-26)
in cancer cells, recruiting chemokine (C-X3-C motif) receptor 1 (CX3CR1) expressing-MDSCs to
primary tumours and promoting HCC tumour growth. Furthermore, inhibition of CCL-26 by the HIF
inhibitor digoxin or through the blockade of CX3CR1 using a neutralizing antibody suppressed MDSC
recruitment and tumour growth [101]. Hypoxia can also directly promote the accumulation of MDSCs.
Upregulation of ectonucleoside triphosphate diphohydrolase (ENTPD2) in HCC cell lines by hypoxia
and HIF-1α, contributed to HCC tumour growth and MDSC accumulation. This effect was mediated
by the prevention of MDSCs differentiation via the conversion of extracellular ATP to 5′-AMP by
ENTPD2. As such, knockdown or inhibition of ENTP2 suppressed tumour growth, enhancing the
efficacy of immune checkpoint inhibitors [102].
TAMs are one of the most abundant forms of immune cell populations within the TME, emerging
as an important regulator in fostering malignancy, cancer progression and therapeutic resistance [103].
Tumour hypoxia has been proven to enhance TAM recruitment and infiltration via the hypoxia-induced
secretion of chemokines (CCL-4, CCL-8,) and metabolites (lipoxygenase metabolites; Figure 2). Hypoxia
and secreted macrophage soluble factors promote glioblastoma (GBM) invasiveness, though enhanced
matrix metalloproteinase (MMP)-9 activity, promoting CCL4-CCR5 signalling between TAMs and U87
GBM tumour cells [104].
Macrophages can also undergo phenotypic changes and different forms of activation depending
on the signal. Typically, classically activated macrophages are stimulated by T helper 1 (Th1)
cytokines (TNF-α, IFN-γ) as well as microbial cell wall components. Indeed, the classical M1
macrophage phenotype is known to possess potential antibacterial and anti-inflammatory activity
through the secretion of reactive oxygen species and nitrogen intermediates, thereby counteracting
cancer progression. An alternative M2 macrophage immunosuppressive phenotype is stimulated by
Th2 cytokines (IL-4, IL-13) and other cytokines, which are responsible for blocking Th1 response and
promote angiogenesis and cell proliferating. Tumour hypoxia has been indicated to play a pivotal role
in the phenotypical control of TAMs [105].
Hypoxia-induced extracellular vesicle (EV) miR-103a from lung cancer cells increased M2-type
polarization, mediated by suppressed PTEN activity and the subsequent activation of the PI3/AKT and
STAT pathway. Inhibition of miR-103a led to a decrease in hypoxia-induced M2-type polarization,
while macrophages treated with EV miR-103a further enhanced cancer progression and tumour
angiogenesis [106]. In addition, hypoxic-conditioned medium can push macrophages towards an M2
phenotype, mediated through the upregulation of neuropilin-1 (Nrp-1). Inhibition of Nrp-1 expression
with siRNA can reduce the recruitment of macrophages and partially reversed the effect of hypoxia on
the induction of the M2 phenotype [107].
Tumour derived exosomes enriched in immunosuppressive proteins including the
chemokines/chemoattractant (CSF-1), monocyte chemoattractant protein-1/C-C chemokine 2
(MCP-1/CCL-2), and TGF-β, are also enhanced during hypoxia, leading to the macrophage recruitment
and M2-like polarization both in vitro and in vivo [108]. Furthermore, hypoxia-induced exosomes can
enhance oxidative phosphorylation in bone marrow. This occurs via the transfer of let-7a miRNA and
subsequent suppression of insulin-Akt-mTOR pathway, resulting in the metabolic reprogramming of
infiltrating monocytic macrophages. Hypoxia also inhibits T-cell anti-tumour functions through the
accumulation of extracellular adenosine, induced through the increased expression of ectonucleotidase
CD73 and CD39, both of which are products of HIF target genes [109,110]. Accumulated adenosine
in the TME acts as a negative regulator of the anti-tumour T cell response, in which the binding of
adenosine to A2AR triggers T-cell apoptosis, contributing to tumour immune evasion [111].
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Upregulation of negative immune checkpoint molecule of programmed death ligand (PD-L1) in
tumour cells, macrophages and dendritic cells under hypoxia, can initiate the interactions between
PD-L1 and cell surface checkpoint receptor programmed cell death-1 (PD-1) expressed on effector T cells,
resulting in the increased apoptosis of cytotoxic T lymphocytes (CTLs) and subsequent downregulation
of T-cell antitumour reactivity. Increased PD-L1 and HIF target genes (CAIX and GLUT1) expression
have been observed in a renal cell carcinoma (RCC) model possessing a VHL mutation. Furthermore,
there is almost no PD-L1 expression in the presence of pVHL or absence of HIF-2α, indicating that PD-L1
expression is specifically regulated by the pVHL/HIF-2α axis in RCC [112]. Hypoxia exposure of DU145
and MDA-MB-231 cells led to the upregulation of PD-L1 expression in a HIF-1α dependent manner,
where HIF-1α suppression led to a reduction in PD-L1 mRNA and cell surface protein in human
prostate and murine melanoma cells. Furthermore, hypoxia induced resistance to CTL-mediated lysis
in B16-OVA cells, which was abolished following a knockdown either HIF-1α or PD-L1 [113].
Reprogramming the Immunosuppressive TME with Nanotherapeutics
Immunotherapy has revolutionised cancer treatment. Immune checkpoint inhibitors, including
those to PD-1, PD-L1 and CTL antigen 4 (CTLA-4), have now been approved for a number of
cancers [114]. However, tumour immune evasion represents a major hurdle for the success of these
therapeutics, which is potentiated during hypoxia as detailed above. Targeted approaches which
temporally or spatially control the hypoxia-induced immune responses within the TME are essential,
given that off-target and adverse effects may occur following manipulation of the immune system [115].
The use of nanotherapeutics as drug delivery approaches are now being considered to specifically
modulate the immunosuppressive microenvironment of the tumour while sparing systemic immune
modulation to induce an anti-tumour immune response [116].
Given their high plasticity, reprogramming or repolarisation of TAMs from an immunosuppressive
M2-like phenotype to an anti-tumourigenic M1-like phenotype is an attractive approach. Furthermore,
as these cells readily internalise particles, nanoparticles may be used to deliver agents directly to
these cells. β-cyclodextrin nanoparticles loaded with the toll-like receptor (TLR) 7 and 8 agonist R848
were selectively delivered to TAMs in vivo, altering the TME phenotype to that of an M1 (Figure 1).
Furthermore, when combined with the immune checkpoint inhibitor anti-PD-1, NPs significantly
improved immunotherapy response rates, with complete tumour regression observed in almost 30%
of CRC-bearing mice [39]. In another study, TAM reprogramming from an M2 to an M1 phenotype
was also performed using baicalin-loaded PLGA nanoparticles containing a TLR 9 agonist and an
antigenic peptide (HgP) to activate immune cells and promote anti-tumour immunity. NPs were
further entrapped in a galactose-modified erythrocyte coating to increase biocompatibility and TAM
targeting, the macrophage galactose-type lectin (MGL; CD301) receptor is expressed on myeloid
antigen-presenting cells including macrophages. These biomimetic NPs also suppressed melanoma
growth in vivo and increased the infiltration of CD8+ T cells into the TME [40].
Targeting the MDSC compartment may be another approach for improving immune tolerance
within the TME. As mentioned above, PI3K signalling is crucial in the functioning of myeloid
suppressor cells in response to chemokines, particularly the PI3K-γ isoform. PLGA NPs have been
developed to incorporate the PI3K-γ inhibitor IPI-549, and co-functionalised to target the TME with
aminoethyl anisamide (AEAA), a ligand for sigma-1 receptor which is overexpressed in a number of
tumour types including pancreatic adenocarcinoma. IPI-549 loaded NPs significantly reduced both
MDSC and tumour associated B cell proportions in KPC pancreatic tumour-bearing mice while also
inhibiting tumour growth in comparison to free-IPI-549 [41]. An alternative approach, to repolarise
MDSCs away from an immunosuppressive phenotype, has also been demonstrated in a glioma model
in vivo. When combined with radiotherapy, magnetic zinc-doped iron oxide nanoparticles modified
with polyethylenimine had the potential to reprogram MDSCs in the TME following intratumoural
injection [42].
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Lyp-1, a Nrp-1-binding peptide, homes to lymphatics, TAMs and tumour cells, particularly
those within hypoxic regions of the tumour [117]. Lyp-1 conjugation has been shown to increase
cellular uptake of PEG-PLGA (Poly (lactic-co-glycolic acid)) nanoparticles in lymphatic metastatic
tumours in vivo [118]. Of particular interest, Lyp-1 may be used to target Nrp-1 expressing Tregs.
Nanoparticles modified with the more potent truncated tLyp-1 peptide reduced immunosuppressive
Tregs in the TME of murine B16/BL6 melanoma tumours in vivo, while activating intratumoural
CD8+ T cells when combined with an anti-CTLA-4 immunotherapeutic (Figure 1). This approach
also enhanced tumour inhibition and survival [43]. Limited infiltration and activation of CTLs,
through Treg-mediated suppression, is another characteristic of the immunosuppressive TME. Recently,
TME-activated nanoparticles conjugated with antibodies against PD-L1 have been co-loaded with
the photosensitiser indocyanine green (ICG). Photodynamic therapy (PDT) combining ICG treatment
with near-infrared (NIR) irradiation induced the generation of ROS, promoting intratumoral CTL
infiltration. Furthermore, this nanoparticle and NIR combination therapy suppressed tumour growth
and lung metastasis in the 4T1 murine mammary cancer model [44]. Interestingly, αvβ3-integrin
(discussed in Section 2.3) has been shown to be a regulator of PD-L1, with αvβ3-integrin depleted
tumour cells exhibiting reduced PD-L1 expression and increased CD8+ T cell infiltration in vivo.
Furthermore, αvβ3-integrin blockade could prime tumours to anti-PD-1 therapy [119]. Therefore,
effective functionalisation of nanoparticles to target and subsequently manipulate immune signalling
or cells of the TME including Tregs and TAMs, may overcome the hypoxia-driven immunosuppression
and also allow greater sensitising to immunotherapeutic strategies.
2.5. Metabolic Reprogramming
Molecular oxygen is a critical component of mitochondrial ATP production. However, tumour
cells often forgo oxidative phosphorylation (OXPHOS) in the mitochondria in favour of increased
glycolysis, even in the presence of oxygen. This aerobic glycolysis phenomenon in tumour cells is
often known as the “Warburg effect”, following observations of Otto Warburg in the early twentieth
century [120,121]. This metabolic transformation of cells can be enhanced by tumour hypoxia. HIF-1α
has been reported to induce multiple changes in gene expression that mediate the switch from OXPHOS
to glycolytic metabolism. These include the upregulation of glucose transporter-1 (Glu-1) and key
glycolytic enzymes, such as lactate dehydrogenase A (LDHA), phosphoglycerate kinase 1 (PGK-1) and
the hexokinase family of proteins (HK-1 and HK-II), resulting in enhanced glycolytic flux in order to
meet cellular demands (extensively reviewed in [66]). Interestingly, bone marrow adipocytes have been
shown to promote the Warburg effect in metastatic prostate cancer cells [122], which could be reversed
following knockdown of HIF-1α. Furthermore, inhibition of HIF-1α hydroxylation and degradation
via EV transmission of HIF-1α stabilising long noncoding RNA (HISLA) from TAMs has also been
shown to enhance aerobic glycolysis and apoptotic resistance of breast cancer cells [123].
In addition to increasing the glycolytic activity, hypoxia can also suppress the production
of mitochondrial ROS by uncoupling glycolysis and OXPHOS via the upregulation of pyruvate
dehydrogenase kinase-1 (PDK-1). Hypoxia-induced PDK-1 expression can block the conversion
of pyruvate to acetyl-CoA, hereby preventing ATP production via the TCA cycle, attenuating ROS
production, which in turn protects cancer cells from hypoxia-induced apoptosis [124]. Hypoxia-induced
expression of PDK-1 has also been shown in pancreatic cells to reduce pyruvate dehydrogenase (PDH)
activity through phosphorylation of the E1α subunit at serine 232 [125]. More importantly, a clinical
cohort of head and neck squamous cell carcinoma biopsies has shown that patients with phosphorylated
E1α or expression of PDK-1 tend to experience a poorer clinical outcome.
Hypoxia attenuation of metabolism may also occur through modulating the function of the
electron transport chain via the downregulation of cytochrome-c oxidase (COX, complex IV). HIF-1α
have been shown to activate the transcription of genes encoding COX4-2 and the mitochondrial
protease LON, leading to the degradation of the COX4-1 subunit, aiding in better adaption to hypoxia
with reduced ROS production [126]. Hypoxia has also been shown to modulate monocaroboxylate
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transport expression (MCT), a group of transmembrane proteins responsible for the regulation of
lactate metabolism. Hypoxia-induced MCT-1 plasma membrane expression, both in vitro and in vivo,
can promote the glycolytic phenotype of glioblastomas. In addition, inhibition of MCT-1 significantly
reduced lactate production, cell proliferation and invasion [127]. Furthermore, HIF-1α knockdown in
the SW48 CRC cell line has also been shown to reduce MCT-4 expression in vitro [128], indicating that
MCTs could be potentially acted on as therapeutic targets.
Nanotherapeutics to Target or Overcome Metabolic Reprogramming
The metabolic transformation of tumour cells to favour glycolysis over OXPHOS represents a
promising therapeutic target that may be exploited by nanoparticles. Among the hexokinase family of
proteins, HK-2, which catalyses the phosphorylation of glucose, is frequently overexpressed in tumour
cells [129]. As a result, inhibitors to HK-2, including 3-bromopyruvate (3-BP), have been utilised
to inhibit glycolysis and subsequently induce cell growth arrest [130]. However, the potential for
off-target effects means that clinical applications have been limited. AuNPs targeted to the mitochondria
and functionalised with 3-BP were able to suppress tumour cell glycolysis, in addition to reducing
mitochondrial OXPHOS in PC3 and DU145 prostate cancer cells in vitro (Figure 1). Furthermore,
the anti-cancer potential of these AuNPs was potentiated in tumour cells when combined with laser
irradiation in comparison to normal hMSC cells, which displayed no significant toxicity following
treatment [45]. MCT-4 is upregulated due to the high rate of glycolysis, which is responsible for
lactate/H+ across the cell membrane and the induction of an acidic tumour microenvironment [131].
Targeting MCT-4 represents another promising approach for modulating glycolysis. For example,
Liu et al. (2018) loaded the amorphous iron oxide NPs with siRNA targeting MCT-4 for the treatment of
prostate cancer [132]; the author found that significant suppression of MCT-4 expression and enhanced
Fenton-like reaction-induced oxidative damages were seen both in vitro and in vivo, leading to a
significant inhibition in tumour growth.
An alternative approach to overcome hypoxia-driven metabolic reprogramming within the TME
is to alleviate tumour hypoxia by reducing the oxygen consumption (OC) within cells. To this end, a
limited number of therapeutics have been identified with the potential to reduce the OC in tumour cells
including the anti-malarial atovaquone and the anti-diabetic metformin. Atovaquone has been shown
to reduce the OC by more than 80% in a number of tumour cells in vitro, and could abolish hypoxia in
xenograft models of head and neck cancer and colon cancer after seven days of treatment, by inhibiting
mitochondrial complex III. This was also associated with an improved radiation tumour growth response
in vivo (growth delay of 13.2 days between control and atovaquone irradiation groups) [133]. NPs
formulations containing atovaquone have previously been developed as long-acting chemoprophylaxis
for malaria in pre-clinical models [134], and to improve the bioavailability of the drug [135]. More
recently, co-functionalised NPs have been developed encapsulating atovaquone with either the
photosensitiser veterporfin or ICG to improve PDT responses in 4T1 mammary tumour-bearing and
HeLa cervical adenocarcinoma-bearing animals in vivo, by increasing intratumoural oxygenation
resulting in greater anti-tumour effects [46,47].
Conversely, the anti-diabetic metformin has been shown to reduce OC by inhibiting complex I
in the mitochondrial electron transport chain, leading to improvements in tumour oxygenation and
radiation responses in models of colon cancer in vivo [136]. PEG-PCL (poly(ε-caprolactone)) liposome
NPs containing metformin and a photosensitizer (IR780) have also been shown to decrease endogenous
OC in gastric cancer cells in vitro and increase ROS generation. In vivo, these co-functionalised NPs
could overcome hypoxia and improve PDT and photothermal therapy (PPT) to attenuate tumour
growth [48]. Tungsten oxide NPs including W18O49 have been used as effective PDT and PPT agents
due to their ability to generate ROS and produce heat when combined with NIR laser irradiation [137].
However, this effect may be limited by hypoxia, as such the development of platelet membrane NPs
co-loaded with metformin and W18O49 have been shown to improve responses to PDT and PPT in vitro
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by reducing the OC in tumour cells, and significantly inhibiting tumour growth and increasing TUNEL
staining (a measure of tumour apoptosis) in Raji-lymphoma xenografts [49].
3. Conclusions and Future Perspectives
Tumour hypoxia is a critical feature of the TME, contributing to disease progression and resistance
to chemo and radiotherapy. The response to tumour hypoxia is mainly driven by oxygen-dependent
HIFs that enable tumour progression. However, a complete understanding of the mechanisms driving
the response to hypoxia within the TME remains elusive. Hypoxia has effects not only on tumour
cells and on the maintenance of CSCs, but also on those cells of the surrounding stroma, driving
angiogenesis, malignant progression, immunosuppression and aiding in metabolic reprogramming
(Figure 2). Despite the fact that nanotherapeutics hold real potential for targeting these physiological
and pathological responses to hypoxia in the TME (summarised in Table 1), most of these hypoxic
based nanotherapeutics remain at a preliminary stage of development.
Significant barriers to the translation of NPs include sufficient tumour penetration, stability
and potential systemic toxicity. However, meaningful achievements have been made to improve
nanomedicine delivery and retention in solid tumours through smart nanoparticle design and TME
modification. Development of self-recognition biomimetic nanodelivery systems have shown great
potential in increasing the circulation and biocompatibility of nanoparticles within the host organism;
this includes coating NPs with an erythrocyte or cancer cell membrane. Alternatively, enhanced tumour
penetration could be achieved through the use of circulating monocytes or macrophages [138]. Tumour
pre-treatments with radiation therapy or mild hyperthermia represent another promising approach for
improving nanoparticle deposition and intratumoural distribution [139]. Furthermore, given that the
EPR effect has been shown to be not recapitulated clinically, approaches that improve the distribution
of NPs into hypoxic regions of the TME are required. Vascular normalisation or ECM modification is
one approach that has been shown to increase the intratumoural accumulation and distribution of
nanomedicine in preclinical models, which may also improve tissue oxygenation alleviating hypoxia
within the TME [140–142]. However, alternative approaches to improve tissue penetration may be
afforded by direct intratumoural administration of NPs.
Future research efforts and clinical translation of nanotherapeutics will require a detailed
understanding of the molecular nature of the hypoxic TME to optimise treatment combinations.
This approach will undoubtedly facilitate the development of more promising nanotherapeutic
platforms for the future treatment of hypoxic tumours that are not only targeted towards tumour cells,
but have dual-targeting effects on cells of the TME in addition to augmenting intratumoural oxygenation.
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Abstract: Fast diagnosis and more efficient therapies for cancer surely represent one of the huge
tasks for the worldwide researchers’ and clinicians’ community. In the last two decades, our
understanding of the biology and molecular pathology of cancer mechanisms, coupled with the
continuous development of the material science and technological compounds, have successfully
improved nanomedicine applications in oncology. This review argues on nanomedicine application
of engineered extracellular vesicles (EVs) in oncology. All the most innovative processes of EVs
engineering are discussed together with the related degree of applicability for each one of them in
cancer nanomedicines.
Keywords: extracellular vesicles; exosomes; chemico-physical functionalization; loading; cancer;
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1. Introduction
The latest literature reports underline that extracellular vesicles (EVs), released by prokaryotic
and eukaryotes cells into the extracellular surroundings, are the main drivers of the intracellular
communication, not only in physiological but also under pathological conditions [1–9].
The International Society for Extracellular Vesicles (ISEV) defines EVs generally as lipid
bilayer-delimited particles released from cells and unable to replicate [10]. Agreement has not yet been
reached on the specific markers for defining EVs subtypes, such as exosomes and ectosomes, originated
from the endosome and the plasma membrane, respectively. Researchers are advised to contemplate the
use of operational terms for EV subtype definition, referring to EVs’ physical characteristics such as size
(<100 nm for “small EVs”, and > 200 nm for “medium/large EVs”), density, biochemical composition
(tetraspanin/Annexin presence, etc.) and reference to condition or tissue/cell biogenesis (podocyte EVs,
cardiosomes and prosatosomes, large oncosomes, apoptotic bodies) [10–12]. More in general, referring
to their dimension and biogenesis’ mechanisms, EVs can be grouped into three broad categories:
apoptotic bodies, ectosomes and exosomes [13,14].
Apoptotic bodies (ApoBDs) are typically 1–5μm EVs released as cells’ blebs during the apoptotic
process. They contain cytoplasm, organelles and often also nuclear fragment, lipids, proteins [15] and
a high amounts of phosphatidylserine [16].
Ectosomes and exosomes formation rests on confined microdomains assembled in the plasma
membrane for ectosomes and in the endocytic membrane system for exosomes [17]. Ectosomes
(100–500 nm diameter) are larger than exosomes (30–150 nm diameter) and both their cargoes and
membranes composition partially differ from each other. Exosomes originate from the endosomal
compartment inside multivesicular bodies and they are released by the fusion with the plasma
membrane. Exosomes’ membranes are rich in tetraspanins (CD9, CD63, CD81, CD82 and CD151) [18],
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sphingomyelin, cholesterol [19] and adhesion molecule (ICAM-1), while the ectosomes’ ones are
characterized by plentiful of glycoproteins, receptors and metallo proteinases [17,20].
Oncosomes are exceptionally large ectosomes, typical of advanced cancers containing active
molecules involved in the metabolic pathways promoting tumoral cell survival and growth [21].
Starting from the key role that the tumor microenvironment plays in cancer establishment and
progression, it is easy to understand how the EVs have an active part in influencing processes as
pre-metastatic niche development, oncogenic transfer, and immune modulation [22,23].
Tumor-derived EVs, by carrying chemokines, are able to induce white blood cells’ chemotactic
response [24]. Tumor-derived exosomes promote inflammation compromising natural immunity and
reprogramming T cells [25], while ApoBDs join in the horizontal oncogenes transfer thanks to the
nuclear material that comes out from the dying cells by which they were produced [26].
Since EVs have an active role in the tumoral intercellular communication and signal transduction
systems, it spontaneously comes out to consider their applications as biomarkers and therapeutic
agents in oncology.
It actually results very interesting to observe how an advanced Web of Science search (carried out
on the 26th September 2019 at the all databases level) for the terms ‘extracellular vesicles cancer’ and
‘extracellular vesicles cancer nanomedicine’ has clearly shown an incredible increase in the number
of publications in the last five years (Figure 1). A further more detailed analysis was carried out on
these results and considered the percentages of the papers’ distribution in the various research areas.
It revealed that, by adding the term ‘nanomedicine’ to the query, the percentage of papers in the section
‘Science technology other topics’ increases from the 25% to the 85%, thus demonstrating the current
interdisciplinary research trend of this topic.
 
Figure 1. Results coming out from a Web of Science search carried out on the 26th September 2019,
at the all databases level, for the terms ‘extracellular vesicles cancer’ (upper panel) and ‘extracellular
vesicles cancer nanomedicine’ (lower panel).
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Current trends refer to EVs as successfully non-invasive diagnostic and prognostic biomarkers:
actually their membrane proteins, their lipid fingerprint (reflecting the protein and lipidic content of
the parent cells at the moment of their formation) and micro RNA load can be easily screened in blood,
urine and in other biological fluids [20,26,27].
Regarding EVs’ application as cancer therapeutics, it basically differs from conventional
approaches, i.e., molecular targeting drugs and chemotherapy. Referring to native EVs, a huge
number of in vivo and in vitro studies have been reported [28–34]. In details, three main approaches
in cancer treatment through native EVs can be identified: the inhibition of EVs production [35–37], the
eradication of circulating EVs, and finally the reduction of EV uptake [38,39].
EVs are usually biocompatible, low immunogenic and non-cytotoxic, with a high loading ability,
long life span in circulation and the capacity to cross barriers, i.e., the cytoplasmic and the blood
brain barriers, making them suitable for drug delivery applications [40,41]. Furthermore, EVs are
internalized 10 times more than liposomes of similar size in cancer cells, showing a higher specificity
towards tumoral cells [42] and, thanks to their dimensions, they can also exploit the enhanced retention
and permeability effect to accumulate in the cancerous tissues and reach easily the bulk of a solid
tumor [43]. The research on EVs is making great strides in cancer medicine and there are already
136 clinical trials on exosomes and 36 on EVs listed on “www.clinicaltrials.gov” both for therapy and
diagnosis. Given these premises, EVs can be considered promising tools for the development of new
engineered devices for therapeutic and diagnostic applications. Starting from scalable, reproducible
and well standardized EVs isolation procedures, it is possible to obtain highly purified products ready
for further microscopic, immunological characterizations or for cryopreservation treatments able to
guarantee the stability and integrity necessary for long-term storage or subsequent modifications.
Otherwise, these modifications can be carried out directly by engineering the parent cells before the
isolation, to obtain already loaded or functionalized EVs (Figure 2).
 
Figure 2. Schematic view of the flow of the different steps concerning the direct and indirect engineering
of extracellular vesicles (EVs) for cancer diagnosis and therapy applications.
In this review we summarize the last studies about the direct and indirect engineering of EVs.
The first one takes place immediately after the isolation or thawing steps, by means of membrane
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permeabilization, surface functionalization or loading strategy. The second engineering method, i.e.,
the indirect one, happens when the engineering process is applied through molecular or genetic
strategies on the parent cell that will secrete the vesicles.
2. EVs’ Post Isolation Direct Engineering
2.1. Chemico-Physical Functionalization
Post-isolation modification techniques, enabling the functionalization of the EVs surface with
specific moieties, improve their targeting abilities and biodistribution, allowing their in vivo and
in vitro tracking.
The methods for the direct engineering of EVs surfaces can be essentially divided in covalent
and non-covalent chemical modifications. In the first case, chemical reactions are performed between
functionalizing molecules or chemical linker and the amine groups, which are reactive functional
units widely expressed on exosomes’ surfaces [44]. Even if EVs, as non-living entities, have major
advantages with respect to cells regarding reagents and reaction conditions, these must be carefully
controlled and optimized in order to avoid vesicles disruption, denaturation and aggregation due to
the use of inappropriate temperature, pressure, and/or osmolarity [16].
The non-covalent approaches, instead, refer to membrane modifications by milder reactions,
based on electrostatic interactions and receptor-ligand binding as well as lipid-conjugated compounds
post-insertion into the EVs’ lipid bilayer [44].
Fluorescent and magnetic labeling represent a couple of the main results of the research on
EV surface modifications [44]. In fact, tracing the cellular trafficking of autologous exosomes or
their biodistribution and pharmacokinetics is essential to investigate their possible diagnostic and
therapeutic applications [45].
EVs can be efficiently labelled after their isolation with organic fluorescent dyes. This class of dyes
is widely used for in vivo and in vitro imaging [45] and includes a variety of fluorophore-conjugates.
These are able to selectively interact with different components of EVs, like RNA and DNA contained
inside them [46] or directly with their lipid bilayer [47,48] or with the amine groups of surface proteins
by covalent bonds [49].
Click-chemistry is successfully used for the functionalization of exosomes with fluorescent,
radioactive and magnetic resonance imaging (MRI) agents for precise in vivo exosomes tracking [50].
In particular, exosomes are chemically modified with terminal alkyne groups by cross-linking the
amine groups of exosomal membrane and the carboxyl group of 4-pentynoic acid using carbodiimide
activation. In a second step, the inserted alkyne terminal groups are reacted with azide-fluor 545 to
form a triazole linkage, according to the typical click-chemistry reaction [51]. In this way the number of
cross-linked alkyne groups is controlled in order to avoid the overmodification of exosomal membrane
proteins. With a standard calibration curve, it is estimated that approximately 1.5 alkyne modifications
are made for every 150 kDa of exosomal protein [50], ensuring the preservation of size of exosomes
and their capability of interaction with recipient cells.
The modification with polyethylene glycol (PEG) is a common approach used to prevent
opsonization and extend the circulation half-life of liposomes and synthetic nanoparticles (NPs),
it has also been successfully transferred to EVs. PEGylation of EVs results in a significant increase
in circulation time after intravenous injection in mice, from 10 min for unmodified EVs to 60 min or
even 240 min for PEG-functionalized exosomes. The decoration of EVs membrane is obtained, at
40 ◦C, by a post-insertion mechanism, combining PEG-phospholipids micelles (i.e., 1,2-dimyristoyl-sn-
glycero-3-phosphoethanolamine (DMPE)-PEG) with EVs extracted from mouse neuroblastoma cells,
maximizing the moieties incorporation while preserving EVs characteristics [52].
While opportunely minimizing the recognition by mononuclear phagocytic system, the PEG
corona strongly reduces the EVs-cell interaction in vitro [52]. The further functionalization of distal end
of PEG chain with appropriate targeting ligands, as already described for synthetic particles [53], can
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easily overcome this drawback and create a promising tool for drug delivery with stealth properties and
targeting abilities. A very recent study [54] described how modify EVs’ surface with the active targeting
ligand mannose. Exosomes’ surface was successfully modified with PEG, avoiding particle aggregation,
through the incorporation of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) into the lipid
layer of the exosome. For targeting purposes, the PEG’s distal end, functionalized with amine groups,
was further conjugated with mannose-isothiocyanate, guaranteeing a better accumulation of functional
exosomes in lymph-nodes [54].
Exosomes loaded with paclitaxel (PTX) are modified with aminoethyl anisamide-polyethylene
glycol (AA-PEG) as targeting ligand toward sigma receptor, overexpressed by lung cancer cells [55].
The AA-PEG complex has been inserted in exosomal membrane conjugated with DSPE lipid by using
a process that includes sonication and incubation steps, already developed by the same laboratory for
the drug loading [56]. The in vitro and in vivo uptake tests, confirmed that AA-PEG exosomes are
taken up in much higher quantities than non-vectorized ones. Furthermore, the in vitro uptake of
PEGylated exosomes without targeting moiety is lower than that of unmodified exosomes, probably
due to the PEG chains blocking interaction of exosomal surface proteins [55].
The same principle of post-insertion of a lipid linked with a molecule able to provide a conjugation
site for targeting ligands is used to functionalize exosomes membranes with folate and two RNA
aptamers, specific for typical cancer receptors (i.e., prostate-specific membrane antigen (PSMA) RNA
aptamer, and epidermal growth-factor receptor (EGFR) RNA aptamer) [57]. A cholesterol-triethylene
glycol (TEG) is conjugated with the engineered packaging RNA-three-ways junction (pRNA-3WJ),
exploiting the spontaneous insertion of the cholesterol via its hydrophobic moiety into the lipidic
bilayer and thus able to anchor the 3WJ into the EVs membrane. The particular spatial conformation
of the conjugate, with the cholesterol specifically placed on the arrow tail of the 3WJ, prevented the
RNA ligand from trafficking into the EVs, ensuring an oriented surface display of targeting ligands for
cancer receptor binding [57].
Enhancement of exosomes’ therapeutic ability has been also obtained by an electrostatic interaction
of original exosomes and cationized pullulan [58]. Nakase et al. used cationic lipids to increase the
exosomal surface charge and help the interaction between EVs and target cells [59]. The membrane
charge modification is obtained by the use of lipofectamine (LTX), a commercially available transfection
reagent containing cationic lipids, which adsorbs on the exosomes surface and can help the interaction
with negatively charged cells surface. The positive charge conferred from cationic lipids is also exploited
to functionalize the exosomes surface with a negative charged pH-sensitive fusogenic peptide, GALA,
able to guarantee an effective intracellular fusion of exosomal and endosomal membranes and the
subsequent cytosolic release of the exosomal contents [60], fundamental for efficient therapeutic
applications. This double membrane functionalization, based on electrostatic interactions and GALA
peptide, provides an enhanced cellular uptake and the cytosolic release of artificially encapsulated
cargo in the treatment of cancerous Hela cells in vitro [59].
It is well known that glycosylation has an important role in different biological function of EVs, like
in the cargo proteins recruitment [61] and in the cellular recognition and uptake [62]. Recent glycomic
analyses [63], performed by lectin microarray technology on EVs derived from different biological
sources, reveal both enrichment and exclusion of glycan epitopes with respect to the membranes
of their parental cells. In general lectin analyses reveal that EVs are enriched in high mannose,
complex N-linked glycan, poly N-acetyllactosamine epitopes and in α-2,6 sialic acid [63], which is
certainly involved in exosomes-cells interaction, thanks to sialic acid-recognizing lectins present on
cell surfaces [64].
Furthermore, alteration in glycosylation pattern has been associated with different pathologies,
including cancer [65], in which glycan changes took a variety of forms, i.e., loss or excessive expression
of certain glycans, increased expression of incomplete or truncated glycans and, less commonly,
appearance of novel glycans [66]. These changes are non-random, but closely correlated with malignant
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transformation and progression [66], making glycan structures valuable targets for anti-tumoral
diagnostic and therapeutic strategies.
Direct manipulation of glycosylation could be used to modify the surface of EVs in order to
obtain enhanced delivery or specific targeting to selected tissues for therapeutic purposes. In a recent
study, modified EVs are produced by treating them with an enzyme (neuraminidase) able to digest the
glycoproteins’ terminal sialic acid residues [67]. The glycosidase treatment produces different in vivo
biodistribution, causing for example a better accumulation in axillary lymph nodes of modified EVs
compared to untreated ones, suggesting their valuable application as drug carriers when the lymphatic
system is targeted [67].
A similar enzymatic treatment with a pan-sialic acid hydrolase is performed to reduce the
expression of immune inhibitory sialic acids on glioblastoma-derived EVs [68]. Lectin-binding analyses
confirmed that surface glycoconjugates of glioblastoma-derived EVs are dominated by immune
inhibitory sialic acid-capped N-glycans and complex bi-antennary glycans [69].
Thus, manipulation of surface glycosylation combined with the insertion of a high affinity ligand
for DC-specific ICAM-3-grabbing non-integrin (DC-SIGN) receptor leads to an enhanced internalization
of glioblastoma-derived EVs in dendritic cells for the triggering of an efficient anti-tumor immune
response [68].
Another valuable application of protein glycoengineering could be found in the stabilization of
targeting peptides fused to exosomal membrane protein. It was demonstrated that peptides expressed
on the N-terminus of lysosome-associated membrane glycoprotein 2b (Lamp2b) could be degraded
during exosomes biogenesis by endosomal proteases [70]. The inclusion of a glycosylation motif to the
N-terminus of the fusion protein efficiently protects the targeting peptide from proteolysis, enhancing
its expression in exosomes membrane while preserving the peptide-target interactions [70].
Other post-isolation functionalization techniques involve biological molecules as receptors or
antigens. A33 antigen has been proven to be overexpressed in colorectal cancer cells, demonstrating to
be a novel target as immunotherapeutic agent for cancer therapy even in clinical trials (NCT00003360,
NCT00199862 and NCT00291486). EVs isolated from colorectal cancer cell line present the A33 antigen
on their surface. These EVs are loaded with doxorubicin and functionalized with superparamagnetic
iron oxide nanoparticles (SPIONs) coated with high-density A33 antibodies, forming a complex with
antitumor activity towards colorectal cancer with reduced systemic toxicity [71].
EVs have been post-extraction engineered also for the treatment of glioblastoma multiforme.
Methotrexate-loaded EVs were functionalized with the pro-apoptotic peptide KLA, and the targeted
peptide, low-density lipoprotein (LDL), to target the LDL receptor overexpressed on the blood brain
barrier and glioblastoma cells [72]. A summary of the post-extraction chemico-physical modifications
of EVs is presented in Table 1.
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Table 1. EVs’ post isolation engineering: direct chemico-physical functionalizations.
EVs Type Nanotechnological Modification Application Reference
Exosomes from 4T1, MCF-7 and PC3
cells Labeling with DiR
a In vivo fluorescence imaging of
tumor-derived exosomes [47]
Exosomes from 4T1 cells Surface conjugation with azide-fluor545by click chemistry In vitro fluorescence imaging [50]
Exosomes from PC12 cells Labeling of exosomes proteins withTAMRA-NHS b In vitro fluorescence imaging [49]
Exosomes from fetal bovine serum
PEGylation by post-insertion of
DSPE-PEG-mannose or chemical
conjugation of NHS-PEG
Stealth and targeted Exosomes for
elevated uptake in DCs [54]
Exosomes from embryonic stem cells DSPE-PEG-c(RGDyK) Targeting glioblastoma, lungcancer and prostate cancer cells [73]
Exosomes from RAW 264.7 cells Post-insertion of DSPE-PEG-AA
Stealth and targeted exosomes for
the in vitro and in vivo treatment
of lung cancer
[55]
EVs from Neuro2A cells Post-insertion of DMPE-PEG-EGa1nanobody
Stealth and targeted EVs for the
in vitro and in vivo treatment of
cancer cells
[52]




Targeted EVs for the in vivo
treatment of breast, prostate and
colorectal cancer
[57]
Exosomes from MSCs Chemical functionalization withcationized pullulan
Targeted exosomes for the in vitro
and in vivo treatment of liver
injury
[74]
EVs from MLP29 cells Modification of EVs surfaceglycosylation by neuraminidase
Modification of EVs glycosylation
for altered in vivo biodistribution [67]
EVs from U87 and GBM8 cells
Enzymatic modification of EVs surface
glycosylation and insertion of targeting
ligand to DC-SIGN
Modification of EVs glycosylation
and insertion of targeting ligand
for improved uptake in DCs
[68]
Exosomes from Hela cells Hexadecaarginine (R16) peptide, anarginine-rich cell-penetrating peptide
Activation of the
macropinocytosis pathway,
affecting cellular uptake of EVs
[75]
Exosomes from HeLa cells Modification with LTX and GALApeptide via electrostatic interactions
Charge modified exosomes for
enhanced cellular uptake and
in vitro cytosolic release
[59]








Exosomes from human colorectal
carcinoma
Fe3O4 Superparamagnetic




Extracellular vesicles from fibroblasts Apoptotic peptide Lys-Leu-Ala (KLA)or LDL
Extravasation across BBB and
target glioblastoma multiforme [72]
Exosomes from bovine milk Folic acid Human lung and breast cancerreduction [41]
Plasma membrane vesicles
Bond of the EGF ligand to the
transmembrane domain of transferrin
receptor
Target EGFR-expressing cancers [76]
Exosomes-like nanoparticles from
grapefruit
Inflammatory related receptor enriched
membranes of activated leukocytes Target inflammatory tumor tissues [77]
Acronym legend: a DiR: DiIC18(7) (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindotricarbocyanine Iodide); b TAMRA-NHS:
carboxytetramethylrhodamine succinimidyl ester.
2.2. Loading Nanotechnological Modification into EVs
EVs can be successfully engineered acting as vehicles to transport different types of cargo such as
drugs, active molecules, nucleic acids and nanoparticles for imaging, tracking or therapeutic purposes
in cancer biology or medicine [78,79].
As widely reported in the literature [16,80], several methods are used to incorporate cargoes
inside EVs. Exogenous methods for loading EVs require the isolation of the vesicles at first, and their
successively loading according to different procedures.
245
Cancers 2019, 11, 1979
One of the simplest way is to co-incubate the EVs with the desired content, which will penetrate
into the vesicle membrane due to the different gradient of its concentration between the two sides of
the EVs membrane [81,82]. In particular, in the case of hydrophobic compounds, the internalization
could be reached by a simple passive diffusion process. The lipidic membrane presents a hydrophobic
region completely separated from the intra and the extra cellular region, thus incubation with high
concentration of drugs, such as doxorubicin, paclitaxel or imatinib, generates EVs loaded with
therapeutics molecules [47,83,84]. This strategy requires minimal manipulations and allows the loading
of a high amount of molecules [85].
Otherwise, the loading of hydrophilic molecules inside the intraluminal space requires the
mechanical or chemical disruption of the lipid envelope. Electroporation is based on the application of
an electric field to the EVs solution to create nanosized pores in the vesicles’ phospholipidic membrane,
enabling the diffusion of the desired drug [59,79,86], small interfering DNA (siRNA) [87,88], DNA [89]
or NPs [90], maintaining the biological activity of the cargo. However, electroporation can change the
physical characteristics of EVs and it is applicable only to small molecules, which can also aggregate
and stick on the EVs’ surface [85].
A sequence of freeze-thawing cycles of the EVs, which leads to the disruption of their membranes,
can be used as exogenous method of loading. Membrane fractures or deformations, due to the
ice-crystals formation, induce the encapsulation of relatively bulky molecules [91] such as proteins [92]
and nanoparticles [93] without affecting their biological activity.
Another method of loading hydrophilic compounds inside EVs is sonication: vesicles and
exogenous molecules can be mixed together and exposed to ultrasound. By disrupting the lipid
membranes, the incorporation of the molecules inside the EVs occurs while the membrane is auto
reconstructing [94]. This method prevents the aggregation of sensitive cargoes such as siRNA [95].
Nevertheless, both sonication and freeze-thawing methods cause a significant increase in the size of EVs,
indicating that their morphofunctional characteristics could be in some way compromised [56,92,96].
EVs and cargo molecules can be also incubated together and then extruded through the use of
a syringe-based lipid extruder. The process disrupts the vesicle membrane allowing the mixing of
the different components in solution [97]. This method is recognized as the most efficient loading
technique for water soluble cargoes such as many anticancer drugs and catalase are [98,99].
EVs’ membranes permeabilization can be achieved also through chemicals stimuli: detergents
like saponin can dissolve cholesterol forming pores in the membrane, altering its permeability and
allowing the cargo penetration inside the vesicles [97,100].
The possibility of being packaged in extracellular vesicles could represent a great plus in oncology
also for a wide range of just Food and Drug Administration (FDA)-approved drugs. Paclitaxel
(PTX) is a potent chemotherapeutic agent, used in multi drug resistant (MDR) cancer treatments.
Its encapsulation into EVs has been largely studied to increase the efficiency of cargo release and
the preferential accumulation into cancer cells, suggesting the possibility to obtain a higher targeting
specificity [47,56,101]. PTX encapsulated in endothelial cell-derived exosomes has the ability to cross
the BBB and be released in brain tumors in vivo [81]. PTX can be also encapsulated in milk-derived
EVs which improve the efficacy of the drug and decrease the immunologic toxicity [41,102].
Doxorubicin (DOX) is an antineoplastic drug used for the treatment of different cancers, such
as breast cancer, leukemia, lymphoma. Its cardiotoxicity, limits its applications and its maximum
tolerated dose, thus a delivery vehicle is needed to improve DOX biodistribution. A wide number of
studies have been done on the encapsulation of doxorubicin in EVs [83,103,104]. The efficiency of the
EVs-DOX nanoconstruct has been validated both in vitro and in vivo, as vehicle for a targeting delivery
of the drug to breast cancer cells, reducing the relative side effects [79,105,106]. The encapsulation
in EVs drastically reduced the in vivo cardiotoxicity of free DOX and the accumulation of the drug
in cardiac tissues is diminished of approximatively the 40%, without affecting the efficacy of DOX
towards cancerous cells [107].
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Curcumin is another drug widely used in clinics with a variety of applications, due to its
antioxidant and anti-inflammatory properties [108]. While curcumin does not show any antitumor
properties when administered via dietary, it reveals a significant inhibition of tumor growth in vivo
when loaded into exosome [109]. Another property of curcumin, loaded in EVs, is the partial reversal
inhibition of NK cell tumor cytotoxicity in breast tumor cells, supporting the anti-cancer behavior of this
bio-system [110]. The safety and efficacy of this system has been largely confirmed, leading to clinical
trials. From 2011 plant exosomes have been used to deliver curcumin in clinical trial (NCT01294072) to
treat colon cancer tissue.
Another category of cargo is composed by biomolecules as siRNA, miRNA (microRNA or miR):
siRNAs are considered as promising anticancer treatment, owing to the ability to modulate oncogene
expression levels [111]. Challenges in the use of RNAs are their rapid clearance into the blood stream
and its inability to cross cell membrane. In this contest EVs could represent are a promising vehicle to
deliver therapeutic RNA, due to their carrying ability and to their affinity with cell’s membrane.
Considering the various types of materials that can be loaded into the vesicles with the techniques
described above, we can assert that NPs can be finely tuned for a wide number of applications through
a strict control of physical and chemical parameters [112]. However, when administered into the body,
they could face some problems such as opsonization and/or aggregation [113,114].
The first phenomenon could lead to their recognition and elimination by the immune system,
while the second one could cause deleterious effects, such as thrombosis and accumulation in off-target
organs as liver, spleen and kidney. The shielding of NPs with EVs can thus potentially help to overcome
these drawbacks: the biomimetic coating can prevent or reduce the aspecific interaction with proteins
and, if further functionalized with targeting molecules, can avoid NPs’ accumulation in undesired
tissues and organs [115–117].
Internalization of gold NPs into exosome has been largely studied for different purposes, such
as therapeutic and diagnostic ones [78]. The combination of gold NPs loaded with doxorubicin and
encapsulated in EVs decreases drug’s toxicity increasing its delivery to the cancer cells [118].
Metal-organic frameworks (MOF) NPs have recently emerged as valuable nanocarriers, due to
their biocompatibility and high loading efficiency. However, cargo leakages and degradation before
they reach their target cells must be avoided, and a biomimetic shield sometimes solves these problems.
The encapsulation of MOF NPs inside exosomes, achieved by simple incubation, allows the delivery of
the anticancer drug as suberoyl bishydroxamic acid [82] or the protein gelonin [119] able to target cancer
cells, avoiding the premature cargo leakage and the degradation caused by the protease enzymes.
Another class of NPs broadly used in the biomedical field is the iron oxide one and, more
specifically, SPIONs are known for their magnetic, imaging, and heating capabilities. Literature
refers to EVs loaded with iron oxide nanoparticles and a clinical photosensitizer molecule (Foscan)
used as biocamouflaged agents for photodynamic therapy, magnetic resonance imaging, magnetic
manipulation, and hyperthermia [120]. Gold-iron oxide NPs covered with tumor cell-derived EVs are
successfully indicated for theranostic applications, as they result suitable for both magnetic resonance
imaging and photothermal treatment at the same time [121].
A new nanoconstruct exploits the peculiar features of zinc oxide NPs (ZnO NPs) to treat cancer
without the addition of drugs. Zinc oxide NPs encapsulated inside the EVs can be efficiently
internalized by cancer cells causing their apoptosis [122]. A summary of cargo-loaded EVs with the
related bibliographic references is provided in Table 2.
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Table 2. Direct loading nanotechnological modification of EVs.




(NPs) In vivo neuroimaging Co-incubation [78]
Exosome from lung cancer
or fibroblasts Gold NPs and doxorubicin Lung cancer treatment Co-incubation [118]
EVs from breast
adenocarcinoma
MOF NPs. NPs matrix contained
gelonin Inhibit adenocarcinoma growth
Sonication and
extrusion [119]
Exosomes from Hela cells MOF NPs Hela cells Co-incubation [82]
EVs from KB cells ZnO NPs Cytotoxic effect against KB cells Co-incubation [122]
EVs from endothelial,











Glioma therapy Co-incubation [73]
Milk-derived exosomes To reduce paclitaxel’s side effects Co-incubation [102]
Exosomes from





Exosomes from brain cell
lines To treat brain tumor Co-incubation [81]





colorectal cancer Dialysis [71]
Exosomes from breast
cancer To treat breast and ovarian cancer Electroporation [106]
Exosomes from breast
cancer
To reduce cardiotoxicity of
doxorubicin Electroporation [107]
Exosomes from 4T1,
MCF-7, and PC3 cell line Breast cancer Co-incubation [47]
Exosomes from mouse
immature dendritic cells




Cervical cancer Co-incubation [109]
Exosomes from lymphoma
cells Activate myeloid cells in vivo Co-incubation [123]
Plant exosomes Colon cancer NCT01294072
Milk-derived exosomes Paclitaxel, Docetaxel, WithaferinA and curcumin
Targeting and therapy of lung
cancer cells Co-incubation [41]
Milk-derived exosomes Celastrol
Inhibition of Hsp90 and NF-κB a
activation pathways in lung
cancer
Co-incubation [124]
EVs from lung cancer Oncolytic adenovirus andpaclitaxel
Enhance immunogenicity in lung
cancer Co-incubation [125]
Exosomes from HEK 293
cells siRNA
Efficient delivery of siRNA in
cancer cells Electroporation [126]




Silencing PLK-1 gene in bladder
cancer cells Electroporation [127]
Exosomes from HEK 293
and MCF-7 cells siRNA, miRNA and ssDNA
b Oncogene knockdown Sonication [95]
Plasma-derived EVs miRNA cel-39 Promote apoptosis ofhepatocellular carcinoma Electroporation [128]
Acronym legend: a NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; b ssDNA: single
stranded DNA.
3. EVs’ Indirect Nanotechnological Modification through Parent Cells’ Engineering
A frequently applied method to modify EVs in vitro, i.e., loading cargo molecules or accomplishing
membrane functionalization, is through the engineering of parent cells. Cell engineering methods,
such as genetic and metabolic modification and exogenous delivery, can alter the surface expression
and cargo content of newly-produced EVs and thus enhance their biocompatibility, targeting and
therapeutic abilities [129].
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3.1. Indirect Surface Functionalization
EVs’ membrane is a complex structure constituted by phospholipids and membrane proteins.
Since the membrane is the first point of contact with the cell, tuning its composition strongly improves
the targeting ability and enhances the therapeutic ability of EVs [85].
This approach can be employed for the non-invasive monitoring of EVs in vivo exploiting the
fluorescence of some binding molecules. Molecular imaging allows a quantification of the EVs
biodistribution and, eventually, a therapeutic effect over the time. For instance, pancreatic cell lines that
stably expresses the green fluorescent protein (GFP) linked to CD63 can produce exosomes consistently
positive to GFP [130–132]. Another effective labelling strategy for EVs is the incorporation of an
azido-sugar in the glycans through a combined metabolic glycan labelling click chemistry reaction.
Tetraacetylated N-azidoacetyl-D-mannosamine (Ac4ManNAz) is placed in culture with the parent cells,
spontaneously incorporated into glycans and uniformly redistributed on their EVs. The azido-EVs
are then labeled with azadibenzylcyclooctyne (ADIBO)-fluorescent dyes by a bioorthogonal click
reaction [133]. Exploiting the principle of bioluminescence for tracking EVs, in vivo Gaussian Luciferase
(Gluc) is linked to a transmembrane domain of a platelet-derived growth factor receptor [134,135],
or a lactadherin [136,137]. Gluc is the only naturally-produced luciferase that can emit flash of
bioluminescence in the presence of oxygen as cofactor for the reaction. After the engineering of parent
cells with Gluc, the produced EVs are extracted and, when administered systemically, they can be
tracked in vivo thanks to their bioluminescence [134,135]. The cellular transgene expression into the
parent cell allows the expression of the candidate protein or peptide in the released EVs. The coding
sequence of the desired ligand is inserted by a gene transfer vector (i.e., lentivirus) between the signal
peptide and the N-terminus of the mature peptide of a transmembrane protein. In this way, the parent
cells can generate EVs with the peptide of interest on their surface [129]. The candidate protein or
peptide, after the transfection in the parent cells, fuses with EVs membrane proteins such as Lamp2b
and tetraspanins CD63 and CD9 [43], thus the produced EVs display the just-engineered molecule on
their surface. For instance, dendritic cells can be engineered to express a protein composed by Lamp2b
and αv integrin-specific iRGD peptide in order to secrete iRGD peptide-EVs. This functionalization
considerably increases the delivery of doxorubicin toαv integrin-positive breast cancer cells in vitro [79].
The transfection can occur by using plasmid vectors. A plasmid vector encoding streptavidin (which
binds to biotin with high affinity) and lactadherin (an exosome-tropic protein) fusion protein allow to
obtain streptavidin-lactadherin-modified exosomes that are mixed with the biotinylated pH-sensitive
fusogenic GALA peptide exerting a lytic activity in acid environment [138]. Lentiviral vector bearing
LAMP2b-Designed ankyrin repeat protein (DARPin) G3 chimeric gene or herpes simplex virus with
plasmid pACgp67B-HER2m, containing the anti-human epidermal growth factor receptor 2 (HER2)
scFv (ML39) antibody DNA sequence, are used to engineer HEK-293T cells. EVs isolated from
transfected cells can bind specifically to HER2/Neu in adenocarcinoma cell lines [139,140]. Human
carcinoembryonic antigen or human HER2/neu can be also inserted into the mouse lactadherin
expression plasmid p6mLC1C2 and transfected into dendritic cells, enhancing the production of
functionalized EVs to target breast cancer cells [141]. Similarly, prostate-specific antigen and prostatic
acid phosphatase linked to the C1C2 domain of lactadherin produce EVs that specifically target prostate
cancer cells [142]. In another study, an anti-epidermal growth factor receptor (EGFR) nanobodies
with anchor signal peptide glycosylphosphatidylinositol (GPI) fusion protein are transfected to parent
cells in order to generate EVs with this functionalization. These EVs show a significantly improved
targeting ability towards EGFR-positive tumor cells [143].
An alternative strategy is the hydrophobic insertion used to functionalize the EVs’ membranes by
exploiting the phospholipid composition of plasma membranes. Amphiphilic molecule DSPE-PEG,
FDA approved for medical applications, can self-assemble in the phospholipid bilayer [144]. Based
on this consideration, if DSPE-PEG is bound to the molecule of interest, it can be incorporated inside
the cell membrane, making it overexpresses the molecule on its surface and producing EVs with the
desired functionalization. The most frequently used molecules are biotin and folate: the first one binds
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selectively with streptavidin, used for further functionalization, and the second one targets specific
cancer cells [86,145–147]. In addition to folate, also other binding sites can be created on EVs using this
approach, for example by adding the RGD sequence or sulfhydryl groups [148].
A summary of EVs ‘surface functionalization nanotechnological modification through parent cells’
engineering with the related bibliographic references is reported in Table 3.
Table 3. EVs’ Surface functionalization by parent cells’ engineering.
EVs Type Nanotechnological Modification Application Reference
Exosomes from breast cancer Ac4ManNAz labeled withADIBO-fluorescent dyes Breast cancer imaging [133]
Exosomes from melanoma
Gaussian Luciferase Biodistribution and tumor targeting
[137]
Exosomes from HEK 293T [134,135]
Exosomes from melanoma [136]
Exosomes from HEK 293T Alexa Fluor 680-Streptavidin Biodistribution and tumor targeting [135]
Exosomes from different cell lines GFP Monitoring and tracking of exosomesuptake in different types of cancer [130–132,149]
EVs from HEK 293T
Palmitoylation signal genetically
fused in-frame to the N terminus of
enhanced green fluorescence protein
(EGFP) and tandem dimer Tomato
(tdTomato)






(DSPE-PEG-SH) and folic acid
Targeting Hela cells [148]
EVs from squamous cell
carcinoma DSPE-PEG-Biotin and folate
Targeting breast cancer for diagnosis
and therapy [145]
Exosomes from HUVEC DSPE-PEG-biotin Targeting hepatocellular carcinoma [147]
EVs from macrophage DSPE-PEG-Biotin and folate Targeting Hela cells [86]
EVs from HUVEC DSPE-PEG-Biotin Targeting melanoma [146]
Exosomes from HEK 293T DARPins
Targeting HER-2 over-expressing
cancer cells (breast, ovarian and
gastric cancers)
[139]
Exosomes from HEK 293 Anti-HER2 scFv antibody (ML39) Inhibit the growth of HER2 positivebreast cancer [140]
Exosomes from murine melanoma
Streptavidin-lactadherin fusion
protein linked with biotinylated
pH-sensitive fusogenic GALA peptide
Cancer immunotherapy [138]
Extracellular vesicles from murine
neural stem cells
Anti-EGFR fused to GPI anchor signal
peptides Targeting of Hela cells [143]
Exosomes from dendritic cells
Lamp2b fused with iRGD
(CRGDKGPDC) targeting peptide for
αv integrin
Targeting breast cancer [79]
Exosomes from dendritic cells
Carcinoembryonic antigen or HER2
linked to the C1C2 domain of
lactadherin
Targeting breast cancer [141]
Exosomes from HEK 293F cells
Prostate-specific antigen, and
prostatic acid phosphatase
linked to the C1C2 domain of
lactadherin
Targeting prostate cancer [142]
Exosomes from fibrosarcoma cells Chicken egg ovalbumin by fusing it tothe C1C2 domain of the lactadherin
In vivo fibrosarcoma. More efficient
antitumor immune response [151,152]
Exosomes from dendritic cell line
C1C2 domain of lactadherin is fused
to soluble proteins or extracellular
domain of membrane proteins
Generate antibodies against tumor
biomarkers
[153]
Transmembrane protein HLA-A2 a
Acronym legend: a HLA-A2: Human leukocyte antigen A2.
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3.2. Indirect Loading
Genetically engineered parent cells allow the production of pre-loaded EVs. This approach
enhances the loading efficiency of molecules inside the EVs compared to the post-isolation techniques,
minimizing the impairment of the structures or of the biological activity of both cargoes and
carriers [44]. Some reports demonstrate the successful internalization of miRNA, siRNA [84,154]
and nanoparticles [155] inside EVs produced from engineered parental cells. Furthermore, cells can
be transfected with short RNA-encoding plasmid DNA (pDNA) in order to generate EVs enriched
with target RNA [121,156]. The efficiency of cargo uptake inside EVs strongly depends on its high
concentration inside the parent cells, because only a small amount is released as packed in the EVs [85].
Loading proteins inside the EVs can be accomplished by transfecting the parent cell with a vector
containing the gene which codifies the specific protein. Proteins encoded by the transfected gene are
synthesized by the cells and then secreted enveloped in EVs. Despite the apparent simplicity of this
approach, many aspects need to be considered. The expression of cytotoxic proteins can inhibit the
growth of the parent cells or induce their apoptosis. Furthermore, impaired biological reactions and
interactions can obstacle the production of EVs ability [40].
Viruses are often used for the transfection of genetic materials or molecules inside the parent
cells in vitro. Different kind of viruses are employed, but the most used is lentivirus because
of its transfection ability and safety. Generally, the transfection of parent cells has the aim to
overexpress a particular therapeutic or anticancer molecule in order to secrete it as enveloped inside
EVs. For example, EVs-enriched human MUC1 (hMUC1) injected intra-dermally suppress the growth
of hMUC1-expressing tumor [157]. Similarly, tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL), a widely tested anticancer protein, causes the apoptosis of transformed or tumoral cells,
but not of the normal ones. Due to its therapeutic efficacy, it has been encapsulated in EVs to overcome
the shortcomings of a poor pharmacokinetic profile and the tumor resistance to drug [158,159]. Target
proteins can also be delivered inside the parent cell by fusion with constitutive proteins of EVs, such as
CD63, to improve the specificity of the protein loaded inside EVs [160]. Nef/E7 DNA vector expressing
Nef exosome-anchoring protein combined with HPV-E7 is delivered to parent cells to make them
able to generate immunogenic EVs containing the Nef-E7 fusion protein to elicit an efficient anti-E7
cytotoxic T lymphocyte immune response for cancer therapy [161]. Another strategy to incorporate
proteins of interest inside EVs is pseudotyping, which packages viral RNAs or DNAs with the envelope
proteins from another virus. The G glycoprotein of the vesicular stomatitis virus glycoprotein (VSVG) is
frequently used for this purpose because of its efficacy in transduction and broad tropism. The selected
protein is fused with VSVG and transfected into different parent cell lines [162]. This method can be
further developed by adding to VSVG cell-recognizing peptides for targeting or engineered therapeutic
antibodies, such as anti-CD19 chimeric antigen receptors, that target specific suppressors of cytotoxic
T cells for cancer therapy [163]. A novel method, called EXPLORs (exosomes for protein loading
via optically reversible protein-protein interactions), allows the loading of cargo proteins inside EVs
through endogenous biogenesis processes, delivering soluble proteins into the cytosol via controlled,
reversible protein-protein interactions. For this purpose, a photoreceptor cryptochrome 2 (CRY2) and
CRY-interacting basic-helix-loop-helix 1 (CIB1) protein module, which regulates the floral initiation
of Arabidopsis thaliana via blue light-dependent phosphorylation, are selected. Then, a transient
docking of CRY2-conjugated cargo proteins is induced by introducing CIBN (a truncated version of
CIB1) conjugated with an exosome-associated tetraspanin protein CD9 and by blue light illumination.
After the release of the EVs with the cargo proteins linked to tetraspanins from the parent cell, they can
be detached from CD9-conjugated CIBN by the removal of the illumination source, releasing them into
the intraluminal space of the EVs [164].
The strategies described above to load EVs with proteins by engineering of the parent cells
can be applied also in the case of nucleic acids. For instance, to reverse the chemoresistance to
cisplatin-refractory gastric cancer, human embryonic kidney 293T (HEK-293T) cells are transfected
with anti-miR-214 and the produced vesicles are administered systemically in combination with
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cisplatin, injected intraperitoneally, to overcome the in vitro and in vivo drug-resistance [165]. EVs
produced by miR-134 or anti-miR-21 transfected mammary carcinoma cells have the ability to reduce
the cellular proliferation and migration and to enhance the apoptosis in breast cancers [121,166].
miR-122 is essential to tune the chemosensitivity of hepatocellular carcinoma cells. Its effective delivery
is accomplished by transfecting adipose-derived mesenchymal stem cells in order to produce EVs
already loaded with miR-122 [167]. EVs from mesenchymal stem cells transfected with miR-146b
expressing plasmid silence the EGFR and significantly decrease glioma growth [168], while EVs
loaded with miR-143 inhibit the migration ability of osteosarcoma cells [169]. Mesenchymal stem cells
can be loaded with anti-miR-9 to produce anti-miR-9 EVs. Anti-miR-9 delivered to cancer cells can
reverse the expression of P-glycoprotein, involved in the chemoresistance, to enhance the efficacy of
the temozolomide in otherwise resistant glioblastomas [170]. HEK-293T cell line can be genetically
engineered to overexpress a suicide gene mRNA and protein-cytosine deaminase fused to uracil
phosphoribosyltransferase in their microvesicles. They can transfer the therapeutic mRNA/protein to
schwannoma cancer cells, achieving the inhibition of tumor growth [171]. Prostate cancer cell line is
incubated with spherical nucleic acids (SNA), which are a new type of therapeutic agent composed by a
core of gold nanoparticle with a dense shell of highly oriented nucleotides. The secreted EVs display a
potent gene knockdown, when internalized in cancer cell, due to the presence of the anti-miR-21 [155].
EVs overexpressing hepatocyte growth factor (HGF) siRNA drastically reduced HGF and vascular
endothelial growth factor (VEGF) expression in gastric cancer [172]. EVs delivery of siRNA against
RAD51 and RAD52 causes an inhibition of proliferation and a massive reproductive cell death in
human breast cancer cells [173].
The previously described method EXPLOR can be also used for the encapsulation of peptides
inside cells, in particular of miR-21 sponges inside HEK-293T cells. The EVs produced are then loaded
with this nucleic acid, which is an inhibitor of miR-21, overexpressed in most cancer types, and reduces
the tumor progression and metastasis. After the collection of EVs loaded with miR-21 sponges, EVs
are functionalized with cholesterol-AS411 aptamers exploiting the interaction with lipids of EVs’
membrane. The expression of AS1411 on EVs allows the targeting of leukemia cells for the interaction
with nucleolin, overexpressed by these cancer lines. miR-21 sponges can inhibit miR-21 functions,
triggering leukemia cells’ apoptosis [174].
Engineering the donor cells in order to make them produce already loaded EVs is possible
also in the case of chemotherapeutic drugs and nanoparticles, as resumed in Table 4. For example,
mesenchymal stromal cells are cultured for 24 h with paclitaxel and, after a change of media,
cells are left to produce EVs with Paclitaxel for 48 h. These EVs can be used in the treatment of
human pancreatic adenocarcinoma and they demonstrate a strong antiproliferative activity [101].
A melanoma cell line is engineered to produced EVs loaded with both survivin T34A and gemcitabine.
Loaded EVs are collected and administered to pancreatic adenocarcinoma cells. The presence of
survivin-T34A, which targets and inhibits survivin, an inhibitor of apoptosis, enhances the toxic effect
of the Gemcitabine with lower dosages [175]. Different cell lines are incubated with methotrexate
or doxorubicin and then irradiated with ultraviolet light to induce cells apoptosis. The produced
ApoBDs, as delivery vehicles of chemotherapeutic drugs, exert a strong cytotoxic effect and inhibit
the drug efflux from cancer cells [176]. A hybrid approach between drugs and nanoparticles involves
the co-incubation of macrophages with both iron oxide NPs and a photosensitizer called m-THPC.
The produced EVs containing both the two cargoes stabilize the strong hydrophobic photosensitizer
drug and are injected into a mouse model. The drug allows the photodynamic therapy on cancer
cells, while nanoparticles, responsive to magnetic fields, can be tracked with magnetic resonance
imaging and used for hyperthermia treatments [177]. A further experiment, carried out by the
previous research groups, besides the iron oxide nanoparticles, includes also a chemotherapeutic
agent (doxorubicin), tissue-plasminogen activator (t-PA) and two photosensitizers (disulfonated
tetraphenylchlorin-TPCS2a and 5,10,15,20-tetra(m-hydroxyphenyl)chlorin-mTHPC) to better enhance
the antitumor ability of the produced EVs [178]. The delivery of compounds to parent cells can
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be difficult, especially in presence of hydrophobic molecules. For this reason, in the case of the
hydrophobic photosensitizer zinc phthalocyanine, it is encapsulated in liposomes and they are used to
treat the parent cells. The hydrophobic compound is secreted from the parent cells by incorporation
in the EVs and then transferred to adjacent cells. This approach allows to significantly penetrates
spheroids and in vivo solid tumors, enhancing the efficacy of the therapy [179]. The same procedure
can be followed also for other molecule, both hydrophobic or hydrophilic, including fluorophores such
as 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocyanine perchlorate (DiD) and carboxy-fluorescein,
drugs (paclitaxel and tirapazamine), lipids and bio-orthogonal chemicals [180]. A similar approach is
used also to incorporate nanoparticles inside EVs. Hollow-gold nanoparticles were shielded with a
PEG functionalization and then incubated with human placental mesenchymal stem cells. After the
uptake, the cells produced EVs loaded with hollow-gold nanoparticles. These EVs allowed to track the
cell-cell communication and also perform the optical hyperthermia for cancer therapy [181].
Table 4. Nanotechnological modification of EVs’ loading through parent cell engineering.
EVs Type Nanotechnological Modification Application Reference
Human placental
mesenchymal stem cells Hollow gold NPs
Hyperthermia therapy against
different type of cancer [181]
Exosomes from hepatocellular
carcinoma
Porous silicon NPs loaded with
doxorubicin




EVs from mesenchymal stem
cells SPIONs Therapy against leukemia [183]





Iron oxide nanoparticles and m-THPC
photosensitizer
Theranostic approach against cervical
and prostate cancer [177]
Microvesicles from different
cancer cell lines
A hydrophobic photosensitizer zinc
phthalocyanine encapsulated in
liposomes
Photodynamic therapy for different




activator and two photosensitizers
Targeting and therapy of ovarian and
prostate cancers [178]
Exosomes from mesenchyme
stromal cells Paclitaxel Treatment of pancreatic cancer [101]
Exosomes from melanoma cell




tumoral cells Doxorubicin or Metotrexate




Exosomes from breast cancer Curcumin Reverse inhibition of NK cell tumorcytotoxicity in breast cancer [110]
Exosomes from HEK 293 P53 gene Transfer p53 gene to p53-deficientcells [184]
Exosomes from HEK 293T miR-21 sponges Therapy for leukemia cells [174]
Extracellular vesicles from
breast cancer Anti-miR-21 Theranostic method for breast cancer [121]
Exosomes from HEK 293T Inhibitor of miR-214 Reverse chemoresistance to cisplatinin gastric cancer [165]
Exosomes from prostate
cancer cells Anti-miR-21 spherical nucleic acid Prostate cancer [155]
Exosomes from mammary
carcinomas miR-134
Increase sensitivity of breast cancers
to chemotherapeutic drugs [166]
Exosomes from mesenchyme
stem cells miR-122
Increase sensitivity of hepatocellular
carcinoma to chemotherapeutic drugs [167]
Exosomes from mesenchymal
stem cells miR-143









stem cells miR-146b Inhibit glioma growth [168]
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Table 4. Cont.
EVs Type Nanotechnological Modification Application Reference
Microvesicles from HEK 293T
Suicide gene mRNA and
protein-cytosine deaminase fused to
uracil phosphoribosyltransferase
Inhibit schwannoma tumor growth [171]
Exosomes from HEK 293T HGF siRNA Inhibition of tumor growth andangiogenesis in gastric cancer [172]
Exosomes from breast cancer





Lung, breast, kidney cancer, pleural




ligand (TRAIL) Enhance apoptosis in lymphoma [159]
Exosomes from HEK 293T VSVG Glioblastoma and liver cancer cells [162]
Exosomes from lymphoblast Nef-E7 fusion protein T lymphocytes immune response [161]
Exosomes from two mouse cell
lines Human MUC1 tumor antigen







The same cancer cell lines used to
produce microvesicles [180]
The engineering of parent cells can also be addressed to obtain EVs loaded with molecules, such
as drugs or nucleic acids, and with a specific surface functionalization (as summarized in Table 5).
HEK-293T cells engineered to express Lamp2b protein, fused with a fragment of interleukin 3 (IL-3),
and then incubated with Imatinib or BCR-ABL siRNA, can produce EVs loaded with the desired
cargoes and expressing the IL-3 fragment on their surface. The IL-3 receptor is overexpressed in chronic
myeloid leukemia and acute myeloid leukemia blasts and almost absent in hematopoietic stem cells.
Exploiting this characteristic, IL-3 expressing EVs can target these cancerous cells and overcome the
drug resistance to imatinib or deliver functional BCR-ABL siRNA towards imatinib-resistant cells [84].
The cell line used above can be also transfected with pDisplay vector encoding GE11 peptide or EGF,
and with let-7a miRNA. The harvested EVs are functionalized with the peptide on their surface and
loaded with the miRNA. Then, EVs are injected intravenously and their surface functionalization allows
the specific targeting of EGFR-expressing cancer tissues, such as breast cancer. The tumor suppressor
let-7a is delivered to the tumor and reduce the expression of RAS and HMGA2 inhibiting the malignant
growth of cancer cells [154]. In another study, adeno-associated virus (AAV) is used as viral vector for
transfection. It is broadly used for gene therapy in human, thanks to its safety profile, but it has some
limitations, such as off-target gene delivery (to liver for example) and low transfection of target cells.
For this reason, by transfecting the parent cells with AAV, capsids associate with the membrane and the
interior part of the newly-produced EVs (called vexosomes). Harvested vexosomes show to be more
resistant to anti-AAV antibodies if compared to naked AAV and they can efficiently transduce cells,
enhancing gene transfer. Furthermore, parent cells are also engineered to express a transmembrane
receptor on the microvesicle surface, i.e., biotin acceptor peptide-transmembrane domain (BAP-TM)
receptor, allowing the specific targeting of glioblastoma cells [185]. Gene engineering method is applied
to HEK-293T cell line to functionalize the CD9 tetraspanin with the RNA-binding protein HuR and
then, they are modified with miR-155 or the clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 system. The produced EVs are effectively enriched by the above mentioned RNAs and
in future these nanoconstructs need to be evaluated in some diseases such as liver cancer [186].
254
Cancers 2019, 11, 1979
Table 5. EVs’ indirect modifications through combined loading and surface parent cells engineering.
EVs Type Nanotechnological Modification Application Reference
Exosomes from HEK 293T Functionalization: CD9-HuRLoad: miR-155 or CRISPR/Cas9
Targeting and therapy of
liver cancer [186]
Exosomes from HEK 293T
Functionalization: Lamp2b, fused to a
fragment of IL-3
Load: Imatinib or BCR-ABL siRNA
Inhibition of chronic
myeloid leukemia growth [84]
Exosomes from HEK 293T Functionalization: GE 11 peptideLoad: let-7a miRNA




Exosomes from HEK 293T cells
Functionalization: BAP-TM receptor
and biotin ligase BirA
Load: viral capside
Gene therapy against glioma [185]
4. Conclusions and Future Outlook
Nanotechnology-modified EVs are promising tools for the next generation of nanomedicine for
both diagnostic and therapeutic purposes with non-cytotoxic effects and a low immunogenic profiles.
In the present review, we have reported how nanoengineered EVs may be obtained either by direct
post-extraction modification or by the indirect nanotechnological modification through the engineering
of the parental cells producing them. From the therapeutic point of view, targeted EVs can promote
the efficacy in cargo transportation toward a target cell or tissue, while also reducing off-target delivery.
EVs can be loaded with very different therapeutic cargos, including both hydrophilic and hydrophobic
drugs, nucleic acids like miRNA, siRNA, and recombinant proteins, or even solid-state nanoparticles.
Various strategies are also available for their surface functionalization, in view of modulating the EV
innate homing capabilities or refine specific targets.
Despite the advances outlined in this review, many challenges still have to be overcome to render
EVs an effective and clinically-approved nanomedicine approach. First of all, achieving large-scale
production of EVs for clinical use is a major challenge. In addition, a careful study on the purification
processes, potentially based on immune-selection and isolation, is surely required in order to achieve
high purity of the nano-engineered EVs and remove all the eventual reaction by-products or uncoupled
molecules, cargos or nanoparticles after the EVs modification. Furthermore, more systematic in vivo
studies are required to gain information about the re-engineered EVs toxicology, biodistribution,
pharmacodynamics and pharmacokinetics.
Finally, the complex structure, the variable composition and functional activity of secreted EVs can
impair their pharmaceutical approval, preventing their systematic clinical use. A potential alternative
can be envisioned in the development of biomimetics EVs, thus assembled using clinical-grade and
purified synthetic lipids and the necessary proteins under controlled GMP procedures to mimic
the naturally-secreted ones. Strikingly, such biomimetic nanotools will not suffer from large-scale
production limitations and variable compositions and can be ideal for the incorporation of many and
different molecules or nanoparticles with biomodulatory, cytotoxic, anti-proliferative and imaging
capabilities. Such re-engineering of EVs would thus allow novel non-immunogenic, highly stable,
hemocompatible nanoplatforms, with customizable targeting and drug delivery abilities.
However, possible drawbacks in terms of manufacture reproducibility and high cost can come
against this vision. Furthermore, the precise components of natural exosomes, that are the key for
obtaining efficient cell homing, therapeutic delivery and biomarker signature, are still under study and
at the infancy of knowledge.
More in general, it is thus clear that the way to efficiently obtain highly purified, well-characterized
and reproducible nano-engineered EVs is still a long way. The fulfillment of these objectives will
allow high performances in terms of targeting, therapeutic and diagnostic abilities, avoiding any
potential side effects. Furthermore, achieving the above-mentioned vision will be the starting point
of the subsequent industrial development of these novel nano-engineered EVs, including scaling up
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and quality control of production, rigorous pharmacokinetic and toxicological studies and, eventually,
clinical testing.
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Abstract: Traditional cancer therapeutics are limited by factors such as multi-drug resistance and
a plethora of adverse effect. These limitations need to be overcome for the progression of cancer
treatment. In order to overcome these limitations, multifunctional nanosystems have recently
been introduced into the market. The employment of multifunctional nanosystems provide for
the enhancement of treatment efficacy and therapeutic effect as well as a decrease in drug toxicity.
However, in addition to these effects, magnetic nanowires bring specific advantages over traditional
nanoparticles in multifunctional systems in terms of the formulation and application into a therapeutic
system. The most significant of which is its larger surface area, larger net magnetic moment compared
to nanoparticles, and interaction under a magnetic field. This results in magnetic nanowires producing
a greater drug delivery and therapeutic platform with specific regard to magnetic drug targeting,
magnetic hyperthermia, and magnetic actuation. This, in turn, increases the potential of magnetic
nanowires for decreasing adverse effects and improving patient therapeutic outcomes. This review
focuses on the design, fabrication, and future potential of multifunctional magnetic nanowire systems
with the emphasis on improving patient chemotherapeutic outcomes.
Keywords: magnetic nanowires; cancer; magnetic hyperthermia; magnetic actuation; magnetic
drug targeting
1. Introduction
Cancer is amongst the most pernicious diseases known, due to the high mortality and incidence
rates reported [1]. Traditional treatment such as chemotherapy, radiation therapy, and surgery has
provided successful treatment and control of cancer to a certain extent [2]. However, each approach
comes with its own difficulties, notably being invasive or unspecific in its killing effect leading to
grave adverse effects. Alternative therapies such as carbon ion therapy and proton therapy are more
specific and carries a lower side effect risk when compared to X-ray radiotherapy. The limitation of
these therapies is that they require specialized equipment and personnel, thus resulting in high cost
and constrained treatment accessibility [3]. Chemotherapy, when looked at in isolation, has further
shortcomings such as short half-life, acquired drug resistance, nonspecific bio-distribution in cells and
tissues, rapid metabolism, and excretion. This leads to a low therapeutic index due to the destruction
of healthy cells and potent toxicity [1].
Multifunctional nanosystems has been of recent interest in anti-cancer-therapy for the purpose of
developing safe, effective, and efficacious drug delivery systems, due to the potential of overcoming
Cancers 2019, 11, 1956; doi:10.3390/cancers11121956 www.mdpi.com/journal/cancers267
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the disadvantages of traditional strategies. Amongst the most promising multifunctional nanosystems
include the use of magnetic drug targeting, actuation, or hyperthermia in amalgamation with triggered
drug release strategies as well as their combination with diagnostic methods such as magnetic resonance
imaging and fluorescence imaging. This can lead to a theranostic approach personalizing cancer
treatment for patients. Amongst the various nanoparticles and nanocarriers that multifunctional
nanosystems are comprised of, nanowires (NWs) are of key interest due to their shape anisotropy and
large surface area. Figure 1 shows a NW system, in which stimuli release the drug in the presence of a
decreased pH after cellular internalization.
 
Figure 1. Schematic showing doxorubicin loaded nanowires being internalized into the cytoplasm
and releasing the drug from the pH stimuli from the endo/lysosome. Where P-gp is P-glycoprotein.
Adapted with permission from Peng et al. [4].
NWs have widespread applications in various fields including drug delivery [5], sensors [6],
biomedicine [7], water purification [8], magnetic storage [9], and electronics [10]. NW application in
drug delivery includes the use in both targeted drug delivery systems such as magnetically responsive
platforms [11,12] and triggered release systems such as pH responsive systems [13]. NWs are also used
to induce non-chemotoxic cell death by using magnetic actuation and induced localized hyperthermia
in the presence of an alternating magnetic field.
NW are structurally characterized as one-dimensional geometry, involving large lengths reaching
micrometer range and small diameters in the nano-range (~10–200 nm). Their length-to-diameter ratio
(aspect ratio) is usually large [14], which differentiates them from nanorods.
These intrinsic properties of NW provide specific advantages in terms of drug delivery, which is of
particular interest with regards to cancer therapeutics, such as a large surface-area-to-volume ratio and
increased biocompatibility by its ability to camouflage and be coated with various biocompatible and
biodegradable coatings (biopolymers and semi-synthetic polymers) increasing its solubility, stability,
and its ability to be functionalized. NWs therefore provide an efficient platform for drug delivery
systems to be based on. The large surface-area-to-volume ratio allows for greater drug loading and
attachment of targeting molecules while the small diameters provide the ability to pass through narrow
capillaries [15]. With regards to magnetically responsive NW, the elongated shape brings inherent
advantages that can be exploited. Their anisotropic magnetic and physical properties allow for easy
magnetization, greater magnetic moments when compared to spherical particles, and NWs also have
large remnant magnetization. The large remnant magnetization intensifies the effectiveness and range
of the magnetic interactions due to its favorable energy configuration [16], which results in magnetic
navigation being able to be carried out at deeper locations inside the body [17].
There are multiple fabrication methods for synthesizing NWs. These include chemical methods,
physical methods, electrodeposition, and electroless deposition [18], which use both the bottom-up and
top-down approaches. In the top-down approach, which is a subtractive technique, material is carved
of a larger starting material block, revealing the NW. On the other hand, the bottom-up approach is an
additive-type synthesis in which smaller particles are bound together to synthesize the NW [19].
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This review will focus on design of multifunctional systems of magnetic NW, including the
fabrication methods of magnetic NW; strategies and application of magnetic NW-based nanosystems
for cancer therapeutics; characterization of the magnetic NW nanosystems including toxicity,
cell internalization, drug loading, and release; and critical evaluation of the performance for NW-based
multifunctional nanosystems, for improved therapeutic outcomes.
2. Considerations and Applications of Magnetic Nanowires for Cancer Therapeutics
In order to design effective cancer therapeutic systems, the applications of the magnetic NW
must be tailored to achieve in the appropriate microenvironment of the targeted cancer, which the
therapeutic system is designed for. Thereafter, the most appropriate applications of magnetic NW must
be synergistically combined to validate the rational of incorporating the NW into a multifunctional
system. Below, the general considerations of tumor microenvironment will be discussed as well as the
applications of magnetic NW in a therapeutic system.
2.1. Considerations of the Microenvironment of Cancerous Tissue for the Design of Magnetic Nanowire
Therapeutic Systems
Tumor microenvironments play an important role in the biological impact of nanosystems as
well their distribution [20]. For nanosystems to be efficacious for cancer therapeutics, it needs to
attain a homogenous distribution intratumorally, however nanosystems need to overcome the tumor
microenvironment’s barriers, which are summarized by Fernandez and co-workers [21]. Although the
enhanced permeability and retention effect promotes extravasation of nanosystems intratumorally,
they must first overcome the high interstitial pressure, abnormal tumor vasculature, and dense
stroma, so that they may be efficacious. Explicit pathophysiological conditions of the targeted tumor,
such as functional proteins and levels of amino acids, as well as endogenous factors of the tumor
microenvironment must be considered in the design of optimal-nanosystems. These factors include
acidosis, hypoxia, hyperthermia, oxidative stress, enzyme activity, redox potential, and high interstitial
fluid pressure. However, these factors can also be exploited in the drug delivery design of nanosystems.
For instance, nanosystems can be designed to take advantage of the tumor acidic environment,
which differs from physiological pH to initiate drug release. This can be achieved by bonding the drug
to the nanosystems using acid hydrolysis sensitive covalent bonds [22]. Active targeting can also be
achieved using pathophysiological conditions of the targeted tumor. This is accomplished by binding
specific antibodies that bind to receptors expressed on the tumor cell such as attaching anti-Her2/neu
antibody to the nanosystem, which binds to Her2/neu receptors on the tumor cell membrane. Aptamers
and ligands can also be used in a similar regard [23]. A promising potential application of magnetic
NW drug delivery systems is the attachment of Wnt inhibitors. Traditionally, Wnt inhibitors are
restricted by high toxicity and inefficient drug delivery systems [24]. However, these limitations can
be overcome by a targeted and stimuli-release drug delivery system, which nanotechnology, and in
particular magnetic NWs, can achieve [24].
2.2. Cancer Therapeutic Applications Employing Magnetic Nanowires
Nanocarriers have been greatly reviewed and have shown to have great therapeutic benefits.
These advantages include the ability to increase the permeation of drugs across the epithelial lining
of the gut wall, half-life, and solubility of hydrophobic drugs. Nanosystems, on the other hand, are
favored due to its ability to overcome the limitations of conventional therapy. For example, being able
to selectively release drug, increase accumulation in the target organ, and design a targeting ability
within the nanosystems. Nanosystems also have the capability to perform multiple roles, such as
theranostics, measuring dose response, and drug efficacy.
NWs can be integrated into such multifaceted drug delivery systems coalescing the
inherent properties of NW and the efficacy of nanosystems, producing an advanced, modifiable,
and functionalizable platform for drug delivery. These platforms are most commonly in a hybrid
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inorganic-polymer NW orientation or synthesized as a silicon core. The NW being the inorganic core
while the surface coatings bring about a variety of biomedical properties. These surface coatings
use various stimuli to illicit responses in a way that allows the systems to become targeted, selective,
and stimulate drug release in order to increase therapeutic outcomes and decrease adverse effects
of therapy.
This combination is effective in the development of drug delivery platforms for cancer treatment
due to the unique merits it provides. It can enhance therapeutic effects by combating multiple drug
resistance in cancers or provide a synergistic combination of therapeutic effects. This combination
also allows for the accumulation of drug at the targeted tumor sites, thus reducing adverse effects of
treatment [25–28].
2.2.1. The Application of Magnetic Nanowires as Magnetic Drug Targeting Agents in
Cancer Therapeutics
Drug accumulation at specific tumor sites can be achieved when an external magnetic field is
used to draw out and trap magnetically active, drug-loaded nanoparticles from the circulatory system.
It is promising for its potential of increasing the saturation of drug at the required site while decreasing
the saturation in healthy tissue. Thus, reducing adverse effects and increasing therapeutic outcomes.
Magnetic targeting is thus dependent on two factors, a nanocarrier that is magnetically responsive and
a magnetic field gradient [29]. Magnet systems employed in magnetic targeting fall into two classes,
the use of an external magnet and the combination of an external magnet with an implanted magnet
near the target area [29]. Magnetic NW systems that are delivered into the blood stream must overcome
the viscous drag force of the blood stream. Therefore, the magnetic NW systems will potentially be
captured from the capillary blood flow by the external magnet to the target area. The large magnetic
moments of magnetic NW reduce the field gradient required to capture the NW [17]. To provide the
magnetic field and magnetic field gradient, there are currently two categories of magnet systems; static
field magnet systems and varying field magnet systems. Static field magnet systems are low cost,
convenient, and simple but lack targeting accuracy, while varying field magnet systems have high
targeting accuracy, which make it possible for employing three dimensional (3-D) precise targeting but
are energy consuming and require complex hardware systems and exact calculations [30].
Magnetic NWs have an inherent advantage over spherical nanoparticles such as superparamagnetic
iron oxide nanoparticles, as the anisotropy of NW allow for deeper tumors to be targeted and have a
higher drug loading capacity [12,31]. Pondman et al. created an iron-palladium (FePd) NW system
functionalized with oleic acid. This resulted in non-immunotoxic, non-cytotoxic delivery platform
granted, unsuccessful in accumulating the NW at the target site in pilot studies. Their FePd NW
dimensions were 1.9 ± 0.3 μm in length and 88 ± 15 nm in diameter resulting in an aspect ratio of
22. When a magnetic field was applied to the NW inside the template in three different directions,
0◦, 45◦, and 90◦ to the NW direction, the wires showed remanence in all three directions and when
tested in random orientations, provided a saturation magnetization (Ms) ± 80 A.m2/kg and a remnant
magnetization (MR) ± 25 A.m2/kg [17]. Pondman and co-workers performed in vivo studies using
Their FePd NW on rats. No negative reactions were shown after intravenous administration with no
FePd NW found in the kidneys and liver. The studies suggested a high circulation time due to the
immune response and first pass filtration of the kidneys not removing the FePd NW system. However,
they were not able to prove significant localization of their NW system at target site. This was likely
caused by the removal of blood from the rat in the fixation process [17]. Alsharif et al. iron (Fe) NW
with an aspect ratio of 75 had a Fe2O3 layer surrounding the Fe NW and provided much larger Ms and
MR of 427 A.m2/kg and 388 A.m2/kg, respectively. This confirmed its permanent magnetic properties
and is indicative of its greater potential as a magnetic targeting agent when compared to the FePd NW.
However, the Fe NWs will have a greater degree of aggregation, which will need to be overcome in
order to be effective and safe as a drug delivery system [32]. The magnetic properties of the cobalt (Co)
NW and functionalized Co NW of Zhu et al. was not characterized by a magnetometer. However, its
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potential for providing targeted chemotherapy was shown by suspending the Co NW, GO-Co NW,
and GO-PEG-Co NW in polyvinyl alcohol (PVA) solution (where GO is graphene oxide and PEG is
polyethylene glycol) and placed near an external magnet. This resulted in each group being attracted
to the external magnet within one minute [33].
2.2.2. The Application of Magnetic Nanowires as Hyperthermic Agents in Cancer Therapeutics
The use of NW as hyperthermic agents is promising due to its ability to be optimally structured
to provide thermal response to stimuli such as low-frequency alternating magnetic fields and of
near-infrared irradiation [34]. Hyperthermia involves the energy insertion into malignant tumors
resulting in the death of the cancer cells. It can be characterized into three states; diathermy (greater
than 41 ◦C), apoptosis (between 42 ◦C and 46 ◦C), and thermoablation (greater than 46 ◦C). Diathermy
stimulates tumor growth, apoptosis is the ideal range for cancer cell destruction, while thermoablation
stimulates heat-induced necrosis [35].
There are two modes of inducing magnetic hyperthermia in the presence of an alternating
magnetic field. These are the Brownian relaxation mechanism and the Néel relaxation mechanism [36].
The Brownian mechanism involves the NW rotation-vibration towards the direction of the external
magnetic field. This results in a mechanical friction caused by the magnetic NW in its suspended
medium, inducing the hyperthermia. The Néel mechanism involves the rotation of the magnetic
moment within the NW in an external magnetic field. Néel’s mechanism therefore induces hyperthermia
by the “internal friction” caused by the magnetic moment movement. The Néel mechanism provides a
more specific cell death mechanism as it induces minor mechanical damage to cells when compared
to the Brownian mechanism, which is non-selective in its mechanical damage of cell membranes.
In addition, heat induced in terms of hysteresis losses is dependent on the particular reversal mechanism.
This is usually mediated by the nucleation and propagation of a magnetic domain wall. The domain
wall is dependent on both the specific materials and geometry and can be of two types, vortex or
transverse domain wall. The domain wall dynamics influences the heating performance of the NW and
creates a certain maximum frequency in which a heating response is elicited [37]. Magnetic heating
has strong dependence on the magnetic properties of the magnetic NW [38]. Specific absorption rate,
which is used to quantify the heating efficiency, is increased when an alternating magnetic field equal
to or lower than the coercive field is applied. Therefore, metallic NWs such as Nickel (Ni) and Fe
have greater heating power when compared to Co due to their coersivity. The coercive field is also
influenced by the geometry of the NW. Consequently, the heating efficiency of thicker NW will be
greater than that of thinner NW and longer NW will be greater than shorter NW [38,39].
The recommended frequencies of electromagnetic fields lie between 50 kHz < f < 1 MHz as
physiological responses such as muscle (skeletal and peripheral) and cardiac stimulation occur with
increasing frequencies [40]. Choi et al. produced Ni NWs and successfully induced hyperthermia
in HEK-293 cells. This was achieved using radio frequency (RF) electromagnetic fields. The Ni NW
was internalized by the cells and after the application of a RF of 810 MHz [41]. Lin and coworkers
fabricated Fe NW with a coercive force of about 9.7 Oe. This provided a high saturated heating
temperature of 73.8 ◦C at a concentration of 500 ppm. During their cytotoxicity studies investigating
hyperthermia derived from Fe NW, they revealed a mortality rate of 80% for EMT-6 cells. This
highlights the feasibility of using Fe NW in hyperthermia therapy [36]. Alonso et al. synthesized FeCo
NW to study their potential in magnetic hyperthermia. They found that the Specific absorption rate
increased with an increase in length and obtained remarkable specific absorption rate values of ∼1500
W/g [39]. Hopkins et al. produced Ni-gold (Au) core-shell NW and for RF initiated hyperthermia for
thermotherapy. During in vivo, the NiAu core-shell NW was intratumorally injected into the mice.
A RF of 950 MHz and power of 10 W was then applied for 30 min with the mice under injectable
anesthesia with a second and third treatment carried out at day 20 and day 30, respectively, after the
first treatment. This resulted in significant damage to the malignant solid tumor on the mice [42].
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2.2.3. The Application of Magnetic Nanowires as Magnetic Actuation Agents in Cancer Therapeutics
Magnetic NW can induce cell death without a heat dependent mechanism in a magneto-mechanical
process as depicted in Figure 2 [43,44]. The first study of magnetic actuation induced cytotoxic effects
arising from alternating magnetic fields at low frequencies was studied by Zablotskii and colleagues [45].
They applied a high-gradient magnetic field with a low frequency (1–10 Hz) as well as mechanical
vibration on incubated mesenchymal stem cells. Their results suggested that both the mechanical
vibration and alternating magnetic field played an active role in the F-actin remodeling and succeeding
down-regulation of the audiogenic genes adiponectin AP2 and PPARγ.
 
Figure 2. Diagram showing proposed mechanism of action for magnetic actuation stimulating
a magneto-mechanical cell death in the presence of an alternating magnetic field. Adapted with
permission from [46].
This mechanism was later applied to a more cancer therapeutic approach by researchers.
The exemplary study of Contreras and co-workers exhibited the use of Ni NW for a non-chemotoxic
approach to cancer cell death. They fabricated Ni NWs with a length 4.1 ± 1.4 μm and a diameter of 30
to 40 nm. The Ms value measured was 46.7 A.m2/kg, which is lower than the reported literature value
for bulk Ni, which is 54.3 A.m2/kg [47]. This phenomenon was associated with the surface oxidation of
the Ni NW according to Contreras and co-workers. When comparing the array Ni NW to a single Ni
NW, the Ms increased to 47.4 A.m2/kg as the single Ni NW acts as a permanent magnet and is free from
magnetostatic interactions, which the array experiences and thus show single domain properties [48].
The behavior of magnetic NW is administrated by its magnetization in the presence of an alternating
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magnetic field. In the case of Ni NW, it is determined by the shape anisotropy and the NW axis
(magnetic easy axis) [44,49]. This results in the Ni NW to produce a torque when trying to align their
magnetic moment with the alternating magnetic field. This mechanism is applicable for all magnetic
NW with the same characteristic. Therefore, when the NWs are exposed to an alternating magnetic
field, they will experience torque, while trying to align the magnetic moment with the field. This torque
results in a force being applied on the cell, which leads to its death in the presence of an alternating
magnetic field as shown in Figure 2. Serrà et al. fabricated a multi-component Au/Ni–nickel oxide
(NiO) NW using pulsed potentiostatic electrodeposition. They incubated the NW with HeLa cells for
24 h, after which 70% of the NW were internalized. They observed 24% cell death after an alternating
magnetic field of 14 and 35 mT and 20 Hz was applied for 15 min. The segmentation of the NW assisted
in tailoring the MR, which in turn decreased the NW agglomeration, and the observed cell death was
not induced by magneto-mechanical effect due to the lower MR, but rather it was associated with the
NW vibration, which further highlights the association of magnetization and NW behavior [46].
Specific loss power (heat produced) frequency dependence is linear for ferromagnetic particles [50].
Therefore, in order to produce the heat required for thermoablation, the amplitude of the alternating
magnetic field necessary is ~10 kA/m and around 100 kHz frequency is required [51,52]. Magnetic
actuation cell deaths were induced at ranges largely below those thresholds. The Fe NW systems of
Martínez-Banderas and co-workers used a 1 mT, 10 Hz alternating magnetic field to induce cell death
while Contreras and co-workers used alternating magnetic fields of 0.5 mT and 0.1, 1, and 10 Hz to
induce cell death. This low amplitude and frequency requirement translate into lower cost of magnetic
actuation cancer treatment and increased safety of patients by reducing the risk of thermoablation [43].
This principle of inducing magneto-mechanical cell death by magnetic actuation can be applied to
cancer therapeutics to induce non-chemotoxic destruction to a malignant tumor. The advantage of
this is that it not only can reduce or eliminate chemotherapeutic side effects, it can also be used as an
alternative cell killing mechanism in multi-drug resistant cancer.
2.3. Magnetic Multifunctional Nanowire Systems in Cancer Therapeutics
The core principle behind formulating NW systems using a magnetic core is magnetic
navigation [17,53,54]. The ability to localize a delivery system using a non-invasive and relatively safe
force is highly remunerative in cancer therapy, as it allows the progression from the limitations of
traditional cancer chemotherapy by allowing therapeutic effects to be directly targeted at the tumor
site, thus reducing secondary effects. In addition to magnetic navigation, magnetic wires are used for
inducing cell death by magneto-mechanical means using magnetic actuation [43] and induced local
hyperthermia [55] by applying a low- and high-frequency alternating magnetic field, respectively.
Magnetic NW cores are functionalized by their surface modifications. These modifications alter
the pharmacokinetics of the magnetic NW systems, adjust the cytotoxicity, allow for attachments of
biomolecules such as ligands, and allow for the conjugation or entrapment of drugs [56]. Surface
modifications are also used to input a responsive behavior to the system usually to provide effects
such as triggered drug release or hyperthermia. The stimuli used to initiate such behavior include
a change in pH and radiation. The coalescence of the magnetic NW and stimuli-responsive surface
coatings create multifunctional magnetic NW systems that have potential advantages over traditional
cancer therapy. Figure 3a depicts Co NWs while Figure 3b,c depict Co NWs with surface modifications
that were designed to increase the biocompatibility, enable drug loading using electrostatic means,
and provide photothermal responsiveness from a stimulus (near-infrared irradiation).
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Figure 3. (a) Microscopy of unfunctionalized Co nanowires (NWs) portraying a rough morphology.
(b) Microscopy of stimuli responsive graphene oxide (GO) functionalized Co NW. (c) Microscopy of
GO-polyethylene glycol (PEG)-functionalized Co NW. Reproduced with permission from [33].
2.3.1. The Use of Magnetic Nanowire Magnetic-Chemo-Photothermal Systems in Cancer Therapeutics
The use of a multifunctional system that is magnetically targeted to deliver a chemotherapeutic
load to the tumor site, in addition to inducing a local hyperthermia in the tumor to induce cell death in
synergy to the chemotherapeutic drug, is advantageous for the following reasons; it decreases drug
adverse and side effects, enhances the efficacy of tumor destruction, and can potentially be used to
combat multi-drug resistance in chemotherapy. This approach was explored by Zhu et al. [33]. They built
this multifunctional nanowire system on Co nanowires treated with GO and PEG, which provided the
desired responsiveness to pH, magnetic fields, and near-infrared irradiation. A template-free reduction
method was used to synthesize the CO NWs in the presence of a magnetic field. This produced
unordered, irregular, and rough NWs on which the PEG and GO were coated. Three different groups
were produced, namely Co NWs, Co NWs-GO, and Co NWs-GO-PEG, and were characterized by
their drug loading ability, toxicity magnetic, and photothermal properties, which are discussed in
the relevant sections below. They produced a system that can potentially be magnetically targeted
to a tumor site, thereafter release the loaded drug due to the combined decrease in PH at the tumor
site, and an application of near-infrared irradiation, which both stimulates drug release and local
hyperthermia; thus, inducing cell death by both the drug and the local temperature increase. This is a
promising model; however, further studies need to be carried out to determine the in vitro and in vivo
magnetic targeting ability so that this system can be phased into clinical trials.
2.3.2. The Use of Magnetic Nanowire Magnetic Actuation-Chemotherapeutic Systems in
Cancer Therapeutics
Martínez-Banderas et al. conducted a study, which used the combined chemotherapeutic effects
of doxorubicin (DOX) and mechanical disturbances, induced by a low-frequency alternating magnetic
field, of their magnetic NWs to prompt cancer cell death. Their system was built upon Fe NWs with an
average length of 6.4 ± 1.3 μm and a diameter of 30 to 40 nm. The Fe NW were coated with bovine
serum albumin (BSA) and (3-aminopropyl) triethoxysilane (APTES) independently and additionally
functionalized with DOX. The Fe NW were synthesized using electrodeposition and formed NWs
of a monocrystaline nature. An interesting aspect of these Fe NWs was that it was found to have a
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4–10 nm thick layer of iron oxide on its surface (monocrystaline Fe NW surface oxide layer caps at
10 nm) [57] as compared to completely oxidized, which occur to polycrystalline Fe NW over time.
This ensures that an Fe core will remain. The oxidation most likely occurred when dissolving the
template in sodium hydroxide (NaOH) as the NaOH provides very good oxidizing conditions for Fe.
The Fe oxide interphase is important for two reasons. The first being that the remnant magnetizations
and magnetic saturation depend on the oxide thickness. The second being it provides a site for the
covalent attachment of surface coating. Martínez-Banderas and colleagues thus created a system in
which cell death was caused by the cytotoxic effect of DOX and structural damage to the cells by the
magneto-mechanical disturbances as shown when tested on MDA-MB-231 cells [11,58].
2.3.3. The Use of Magnetic Nanowire as a Theranostics System in Cancer
It is important to note the role of magnetic NW in theranostics, a paradigm shift promoting
personalization of treatment through the combination of diagnostics and therapeutics. The role of
magnetic NW platforms in therapeutics encompasses targeted and triggered release drug delivery,
photothermal therapy, and magnetic actuation systems as discussed above [59]. In terms of diagnostics,
the large surface area of NW increases the efficacy of fluorescence labelling while in terms of magnetic
NW, it increases the magnetic moment, making it attractive in fluorescence imaging and magnetic
resonance imaging (MRI), respectively. Contrast agents for MRI are grouped into two categories,
namely T1 and T2. The distinguishing factor between T1 and T2 agents is that T1 is based on longitudinal
magnetization recovery while T2 is based on transverse magnetization decay [60]. In this regard,
Fe and Ni NW have been shown to be useful T2 contrast agents with Ni NW being comparable to
commercial agents [61,62]. The effectiveness of NW in both therapeutics and diagnostics makes NW
and magnetic NW an attractive prospect for designing theranostics systems for cancer.
3. NW Fabrication and Synthesis of Magnetic Nanowire Drug Delivery Systems
3.1. Fabrication Methods of Magnetic Nanowires
There are two main approach strategies for the fabrication of NW. Namely, the bottom-up and
top-down approaches. The bottom-up approach involves the spontaneous assembly of small substrates
(atoms or molecules) into the desired nanostructure while the top-down approach involves the
breakdown of a suitable starting material until the desired nanostructure is formed [63].
A common top-down technique is lithography. Lithography is further divided into various
techniques including photolithography and electron beam lithography. The main principle of these
techniques is that a pattern is engraved onto an underlying substrate and the desired material
is transferred onto the pattern. Therefore, these techniques are a hybrid of the top-down and
bottom-up approaches.
These techniques have the advantage of easily being scaled up and can be used for the production
of one- and two-dimensional particles that has at least one lateral dimension in the nanoscale range,
however the resolution achieved is low and has etching and coating constraints, thus making it
impractical for the use in drug delivery [63,64].
Bottom-up techniques enable the synthesis of complex structures such as non-straight vertical
structures, structures made up of multiple components, and structures that have changes in the chemical
composition. The main advantage provided by bottom-up techniques is the ability to synthesize
structures with high aspect ratios. Bottom-up techniques employ chemical [33,65], physical [66],
and electrochemical [67] methods to produce nanowires.
The NW fabrication techniques are summarized in Table 1, noting the advantages and
disadvantages of each while selected fabrication techniques of promising methods used for the NW
synthesis in drug delivery are discussed in further detail below, further highlighting the advantages
and disadvantages of the technique and evaluating the potential for each technique to advance
drug delivery.
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3.1.1. Electrodeposition of Magnetic Nanowires
A very convenient and common method for nanoparticle synthesis is electrodeposition. It was
traditionally used as a conventional surface modification method for adjustments of surface morphology
and characteristics and can be used to fabricate nanoparticles of single or multiple composition [78–81].
Electrodeposition is the formation and deposition of solids through electrochemical reactions. These
solids are usually formed by the reduction of an electroactive species contained in an electrolyte by
applying a potential. This distinguishes it from electroless deposition in which a reducing agent
replaces the applied potential [82].
A further distinction can be made in the electrodeposition of NW; deposition using templates and
template-less deposition [70]. There are two types of templates, soft templates and hard templates.
Soft templates are non-rigid structures that are used to control the direction of growth and therefore
resultant shapes of nanoparticles produced. Soft templates include surfactant aggregates, micelles,
and co-block polymers, and can be used to generate porosity and texture control of the resultant NW.
The downside of soft templates is that the baths containing the soft templates usually express a low
conductivity, which in turn hinders the electrodeposition process. Hard templates are rigid structures
that are conductive on one end and regulate the size and shape of the synthesized nanoparticles by
the shape of the template itself. The pioneering work of Possin first demonstrated this principle of
fabricating small diameter NW in porous membranes [83]. Hard templates are extremely versatile,
convenient, and are recurrently used in the synthesis of NW. The most common hard templates are
anodized alumina, polycarbonate membranes, and mesoporous materials [84]. Hard templates allow
for the synthesis of freestanding NW as well as both orientated and non-orientated NW. They also
facilitate the synthesis of complex one-dimensional NW [70]. The downside of using hard templates
include the removal of the template as it can affect the NW, diffusion of the electroactive species
through the narrow diameter pore channels, difficulty in upscaling due to the difficulty of producing
large templates with homogenous pore distribution (with small pore diameters), and the difficulty of
producing templates with uniform pore diameters. When no physical template is used for controlling
the morphology and shape of the produced nanoparticle, deposition rates are used in its place. Control
of deposition rates is achieved by the modification of current density concentration of the electroactive
species, temperature, and applied potentials.
Electrodeposition therefore has the potential of producing NW for effective drug delivery systems
as precise control of the NW dimensions can be achieved, which is essential for positive cell interaction,
control of magnetic ability, and drug loading. This technique can produce a variety of non-toxic,
biocompatible NW including iron oxide, iron, and iron–palladium NWs, as well as segmented NWs in
a convenient, scalable, and reproducible way; thus, providing a stable platform in which drug delivery
systems can be engineered onto while keeping the inherent benefits of a NW for multifunctional systems.
3.1.2. Pulsed Laser Deposition of Magnetic Nanowires
Another common and valued growth mechanism for the synthesis of nanowires is pulsed laser
deposition (PLD) [85–88]. A pulsated high-powered laser beam is used to excite the surface energies of
a target substrate in a controlled atmosphere producing an ejected plume. The vapor is then deposited
onto a sample stage producing thin films or nanoparticles with the same composition as the target.
PLD allows for synthesis of nanoparticles with a monocrystalline nature, high purity, and low defects
to be synthesized. Other advantages of PLD is that it has a fast production rate and it is scalable.
Shkurmanov and co-workers studied the growth of zinc oxide (ZnO) nanowires via PLD in order
to understand the mechanism in which the nanowires are formed [89]. They observed that the NW
growth was non-linear and can be explained in terms of the number of laser pulses applied and its
interaction with four distinct flows of particles. The first flow forms the nuclei in which the NW will
grow from, while the second flow is responsible for the vertical growth of the nanowire. The third
flow was found to cause a backflow and decreased the length of the NW. Lastly, the fourth flow was
277
Cancers 2019, 11, 1956
responsible for the lateral growth of the NW. This proved that geometric parameters can be controlled
when using PLD.
An exemplary study of Nikov et al. paved the way for the formation of magnetic NW using PLD
by employing the aid of a magnetic field [87]. This study provided a simple method of producing
magnetic NWs, which increases its industrial value. This method also produces NWs composed of
smaller nanoparticles. This property can be exploited to potentially positively affect drug loading
capabilities of drug delivery systems. Furthermore, Nikov and co-workers used this method to
fabricated iron oxide NW [90]. This study further demonstrated that the pressure and surrounding gas
can be used to manipulate the type of oxide formed. Another interesting effect of the magnetic field is
that it allowed the deposition of the iron oxides in arranged nanowire structures at a low pressure and
a target substrate distance of 40 mm.
PLD provides an effective method of producing NW arrays, which are especially promising in
implantable and transdermal drug delivery systems. It excels in producing NW composed of magnetic
materials, which is a property that can be exploited in the development and commercialization of
multifunctional drug delivery systems.
3.1.3. Other Synthesis Techniques of Magnetic Nanowires
There are various other fabrication techniques in which NWs can be synthesized. However,
the most promising fabrication technique is electrodeposition due to its precise dimension control.
These techniques are commented on in Table 1 and include atomic layer deposition, chemical vapor
deposition, pulsed laser deposition, focused electron beam induced deposition, chemical reduction,
solvothermal, hydrothermal, sol-gel, and lithography techniques such as photolithography and electron
beam lithography.
3.2. Magnetic Properties and Advantages of Nanowires in Drug Delivery Systems
NW are synthesized from both magnetic and non-magnetic substrates. Both NW and magnetic
NW offer potential advantages over nanoparticles and magnetic nanoparticles due to their larger
surface area to volume ratio (high aspect ratio), which allows for greater drug loading, increased
attachment sites, for decorations such as proteins, peptides, and polymers, and increased binding to
cells. Magnetic NW have greater advantages when compared to magnetic nanoparticles due to their
strong shape anisotropy and energetically favorable magnetization. They provide greater magnetic
moments and in the presence of an alternating magnetic field, can either provide mechanical motion by
aligning to the magnetic moment with an applied low-frequency alternating magnetic field or induce a
local hyperthermia at a high-frequency (~100 kHz) alternating magnetic field [11].
The most frequently used materials for synthesizing the magnetic components of magnetic NWs
for drug delivery systems are Fe, Ni, Co, as well as their compounds and alloys. Magnetic NWs
display specific advantages when compared to spiracle and other nanoparticles as well. The increased
aspect ratio of ferromagnetic NWs provides stronger magnetic moments per unit volume and large
remnant magnetizations without decreasing the mobility of the nanoparticles. The larger remnant
magnetization allows the NW to be used in low-field environments, which in turn translates into NWs
being able to target deeper tissues with smaller and weaker magnets as the geometry of NWs has an
increasing effect on force applied by the magnetic field. NWs with aspect ratios greater than three
show larger magnetic dipoles when compared same volume spherical nanoparticles [12]. This results
in the potential of a more efficient magnetic system to be designed for magnetic drug targeting for
cancer therapeutics.
3.3. Stabilization and Functionalization of the Magnetic Nanowires
The surface area of NWs are decorated with coatings mainly for three intended purposes:
To increase the biocompatibility of the NW, stabilize the NW (prevent NW agglomeration), and to
functionalize the NW in order to tailor the NW to excel in the niche of interest [43].
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The work by Zhu et al. used a coating of PEG and GO to both stabilize and functionalize their Co
NW, thereby increasing its drug loading capacity and biocompatibility. Both the PEG and GO were
attached to the Co NW by electrostatic adsorption using an ultrasonic dispersion method. The GO
played a dual role; to enhance the photothermal therapy efficacy, as it is a known photothermal agent,
and to provide attachment points for the loaded drug (Doxorubicin) [33]. When irradiated with a
808 nm laser for six minutes, the Co NW and GO-functionalized CO NW heated to a temperature of
39.1 ◦C and 40.6 ◦C, respectively, indicating the ability of GO to improve the excellent photothermal
effect of Co NW.
Magnetic NWs can also be functionalized by the attachment of antibodies to target specific cells,
thus increasing its selectivity. Contreras et al. successfully functionalized their Ni NWs with EGFR
antibody (ab62 abcam®). This was achieved by first modifying the antibody with N-Succinimidyl
S-acetyl thioacetate. Thereafter, it was further modified to introduce sulfhydryl groups so that it could
attach to the Ni NW [91].
The NW system of Martínez-Banderas and research group was tested with three distinct coatings,
BSA, APTES, and APTES-PEG. The BSA and APTES were covalently bonded to the surface Fe2O3
interphase of the Fe NW while they functionalized APTES with PEG by activating the APTES with
sulfhydryl groups and the reacting with the thiol group in thiol-PEG, thus achieving disulfide bonds.
The three coatings were compared using MDA-MB-231 breast cancer cells, which were incubated
with the coated Fe NW and added cyanide Fe salt. Bright field imaging was used to determine the
distribution, size, and morphology of the Fe NW agglomerates. All three coatings reduced the size of
the agglomerates, thus ensuring a greater homogeneity of the Fe NW distribution across the sample.
APTES-PEG had the least efficacy of this effect [11]. Figure 4A,B depicts the transmission electron
microscopy image of the APTES-NW and BSA-NW respectively, visualizing the coating on the NW.
 
Figure 4. Figure showing surface modifications on magnetic NW for stabilization. (A) (3-aminopropyl)
triethoxysilane (APTES)-coated Fe NW. (B) Bovine serum albumin (BSA)-coated Fe NW. Reproduced
with permission from [11]. Scale bars: 50 nm.
Contreras and co-workers did not stabilize their Ni NWs with any coating, which thus caused the
aggregation of the Ni NW. The Ni NW zeta potential was measured to be a low value of −15.1 mV [92].
This value infers a weak electrostatic repulsive force which correlates with Contreras’ observation of
released Ni NW aggregating. This study highlights the efficacy of surface coatings to stabilize NW
in terms of aggregation of the NW. Preventing the NW tendency to aggregate is essential as particle
aggregates in the bloodstream can cause an embolism, while in tissue it can cause heterogeneous
cytotoxic activity. Martínez-Banderas and research group managed to reduce the aggregation of Fe
NWs, which is known to have higher remnant magnetization, which makes it inherently unstable.
The stability of the Ni NW can be increased with surface modification such as coating with charged
polymers or non-magnetic metal such as Au. The increase in magnetic NW stability increases its
desirability in drug delivery as it will allow for safer therapy a formulation with a longer shelf life.
Stabilizing NW is therefore indispensable in the design and formulation of NW drug delivery
systems as it prevents the aggregation of magnetic cored NW caused by their remnant magnetization.
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This, in turn, reduces the probability of mechanical obstruction in the circulatory system caused by
NW aggregation. Therefore, NW coatings allow for the optimal design of multifunctional systems,
which is essential in potentially improving cancer therapeutic outcomes.
3.4. Chemotherapeutic Drug Loading and Release of Magnetic Nanowire Systems
Large surface area has a positive influence on the drug loading capacity of nanosystems. Thus, NW
morphology has a direct impact on drug loading capacity. Although NWs inherently have large
surface areas, their surface area can be increased further by changing their morphology to include
rough surfaces [93,94] or by synthesizing porous NWs [95,96]. Guo and co-workers achieved a
high drug loading of 2000 mg/g using porous NW while Zhu and co-workers achieved a high drug
loading capacity of 992.91 mg/g with their Co NW, which had a rough morphology. The GO in the
functionalized Co NW of Zhu and research group provided attachment points for DOX or other
therapeutic agents as it is decorated with many functional groups on its surface such as hydroxide
radicals. In the case of DOX, it is hypothesized that it is also able to absorb directly onto the GO via
π-π interactions. Their NW system also exhibited a higher drug release profile in acidic environments
and after near infrared radiation when compared to the control [33]. The decrease in PH made the
DOX more hydrophilic and soluble due to the protonation of the NH2 group on it, thus causing the
release from the Co NW-GO. They also proved a direct correlation between drug release and laser
power intensity.
The BSA and APTES coated Fe NW of Martínez-Banderas and colleagues were functionalized
using PH responsive covalent bonds. This was achieved by introducing free thiol groups to the coated
Fe NW by reacting 2-IT and amine groups on the coated Fe NW. The free thiol groups were then reacted
to the maleimide group of a DOX derivative (5-Maleimidovaleroyl) hydrazone of Doxorubicin in order
to attach it. This yielded low loading capacities of 50 μmol DOX/g Fe (27 mg/g) for the DOX-APTES-Fe
NW and 25 μmol DOX/g Fe (13.6 mg/g) in the case of DOX-BSA-Fe NW [11]. The low loading was
due to the relatively smooth surface of the Fe NW, highlighting the importance of morphology on
drug loading.
4. Cellular Interactions and Toxicity Between Magnetic Nanowires and Cells
4.1. Cellular Internalization of Magnetic Nanowires
Cellular internalization of NW supports the NW utilization and efficacy. There are three main
potential uptake mechanisms for nanoparticles; receptor-mediated endocytosis, pinocytosis, and
phagocytosis [97]. NW suffers an inherent disadvantage when compared to spherical nanoparticles
in terms of cell internalization. It is speculated that the different curvatures between the two shapes
has a direct effect on cell binding. When the longitudinal axis of NW is bound to the cell membrane,
the larger surface contact area blocks available membrane receptors, thus reducing cell internalization.
There are many factors that govern cell internalization of nanoparticles besides shape. These are
extensively discussed in a review conducted by Murugan et al. of the Wits Advanced Drug Delivery
Platform, South Africa [98]. Briefly, in order to design smart nanosystems, an understanding of
physicochemical properties is essential. Other determinant factors in terms of cell internalization
include uptake pathways and interaction of the nanoparticles with receptors. Neutral and cationic
nanoparticles have higher transport efficiency into the cells when compared to negatively charged
nanoparticles [99,100]. This phenomenon is the result of anionic particles having smaller binding
efficiency to cell surfaces when compared to cationic and neutral particles, leading to a reduction
in membrane-wrapping phenomena resulting in a decrease in cellular internalization [99,101,102].
Hydrophilic outer protective layers increase circulation time while nanoparticles functionalized with
proteins or peptides directly increase cellular uptake by localizing the nanoparticle at the targeted site,
receptor-mediated endocytic pathways, and direct cell penetration. Nanoparticle size also plays an
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important role in cellular uptake; 95–200 nm is the ideal size according to the literature for increased
cellular uptake [103]. In terms of NWs, high aspect ratio NWs can also be internalized [104].
Fe NW also have good cell internalization as shown by [105] and further demonstrated by
Martínez-Banderas and co-workers. Martínez-Banderas and co-workers had a total cell internalization
for their APTES-Fe NW and BSA-Fe NW of 19% and 15%, respectively. These values were determined
using Inductively Coupled Plasma Mass Spectrometry (ICP-MS) measurements on their incubated
cells with the coated Fe NWs. The results yielded no significant difference for the APTES-Fe NW
and BSA-Fe NWs in the cellular internalization [11]. Figure 5A,B shows the cellular uptake using
HeLa cells of uncoated, positively charged, non-uniformly sized Fe NWs of Song and co-workers.
The weakly negatively charged Ni NW of Contreras and research group also had a high affinity
to cell internalization. Similar results were achieved for other Ni NWs, including those with large
lengths [106]. The cellular uptake of FePd NW of Guo and co-workers was studied on RAW264.7
and HeLa cells. Both cell lines took up both single NW and NW clusters with RAW264.7 cells having
greater cell internalization, suggesting rapid removal from blood stream.
 
Figure 5. Cellular internalization and accumulation of magnetic NW into cells. (A,B) Internalized Fe
NW in HeLa cells. Adapted with permission from [105]. Scales bars: 10 μm.
4.2. Cellular Toxicity of Magnetic Nanowires and Drug Loaded Magnetic Nanowires
Toxicity is important when designing nanosystems. The coatings used in NW systems are usually
well-known biocompatible molecules used to counter the toxicity of toxic inorganic NW. Common
NWs used in NW systems are silicon, Au, silver, Co, Fe, and Ni, amongst which Co, Fe, and Ni and
their compounds produce magnetic NWs. From these, Co and Ni are the most toxic while Fe and
silicon are deemed biocompatible. However, in comparison to Fe NW, a large number of studies have
been conducted on Ni NW despite Ni’s known cytotoxicity, carcinogenicity, and genotoxicity [107,108],
and the literature reveals that Fe is less toxic. The reason for this is that the large remnant magnetization
of Fe NWs causes stronger aggregation and thus limits its use in the single NW form. Metal alloys are
also used to synthesize NWs, such as iron palladium (FePd) NWs. FePd NWs are non-toxic and do not
readily undergo oxidation [17,109]. Si NWs are also known to be non-toxic, have high biocompatibility,
improve hydrophilicity, and can be made magnetic by decorating with Fe oxide nanoparticles. In terms
of the effect of the NW length on cellular toxicity, Donaldson et al. reviewed the effect of fiber like
particles and found that longer fibers were more toxic then shorter fibers [110]. However, Song et al.
showed that at the same concentration, Fe NWs of shorter lengths (2 μm) were more toxic then longer
lengths (5 μm) of Fe NWs [105]. According to Song et al., this was attributed to smaller size particles
having greater cellular internalization [111].
The toxicity of magnetic NW can be altered by surface modifications of the NW. Zhu et al.
conducted biocompatibility tests of their GO and PEG decorated Co NW by determining its cytotoxicity
using 3T3 and 4T1 cells and hemocompatibility by determining if the Co NWs, Co NWs-GO, and
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Co NWs-GO-PEG caused thrombosis or hemolysis. The Co NW itself was found to be very toxic.
However, the addition of GO and PEG decreased the cytotoxicity of the system to a great extent.
The cell viability of 3T3 and 4T1 cells after culturing with the NW was 35% and 32%, respectively,
for the Co NW, while it increased to 96% and 89%, respectively, for the Co NWs-GO-PEG for both at
50 μg/mL concentration. Their results also show no significant difference in the thrombosis time and
did not cause hemolysis [33].
Applying an alternating magnetic field to magnetic NW while it is incubated with cells increases
the toxicity of the NW. When incubating their Ni NW with HCT116 cells, Contreras and co-workers
measured no significant drop in cell viability using 2.4 μg/mL of Ni NW without the presence of an
alternating magnetic field, while at a concentration of 12 μg/mL, the cell viability dropped to slightly
below 90%. When an alternating magnetic field is applied at 1 Hz, 0.5 mT for 1 h, the cell viability for
2.4 μg/mL drops to around 75% while using a concentration of 12 μg/mL causes the cell viability to
drop to slightly below 70%. This shows that higher concentrations of magnetic NWs have a greater
effect at inducing cell death [43].
The cellular toxicity of magnetic NWs increases when functionalized with cytotoxic agents both
with and without the presence of an alternating magnetic field. Martínez-Banderas and co-workers
conducted cell studies for their Fe NW systems using Alamar Blue assay and MDA-MB-231 cells to
determine their systems ability to induce cell death in cancer by combining the cytotoxicity of DOX
and the mechanical motion provided by the low-frequency alternating magnetic field. Their results
showed that alternating magnetic field without the Fe NW systems had no effect on the cell viability
and cytotoxicity of DOX. The coated Fe NW systems without the alternating magnetic field present
had no significant decrease in the cell viability, which is testament to its biocompatibility while when
in the presence of an alternating magnetic field produced a significant decrease in cell viability of 23%
and 28% for the and APTES- Fe NW (26 μg of Fe/mL) and BSA-Fe NW (28 μg of Fe/mL), respectively,
showing possible cancer cell death by Magnetic actuation. For the DOX-Fe NW systems, they showed
a decrease in cell viability of 54% and 58% for DOX-APTES-Fe NW (26 μg of Fe/mL, 1.3 μM DOX) and
DOX-BSA-Fe NW (28 μg of Fe/mL, 0.73 μM DOX), which is indicative of their selective intracellular
drug release and the efficacy of Fe NW as nanocarriers. The addition of an alternating magnetic
field to the DOX loaded Fe NW systems yielded a further 10% and 8% reduction in cell viability for
DOX-APTES-Fe NW (26 μg of Fe/mL, 1.3 μM DOX) and DOX-BSA-Fe NW (28 μg of Fe/mL, 0.73 μM
DOX), respectively, showing a weak additive effect instead of a synergistic effect for the combination of
chemotherapy and magneto-mechanically induced cancer cell death [11].
It is interesting to note that although the BSA-Fe NWs had a lower drug loading capacity compared
to APTES-Fe NWs, their efficacy in cytotoxic activity was similar. This was attributed, according
to Martínez-Banderas and research group, to the greater cell internalization of the BSA-Fe NWs.
Another point of interest is that NW can be used for the separation of biomolecules, their purification,
and manipulation, which is applicable in the development of biosensors. This technology can lead
to the ability to effectively detect circulating tumor cells leading to a better prognosis for cancer
patients [112].
4.3. Cellular Degradation of Magnetic Nanowires
Understanding carrier degradation or metabolism is important in nanoparticle drug delivery
to ensure high therapeutic efficacy [113]. The innovative work by Safi et al. revealed that cells are
able to degrade NWs as well as decrease the size of the aggregates with their remains found directly
dispersed in the cytosol or in vesicular compartments. Singular NWs, on the other hand, were found
in endosomal compartments only [114]. Fe NWs and Ni NWs have oxidized surfaces and continue
to be oxidized, degraded, and dissolved intracellularly by the lysosomal compartments. Perez et al.
reported that ~2% of the Ni NWs dose was dissolved intracellularly after 71 h [115] and Fe experienced
the same fate with the lysosomes without cytotoxic contribution. The fate of both the degraded and
non-degraded NWs is potentially renal clearance. High aspect ratio nanoparticles have been found to
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be renally clearable with high efficiency of elimination. This is caused by the flow orientation of high
aspect ratio nanoparticles, which aligns the long axis of the nanoparticle to point to the glomerular
capillary pore openings [116].
5. Conclusions and Future Prospects
The application of magnetic NW has great potential for improving therapeutic outcomes for cancer
therapy. They provide the benefits of traditional nanoparticles in addition to the inherent advantages of
NW, thus making NW an ideal platform to build multifunctional nanosystems upon. However, the full
potential of magnetic NW in drug has yet to be reached as further applications and functionalizations
that can be molded onto the versatile magnetic NW platform such as Wnt inhibitor delivery systems,
attachment of ligands in order to increase the selectivity, and a theranostic system that includes the
attachment of fluorescent compounds, chemotherapeutic drugs, and modifications that increase cancer
cell selectivity, require further research. Effective in vivo studies for multifunctional NW nanosystems
is essential for the progression of this technology into the pre-clinical phase. The magnetic applications
of NWs such as magnetic hyperthermia, magnetic actuation, and magnetic drug targeting has shown
great potential for improving cancer therapeutics and therefore requires further research to optimize
an efficacious multifunctional therapeutic system that will better the prognosis and increase the quality
of life for cancer patients. Improvements can be made in tumor targeting so that magnetic NW can be
accumulated into the tumor using a three-dimensional targeting model. The control of temperature
change needs to be studied and optimized in in vivo studies.
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Abstract: Starting with the enhanced permeability and retention (EPR) effect discovery,
nanomedicine has gained a crucial role in cancer treatment. The advances in the field have led to
the approval of nanodrugs with improved safety profile and still inspire the ongoing investigations.
However, several restrictions, such as high manufacturing costs, technical challenges, and effectiveness
below expectations, raised skeptical opinions within the scientific community about the clinical
relevance of nanomedicine. In this review, we aim to give an overall vision of the current hurdles
encountered by nanotherapeutics along with their design, development, and translation, and we offer
a prospective view on possible strategies to overcome such limitations.
Keywords: cancer nanomedicine; EPR effect; tumor microenvironment; nanoparticles;
nano–bio interactions; clinical translation
1. Introduction
Nanomedicine is an emerging key technology of the 21st century. Although the fundamental
concept of a new era of nanotechnology dates back to 1959 with the renowned visionary speech of
Richard Feynman at Caltech [1], the optimistic expectation that nanoparticles and other nanoscale tools
could be successfully exploited to improve the diagnosis and pharmacological treatment of several
human diseases was only first established in the 1990s [2]. During the last three decades, we have
witnessed impressive advances in the field, and our scientific understanding of the mechanisms
regulating matter organization and interaction with biological systems at the nanoscale has progressed
significantly. Nanomedicine, taking advantage of the use of engineered particles having size typically
ranging from 1 to 100 nm, aims to exploit nanotechnology for several biomedical applications,
mainly disease treatment, diagnosis, and molecular imaging, as well as regenerative medicine and
tissue engineering. From the beginning, nanomedicine has been frequently associated with the use of
nanoparticles in oncology [3].
In 1986, Maeda and coworkers observed a substantial accumulation of macromolecules in
the tumor tissue attributable to a hyperpermeable neovasculature and compromised lymphatic
drainage [4]. In principle, the fenestrated endothelial wall in proximity to tumor tissues
represents a sort of privileged gate giving selective access to particles in the sub-micrometer
scale. Since then, the so-called enhanced permeability and retention (EPR) effect has been
validated for particles up to 400–600 nm [5], becoming the pillar of the research in cancer
Cancers 2019, 11, 1855; doi:10.3390/cancers11121855 www.mdpi.com/journal/cancers291
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nanomedicine [6]. The general purpose was to improve the performance of chemotherapeutics,
both in terms of efficacy and safety. These efforts resulted in the approval of several innovative
nanodrugs and still inspire ongoing investigations [7]. However, after 30 years of exciting discoveries,
together with the progress in clinical exploitation, several challenges and limitations are now
emerging. Notably, nanomedicine-based treatments often resulted in the lack of, or the limited
gain in, overall patient survival [8]. For instance, the first approved PEGylated liposomal
doxorubicin formulations (Doxil®, Baxter Healthcare CorporationDeerfield, IL, USA and Caelyx®,
Janssen Pharmaceutica NV, Turnhoutseweg, Beerse, Belgium) showed improvements in safety but
not in efficacy compared to the standard therapies [9]. Moreover, although all the attempts to develop
advanced nanosized drug delivery systems (DDSs) alternative to the conventional approved liposomal
formulations, their clinical translation has been frequently hampered by several technical and cost
challenges. Therefore, a serious skepticism towards the use of pharmacological nanocarriers (NCs) is
growing in the scientific community [10–12].
However, such uncertainty seems to be somewhat overestimated. Indeed, the mentioned
limitations highlight the poor understanding of tumor biology as a consequence of the incomplete
predictability of the available preclinical models and the large heterogenicity in the patient population.
Particularly, the relevance of the EPR effect, which was acknowledged as the “royal gate” in the
DDS field, should be now reconsidered in the light of the inter- and intra-patient variability [13].
Additionally, deeper comprehension of the nano–bio interactions may point out new perspectives as
well as indicate the most promising approaches to be pursued. Indeed, besides ameliorating the delivery
of small chemotherapeutic agents to the tumor cells, new strategies are currently under investigation,
including the possibility of exploiting nanoparticles for biologics administration and targeting or
activating cellular populations different from the cancer cells (e.g., improving the immunotherapy
efficacy) [13,14].
This review aims to disclose the current hurdles encountered in the clinical translation of
nanotherapeutics that have been validated at the laboratory level, focusing on the products’
development as well as their biological fate after in vivo administration. We also discuss the
nanomedicine impact in the oncology field and propose innovative strategies for maximizing
their performance.
2. State of the Art in Nanomedicine Research
The main purpose of this section is to give a general picture of the biological processes in which the
NCs are involved, once administered in vivo, as well as their clinical implications. However, it is worth
mentioning that the NCs’ fate and therapeutic outcome is strongly affected by their particular chemical
composition and other specific structural features, including surface properties (e.g., charge and
hydrophilic to hydrophobic ratio), general physical characteristics (e.g., size, shape, and stiffness) and
functionalization (Figure 1).
2.1. Protein Corona
One of the main issues relating to the clinical translation of NCs is represented by the lack of
comprehensive knowledge about the interaction between NCs and biological fluids. In particular,
the high protein concentration of the physiological environment greatly affects the NCs’ biological
behavior. Indeed, in response to the characteristics of the administered nanoparticles, endogenous
proteins promptly adsorb on the surface, creating the so-called protein corona (PC). As established by
several groups, this layer is highly dynamic, and its composition is strongly influenced by the biological
milieu [15,16]. The protein adsorption impacts particle size, stability, surface properties, and defines
the NCs’ biological identity and, therefore, their fate [13]. For instance, binding with opsonins
(e.g., IgGs and complement proteins), as well as some conformational changes in the attached proteins,
trigger NCs uptake by the mononuclear phagocyte system (MPS) [17]. Although in early studies,
the PC relevance was confined to some undesirable effects, including NCs clearance and activation of
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the immune system, it is now believed that in several circumstances, PC also dictates the cellular uptake
and intracellular localization of NCs [17–19]. While most studies involving nanoparticles as DDSs were
originally intended to discourage the protein adsorption by surface coating with hydrophilic polymers
(e.g., polyethylene glycol, PEG; zwitterions; carbohydrates; etc.), more recently, some innovative
strategies have attempted to benefit from these spontaneous interactions. Such strategies may be
accomplished by promoting the adsorption in vivo or by decorating in vitro the NCs surface with
specific proteins, which decrease the MPS uptake and/or preferentially lead to a targeted delivery [20].
A recent example of the latter approach was the regulation of the PC formation by precoating the
NCs with a HER2 affibody–glutathione–S–transferase fusion protein. This study demonstrated that
the formation of a protein shield reduces the adsorption of serum proteins maintaining the selective
targeting ability of the targeting molecule [21].
Figure 1. Tunable physical and chemical properties of nanocarriers (NCs).
Considering the multitude of processes in which the PC is directly involved, it is of paramount
importance to better understand the driving forces that lead to the PC formation and how it can be
manipulated to predict the NCs’ fate after their administration in vivo. Nowadays, despite many
efforts, a validated model to mimic the in vivo PC generation, as well as an affordable characterization
method, are still missing.
2.2. Pharmacokinetics and Biodistribution
Several parameters affect the pharmacokinetics and biodistribution of NCs, including the
administration route and NCs’ features, such as size, shape, surface, and mechanical properties.
After systemic administration, the major clearance organs are lungs, liver, spleen, kidneys;
the relationships between the biodistribution in such organs and the NCs properties are reported
in Table 1. In general, for particles above the renal threshold (size > 5.5 nm) [22], the elimination
is performed by tissue-resident macrophages, monocytes, and dendritic cells belonging to the MPS,
although the role of endothelial cells has been recently reconsidered [23,24].
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Table 1. Properties-dependent clearance of nanocarriers (NCs).




Renal excretion is particularly relevant for NCs below the threshold value (ca. 5.5 nm) [25].
MPS clearance is operated by liver>spleen>lung phagocytes. However, the spleen and lung fraction
increase with the particle size: NCs > 150 nm are more prone to splenic filtration, while lung













It is generally accepted that positively charged NCs are more rapidly sequestered by MPS than negative
and neutral NCs due to the highly-dense coating of serum proteins formed on the administration [27].




PE NCs’ shape determines the movement in blood circulation and the organ-specific biodistribution [25].
Spherical NCs presented the longest circulation time, while rod-, disc-, cage- particles exhibited an






Due to the intrinsic deformability, soft NCs have prolonged circulation lifetimes and reduced splenic
accumulation when compared with rigid NCs [30].
As already mentioned, several strategies have been developed to escape the MPS recognition,
and the most established exploits antifouling polymer grafting (e.g., PEG) onto NCs surface.
Thus, some clinical products (i.e., Doxil® and Onivyde®, Les Laboratoires Servier Industrie,
Route de Saran, Gidy, France) take advantage of PEGylation to facilitate the immunoevasion.
However, the steric barrier created by this polymer does not specifically prevent the interaction with
the MPS. Additionally, in some patients, phenomena such as complement activation, infusion reactions,
and the production of PEG antibodies have been observed [31–33]. Alternative and more effective
strategies are currently under investigation, including the functionalization with CD47 self-peptide
and the use of engineered extracellular vesicles or cell membrane-coated particles [34,35]. All these
approaches are intended to prolong the circulation time of NCs, although the extended half-life is
not always associated with an improvement in the tumor accumulation. In this context, the drug
release kinetics (Section 2.5), along with target accessibility (Section 2.3), have been demonstrated to
significantly contribute to the treatment response.
2.3. Tumor-Specific Accumulation
A tumor mass consists of proliferating cancer cells and stromal cells (i.e., fibroblasts, immune,
and perivascular cells), supplied with a dense extracellular matrix (ECM) and a tortuous and chaotic
blood vessels’ network. The architecture and properties of this organ-like entity are illustrated in Figure 2.
In addition to cancer onset and progression, the so-called tumor microenvironment (TME) is closely
involved in tumor resistance to treatments [36,37]. The understanding of tumor biology is of utmost
importance in nanomedicine also because TME was clearly demonstrated to minimize the NCs’ efficacy
by opposing several barriers. First of all, the nanocomplex extravasation is required and generally
associated with the EPR effect that characterizes the tumor region [38]. Actually, the discontinuous and
fenestrated blood vessels, together with the poor lymphatic drainage, led to optimistic over-expectations
in nanomedicine. However, differently from the experimental confirmations achieved from preclinical
models, increasing evidence suggests that the great variability in the extent of the EPR effect can be found
both among patients and tumor types [39]. Moreover, recent studies revealed that, besides the leaky
blood vessels, endothelial transcytosis, as well as vascular bursts, enhance tumor permeability [40,41].
Once extravasated, NCs are expected to homogeneously distribute within the tumor area, but tissue
penetration is strongly hampered by several obstructing factors, including the elevated interstitial fluid
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pressure (IFP) caused by inefficient lymphatic drainage and blood vessel compression, and solid stress
associated with high cellular density and excessive production of ECM [6]. These factors restrict the
NC action to the cells located in the perivascular space, hiding the more resistant cells placed in the
hypoxia regions.
Figure 2. Tumor microenvironment. Tumor tissue is characterized by a high cellular density that
hampers oxygen and nutrient perfusion. Accordingly, cancer cells are genetically and epigenetically
heterogeneous, and those located far from the blood vessels: (1) favor an anaerobic metabolism that
leads to the environment acidification; (2) are more resistant to pharmacological treatments because of
their low division rate and genetic instability [42]. Fibroblasts and pericytes are responsible for tissue
remodeling, while the immunosuppressive milieu hinders immune cell activity. NCs extravasation and
penetration are mainly limited by solid stress and high interstitial fluid pressure, which in certain areas
may reach values close to the aortic pressure [43].
Therefore, the tumor accumulation can be considered as the major hurdle to the clinical translation
and application of nanosized DDSs. For this reason, the TME modulation and the patient stratification
have been recently proposed as strategies to improve the nanodrugs’ performance, as discussed below.
In addition, an exhaustive understanding of the factors that guide the tissue penetration is extremely
urgent. Size, shape, and surface chemistry have been identified as the major characteristics responsible
for NCs diffusion inside the tumor mass [44,45]. Beside some universally accepted correlation, such as
the inverse proportion between NC size and penetration ability, there are still controversial opinions
about the impact of surface charge [46,47]. The functionalization of the NC surface with tissue and
cell-penetrating peptides, such as the iRGD peptide, is a promising strategy to increase vascular and
tissue permeability. Specifically, iRGD interacts with αν integrins on the endothelium, stimulating a
proteolytic cleavage, and the subsequent binding of the released C-end-R peptide with neuropilin-1,
ensuring both the tumor homing and tissue penetration [48]. Recent concerns about possible non-specific
interactions of iRGD that might reduce the target accumulation of NCs could be overcome by triggering
the penetrating peptide exposure in the TME following specific stimuli [49]. Another common approach
to minimize the interaction between NCs and the ECM is surface PEGylation, as has been demonstrated
in different tumor models, such as orthotopic brain and lung cancers [50,51]. However, a dense PEG
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layer may discourage interaction with target cells. Hence, the NC properties should be carefully
optimized to balance their diffusion and target recognition capabilities.
2.4. Cellular Internalization
An effective cellular uptake has an impact on the therapeutic response, as many drugs are directed
towards intracellular targets. Notably, an enhanced internalization is crucial for improving the activity
of both biologics and small molecules, as it allows poor cellular permeability to be overcome, and the
multidrug efflux transporters to be bypassed, respectively [52,53]. The most common approach to
increase the NCs uptake is “active” (i.e., molecular) targeting. This strategy aims at improving the
selectivity of NCs toward the target cells by decorating their surface with affinity ligands that recognize
receptors specifically overexpressed on tumor vasculature or tumor cells [54]. However, the molecular
forces that drive ligand–receptor binding only extend over 0.3–0.5 nm [55]. Thus, to promote tumor
retention and increase cellular uptake, an efficient NC extravasation is needed [12]. It should
be noted that the NC functionalization is expected to alter their physical–chemical properties,
affecting the MPS uptake as well as the intratumoral penetration [31]. Moreover, the targeting receptor
should be carefully selected, taking into account its preferential tumor expression compared to
normal tissues and immune cells, as well as its capability to internalize the NCs upon interaction.
A big concern for active targeting success is posed by cancer cell heterogeneity: indeed, it is well
known that the cancer cells’ epigenetic diversity leads to different expression levels of the targeting
receptor [10]. On the other hand, cellular internalization is performed by receptor-mediated endocytosis,
which usually leads to NC degradation. In this context, for all the therapeutics that are susceptible
to lysosomal digestion (e.g., biologics), an efficient endosomal escape is essential to preserve drug
efficacy [56]. Different strategies have been proposed to promote this event, such as membrane
fusion, osmotic rupture, particle swelling, and membrane destabilization [57]. Despite these efforts,
the proportion of NCs that actually perform the endosomal escape remains extremely low, and thus,
more efficient or alternative approaches are demanded [58]. For instance, Rotello and coworkers
proposed an endosomal-free cytosolic delivery based on the direct fusion between the nanoassemblies
and the plasma membrane [59], whereas Gong and colleagues have recently developed a polymeric
coating, termed nanocapsule, with an improved endosomal escape compared with commercial
agents [60]. All these concerns underline that, although targeted nanomedicine was proposed as a
magic bullet for cancer treatment, its clinical relevance still needs to be validated. Indeed, despite the
superiority of the active over the merely passive targeting demonstrated in preclinical models,
at present, none of these nanodrugs have been approved [8]. Therefore, increased awareness of the
molecular mechanisms governing active targeting is imperative, considering that common belief
on nanoparticle-biosystem interactions do not always allow for reliable predictions. For instance,
as demonstrated by Colombo et al., maximizing the number of targeting moieties on the NC is
indeed expected to improve the molecular targeting in vitro but does not necessarily result in superior
therapeutic performance in vivo [61].
2.5. Drug Delivery and Release
In a drug delivery framework, the nanoformulation is intended to enhance the drug protection
and permeability, to extend the therapeutic agent half-life, to improve the drug solubility
and/or increase its therapeutic index [62]. As already stressed above, different types of drugs,
including both small molecules and biologics, can benefit from nanoscale DDSs in enhancing their
therapeutic efficacy. Indeed, NCs may broaden the spectra of the administered drugs when they
are small molecules, whereas they may overcome the drawbacks associated with large, hydrophilic,
and delicate biological molecules improving their availability or helping them to cross the biological
barriers [63,64]. However, it is worth mentioning that the release performance of these DDSs should
be carefully investigated, and the NCs’ design possibly optimized. Especially for long-circulating
NCs, minimizing the premature drug release is fundamental to improve its therapeutic outcome [65].
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Additionally, new nanoparticle-based classes of DDSs have been recently developed to precisely
control the drug release in response to specific conditions, such as the stimuli-responsive NCs that will
be discussed further below (Section 5.1.2) [13,43].
3. Controversies Around Clinical Translation of Cancer Nanomedicines
The first nanomedicine that received clinical approval was the PEGylated liposomal formulation
of doxorubicin in 1995 (Doxil®/Caelyx®). Since then, 15 nanodrugs have been developed and
tested for cancer treatment and have entered the market (Table 2). Doxil®/Caelyx®, together with
the albumin-based formulation of paclitaxel (commercialized by Celgene corporation under the
Abraxane®, Summit, NJ, USA trademark), currently represents the top-selling nanomedicines in
2018, accounting for $252 M and $950 M, respectively [8]. The liposomal doxorubicin formulations
demonstrated a different drug distribution compared to standard treatments, limiting the cardiotoxicity
induced by anthracyclines [66]. The new therapeutic index achieved broadened the spectrum of
treatable candidates and improved patient compliance. In turn, Abraxane® strongly enhanced
paclitaxel tolerance, allowing drug administration without the use of toxic solubilizing surfactants
(e.g., castor oil—cremophor EL®). Notably, clinical studies have demonstrated a significant increase in
the maximum tolerated dose as well as shorter infusion time of Abraxane® compared to a cremophor
EL®-based formulation [67].
Table 2. Clinically approved cancer nanomedicines [8,31].
Product Name Composition Indications First Approval
Doxil/Caelyx PEGylated liposomal doxorubicin Myeloma, Kaposi’s sarcoma,breast, and ovarian cancer Approved in the US (1995)
DaunoXome liposomal daunorubicin Kaposi’s sarcoma Approved in the US (1996)
Myocet liposomal doxorubicin Breast cancer Approved in Europe/Canada (2000)
Abraxane albumin-bound paclitaxel Breast, non-small-cell lung,and pancreatic cancer Approved in the US (2005)
Lipusu liposomal paclitaxel Breast and non-small-celllung cancer Approved in China (2006)
Oncaspar L-asparaginase conjugate Acute lymphoblastic leukemia Approved in the US (2006)
DepoCyt liposomal cytarabine Lymphoma, Leukemia Approved in the US (1999)
Genexol-PM paclitaxel micellar Breast, non-small-cell lung,ovarian, and gastric cancer Approved in Korea (2007)
Mepact liposomal mifamurtide Osteogenic sarcoma Approved in Europe (2009)
NanoTherm Iron oxide nanoparticles Brain tumors Approved in Europe (2011)
Marqibo Liposomal vincristine sulfate Acute lymphoblastic leukemia Approved in the US (2012)
ONIVYDE liposomal irinotecan Advanced pancreatic cancer Approved in the US (2015)
DHP107 paclitaxel lipid nanoparticles(oral administration) Gastric cancer Approved in Korea (2016)
Vyxeos liposomal daunorubicin and cytarabine High-risk acute myeloid leukemia Approved in the US (2017)
Apealea paclitaxel micellar Ovarian, peritoneal, and fallopiantube cancer Approved in Europe (2018)
Hensify hafnium oxide nanoparticles Locally-advanced softtissue sarcoma Approved in Europe (2019)
However, despite the important advantage of these nanomedicines in terms of safety, the treatment
efficacy did not increase as expected. So far, most approved nanodrugs exhibited only a moderate impact
on overall survival as compared to relevant standard therapies [8]. Among the nano-based products
under clinical investigation, some of them aim to ameliorate the cancer treatment performance by means
of active targeting (e.g., BIND-014) and stimuli-responsive drug release (e.g., ThermoDox) [68,69].
Nevertheless, the low efficacy still represents the main hurdle to the nanodrugs’ clinical translation.
In particular, among the 94% successful phase I trials, only 14% concluded phase III with positive
outcomes [8]. This disappointing efficacy is likely due to multiple factors, such as an incomplete
knowledge about the nano–bio interactions (Section 2) and poor reliability of the existing preclinical
models. Lack of reliable disease models is particularly disappointing, as mouse tumor models fail to
recapitulate the complexity of human tumors mainly because of their large size, the limited cancer cell
heterogenicity, the exaggerated EPR effect, and general immunodeficiency [70].
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Additional drivers behind the modest clinical translation of nanomedicines are technical and cost
challenges in product manufacturing and scale-up. Several clinical trials were terminated or delayed
due to unaffordable financial burdens. Indeed, the development of next-generation products other
than the conventional liposomal formulations requires huge investments and poses serious issues
about the process reproducibility [8,9]. Overall, the large pharma companies, the only entities that can
afford such a prohibitive expense, are discouraged from supporting the clinical investigation because
of the low perceived success chances. Therefore, it is of utmost relevance to consider that product
clinical outcomes and funding availability are closely related since pharmaceutical companies and the
healthcare system are more prone to invest if the improvement in treatment efficacy is significant [8].
4. Is It Still Reasonable to Invest in Cancer Nanomedicine?
As already mentioned, nanotechnology has attracted great interest in cancer treatment due to
the unique physiochemical properties of nanostructures that can be exploited for diagnostic and
therapeutic purposes. Searching “Nanoparticles” on Scopus.com, a publication peak is notable in
2018 with 57,434 documents (Figure 3A) and 22.7% (16,395 documents) of them related to cancer
treatment and diagnosis. However, focusing on the subject area (Figure 3B), most of these works
were reported in materials and chemistry-related journals, whereas only 17.3% were published in
journals referring to the medical research area (including pharmacology, toxicology, and pharmaceutics;
medicine; immunology and microbiology).
Figure 3. (A) Publication peak of “nanoparticles” related papers; (B) Subject areas of
“nanoparticles + cancer” papers. Elaborated data are derived from the Scopus research tool.
Such publication distribution corroborates the assumption that cancer nanomedicine is more
focused on a “formulation-driven” rather than a “disease-driven” approach. Many researchers
have pointed out that this one, together with overgeneralizing drug-targeting/delivery concepts and
overselling preclinical studies, are the main causes of the suboptimal clinical translation of cancer
nanomedicine [71]. In fact, even if the cancer nanomedicine research comprises different types of
materials used for synthesizing NCs, only lipidic, one protein-based, a few polymeric and inorganic
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nanovehicles have been approved for marketing (Table 2) [72]. These considerations highlight the
current limitation of nanomedicine in cancer treatment, leading the scientific community to ask if it is still
reasonable to continue to invest in this field. As it can be inferred by Section 2 of this review, ready after
administration NCs have to face many hurdles that can reduce therapeutic/targeting/accumulation
efficiency. However, it is worth mentioning that both successes and failures have contributed to change
the focus of studies to better understand the interaction between NCs and numerous cancer biological
mechanisms, triggering new discoveries and future ambitions [9,13,73]. To make some examples,
the emerging concerns regarding the real efficacy of the EPR effect in humans forced scientists to go
in-depth in defining human TME characteristics to develop NCs with different size, shape, and surface
properties to increase their penetration into the tumor mass [13]. Otherwise, the modulation of TME
components (e.g., vasculature, ECM) is another interesting point of view to improve the delivery of
nanomedicine to solid tumors [12,74].
Another crucial step in cancer nanomedicine is the relationship between the treatment efficacy
and the immune system response. This vast branch of nanomedicine offered the opportunity to
understand that (1) the available animal models are largely unsuitable, because usually scientists make
use of immunodeficient mice, and (2) NCs can be sequestered or opsonized by immune cells [75,76].
In particular, tumor-associated macrophages (TAMs) are one of the primary biological barriers in cancer
tissue invariably encountered by NCs, so that scientists tried to exploit this “disadvantage” using TAMs
as a reservoir of nanovehicles, to increase the site-specific drug release [13,77]. Another interesting
progress is the design of NCs that can avoid phagocytosis through the modification of their surfaces
(e.g., with CD47) [78] or that can modulate the polarization and activity of macrophages [79,80].
In addition, studies about the numerous molecular targets found to develop specific active targeted
NCs brought huge knowledge. Even if the real efficacy of active targeting in cancer affected patients
is still in debate, this kind of approach allowed improvement in the awareness about the molecular
characteristics of different cancer types [10,72,81]. Moreover, the evidence that NCs could be entrapped
inside endosomes and/or lysosomes led the scientists to study this mechanism developing NCs able
to reach the cell cytosol by clever strategies, including direct fusion with the plasma membrane [59]
or by performing enhanced endosomal escape [82–84]. The use of engineered NCs can bring other
opportunities, such as the encapsulation of poorly soluble drugs [85–87], as well as the delivery of
biologics improving their bioavailability, permeability, and stability in the biological environment [53,72].
Thanks to NCs, it is possible to use drugs already accepted by clinical trials, opening the chance
to administer them by different routes (i.e., topic [88], oral [89], and inhalation [90] rather than
intravenous). This is a relevant point in locally administered therapies because this approach could
re-establish the importance of active targeting by decreasing the number of physical and biological
barriers that NCs need to overcome.
All these observations justify the ongoing enthusiasm which believes in nanomedicine that will
lead to further investment in this field regardless of the unsatisfactory success rate hitherto achieved.
However, it is urgent to reduce the gap between the huge number of published papers and the poor
clinical outcome of these technologies. First, a sincere effort in the establishment of more clinically
relevant models is required. In this context, 3D cultures (e.g., organoids and spheroids) have been
proposed as an alternative to 2D cultures for in vitro purposes [91,92], whereas innovative in vivo
models, such as patient-derived xenografts and genetically engineered mice, aim to recapitulate
the complexity of human tumors [93]. Interestingly, the chicken chorioallantoic membrane (CAM)
is emerging as a less time-consuming and a cost-effective alternative to the conventional mouse
models [94]. Moreover, it is equally necessary to improve the research data collection to make them as
informative as possible. In this regard, Caruso et al. suggested standardization of bio–nano experimental
investigations [95], although, among the scientific community, the debate about aspects that need
to be improved is still open [96]. Finally, other key points have been suggested by the European
Technology Platform for Nanomedicine (ETPN) Agenda to ameliorate the clinical translation: (1) to
change from a “formulation-driven” to a “disease-driven” approach considering the influence of tumor
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pathophysiology in the clinical outcome and/or focusing on unmet medical needs; (2) to facilitate and
increase the dialogue between all the scientific disciplines that play a role in cancer nanomedicine;
(3) to consider the balance between benefit for patients and cost constraints for the healthcare system;
and (4) to sustain competitiveness of the healthcare economy at the global market [73].
5. Outlook on Future Strategies
Many factors still limit nanomedicine clinical translation and application. However, the presence
of several currently active research areas demonstrates that there is still a lot of interest in filling this
gap. Accordingly, this section aims to discuss the most promising strategies.
5.1. Strategies to Enhance Tumor Accumulation
Among the above-mentioned issues that hampered the clinical translations of nanomedicines,
including overcoming biological barriers, increasing bioavailability, and circulation time of nanodrugs,
improving active targeting, etc., enhancing tumor accumulation remains a primary objective.
The following approaches are envisioned to allow researchers to step forward.
5.1.1. Priming of the TME
Since several barriers in the TME prevent the nanomedicines delivery, many attempts,
extensively reviewed elsewhere [97–99], have been made to improve the EPR effect by lowering
the solid stress as well as the IFP. Among them, the normalization of the abnormal tumor vasculature
aims to restore a more physiological condition, reducing the vessel leakiness, strengthening the structure
of the basement membrane, and improving the coverage of pericytes. Although anti-angiogenic therapy
may appear to prevent the tumor accumulation, it has been demonstrated that the vasculature is still
permeable to relatively small NCs (20–40 nm), and the significant reduction in the IFP causes increased
tumor retention [100,101]. The normalization process is usually achieved by inhibiting pro-angiogenic
effectors, such as the VEGF (e.g., through bevacizumab) or PDGF (e.g., using imatinib) [100,101].
Another reported approach is the reduction of solid stress by inducing the tumor cells’ apoptosis.
Indeed, the rapid cancer cell proliferation causes a compression of lymphatic and blood vessels
promoting hypoxia, inflammation, immunosuppression, and metastasis, also representing an obstacle
for drug penetration [102]. In this context, it has been observed that paclitaxel tumor priming reduces
cell density and IFP, improving the penetration of several NCs, as observed for doxorubicin-loaded
liposomes and lipid siRNA complexes [103–105]. Furthermore, ECM degradation has been proposed
to alleviate solid stress and enhance NCs intratumoral accumulation. Notably, the use of collagenases,
relaxin, and hyaluronidases have been explored for this purpose, and their association with
chemotherapeutics is already under clinical trials [106–108]. Although efficient in promoting the tumor
accumulation, the clinical application of such strategies is hampered by safety concerns, high costs,
and the intrinsic instability of biologic drugs. To tackle these limitations, delivery improvement of these
agents and/or the use of alternative cost-effective and well-tolerated small molecules (e.g., the already
available Celecoxib) are under investigation [109]. Additionally, another relevant drawback of TME
alteration is the possible promotion of tumor progression and invasiveness [31].
In addition to all the above, NCs biodistribution can be ameliorated by interfering with the MPS
activity. Notably, tumor homing can be improved by saturating the main clearance organs with decoy
NCs or by inhibiting the MPS uptake. Indeed, considering the negligible fraction of NCs that reach the
tumor after administration, even small changes in clearance organs accumulation could significantly
affect the therapeutic outcome [31,110–112].
5.1.2. Nanocarriers Engineering
In addition to tumor priming, NC engineering may represent a valid strategy for improving
nanomedicine performance. Among the reported approaches, stimuli-responsive NCs play a prominent
role. These nanoformulations exploit specific endogenous or exogenous stimuli that trigger drug
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release, specifically within the tumor tissue. In the first case, NCs responsive to acidic pH,
hypoxic environment [113–115], overexpression of tissue remodeling enzymes (e.g., MMP2-9) [116]
or the high intracellular concentration of glutathione demonstrated an increase in the cargo
therapeutic efficacy and safety [117]. On the other hand, magnetic, thermo-, electric-, light- and
ultrasound-sensitive materials may be employed for nanodrugs development to promote the
intratumoral drug delivery [118–120]. In this context, several products, such as thermosensitive
liposomes (Thermodox), enzyme activated polymeric NCs (Opaxio), as well as magnetic nanoparticles
(MTC-Dox), are currently under clinical investigation or approved [43]. Moreover, the combination
of different stimuli has recently been proposed to further improve the efficacy of nanoscale DDSs
for cancer treatment [43]. In general, the concept of multifunctional vectors is slowly establishing
together with a wider comprehension of nano–bio interactions. In particular, novel systems capable
of modifying their proprieties in a spatiotemporal way (multistage DDSs) have been developed.
For instance, relatively big NCs (<200 nm) can respond to specific stimuli releasing small particles
(5–15 nm) able to deeply penetrate into the tumor tissue [121,122]. Alternatively, in multi-layered
NCs, the external shell (e.g., PEGylated responsive materials) is expected to change in proximity
to a tumor, exposing the hidden penetrating peptides or targeting agents [123–125]. Despite the
interesting results, it remains questionable whether increasing the complexity of NCs could excessively
hinder their clinical translation. In light of the above consideration, another option may be using
nature-inspired NCs composed of biological materials, such as proteins (e.g., albumin, lipoproteins,
ferritin) or cellular-derived membranes (e.g., cancer cells, platelets, erythrocytes, and leukocytes) [126].
These materials are generally well-tolerated, less recognized by MPS, and are eventually able to increase
tumor targeting. For instance, ferritin-based NCs showed an intrinsic tumor homing as well as an
improved performance compared to the liposomal formulation, when loaded with doxorubicin [127].
Another pioneering approach exploited the use of engineered leukocytes membrane to enhance the
NCs’ accumulation in the proximity of inflamed tumor tissues [128].
5.1.3. Optimizing the Administration Route
Currently, most of the nanomedicines are intravenously injected, but to increase the NCs potential
and adopt a more “disease-driven” approach, alternative administration routes might be considered.
For instance, the local administration of drug-loaded NCs could perform better than the systemic one
because it could reduce the off-target toxicity as well as increase the tumor accumulation bypassing the
physiological barriers [54]. This strategy is particularly recommended for non-metastatic tumors or
when surgery is contraindicated [54]. As recently reviewed, for lung cancer therapy, the pulmonary
route has been explored to improve drug delivery [129]. The local administration proved to be effective
even in glioma models where drug-loaded NCs could show a safer toxicity profile compared to the free
molecule [50]. Furthermore, some clinically approved products take advantage of local administration:
Hensify® (Nanobiotix, Rue de Wattignies, Paris, France) enhances the performance of radiotherapy in
advanced soft tissue sarcoma, whereas intracranially injected iron oxide nanoparticles (Nanotherm®)
efficiently induced hyperthermia in glioblastoma treatment [130,131]. In addition, non-conventional
systemic administration routes may be investigated to specifically accumulate drugs to cellular or tissue
targets. Particularly, non-invasive intranasal administration may be exploited for the nose-to-brain
delivery, circumventing the first passage in the liver and the blood–brain barrier, thus increasing the
fraction of drug at the target site [132,133]. On the other hand, intraperitoneally injection proved to
be effective in targeting circulating macrophages, which, once repolarized, exhibited inherent tumor
tropism [134]. Finally, as demonstrated by the recent approval of DHP107 (Liporaxel®, DAE HWA
Pharm, Seoul, Korea) the oral route has been investigated for increasing patient compliance and reduce
the therapy costs [135].
301
Cancers 2019, 11, 1855
5.2. Nanoimmunology and New Targets
Although classical nanotherapies are directed towards cancer cells, innovative approaches rely on
targeting alternative cellular components. Considering the increasing role of cancer immunotherapy,
not surprisingly, most of these new targets belong to the immune system. As extensively reviewed,
many approaches have been investigated to ameliorate the impact of cancer immunotherapy through
the use of nanomedicine [14,136,137]. Here we focus on those that directly modulate the activity
of particular cellular mediators, such as tumor-associated macrophages (TAMs), myeloid-derived
suppressor cells (MDSCs) and regulatory T cells (Treg) [138]. TAMs are usually characterized
by a high M2/M1 ratio, leading to an immunosuppressive environment that promotes tumor
progression [139]. The three main strategies, which target TAMs are (1) repolarization of M2 in
M1; (2) abolishment of macrophage recruitment via cytokines inhibition; (3) eradication of M2
cells [138,140]. Notably, the selectivity towards M2 can be achieved by targeting the overexpressed
mannose receptor [141]. Moreover, the targeting of CD44, along with the intraperitoneal injection,
leads to the macrophage-specific delivery exploitable for the repolarization strategy [134].
Other currently investigated targets are the MDSCs, immature cells that contribute to tumor
progression by releasing immunosuppressive cytokines [138]. Nanomedicine aims to promote their
differentiation into mature cells [142,143], as well as interfere with MDSCs accumulation/activity,
by improving the drug delivery [144].
Similarly, Tregs mediate the immunosuppression by inhibiting the activation and expansion of
effector T cells, and their downregulation could be ameliorated by the use of NCs. In particular, Tregs can
be actively targeted by using their specific markers, such as glucocorticoid-induced Tumor Necrosis
Factor Receptor-related protein (GITR), or neuropilin-1 receptor by binding of tLyp1 peptide [145,146].
However, this therapeutic strategy needs to be further validated because Tregs instability could be
associated with the onset of autoimmune disorders [147].
In addition to immune cells, cancer-associated fibroblasts (CAFs) have been recently identified as
candidates for antitumoral therapies because they are responsible for both immunosuppression
and TME reorganization [148,149]. Alternatively, the TME can be directly modulated by NCs.
Indeed, the reduction of tumor hypoxia, the restoration of physiological pH, and the inhibition
of immunosuppressive soluble mediators impair the tumor progression improving the outcome of
current therapies [150].
5.3. Companion Diagnostic
A promising strategy to improve nanomedicine efficacy is the companion diagnostic, which refers
to a stratification of patients based on tumor characteristics. Different strategies are currently under
investigation based on the use of biomarker profiles and imaging data. The first aims to identify
circulating proteins associated with the TME and positively correlated to the EPR effect. For instance,
the ratio of MMP9 to the tissue inhibitor of metalloproteinase 1, the collagen content in the capillary
walls, and some angiogenesis markers have been shown to predict the EPR entity [13]. On the other
hand, radio-labeled and ferumoxytol-loaded NCs have been adopted to monitor their biodistribution
by non-invasive techniques (e.g., Single Photon Emission Computed Tomography or Photon Emission
Tomography and magnetic resonance imaging, respectively) [13]. The final goal is selecting patients
that present the highest probability to positively respond to a specific therapeutic treatment [31].
However, to reach a real utility in clinics, these approaches need to be further validated by accurate
correlative studies, defining a clear set of parameters and criteria able to predict the therapeutic
outcome [9].
6. Conclusions
The unique attributes of nanoparticles allow clinicians of the 21st century to design innovative
therapeutic strategies for use as monotherapies or to be combined with existing chemotherapeutic
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treatments or conventional radiotherapy. The recent advances achieved by researchers in the
development of tumor-targeting NCs together with a faster data collection deriving from the study of
their communication with the biological milieu has generated optimistic expectations for the rapid
translation of this basic research into the clinical practice with immediate benefits for oncology patients.
However, only a few nanodrugs have actually reached the marketplace and are now approved by the
FDA or EMA for specific cancer treatments. This transitory failure has raised some criticisms on the
real effectiveness of nanomedicine so that the huge amount of resources dedicated to the research
in this field in the last decade has been questioned. This review highlights the main challenges that
the scientific community, assisted by the health system and industry, should face in a virtuous joint
effort aimed to bring the new discoveries to an established practice that would allow the regulatory
bodies to accelerate the process toward the bedside (Section 4). A well-standardized toolkit for
the physicochemical, pharmacological, and immunological characterization of all newly developed
nanodrugs should be defined before they can be approved for use in humans. The distribution of
nanoparticle size, uniformity, surface coating, colloidal stability, and reproducibility from batch to batch
also needs to be accurately regulated. Recently, attempts to overcome such barriers to the progression
of nanooncology have suggested the definition of a “minimum information standard” for experimental
protocols associated with the investigation of the nano–bio interface, leading to the so-called MIRIBEL
(minimum information reporting in bio–nano-interaction) paradigm [95]. The collection of three
standard categories should be satisfied to fulfill the minimal requirement for good practice in
nanomedicine, including appropriate material characterization, biological characterization, and details
of experimental protocols. Furthermore, standardized assays for the assessment of short-term and
long-term toxicity of nanoparticles will also need to be defined in 2D/3D cell cultures and animal
models before approval for clinical trials. Eventually, the cross-fertilization of nanotechnology with
recent progress in advanced immunotherapies, together with a renowned knowledge of the impact of
environmental factors (e.g., microbiota) on cancer, is expected to trigger a new spur in nanomedicine
discovery [151,152]. This entails that nanomedicine researches in the future will be invited to move
from a limited “formulation-driven” approach to a preferential “disease-driven” setting, leading to a
new era of nanooncology.
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Abstract: Cancer is a global health problem in need of transformative treatment solutions for improved
patient outcomes. Many conventional treatments prove ineffective and produce undesirable side
effects because they are incapable of targeting only cancer cells within tumors and metastases post
administration. There is a desperate need for targeted therapies that can maximize treatment success
and minimize toxicity. Nanoparticles (NPs) with tunable physicochemical properties have potential
to meet the need for high precision cancer therapies. At the forefront of nanomedicine is biomimetic
nanotechnology, which hides NPs from the immune system and provides superior targeting
capabilities by cloaking NPs in cell-derived membranes. Cancer cell membranes expressing “markers
of self” and “self-recognition molecules” can be removed from cancer cells and wrapped around
a variety of NPs, providing homotypic targeting and circumventing the challenge of synthetically
replicating natural cell surfaces. Compared to unwrapped NPs, cancer cell membrane-wrapped
NPs (CCNPs) provide reduced accumulation in healthy tissues and higher accumulation in tumors
and metastases. The unique biointerfacing capabilities of CCNPs enable their use as targeted
nanovehicles for enhanced drug delivery, localized phototherapy, intensified imaging, or more potent
immunotherapy. This review summarizes the state-of-the-art in CCNP technology and provides
insight to the path forward for clinical implementation.
Keywords: biomimetic; nanocarrier; membrane-wrapped; cancer; targeted delivery; drug delivery;
immunotherapy; photothermal therapy; photodynamic therapy; imaging
1. Introduction to Cancer and Nanomedicine
Cancer is a devastating global public health problem in desperate need of transformative solutions.
It is the second leading cause of death in the United States and predicted to take 1700 lives per day
in 2019 [1]. There is approximately a 37% chance a person will be diagnosed with cancer in their
lifetime [1]. These alarming statistics indicate a critical need for technologies that can improve the
early diagnosis and effective treatment of cancer.
Conventional methods to treat cancer involve the surgical resection of tumors followed or preceded
by aggressive chemotherapy and localized radiotherapy [2,3]. However, if tumors are non-resectable
or metastasized, chemotherapy is the only therapeutic resolution to attempt to control the size and
spread of the cancer [3]. Despite being the main clinical strategy, cytotoxic chemotherapeutics are
incapable of targeting only cancer cells post-systemic administration [3,4]. Only a small fraction of
drugs will accumulate in the desired tumor regions and metastatic lesions before being cleared from
the body or entering non-targeted tissues [2,3,5]. Consequently, adverse side effects to healthy tissues
limit the dosage of free drugs that can be administered, which reduces efficacy [6,7]. Further, due to
the heterogeneous nature of tumors, which contain multiple cellular phenotypes, clinical practice and
exploratory studies have shown that treatment regimens that employ only a single therapeutic agent
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are incapable of eliminating whole tumors and are even less effective in reducing and preventing
metastasis [6]. There is a need for multimodal and synergistic cancer therapies that can improve patient
outcomes [6,7].
Nanotechnology offers the opportunity to create nanovehicles that can carry either single or
multiple therapeutic cargos, as well as contrast agents, to tumors for improved treatment and imaging.
Nanoparticles (NPs) can be “smart designed” for enhanced drug delivery, phototherapy, vaccination,
immunotherapy, and imaging [6,8]. Additionally, NPs can be synthesized with diverse physicochemical
and surface properties that can be tailored to enhance cellular and molecular delivery, increase circulation
times, facilitate crossing of biological barriers, and control cargo release [7–9]. Some nanomaterials can be
designed with inherent optical or chemical properties that can be harnessed to enable stimuli-responsive
therapy [10]. Nanovehicles can also be designed to integrate multiple therapeutic modalities in a single
system to overcome the barriers experienced by cancer monotherapies [6].
The tumor microenvironment is characterized by leaky tumor vasculature and poor lymphatic
drainage [3,8,9]. All systemically administered nanovehicles exploit this tumor pathophysiology to
passively accumulate and be retained in tumor tissue; this is known as the enhanced permeability and
retention (EPR) effect [4,11–14]. However, for NPs to utilize the EPR effect, they must first navigate the
bloodstream, where they will be exposed to various proteins that may alter their surface chemistry.
When NPs are coated with opsonin proteins, they are rapidly cleared by tissue resident macrophages of
the liver and spleen, which limits their tumor delivery. For nanovehicles to efficiently enter tumors and
be effective, they must evade detection by the immune system to exhibit long circulation, and protect
their cargo from degradation or premature release [3,4,15]. Historically, NPs have been decorated with
surface modifications, such as polyethylene glycol (PEG), to decrease their rapid opsonization and
phagocytosis and increase their anti-tumor efficacy [3,4,7,16–19]. However, PEG-functionalized NPs
can induce an “anti-PEG” immunological response and PEG does not impart NPs with cell-specific
binding capabilities [3,16]. Additionally, PEGylated NPs are still cleared from the body, necessitating
the use of more diverse and effective coatings. Researchers have coated NPs with ligands designed to
enhance their cell-specific internalization via receptor-mediated processes to increase tumor retention
and reduce off-target effects [17,18,20,21]. Still, there is substantial room for improvement.
While ligand-targeted NP delivery to desired tumor cells is often depicted as a straightforward
and easily accomplished task, it is extremely challenging to achieve this goal [21]. In part, this
is due to the immense diversity in the abundance, variety, and complexity of proteins found on
cancer cell membranes that might be targeted by NPs [3,10,22]. In addition to choosing the right
molecule or combination of molecules to target, researchers must also carefully select the conjugation
chemistry for ligand attachment to NPs [17,23]. Ligands that are too densely packed on an NP
surface can cause a non-cooperative effect on target receptor binding, increased uptake by immune
cells, and nonspecific binding to perivascular cells after extravasation [21,23,24]. This limits the
NPs’ success due to low circulation time, early clearance from the body, and unwanted immune
responses [16,18,19]. Further, serum proteins and opsonins can quickly coat ligand-targeted NPs in
the bloodstream, rendering the targeting agents ineffective and increasing the rate of NP clearance
from the body. These shortcomings create a need for surface modifications that can better disguise
nanovehicles from the immune system, prolong circulation time, and provide enhanced targeting and
cell internalization capabilities.
Biomimetic nanotechnology harnesses the unique biological makeup of cell membranes and
combines it with the flexibility of NP substrates and a wide range of payloads to improve targeted
delivery. The general concept is to wrap NPs with cell-derived membranes that provide the complex
biological entities found on natural cell membranes (Figure 1), which are nearly impossible to
synthetically replicate via ligand attachments [22,25,26]. Since cell membranes contain both “markers of
self” and “self-recognition molecules”, NPs wrapped in cell membranes can avoid immune recognition
to maximally accumulate in tumors. Cell membrane coating technology was first introduced as a
method to prolong NP circulation by using red blood cell (RBC) membranes to provide “stealth”
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properties to synthetic NPs [27]. It was shown that RBC-coated NPs exhibited a circulation half-life of
39.6 hours, substantially improved versus the 15.8-hour half-life of PEGylated NPs [27]. The field of
cell membrane coating nanotechnology has since exploded with variations on this design [15,28–32].
Currently, cell membrane coating technology has been applied with many cell types, including platelets,
leukocytes, cancer cells, stem cells, and more [33–39]. Cell membrane coatings have also been wrapped
around a variety of materials, ranging from polymers to metals, to enhance their biointerfacing
capabilities [2,8,22,40]. The two main advantages obtained from cell membrane wrapping are (1)
reduced nonspecific uptake and (2) higher levels of specific targeting compared to non-wrapped
NPs [2,25]. Notably, the hydrophobicity, charge, size, and structure of the core nanovehicles can
be tailored to load desired cargoes within the interior without inhibiting the stealth or targeting
properties of the membrane coating exterior [10]. Accordingly, cell membrane-coated NPs prove
superior to previous NP synthesis techniques that have tried to reverse-engineer biological functions
and interactions with limited success [3,4,41].
Figure 1. Scheme depicting the components of a representative membrane-wrapped nanoparticle.
Cancer cell membranes are the ideal candidate to wrap around NPs for oncological applications [8,22].
Cancer cells are robust and easy to culture in large volumes in vitro for mass membrane collection and also
possess the unique ability to self-target homologous cells (also known as homotypic targeting), unlike most
other membrane donors [8,9,40,42]. This unique ability translates to cancer cell membrane-wrapped NPs
(CCNPs), which retain the ability to homotypically target primary tumors and metastatic nodules [40,42–45]
(Figure 2). Additionally, CCNPs display unprecedented binding and selective uptake in tumor cells
matched to those from which they were derived, as well as have reduced immune clearance after
systemic administration compared to non-coated NPs [22,40,42,44,46,47]. These unique properties enable
CCNPs to be used as nanovehicles for enhanced chemotherapeutic drug delivery, localized phototherapy,
intensified tumor imaging, or potent immune modulation.
 
Figure 2. Scheme depicting the delivery of cancer cell membrane-wrapped nanoparticles (CCNPs) to
tumors. Upon systemic administration, CCNPs exhibit long circulation due to the presence of “markers
of self” on the membrane surface that minimize immune recognition. Additionally, CCNP membranes
contain “self-recognition” molecules that allow the NPs to bind homotypic tumor cells after escaping
from tumor vessels.
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In the following sections, we describe the synthesis and characterization of CCNPs and the different
types of treatments these unique NPs can accomplish. We also provide a forward-looking perspective on
the challenges to be addressed as this technology progresses from the laboratory setting to the clinic.
2. Cancer Cell Membrane-Wrapped Nanovehicles
2.1. Multi-step Synthesis of Cell Membrane-Wrapped Nanovehicles
The synthesis of cell membrane-coated nanovehicles involves three steps: (1) membrane extraction
from source cells, (2) fabrication of the nanoparticulate core, and (3) fusion of the membranes and
nanoparticulate cores to form core-shell membrane-wrapped NPs (Figure 3). Below, each step is
described in detail.
 
Figure 3. Illustration of the synthesis of membrane-wrapped nanoparticles. (A) Cell membranes
can be extracted from their source cells by applying one of three methods. (B) Membranes can be
wrapped around different types of nanoparticles using one of the three membrane–core fusion methods.
(C) Transmission electron microscopy images of a (i) 4T1 breast cancer cell membrane vesicle, (ii) bare
poly(lactic-co-glycolic acid) (PLGA) nanoparticle, and (iii) 4T1 cancer-cell membrane-wrapped PLGA
nanoparticle prepared by the authors using the hypotonic lysis method depicted in (A) and the physical
extrusion method depicted in (B).
2.1.1. Membrane Extraction
At its most basic level, membrane extraction requires that internal cell components are
removed while leaving the functional components of the membrane intact. This membrane
extraction procedure requires large volumes of cells to be harvested from culture dishes or blood
and tissue samples [8,22,31,48,49]. This process has been accomplished in many ways including
freeze–thaw cycling [36,48,50], electroporation [51], and osmosis-based lysis coupled with physical
homogenization [22,48] (Figure 3A). For freeze–thaw techniques, cells are frozen at −80 ◦C and thawed
at either room temperature or 37 ◦C in repeated cycles. These cycles cause damage to cell membranes
due to breakage of ice crystals, which leads to the removal of the cytosol and retention of the membranes.
This technique is most appropriate for non-nucleated cells, such as RBCs or platelets, since the freeze
steps can potentially cause damage such as loss of membrane structure, reduced protein stability,
and consequent protein unfolding and reduced membrane function [10,36,48].
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Electroporation lyses cells by exposing them to strong electric fields, causing temporary loss of
semi-permeability, and pore formation in the cell membrane, releasing intracellular components [51].
Consequently, electroporation disruption of membranes results in irreversible deterioration of structural
integrity, denaturation of membrane proteins, and loss of lipid asymmetry. Therefore, care must be
taken when designing the experimental set-up of electroporation as conditions that are too harsh can
cause loss of natural membrane potential [51,52].
The most popular method to extract cancer cell membranes involves osmosis-based cell lysis with
a mild hypotonic solution, followed by mechanical membrane disruption with a homogenizer [48].
Discontinuous gradient centrifugation removes intracellular biomacromolecules, intracellular vesicles,
and nuclei, and the membrane-rich fraction is washed with isotonic buffers to obtain membrane
vesicles [23,53]. These vesicles can then be further sonicated or extruded through polycarbonate
membranes to produce vesicles of the desired size [48]. Cancer cells require milder lysis conditions and
greater ultracentrifugation speeds compared to non-nucleated cells. The differences in osmosis-based
membrane extraction methods deviate between cell types due to eukaryotic cells’ phospholipid bilayer
fluidity and smaller cell size [10].
2.1.2. Selection of Nanoparticle Core
As a variety of NP core designs may be utilized to produce CCNPs, depending on the intended
application, it is unwarranted to describe any one specific NP synthesis here. The main criterion,
independent of core material, is that the NPs have a negative zeta potential. This will facilitate
proper orientation of the membrane around the NP owing to electrostatic repulsion between the NP
surface and negative extracellular membrane components [27]. To date, the types of synthetic NPs
that have been wrapped with cell-derived membranes for cancer therapies include nanocrystals [54],
nanocages [42], mineral-based or mesoporous silica [35,49,55–58], polymeric cores [30,40,45,59–64],
organic and inorganic metal frameworks [44,51,65–67], protein cores [68,69], and gold-based or
magnetic nanoparticles [70–72] (Figure 4, Table 1). Poly(lactic-co-glycolic) acid (PLGA) is one of the
most widely used NP cores due to its biodegradability, FDA approval, and ability to encapsulate many
products [17–19]. Metallic-based NPs have also been widely used because they can aid in imaging and
thus provide multiple functions [32,61,65,71,72]. Overall, the composition of the nanovehicle core is an
important consideration when designing CCNPs as it dictates the release and efficacy of the cargo once
it has been guided to the desired cells by the membrane coating.
 
Figure 4. Summary of various nanoparticle formulations that have been wrapped with cell-derived
membranes to enable cancer treatment and imaging.
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2.1.3. Fusion of Membrane Vesicles with Nanoparticle Cores
Methods of coating NPs with membranes can be divided into three generalized strategies: physical
extrusion, sonication, and microfluidic coating (Figure 3B). All of these methods take advantage of
electrostatic interactions between the nanoparticulate core and membrane components to form a
stable and energetically favorable core-shell structure with the right-side-out membrane topological
orientation [27,36,48]. In physical extrusion, nanovehicles and membrane vesicles are co-extruded
through a porous membrane, similar to how membrane vesicles are formed by mechanical extrusion [27].
The force provided by the extrusion disrupts the membrane structure and enables it to reform around the
NP cores [27,48]. A representative transmission electron micrograph of a CCNP prepared by extrusion
in the authors’ lab is shown in Figure 3C. Here, the CCNP is composed of a PLGA core surrounded by
a membrane derived from a 4T1 mouse breast cancer cell. In the authors’ experience, the extrusion
method is very robust in terms of reproducibility and creating CCNPs with consistent characteristics
(size, zeta potential, membrane thickness, etc.). In sonication-based methods, nanovehicles and
membranes are again combined, and ultrasonic energy provides disruptive forces that result in
spontaneous formation of core-shell nanostructures [53,59]. This technique has the added benefit of
losing less material than physical extrusion. Lastly, a relatively new approach to enable membrane
coating is to employ microfluidics. This fabrication technique combines rapid mixing of NPs and
membrane vesicles with electroporation and has successfully been used to coat RBC membranes
around magnetic NPs [51]. For this strategy to be successful, the process pulse voltage, duration,
and flow velocity all have to be optimized, making it a potentially more difficult method to attempt for
those not already familiar with microfluidics.
2.2. Characterization of Membrane-Coated Nanoparticles
It is critical to compare various features between bare and wrapped NPs to confirm complete
membrane wrapping. Successful wrapping can be validated by observing a 10–20 nanometer increase
in particle size after wrapping, equating to the thickness of the membrane layer. This can be measured
by dynamic light scattering (DLS), transmission electron microscopy (TEM) (Figure 3C), or nanoparticle
tracking analysis (NTA). Analysis of the NPs’ zeta potential, or surface charge, can also be used
to confirm membrane wrapping. The final charge of the CCNPs must be similar to that of the
membrane vesicles used to prepare them, as the bare NPs inherit the surface charge of the membranes
after successful wrapping. To further confirm successful membrane wrapping and the removal of
intracellular components, Western blotting and SDS-PAGE can be performed to identify the main protein
components of whole cell lysate, membrane lysate, and membrane-wrapped NPs. Membrane-wrapped
NPs should share nearly identical protein content to the membrane lysate, but lack the nuclear and
mitochondrial components of the whole cell lysate. Individual membrane surface markers can also
be identified and their intensity compared between samples to confirm their successful translocation
onto NPs from source cells during membrane wrapping. For example, Fang et al. showed by Western
blotting that CCNPs prepared by physically extruding PLGA NPs with B16-F10 mouse melanoma
membranes collected by hypotonic lysis were positive for the membrane markers pan-cadherin,
Na+/K+-ATPase, and gp100, but lacked the intracellular markers histone H3, cytochrome c oxidase,
and glyceraldehyde 3-phosphate dehydrogenase [45]. These data indicate that the preparation of
CCNPs by hypotonic membrane lysis followed by physical extrusion with core NPs offers excellent
preservation of the components of the original cell membrane. In the future, researchers utilizing other
methods to prepare CCNPs should perform similar analyses to reveal which method imparts CCNPs
with the greatest resemblance to their source cells.
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3. Applications of Membrane-Wrapped Nanoparticles in Cancer
3.1. Drug Delivery
Cancer drug delivery is one field in which membrane-wrapped nanovehicles, and CCNPs in
particular, have substantial potential to improve the state-of-the-art. Encapsulating drug cargo
within nanocarriers that offer tailorable control of release kinetics, such as polymer-based cores,
can dramatically improve bioavailability, and tumor-specific delivery can be further enhanced by
coating these vehicles with cancer cell membranes [17–19]. Moreover, synthetic NPs’ physicochemical
properties can be modified for sustainable or triggered cargo release, resulting in less systemic toxicity
than freely delivered cargo [4,22,47,77]. As an extra benefit, membrane coatings can provide an
additional decrease in premature drug release by slowing diffusion and allowing nanovehicles to
accumulate in tumors before too much drug is lost [10,22]. Increasing the ratio of drug that reaches
tumors versus normal tissue is critical to maximize therapeutic effects and safety.
Doxorubicin (DOX) is a commonly used chemotherapeutic that intercalates into DNA to yield
topoisomerase II-mediated DNA damage followed by cell death [78]. DOX has been used clinically to
treat many cancers, including breast cancer, ovarian cancer, and various lymphomas and leukemias [78].
Several researchers have shown that encapsulating DOX in membrane-wrapped NPs is advantageous
compared to freely delivered DOX [56,62,63]. For example, Xu et al. developed PLGA-DOX NPs
wrapped in membranes derived from HepG2 hepatocarcinoma cells and showed these NPs could
deliver an effective drug payload to Hep2G tumors in mice [62]. Additionally, the CCNPs exhibited
less systemic toxicity than freely delivered DOX. This was attributed to enhanced DOX accumulation
at the tumor site (and less accumulation at off-target sites) due to lack of premature release from
the particles [62]. Another chemotherapeutic small molecule, paclitaxel (PTX), which is clinically
used to treat AIDS-related Kaposi sarcoma, breast, non-small cell lung, and ovarian cancers [79–85],
has been explored in conjugation with membrane-wrapped NPs. In one study, PTX was loaded
into poly(caprolactone) (PCL) and pluronic copolymer F68 cores that were wrapped with 4T1 mouse
mammary breast cancer cell membranes [40]. The homotypic targeting and drug delivery capabilities
of these cancer cell membrane-wrapped PTX-loaded polymeric nanoparticles (CPPNs) were explored
in a highly metastatic 4T1 in vivo tumor model. CPPNs remarkably targeted and inhibited the growth
of homotypic 4T1 primary tumors and metastatic nodules in orthotopic mammary tumor models and
in blood-vessel-metastasis mouse models, with 6.5-fold fewer metastatic nodules than unwrapped
PPNs [40]. The intact 4T1 cell membrane wrapping decreased phagocytic uptake and increased
blood-circulation time to increase the antitumor effect of the drug payload.
In addition to single drugs, multiple cargoes with synergistic actions can be encapsulated in
CCNPs. This ensures the cargos are delivered to the same cells within tumor sites for improved
anticancer effects. This was demonstrated with PLGA cores that were loaded with hemoglobin (Hb) and
DOX and coated with MCF-7 human breast cancer cell membranes with a PEGylated phospholipid to
overcome hypoxia-induced chemoresistance [63]. By suppressing the expression of hypoxia-inducible
factor-1α, multidrug resistance gene 1, and P-glycoprotein, the biomimetic oxygen nanocarriers were
able to perform safe and highly efficient O2-interfered chemotherapy by reducing the exocytosis of
DOX. Simultaneously, the system achieved higher tumor specificity and lower DOX toxicity due to the
cancer cell adhesion molecules retained on the NP surface [63]. This was an excellent demonstration
of the potential for CCNPs to achieve multi-therapeutic delivery. In a similar approach, Chen et al.
developed CCNPs to deliver DOX in combination with small interfering RNA (siRNA) against PD-L1,
a gene that is overexpressed on tumor cells and whose inhibition could lead to an increased anti-tumor
immune response [46]. Here, both cargos were loaded into PLGA NP cores and homotypic targeting
was achieved by wrapping the NPs with HeLa cervical cancer cell membranes [46]. The CCNPs
exhibited preferential uptake by HeLa cells versus non-targeted MDA-MB-231 breast cancer cells,
and were able to suppress PD-L1 expression and reduce cell viability. Future studies are necessary to
evaluate the impact of this system in vivo.
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CCNPs that incorporate stimuli-responsive features have also been designed to take advantage
of the acidic tumor microenvironment as a trigger for localized drug release [63]. In one example,
mesoporous silica nanoparticle (MSN) cores were used to encapsulate DOX with the addition of a
unique CaCO3 interlayer [56]. The interlayer acted as sheddable pH-sensitive gatekeeper to allow
drug release only in the acidic tumor microenvironment. MSNs were wrapped with LNCaP-AI
prostate cancer cell membranes (MSN/DOX@CaCO3@CM) to improve the colloidal stability and tumor
accumulation of the system. In comparison to free DOX, MSN/DOX@CaCO3@CM NPs exhibited
increased cell uptake and induced higher rates of apoptotic death in prostate cancer cells. In vivo
experiments demonstrated that the NPs had remarkable antitumor effects and suppressed tumor
growth [56]. Overall, this study demonstrated that coupling the increased localization of CCNPs in
tumor microenvironments with pH-stimulated release of chemotherapeutic drugs is a potent strategy
to enhance therapeutic ratios.
Importantly, across various platforms, it has been shown that cancer cell membrane coatings do
not negatively interfere with drug loading inside NPs. As demonstrated by the examples discussed,
there is great promise in the field for CCNPs to enhance drug delivery to desired sites to improve
safety and efficacy. This opens the door for the development of many new treatment strategies.
3.2. Photothermal and Photodynamic Therapy
While some NPs exploit features of the tumor microenvironment such as low pH or presence
of specific enzymes to enable stimuli-responsive drug release and high precision therapy, another
route to enable site-specific treatment of tumors is to utilize nanomaterials that are inactive until
they are triggered with externally applied light. The two main examples of this are photothermal
therapy (PTT) and photodynamic therapy (PDT), and both have recently been explored in conjugation
with membrane-wrapped NPs. In photothermal therapy, NPs with unique optical properties are
delivered into tumors, which are then irradiated with near-infrared light that causes the NPs to
produce heat capable of thermally damaging cancer cells [86–92]. Similarly, in PDT, photosensitizers
are delivered into tumors, and subsequent irradiation of the tumor causes the photosensitizer to
transfer the absorbed energy to adjacent tissue oxygen molecules, producing toxic singlet oxygen
that destroys cancer cells [89]. While there are some examples of membrane-wrapped NPs being
used strictly for PTT or PDT to treat cancer [70,93–98], these singular treatments use non-cancer cell
membranes. When cancer cell membranes are used for wrapping, they are commonly studied in
combination with other therapeutic strategies, such as drug delivery. Some accomplishments in this
field are summarized below.
3.2.1. Combination Photothermal Therapy and Chemotherapy
Combining PTT with chemotherapy offers many advantages versus either treatment alone.
Several studies have shown that PTT can elevate drug delivery into tumors or into cancer cells by
increasing vascular permeability and cancer cell membrane permeability [86,99]. Additionally, PTT
alone is best suited for primary tumors, as it cannot be readily applied to disseminated metastatic tumors.
Combining PTT with chemotherapy offers a way to treat both primary tumors and metastatic lesions.
Further, there is some evidence that under the right conditions, combined PTT and chemotherapy
can lead to anti-cancer immune responses that maximize the duration of response [100]. Given these
advantages, researchers have explored the co-delivery of photothermal agents and cytotoxic drugs to
cancer using CCNPs.
Combination PTT and chemotherapy mediated by CCNPs has been most widely explored using
DOX as the chemotherapeutic agent [42,57,76]. In all cases, the DOX had improved tumor delivery due
to the cancer cell membrane coating of the system and DOX was able to act successfully in combination
with PTT to decrease tumor growth. In one study that co-loaded DOX and indocyanine green (ICG)
photothermal agents in membrane-wrapped NPs, DOX was delivered in a “bomb-like” manner to the
tumor surroundings [76]. This was due to the HeLa cervical cancer cell membrane wrapped around the
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cargo being disrupted by PTT, which led to enhanced chemo-PTT efficacy [76]. In an unusual case of
using multiple types of membranes to coat NPs, RBC and B16-F10 mouse melanoma membranes were
mixed to create a hybrid membrane that provided increased immune evasion and tumor targeting,
respectively. The membranes were wrapped around DOX-loaded copper sulfide NPs, and these NPs
exhibited synergistic effects with close to 100% tumor growth inhibition [57]. Lastly, when DOX was
loaded into the core of gold nanocages, the hyperthermia induced-release of DOX in the targeted cells
inhibited the growth of both primary tumors and metastatic nodules in a highly metastatic 4T1 mouse
mammary tumor model [42]. These findings demonstrate the immense potential of combining PTT
with chemotherapy using CCNPs.
3.2.2. Photodynamic Therapy Combined with Chemotherapy or Starvation Therapy
The benefits of combining chemotherapy with PDT include having reactive oxygen species (ROS)
available to initiate drug release and promote intracellular drug delivery, as well inducing hypoxia
in the tumor region for activating encapsulated drugs [6]. Conversely, a limitation of PDT is that it
relies on tumor oxygen, and is therefore not effective in hypoxic tumor regions. By combining PDT
with drugs that are not hindered by hypoxia, more thorough tumor treatment can be achieved. In one
example of dual PDT/chemotherapy, a porphyrinic metal organic framework (a PDT photosensitizer)
was combined with tirapazamine (TPZ, a bioreactive chemotherapeutic) [73]. These agents were
wrapped in membranes derived from 4T1 breast cancer cells, and the resultant NPs were delivered
to mice bearing orthotopic 4T1 breast cancer tumors. Following irradiation, the porphyrinic metal
organic frameworks produced ROS, leading to local hypoxia within the tumors, which accelerated the
activation of TPZ for an enhanced chemotherapeutic effect. Because the treatment was activated only
in the presence of light at the tumor site, negligible side effects were observed [73].
Besides being combined with chemotherapy, PDT has also been combined with starvation therapy.
In starvation therapy, glucose oxidase (GOx) is delivered to tumors. GOx will transform glucose
into gluconic acid and hydrogen peroxide, starving the cells of glucose, a vital nutrient for tumor
growth. In one example, a cascade reaction system made of hollow manganese dioxide (MnO2)
NPs encapsulating a photosensitizer and coated with GOx were wrapped in B16-F10 cancer cell
membranes [67]. Once delivered to tumors, the MnO2 reactors were irradiated for continuous oxygen
generation, supported by the conversion of glucose to singlet oxygen. This system has potential to solve
hypoxia issues in tumors and promote starvation. Starvation therapy mediated by membrane-wrapped
NPs has also been explored without PDT [55]. In this study, GOx-loaded membrane-wrapped
mesoporous silica NPs were combined with PD-1 antibody treatment and shown to be more effective at
stimulating an anti-cancer immune response than the single therapies, resulting in better cancer ablation.
The above examples demonstrate that CCNPs have the ability to target tumor cells throughout the body
and enable PTT or PDT in combination with chemotherapy or starvation therapy. These combinatorial
delivery systems are more effective than monotherapies and offer extremely high precision treatment
of tumors since they are activated only when light and NPs are combined at the tumor site. Continued
development of these platforms will likely yield impressive results against a variety of tumor types.
3.3. Tumor Imaging
In many cases, it is desirable to monitor the accumulation of membrane-wrapped NPs within
tumors, as this can guide and inform drug delivery, PDT, and PTT [44,61,72,74]. Most NP cores
that enable imaging with high contrast are metallic-based, such as iron oxide or lanthanide-doped
nanocrystals, but development of organic or polymer-based nanoparticles as imaging agents has also
been explored [44,54,72,74].
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In a study whose sole purpose was to view homologous targeting of upconversion nanoprobes
(UCNPs), researchers used multiple types of cancer cell membranes (breast, prostate, colorectal,
and squamous cell cancer) to prepare corresponding batches of wrapped lanthanide-doped
nanocrystals [54]. These NPs could convert near-infrared (NIR) light into visible light, providing high
signal-to-noise ratio. The specificity of homotypic membrane-mediated targeting was beautifully
exhibited when mice bearing MDA-MB-435 breast cancer tumors were separately treated with each type
of membrane-wrapped UCNPs, as only UCNPs wrapped in membranes derived from MDA-MB-435
cells exhibited notable tumor retention. This indicates that while the cancer-membrane-wrapped NPs
possess the same immune evasion potential as RBC-wrapped NPs, mismatch of the donor membranes
and host tumor cells leads to little tumor targeting. In a similar study, researchers developed magnetic
iron oxide NPs loaded with DOX-HCl and coated them in either UM-SCC-7 squamous cell carcinoma
or H22 hepatocellular carcinoma membranes [44]. The team used magnetic resonance imaging to
show in mice bearing each type of tumor that the particles could bypass the heterologous tumor and
preferentially target their homotypic tumor (Figure 5). Future research could evaluate the degree of
mismatch that is acceptable when preparing CCNPs to maintain homotypic binding. While both of
these studies used cells derived from different tumor types to demonstrate that homotypic binding
requires membrane:tumor matching, it would be interesting to investigate if membranes derived from
cancer cells that are from the same tissue but exhibit different biomarkers can provide targeted delivery.
Figure 5. Demonstration of homotypic tumor targeting by CCNPs. (A) Illustration of experimental
design for data shown in (B). Mice bearing human squamous carcinoma (UM-SCC-7) tumors were treated
with doxorubicin (DOX) alone or with DOX and magnetic iron oxide nanoparticles that were wrapped
with membranes derived from three different sources (COS7 monkey kidney cells, HeLa cervical cancer
cells, or homotypic UM-SCC-7 squamous carcinoma cells). (B) In vivo fluorescence images of mice
bearing UM-SCC-7 tumors 24 hours post-injection with membrane-wrapped nanoparticles prepared
with (a) UM-SCC-7, (b) COS7, or (c) HeLa membranes as described in A, or post-injection with (d)
DOX at an equivalent DOX dosage. The highest tumor accumulation is observed for homotypic
membrane-wrapped nanoparticles. (C) Illustration of the dual tumor-bearing mouse model in which
one flank harbored a hepatocellular carcinoma (H22) tumor and the other harbored a UM-SCC-7 tumor.
The animals were injected with membrane-wrapped NPs designed to homotypically target one tumor
or the other. Twelve hours post-injection, in vivo fluorescence images and ex vivo images of tumors
were acquired. Both types of membrane-wrapped nanoparticles evaluated exhibited preferential
accumulation in homotypic tumors (matched to the source membrane) versus heterotypic tumors with
membrane mismatch. Reprinted (adapted) with permission from Reference [44]: Zhu, J.Y.; Zheng,
D.W.; Zhang, M.K.; et al. Nano Lett. 2016, 16, 5895–5901. Copyright (2016) American Chemical Society.
Membrane-wrapped NPs that incorporate both contrast agents and photoactive agents have
also been used for tumor imaging and phototherapies. In one study, ICG-loaded NPs wrapped with
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MCF-7-PEG fused membranes exhibited a PTT response, but also had fluorescence and photoacoustic
(PA) imaging capabilities [74]. PEG incorporation in this system diminished non-specific binding
of serum proteins and helped stop aggregation and opsonization leading to phagocytosis in vivo.
This particle formulation ablated tumors after a single dose and laser irradiation, and provided high
spatial resolution imaging of the tumor microstructure through PA imaging of the ICG signal in and
around tumor microvesicles. In another study, MCF-7 membranes were fused with RBC membranes to
coat melanin nanoparticles [68]. The biocompatible melanin core provided both PTT and PA imaging
and the size dependence of the particles for optimal PTT and PA imaging were explored to find the
balance between the two.
Similarly, dual-modal imaging has been used with PDT by loading photosensitizers into magnetic
nanobeads to target hepatocellular carcinoma [72]. Both near-infrared (NIR) fluorescence imaging
and magnetic resonance (MR) imaging could be accomplished with this system, with NIR enabled by
the loaded chlorin e6 (Ce6) photosensitizers that also provided PDT capabilities, and MR provided
by the superparamagnetic iron oxide nanostructures. In an even more complex system, multimodal
cancer phototheranostics were explored for the early diagnosis and precision therapy of cancer [61].
Here, organic, multimodal, NIR-semiconducting polymer NPs were produced, generating NIR and
PA signals for imaging, as well as singlet oxygen and cytotoxic heat for combinatorial PDT-PTT
effects. These NPs were coated in either activated fibroblast membranes or 4T1 cancer cell membranes,
where interestingly, the fibroblast-coated NPs performed better than their cancer cell membrane-coated
counterparts [61]. Although the 4T1 membrane NPs targeted cancer cells, they were limited by the
abundance of cancer-associated fibroblasts in the tumor environments, making their accumulation
only marginally higher than non-targeted particles. The activated fibroblast-coated NPs, in contrast,
exhibited heightened tumor accumulation through their homotypic targeting of cancer-associated
fibroblasts at the tumor site.
3.4. Immune Stimulation
There is growing interest in the field of oncology in using technologies to stimulate the body’s
immune system to attack tumor cells. Immunotherapy can be applied as either a cancer treatment
or as a preventative cancer vaccination, and is advantageous over cytotoxic agents because of its
high specificity and low toxicity [2,6,18,75,101–106]. Effective immune stimulation typically requires
that both adjuvants and tumor antigens be delivered to the body. One advantage of CCNPs is that
their membrane coatings carry a full array of cancer cell membrane antigens that can stimulate an
anticancer immune response. Thus, combining CCNPs with adjuvant technologies is a promising
strategy to elicit robust anti-tumor responses. In the following sections, it is assumed readers have
a basic familiarity with cancer immunotherapy. For detailed reviews, we refer the readers to recent
publications [102,105–110].
Exploring the immune stimulatory capabilities of membrane-wrapped NPs, Fang et al. prepared
PLGA NPs wrapped in B16-F10 melanoma or MDA-MB-435 human breast cancer membranes and
utilized these NPs to deliver antigens to source tumor cells and antigen presenting cells (APCs) [45].
The CCNPs enhanced source cell-specific binding and uptake compared to RBC-wrapped NPs
and bare NPs. They also successfully delivered membrane-bound tumor-associated antigens to
APCs. However, this was insufficient to induce dendritic cell maturation due to the limited
immunogenicity of syngeneic cancer cell membrane material. To overcome this issue, the team
incorporated monophosphoryl lipid A (MPLA), an immunoadjuvant lipopolysaccharide derivative
that binds to toll-like receptor 4 (TLR-4), into the CCNPs, and this significantly increased the APC
maturation to promote an anticancer immune response [45]. In a similar approach, Kroll et al.
developed B16-F10 melanoma membrane-wrapped PLGA NPs loaded with CpG oligodeoxynucleotide
1826 (CpG), a nucleic acid-based immunological adjuvant known to trigger APC maturation, and tested
these in combination with a CTLA4 and anti-PD-1 checkpoint blockade cocktail [75]. The nanovehicles
simultaneously delivered syngeneic cancer antigens with a powerful immunological adjuvant to
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promote antigen presentation. When applied separately in vivo, the CpG-CCNPs or checkpoint
blockade cocktail did not significantly impair the growth of B16-F10 tumors. However, when combined,
the systems synergistically promoted a strong antitumor response and modulated various aspects of
the immune system [75]. Together, both of these studies indicate the potential for CCNPs to trigger
superior anti-cancer immune responses by enabling codelivery of tumor antigens and adjuvants.
As the field matures, researchers will continue to design new ways to enhance immunotherapy
mediated by CCNPs. Yang et al. recently showed that CCNP delivery to dendritic cells (DCs) could
be enhanced by modifying CCNPs with mannose (which binds receptors on DCs) through lipid
anchors [64]. The CCNPs consisted of PLGA cores encapsulating R837, an agonist against toll-like
receptor 7 (TLR-7), wrapped with B16-OVA melanoma cancer cells and functionalized with mannose.
The mannose-modified nanovaccine exhibited impressive DC uptake, triggering DC maturation.
It also successfully traveled to draining lymph nodes post-transdermal injection and facilitated
potent tumor-specific immune responses [64]. In another unique nanovaccine design, melanoma
cell membrane fractions were coated onto PLGA NPs and their ability to effect fibroblast-mediated
invasion, change experimental metastasis, and induce an immune response in immunocompetent
mice was evaluated [43]. The nanovaccine successfully inhibited cancer cell migration toward
fibroblasts, significantly decreased metastatic burden, and increased cytotoxic T lymphocytes, indicating
membrane-wrapped nanovaccines not only show potential as antigen delivery vehicles for primary
tumor elimination, but also as metastasis inhibitors.
In summary, CCNPs have great potential as either prophylactic vaccines to protect patients from tumor
cell challenges or as therapeutic agents to shrink tumors by inducing anti-cancer immune responses. It is
observed that tumor antigen presentation from the membrane coating alone, even in highly immunogenic
contexts, may not be powerful enough to overcome the immunosuppressive tumor microenvironment.
Therefore, technologies must be combined with adjuvants, immune checkpoint blockade therapies,
or other approaches to achieve optimal anti-cancer effects. Nevertheless, the biocompatible nature of
CCNPs makes them promising as personalized therapies to induce cancer-specific immune responses for
individual cancer patients.
4. Challenges and Path Forward
While many of the described successes of CCNP systems are extremely encouraging, there are still
many challenges to address before these technologies become commercially available. One potential
issue is the need for patient education, as concern may develop over having cancer cell-derived material
injected into the body. Although patients who already have cancer may be willing to overlook this
concern if it provides a chance to eradicate their disease, healthy patients who are at-risk for certain types
of cancer and wish to use this technology as a preventative vaccine may be less receptive. In addition
to educating the population, stringent testing and procedures will have to be developed to ensure
that the membrane coatings are pure (lacking any internal component of the source cells) and do not
contain any molecules that might promote cancer growth. As the development of membrane-wrapped
NPs is already becoming more mature, with proper tests this should not be an issue and this hurdle
could be feasibly overcome.
One of the biggest draws of using cell membranes to coat NPs is the ability to have a personalized
treatment. NPs coated with membranes derived from a patient’s own cells should be able to
evade unwanted immune responses that can occur when foreign material is introduced to the
body. However, the feasibility of creating CCNPs for each individual patient is a significant
question. Preparing patient-specific CCNPs will require strict quality control and regulatory methods.
Additionally, while biopsy samples could be used to create CCNPs for patients with existing tumors,
the production of CCNPs for prophylactic vaccination will require a different approach. Donor cells
could possibly be used, but immunostimulatory issues may arise. One way this could be mitigated is
by preparing particles with mixed membrane coatings, as several studies have shown this can imbue
the NPs with properties of both membranes [57,68,111]. In this case, donor cancer cell membranes
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could be mixed with RBC or platelet membranes from the patient, lessening the portion of foreign
membrane material to minimize an immune response. This strategy needs to be explored in many
models in order to validate its use. An additional consideration for the use of CCNPs in a prophylactic
setting is the need to define the appropriate patient population based on genetic testing or family
history of specific cancers. However, if the concerns mentioned here can be sufficiently addressed, the
potential impact of CCNPs for personalized cancer therapy is vast.
Lastly, for CCNPs to be successful in the clinic, methods for manufacturing scale-up need to be
developed. Particle replication on a small laboratory scale is already difficult due to the complex
biological components involved and concerns of batch to batch consistency need to be addressed.
One of the largest hurdles in scaling up the process is the need for large quantities of membranes.
This requires millions, if not billions, of cells, and the facilities to grow them. Besides producing
the necessary amount of membrane material, the scaling up of the NP cores is another concern,
especially if the design is more complex or a multi-component system. The more complicated a
nanotherapy fabrication is, the more difficult it is to create reproducible and identical particles at large
scale. Finally, the assembly of how membrane vesicles are fused with NP cores could be difficult to
replicate at a large scale. In short, the more steps to the process, the more difficult it will be to produce
commercial quantities of high-quality material. This must be addressed before membrane-wrapped
NP technologies can reach clinical trials or achieve FDA approval.
5. Conclusions
This review has highlighted the current state-of-the-art in developing CCNPs for the management
of cancer. CCNPs have immense potential as tools to improve the imaging and treatment of tumors,
but they also face substantial challenges in translating to the clinic. The future of the field lies in
solving these issues or working around them to deliver specific, personalized therapy to single patients.
While difficult to accomplish, the chance of eradicating even a single type of cancer, whether by
therapy or vaccine, will continue to drive the many paths of research surrounding CCNPs described in
this Review.
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Abstract: Due to advancements in nanotechnology, the application of nanosized materials
(nanomaterials) in cancer diagnostics and therapeutics has become a leading area in cancer research.
The decoration of nanomaterial surfaces with biological ligands is a major strategy for directing the
actions of nanomaterials specifically to cancer cells. These ligands can bind to specific receptors
on the cell surface and enable nanomaterials to actively target cancer cells. Integrins are one of the
cell surface receptors that regulate the communication between cells and their microenvironment.
Several integrins are overexpressed in many types of cancer cells and the tumor microvasculature
and function in the mediation of various cellular events. Therefore, the surface modification of
nanomaterials with integrin-specific ligands not only increases their binding affinity to cancer cells but
also enhances the cellular uptake of nanomaterials through the intracellular trafficking of integrins.
Moreover, the integrin-specific ligands themselves interfere with cancer migration and invasion by
interacting with integrins, and this finding provides a novel direction for new treatment approaches
in cancer nanomedicine. This article reviews the integrin-specific ligands that have been used in
cancer nanomedicine and provides an overview of the recent progress in cancer diagnostics and
therapeutic strategies involving the use of integrin-targeted nanomaterials.
Keywords: nanomedicine; nanoparticles; integrin; RGD peptide; active targeting; cancer diagnosis;
drug delivery; radiotherapy; hyperthermia therapy
1. Introduction
1.1. Cancer Nanomedicine
An increasing number of nanotechnologies have been applied to the screening, diagnosis,
and treatment of cancer in the field of cancer nanomedicine. Since the first nanomedical cancer drug
Doxil (liposomal doxorubicin) received approval by the food and drug administration of America
(FDA) in 1995 [1], the number of new applications in cancer nanomedicine has increased. Compared
with conventional cancer interventions, nanomedicine, which involves the nanoscale application of
highly specific medical interventions, has unique features. For example, nanomedicine offers the
ability to specifically target and greatly enhance the detection of tumors [2,3]. In cancer treatment,
nanomedicine not only improves the therapeutic indexes of traditional medications but also provides
innovative concepts for new treatment approaches [4]. Those appealing advantages have incentivized
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more scientists to undertake research in cancer nanomedicine, and these studies have contributed to
the development of promising treatments for overcoming cancer in the future.
1.2. Characterization of Nanoparticles
To produce nanomedical agents for cancer diagnosis or treatment, scientists first select the
nanoparticle (NP) platform on the basis of the therapeutic approach. The main structure of NP
platforms can be divided into organic and inorganic materials. Organic NPs, such as liposomes [1],
polymeric NPs [5], dendrimers [6], viral NPs [7], and exosomes [8], are usually used for drug delivery
or gene therapy, and inorganic NPs include carbon-based NPs [9], metal-based NPs [10], mesoporous
silica [11] and quantum dots (QDs) [12]. Over the last few decades, these NPs have become increasingly
advanced with new designs and applications, such as functionalization for achieving stimuli-responsive
effects [13]. For example, Gao et al. used inorganic NPs to induce heat after exogenous stimulation to
trigger the release of cytotoxic agents [14]. In addition, due to their unique physical properties, inorganic
NPs, such as metal-based NPs, can be used in innovative approaches, including the enhancement of
radiotherapy [15] and the induction of hyperthermia in cancer cells [16].
Subsequently, the delivery of NPs is considered, and there are two major approaches for
transporting NPs to cancer cells: passive targeting and active targeting (Figure 1). By leveraging
the pathophysiological processes in cancer (for example, leaky tumor vasculature, poor lymphatic
drainage, and tumor microenvironment interactions), NPs can take advantage of the enhanced
permeability and retention (EPR) effects to accumulate around tumoral tissue, and this process is
called passive targeting [17]. The first-generation nanomedicine drugs, such as Doxil, Myocet (non-
polyethylene glycosylated (PEGylated) liposomal doxorubicin) and DaunoXome (non-PEGylated
liposomal daunorubicin), are EPR effect-based nanomedical drugs that have already been routinely
used for treating patients [18]. However, the use of NPs through only passive targeting does not achieve
the best therapeutic effects because the EPR effect applies not only to tumors but also to some normal
tissues [19,20], such as hepatic or splenic tissue with fenestrated blood vessels, and leads to unexpected
NP accumulation in these normal tissues. In addition, solid tumor tissues are heterogeneous neoplasms
composed of different types of cells, including cancer cells, mesenchymal cells, endovascular cells,
and immune cells [21]. This heterogeneity of tumoral tissue limits the ability of delivering NPs
specifically to tumor cells.
To enhance the accumulation of NPs in cancer cells, scientists decorate NPs with targeting
ligands that recognize specific receptors on the tumor cell surface, and this approach is called active
targeting [22]. Active targeting effectively increases not only the tumor uptake of NPs independent
of the EPR effect but also the ability of NPs to cross physiological barriers, such as the intestinal
mucosa [23] or the blood–brain barrier [24]. Selecting the appropriate targeting ligand is critical for
optimizing the efficiency of active targeting. Representative ligands used for the active targeting of
NPs include antibodies, peptides, nucleic acids, sugars, and/or other small molecules [25]. In the
past, antibodies have generally been selected as targeting moieties for use in nanomedicine due to
their high specificity and wide availability [26]. However, the clinical use of antibody-based NPs is
limited by certain features of the antibodies, such as the large size of antibodies, which impedes the
effectiveness of surface conjugation [27], or the immunogenicity of antibodies, which leads to high
clearance from the blood [28]. In addition, the easy degradation of antibodies during environmental
changes (temperature, pH level, photostability, oxidation, etc.) is also a problem [29]. Peptides with
smaller molecular sizes and simple three-dimensional structures do not have the disadvantages of
antibody-based NPs. In addition, the synthesis of peptides is relatively simple and inexpensive
compared with the production and cost of antibodies, which facilitates their translation to the clinic.
Research on nucleic acids is relatively more recent than that on peptides, and the lack of safety
data and clinical reports on nucleic acids limits their application [30]. Sugars (such as saccharides,
oligosaccharides, and polysaccharides) are larger than peptides, which affects their application for NP
modification. Compared with other small-molecule agents, peptides are more specific to their targets
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because they are derived from linear protein sequences [31]. Therefore, peptides that can specifically
bind to surface receptors on cancer cells, particularly integrin-targeted peptides, have attracted
extensive attention.
 
Figure 1. Uptake of nanoparticles (NPs). (A) Representative NPs used for cancer nanomedicine.
(B) Accumulation of NPs in the human body. The organs that typically show the highest NP
accumulation are the liver and kidney. (C) Schematic of passive targeting (enhanced permeability and
retention (EPR) effects). NPs preferentially accumulate within tumors due to their leaky vasculature
and poor lymphatic drainage. (D) Schematic of the active targeting of NPs conjugated with specific
ligands that target surface receptors on cancer cells. (E) Schematic of intracellular uptake. This figure
shows an example of the internalization of integrin-targeted NPs by cells through endocytosis after
binding to integrins.
1.3. Integrins in Cancer Nanomedicine
Integrins constitute a family of cell surface receptors that mainly facilitate cell-to-extracellular
matrix (ECM) adhesion. Each integrin belonging to this family of heterodimeric transmembrane
receptors is composed of an α subunit and a β subunit. Mammals have 18 α-subunits and eight
β-subunits, and these subunits form 24 different integrins [32]. Various integrins play two major
functions: attaching the cell body to the ECM and receiving signals transduced from the ECM.
The extracellular domain of these integrins shows strong affinity for ECM proteins, including fibronectin,
vitronectin, collagen, and laminin. After binding to ECM and clustering, these integrins also activate
signal transduction pathways that mediate cellular signals related to cell growth, survival, division,
and migration [33]. In contrast, the overexpression of certain integrins has been observed in highly
337
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malignant cancer cells (Table 1) and plays an important role in malignant properties, including cancer
progression [34], invasion/metastasis [34], tumor angiogenesis [35], and even resistance to conventional
cancer therapy [36,37]. These facts suggest that targeting integrins overexpressed in cancer cells is a
feasible strategy for use in cancer nanomedicine.




Specific Functions in Cancers




Increases tumor progression [38]
Increases cancer invasion [39]
Mediates resistance to radiotherapy [36]
Head and neck cancer [40,41]
Vitronectin Non-small cell lung cancer [42]
Fibrinogen Breast cancer [43]





Increases tumor progression [47]
Increases lymph node metastasis [48]
Increases bone metastasis [49]
Is involved in cancer immune evasion [50]
Glioma [51]
Vitronectin Head and neck cancer [40]
Fibrinogen Non-small cell lung cancer [52]










Increases tumor progression [56]
Is involved in glioma invasion [57]
Lung cancer brain metastases [53]
Vitronectin Non-small cell lung cancer [52]
Fibrinogen Gastric cancer [54]
Osteopontin Prostate cancer [55]
αvβ6
Fibronectin
Promotes hepatic tumorigenesis [58]
Increases tumor progression [59]
Increases lymph node metastasis [60]
Mediates resistance to chemotherapy [61]
Head and neck cancer [62]
Vitronectin Non-small cell lung cancer [63]
Fibrinogen Breast cancer [64]







Basal cell carcinoma [69]
αvβ8
Fibronectin
Is involved in cancer immune evasion [70]
Mediates resistance to chemo- and
radiotherapy [71]
Head and neck cancer [72]
Vitronectin Non-small cell lung cancer [52]
Fibrinogen Prostate cancer [55]
Osteopontin
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The Arg-Gly-Asp (RGD) peptide is the most representative binding motif involved in the
interactions of ECM proteins with integrins [73]. Since the RGD peptide was first discovered in
1984 [74], studies on integrin-targeted peptides in cancer diagnosis and treatment have become
popular [75]. Interestingly, some of the artificial integrin-targeted peptide mimics act as antagonists
that can inhibit integrin-mediated functions [76,77]. Through modification with integrin-targeted
peptides, these NPs have been shown to exhibit not only high affinity to integrin-overexpressing
cancer cells but also potential efficacy to suppress cancer progression through the inhibition of
integrin-mediated functions [78,79].
In addition to the above-described features, the intercellular uptake and trafficking of integrins
constitute another process that might be related to the efficacy of NPs. After binding to ECM
ligands, integrins trigger ‘outside-in’ signals that promote downstream signaling to regulate the
above-described cell behaviors [80]. Consequently, ligand-bound integrins are internalized by
cells for focal adhesion turnover mainly by clathrin-mediated endocytosis and then transported
to late endosomes or lysosomes [81]. In the acidic environment of late endosomes or lysosomes,
some integrins are detached from the binding ligands, and the unbound free integrins are recycled
back to the plasma membrane [80,82]. Incidentally, the required factors for regulating the recycling of
integrins back to the plasma membrane are specifically upregulated in cancer cells and thus related
to cancer progression [80,82]. Due to these characteristics (endocytosis and recycling of integrins),
the integrin-targeted NPs are able to interact with integrins on the cell surface and are effectively
internalized by the cancer cells together with the ligand [83], and some of these NPs accumulate in late
endosomes and lysosomes [78].
2. Ligands Used in Integrin-Targeted NPs
By modification with integrin-targeted ligands on their surface, NPs can specifically target
integrin-expressing cancer cells. As described above, the RGD motif is the first-discovered and the
most widely studied integrin-targeted ligand [74] and can be recognized by integrins that are important
for cancer progression and metastasis, including αvβ3-, αvβ5-, αvβ6-, αvβ8-, and α5β1-integrins [73].
In addition to the RGD motif, several non-RGD motifs have also been found to serve as specific
integrin-target ligands and have characteristics that differ from those of RGD motifs (see below).
2.1. RGD-Based Integrin-Targeted Ligands
The RGD sequence has been found in many ECM proteins, including fibronectin [74],
vitronectin [84], von Willebrand factor [85], osteopontin [86], and laminin [87]. The RGD-containing
peptides can generally be divided into those with linear and those with cyclic structures. The cyclic
RGD (cRGD) peptides display higher activity than the linear RGD peptides due to a less flexible
conformational structure that resists proteolysis [88,89]. To enhance the biological properties and
pharmacokinetics of RGD peptides, including their affinity, various strategies have been used to modify
the structure of RGD peptides, such as altering their structure [90] and the stereochemical configuration
of the constituent amino acids [91], introducing other amino acids to flank the RGD sequence [92],
and N-methylation [93,94]. The modification of NPs with RGD peptides could increase their binding
affinity to specific integrins. For example, Maltsev et al. transformed the long binding helix of an
RGD ligand to an enzymatically stable cyclic peptide endowed with subnanomolar binding affinity
toward the αvβ6-integrin receptor [90], and the resulting molecule could be used for intraoperative
cytological assessment of bony resection margins in patients with head and neck cancer [95]. Cilengitide
(Merck, Germany), an N-methylated cRGDfV derivative [c(RGDfNMeVal)], is a very potent antagonist
of ανβ3-, ανβ5-, and α5β1-integrins [96]. Compared with other compounds, Cilengitide exhibits
significantly higher binding affinity for these integrins [97]. Although Cilengitide failed to improve
the treatment outcomes of glioblastoma multiforme in phase III clinical trials [98], NPs modified with
Cilengitide show promising results in preclinical research [99]. Other well-known RGD peptides include
cRGDfV [91] (the parent peptide of Cilengitide), cRGDfK [100], and RGD4C (ACDCRGDCFCG) [101].
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In addition, iRGD (CRGDK/RGPD/EC), a relatively new compound, was produced to induce a multistep
tumor-targeting process that differs from that of the other RGD peptides [102]. After binding to
αv-integrins, iRGD is cleaved by a protease to expose the binding motif for neuropilin-1. Consequently,
the iRGD-conjugated material is transferred from the integrins to neuropilin-1 and deeply penetrates
into the tumor. This unique delivery method has been used in ongoing research in the field of cancer
nanomedicine [103].
2.2. Non-RGD Integrin-Targeted Ligands
In addition to the RGD peptide, the Asp-Gly-Arg (NGR) peptide is an integrin-binding motif
found in fibronectin [104]. On the basis of the structure of the NGR peptide, another peptide motif,
isoDGR, which is found in fibronectin, was produced by in situ rearrangement to convert asparagine
into iso-aspartate [105]. A survey of the binding affinity of integrin-targeted ligands to integrins
revealed that the compound c(phgisoDGRk), which contains isoDGR, shows high affinity to ανβ6-,
ανβ8-, and α5β1-integrins [97]. Several groups have used isoDGR ligands to modify NPs to target
integrins [106,107]. Another non-RGD pentapeptide derived from the synergy domain of fibronectin is
Ac-PHSCN-NH2, which was clinically developed under the trade name ATN-161 for the treatment
of several solid tumors [36,108] due to its high affinity for α5β1-integrin and relatively lower affinity
for αvβ3- and αvβ5-integrins [109]. Other integrin-targeted peptidomimetics, including SCH221153
(αvβ3- and αvβ5-integrin specific), BCH-15046 (αvβ3-, αvβ5-, and α5β1-integrin specific), SJ749
(α5β1-integrin specific), JSM6427 (α5β1-integrin specific), and A20FMDV2 (αvβ6-integrin specific),
have been developed, and these have shown anticancer activities in preclinical models and when used
on NPs [110,111].
In addition to the ECM-related peptides, tetraiodothyroacetic acid (tetrac), a thyroid hormone
analog, has recently been used as an αvβ3-integrin-targeted ligand. Thyroid hormones induce tumor
growth and angiogenesis via αvβ3-integrin [112,113]. On the basis of this concept, researchers have
used tetrac to manufacture integrin-targeted NPs, which have recently shown promising results in
preclinical studies [114,115].
3. Applications of NPs in Cancer Diagnosis
NPs have a wide range of applications, particularly in the field of molecular imaging.
The introduction of molecular imaging to cancer diagnosis has provided a new approach for
understanding tumor characteristics without depending on invasive diagnostic procedures [116].
Kircher et al. [117] defined molecular imaging as the noninvasive imaging of cellular and subcellular
events. The advent of nanotechnology has led to the use of NPs in cancer diagnosis, and this targeted
molecular imaging method offers a better approach for detecting cancer cells.
NPs with conjugated integrin-targeted ligands can be used to obtain images of integrins [118–121],
which are overexpressed in many cancer cells and angiogenic vessels, as previously described. Among
the advantages of imaging integrins, the following are specific to clinical cancer diagnosis: (i) the
imaged integrins can be used to identify integrin-overexpressing tumors, which represent highly
invasive or high-grade tumor disease for which a precise personalized cancer treatment can be applied;
(ii) tumor imaging can lead to the early detection of metastatic disease; and (iii) the imaging of tumors
can reveal tumor neoangiogenic activity that requires antiangiogenic therapies. The composition
of the integrin-targeted NPs is an important factor for obtaining precise and useful integrin images.
In addition, selecting the appropriate diagnostic tool for imaging integrins is another important issue to
consider. Several imaging modalities have been employed for accurate cancer diagnoses, but different
studies have shown that positron emission tomography (PET) imaging [2], magnetic resonance imaging
(MRI) [122], fluorescence reflectance imaging (FRI) [123], and fluorescence molecular tomography
(FMT) [3] are particularly effective methods for imaging integrin-targeted NPs due to their high spatial
resolution and ability to capture images in real time.
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In this section, we review the representative means for fabricating and characterizing
integrin-targeted NPs for use in cancer diagnosis and then describe the associated techniques.
3.1. Fabrication of Integrin-Targeted NPs for Cancer Diagnosis
To obtain highly precise images of integrins targeted by NPs, several factors should be considered.
Montet et al. [123] used cRGD-conjugated fluorescence-based NPs to detect integrin-expressing cancer
cells in tumor-bearing mice through MRI, FRI, and FMT images. These researchers suggested that (i)
the expression level of integrins in tumor cells, (ii) the pharmacokinetics of NPs (which should have a
sufficient half-life in blood to slowly escape from the vasculature over a long circulation time), and (iii)
the vascularized nature of tumors (through which NPs enter the cancer cells efficiently) are the factors
that influence RGD-conjugated NPs to allow the efficient imaging of integrins.
In addition to the detection of integrin-expressing cancer cells at their site of origin, NPs can be
used for the early detection of metastatic cancer cells, which makes NPs attractive for use in cancer
diagnosis. A significant proportion of deaths result from cancer metastases [124]. Several studies have
suggested that early metastatic cancer cells can be targeted with NPs [125,126], although the targeting
of metastatic cancers with nano-objects, which have a relatively small size and low vascularization,
has proven to be a Herculean task. To achieve this goal, Peiris et al. fabricated chain-shaped NPs with
c(RGDfC) conjugated on their surfaces for tumoral vascular targeting [3]. Nanochain technology was
deployed to fabricate four iron oxide nanospheres [127] that were then fused with cRGD to create
chain-shaped NPs, and the resulting NPs were linearly assembled via chemical reaction [128]. Due to
the high metastatic potential of 4T1 breast cancer cell lines [129], Peiris et al. used 4T1 tumor-bearing
mice to evaluate the uptake of the NPs by metastatic cancer cells [3]. These researchers reported that
the cRGD-conjugated chain-shaped NPs have the potential to detect metastatic tumors in addition to
primary tumors.
Similarly, another study fabricated RGD peptides with green fluorescent zinc oxide nanowires
(ZnO-NWs) [130]. Zinc oxide is a biocompatible multifunctional material with excellent piezoelectric
and pyroelectric properties that can be used as a medical fluorescent material [131,132]. In addition,
the low toxicity and biodegradable properties of nanomaterials in the human body are also
important features of ZnO and make it a great candidate for use in cancer nanomedicine [133].
To produce compact and useful ZnO-based NPs for cancer diagnosis, Hong et al. synthesized
specific green fluorescent ZnO-NWs and further conjugated ZnO-NWs with the c(RGDyK) peptide
to target αvβ3-integrin [130]. These researchers demonstrated the usefulness of ZnO-NWs for
the cancer-targeted optical imaging of U87MG human glioblastoma cells with high αvβ3-integrin
expression. However, αvβ3-integrin-negative cells, such as MCF-7 human breast cancer cells, did not
show fluorescence signals.
Biocompatible QDs conjugated with RGD peptides have also been considered nanomaterials for
detecting the tumor vasculature [134]. The introduction of QDs for biological and optical imaging
was largely based on the ability to deliver these nanosized objects to cancer cells [134,135]. In fact,
Cai Weibo et al. reported the use of QDs conjugated with the RGD peptide (QD705) for imaging the
αvβ3-integrin-positive tumor vasculature in living mice [134]. The study also reported that during
angiogenesis, the overexpression of αvβ3-integrin was detected in the tumor vasculature, and this
observation paved the way for using QDs for optical integrin-targeted imaging in cancer diagnosis.
Similarly, Smith et al. investigated the tumor neovasculature in mice by conjugating the QDs with
RGD peptide, which bind to luminal endothelial cells, to capture images of αvβ3-integrin [136].
These researchers revealed that QDs bind aggregately rather than individually, which indicates the
unexpected distribution pattern of αvβ3-integrin in the tumor neovasculature. However, the challenge
of using QDs is that their large size causes them to be retained in the vascular system, which could
restrict their exudation from the blood vessels and lead to diffusion to cells distant from the vessels.
It has been reported that these effects could potentially induce toxicity to normal tissues and thus
reduce the imaging efficiency and sensitivity of QDs [137]. To correct this anomaly, an ultra-small sized
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luminescent silver sulfide (Ag2S) NP was developed, and the resulting Ag2S QDs induced negligible
toxicity in tissues [138]. In contrast, Lin et al. synthesized ultrasmall superparamagnetic iron oxide
NPs (USIO-NPs) using a coprecipitation method and conjugated the USIO-NPs with RGD peptides to
target integrins [139]. Their study further revealed that RGD-conjugated USIO-NPs have the potential
to differentiate human cancer tumors and cells with different integrin expression levels, such as MCF-7,
A549, HT-29, and HT-1080 cells [139].
3.2. Techniques for Imaging Integrin-Targeted NPs
As described above, PET [2], MRI [122], FRI [123], and FMT [3], among others, have proven to be
effective methods for imaging integrin-targeted NPs. With the aid of a small-animal PET system, tumor
imaging has been performed with iodine-124 dimeric cyclic RGDyk upconversion nanophosphors
[124I-(cRGDyk)2-UCNPs] in a U87MG tumor model [2]. Images of αvβ3-integrin were taken after the
administration of a conjugated radionuclide during PET scanning, which lasted for approximately 1 h.
In contrast, MRI technology is considered an effective imaging modality due to its high spatial
resolution and its non-reliance on ionizing radiation (IR). In fact, Vargas et al. suggested that
diffusion-weighted MRI can be used to detect aggressiveness in certain malignancies [140]. Goswami
et al. conjugated cRGD peptides to a vertex-differentiated contrast agent, [closo-B12]2− (CA-12),
and investigated its ability to target αvβ3-integrin following in vivo MRI analysis [122]. The study
confirmed the ability of cRGD-conjugated CA-12 to selectively target αvβ3-integrin while inducing
negligible toxicity in the site injected with the contrast agent. This kind of study might improve MRI
by overcoming its low specificity in several situations (such as the false-positive rate of 10% for breast
cancer [141]) and are thus likely to have a significant impact on cancer diagnosis in the future.
Additionally, optical imaging is considered a suitable preference for imaging cellular and molecular
processes due to its high sensitivity. In further prospective research, Akers et al. [142] reported that for
imaging αvβ3-integrins, RGD-conjugated NPs can be used to delineate tumor-induced angiogenesis
by optical imaging. They suggested that when developing new molecular agents for cancer imaging,
the animal model selected might influence the outcome. The use of multiple animal models is important
for assessing the robustness of these molecular agents with high tumor-to-surrounding tissue contrast.
4. Applications in Cancer Treatment
4.1. Drug Delivery
A conventional method of treating cancer involves chemotherapy. However, systemic toxicity,
severe side effects, and the inability to achieve sufficient drug accumulation in the tumor remain
the current challenges associated with the use of chemotherapeutic agents [143,144]. To overcome
these challenges, Tian et al. suggested that innocuous, tissue-specific, and noninflammatory (i.e.,
avoiding the induction of side effects caused by innate immune activation) delivery technologies
should be developed and translated into clinical practice for cancer therapy [145]. Further studies
revealed that with the aid of nanotechnology, specifically designed NPs, which act as delivery vehicles,
can control therapeutic processes in cancer therapy [146,147]. In fact, several studies on the use
of ligand-mediated “smart drug delivery systems” have revealed that therapeutic agents can be
more specifically transported to tumor sites by targeting αvβ3-integrins on cancer cells, and these
types of agents have proven to be efficient in a cancer therapy regime [148–151]. Several typical
chemotherapeutic agents, such as doxorubicin [145,152–154], cisplatin [149], and paclitaxel [155–157],
have been combined with RGD-conjugated NPs to target integrin-overexpressing tumors.
Doxorubicin is an important cancer therapeutic agent that is currently used as the standard
treatment for many neoplastic diseases. However, it has also been reported that the dose-dependent
cardiac toxicity of this agent, which leads to cardiomyopathy, has limited its clinical use [158].
To overcome the short biological half-life and adverse effects of doxorubicin, polymer-based
NPs conjugated with RGD peptides were developed to deliver doxorubicin directly to a tumor
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site [159–162]. Moreover, a similar study using RGD-conjugated polymer-based NPs further
modified these NPs with organelle-targeting ligands [163]. In the study, the NPs that targeted the
nucleus, which were achieved with RGD4C-PEO-b-P(CL-Hyd-DOX) (RGD ligand poly(ethylene
oxide)-block-poly(ε-caprolactone) with doxorubicin conjugated to the core using pH-sensitive
hydrazone bonds), induced the highest cytotoxic response in doxorubicin-sensitive cancer cells,
and the mitochondrion-targeted NPs, which were obtained with RGD4C-PEO-b-P(CL-Ami-DOX)
(RGD ligand poly(ethylene oxide)-block-poly(ε-caprolactone) with doxorubicin conjugated to the core
using stable amide bonds), induced the highest cytotoxic response in doxorubicin-resistant cancer
cells [163]. In addition to polymer-based NPs, Tian et al. manufactured iRGD-conjugated exosomes
(iRGD-Exos) by engineering immature murine dendritic cells with the aim of producing drug-carrier
NPs that induce low inflammatory and toxicity [145]. The iRGD-Exos were loaded with doxorubicin
by electroporation to create iRGD-Exos-Dox. Compared with doxorubicin alone or Exos-Dox without
iRGD conjugation, iRGD-Exos-Dox exerted a superior cytotoxic effect in αv-integrin-positive breast
cancer cells in both in vitro and in vivo experiments. The study suggests a possible clinical approach for
using an integrin-targeted exosome-based drug delivery system for the treatment of tumor disease [145].
In addition to doxorubicin, cisplatin is a widely used anticancer drug [164]. It has been estimated
that only a small proportion (only 1% or less) of the Pt(II) compound cisplatin is delivered to the cells
and binds to DNA, whereas a significant proportion (approximately 90%) is targeted toward proteins
and low-molecular weight biomolecules [165,166]. To overcome this disparity, a novel method was
developed to convert Pt(IV) complexes into prodrugs that can be intracellularly activated by reduction
to generate Pt(II), and as a result, a large fraction of platinum can be delivered to the cancerous
cells [166]. Graf et al. [149] synthesized a polymeric NP system that consists of an encapsulated
Pt(IV) prodrug and cRGD peptides targeted to αvβ3-integrin on cancer cells and performed in vitro
tests. Their results revealed that the synthesized NPs exhibited enhanced cytotoxicity compared with
cisplatin administered at its conventional dosage in prostate and breast cancer cell lines.
Other chemotherapeutic drugs, such as paclitaxel, which has the trade names Taxol and
Abraxane [155,156]; cetuximab, which is also known as Erbitux [167]; and temozolomide, which is an
oral alkylating chemotherapeutic drug [168], have shown strategic promise in cancer therapy when
loaded onto integrin-targeted NPs, which has resulted in an improved treatment efficacy.
Different therapeutic agents induce cytotoxic effects in cancer cells via different mechanisms and
thereby produce drug resistance in different ways [169]. Hence, the simultaneous combination of
different chemotherapeutic agents for the treatment of tumor disease has been used to improve the
therapeutic outcomes. However, the therapeutic outcomes of combination chemotherapy remain
unsatisfactory due to discrepancies in tumor uptake and their different pharmacokinetic profiles [170].
These obstacles can be overcome by nanomedicine. Several studies used integrin-targeted NPs and
loaded them with two different therapeutic agents. For example, some researchers loaded topotecan
(TPT) and quercetin (QT) on mesoporous silica NPs for the treatment of integrin-expressing breast
cancer cells [171], another group loaded paclitaxel and cisplatin onto RGD-conjugated lipid-polymer
NPs for the treatment of lung tumor [172], and another study combined doxorubicin with c-Myc small
interfering RNA (siRNA) and loaded these onto RGD-conjugated NPs [173]. These new-generation
NP-based drugs provide a promising future for improving chemotherapy.
4.2. Radiotherapy, Hyperthermia Therapy, and Photodynamic Therapy
In addition to serving as drug delivery carriers, NPs have other applications, such as enhancers
or producers of therapeutic effects by themselves. These types of NPs are mainly metal-based NPs,
which can cause greater damage directly in cancer cells following external excitation. In this section,
we discuss the application of integrin-targeted NPs in radiotherapy, photothermal therapy (PTT),
magnetic hyperthermia therapy (MHT), and photodynamic therapy (PDT).
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4.2.1. Radiotherapy
Radiotherapy is one of the standard and effective cancer therapies based on IR. Over the
last decades, clinical and in vitro studies have revealed that elements with a high atomic number
(Z) can enhance the external radiation effect [174,175]. The application of IR to high-Z material
generates several types of emissions, including scattered X-rays/photons, photoelectrons, Compton
electrons, Auger electrons, and fluorescence photons, which can enhance the radiation effect in
the area around the high-Z material [176]. With recent advances in nanomedicine, the application
of high-Z metals as radiosensitizers has attracted the interest of researchers in radiation oncology.
Among the high-Z metals, gold (Au, Z = 79) is the element most often used as an NP platform.
Gold NPs (AuNPs) possess several advantages over other materials: (i) good biocompatibility, as
indicated by the ease with which AuNPs enter the human body without inducing harmful effects [177];
(ii) the straightforward nature of the synthesis of different-sized AuNPs [178]; and (iii) the easy
functionalization of AuNPs by conjugating ligands to its surface [179]. These characteristics have
inspired individuals to conjugate integrin-targeted ligands to the surface of AuNPs, which illustrates the
concept of “targeted radiosensitizers”. We have reported the radiosensitizing effects of RGD-conjugated
polyethylene-glycosylated AuNPs (RGD/P-AuNPs) on integrin-overexpressing breast cancer cells [78].
Our study showed that RGD/P-AuNPs are efficaciously internalized into integrin-overexpressing
cancer cells subjected to an increase in radiation-induced DNA damage. Interestingly, the IR-induced
invasiveness [180] was also suppressed by the RGD/P-AuNPs [78]. Several studies have revealed
that some cancer cells that survive radiotherapy might exhibit enhanced invasiveness (IR-enhanced
invasiveness) [181,182] or acquire an invasive phenotype [183], which might lead to a higher proportion
of distal recurrences after radiotherapy. Because integrins play important roles in cancer invasion and
migration [184], it is not surprising that integrin-targeted NPs may influence the IR-induced invasiveness
of cancer cells. However, although invasion is an important hallmark of cancer cells [185], most studies
on nanomedicine have not focused on the effect of cancer invasion after integrin-targeted NP treatment.
Hence, the evaluation of cancer cell invasiveness in studies on integrin-targeted NPs would provide
important and useful information for researchers in the field of cancer biology and nanomedicine.
Consistent with our in vitro study, an in vivo study performed by Liang et al. [186] demonstrated
the capacity of RGD-conjugated AuNPs to increase the therapeutic effect of IR. These researchers
produced c(RGDyC)-AuNPs and reported that c(RGDyC)-AuNPs are more highly accumulated
in tumors compared with non-RGD-conjugated AuNPs. Their results also showed that the use
of c(RGDyC)-AuNPs followed by radiotherapy effectively reduces the tumor size. In addition to
conventional X-ray irradiation, Enferadia et al. [187] used protons (particle radiotherapy) combined
with c(RGDfK)-conjugated ultrasmall AuNPs (1.8-nm diameter) in a murine glioma cell model and
compared the results with those obtained with kilovolt and megavolt X-ray therapy. Their results
showed that the c(RGDfK)-AuNPs enhanced the efficacy of all the combined treatments, but no obvious
differences were found between the different radiation modalities.
In addition to sensitizing cells to external IR treatment, another approach is the conjugation of
radiolabeled peptides to AuNPs. Vilchis-Juárez et al. produced c[RGDfK(C)] conjugated-177Lu-Labeled
AuNPs (177Lu-AuNP-RGD) and validated their therapeutic effect in glioma-bearing mice [188].
Their results showed that Lu-AuNP-RGD delivered the most highly absorbed tumor radiation dose in
tumor cells compared to that of Lu-AuNPs or Lu-RGD. The uptake of Lu-AuNP-RGD by nontargeted
organs was low in the treated mice. As described above, the therapeutic efficacy of both external
radiotherapy and radioactive treatment can be enhanced by integrin-targeted AuNPs.
4.2.2. Hyperthermia Therapy
Hyperthermia therapy (also known as thermotherapy) generally described the use of heat (i.e.,
a temperature higher than the normal body temperature (>37 ◦C)) to treat disease [189]. The use of
hyperthermia as a method for treating cancer has a long history, dating back to approximately 3000 B.C.
in ancient Egypt [190]. The temperature used in hyperthermia cancer treatments can be categorized as
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nonlethal (39 to 42 ◦C) or lethal (>42 ◦C). At a nonlethal temperature, tumor oxygenation is improved,
which makes cancer cells more sensitive to radiotherapy or chemotherapy [191]. At lethal temperatures,
cancer cells are more greatly damaged than normal cells because heat cannot be readily dissipated by
the circulating blood in tumor tissue [192]. Although hyperthermia research continues to improve
adjuvant or direct therapy, the means of heating tumor tissue to an effective temperature remains a
critical problem. Conventional external heat sources, such as microwave or ultrasound, have limited
by their inability to conduct heat to a high depth in tumor tissues [193]. With the advancement of
nanomedicine, several metal NPs were found to have a high capacity to induce heat through energy
transduction [194]. This phenomenon introduced the “inside-out” hyperthermia therapy because
the heat source, an NP, is placed in the cancer cells. According to their different trigger approaches,
these types of therapy can be generally identified as PTT and MHT. Photothermal therapy usually
utilizes external near-infrared (NIR) radiation (wavelength from 750 to 2500 nm) to irradiate the
light-absorbing NPs that accumulate in cancer cells. The absorption and scattering of NIR radiation
in the human body are minimal but can increase the temperature of light-absorbing NPs to higher
than 42 ◦C [195]. The most characterized light-absorbing NP platform is based on AuNPs due to
their incomparable absorbance of NIR radiation [196]. Several studies have shown promising results
regarding the use of cRGD-conjugated AuNPs in PTT for the treatment of breast cancer cells [197],
melanoma cells [198], and human glioma cell-bearing mice [199]. In addition to AuNPs, NPs of copper
sulfide (CuS) also show good photothermal properties and can thus be used in PTT. A study used
cRGD-conjugated CuS NPs to treat human gastric tumor cell-bearing mice by PTT, and the results
showed that cRGD-CuS NPs selectively entered primary and lymph node metastatic tumor cells to
treat cancer without obvious side effects [200]. In addition to using the hyperthermia effect of Cu to
kill cancer cells, novel Cu-based NPs were recently developed to induce cancer cell cytotoxicity using
another approach [14]. Vinyl azide, a cytotoxicity agent, is encapsulated into c(RGDfE)-conjugated
hollow copper sulfide NPs. Upon NIR irradiation, the local temperature increases to trigger the
vinyl azide to rapidly release N2 bubbles, and these N2 bubbles instantly explode to destroy the
neovasculature that expresses αvβ3-integrin and further induce necrosis of the surrounding tumor
cells. This notion, which was inspired by PTT, provides a novel approach in cancer nanomedicine for
the future development of more effective therapies.
In contrast to PTT, MHT utilizes an alternating magnetic field (AMF) instead of irradiating light to
generate heat in magnetic NPs. Iron oxide NPs (or ferrite NPs) are the most studied magnetic NPs to
date. A study showed that cRGD-conjugated iron oxide NPs can be used for tumor detection by MRI
and induce MHT to treat cancer cells [201]. However, although MHT is the oldest and best-known
external localized heat therapy, the use of AMF is complicated, and the heating efficacy of MHT is
unclear compared with that of PTT, the application of MHT faces challenges. A study used RGD
peptide-conjugated magnetosomes (synthesized by magnetotactic bacteria, which show efficacy for
MHT) to treat human prostatic and uterine cancer cells by PHT and MHT excitation, respectively [202],
and their results showed that PHT was much more efficient than MHT in both cellular and in vivo
models. Therefore, identification of the appropriate approaches for inducing hyperthermia therapy
should be carefully considered.
Although the use of hyperthermia as the single cancer treatment modality still faces
many challenges [192], recent studies have yielded promising results from the combination of
hyperthermia with other treatment modalities, such as chemotherapy [203], radiotherapy [204],
and immunotherapy [205]. With the assistance of integrin-targeted NPs, the application of hyperthermia
to increase the therapeutic efficacy of other treatments might become more feasible and can possibly
improve cancer therapy.
4.2.3. Photodynamic Therapy
Photodynamic therapy (PDT) for cancer deploys the use of photosensitizing agents that are
injected into the bloodstream and transmitted to cancerous cells and thereby expose a tumor
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to a wavelength of light that causes the direct killing of cancer cells or shrinkage of the tumor
volume [206,207]. To specifically deliver photosensitizing agents into cancer cells, several studies
have used integrin-targeting NPs as carriers. Wang et al. conjugated carboxyl functionalized iron
oxide NPs with a fibronectin-mimetic peptide (PR_b, [KSSPHSRN(SG)5RGDSP]) [208], which contains
RGD and another fibronectin sequence, Pro-His-Ser-Arg-Asn (PHSRN) [209], that binds integrins.
The study revealed that the combination of a second-generation photosensitizing agent, Pc 4, with these
RGD-conjugated iron oxide NPs showed promising advantages compared with ordinary Pc 4 in the
treatment of head and neck cancer. In addition, the combination of Pc 4 with these NPs also improved
the MRI contrast [208]. Li et al. used c[RGDfK(Ac-SCH2CO)] peptides conjugated with albumin-based
NPs with a photosensitizer IRDye 700DX to treat ovarian cancer in three dimensional (3D) culture,
and the results showed a significant cytotoxic effect in cancer cells [210]. Other studies have also
shown promising results regarding the use of integrin-targeted NPs to deliver photosensitizing agents
to cancer cells [211–213].
5. Issues of Integrin-Targeted NPs
The modification of NPs with integrin-targeted ligands has become a useful practice in cancer
nanomedicine, but several issues remain to be considered. For example, integrin-targeted NPs might
have a lower efficacy for the treatment of low-integrin-expressing cancer cells. To overcome this
problem, some groups have attempted to mix different ligands to enhance the targeting ability of the
NPs; for example, some researchers have conjugated RGD and folate (to target the folate receptor,
which is overexpressed in many tumor cells) together [214] or have used an anti-vascular endothelial
growth factor (VEGF) aptamer together with RGD on NPs [215]. Another problem is the localization
of AuNPs in cells. As described above, integrin-targeted NPs mainly accumulate in late endosomes
and lysosomes [78]. This localization suggests that NPs appear to work in lysosomes, but in some
situations, the function of the lysosomes might decrease NP efficacy. For example, some studies
have used NPs to deliver siRNA into cancer cells for gene therapy, but the siRNA might be digested
in lysosomes [216]. To overcome this problem, several strategies for facilitating endosome escape,
such as ion pair formation, the “proton sponge effect”, destabilization of the endosome membrane,
and the hydrophobic modification of the NPs, have been researched [217]. These types of efforts might
compensate for the shortage of integrin-targeted peptides and achieve the goal of using NPs to reach
the anticipated goals.
6. Conclusions
The use of integrin-targeted NPs significantly improves the efficacy of cancer nanomedicine.
The benefit of these integrin-targeted NPs has been comprehensively examined in various applications
of cancer nanomedicine. We believe that the use of integrin-targeted NPs will be widely used in the
future in clinical settings, where they will improve the efficacy of cancer diagnosis and treatment.
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Abstract: Targeting nanoparticle (NP) carriers to sites of disease is critical for their successful use
as drug delivery systems. Along with optimization of physicochemical properties, researchers have
focused on surface modification of NPs with biological ligands. Such ligands can bind specific
receptors on the surface of target cells. Furthermore, biological ligands can facilitate uptake of
modified NPs, which is referred to as ‘active targeting’ of NPs. In this review, we discuss recent
applications of biological ligands including proteins, polysaccharides, aptamers, peptides, and small
molecules for NP-mediated drug delivery. We prioritized studies that have demonstrated targeting in
animals over in vitro studies. We expect that this review will assist biomedical researchers working
with NPs for drug delivery and imaging.
Keywords: nanoparticle; drug delivery; ligand; active targeting; tumor targeting; biodistribution
1. Introduction
The site where a drug is administered is most often very distant from the site of expected therapeutic
effect. Thus, there has been significant research in the field of targeted drug delivery. Nanoparticle (NP)
drug delivery systems represent the cumulative research efforts of numerous fields, including chemistry,
biology, material science, pharmaceutics, and clinical medicine [1]. Commercialized formulations
such as Doxil and Abraxane are excellent examples of NP drug delivery systems that have improved
therapy in patients [2,3]. NPs can disperse hydrophobic drugs stably in aqueous conditions without
aggregation. [4]. Importantly, their physicochemical properties, including size and surface charge,
can easily be modified by adjusting the component molecules or fabrication method [5]. NPs can
delay early release of drugs in order to allow sufficient time for therapeutic action. NPs also allow for
controlled release of drugs, which in some cases can be tailored to respond to specific stimuli such as
pH, light, heat, or enzymes [6].
With respect to targeted drug delivery, NPs utilize two basic strategies comprising either passive or
active targeting [7]. Passive targeting is based on physicochemical properties [8]. Specifically, when NPs
employing a passive targeting release method are injected intravenously, they generally circulate longer
in the blood stream compared to free drugs. In angiogenic tissues such as tumors, NPs employing
passive targeting penetrate the fenestrated structure of blood vessels more at the disease site, which in
turn leads to significant accumulation of the drug, which is aided in part by slow lymphatic drainage.
This scenario is referred to as the enhanced permeability and retention (EPR) effect. The EPR effect is
Cancers 2019, 11, 640; doi:10.3390/cancers11050640 www.mdpi.com/journal/cancers359
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supported by promising data from many reports on NPs [9]. Compared to passive targeting, active
targeting relies on a biological interaction between ligands on the surface of NPs and the cell target.
A large number of biological ligands have been identified and studied for facilitating active
targeting of NPs [10]. Such biological ligands often bind to specific receptors on the surface of the target
cells, and in this way increase cellular uptake of drug-containing NPs and also increase therapeutic
efficacy [11]. Compared to singular ligand, an increased density of ligands is advantageous for
promoting binding and cellular uptake through the multivalent effect [12]. Various types of ligands
have been employed for this purpose, including proteins, polysaccharides, nucleic acids, peptides,
and small molecules (Scheme 1). Generally, NPs are functionalized with these ligands by two ways.
They can be chemically conjugated or physically adsorbed on the NPs after formation of NPs, or can
be linked with NP components, such as polymers, before formation [13,14]. In this review, we discuss
different types of biological ligands and review their current applications in NP-based drug delivery
systems, focusing primarily on studies reporting promising outcomes in vivo (Table 1).
 
Scheme 1. Illustration of biological ligands for active targeting of nanoparticle drug carriers.
2. Biological Ligands and Their Applications for Nanoparticles
2.1. Proteins and Polysaccharides
Among biological ligands, antibodies have the longest history with respect to targeting specific
receptors [15]. Antibodies are tens of kilodaltons in size and have high specificity, consistent with the
generalized trend that larger ligands exhibit more specific binding [16]. In particular, many antibodies
can be used not only for targeting, but for therapeutic purposes as well [17]. Nevertheless, the large size of
antibodies limits their density on the surface of NPs during modification. In 2018, Roncato et al. reported
the use of antiepidermal growth factor receptor (EGFR) antibody (cetuximab) in antibody-guided
avidin-nucleic-acid nanoassemblies (ANANAS) for efficient cancer therapy (Figure 1) [18]. Specifically,
they synthesized poly-avidin cores combined with biotin-conjugated molecules. They evaluated the
targeting efficacy of the antibody–drug conjugates (ADCs), which are widely used in personalized
cancer therapy. The authors found that cetuximab-guided ANANAS could increase the drug–antibody
ratio more than ADCs, which they attributed to the ability of the avidin–biotin interaction to
increase the drug capacity of ANANAS carriers. In that same study, ANANAS were modified
with biotin-poly (ethylene glycol) (PEG)-cetuximab for targeting, biotin-PEG-Atto488 for imaging,
and biotin-hydrazine-doxorubicin for therapy. They also investigated hydrazine bonds, which
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are acid-reversible and can release drugs under mild acidic environments such as lysosomes after
cellular uptake. Cetuximab-guided ANANAS exhibited faster cellular internalization than both
untargeted ANANAS and antibody alone in MDA-MB-231 (EGFR-expressing cells). In MDA-MB-231
tumor-bearing mice, cetuximab-guided ANANAS-treated groups showed improved therapeutic
efficacy compared to other groups because of their high drug–antibody ratio and targeting ability
with cetuximab.
 
Figure 1. Antibody-conjugated nanoparticles (NPs). (A) Schematic illustration of antibody-guided
avidin-nucleic-acid nanoassemblies (ANANAS) modified with antiepidermal growth factor receptor
(EGFR) antibody (cetuximab) for enhancing cancer targeting. (B) Cell viability assay of cetuximab-guided
ANANAS in MCF-7 and MDA-MB-231 cell lines. (C) Tumor growth in mice bearing MDA-MB-231
tumors after intravenous injection of cetuximab-guided ANANAS. Reproduced with permission from
Reference [18].
Affibodies (Afbs) are engineered, high-affinity proteins that are smaller than normal antibodies [19].
Recently, Oh et al. successfully used Afbs for active targeting of NPs [20]. To avoid clearance of NPs
by the mononuclear phagocyte system (MPS), Oh et al. suggested a protein corona shield concept.
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They decorated the surface of mesoporous silica NPs (MSNs) containing camptothecin (CPT) with
human epidermal growth factor receptor 2 (HER2) binding Afbs by supramolecular interaction.
The resulting Afb-CPT-MSNs were approximately 270± 20 nm in size and had superior colloidal stability
that afforded extended blood circulation time without the need for a traditional polyethyleneglycol
(PEG) coating. They showed fast cellular uptake in the HER2-receptor-overexpressing SK-BR-3 breast
cancer cell line, but not in control MCF-10A cells. Interestingly, in RAW264.7 murine macrophage-like
cells, Afb-CPT-MSNs exhibited reduced internalization compared to free CPT, which was otherwise
highly cytotoxic. In SK-BR-3 tumor-bearing mice, the Afb-modified NPs accumulated to higher
levels in tumor tissue after intravenous injection compared to PEG-coated control NPs. Furthermore,
they inhibited tumor growth by approximately 90%, and were found to escape from reticuloendothelial
organs during ex vivo experiments. Taken together, these results demonstrated that Afb modification
of NPs by protein engineering could be used to enhance the stealth effect of NPs in order to facilitate
better escape from MPS compared to PEG coating while minimizing serum protein adsorption due to
the presence of a protein corona.
Transferrin (Tf) is an iron-binding glycoprotein that is responsible for iron transport in the
body [21]. Tf receptors are highly expressed in specific tissues and cells, which can be targeted by
Tf-modified NPs. The Davis group used conjugated NPs to target Tf receptors on the blood side of
the blood–brain barrier (BBB) to deliver therapeutic drugs through the BBB [22]. They anticipated
that Tf-modified NPs that specifically bind Tf receptors would be unable to pass through the BBB,
and thus be limited to the blood side of the BBB. To overcome this potential limitation, they used
the acid-cleavable linkage DAK [2,2-bis-(aminoethoxy)-propane] to conjugate Tf to NP cores. DAK
exhibits good stability at a neutral pH, with a hydrolysis half-life of 60 min at pH 5.5. Owing to the
nature of the DAK linkage, transcytosis of Tf-modified NPs results in separation from the NP core
under acidic environments and subsequent release into the parenchyma for therapy. Importantly,
the Davis group showed that the cleavable DAK moiety was helpful in facilitating specific delivery
to the brain, with an ideal ratio of 200 Tf molecules per NP for this purpose. This strategy of using
Tf-modified NPs and cleavable linkages supports the possibility of NP-mediated drug delivery in
brain disease, and further drug applications are expected.
Hyaluronic acid (HA) is a polymer capable of binding cell surface receptors for active targeting.
HA is a polysaccharide and one the main components of the extracellular matrix along with collagen.
HA binds CD44, which is often overexpressed on the surface of cancer cells and is believed to be
a representative marker of cancer stem cells [23]. Interestingly, HA can be used simultaneously as
a hydrophilic backbone polymer of NPs and a targeting moiety as demonstrated by Choi et al. [24].
Furthermore, HA is degraded by the enzyme hyaluronidase 1 (Hyal-1), which is highly expressed
in various malignant cells and thus can accelerate drug release in target tissue. In the study by Choi
et al., the HA-NPs consisted primarily of HA modified with PEG and hydrophobic cholanic acids to
create a self-assembled amphiphilic structure. The as-prepared HA-NPs were not sequestered by the
reticuloendothelial system (RES) and exhibited long blood circulation times, which in turn promoted
specific accumulation in tumors. In one study, hydrophobic camptothecin (CPT) was loaded into
the HA-NPs as an anticancer therapeutic. In the presence of Hyal-1, the CPT-loaded HA-NPs were
rapidly degraded, which in turn led to quick release of CPT. In cancer cells, the CPT-HA-NPs showed
dose-dependent cytotoxicity, but their cytotoxicity was highly reduced in normal cells with low CD44
expression. After that, the tumor-targeting capability of CPT-HA-NPs as well as their antitumor effect
were also demonstrated in SCC7 and MBA-MB-231 tumor-bearing mice models.
2.2. Peptides
Among targeting ligands, peptides have several advantages such as low cost of production, good
stability, and ease of conjugation to the surface of NPs at a high density due to their small size [25].
To target interleukin-4 receptor (IL-4R) expressed in both lung tumor cells and tumor endothelial cells,
Chi et al. reported using an IL-4R-binding peptide-1 (IL4RPep-1) with the sequence CRKRLDRNC
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identified using a phage-display technique [26]. The IL4RPep-1 showed excellent binding to H226
human lung cancer cells overexpressing IL-4R and was stable in whole serum for up to 4 h. Based on
these findings, the authors further developed IL4RPep-1-labeled liposomes incorporating doxorubicin
(IL4RPep-1-L-Dox). Cell binding and uptake of IL4RPep-1-L-Dox were more efficient than that of
unlabeled liposomes (L-Dox) due to the peptide moiety. Intravenously injected IL4RPep-1-L-Dox into
H226 tumor-bearing mice was also found to accumulate more significantly and had greater antitumor
activity compared to L-Dox without peptide. Using immunofluorescence, the authors demonstrated
that IL4RPep-1-L-Dox was present in vascular endothelial cells of tumor tissues. Taken together, these
data confirmed successful targeting of IL4RPep-1-L-Dox to tumor blood vessels with concomitant
improvement in chemotherapeutic efficacy.
The arginylglycylaspartic acid (RGD) peptide binds integrins, which are particularly overexpressed
in vascular endothelial cells present in tumor tissue, and for this reason is a well-known tumor-targeting
peptide [27]. The sequence of the RGD peptide originates from cell attachment proteins including
fibronectin, vitronectin, and laminin [28]. In 2018, Lu et al. developed size-shrinkable NPs for enhanced
cancer therapy using the RGD peptide as the targeting ligand (Figure 2) [29]. For deeper penetration
into tumor tissue, small NPs containing metformin (MET) or doxorubicin (DOX) were linked to the
surface of large gelatin nanoparticles (GNP). In addition, Lu et al. generated small NPs containing RGD
peptides as well as therapeutic agents to target tumors with overexpression of integrin. They used MET
as an anti-inflammatory drug for combination with DOX, and both drugs were conjugated to small NPs
via degradable imine bonds. Large GNPs can be degraded by matrix metalloproteinases-2 (MMP-2)
overexpressed in cancer, while small NPs decorated with RGD peptide can easily penetrate deeply into
tumor tissues. MET and DOX are then released from small NPs after degradation of imine bonds in the
acidic environment of tumor tissues. In this way, nuclear factor-kB (NF-kB) inducing cancer-related
inflammation can be inhibited by MET, while DOX exerts cytotoxic effects in cancer cells. Both GNP
and RGD NPs exhibit improved accumulation in 4T1 and CT26 tumors via targeting ligand RGD and
size shrinkage. Coadministration of MET and DOX-containing NPs revealed superior antitumor and
antimetastatic effects in 4T1 and CT26 tumor-bearing mice. Furthermore, the anti-inflammatory effect
of MET-containing NPs was successfully evaluated during analysis of TNF-α, NF-kB, IL-6, and Ki67.
In addition to the RGD peptide, the iRGD peptide represents an RGD-containing peptide
sequence initially characterized by its ability to bind αv integrins expressed on tumor endothelial cells.
Interestingly, when the iRGD peptide is cleaved by proteases in tumor cells, it produces a CRGDK/R
derivative peptide that has diminished affinity for αv integrin but increased affinity for neuropilin-1
(NRP-1) [30]. This switch in affinities promotes tumor-specific penetration of molecules due to the
presence of the CendR peptide motif. These unique characteristics of the iRGD peptide make it useful
for enhanced drug delivery in tumor tissues. For example, the Ruoslahti group showed that the iRGD
peptide produced increased tumor-specific vascular permeability in five tumor models compared to
a control peptide lacking the CendR motif [31]. In particular, even when not conjugated to drugs
or NPs, the iRGD peptide effectively increased particle tumor accumulation owing to the natural
structure of the iRGD and CendR motifs. Therefore, iRGD combination groups with free drugs or NPs
enhance cancer therapy compared to free drug or NP alone. This special ability of iRGD is different
from other biological ligands and may be worth pursuing in the future as a way to reduce the amount
of chemotherapy needed to treat certain types of cancer [32].
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Figure 2. Peptide-conjugated NPs. Schematic illustration of RGD-doxorubicin (DOX)-dendri-grafted
poly-L-lysine (DGL)-gelatin nanoparticles (GNP) (RDDG NPs) and RGD-metformin (MET)-DGL-GNP
(RMDG NPs). (A) Synthetic procedure for RGD-DGL-GNP (RGD NPs). Chemical structure and
synthetic procedure for (B) 4-Carboxybenzaldehyde (p-CBA)-MET (pCM) and (C) p-CBA-DOX
(pCD). Illustration of the RDDG NPs and RMDG NPs in the tumor microenvironment (D) and their
antitumor/anti-inflammatory effects (E). (F) In vivo fluorescence images showing tumor accumulation
of NPs with or without RGD ligand. Reproduced with permission from Reference [29].
2.3. Aptamers
Aptamers are a class of short nucleic acid (DNA or RNA) comprising several nucleotides. Aptamers
are small, highly sensitive, biodegradable, and have immunogenicity, making them good candidates for
active targeting ligands [33]. In 2018, Duo et al. used the AS-1411 aptamer to target mesoporous silica
NPs containing CX-5461 to the nucleus of tumor cells (Figure 3) [34]. The AS-1411 G-rich DNA aptamer
specifically recognizes nucleolin, a protein upregulated in many cancer cell lines. Nucleolin, which is
present in nucleoli, nucleoplasm, cytoplasm, and on cell surfaces, can facilitate transport of bound
NPs to the nucleus after cellular uptake. CX-5461 is a well-known small-molecule inhibitor of rRNA
synthesis that triggers prodeath autophagy in tumor cells. In the study by Duo et al., CX-5461-loaded
MSNs were coated by polydopamine to increase loading stability, after which AS-1411 aptamers were
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conjugated on the surface of NPs. After treatment, the resulting NPs successfully accumulated in the
nucleolus of HeLa cells and inhibited cell growth through induced prodeath autophagy. In a HeLa cell
xenograft mice model, aptamer-modified NPs exhibited higher accumulation in tumors compared
to NPs without aptamers. Correspondingly, tumor growth in vivo was effectively suppressed by the
AS-1411 aptamer-modified NPs without significant toxicity.
Figure 3. Aptamer-conjugated nanoparticles (NPs). Scheme of CX-5461-loaded mesoporous silica NPs
modified with AS-1411 aptamers to increase nucleoli targeting. Reproduced with permission from
Reference [34].
Recently, Xi et al. used the GBI-10 aptamer for tumor-targeting of NPs [35]. GBI-10 is a single strand
DNA aptamer that strongly interacts with tenascin-C, a protein overexpressed in the extracellular matrix
(ECM) of pancreatic ductal adenocarcinoma. For enhanced tissue penetration and cellular uptake, the
authors also simultaneously used a cell-penetrating peptide (CPP). The cell-penetrating function of the
CPP is not specific to tumor cells, and it was shown that GBI-10 uses electrostatic attraction to avoid
nonspecific accumulation at the site of injection. Dimeric camptothecin prodrug (CPTD) was loaded in
these NPs modified with aptamer and CPP, which showed greater triggered release under high redox
potential after cellular uptake. Cytotoxicity testing showed that the resulting GBI-10 aptamer and
CPP-modified NPs containing CPTD (Apt/CPP-CPTD NPs) have a higher IC50 than CPP modified
NPs (CPP-CPTD NPs) due to the camouflaged CPP. However, Xi et al. asserted that GBI-10 aptamers
detach from Apt/CPP-CPTD NPs in tumors secondary to the high-affinity relationship between
GBI-10 and tenascin-C. Recovered cell-penetrating ability of Apt/CPP-CPTD NPs was demonstrated
by Miapaca 3D tumor spheroid microscopic images. Finally, the Apt/CPP-CPTD NPs were injected
intravenously into orthotopic pancreatic cancer xenograft mouse models. Fluorescent images of mice
also showed high accumulation in tumor sites at all time points. Accordingly, Apt/CPP-CPTD NPs
showed enhanced antitumor efficacy and survival rates in vivo over other control groups, thereby
demonstrating successful active targeting of NPs with the GBI-10 aptamer and CPP.
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2.4. Small Molecules
Folate (FA) receptors are well known to be overexpressed in solid tumor cells and macrophages,
making them attractive targets for many NPs via receptor-mediated endocytosis [36–38]. For example,
Lv et al. prepared mesoporous silica NPs (MSNs) modified with FA for active targeting, and decorated
NPs using the large gas-filled microbubble (MB) technique [39]. In this method, the gas-filled MB is
destroyed under local ultrasound irradiation, resulting in the release of FA-modified MSNs across the
endothelial layer and into the target tissue. Using this technique, one study loaded tanshinone IIA (TAN),
a hydrophobic drug, into MSNs and demonstrated both a high loading capacity and potent ability
to induce tumor cell apoptosis. The FA-modified MSNs and MB also showed negligible cytotoxicity
in both HeLa and A549 cells without TAM and which expressed relatively high and low levels of
the FA receptor, respectively. However, the MSN-FA-TAN-MB showed enhanced cellular uptake via
receptor-mediated endocytosis and increased apoptosis of HeLa cells compared to A549 cells. During
in vivo testing with an H22-tumor-bearing mouse model, intravenously injected MSN-FA-TAN-MB
showed greater antitumor efficacy when the tumor site was irradiated with ultrasound. These results
demonstrated that a combination strategy based on the ultrasound-guided releasing and FA-mediated
active targeting of NPs could be used effectively for drug delivery.
Anisamide is a benzamide known to bind sigma-1 receptors overexpressed in cancer cells [40].
In 2017, Huo et al. showed improved vaccine therapy for melanoma using the tyrosinase-related
protein 2 (Trp2) vaccine and sunitinib, a known tyrosine kinase inhibitor [41]. Sunitinib inhibits tyrosine
kinase activity, thereby blocking tumor growth and inducing tumor apoptosis. As sigma receptors
are overexpressed in melanoma, anisamide was employed as a targeting ligand to facilitate efficient
delivery of sunitinib to melanoma tumors. Specifically, the authors prepared sunitinib base-loaded
polymeric micelles (SUNb-PM) modified with anisamide. In B16F10-tumor bearing mice treated with
these modified NPs, the tumor inhibition ratio was the greatest for Trp2 + SUNb-PM. Furthermore,
as a result of the immune response elicited by Trp2, the number of CD8+ T cells in Trp2+SUNb-PM
groups was significantly increased. On the other hand, there was a decrease in the abundance of
myeloid-derived suppressor cells and T regulator cells, both of which play important roles in immune
suppression. They found that T helper 1 and 2 cytokine levels were appropriately altered in order
to enhance antitumor immune responses. Based on these findings, the authors concluded that
anisamide-modified NPs containing tyrosine kinase inhibitors combined with a vaccine may afford
synergistic antitumor effects. The mechanism of anisamide remains controversial. The Leroux group
insisted that cellular uptake of anisamide-modified NPs is not related to Sigma-1 receptors [42].
They also suggested the possibility that anisamide binds to Sigma-2 receptors instead of Sigma-1
receptors, and suggested that further studies are needed to identify the exact mechanism of action of
anisamide [43].
Table 1. Ligands for active targeting of nanoparticle drug delivery systems.
Type Ligands (Example) Advantage/Disadvantage References
Proteins Antibodies,transferrin High specificity/large size, low stability [18,19,22]
Polysaccharides Hyaluronic acid





Easy fabrication, small size/cleavable by
peptidase [26,29,31]
Aptamers AS-1411,GBI-10
High specificity, small size/cleavable by





Small size, very low cost/targets are also
expressed in normal tissues [39,41,44]
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In another example showing the feasibility of small molecule targeting ligands, the Kataoka group
demonstrated that phenylboronic acid (PBA) strongly binds N-acetylneuraminic acids, which are the
main components of sialic acid (SA) compared to other sugars including galactose, mannose, and
glucose (Figure 4) [44]. In particular, the difference in binding affinity is further increased at pH 6.5,
which is consistent with the acidic intratumoral environment. Taking into consideration the abundance
of SA present on the surface of tumor cells, they designed phenylboronic acid (PBA)-installed micelles
for drug delivery, specifically, the prepared PBA-modified poly-(ethylene glycol)-b-poly-(L-glutamic
acid) (PEG-PLGA) micelles containing dichloro-(1,2-diamino-cyclohexane)-platinum (II) (DACHPt),
an anticancer drug. After a nine-hour incubation in vitro, they found large amounts of internalization
of PBA-modified micelles in B16F10 tumor cells, while control NPs without PBA exhibited decreased
uptake. Further in vivo studies with B16F10 tumor-bearing mice showed that PBA-modified micelles
containing DACHPt inhibited both tumor growth and metastasis, which was attributed to their
excellent accumulation of tumor cells. However, PBA needs to be applied as a ligand for drug delivery
carefully, because the amount of SA varies significantly among different cancer cell lines.
 
Figure 4. Small molecule-conjugated nanoparticles (NPs). (A) Scheme of phenylboronic acid
(PBA)-conjugated dichloro-(1,2-diamino-cyclohexane)-platinum (II) (DACHPt)-loaded micelles
(PBA-DACHPt/m) by self-assembly via polymer−metal complex formation. (B) Blood circulation
time of intravenously injected DACHPt/m, PBA-DACHPt/m, and oxaliplatin. (C) Tumor accumulation
of DACHPt/m and PBA-DACHPt/m in an orthotopic B16F10 mouse model. (D) Tumor volume of
orthotopic B16F10 tumors after treatment with oxaliplatin (8 mg/kg), DACHPt/m, or PBA-DACHPt/m
(3 mg/kg). (E) Ex vivo fluorescence images showing tumor tissue accumulation of DACHPt/m and
PBA-DACHPt/m. Reproduced with permission from Reference [44].
3. Conclusions
To date, we have summarized the representative examples of biological ligands for targeting of
NPs. Various ligands including proteins, carbohydrates, nucleic acids, peptides, and small molecules
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are capable of increasing the specific binding of NPs containing drugs to disease cells to increase
the efficacy of chemotherapy. Active targeting is a term that is often misunderstood as the ability
of a ligand to control and direct the movement of conjugated NPs to target cells in vivo like guided
missiles. However, dramatic changes in organ distribution of NPs do not occur in many cases, and the
ligands present on NPs only help the binding of NPs on target cells. As observed in the studies of the
Davis group, biodistribution and organ distribution of NPs in vivo changed only slightly following
conjugation of biological ligands, especially on whole-body imaging [45]. Nevertheless, the ligands
significantly enhanced the binding and uptake of NPs after reaching tumor tissue, which may improve
therapeutic efficacies, not large-scale distribution [46].
Physicochemical properties such as size, shape, rigidity, or surface properties are very important to
determine the large-scale distribution of NPs. It is known that nanoparticles from 10 to 500 nm can move
through vessels and accumulate in tumor tissue [9]. Strong cationic charges increase liver accumulation
and antifouling PEG modification helps tumor targeting [47]. Recent studies showed that soft NPs
are advantageous for accumulation and penetration in tumor tissue [48,49]. In addition, the study of
Reuter et al. showed unexpected lower tumor accumulation of RGD peptide-modified NPs compared
to control PEG-modified NPs [50]. It demonstrated the importance of physicochemical properties of
NPs and the unintended result of ligand modification. Thus, it is important for researchers to consider
these properties while at the same time not overestimating the effect of biological ligands [46].
Another important consideration of NP ligands is their cost [51]. For example, antibodies are
attractive ligands due to high specificity and diverse targets, but their production and conjugation cost
a lot [52]. Development of more efficient methods for coupling of antibodies onto NPs may reduce the
cost. From this point of view, small chemical molecules are generally cheaper than proteins or aptamers.
Furthermore, first-generation nanomedicines including Doxil and Abraxane have insufficient specificity
on their own, while many NPs using biological ligands remain in various stages of clinical development.
We expect that drug-eluting, targeted NPs will become increasingly commercialized and available
for use in the clinic in the near future to provide greater benefit to reduce side effects and improve
therapeutic efficacy.
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Abstract: Overexpression of oncogenes and cross-talks of the oncoproteins-regulated signaling
cascades with other intracellular pathways in breast cancer could lead to massive abnormal
signaling with the consequence of tumorigenesis. The ability to identify the genes having vital
roles in cancer development would give a promising therapeutics strategy in combating the disease.
Genetic manipulations through siRNAs targeting the complementary sequence of the oncogenic
mRNA in breast cancer is one of the promising approaches that can be harnessed to develop more
efficient treatments for breast cancer. In this review, we highlighted the effects of major signaling
pathways stimulated by oncogene products on breast tumorigenesis and discussed the potential
therapeutic strategies for targeted delivery of siRNAs with nanoparticles in suppressing the stimulated
signaling pathways.
Keywords: breast cancer; siRNA; cell signaling; active targeting; passive targeting; EPR effect;
oncogenes; nanoparticles; nanomedicine
1. Introduction
Breast cancer is one of most common life-threatening cancers and the second leading cause of
female deaths worldwide. About 1.67 million new cases of breast cancer were diagnosed in 2012
worldwide [1]. According to the data revealed by the American Cancer Society, around 266,120 new
cases of invasive breast cancer will be diagnosed in American women in 2018 [2]. The statistics
emphasized that one in every eight women in the United State of America is at risk of having breast
cancer. Based on the Malaysian National Cancer Registry Report (2007–2011), 1 in 30 females is at risk
of having breast cancer in a lifetime [3]. The mortality rate of breast cancer in Malaysia is estimated to
be ~16.7 to 20 in 100,000 [4].
Breast cancer is the malignant cell growth that originates from the breast cells at the inner lining
of the breast ducts or lobules that supply milk [5]. There are stages of breast cancer diagnosis, where at
stage 0, the cancer cells are found to be localized at the lobules or ducts of the breast. At stage I, II, and
III, the cancer may be defined by the size of the tumors and the area that the cancer cells have spread,
such as the chest wall, skin, or the lymph nodes surrounding the breast. At the advanced or metastatic
stage (stage IV), the cancer cells have metastasized to other organs or lymph nodes that are further
away from the breast [5,6]. Breast cancer is a heterogeneous disease, as there are many distinct genes
being overexpressed and acting as key players in the progression of the breast cancer cells [7]. The
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expression of breast cancer markers, such as estrogen receptor (ER), human epidermal growth factor
receptor 2 (HER2/neu), progesterone receptor (PR), and urokinase plasminogen activator (uPA) has
been used to evaluate the progression and aggressiveness of the disease [7–9]. The untreated lesion of
the ducts or lobules may lead to proliferation and formation of metastatic cells that can develop the
ability to invade blood and lymphatic vessels and metastasize to other parts of the body, such as brain,
lung, liver, and bones [10]. The common symptom of the disease is the formation of lumps in the
breast. Other than that, patients may also experience changes in the breast’s features such as thickening,
swelling, distortion, tenderness, skin irritation, redness, nipple abnormalities, and discharge.
Factors that have been associated with increased risk of breast tumorigenesis are sex, age, family
history, breast condition, and endogenous estrogens. Females are more frequently diagnosed with
breast cancer than males. The risk also increases with age, and postmenopausal women have been
considered to have more risk. Women and men with first-degree relatives with breast cancer are shown
to be at higher risk of getting the disease compared to those without family history of breast cancer. The
mutations of the well-known tumor suppressor genes, BRCA1 and BRCA2, are frequently associated
with breast cancer. The faulty genes impairing the DNA repair process increase the chances of breast
cancer. Conversion of proto-oncogenes into oncogenes via mutations is one of the prominent causes of
the disease, promoting overexpression of growth factor receptors and subsequent cross-talks among
their downstream signaling cascades, and can lead to proliferation and survival of cancer cells [11].
Besides that, an increase in mammographic breast density indicates a higher chance of the individual
to develop breast cancer [12]. The presence of fat tissues, which can be the source of cholesterol, may
increase the production of estrogens in high-density breast. Aromatase is the enzyme that promotes
the production of estrogen from the androgens [13]. Other than that, there are studies showing that
higher levels of estrogens are associated with the development and progression of breast cancer [14].
Biopsy taken from the mass formed in the breast confirms the presence of malignancy through
laboratory screening. To date, there are few treatments of breast cancer such as surgery, radiotherapy,
chemotherapy, hormonal therapy, and monoclonal antibody therapy [6]. The surgical procedure
involves the removal of the tumors localized in the tissue, and mastectomy, which is the removal
of the affected breast. Radiotherapy uses high-energy rays that kill the actively dividing cancerous
cells [15]. Chemotherapy for breast cancer is a treatment by delivering cytotoxic drugs either through
intravenous injection or oral delivery, allowing the drugs to travel through the blood circulation before
reaching the cancer cells [6]. Monoclonal antibody therapy for breast cancer attempts to trigger the
immune system to destroy the cancer cells by allowing binding of the antibody with the antigens
that are present on the cancer cells. For example, introduction of traztuzumab that targets HER2
on breast cancer cells causes arrest of cancer cells at the G1 phase of the cell cycle, thus reducing
the process of cell proliferation. Further, it may down-regulate the expression of HER2 and reduce
the dimerization of the receptor [16,17]. Hormonal therapy is performed, for instance, by using
estrogen antagonist that blocks the action of estrogen, such as tamoxifen and raloxifene or aromatase
inhibitors (anatrozole and exemastene) [6]. As research showed that 70% of the breast cancer cases
are estrogen-receptor positive, the usage of estrogen antagonist and aromatase inhibitor is commonly
employed to treat breast cancer. As breast cancer is a heterogenous disease, there is rapid growth of
ongoing research on developing breast cancer therapeutic strategies to encounter the likely cause of the
disease. Triple-negative breast cancer (TNBC) defines the disease without or having less expression of
the well-known breast cancer markers like ER, PR, and HER/neu [18], therefore, requiring different
treatment approaches. Glycotherapy is one of the potential strategies to target aberrant glycosylation
that promotes abnormal cellular activities and carcinogenesis [19]. The aspragine-linked (N-linked)
glycoprotein was found to have roles in the progression of breast cancer, such as angiogenesis [20].
Banerjee et al. (2011) has shown that Tunicamycin is able to inhibit angiogenesis in vitro and in vivo.
They have observed reduced expression of vascular endothelial growth factor receptors (VGFRs)
and N-glycan in the tumor micro-vessels [21]. Another field of research is immunotherapy, which
comprises, for instance, targeting the pathway of programmed death 1/ programmed death ligand
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1 (PD-1/PD-L1), which involves responses from T-cells [22]. PD-L1 that is expressed by the tumor
cells binds to PD-1 proteins expressed by T-cells. The interaction of PD/PD-L1 inhibits T-cells from
killing the tumor cells. Atezolizumab (Tecentriq TM) is known as a checkpoint inhibitor and functions
as an anti-PD-L1 monoclonal antibody. The inhibition of PD-1/PD-L1 binding enables the killing of
tumor cells by T-cells. There are also studies on complementary and alternative medicines (CAM) as
a treatment option of breast cancer, such as Ayuverda (traditional Indian medicine) and traditional
Chinese medicine [23]. Several patients opted for CAM as they have experienced failures in other
treatments. CAM typically employs herbal and botanical therapy (e.g., homeopathy), mental therapy
(e.g., meditation and hypnosis), and physical therapy (e.g., acupuncture, massage, yoga, and Chi
Gong). Thus far, there lacks scientific evidence of CAM, with no successful clinical trials reported in
effectively curing the disease [24].
Numerous short- and long-term effects from the chemotherapy such as risks of cardiac toxicity,
development of secondary cancer, neurotoxicity, premature menopause, and effects on sexuality with
high costs of drugs and treatments have led to emotional, physical, and financial burden for the patients
and the community [25]. Thus, it is crucial to identify key players of the disease’s development and to
develop effective therapeutic strategies in targeting breast cancer with or without minimal side effects.
2. Signaling Pathways and Oncogene Involvement in Breast Cancer
Cell membrane receptors and ion channels receive stimuli such as hormones, neurotransmitters,
antibodies, cytokines, growth factors, and ions from the extracellular region that influence cell
signaling [26]. The interactions between the stimuli and the receptors or ion channels may
trigger various downstream signaling pathways, such as Mitogen-activated protein kinase (MAPK)
and phosphoinositide-3-kinase–protein kinase B (PI3K/AKT) and Ca2+ signaling pathways at the
intracellular level (Figure 1). The interplay or cross-talks between the signal transduction pathways
build up the complexity of breast cancer signaling cascades, thus, complicating the process of curing
the disease. The interconnected signaling pathways may induce the breast cancer cells to proliferate
and survive under a heterogeneous condition with various up-regulated and down-regulated proteins.
Proto-oncogenes and tumor suppressor genes are involved in the maintenance of the normal cell
functions such as growth, division, and survival. However, mutations of these genes in the form
of deletions, insertions, or substitutions, resulting in gain or loss of functions, may constitutively
activate the signaling pathways, initiating the tumorigenesis [27,28]. Thus, identifying the oncogenes
and tumor suppressor genes governing the breast cancer signaling pathways is an important goal in
therapeutic intervention of breast cancer.
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Figure 1. Diagram of several signaling pathways in breast cancer that lead to proliferation and survival
of breast cancer cells.
2.1. Mitogen-Activated Protein Kinase (MAPK) Pathway
Gene therapy has been advocated to treat cancers. There are many genes and proteins that are
being up- or down-regulated in the signaling pathways, thus promoting the proliferation and survival
of breast cancer cells. For example, mitogen-activated protein kinases (MAPKs) are the proteins that
function in delivering and amplifying the extracellular signals. Researchers have identified six different
groups of MAPKs, which are extracellular signal-regulated kinases (ERK)1/2, ERK3/4, ERK5, ERK7/8,
Jun N-terminal kinase (JNK)1/2/3, and the p38 isoforms α/β/γ (ERK6)/δ [29–31]. MAPK signaling
through the ERK pathway activation is regularly being activated via the binding of ligand with the
cell membrane receptor, such as the receptor tyrosine kinase (RTK). These will later promote the
downstream responses of the pathway, for example, the activation of Ras protein. The activation of Ras
may lead to subsequent stimulation of ERK1/2 signaling proteins to transmit signals into the nucleus
for gene transcription and expression; thus, cell proliferation, survival, apoptosis, and differentiation
are turned on [32]. Hyper-expression of MAPK was found in the primary human breast cancer tissue
compared to the benign portion, which is related to metastatic potential of the disease [33]. Studies on
down-regulating the expression of MAPK have shown the decrease in breast cancer cell proliferation
and migration [34].
2.2. PI3K/AKT Pathway
AKT or protein kinase B is also an important factor in regulating the cell proliferation, survival,
glycogen metabolism, and motility [35]. It exists in three isoforms in mammals; AKT1, AKT2, and
AKT3. Phosphatidylinositol 3-kinase (PI3K) is the vital protein in connecting the signals from the
cognate receptor tyrosine kinase towards AKT [36]. Numerous studies have revealed the deregulation
and mutations of genes of this pathway in 70% of the breast cancers [37,38]. Upon stimulation by ligand
binding to the receptor tyrosine kinase, PI3K signaling pathway may be activated, thus transferring
the message down to the AKT pathway, such as the mTOR signaling pathway. The phosphorylation of
AKT (pAKT) promotes cellular functions, such as proliferation and survival. However, overexpression
of pAKT proteins was found in 33% of ductal carcinoma in situ and in 38% of the invasive breast cancer
cases through the immunohistochemistry of tissue microarray [39]. In another study involving siRNA
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knockdown targeting the AKT in MCF-7 human breast cancer cell line, the introduction of the siRNA
has reduced the expression of AKT and BCL-2 (anti-apoptotic protein) proteins, which may enhance
the probability of cancer cell death [40].
2.3. Calcium Signaling Pathway
Calcium ion (Ca2+) is known to be a ubiquitous cellular signal and is one of the important
second messengers in cell signaling. It is crucial to maintain its homeostasis in normal cell signaling
series. Ca2+ is released in cytosol either from internal stores, such as endoplasmic reticulum or
from external medium through different cell membrane-associated channels, through the action of
Ca2+ itself, intracellular messengers, such as inositol-1,4,5-trisphosphate, or the status of intracellular
Ca2+ storage. It may initiate different types of protein activation or phosphorylation and changes
in protein shapes and charges, which may subsequently vary the interactions with other respective
components [41]. Moreover, Ca2+ plays a role in cell proliferation, as it is involved with the activation
of the cyclin-dependent kinases (CDK4 and CDK2) for the progression of the cell cycle from the G1 to S
phase [42]. In the pathological environment, malignant cells may acquire the six hallmarks of cancers,
as described by Hanahan and Weinberg (2000): (a) Self-sufficiency in growth signals, (b) insensitivity
to growth-inhibitory signals, (c) evasion of programmed cell-death (apoptosis), (d) limitless replication
potential, (e) sustained angiogenesis, and (f) tissue invasion and metastasis [43]. Any disturbance of
Ca2+ homeostasis may alter the cell cycle progression and trigger the emergence of one or more of
the cancer hallmarks. Di et al. (2015) [44] showed that the overexpression of Rap2B, a GTP-binding
protein, increased the intracellular calcium level, thus later promoting the phosphorylation of ERK1/2 in
Bcap-37 and MDA-MB-231 breast cancer cells. They also observed increase in proliferation, migration,
and invasion of the cancer cells [44].
Endoplasmic reticulum release of Ca2+ and subsequent uptake by mitochondria involves
programmed cell death. Nevertheless, increases in Ca2+ influx activates the survival signaling
pathways of the cancer cells. Cancer cells develop an antioxidant system against the reactive oxygen
species (ROS) such as hydrogen peroxide (H2O2) to maintain cells’ activities. H2O2 produced by
mitochondria mediates cysteine oxidation on transient receptor potential ankyrin 1 (TRPA1). TRPA1,
a cation channel on the cell membrane, enables the up-regulation of Ca2+ into the cellular region and
activates the anti-apoptotic pathway such as the PI3K/AKT signaling pathway [45]. Data analysis from
the cancer genome atlas found the overexpression of TRPA1 in breast cancer.
2.4. Notch Signaling Pathway
Notch signaling pathway begins with the interaction of the DSL (Delta/Serrate/LAG-2) ligands on
one cell and Notch receptor on the adjacent cell [46]. The signaling pathway is associated with the
cellular progression, such as proliferation, apoptosis, angiogenesis, hypoxia, cancer stem cell activity,
epithelial to mesenchymal transition (EMT), and metastasis. In breast cancer, Notch receptors and
their ligands were found to be overexpressed. Notch receptors have been categorized into four groups,
Notch1 to Notch4; while the DSL ligands, which are transmembrane ligands, have five groups (Jagged1,
Jagged2, Delta-like1, Delta-like3, and Delta-like4). The expressions of cyclinA, cyclinB, and cyclinD1
genes were found to be upregulated in Notch signaling cascade, while the survival of breast cancer
cells might be induced via AKT pathway activation by Notch signaling pathway [46–48].
2.5. Hedgehog Signaling Pathway
Hedgehog signaling pathway controls the process of cell proliferation, survival, differentiation,
tissue homeostasis, regeneration, and stem cell maintenance [49]. Most of the basal-like breast cancers
(BLBC) have the triple negative phenotype of the important receptors (ER−, PR−, and HER2) and are
resistant to chemotherapy treatments. The BLBC has an aggressive growth and has the possibility to
metastasize to other organs. Mott et al. (2018) has shown that the forkhead-box transcription factor
C1 (FOXC1) plays a role in 4T1 murine metastatic breast cancer cell proliferation, migration, and
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invasion, although no significant effects were reported in the in vivo study [50]. FOXC1 was found to be
overexpressed in BLBC and was able to activate the hedgehog signaling pathway [51]. In another case,
this pathway might be initiated by the interaction of modified Hedgehog ligand towards the patched
(Ptch1) receptor, a 12-pass transmembrane receptor. This event led to the activation of smoothened
(Smo), a seven transmembrane protein that further stimulated multi-complex proteins that contained
Gli protein. A zinc finger transcription factor then traveled into the nucleus to initiate the transcription
of targeted genes [52,53]. Overexpression of Gli 1 protein (belonging to the family of Gli transcription
factors) was observed to be associated with the unfavorable prognosis and survival of the breast cancer
cells [54,55].
2.6. JAK/STAT Signaling Pathway
Extracellular stimuli such as cytokines (e.g., interleukins, interferons, and growth factors) can
activate the JAK/STAT signaling pathway. JAK or Janus kinase and STAT (signal transducers and
activator of transcription) are the intracellular proteins that cooperate with the transmembrane receptor
in conveying signals down to the nucleus for DNA transcription and gene expression. STAT acts
as the substrate of JAK, becomes phosphorylated, and travels into the nucleus to promote gene
transcription. JAK/STAT signaling pathway is involved in stem cell maintenance, hematopoiesis,
and participate in the process of inflammatory response. This signaling pathway may promote
cell proliferation, differentiation, and has a role in controlling cellular apoptosis. The suppressor
of cytokine signaling proteins (SOCS) is the regulator of the JAK/STAT negative feedback loop that
functions as competitive inhibitors to STAT while STAT is the stimulator of the transcription of SOCS
genes [56]. Dolled-Filhart et al. (2003) showed that STAT3 (a protein under the STAT family) and
phosphorylated-STAT3 were overexpressed in 69.2% of breast cancer tumors [57]. Other investigations
of STAT3 have confirmed the involvement of this protein in breast cancer malignancies [58,59].
2.7. Anti-Apoptotic Signaling Pathway
The anti-apoptotic signaling pathway is another pivotal component in breast cancer maintenance.
BCL-2, BCL-XL, BCL-W, MCL-1, and BFL-1/A1 are the anti-apoptotic proteins in the BCL2 family.
These gene are overexpressed in many cancers such as prostate, lung, stomach, ovarian, and breast
carcinoma [60]. The BCL-2 (B-cell lymphoma 2) protein plays an anti-apoptotic role, leading to
prolonged cancer cell survival [61–64]. Activation of the growth factor receptors, such as HER2, could
modulate expression of BCL-2 via activation of PI-3 kinase signaling [63]. The cross-talks between the
estrogen receptor (ER) with other membrane receptors might induce the transcription of target genes
such as BCL-2 gene expression. BCL-2 functions by inhibiting the pro-apoptotic proteins (e.g., BAD
and BAX) in inducing cell death, thus, prolonging the survival of the cancer cells [64].
3. Growth Factor Receptors and Breast Cancer
The expression of the growth factor receptors (GFRs) is an important regulatory element that
contributes to cell proliferation and survival. Regularly, the GFRs require ligand binding in order to
transmit the downstream commands. The ligands may exist in the forms of growth factors, cytokines,
or hormones.
3.1. Epidermal Growth Factor Receptor (EGFR)
The EGFR is a transmembrane receptor that falls under the receptor tyrosine kinase family [10].
The EGFR family consists of four sub-proteins which are EGFR1 to 4 (also known as ErbB 1 to 4). EGFR
is regularly activated by the EGF, which acts as the ligand and the downstream signaling cascades such
as the Ras/Raf, MAPK, and the PI3K/AKT which may be stimulated to govern cell proliferation and
survival [65]. EGFR is one of the receptors that has been associated with the progression of breast cancer
and the overexpression of the EGFR is often associated with poor prognosis [66]. Price et al. (1999)
has worked on the MDA-MB-231 breast cancer cell line and found that the EGF might stimulate
378
Cancers 2019, 11, 632
the migration of the breast cancer cells via the activation of ERK1/2 signaling pathway [67,68]. In
the case of molecular apocrine breast cancer (MABC), this molecular subtype of breast cancer is
associated with poor prognosis as this subtype has negative expression of the estrogen receptor.
Liu et al. (2018) [69] has found 53% of the MABC and non-MABC cases to be positive with EGFR
expression via immunohistochemical analysis. The expression of EGFR was alongside the expression
of other prominent breast cancer biomarkers such as the androgen receptor and Ki67 protein (the
cellular marker for cell proliferation), thus suggesting EGFR is another therapeutic target for breast
cancer treatment [69].
3.2. Insulin-Like Growth Factor 1 Receptor (IGF1R)
The IGF1R is a receptor that belongs to the IGFR family. It is a heterodimeric cell membrane
receptor that comprises α- (subunit binding site) and β-(linked to the tyrosine kinase domain) chains
that are projected towards the extracellular compound; whereas the tyrosine kinase domains are
embedded within the layers of cell membrane [11,70]. The binding of IGF1 to the IGF1R results in the
auto-phosphorylation of the tyrosine kinases and further activates the downstream signaling cascades,
such as the PI3K/AKT and MAPK pathways [65]. The IGF family members, together with the IGF1R,
were found to be overexpressed in breast cancer tumors and associated with cancer progression [71].
3.3. Transforming Growth Factor-Beta Receptor (TGF-βR)
TGF-βR has the TGFβ as the protein ligand which is available in the extracellular matrix (ECM)
in order to encourage the intracellular signaling pathways [11]. There are three types of TGF-βR which
are TGF-βR1, TGF-βR2, and TGF-βR3. The TGFβ1 and TGFβ3 ligands, once activated, will bind to the
TGF-βR2, while the TGFβ2 has more affinity towards the TGF-βR3. The interaction between TGF-βR2
and its ligand may encourage the activation of TGF-βR1 [72,73]. Busch et al. (2015) showed that loss
of expression of TGF- βR2 in the mammary fibroblast might stimulate tumorigenesis with increased
tumor volume in the mouse xenograft model [74].
3.4. Vascular Endothelial Growth Factor Receptor (VEGFR)
The VEGFR is also a tyrosine kinase receptor that has seven immunoglobulin (Ig)-like domains
projected at the extracellular region of the cell. The tyrosine kinase domains are rooted within the cell
membrane layers (11). The VEGF–VEGFR interaction has often been associated with the angiogenesis
or vasculogenesis of blood vessel in tumors, where the enlargement or growing tumors are in need
of more nutrients supply as rapid growth rate is usually observed [75]. It has been shown that the
growth of breast tumor in the murine model benefited from the expression of VEGFR1 expression [76].
VEGFR2 was confirmed to have roles in breast cancer angiogenesis and the inhibitor [YLL545, a novel
synthesized compound from commercially available 1H-pyrazolo[3,4-d]-pyrimidin-4(5H)-one [1] for
VEGFR2 has been shown to inhibit the downstream signaling regulators such as phosphor STAT
and phosphor ERK1/2 [77]. Another compound named isomangeferin (a xanthone C-glucoside), was
shown to bind to the VEGFR2 and suppressed tumor growth, metastasis, and angiogenesis [78].
3.5. Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2)
HER2 is one of the members of receptor tyrosine kinase family that is encoded by ERBB2 gene.
The transmembrane receptor plays important roles in various cellular functions such as cell growth
and differentiation [79,80]. However, 20%–30% of amplification of this gene is often seen in tumors of
breast cancer [81]. Cross-talks between HER2 and other cell membrane receptors such as estrogen
receptor (ER), IGFR, and EGFR may initiate downstream signaling through MAPK and PI-3 kinase
pathways in breast cancer cells [82], suggesting the importance to determine the genes crucial in the
cross-talks for therapeutic purpose. Moreover, there are other molecules that assist HER2 in governing
breast cancer progression. The epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein
that functions as a cell adhesion molecule in normal cells. However, it has been observed to be highly
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expressed in cancers including breast cancer [83–85]. N-glycosylation of the EpCAM was observed in
parallel with overexpression of HER2 in breast cancer tissues. Furthermore, this event was shown to
increase cancer cell proliferation and prevent apoptosis [86]. A study by Peiris et al. (2017) has shown
that the co-translational modification of the glycans, such as the N-linked glycans, reduced the binding
efficiency of Herceptin towards HER2, thus decreasing the competency of the treatment [87]. Therefore,
HER2 and associated glycoproteins could be targeted with an aim to reduce breast cancer progression.
4. siRNA Silencing Technique
Malignancies are often being associated with up-regulation of genes that causes overexpression
of oncogenes [88–91]. Genetic manipulation, such as the introduction of the small interfering RNAs
(siRNAs) has become one of the promising therapeutic approaches that is rapidly expanding. siRNA is
a duplex RNA of 21–28 nucleotides that selectively degrades a mRNA transcript and thereby blocks
its translation into a particular protein [92]. In eukaryotes, protein-coding genes are transcribed by
RNA polymerase II to produce pre-mRNA which, upon further processing, becomes the mature
mRNA [93]. The mature mRNAs travel from the nucleus into the cytoplasm for protein translation
by ribosomes. The introduction of exogenous siRNA into the cells results in the formation of the
RNA-induced silencing complex (RISC) by assembling with other proteins such as Argonaute and
Dicer (Figure 2). Argonaute proteins are then activated to cleave the siRNA to become single stranded.
In the cytoplasm, RISC carrying the single stranded siRNA binds to the complementary sequence on
the targeted mRNA in a sequence specific manner. Slicer or Argonaute proteins will then cleave the
mRNA complementary to the antisense strand in the newly formed double-stranded RISC-mRNA
complex. The cleaved mRNA strands are recognized by the cell as aberrant and destroyed; thus, the
expression of the targeted gene has successfully been ‘silenced’ [94,95].
Figure 2. Schematic diagram of the mechanism of small interfering RNA (siRNA) in targeting mRNA
for gene silencing (left) and exogenous siRNA duplex delivery into the cytoplasmic region via passive
and active targeted delivery (right).
4.1. Advantages of siRNA Delivery
As a promising cancer therapeutic strategy, siRNA has several potential advantages over
chemotherapeutic drugs. Firstly, siRNA has a high degree of safety, since it inhibits the
post-transcriptional stage of gene expression through complementary base pairing with a target
mRNA without interacting with chromosomal DNA; thereby, the risks of mutation and teratogenicity
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are less [96]. The second advantage is its high degree of specificity in targeting a particular mRNA
through RNA interference system, with the unlimited choice of targets. Another crucial advantage of
siRNA is its high efficacy, suppressing the expression of a target gene strikingly in a single cancer cell
with just several copies. Synthesis of siRNA is also much cheaper than that of antibodies or proteins.
4.2. Limitations of siRNA Delivery
There are several limitations to the clinical applications of siRNAs as therapeutics. The main
challenge is the difficulty in passively delivering the siRNA which carries a negative charge due
to the strong anionic phosphate backbone. The cell membrane which carries net negative charges
repels the anionic siRNA, thus causing the process of passive diffusion of the exogenous siRNA to
be challenging [97]. The water-soluble characteristic of the siRNA has further added hurdles to the
process [98]. Despite the remarkable potency of siRNA in silencing specific gene expression, its half-life
is too short because of the risk of degradation by serum nucleases which could affect the stability of
siRNA, and quick elimination of the degraded products through the kidneys. In addition, ‘naked’
siRNA is hardly able to penetrate the tissue owing to its negatively charged phosphate backbone
that could be repelled by anionic extracellular matrix molecules [99]. Even though siRNA molecules
enter the cell through endocytosis, the fusion of endosomes with lysosomes results in degradation
of the entrapped siRNAs. Nonetheless, various nanotechnology approaches have been harnessed to
design suitable carriers for the siRNA to avoid degradation and assist in cellular delivery. Therefore, a
suitable nano-carrier to transport siRNA molecules into tumor cells via endocytosis and subsequently
release them in the cytoplasm is the prerequisite for achieving the maximum therapeutic outcomes
from siRNA-mediated cleavage of the targeted mRNA. However, nanoparticles are prone to interact
with reticuloendothelial system (RES) and hence, require surface modification prior to being used for
systemic delivery of siRNA.
5. Delivery Systems of Potential Therapeutic siRNAs
Nanoparticles have emerged in the last few years as an alternative material for advanced diagnostic
and therapeutic applications in medicine. A nanoparticle-based drug delivery system has two main
targeting systems: Passive and active. Passive targeting relies on enhanced permeability and retention
(EPR) effects of leaky vasculature (Figure 3) [99]. Tumor formation leads to underdevelopment of
blood vessels that impairs the lymphatic drainage especially surrounding the tumor site. The leakiness
of neoplastic blood vessels has great benefit in delivering and accumulating drugs up to 400 nm
of size onto target sites [100]. Hobbs et al. (1998) showed that the vasculature of the tumors that
was induced subcutaneously in mice had cut-off pore sizes in the range of 200 nm to 1.2 μm [101].
Active targeting includes ligand-mediated targeting, where ligands such as peptides or antibodies
with affinity towards the nanoparticles or/and drugs are incorporated. The complex may recognize the
targeted cells through binding to the receptors present on the cell surface. Active targeting may further
augment the drug-delivery process to be more specific [100,102]. Therefore, it is crucial to identify
highly expressed receptors, particularly on the breast cancer cells, to increase their specific binding
with the ligands on the siRNA complexes and successful delivery of siRNA to the targeted sites.
Nanoparticles with size ranging 1–100 nm in diameter and large surface area [103] have been
designed to bind and deliver siRNA, since naked siRNA is prone to degradation by serum nucleases
and clearance by kidneys. Hence, the siRNA needs to be encapsulated with nanoparticles. Moreover, as
mentioned above, nanoparticles can also be employed for targeted delivery of siRNA to tumor cells [104].
In addition, nanoparticles have the potential ability to penetrate and accumulate within tumor cells
efficiently, as they have enhanced circulation time particularly when they possess hydrophilic coating
on their surface, thus allowing for better therapeutics efficacy and, at the same time, minimizing the
side effects of drugs. Nanoparticles can easily be imaged to track their progress in vivo.
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Figure 3. A schematic diagram showing ‘leaky’ vasculature of blood vessels at the tumor site, thus
encouraging passive targeting of drug delivery. Active targeting employs the protein coating on the
drug’s surface to attract receptor binding upon drug delivery into the target site.
6. Current Targets for Nanoparticles-Facilitated siRNA Silencing
A combination of activated oncogenes and dysfunctional tumor suppressor genes lead to
uncontrolled cell growth and blockage of natural apoptotic processes. Since crucial gene mutations
responsible for cancer initiation and progression have been identified, the siRNA technology emerges
as one of the highly promising approaches in treating breast cancer [105]. siRNA could be effective
in cancer treatment as it is able to specifically inhibit any of the cancer-associated genes without
being specific to their protein products. siRNA allows us to conceivably target the resistant cells
in cancer treatment. Intriguingly, various sets of therapeutic siRNA molecules can be developed to
target genes that are correlated with the multiple signaling pathways aberrantly activated in tumors.
Nanotechnology is currently being explored in the development of nano-size drugs to efficiently
deliver chemotherapy drugs to breast cancer cells and address the toxicity concern in relation to
administration of higher doses of the drugs [106]. Introduction of exogenous siRNA into the breast
cancer cells might be harnessed in order to overcome dose limitation of the chemotherapeutic drugs
in clinical settings. However, since siRNA-loaded nanoparticles are accumulated in several other
organs, in addition to the tumor, and the target genes that are overexpressed in breast cancer can also
be expressed in those organs although at much lower level, silencing of those genes in non-target genes
could produce adverse effects. Therefore, selection of target genes could be of crucial importance for
clinical implications of siRNA-based nanotherapeutics. Table 1 showed the targeted genes for siRNA
knockdown in breast cancer cells.
siRNA silencing of the MAPK pathway genes by targeting either the raf-1, mekk1, or mlk3 in
acute myeloid leukemia (AML) cells was found to knockdown expression levels of between 40% and
60%. The data showed that when MAPK signaling pathway was partially blocked, the apoptosis
pathway was upregulated and led to programmed cell death. Multiple siRNAs could be used together
to target multiple genes of the MAPK pathway [107]. Bakhtiar et al. (2017) has developed nanoparticles
from barium salts targeting the MAPK transcript in MCF-7 cell line and breast tumor in their in vivo
study [108]. They have found success in delivery of the siRNAs, thus reducing the cell viability and
inhibiting tumor growth. Silencing the MAPK genes specifically in MCF-7 cells caused the suppression
of expression MAPK and activation of AKT, two important signaling molecules in both MAPK and PI3K
pathways. On the other hand, our data have shown that delivery of selective siRNAs via carbonate
apatite nanoparticle against the mRNA transcripts of the growth receptors including Estrogen Receptor
1 (ESR1) along with anti-apoptotic genes (BCL2), or with ERBB2 and EGFR, critically contributes to the
induction of cell deaths in human and murine breast cancer cell lines by inhibiting the activation of
MAPK and PI3K pathways [82]. Moreover, intravenous delivery of the selected siRNAs was able to
retard tumor growth in mice.
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Expressions of the BCL-2 and BCL-xL genes could promote cell survival by inhibiting apoptosis.
Silencing of BCL-2 with the use of an antisense oligonucleotide appeared to be a promising cancer
therapeutic approach. Silencing of Bcl-2 by siRNA followed by treatment with etoposide or doxorubicin
had reduced the number of viable cancer cells and sensitized them to drug-induced apoptosis [109].
In addition, a calcium phosphate with polyelthyleneglycol (PEG)-polyanion polymer has recently
been used to promote the delivery of siRNAs targeting the anti-apoptotic genes BCL-2 and BCL-xL in
human breast cancer cells (MCF-7). The expression of BCL-2 and BCL-xL genes were decreased to 49%
and 23%, respectively, after 48 hours of incubation with the respective siRNA. Silencing antiapoptotic
genes such as BCL-2 and BCL-xL via the application of siRNAs delivered by hybrid nanoparticles was
shown to be an effective and promising strategy against breast cancer [109].
Many cancer cells upregulate the expression of VEGF, thereby promoting angiogenesis that plays
a crucial role in tumor development and metastasis. Previous study has shown that silencing VEGF
expression by siRNA via polycation liposome-encapsulated calcium phosphate nanoparticles (PLCP)
caused significant inhibition of tumor growth and angiogenesis in MCF-7 xenografts mice. Thus, the
delivery of VEGF siRNA via PLCP to inhibit angiogenesis could be a promising strategy for breast
cancer treatment, particularly when combined with DOX [110].
Since EpCAM, a cell surface molecule, is found to be overexpressed in cancers, Subramaniam et al.
(2015) employed a novel aptamer-polyethyleneimine (PEI)-siRNA nanocomplex to target EpCAM
in MCF-7 and retinoblastoma cell line (WERI-Rb1). They observed downregulation of EpCAM and
inhibition of cell proliferation in the two cell lines [111].
Polo-like kinase 1 (PLK1) is a gene that is vital in cell division and DNA damage response and
was found to be expressed in actively dividing cancer cells. PLK1 was targeted in metastatic breast
cancer and triple negative breast cancer (TNBC). siRNA against the targeted gene was delivered via
polymer-coated mesoporous silica with polyethyleneimine (PEI) and it was shown to inhibit cancer
cell migration and invasion in TNBC cells. In the in vivo study, 80% of the target gene knockdown was
observed in the mouse lung besides reduction in tumor incidence [112].
Moirangthem et al. (2016) [113] successfully transfected MDA-MB-231 human breast cancer cells
with siRNA against uPA and matrix metalloproteinase 9 (MMP9) transcripts via lipid transfection.
They showed that the cells were arrested in the S and G2-M after flow cytometry analysis [113]. Li et al.
(2014) found that transfection of the siRNA with Lipofectamine 2000 against the cyclin-dependent
kinase (CDK) 8 transcript was able to cause a significant decline in cell proliferation in MDA-MB-231
and MCF-7 cell lines [114]. Receptor tyrosine kinase expression, originated from the ROS1 oncogene,
was found to be expressed in breast ductal carcinoma. Chua et al. (2013) employed carbonate apatite
as the siRNA carrier targeting the c-ROS1 gene in MCF-7 cells. They observed enhancement in
chemo-sensitivity of the cells towards cisplatin and paclitaxel treatments [115]. When the siRNA
against IKKε was transfected into SK-BR-3 and MCF-7 human breast cancer cell lines, the siRNA was
able to significantly reduce cell migration, invasion, and proliferation of both cell lines [116].
Silencing of the cyclin E expression by oligofectamine-facilitated siRNA delivery successfully
reduced the expression of the targeted protein and led to apoptosis in SK-BR3, MDA-MB-436, and
MDA-MB-157 cell lines. The xenografts of MDA-MB-436 implanted into the nude mice were successfully
suppressed by cyclin E knockdown by employing the siRNA silencing technique [117].
HER2 siRNA-based therapeutics delivered using functionalized mesoporous silica nanoparticles
coated with a cationic polymer and PEG conjugated to trastuzumab for HER2 targeting was shown to
have an excellent safety profile. It could overcome intrinsic and acquired resistance to trastuzumab and
lapatinib in HER2-positive breast cancer in vitro and in vivo [118,119]. For the long-term treatment
effect of the therapeutic HER2 siRNA, the treated cells grew much slower and showed 67% increase
in doubling time than cells that did receive any treatment [120]. The data indicated that the HER2
siRNA-based therapeutic provided a more durable inhibition of HER2 signaling to the cells.
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Table 1. List of targeted genes for siRNA knockdown in breast cancer.
Targeted Genes Delivery Carrier Cell Line Animal Model References
ER, BCL-2, ERBB2,
and EGFR Carbonate apatite MCF-7, MDA-MB-231 Balb/c [82]
egfr1 and erbb2 Carbonate apatite MCF-7 Balb/c [114]
BCL-2 and
BCL-XL Calcium phosphate pEG-polyanion MCF-7 NA [109]






EpCAM Polyethyleneimine MCF-7 and WERI-Rb1 NA [111]





uPA and MMP9 Interferin transfection reagent MDA-MB-231 NA [113]
CDK8 Lipofectamine 2000 MDA-MB-231 andMCF-7 NA [114]
c-ROS1 Carbonate apatite MCF-7 NA [115]






HER2 Mesoporous silica coated withcationic polymer and PEG BT474 NA [118]
NA: No information available.
7. Clinical Trials of nano-siRNA for Cancer Therapy
The first clinical trial of siRNA therapeutics was developed in 2004, not long after the discovery of
RNAi. The rapid growth of siRNA accelerating into clinical trials is possibly due to the experience
acquired during development of antisense and other nucleic acid-based therapies. To date, about
30 siRNA candidates have reached numerous stages of clinical trials for the treatment of different
diseases including cancer [121–123]. Approximately one third of the siRNA-based therapeutics in
clinical trials are targeted at cancer.
A cyclodextrin polymer-based system designated as CALAA-01 was the first systemic
siRNA delivered using targeted nanoparticles in human. The siRNA-nanoparticle formulation
contained four components, which includes a duplex synthetic non-chemically modified siRNA,
a cyclodextrin-containing polymer, stabilizing agent, and targeting agent that contained the human
transferrin protein. The human transferrin functions as targeting ligand. CALAA-01 contained the
anti-R2 siRNA targeting ribonucleotide reductase subunit M2 (RRM2) for the treatment of solid
tumor. Since RRM2 regulates BCL-2 in various types of cancers and plays an active role in tumor
progression, it can serve as a potential target for cancer therapy [122]. A phase-I study involving
systemic administration of CALAA-01 showed that the cancer-associated gene was silenced by RNAi
mechanism in target tumor cells. In addition, the patients also showed inhibition of tumor growth, as
siRNA treatment was able to reduce the expression of the M2 subunit of RRM2 [122,124]. CALAA-01
treatment was carried on until the disease progressed or the treatment may no longer tolerated by the
patient. About 21% of the patients discontinued the test for the reason of adverse effects. No objective
tumor responses were noticed with the exception of one patient who had stable disease following four
months of treatment at the dose 30 mg/m2 [125].
Besides CALAA-01, Silence Therapeutics conducted a phase-I study of the siRNA therapeutic
Atu027 for the treatment of advanced solid tumor [125–127]. Atu027 was formulated as a liposomal
particle containing siRNA that targeted protein kinase N3 (PKN3) gene. PKN3 is a downstream effector
of PI3K signaling that is believed to be involved in cancer progression through the metastasis process.
Inhibition of PKN3 caused significant reduction of tumor growth, as well as reduction of lymph node
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metastasis in vivo [128]. Early results showed that after eight weeks of treatment, Atu027 was safe in
patients with advanced solid tumor with no further progression of tumors in 41% of patients [127].
Further, a phase-Ib/IIa study for Atu027 in combination with gemcitabine was achieved after the
lead-in safety period [129].
ALN-VSP02 was the first dual target of a siRNA drug carried by lipid nanoparticles developed
by Alnylam Pharmaceuticals (Cambridge, MA, USA). This Stable Nucleic Acid Lipid Particle
(SNALP)-formulated siRNA suppressed not only VEGF, but also the cell-cycle protein kinesin spindle
protein (KSP) that promoted cell-cycle arrest and, subsequently, cell death [129–131]. A phase-I
dose-escalation study was proposed in 2009. Provisional data from pharmacodynamics measurements
showed preliminary evidence of clinical efficacy in the treatment of advanced solid tumor. Nevertheless,
the study did not achieve the highest tolerated dose and the trial is still ongoing, to enroll more patients
in a dose-escalating manner [121]. Analysis of phase-1 clinical trials showed comparable maximum
concentration and area under the curve for VEGF and KSP upon single systemic injection of ALN-VSP.
The treatment normalized the tumor vasculature as determined by VEGF mRNA levels and was
associated with a decrease in tumor blood flow as observed via DCE-MRI. Further, the mRNA levels of
KSP that influence the mitotic cell cycle was also observed by extrahepatic tumor biopsy [125,131]. The
pharmacodynamic effect observed in biopsy sample from patients validated the successful delivery of
the two siRNAs, indicating stability of the nanoparticles during systemic circulation.
A phase-I clinical trial of siRNA-EphA2-DOPC was recently authorized by the FDA and initiated
by the MD Anderson Cancer Center. DOPC (1,2-dioleoylsn-glycero-3-phosphatidylcholine) is based on
a type of neutral lipid to enhance siRNA entrapment efficiency. siRNA-EphA2-DOPC was constructed
to shut down the activity of a genetic biomarker called EphA2. EphA2 overexpression is common in
many human cancers, including breast cancer. EphA2 siRNA incorporated in DOPC nanoliposomes
was greatly effective in lowering EphA2 protein levels after a single dose, and significantly reduced
tumor growth three weeks after treatment [130].
Another ongoing phase-1 clinical study utilizing siRNA-transfected peripheral blood mononuclear
cells (PBMCs) was APN401 for treatment of solid tumors that spread to other areas in the body or have
relapsed [130]. APN401 might stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. APN401 is a suspension of autologous PBMCs transfected with a siRNA that knock
down Casitas-B-lineage lymphoma protein-b (Cbl-b). A single intravenous infusion of APN401 into
patients with resistant solid tumors is possible and safe. This result supported phase-II clinical trials of
multiple infusions of APN401 [132].
Other nanomedicines against breast cancer that have been approved or undergoing clinical trials
were Myocet, LEP-ETU, EndoTAG-1, Lipoplatin, Genexol-PM, and Narekt-102 [133]. So far, clinical
trials have shown great outcomes with no indication of adverse side effects. Moreover, avenues
utilizing collateral treatment had produced promising results, hence indicating the possibility of
personalized cancer treatment in the future.
8. Conclusions
Chemotherapy as cancer treatment stimulates various side effects that are unbearable for the
patients. RNAi technique via siRNA gene silencing should be explored in depth to further develop
and enhance tumor targeting treatments, thus making it as an efficient method to combat breast cancer
and other cancers. The various oncogenic genes involved in the signaling pathways in breast cancers
are suitable candidates for therapeutic targets. The flexibility of employing nanoparticles to deliver
siRNAs against single or multiple oncogenic genes has made the treatment strategy highly promising.
Moreover, by enabling tumor-selective delivery either through passive and/or active targeting, and
subsequently, promoting efficient cellular uptake, nanoparticles could be harnessed to minimize the
cost of siRNAs. In addition to that, siRNA might be the solution to increase the treatment efficiency by
combating classical drugs resistance.
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Abstract: Lung cancer is one of the leading causes of cancer-related death worldwide. Non-small
cell lung cancer (NSCLC) causes around 80% to 90% of deaths. The lack of an early diagnosis
and inefficiency in conventional therapies causes poor prognosis and overall survival of lung
cancer patients. Recent progress in nanomedicine has encouraged the development of an alternative
theranostics strategy using nanotechnology. The interesting physico-chemical properties in the
nanoscale have generated immense advantages for nanoparticulate systems for the early detection
and active delivery of drugs for a better theranostics strategy for lung cancer. This present review
provides a detailed overview of the recent progress in the theranostics application of nanoparticles
including liposomes, polymeric, metal and bio-nanoparticles. Further, we summarize the advantages
and disadvantages of each approach considering the improvement for the lung cancer theranostics.
Keywords: lung cancer; nanomedicine; theranostics; clinical status; cancer therapy
1. Introduction
Lung cancer is one of the prevalent malignancies and leading causes of cancer-related mortality
and the most common cancer in men, accounting for an estimated 154,050 deaths in 2018 and
worldwide [1–3]. As per the GLOBOCAN, a project of the International Agency for Research on Cancer
(IARC), estimation, approximately 18.1 million new cancer cases would have been detected in 2018 [2].
This dreadful disease owes its origin mostly (85%) to long term tobacco smoking [4]. It turns out that
at the time of diagnosis lung cancer in many patients has metastasized to other tissues in the body.
According to the 2012 global lung cancer statistics, an estimated 1.8 million new cases were reported
58% of which occurred in less developed countries [5]. The American Cancer Society reported over
221,200 estimated new cases of lung cancer and 158,040 death cases in 2015 in the United States [2,3].
Around 85% of lung cancer patients had non-small cell lung cancer while the remaining 15% had small
cell lung cancer. The survival rate in lung cancer patients depends primarily on early diagnosis and
surgical resection of the tumor tissue is often the preferred therapy [6,7]. Clinically used therapeutic
modalities are still associated with a poor outcome: Only <20% five-year overall survival is reported as
cancer cells routinely become impervious to drugs. Among all the presently available cancer therapies,
chemotherapy is the most widely used treatment strategy for lung cancer. The insufficient drug
concentration in the tumor tissue is one of the major impediments retarding the clinical success of lung
cancer chemotherapy. To meet this up-hill therapeutic challenge, repeated applications of anti-cancer
agents at high concentrations are being used in systemic chemotherapy which is causing adverse side
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effects. The commonly observed adverse side effects in chemotherapy based cancer treatments mostly
originate from the ability of many potent cytotoxic drugs to penetrate non-cancerous healthy body
tissues in addition to tumor tissues [8]. Novel therapeutic modalities for more effective treatment of
lung cancer are, therefore, urgently needed.
In recent years, enormous endeavors have been directed toward the development of new
warheads and their effective carriers to reduce the probability of occurrences of multi-drug
resistance, combinations of hydrophilic with hydrophobic drugs, small interfering RNA (siRNAs) with
hydrophobic drugs being majorly explored among them [9]. Global efforts are also being witnessed on
delivering potent anti-cancer drugs selectively to tumor tissues by encapsulating the drugs within
various types of drug carriers [10–12]. The exo-surfaces of such drug carriers are covalently grafted with
tumor-specific targeting motifs including small peptides, aptamers, proteins, and antibodies [13–17].
Much to our intrigue, theranostics (therapy plus diagnostic) nanomedicine has emerged as
a propitious paradigm in cancer therapy. It involves advantages of the both world: highly efficacious
nanocarriers to ferry cargo while loading onto them both imaging and therapeutic agents. The idea
spawned a plethora of nanoparticles, well suitable for drug delivery as well as diagnosis, facilitating the
advent of personalized medicine. There exists four crucial aspects to take into account while designing
an efficacious nanoplatform based therapeutics: (i) Selecting a potent therapeutic, ranging from small
molecule drugs to larger peptide or nucleic acid; (ii) to choose a stable carrier; (iii) to adopt a targeting
and drug release strategy; and (iv) to carefully single out an imaging agent [18–24].
The present review is an attempt to update major advancements in lung cancer theranostics:
A description of development of various nanosystems (liposomes, polymeric nanoparticles, metal
nanoparticles, bio-nanoparticles, etc.) for efficient delivery of an array of theranostics in lung cancer.
2. Lung Cancer: Category, Cause, Molecular Target, and Limitations of Conventional Therapy
Non-small cell lung cancer is the most prevalent cancer and can be further categorized into two
major subtypes which include small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)
based on the histological appearance. Though SCLC is more aggressive but less frequent as compared
to NSCLC. NSCLC can be sub-classified into three major histological subtypes: Adenocarcinoma,
squamous cell-carcinoma, and large cell-lung cancer. Again, each of the subtypes is distinct and
responds differently to available therapies.
Lung carcinogenesis is influenced by the interaction of ecological factors, for example, tobacco
smoke, and genetic susceptibility. The cancer susceptibility increases significantly with rare germ
line mutations like p53, retinoblastoma, epidermal growth factor receptor (EGFR), etc. Moreover,
reduced DNA repair efficiency may also play a critical role in lung carcinogenesis [25]. Chemicals
in tobacco smoke are reported to play a major role in lung carcinogenesis. Research advances have
provided clear evidence for the role of tyrosine kinases in the pathophysiology of lung cancer.
Constitutive kinase activation and downstream signaling may arise due to mutation(s), overexpression,
and autocrine paracrine incitement, leading to cancer. Oncogenic activation of tyrosine kinase like
EGFR, PIK3CA, MET etc. are frequently observed in NSCLC and thereby offer opportunity for
therapeutic targeting [25,26].
Despite the fact that progresses are made in the treatment of non-small cell lung cancer (NSCLC),
the five-year survival rate for lung malignant growth has expanded by just 5% in recent years. Surgery
serves an important treatment modality of early stage disease but surgery for lung cancer is complex
and can have serious consequences. Early detection of lung malignant growth is another hurdle
in effective treatment of lung cancer patients. Roughly seventy five percent of patients with lung
disease will present symptoms, and the majority of these have an advanced stage of tumor at the time
of diagnosis.
The emergence of cancer chemotherapy and radiation therapy is partially effective in the initial
stage of NSCLC treatment. Due to the advent of robust sequencing techniques and initiation of large
genome wide association studies it is quite clear that molecular heterogeneity exists even in the same
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cancer subtypes. Heterogeneity can exist among the primary tumor and the metastatic counterpart,
even within the cells of a particular tumor or based on the cell of origin. The molecular diversity and
the cancer cells ability to acquire adaptive resistance create a definite challenge in planning an effective
therapy [27]. A new approach addressing patient specific molecular specificities and patient centered
approach is needed.
3. Alternative Theranostics by Nanomedicine
Nanotechnology is one of the fast growing fields in the area of biomedical science that has
been utilized to solve different biological problems including therapeutics and diagnostics. Recently,
nanotechnology has been widely utilized for the treatment of various diseases including cancer,
diabetes, bacterial infections, cardiovascular diseases, etc. [28–30]. Due to several limitations in the
conventional therapeutic strategies for lung cancers, scientists and researchers have focused on the
development of the nanoscale therapeutic agents, whereas the delivery system includes liposomal
nanoparticles, polymeric nanoparticles, metal nanoparticles, and bio-nano particles. The lung cancer
theranostics applications of these nanoparticles has been largely effective due to their small size,
that enables them to specifically accumulate in tumor cells due to an enhanced permeability and
retention effect (EPR) [31]. Moreover, nanoparticles are easy to functionalize and demonstrates high
drug loading due to large surface area to volume [29]. Apart from that, due to good biocompatibility
and the capability of overcoming clearance by the kidney effacing long circulation nanoparticles
holds edge over conventional therapeutic treatments. Moreover, several nanoparticles displayed
multifunctional abilities like imaging, diagnostics, therapeutics, sensing that helps researchers to
utilize these nanomaterials for multifunctional biomedical applications in lung cancer theranostics.
Here in this review, we have focused on the theranostics applications of various types of nanomaterials
that have shown enormous promise for the applications in lung cancer diagnosis and therapy
including (a) liposomal nanoparticles, (b) polymeric nanoparticles, (c) bio-nanoparticles, and (d) metal
nanoparticles (Figure 1).
Figure 1. Schematic representation of different theranostics nanomedicine approaches in lung
cancer theranostics.
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4. Liposomal Nanoparticles for Lung Cancer Theranostics
Liposomes are artificially generated vesicles with a bilayer structure spontaneously formed when
natural or synthetic amphiphatic lipids get dispersed in water. Ever since their inception, they have
largely been explored as drug delivery vehicles because of their biocompatibility and beneficial
safety profile. The bilayer structure of liposomes comprises of phosphatidylcholine, cholesterol,
etc. and they are known to carry an array of small molecule and large molecule therapeutics
of hydrophobic and hydrophilic origin. Their surface can be modified by grafting polyethylene
glycol (PEG), which prolongs their half-life in circulation [32,33]. Doxil and Myocet, two leading
Doxorubicin liposomes, received FDA approval in 1995 and 1999, respectively, followed by many of
the category [34,35]. Despite availability of around sixteen liposomal drugs in the market as of now,
very few formulations are designated as the treatment modality for NSCLC. Here we summarize a few
recent examples of liposomes for pulmonary delivery of therapeutics.
In 2014, Cheng et al. [36] exploited EGFR binding affinity of a novel peptide GE11 in
doxorubicin-loaded liposomes and characterized them in terms of size distribution, zeta potential,
drug entrapment efficiency, and morphology. It turned out that optimal GE11 density was 10% in A549
cytotoxicity. Major involvement of clathrin-mediated endocytosis pathway was also determined by
cellular uptake experiments. Using a near infrared (NIR) fluorescence imaging system, they found
that the accumulation and retention of the GE-11 modified liposomes was 2.2-fold higher compared
to unmodified liposomes [36]. For effective delivery of triptolide (TPL) to NSCLC by pulmonary
administration, a dual ligand (anti-carbonic anhydrase IX (anti-CA IX) antibody and CPP33) modified
triptolide-loaded liposomes (dl-TPL-lip) was designed, synthesized, and characterized by Lin et al. [37]
in 2018. The cell killing ability was evaluated by an apoptosis assay. Importantly, superior tumor
penetration and tumor growth inhibition efficacy of the liposomes were further demonstrated using 3D
tumor spheroids. Pharmacokinetics studies in rats after endotracheal administration of the liposomal
formulations exhibited a lower concentration of TPL in circulation [37]. In 2017, Song et al. [38]
came up with a multifunctional targeting liposome for the treatment of NSCLC and achieved better
in vivo effects. They decorated the liposome surface by Octreotide (OCT), a synthetic 8-peptide
analog of somatostatin that binds to somatostatin receptors overexpressed in a variety of tumors.
Two drugs were co-encapsulated in the liposome: Honokiol into the lipid bilayer to reduce tumor
metastasis and inhibit vasculogenic mimicry channel formations, and epirubicin into the aqueous
core as an antitumor drug. Mechanistic investigation studies revealed that these liposomes could
downregulate PI3K, MMP-2, MMP-9, VE-Cadherin, and FAK and activate caspase 3 [38]. In 2013,
Mukherjee et al. designed and synthesized a series of guanidinylated cationic amphiphiles and
demonstrated that systemic administration of a 19 bp synthetic CDC20 siRNA encapsulated within
liposomes of guanidinylated cationic amphiphile with stearyl tails inhibits B16F10 solid tumor growth
and intravenous administration of the same liposomal formulation inhibits B16F10 melanoma growth
on lung (metastases) in a syngeneic C57BL/6J mouse tumor model [39].
As a suitable alternative, pulmonary drug delivery strategy, i.e., local delivery via inhalation
has gained substantial attention of researchers across the globe. This enables us to reach higher local
drug concentration to the specific site of action. This also demands a low dose of therapeutics with
reduced toxicity. We intend to provide few examples of liposomes to be inhaled as reported in the last
two decades: In 2000, Anderson PM and coworkers designed a phase I study to examine the efficacy
and toxicity of administering interleukin (IL)-2 liposomes by aerosol to patients with lung metastases.
The liposome-aerosol was inhaled for ~20 min thrice a day. The dose chosen was based on previous
studies. Nine patients were treated in three cohorts of three patients at varying IU of IL-2 thrice
a day. Authors reported that inhalation of IL-2 liposomes is well tolerated with any reduced systemic
toxicity [40]. In another phase I dose-escalating study performed by Wittgen et al. [41] safety, efficacy
and PK of aerosolized liposomal (sustained release lipid inhalation targeting, SLIT) cis-platin were
investigated in patients having lung cancer. In seventeen patients SLIT cis-platin was well tolerated.
No nephrotoxicity, ototoxicity, hematologic toxicity, or neurotoxicity was revealed by safety data.
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Together, they concluded that the use of aerosolized liposomal cis-platin was feasible and safe [41].
Importantly, in 2010, Makale and co-workers developed a PEGylated DOX liposome with a dextran
core, containing iron oxide for MRI contrast and Bodipy for fluorescence and demonstrated robust
imaging ability of these nanoparticles (NPs) in an in vivo murine Lewis lung carcinoma model [42].
In 2011, Lowery et al. [43] decorated the surface of a DOX entrapped liposome with a phage displayed
peptide HVGGSSV to achieve radiation guided selective drug delivery to tumors. Liposomes were
labeled with Alexa Fluor 750 and the biodistribution of the labeled liposomes was studied in a murine
Lewis lung carcinoma model by near infrared (NIR) imaging [43]. The liposomes are widely applied
for lung cancer theranostics as they show immense promise due to their excellent biocompatibility
and biodegradability [44,45]. Moreover, liposomes hold the edges over other nanoparticles as they
are useful to load a high amount of therapeutic agents and can be easily controlled for sustained
drug delivery [44,45]. However, liposomal nanoparticles have some disadvantages like batch to
batch variability, high manufacturing cost, possible drug leakage, etc. [44]. Hence, careful fabrication
strategies are required to overcome these challenges and reduction of the cost.
5. Polymeric Nanoparticles for Lung Cancer Theranostics
Polymeric NPs, on the other hand, can be prepared either by nanoprecipitation or a double
emulsion method via self-assembly of biodegradable amphiphilic block-copolymers with varying
hydrophobicity’s between blocks and are suitable for systemic administration. The core-shell structure
of polymeric NPs facilitates encapsulation of hydrophobic drugs, extension of circulation time,
and sustained drug release. Their surfaces can also be decorated for targeted drug delivery [46,47].
For instance, Genexol-PM is a formulation of paclitaxel and poly (D,L-lactide)-b-polyethylene
glycol-methoxy (PLGA-mPEG), which is already marketed for metastatic breast cancer therapy
in Korea and other European countries [48,49]. Here we summarize a few recent interesting examples
of usage of polymeric NPs for treatment of lung cancer.
In 2015, Jiang [50] developed a nano-carrier encapsulating Crizotinib (approved for EML4-ALK
fusion positive lung cancer) within polylactide tocopheryl polyethylene glycol 1000 succinate
(PLA-TPGS), which showed a sustained release, induced remarkable cytotoxicity in NCIH3122
lung cancer cells, and noticeable early and late apoptosis. The polymeric nanoparticle followed
an endocytosis-mediated cellular uptake [50]. Interestingly, in 2017 Hu et al. [51] reported on the
efficiency of paclitaxel (PTX) loaded Polycaprolactone/ Poly (ethylene glycol)/Polycaprolactone (PCEC)
nanoparticles combined with chronomodulated chemotherapy for use in lung cancer. The authors set
out to map the suitable time of the day for administering drug loaded nano-carriers by making out
the crucial role of circadian rhythms in cancer propagation. The combination therapy demonstrated
remarkable tumor growth inhibition in vivo, while it turned out that 15HALO is optimal for
chemotherapy [51]. Very recently, to circumvent the low targeting capacity of nanoparticles, Wang et al.
used mesenchymal stem cells (MSC) as a carrier for drug delivery loaded with nanoparticles with
docetaxel (DTX). MSC proved its superiority over fibroblasts in drug loading. Both cellular and
animal experiments justified the intercellular translocation of nanoparticles from MSC to cancer cell.
It also inhibited primary tumor growth in vivo [52]. Much to our intrigue, Ganesh et al. explored
HA-PEI/PEG nano-carriers for CD44-targeted siRNA delivery to lung cancer cells. They undertook
a detailed structure-activity study for optimal siRNA encapsulation efficiency. Importantly, the targeted
HA-PEI/PEG nanosystems encapsulating SSB/PLK1 siRNA showed higher cellular uptake and sequence
specific gene knockdown in vivo both in sensitive and resistant A549 primary and metastatic [53].
Polymer based delivery of chemotherapeutics via inhalation has also made substantial progress in
recent years. Kim et al., in 2013, made an attempt to make highly porous PLGA microparticles entrapping
doxorubicin where the surface of the particles was decorated with Apo2L/TRAIL (tumor necrosis
factor (TNF)-related apoptosis-inducing ligand) that binds selectively to death receptors such as
DR4/TRAIL-R1 expressed specifically on cancer cells. The particles got deposited in a mouse lung
followed by pulmonary administration and exhibited tumor growth inhibition in nude mice with
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H226 metastatic lung cancer cells [54]. Furthermore, for pulmonary inhalation treatment, Feng et al.
developed a two-in-one nanosystem comprising of doxorubicin and paclitaxel encapsulated into
a porous PLGA microparticles and established a synergy between the two drugs at DOX:PTX 5:1 in vitro.
Co-delivery remained superior over their individual counterparts in vivo as well [55]. Khatun et al. [56]
demonstrated multifunctional cancer theranostics application of graphene-doxorubicin in a HA nanogel
in human lung cancer cell line (A549). This nanocomposite was used as thermo and chemotherapeutic,
real-time noninvasive optical imaging, and a controlled drug release [56] (Figure 2). Importantly,
in a study performed in 2006, Mitra et al. [57] observed an enhanced tumor targeting the capability of
N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers when coupled with RGDfK and RGD4C in
C57BL/6NHsd mice bearing Lewis lung carcinoma. They conjugated radionuclides with longer half-life
such as 111In compounds to HPMA for scintigraphic imaging and detected contrast enhancement
at the tumor site after 24h of injection [57]. In 2010, Gao and co-worker developed an MRI-visible
PLA polymeric micelle whose surface was decorated by a peptide RGDLATLRQL directed towards
αvβ6 integrin over-expressing human NSCLC cell H2009. DOX and super-paramagnetic iron oxide
nanoparticles (SPIONs) were loaded inside the micelle core for drug delivery and MR imaging,
respectively [58]. The polymeric nanoparticles are extensively applied for lung cancer theranostics due
to their biocompatibility, biodegradability, high drug pay load, sustained drug release, high scalability,
low batch variability, low cost production, and easy tunability [44,45].
 
Figure 2. In vivo optical imaging and thermo-chemotherapy using the nanogel. (a,b) are optical images
of healthy mice and tumor bearing mice, respectively. (c) Light responsive imaging. The nanogels were
intravenously injected and 670 nm laser was applied to the tumors for 30 min. (d) Ex vivo imaging and
fluorescence intensities of tumors and normal tissues. Organs were arranged in the following order:
Tumor (T), kidney (K), heart (H), spleen (S), liver (Li), and lung (Lu). (e) Thermo-chemotherapy after
treating doxorubicin and the nanogels with and without laser irradiation. (f) Body weight changes of
mice after treatment with the nanogels. The data were plotted as mean ± SEM (n = 5). Reproduced
from [56]. Copyright© 2015 Royal Society of Chemistry.
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6. Bio-Nanoparticles for Lung Cancer Theranostics
Due to high biocompatibility, better stability and biodegradability current researchers have shifted
their focal point of research towards using the bio-nanoparticles including protein nanoparticles, solid
lipid nanoparticles, viral nanoparticles, aptamers, and apoferritin, wherein a bio-mimicking component
is incorporated to the therapeutic nanoparticles [59,60]. In the recent past, these types of nanoparticles
were successfully designed, synthesized, and utilized for cancer theranostics applications in lung
cancer [59,61,62].
6.1. Viral Nanoparticles
Viral nanoparticles (VNPs) obtained from viruses and bacteriophages have gained immense
interest for various biomedical applications including drug delivery, biosensing, bioimaging,
and vaccine development due to their biocompatibility, flexibility in sizes and shapes, and easy surface
modification [63]. Many researchers have developed a combinational approach with chemotherapy and
immunotherapy for the treatment of lung cancer due to challenges of drug resistance. Veljanski et al.
has published an exciting review about the use genetically modified oncolytic viruses (OVs) with
conventional chemotherapies in the treatment of lung cancer. The inability of chemo-drugs to destroy
the cancer stem cells is well compensated by OVs-based gene therapy [64]. The cowpea mosaic virus
(CPMV) with an average size of ~28 nm has a high potential for vaccination therapy in lung cancer [65].
6.2. Protein-Based Nanoparticles
Protein nanoparticles prepared from a naturally occurring protein, such as gelatin, gliadin,
albumin, and legumin have been recently used for the drug and gene delivery purposes either alone or
in a mixture with biodegradable polymers in lung cancer therapy due to their excellent biocompatibility,
and lack of inflammation in human bronchial cells and high cellular uptake [66–68]. Cationic bovine
serum albumin (CBSA) has been utilized for the delivery of siRNA for the metastatic lung cancer
therapy [69].
6.3. Apoferritin
Apoferritin is the hollow protein nanocage without the iron core that is composed of self-assembling
24 polypeptide subunits and has internal and external diameters of 8 nm and 12 nm, respectively.
Upon removal of the iron core the apoferritin undergoes a process of assembly and disassembly with
the change in pH that is extensively utilized for the synthesis of various nanoparticles for lung cancer
theranostics [70,71]. Li et al. demonstrated the lung cancer diagnosis of A549 cells by using fluorescence
and MR imaging of apoferritin, a ferritin-based multifunctional nanostructure [71]. The authors
synthesized multifunctional hybrid nanostructures made of ferritin that showed green fluorescence
and had ferrimagnetic iron oxide nanoparticles into the hollow ferritin cavity. This multifunctional
apoferritin was used for the imaging αvβ3 integrin upregulated cancer cells. In another recent paper
by Luo et al., demonstrated the use of hyaluronic acid (HA)-conjugated apoferritin nanocages for
pH-responsive controlled intracellular prodrug release of the anticancer drug daunomycin (DN),
which was encapsulated into the interior of apoferritin [72]. Moreover, the authors modified the
apoferritin by HA to target and kill the cancer cells (embryonic lung MRC-5 cells and lung cancer A549
cells) upon binding to the HA-receptor CD44.
Bio-nanoparticles are widely applied for lung cancer theranostics as they demonstrate huge
promise due to their good biocompatibility and biodegradability. However, the synthesis strategies can
be complex at times and that can increase the cost and time of manufacturing. Hence, more research
needed to manufacture these bio-nanoparticles from lab-scale to commercial industrial scale.
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7. Inorganic Nanoparticles for Lung Cancer Theranostics
Inorganic nanoparticles have long been used for various biomedical applications including
drug delivery, nucleic acid delivery, bio-sensing, diagnostics, imaging, and cancer therapy due to
their exciting physico-chemical properties in the nanoscale range [73–76]. Among various inorganic
nanoparticles, gold, silver, iron oxides, silica, rare earth oxides, carbon dots, and nanodiamonds were
extensively studied in lung cancer theranostics [77–79]. Moreover, these nanoparticles demonstrated
prominent cytotoxic effects on various lung cells in vitro and in vivo that depend largely on their
size, shape, surface charge, concentration, and time of exposure. An accurate control over these
physico-chemical parameters can facilitate their meaningful application in lung cancer theranostics.
7.1. Gold Nanoparticles (AuNPs)
Gold nanoparticles were extensively used for cancer theranostics applications due to easy
synthesize and functionalize high biocompatibility, and multifunctional theranostics properties [80–82].
Several research groups utilized AuNPs for lung cancer theranostics [77]. For example, Nanospectra
has developed a silica-gold nanoshells stabilized by (poly)ethylene glycol (PEG) for the photothermal
therapy to the solid tumors using an NIR light source [83]. More importantly, in a recent clinical
trial, AuroLase® was used for the photothermal therapy of primary or metastatic lung tumors
(NCT01679470) [84]. In a recent published report by Knights et al. the authors demonstrated the
size dependent effects of gold nanorods (AuNRs) on the photoacoustic (PA) imaging response and
pulsed-wave photothermal therapeutic (PW-PPTT) efficacy, which is crucial for the clinical translation
of AuNRs [77]. Interestingly, the PA intensity increased with the AuNR size due to the overall mass of
the nanoparticles. All the different sized AuNRs showed toxicity in lung cancer cells upon laser fluence
with a highest cell death in the smallest AuNR treatment, indicating the theranostics potential of AuNRs
combined with PW lasers in lung cancer. In another recent report, Ramalingam et al. [85] showed the
enhanced anti-cancer efficacy of doxorubicin (DOX) using polyvinylpyrrolidone functionalized AuNPs
(Dox@PVP-AuNPs) in lung cancer cells. Mechanistic studies demonstrated that Dox@PVP-AuNPs
treatment to lung cancer cells increases reactive oxygen species (ROS) generation, up-regulates the
tumor suppressor genes, sensitize mitochondrial membrane potential and further induces apoptosis [85].
Peng et al. exhibited that novel sensors based technology using gold nanoparticles could be used for
a non-invasive and inexpensive diagnostic tool for lung cancer [86].
7.2. Iron Oxides Nanoparticles (IONPs)
Supermagnetic iron oxide nanoparticles is extensively used as a MRI contrast agent, and also can
be utilized as a delivery carrier in cancer theranostics applications. Iron oxides nanoparticles were long
used for various biomedical applications including MRI imaging, drug delivery, magnetic hyperthermia,
and cancer theranostics in lung cancer [87–90]. Wang et al., recently demonstrated MRI and magnetic
resonance-guided focused ultrasound ablation therapy using iron oxide nanoparticles in lung cancer
(Figure 3) [87]. The authors synthesized an epidermal growth factor receptor targeted PEGylated iron
oxide nanoparticles (IONPs) for targeted delivery and imaging to lung cancer in an in vitro and in vivo
rat xenograft model of human lung cancer (H460). In another study, Sadhuka et al. showed the usage
of EGFR-targeted inhalable iron oxide nanoparticles for magnetic hyperthermia in lung cancer [89].
The authors showed that EGFR targeting enhanced the tumor retention of IONPs. Moreover, magnetic
hyperthermia treatment by EGFR-targeted IONPs caused in major inhibition of lung tumor growth in
in vivo orthotropic lung cancer model.
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Figure 3. (a) Sonication process images. Treatment planning software on the MRgFUS workstation.
In total, five sonications are needed to measure the circumference of this tumor. (b) Tissue temperature
mapping during MRgFUS ablation. (c) Real-time temperature change in MRgFUS ablation monitored
by MRI. (d) Schematic illustration of therapeutic temperature map in tumor center and margin.
Sonication energy (e) and therapeutic peak temperature (f) of negative control (low power, 54 W),
control (76 W), PEG-SPIO (54 W), and anti-EGFR-PEG-SPIO (32 W) at 4 h post-injection of SPIO
nanoparticles. (g) Anti-EGFR-PEG-SPIO group: Coronal T2WI image signal intensity of tumor before
treatment and after treatment. The coronal T2WI signal intensities of tumor increased significantly
after therapy compared to before therapy (Figure 6g). Enhanced axial T1WI-weighted images after
injection of Gd-DTPA. Axial contrast-enhance T1WI subtraction images after injection of Gd-DTPA
showed a small focal area of nonperfusion. Reproduced from [87]. Copyright© 2017. Elsevier.
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7.3. Silver Nanoparticles (AgNPs)
Silver nanoparticles were long used for various biomedical applications including anti-bacterial
applications, anti-cancer applications, fluorescence imaging, and biosensors [91]. Recently, He et al.
demonstrated the antitumor activity of biosynthesized AgNPs against lung cancer in in vitro H1299
lung cancer cells and an in vivo xenograft immunodeficient (SCID) mouse model [92]. The potent
cytotoxicity effect of AgNPs was showed by trypan blue and MTT assay. Mechanistic studies showed
that AgNPs caused apoptosis (increase in caspase-3 and decrease in bcl-2) in lung cancer cells that
connected well with an inhibition of NF-κB activity [92]. The cytotoxicity of AgNPs largely depends
on their size, shape, morphology, and surface chemistry [93]. In another recent published report,
Jeong et al. [94] explored the basic mechanism of hypoxia on AgNPs induced apoptosis that showed the
upregulation of HIF-1α expression under both normoxic and hypoxic conditions. Moreover, the AgNPs
treatment caused programmed cell death in lung cancer cells but not in normal cells. Notably, HIF-1α
protected AgNPs-induced apoptosis by regulating autophagic flux through controlling the ATG5, p62,
and LC3-II. Hence, these results suggest that hypoxia-mediated autophagy could be used to inhibit the
AgNPs mediated apoptosis involving the HIF-1α as a potential target in lung cancer therapy [94].
7.4. Other Metal Nanoparticles
Among other nanoparticles rare earth, silica, and nanodiamond were used for the cancer
theranostics application in lung cancer [95–97]. Wu et al., showed the application of a silica-polymer
nanocomposite for p53 gene therapy and near infrared tumor targeted imaging of lung cancer in vitro
and in vivo [95]. A nanodiamond (ND) was also utilized for the delivery of paclitaxel in lung cancer
therapy. This nanodrug delivery exhibited significant tumor regression ability in immunodeficiency
mice, in a lung cancer cell model. Mechanistic studies revealed that ND caused mitotic arrest and
apoptosis that led to lung cancer cell death [97]. In another report, Zhang et al. developed a silica
based imaging agent to detect a single miRNA in lung cancer cells that can be used for biosensing
applications [96]. In another published report, Chen et al. showed the application of micromolar
concentration of the neodymium oxide nanoparticles (Nd2O3) for the induction of extensive autophagy
and immense vacuolization in NSCLC cells [98]. Wu et al. [99] developed a multi-functionalized,
carbon dots based theranostics nanoagent that can be used for bioimaging as it emitted visible blue
photoluminescence when excited at 360 nm and also can be utilized as a gene delivery vehicle for
multiple siRNAs (EGFR and cyclin B1) in lung cancer. Moreover, this nanoagent was found to be
accumulated in lung cancer cells by receptor mediated endocytosis in a targeted manner, resulting in
improved gene silencing and anti-cancer efficacy.
Scientists and researchers are excited with metal nanoparticles in the recent past due to their
small size, high surface to area, easy synthesis and scale up, low cost, multifunctional theranostics
applications, exciting physico-chemical properties. However, due to the lack of enough knowledge
about their long-term toxicity, pharmacokinetics, pharmacodynamics, and degradability, the clinical
translation of these nanomaterials is still not widely possible compared to its other counterparts [29].
8. Clinical Status of the Nanotheranostics in Lung Cancer
Advances in nanoparticle designing and formulations are related to numerous applications in
the detection and treatment of malignant growth. Ongoing advances in nanotheranostics in imaging
and therapeutics of lung cancer are as follows. Porphyrins due to their favorable photophysical
properties have been particularly successful for cancer imaging and photodynamic therapy (PDT).
Hematoporphyrin derivative (HpD), porfimer sodium has been approved in over 120 countries since
1993 for the detection and photodynamic therapy of esophageal, lung, superficial bladder, gastric,
cervical, and endobronchial cancers [100–102]. Though relatively non-toxic, HpD is not very effective
as a primary therapy in lung cancer [103]. Laserphyrin 664 is approved for PDT in Japan for treating
early centrally located lung cancer. PET (positron emission tomography) is a nuclear medicine imaging
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method, frequently used in combination with FDG (fluorine-18 combined with deoxy-glucose) [104].
FDG is a glucose analogue that is extensively used in cancer staging, restaging and for the analysis
of tumor response to treatment. The most frequent application of theranostics is for the palliative
treatment of bone metastases from lung cancer. EDTMP marked with 153Sm [105] and 99mTc-MDP
an analogue of pyrophosphate similar to bone scanning agents and provides high doses of localized
radiation because of its β-particle emissions.
Peptidomimetics like [68Ga]Ga-NODAGA-THERANOST™ is a 3 integrin antagonist first used in
humans for lung and breast cancer diagnosis and anti-angiogenic therapy [106]. Ongoing advances
in nanotheranostics for drug delivery have been mostly attempted using liposomal formulations.
Irinotecan liposome injection (ONIVYDE®) is being investigated versus topotecan in patients with
small cell lung cancer after platinum-based first-line therapy (Phase3; 2018–2022 study). To find the
highest dose of DOTAP:Chol-fus1 liposomal formulation that can safely be given in combination
with tarceva (erlotinib hydrochloride) to patients with NSCLC (Phase2; 2014–2019 study) is currently
undergoing. Another trial is investigating the pain management efficiency of liposomal bupivacaine
after elective thoracoscopic lobectomy (Phase3; 2018–2021 study) for non-small cell lung cancer.
An exosome is a nano-sized vesicle secreted from different cell types and has a natural ability to
carry functional biomolecules, such as small RNAs, DNAs, and proteins in their lumen. This unique
signature of particular cells also makes them attractive for use in drug delivery and molecular diagnosis.
Moreover, exosomes can be coupled to nanoparticles and used for high precision imaging. Exosomes
are considered as an important component in liquid biopsy assessments, which are useful for detecting
cancers, including lung cancer. Several studies are currently underway to develop methods of
exploiting exosomes for its use as efficient drug delivery vehicles and to develop novel diagnostic
modalities. Srivastava et al., 2018 combined the diagnosis of CT and exosome in early lung cancer
2018–2019. Another theranostics-based use of exosome is for the dynamic monitoring circulating
tumor DNA in surgical patients with lung cancer, 2017–2023 [107]. Albumin based nanoparticles are in
use in different phases of clinical trials for the delivery of paclitaxel, cisplatin in NSCLC [62,108–110].
The development of lung cancer nanotheranostics, with an accentuation on clinical use is
limited by several lacunae. The reproducible synthesis of several nanoplatforms with composite
structures and its scale-up produces significant complications. Sterility can also hamper such processes.
Another important aspect worth considering is nanoparticles-induced cytotoxicity, genotoxicity,
and immunotoxicity related to their nanometer size. Industrial vendors and pharmaceutical companies
have fewer incentives to move on with theranostics-based blockbusters because of the projected
final product price as compared to conventional therapy. Though, coupling therapy with diagnosis
together into a single theranostics platform should provide significant advantages but the imaging and
tumor targeting components might have different pharmacokinetics and dynamics and can mount
a significant manufacturing challenge.
Delay in the transition for theranostics from bench to bedside is mainly due a lack of basic-clinical
scientific collaborations. Basic scientists and many clinical scientists lack the information or time to
comprehend, envision, oversee cons, and manage the nuances of the multistep compliance guidelines
of the clinical trial phases. Being oblivious about the obligation regarding guaranteeing consistency
with the guidelines and related regulatory aspects delays the process of bringing cancer theranostics
from the laboratory to clinical use. Though FDA is bringing a change in the regulatory changes to the
regulatory procedures and developing tools to reduce the development time of theranostics. Weighing
the potential benefits to possible adverse health risk assessment of lung cancer nanotheranostics needs
to be considered based on scientifically sound, evidence-based and well-controlled clinical studies.
9. Conclusions and Future Perspectives
Theranostics or personalized cancer treatment is proof based, an individualized prescription that
warrants the right treatment at the correct time, leading to significant efficacy and improvements
of patient’s condition and a decrease in medicinal and services costs. Theranostics medicine is
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employed for delivering both therapeutic and imaging agents to the targeted area of the body,
using a nanotechnology-based delivery platform. Nanomaterials have proved to be tools with
tremendous benefit and are now finding application in the clinic. Nanostructures, due to their
novel physical properties can often overcome solubility and stability issues through surface
modification/wrappings or additional formulation. The integrated approach of combining ligands,
drugs, biomolecules, and imaging agents into a functionalized nanoparticle enables targeted drug
delivery and diagnostics. Another aspect that aids in the higher therapeutic payload is the high surface
area because of their nanosize. Nanoparticle-based targeting specific cancer cells and specific delivery of
therapeutic payloads at cancer sites via passive or active targeting can significantly reduce nonspecific
toxicity. In spite of the advantages, a lot of unsolved challenges remain including scale-up problems,
economical production, the pharmacokinetics of the drug, and the imaging construct. Additional
issues with nanotoxicity and regulatory guidelines and hurdles need to be resolved in order to see
lung cancer theranostics in the clinic. Though nanotechnology has achieved great strides but still is not
used to maximal impact in lung and other malignancies.
With the advent of stronger sequencing, immunohistochemistry, and proteomic techniques,
a better understanding of the mechanisms of cancer and identification of new definitive biomarkers
are on the way. Greater funding for multi-center cohort studies and the advent of landmark genomic
program like the Cancer Genome Atlas (TCGA) and cancer proteome studies the human protein atlas
have also created new inroads in the understanding of cancer. In 2018, theranosticsimaging using PSMA
(prostate specific membrane antigen) PET (positron emission tomography) and image-guided therapy
using PSMA targeted radionucleotide lutetium-177 PSMA617 has shown to be a paradigm-changing
practice for improving prostate cancer patient outcomes. The advances of theranostics-based radiomics
will span from the current effort to the expected future of using deep learning. Development of
theranosticstools for ultrasensitive and quantitative measurement of theranostics biomarkers, ability to
diagnose and quantify cancer at its earliest stage with high resolution, and early prediction response to
cancer therapy will also depend on how new assisting tools (e.g., artificial intelligence) are going to be
harnessed. The integration of all the advances in these allied fields together as cancer theranosticsis
poised to revolutionize the future of therapeutics for the ultimate eradication of cancer.
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